Genes,DisGeNET_Term,DisGeNET_Pvalue_Adjusted,GeDiPNet_Term,GeDiPNet_Pvalue_Adjusted,Orphanet_Term,Orphanet_Pvalue_Adjusted,Virus_Host_Term,Virus_Host_Pvalue_Adjusted,Host organism(s)_Intact,Confidence value(s)_Intact,Taxid interactor A_Intact,Taxid interactor B_Intact
AANAT,"Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; melanoma; Malignant neoplasm of breast; Malignant Neoplasms; Malignant neoplasm of large intestine; Unipolar Depression; Major Depressive Disorder; Neoplasms; Primary malignant neoplasm; Diabetes Mellitus, Non-Insulin-Dependent; Shift-Work Sleep Disorder; Sleep Disorders, Circadian Rhythm; Non-24 Hour Sleep-Wake Disorder; Nonorganic Sleep Wake Cycle Disorders; Asthma; Advanced Sleep Phase Syndrome; Autism Spectrum Disorders; Mental Depression; Delayed Sleep Phase Syndrome; Depressive disorder; Retinoblastoma; Depression, Bipolar; Reticulocyte count (procedure)",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0991201145654548; 0.13167400689206; 0.13167400689206; 0.21122597829463; 0.2714542429024338; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.4115056600660309; 0.4115056600660309; 0.425419812815905,Shift-Work Sleep Disorder; Non-24 Hour Sleep-Wake Disorder; Nonorganic Sleep Wake Cycle Disorders; Delayed Sleep Phase Syndrome; Advanced Sleep Phase Syndrome; Mental Depression; Bipolar Disorder,0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4541466895915311; 0.4560460337187313; 0.4875380732267193,,,,,,,,
ABCB1,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Retroviridae Infections; melanoma; Adenocarcinoma; Proliferative vitreoretinopathy; Squamous cell carcinoma; Esophageal Neoplasms; Malignant mesothelioma; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Hematopoietic Neoplasms; Medulloblastoma; Epithelial ovarian cancer; Brain Tumor, Primary; Malignant neoplasm of prostate; Carcinoma; Central neuroblastoma; Carcinomatosis; Primary malignant neoplasm of brain; Mammary Neoplasms, Human; Brain Neoplasms; Neoplasm Metastasis; Mucoepidermoid Carcinoma; Renal Cell Carcinoma; Neuroblastoma; Malignant neoplasm of pancreas; Glioma; Osteoporosis; Lymphoma; Endometrial Neoplasms; Glioblastoma; Pancreatic carcinoma; Carcinoma breast stage IV; Liver Cirrhosis, Experimental; Liver Cirrhosis; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Colorectal Neoplasms; Stage IV Bladder Cancer AJCC v6; Anaplastic carcinoma; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Adult Acute Lymphocytic Leukemia; Squamous cell carcinoma of esophagus; Liver carcinoma; Malignant Neoplasms; Osteosarcoma; Colon Carcinoma; Adenocarcinoma of colon; Skin toxicity; Cardiac Carcinoma; Chronic Lymphocytic Leukemia; Small cell carcinoma of lung; ADENOMAS AND ADENOCARCINOMAS; Hematologic Neoplasms; Secondary malignant neoplasm of bone; MYELODYSPLASTIC SYNDROME; Esophageal carcinoma; Tumor Initiation; Undifferentiated carcinoma; Clear-cell metastatic renal cell carcinoma; Carcinoma, Transitional Cell; Oral Cavity Carcinoma; Phototoxicity; Malignant neoplasm of large intestine; Carcinoma of bladder; Malignant neoplasm of endometrium; Papillary serous cystadenocarcinoma; Unipolar Depression; Uterine Corpus Cancer; Myocardial Infarction; Hyperactive behavior; Solid Neoplasm; Colonic Neoplasms; Liver neoplasms; Rheumatoid Arthritis; Sarcoma; Renal fibrosis; Sickle Cell Dactylitis; Palmar-plantar erythrodysesthesia syndrome; Breast Cancer, Familial; Carcinoma testes; Chronic leukemia (category); Leukemia, Myeloid, Chronic-Phase; Visual seizure; stage, ovarian epithelial cancer; Dermatitis, Phototoxic; TARSAL-CARPAL COALITION SYNDROME; Acute Myeloid Leukemia (AML-M2); cervical cancer; Seizures; Malignant tumor of peritoneum; Lung Neoplasms; Osteosarcoma of bone; Major Depressive Disorder; Connective Tissue Diseases; Uterine Corpus Sarcoma; Cataract; Malignant tumor of colon; Prostatic Neoplasms; Adverse reaction to drug; Drug toxicity; Hodgkin Disease; Burkitt Lymphoma; Hepatoblastoma; Malignant Head and Neck Neoplasm; B-Cell Lymphomas; Malignant neoplasm of liver; Opiate Addiction; Chondrosarcoma; Neoplasms; Malignant tumor of cervix; Malignant ascites; Parasitic Diseases; Malignant neoplasm of lung; Kidney Neoplasm; Diabetes Mellitus, Insulin-Dependent; 5,10-Methylenetetrahydrofolate reductase deficiency; Mental Disorders, Severe; Secondary malignant neoplasm of lung; Cervix carcinoma; Acute leukemia; Neoplasms, Intracranial; Adult Hepatocellular Carcinoma; Cirrhosis; Gastrointestinal Diseases; Hyperbilirubinemia; Conventional (Clear Cell) Renal Cell Carcinoma; Breast cancer, lobular; Pancolitis; Triple Negative Breast Neoplasms; Myeloid Leukemia; Heart Septal Defects; Endometrial Carcinoma; Neuroepithelioma; Childhood Acute Lymphoblastic Leukemia; Malignant Squamous Cell Neoplasm; Anaplastic Oligodendroglioma; Gastrointestinal Stromal Tumors; Cholangiocarcinoma; Marijuana Abuse; Ischemic stroke; Blast Phase; Leukemogenesis; Rhabdomyosarcoma; Uterine Cancer; Pregnancy in Diabetics; Carcinoma of lung; Tuberculosis; Anaplastic astrocytoma; Primary malignant neoplasm; Undifferentiated leukemia; Complex partial seizures; Tuberculosis, Pulmonary; Cardiac Lymphoma; hiv-infection/aids; Primary malignant neoplasm of lung; Bone necrosis; Secondary malignant neoplasm of lymph node; Amyloidosis; Hallucinations; Chronic myeloproliferative disorder; Gallbladder Carcinoma; Diagnosis, Psychiatric; Progressive intrahepatic cholestasis (disorder); Epstein-Barr Virus Infections; Bipolar Disorder; Plaque, Amyloid; Peripheral T-Cell Lymphoma; Adenocarcinoma of large intestine; Columnar Cell Change of the Breast; Diabetes Mellitus, Non-Insulin-Dependent; Inflammation; Harlequin Fetus; Generalized seizures; Pancreatitis, Chronic; Interstitial lung fibrosis; Kidney Diseases; Nasopharyngeal carcinoma; Non-small cell lung cancer stage I; Parathyroid Adenoma; Nephroblastoma; Schizophrenia; Malignant Glioma; Adrenocortical carcinoma; Seizures, Focal; tumor vasculature; Non-Small Cell Lung Carcinoma; Infection caused by Helicobacter pylori; HTLV-I Infections; Hypertensive disease; Secondary malignant neoplasm of liver; Juvenile rheumatoid arthritis; Leukemia, Myelocytic, Acute; Splenic Neoplasms; Sarcoma, metastatic; Visual disturbance; Acute postoperative pain; Central nervous system depression (disorder); HIV Infections; Milroy Disease; Soft Tissue Neoplasms; Hurthle Cell Tumor; Stage 4S neuroblastoma; Lymphoma, T-Cell, Cutaneous; DOSAGE-SENSITIVE SEX REVERSAL; Arthritis, Psoriatic; Chordoma; Alzheimer's Disease; Anxiety Disorders; Coumarin Resistance; Neonatal Abstinence Syndrome; Prolymphocytic Leukemia; Malaria, Falciparum; Creutzfeldt-Jakob disease; Liver and Intrahepatic Biliary Tract Carcinoma; Lymphoma, Non-Hodgkin; Epiretinal Membrane; Acute lymphocytic leukemia; Lip and Oral Cavity Carcinoma; Stomach Neoplasms; Inflammatory Bowel Diseases; Acute Promyelocytic Leukemia; Parkinson Disease; Coronary heart disease; Glomerulonephritis; Postoperative Nausea and Vomiting; Arthritis, Adjuvant-Induced; Arthritis, Collagen-Induced; Arthritis, Experimental; Behavior Disorders; Granulomatous Disease, Chronic, X-Linked; Cerebral Amyloid Angiopathy; Lymphoid leukemia; Adenoma; Glioblastoma Multiforme; synovial sarcoma; Adult Soft Tissue Sarcoma; Asthenia; Childhood nephrotic syndrome; Metaplastic breast carcinoma; Disseminated neuroblastoma; Anemia; Malignant neoplasm of kidney; Neoplasm, Residual; Fabry Disease; Rash and Dermatitis Adverse Event Associated with Chemoradiation; Single Seizure; Seizures, Auditory; Seizures, Clonic; Seizures, Sensory; Seizures, Somatosensory; Vertiginous seizure; Atonic Absence Seizures; Generalized Absence Seizures; Gustatory seizure; Jacksonian Seizure; Non-epileptic convulsion; Nonepileptic Seizures; Olfactory seizure; Acute Erythroblastic Leukemia; Epilepsy; Variegate Porphyria; COLCHICINE RESISTANCE; Renal carcinoma; Thyroid carcinoma; Epileptic Seizures; androgen independent prostate cancer; Mental Depression; Tonic Seizures; Ki-1+ Anaplastic Large Cell Lymphoma; Pituitary Neoplasms; Malignant neoplasm of brain; Recurrent Endometrial Cancer; Parkinson Disease, Secondary Vascular; Sleep Apnea, Mixed Central and Obstructive; Atherosclerotic Parkinsonism; Benign neoplasm of liver; Cannabis-Related Disorder; Hashish Abuse; Hypersomnia with Periodic Respiration; pediatric AIDS; Pulmonary Blastoma; Hereditary hemochromatosis; Progressive Neoplastic Disease; Progressive cGVHD; Senile Plaques; Dizziness; Schizoaffective Disorder; Convulsive Seizures; Depressive disorder; Secondary Parkinson Disease; Childhood Absence Epilepsy; Chronic Liver Failure; Kernicterus; Vertigo; Meningioma, benign, no ICD-O subtype; Chronic Kidney Diseases; Kidney Failure, Acute; Neuroectodermal Tumor, Primitive; leiomyosarcoma; Refractory cancer; Carcinoma of larynx; Intrahepatic Cholangiocarcinoma; Celiac Disease; Schizophrenia and related disorders; Childhood Acute Megakaryoblastic Leukemia; Gastric Adenocarcinoma; Extrapyramidal Disorders; Epileptic drop attack; Cholestasis; Drug Resistant Epilepsy; Acute myocardial infarction; Multiple Myeloma; Epilepsy, Temporal Lobe; Convulsions; Nephrotic Syndrome; Xeroderma pigmentosum, group B; AIDS-Related Non-Hodgkin Lymphoma; Cancer Relapse; Anxiety; Retinoblastoma; MYELOPROLIFERATIVE SYNDROME, TRANSIENT; Viremia; Aura; Awakening Epilepsy; Cerebrovascular accident; Alzheimer Disease, Late Onset; Acute Megakaryocytic Leukemias; Sphenoid Wing Meningioma; Peroxisome Biogenesis Disorder, Complementation Group D; Core binding factor acute myeloid leukemia; Malignant histiocytosis; Epilepsy, Cryptogenic; Acute Coronary Syndrome; Juvenile arthritis; Absence Seizures; Acquired Immunodeficiency Syndrome; Malignant Peripheral Nerve Sheath Tumor; Down Syndrome; Mental disorders; Balkan Nephropathy; Cannabis Abuse; Central nervous system lymphoma; Multiple Chronic Conditions; Oxyphilic Adenoma; Liposarcoma, Pleomorphic; Aggressive natural killer-cell leukemia; Erythema Multiforme; Poisoning; Lupus Erythematosus, Systemic; Simple Partial Status Epilepticus; Status Epilepticus, Subclinical; Complex Partial Status Epilepticus; Grand Mal Status Epilepticus; Non-Convulsive Status Epilepticus; Thrombocytopenia; Malignant neoplasm of mouth; Benign Neoplasm; Ovarian adenocarcinoma; PACHYONYCHIA CONGENITA 3; Congestive heart failure; Neurilemmoma; secondary acute myeloid leukemia; Tuberculosis, Drug-Resistant; Intestinal Volvulus; Lipidemias; Rectal Carcinoma; Heart failure; Infant, Premature; Psoriasis; Undifferentiated (Embryonal) Sarcoma; Idiopathic Nephrotic Syndrome; Pouchitis; Addictive Behavior; Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Malignant Fibrous Histiocytoma; Early-Stage Breast Carcinoma; Petit mal status; Squamous cell carcinoma of lung; Neurodegenerative Disorders; Neuropathy; Indolent Non-Hodgkin Lymphoma; Infantile nystagmus syndrome; Niemann-Pick Disease, Type C; Carcinoid Tumor; Meningioma; Encephalitis; Dyslipidemias; Depressive Symptoms; Monosomy; Leukemia secondary; Peptic Ulcer; Precancerous Conditions; Status Epilepticus; Lymphoma, Large-Cell, Follicular; Acute myeloid leukemia, minimal differentiation; Alcohol or Other Drugs use; Hyperlipoproteinemia Type IIa; Steroid resistant nephrotic syndrome of childhood; leukemia; Chronic gastritis; Myoclonic Seizures; Hypotension, Orthostatic; Steroid-resistant nephrotic syndrome; Increased drug resistance; Klatskin Tumor; Plasmablastic lymphoma; Mesothelioma; Malignant neoplasm of skin; Encephalopathy, Toxic; Toxic Encephalitis; Primary Malignant Liver Neoplasm; Chronic kidney disease stage 5; Huntington Disease; Uveal melanoma; Myeloid Leukemia, Chronic; Lymphoma, AIDS-Related; Pain, Postoperative; Agranulocytosis; Febrile Neutropenia; Philadelphia chromosome positive chronic myelogenous leukemia; Adenomatous Polyposis Coli; Manic; Malignant melanoma of eye; Psychotic Disorders; Hypercholesterolemia; Myelodysplasia; Rheumatism; Anorexia Nervosa; Lymphadenitis; Polydipsia; Breast adenocarcinoma; Steroid Sulfatase Deficiency Disease; Cyst; Kaposi Sarcoma; Pain; Cannabis Dependence; Neurotoxicity Syndromes; Tonic - clonic seizures; Diarrhea; Primary biliary cirrhosis; Acute biphenotypic leukemia; X-Linked Combined Immunodeficiency Diseases; Oral cleft; Pemphigus; Primary Lesion; Sleep disturbances; Anaplastic thyroid carcinoma; Adult Acute Myeloblastic Leukemia; Crohn Disease; Neutropenia; Ichthyosis, X-Linked; Ulcerative Colitis; Juvenile Myoclonic Epilepsy; M5b Acute differentiated monocytic leukemia; Hepatitis A; Coronary Arteriosclerosis; Obesity; Tubular Aggregate Myopathy; Escherichia coli Infections; Immunoblastic Large-Cell Lymphoma; Adenocarcinoma of lung (disorder); Reperfusion Injury; Painful Bladder Syndrome; Ewings sarcoma; Malignant neoplasm of adrenal cortex; nervous system disorder; Kidney Failure, Chronic; Adenocarcinoma, Clear Cell; Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome; Congenital Abnormality; Colitis; Bacterial Infections; Nephrotic Syndrome, Minimal Change; Pancreatitis, Alcoholic; Gastrointestinal mucositis; Lymphoma, Follicular; Congenital Heart Defects; Tuberous Sclerosis; Precursor Cell Lymphoblastic Leukemia Lymphoma; Carcinoma of urinary bladder, superficial; Hyponatremia; Pyruvate Carboxylase Deficiency Disease; Precursor B-cell lymphoblastic leukemia; Malignant neoplasm of gallbladder; Delirium; Autoimmune Diseases; Childhood Osteosarcoma; Sleep Apnea, Central; Sleep Disorders; Ependymoma; liposarcoma; Malaria; cardiac event; Primary sclerosing cholangitis; Lymphoproliferative Disorders; Cockayne Syndrome, Type I; Pain, Crushing; Pain, Migratory; Pain, Splitting; Suffering, Physical; Ache; Radiating pain; Drug usage; Nonorganic psychosis; Leukemia, Lymphocytic, Acute, L2; Pain, Burning; Peripheral Neuropathy; Diffuse Large B-Cell Lymphoma; Agnosia for Pain; Thyroid Diseases; Adult Cholangiocarcinoma; Familial Mediterranean Fever; Glucocorticoid Receptor Deficiency; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Congenital chromosomal disease; Hyperlipidemia; Carcinoma, Lobular; Congenital defects; Nausea; Oncocytic Neoplasm; Sleep Apnea Syndromes; Herpes Simplex Infections; Hematological Disease; Hepatitis, Toxic; Chemical and Drug Induced Liver Injury; Chemically-Induced Liver Toxicity; Drug-Induced Acute Liver Injury; Heart Diseases; Absence Epilepsy; Cystic Fibrosis; Hepatitis B, Chronic; Hepatitis, Drug-Induced; Heroin Dependence; Tumor Angiogenesis; Viral hepatitis; Monocytic leukemia; Cytogenetically normal acute myeloid leukemia; Leukopenia; Cocaine Dependence; Brain Diseases; Cervical Adenocarcinoma; Metastatic Renal Cell Cancer; Cockayne Syndrome; Withdrawal Symptoms; Childhood Leukemia; Renal Insufficiency; Myeloproliferative disease; High-Grade Prostatic Intraepithelial Neoplasia; Leukemia, T-Cell; Chronic granulomatous disease; Myasthenia Gravis; Sensory neuropathy; Gastritis; Drug-Induced Liver Disease; Vomiting; Lipoma; Age at menarche; Influenza; Coronary Artery Disease; Childhood Neuroblastoma; Childhood Acute Myeloid Leukemia; Congenital contractural arachnodactyly; Hepatitis; Benign Prostatic Hyperplasia; T-Cell Lymphoma; Fatigue; Encephalopathies; CNS disorder; Hyperthyroidism; Impaired cognition; early pregnancy; Nausea and vomiting; Malignant neoplasm of gastrointestinal tract; Disease Exacerbation; Adult T-Cell Lymphoma/Leukemia; Hypercholesterolemia, Familial; Hepatitis B",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0308703957553632; 0.0334891258932371; 0.0354767239335874; 0.0387439397151409; 0.044151975756427; 0.0569142010728473; 0.0593779966354549; 0.0593779966354549; 0.0617471306652618; 0.064548079316548; 0.064548079316548; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0747863377072194; 0.0773771948186562; 0.0773771948186562; 0.0775520919998773; 0.0827744840860166; 0.084286432100041; 0.084286432100041; 0.084286432100041; 0.0891725280554336; 0.0919714360040484; 0.0919714360040484; 0.095319386034013; 0.0991201145654548; 0.1029977559100099; 0.1062239757831962; 0.1112281755580192; 0.1138051695421299; 0.1138051695421299; 0.1147307578771389; 0.1193558174333938; 0.1193558174333938; 0.1253114324938153; 0.1253114324938153; 0.1254380558571286; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1352936728187231; 0.1387448809655294; 0.1413782599148022; 0.1454373331146953; 0.1454373331146953; 0.1537760235124317; 0.1537760235124317; 0.1602092191314262; 0.1602092191314262; 0.1602092191314262; 0.1602092191314262; 0.1653491983554358; 0.1653491983554358; 0.1662487420178625; 0.1735868515093891; 0.1874735657311888; 0.1897991423047819; 0.1906413554467301; 0.2050045461627939; 0.2050045461627939; 0.2053083986145698; 0.2062010908869036; 0.2062010908869036; 0.2109483801368481; 0.21122597829463; 0.2139814021986384; 0.222537307875512; 0.223747154820789; 0.223747154820789; 0.223747154820789; 0.223747154820789; 0.223747154820789; 0.2454476567103779; 0.2521987644415915; 0.2522264785494494; 0.2522264785494494; 0.2522264785494494; 0.2643145809900195; 0.2643145809900195; 0.2643145809900195; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2723545094624877; 0.2834835531038365; 0.2835142372342932; 0.290158730291654; 0.290158730291654; 0.2923761731100008; 0.2980670559114652; 0.2980670559114652; 0.2980670559114652; 0.2980670559114652; 0.2980670559114652; 0.2980670559114652; 0.2980670559114652; 0.3044782497745498; 0.3044782497745498; 0.3099246715197673; 0.3099246715197673; 0.3104232675696299; 0.3176684185973055; 0.3199171478489988; 0.340892538685018; 0.3418217363648192; 0.3486533561309259; 0.3494455519738624; 0.3510063969122338; 0.3510063969122338; 0.3544355608905275; 0.3638414818541592; 0.3663130598151661; 0.3706856725676674; 0.3763374964032415; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4037249857069285; 0.4100901006059349; 0.4100901006059349; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4118266358241932; 0.4118266358241932; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.4192169590514327; 0.4192169590514327; 0.4192169590514327; 0.4192169590514327; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.424575176503444; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.429029854971378; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4314759856195063; 0.4330362522463816; 0.4330362522463816; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4352815161963393; 0.4381343267935581; 0.4396723023384634; 0.4396723023384634; 0.4421745246585178; 0.4459714599189374; 0.4459714599189374; 0.4459714599189374; 0.4459714599189374; 0.4479115285676636; 0.4506578937113162; 0.4506578937113162; 0.4506578937113162; 0.4506578937113162; 0.4564472886428772; 0.4564472886428772; 0.4588513406515081; 0.4615352570710579; 0.4615352570710579; 0.4615352570710579; 0.4615352570710579; 0.4615352570710579; 0.4615352570710579; 0.4615352570710579; 0.4635211539849193; 0.466957409863091; 0.4675904598629673; 0.4675904598629673; 0.4675904598629673; 0.4704594475773637; 0.4704594475773637; 0.472444704048021; 0.472444704048021; 0.472444704048021; 0.472444704048021; 0.472444704048021; 0.472444704048021; 0.472444704048021; 0.4749780675672355; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4755217870653703; 0.4790179402069343; 0.4790179402069343; 0.4790179402069343; 0.4790179402069343; 0.4790179402069343; 0.4810435657134442; 0.4840863724482356; 0.4850576707687362; 0.4851378030288289; 0.4871698998714747; 0.4906258721078565; 0.4906258721078565; 0.4919605488358906; 0.4923669467696064; 0.4923669467696064; 0.4923669467696064; 0.4923669467696064; 0.4923669467696064; 0.4923669467696064; 0.4923669467696064; 0.4929829683479762; 0.4952592576151974; 0.4981941174985421; 0.4981941174985421; 0.498994845947585; 0.4990401620718274; 0.5001612228394569; 0.5019670090704682; 0.504136641473215; 0.5090214163899865; 0.5140447474168605; 0.5140447474168605; 0.5140447474168605; 0.5140447474168605; 0.5140447474168605; 0.51550637274795; 0.5188223685230745; 0.5188223685230745; 0.5251317541886066; 0.5251317541886066; 0.5276472086074249; 0.5299466034567416; 0.5299466034567416; 0.5299466034567416; 0.5305233935923577; 0.5323590634832615; 0.5337853752290136; 0.5337853752290136; 0.5337853752290136; 0.5337853752290136; 0.533913711453195; 0.533913711453195; 0.5359212109443033; 0.5393787854381349; 0.5393787854381349; 0.5393787854381349; 0.5393787854381349; 0.5451009374855866; 0.5496357724684553; 0.549941235475765; 0.5512224939896888; 0.553002957824355; 0.553002957824355; 0.5619299124666532; 0.563120546412355; 0.5655222348249326; 0.5655222348249326; 0.5655222348249326; 0.5682392297191953; 0.5696906826730043; 0.5710095678317721; 0.5710095678317721; 0.5710095678317721; 0.5710095678317721; 0.5710095678317721; 0.5710095678317721; 0.5710095678317721; 0.5768212166102149; 0.578835730221474; 0.582492855487907; 0.582492855487907; 0.5851527280548257; 0.5913651925298382; 0.5916904943304121; 0.5936773368594411; 0.5956632182199403; 0.5956632182199403; 0.5956632182199403; 0.6035970790768342; 0.6035970790768342; 0.6035970790768342; 0.6035970790768342; 0.6035970790768342; 0.6035970790768342; 0.6035970790768342; 0.6084642888478995; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.6124306570512981; 0.6150955455771212; 0.6189532555846575; 0.6196470808426647; 0.6218520979526325; 0.6222451141623291; 0.6222451141623291; 0.625027955184583; 0.6274540883972485; 0.6304655343580164; 0.6319938293757544; 0.6319938293757544; 0.6319938293757544; 0.652707626880454; 0.655573080043894; 0.656104947944719; 0.658736510383757; 0.6592493193460769; 0.6691893635307453; 0.6691893635307453; 0.6761967139251879; 0.6821087736355662; 0.6841967398409226; 0.6875373888914498; 0.6910672612216457; 0.6980473696540115; 0.701831040553294; 0.7096959691931399; 0.7149953523738256; 0.7240930522443176; 0.738047882208201; 0.7433468668038986; 0.7467967658079964; 0.7484342194688707; 0.7491018580851883; 0.7577323833810212; 0.7658980225613361; 0.7815030391631113; 0.7935206698366561; 0.7935206698366561; 0.8000044931629623; 0.8048897980514186; 0.8109066403528201; 0.8245140009975604; 0.8306551823873084; 0.8367216325123092; 0.8455269088566324; 0.9169959402964138,Breast Carcinoma; Esophagus Neoplasm; Marfan Syndrome; Mammary Neoplasms; Anaplastic Carcinoma; Breast Cancer; Liver Carcinoma; Schizophrenia; Carcinoma; Kidney Cancer; Kidney Neoplasm; Epilepsy; Parkinson Disease; Carcinoma Of The Head And Neck; Mental Disorders; Colorectal Cancer; Lung Carcinoma; Rheumatoid Arthritis; Mental Depression; Nervous System Disorder; Atherosclerotic Parkinsonism; Behavior Disorders; Psychosis; Colorectal Neoplasms; Hematologic Neoplasms; Benign Neoplasm; Neoplasms; Neuroblastoma; Lymphoblastic Leukemia; Adrenocortical Carcinoma; Malignant Neoplasm; Nervous System Diseases; Ulcerative Colitis; Diffuse Lymphoma; Inflammatory Bowel Disease; Congenital Heart Defects; Neutropenia,0.0075861267486594; 0.0102679590519094; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0402286636010764; 0.0520696613701797; 0.0531117779464085; 0.0534520155998091; 0.3094716280561038; 0.336287627428424; 0.3449614869411272; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4602028929328057; 0.4624858551053053; 0.4646409362700993; 0.5127628024019304; 0.5129298662020659; 0.525214105372123; 0.5973360026714207; 0.6420878824691651; 0.6990462534407934; 0.7300866884650863; 0.7662135194687344; 0.776786668801341; 0.8373515856057342,Renal pseudohypoaldosteronism type 1 ORPHA:171871; Low phospholipid-associated cholelithiasis ORPHA:69663; Progressive familial intrahepatic cholestasis type 3 ORPHA:79305; NON RARE IN EUROPE: Ulcerative colitis ORPHA:771,0.3762014630157917; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Human adenovirus 18 IVa2 protein (gene: IVa2); Human adenovirus 31 IVa2 protein (gene: IVa2); Human alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5); Macacine alphaherpesvirus 1 helicase-primase helicase subunit (gene: UL5); Human adenovirus B3 protein IVa2 (gene: IVa2); Cercopithecine betaherpesvirus 5 helicase-primase helicase subunit (gene: UL105); Human mastadenovirus B encapsidation protein IVa2 (gene: IVa2); Human mastadenovirus F encapsidation protein IVa2 (gene: IVa2); Human alphaherpesvirus 3 helicase-primase helicase subunit (gene: ORF55); Human herpesvirus 4 type 2 helicase-primase subunit BBLF4; Human adenovirus 43 encapsidation protein IVa2 (gene: IVa2); Human adenovirus 68 maturation protein IVA2 (gene: IVa2); Human adenovirus 46 IVa2; Monkeypox virus putative ATPase; Human adenovirus 61 pIVa2; Human adenovirus 6 maturation protein pIVa2 (gene: pIVa2); Human adenovirus 14 IVa2 protein (gene: IVa2); Human adenovirus 55 pIVa2 50.9 kDa protein; Human herpesvirus 3 strain Dumas helicase; Human adenovirus 21 maturation protein IVa2 (gene: IVa2); Human adenovirus 34 maturation protein IVa2 (gene: IVa2); Human adenovirus 35 IVa2; Human adenovirus 3+7 maturation protein IVA2 (gene: IVa2); Cowpox virus CPXV167 protein (gene: CPXV167 CDS); Human alphaherpesvirus 1 helicase-primase helicase subunit (gene: UL5); Human gammaherpesvirus 4 putative helicase (gene: BBLF4); Cercopithecine alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5); Human adenovirus 52 IVa2 (gene: IVa2); Human adenovirus 63 IVa2 protein (gene: IVa2); Human adenovirus 22 IVa2 (gene: IVa2); Human adenovirus 64 IVa2 protein; Human adenovirus D37 pIVa2 (gene: pIVa2); Human adenovirus Chiba_E086/2012 pIVa2 (gene: pIVa2); Human adenovirus 7d2 maturation protein IVA2 (gene: IVa2); Human adenovirus 50 maturation protein IVa2 (gene: IVa2),0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6481498905276316; 0.7079503198328393,,,,
ABCC2,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Malignant neoplasm of breast; Fibrosarcoma; Carcinogenesis; Malignant neoplasm of ovary; Hematopoietic Neoplasms; Epithelial ovarian cancer; Malignant neoplasm of prostate; Renal Cell Carcinoma; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Lymphoma; Pancreatic carcinoma; Biliary tract abnormality; Liver Cirrhosis, Experimental; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Biliary Tract Diseases; Colorectal Neoplasms; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Squamous cell carcinoma of esophagus; Liver carcinoma; Small cell carcinoma of lung; Cholestasis, Extrahepatic; Clear-cell metastatic renal cell carcinoma; Malignant neoplasm of large intestine; Carcinoma of bladder; Colonic Neoplasms; Liver neoplasms; Rheumatoid Arthritis; Sarcoma; Visual seizure; stage, ovarian epithelial cancer; Seizures; Malignant tumor of peritoneum; Lung Neoplasms; Connective Tissue Diseases; Adverse reaction to drug; Drug toxicity; Hepatoblastoma; B-Cell Lymphomas; Malignant neoplasm of lung; Diabetes Mellitus, Insulin-Dependent; Gastrointestinal Diseases; Hyperbilirubinemia; Childhood Acute Lymphoblastic Leukemia; Cholangiocarcinoma; Pregnancy in Diabetics; Carcinoma of lung; Complex partial seizures; Teratoma; Primary malignant neoplasm of lung; Progressive intrahepatic cholestasis (disorder); Adenocarcinoma of large intestine; Diabetes Mellitus, Non-Insulin-Dependent; Generalized seizures; Pancreatitis, Chronic; Nasopharyngeal carcinoma; Adrenocortical carcinoma; Seizures, Focal; Non-Small Cell Lung Carcinoma; Hypertensive disease; Leukemia, Myelocytic, Acute; Oculocerebrorenal Syndrome; HIV Infections; Alzheimer's Disease; Acute lymphocytic leukemia; Non-small cell lung cancer metastatic; Adenoma; Hyperbilirubinemia, Hereditary; Urine color abnormal; Bone marrow toxicity; Cholestasis of pregnancy; Malignant neoplasm of kidney; Epilepsies, Partial; Single Seizure; Seizures, Auditory; Seizures, Clonic; Seizures, Sensory; Seizures, Somatosensory; Vertiginous seizure; Atonic Absence Seizures; Generalized Absence Seizures; Gustatory seizure; Jacksonian Seizure; Non-epileptic convulsion; Nonepileptic Seizures; Olfactory seizure; Epilepsy; De Toni-Debre-Fanconi Syndrome; Renal carcinoma; Epileptic Seizures; Tonic Seizures; Convulsive Seizures; Refractory cancer; Jaundice, Chronic Idiopathic; Cholera Infantum; Fanconi Syndrome; Epileptic drop attack; Cholestasis; Drug Resistant Epilepsy; Multiple Myeloma; Convulsions; Female pattern alopecia (disorder); Oral Mucositis; Absence Seizures; Acquired Immunodeficiency Syndrome; Adenoma of large intestine; stage, non-small cell lung cancer; Pseudopelade; Lupus Erythematosus, Systemic; Simple Partial Status Epilepticus; Status Epilepticus, Subclinical; Complex Partial Status Epilepticus; Grand Mal Status Epilepticus; Non-Convulsive Status Epilepticus; Congestive heart failure; Jaundice, Obstructive; Adenocarcinoma of pancreas; Petit mal status; Severe diarrhea; Stomatitis; Functional Gastrointestinal Disorders; Status Epilepticus; leukemia; Myoclonic Seizures; Conjugated hyperbilirubinemia; Mesothelioma; Chronic kidney disease stage 5; Alopecia, Male Pattern; Pain; Gilbert Disease (disorder); Tonic - clonic seizures; Diarrhea; Primary biliary cirrhosis; Biliary Cirrhosis, Secondary; Neutropenia; Intrahepatic Cholestasis; Hepatitis A; Salmonella infections; nervous system disorder; Kidney Failure, Chronic; Adenocarcinoma, Clear Cell; Fatty Liver; Drug Allergy; Renal tubular disorder; Pancreatic Diseases; Epilepsy, Generalized; Hepatitis, Toxic; Chemical and Drug Induced Liver Injury; Chemically-Induced Liver Toxicity; Drug-Induced Acute Liver Injury; Heart Diseases; Fatty Liver, Alcoholic; Androgenetic Alopecia; Hepatitis, Drug-Induced; Non-alcoholic Fatty Liver Disease; Icterus; Leukopenia; Cholecystolithiasis; Drug-Induced Liver Disease; Spina Bifida; Fanconi Anemia; Cholestasis in newborn; Hepatitis C; Liver diseases; Congenital contractural arachnodactyly; Hepatitis; Alopecia; Cholelithiasis; Biliary cirrhosis; High density lipoprotein measurement; Virus Diseases",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0334891258932371; 0.0387439397151409; 0.0569142010728473; 0.0648809611869375; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0747863377072194; 0.0773771948186562; 0.0775520919998773; 0.0775520919998773; 0.0827744840860166; 0.084286432100041; 0.0891725280554336; 0.0919714360040484; 0.095319386034013; 0.1193558174333938; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1454373331146953; 0.1454373331146953; 0.1537760235124317; 0.1537760235124317; 0.1735868515093891; 0.1874735657311888; 0.2053083986145698; 0.2062010908869036; 0.2062010908869036; 0.2139814021986384; 0.223747154820789; 0.223747154820789; 0.2522264785494494; 0.2522264785494494; 0.2714542429024338; 0.2714542429024338; 0.2980670559114652; 0.2980670559114652; 0.3099246715197673; 0.340892538685018; 0.3638414818541592; 0.3663130598151661; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4037249857069285; 0.4100901006059349; 0.4100901006059349; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4186011760974318; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.4304973629098372; 0.4325044517055656; 0.4335751357405352; 0.4335751357405352; 0.4459714599189374; 0.4459714599189374; 0.4506578937113162; 0.4588513406515081; 0.4615352570710579; 0.4615352570710579; 0.4635211539849193; 0.4704594475773637; 0.4852430673532381; 0.4871698998714747; 0.4906258721078565; 0.4919605488358906; 0.4923669467696064; 0.4923669467696064; 0.4981941174985421; 0.498994845947585; 0.5019670090704682; 0.5090214163899865; 0.5188223685230745; 0.5276472086074249; 0.5299466034567416; 0.5299466034567416; 0.533913711453195; 0.5359212109443033; 0.5619299124666532; 0.5885228491254589; 0.5916904943304121; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.6189532555846575; 0.625027955184583; 0.625112405383346; 0.6274540883972485; 0.6878314377608323; 0.6910672612216457; 0.7045203904267408; 0.7053337831155875; 0.7156410971578294; 0.7169459458481418; 0.7337030585693298; 0.7467967658079964; 0.7484342194688707; 0.7533159919746161; 0.8178117518835931; 0.8470105161823033; 0.8913309410682808; 0.9692165430561782,"Esophagus Neoplasm; Hyperbilirubinemia; Cholestasis; Carcinoma Of The Head And Neck; Pseudoxanthoma Elasticum; Colorectal Cancer; Cholestasis Of Pregnancy; Rheumatoid Arthritis; Nervous System Disorder; Functional Gastrointestinal Disorders; Colorectal Neoplasms; Gastrointestinal Diseases; Pseudopelade; Conjugated Hyperbilirubinemia; Non-Alcoholic Fatty Liver Disease; Jacksonian Seizure; Seizure; Clonic Seizures; Biliary Cholangitis; Heart Diseases; Androgenetic Alopecia; Hypotonic Seizures; Alopecia, Male Pattern; Nonconvulsive Status Epilepticus; Petit Mal Status; Grand Mal Status Epilepticus; Biliary Cirrhosis; Status Epilepticus; Alopecia",0.0102679590519094; 0.3094716280561038; 0.336287627428424; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4646409362700993; 0.504364324740411; 0.5234357475824973; 0.5576425853515448; 0.5762801672039276; 0.6030919130927346; 0.6030919130927346; 0.6329251700753155; 0.6344671175966539; 0.6524705037929849; 0.6798971073653743; 0.6798971073653743; 0.6798971073653743; 0.6899894525110877; 0.7049836926927165; 0.7167438233451096,Autosomal recessive infantile hypercalcemia ORPHA:300547; Glutamate-cysteine ligase deficiency ORPHA:33574; Dubin-Johnson syndrome ORPHA:234; Hawkinsinuria ORPHA:2118; Tyrosinemia type 3 ORPHA:69723,0.0083045131203191; 0.0586579655822394; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782,Human adenovirus 18 IVa2 protein (gene: IVa2); Human adenovirus 31 IVa2 protein (gene: IVa2); Human alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5); Macacine alphaherpesvirus 1 helicase-primase helicase subunit (gene: UL5); Human adenovirus B3 protein IVa2 (gene: IVa2); Cercopithecine betaherpesvirus 5 helicase-primase helicase subunit (gene: UL105); Human mastadenovirus B encapsidation protein IVa2 (gene: IVa2); Human mastadenovirus F encapsidation protein IVa2 (gene: IVa2); Human alphaherpesvirus 3 helicase-primase helicase subunit (gene: ORF55); Human mastadenovirus D encapsidation protein IVa2 (gene: IVa2); Human adenovirus D10 pIVa2 (gene: pIVa2); Human herpesvirus 4 type 2 helicase-primase subunit BBLF4; Human adenovirus 68 maturation protein IVA2 (gene: IVa2); Human adenovirus 16 maturation protein IVA2 (gene: IVa2); Human adenovirus 6 maturation protein pIVa2 (gene: pIVa2); Human mastadenovirus A IVa2; Human adenovirus 14 IVa2 protein (gene: IVa2); Human adenovirus 55 pIVa2 50.9 kDa protein; Human herpesvirus 3 strain Dumas helicase; Titi monkey adenovirus ECC-2011 IVa2; Human adenovirus 21 maturation protein IVa2 (gene: IVa2); Human adenovirus 34 maturation protein IVa2 (gene: IVa2); Human adenovirus 35 IVa2; Cercopithecine alphaherpesvirus 2 DNA replication origin-binding helicase (gene: UL9); Human adenovirus 3+7 maturation protein IVA2 (gene: IVa2); Human adenovirus 11a IVa2; Human adenovirus 1 IVa2; Human adenovirus 5 IVa2; Human mastadenovirus C encapsidation protein IVa2 (gene: IVa2); Human adenovirus 2 IVa2; Human adenovirus 41 IVa2; Macacine alphaherpesvirus 1 DNA replication origin-binding helicase (gene: UL9); Human adenovirus 11+34 encapsidation protein IVa2 (gene: IVa2); Papiine alphaherpesvirus 2 DNA replication origin-binding helicase (gene: UL9),0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6386053036162835; 0.6462089477181691; 0.6532977594572624; 0.7748546750678369,,,,
ABHD14B,Neoplasm Metastasis,0.0648809611869375,,,Carnitine palmitoyl transferase 1A deficiency ORPHA:156; Acatalasemia ORPHA:926; Dominant hypophosphatemia with nephrolithiasis or osteoporosis ORPHA:244305; 3-hydroxy-3-methylglutaric aciduria ORPHA:20; Acrodermatitis enteropathica ORPHA:37; B4GALT1-CDG ORPHA:79332; Mucopolysaccharidosis type 7 ORPHA:584; Short chain acyl-CoA dehydrogenase deficiency ORPHA:26792; Carnitine-acylcarnitine translocase deficiency ORPHA:159; Ethylmalonic encephalopathy ORPHA:51188; Tyrosinemia type 1 ORPHA:882; Familial porphyria cutanea tarda ORPHA:443062,0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Yaba monkey tumor virus monoglyceride lipase,0.6362779693488597,In vitro,0.35,Homo sapiens,Homo sapiens
ACBD7,,,,,15q13.3 microdeletion syndrome ORPHA:199318; NON RARE IN EUROPE: Non rare obesity ORPHA:521399; Bradyopsia ORPHA:75374; Male infertility with azoospermia or oligozoospermia due to single gene mutation ORPHA:399805; L-2-hydroxyglutaric aciduria ORPHA:79314; Macular corneal dystrophy ORPHA:98969,0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.4548046963946745; 0.6239678957896782; 0.7068064785325423,"Hepatovirus A 3D mature peptide; Human enterovirus C104 3D; Human parainfluenza virus 4b nucleoprotein; Echovirus E14 3D; Echovirus E11 3D; Echovirus E4 3D; Coxsackievirus A22 3d; Enterovirus C109 3D; Coxsackievirus A1 3D; Enterovirus B 3D; Enterovirus H 3D; Echovirus 9 strain Hill polyprotein region 11; Echovirus E32 3D; Echovirus E17 3D; Yaba monkey tumor virus 72L; Human enterovirus 94 3D; Echovirus E3 3D; Enterovirus D 3D-POL; Echovirus 9 strain Barty polymerase; Echovirus E6 3D; Echovirus E21 3D; Machupo mammarenavirus L protein; Vaccinia virus ser/thr kinase (gene: B1R); Vaccinia virus Ankara Serine/threonine-protein kinase; Lassa mammarenavirus L protein; Horsepox virus HSPV179 (Serine/Threonine protein kinase, Vaccinia Related Kinase); Norovirus Hu/GII.2/HS255/2011/USA NTPase (gene: POL); Human rhinovirus QCE 3D; Human T-cell leukemia virus type I p21 TM (gene: env); Human rhinovirus A65 3D; Human rhinovirus A71 3D; Human immunodeficiency virus 2 vpx protein; Human rhinovirus A20 3D; Human rhinovirus A80 3D; Influenza A virus (A/California/04/2009(H1N1)) polymerase PB1 (gene: PB1); Influenza A virus (A/California/07/2009(H1N1)) polymerase PB1 (gene: PB1); Influenza A virus (A/Korea/426/1968(H2N2)) PB1 polymerase subunit (gene: PB1); Influenza A virus (A/New York/392/2004(H3N2)) polymerase PB1 (gene: PB1); Influenza A virus (A/New York/599/1996(H3N2)) polymerase PB1 (gene: PB1); Influenza A virus (A/New York/602/1996(H3N2)) polymerase PB1 (gene: PB1); Influenza A virus (A/Northern Territory/60/1968(H3N2)) polymerase PB1 (gene: PB1); Influenza A virus (A/Puerto Rico/8/1934(H1N1)) polymerase PB1 (gene: PB1); Influenza A virus (A/Shanghai/02/2013(H7N9)) polymerase PB1 (gene: PB1); Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) polymerase (gene: PB1); Human enterovirus C118 3D; Influenza A virus (A/Korea/426/1968(H2N2)) nonstructural protein 1 (gene: NS1); Junin mammarenavirus L protein; Monkeypox virus cowpox A-type inclusion protein; Guanarito mammarenavirus L protein; Variola virus hypothetical protein (gene: A28L); Influenza B virus nonstructural protein 1 (gene: NS1); Influenza B virus (B/Memphis/12/97) NS protein; Horsepox virus HSPV011c (ankyrin repeats); Influenza A virus (A/New York/599/1996(H3N2)) matrix protein 1 (gene: M1); Influenza A virus (A/New York/602/1996(H3N2)) matrix protein 1 (gene: M1); Influenza A virus (A/Northern Territory/60/1968(H3N2)) matrix protein 1 (gene: M1); Influenza A virus (A/Korea/426/1968(H2N2)) membrane protein M1 (gene: M1); Influenza A virus (A/Shanghai/02/2013(H7N9)) matrix protein 1 (gene: M1); Vaccinia virus cowpox A-type inclusion protein; Yaba-like disease virus 148R protein (gene: 148R)",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6806291584193672; 0.7017760963861425; 0.7017760963861425; 0.830387084488226; 0.8373747313517419; 0.8373747313517419; 0.8373747313517419; 0.8390943852085586; 0.8458935424065495; 0.8834254233868516; 0.9055720084468104,,,,
ACSL5,"Colorectal Carcinoma; Epithelioma; Colorectal Cancer; Adenocarcinoma; Carcinogenesis; Glioma; Glioblastoma; Malignant Neoplasms; ADENOMAS AND ADENOCARCINOMAS; Neoplasms; Malignant Glioma; Arthritis, Adjuvant-Induced; Arthritis, Collagen-Induced; Arthritis, Experimental; Adenoma; Anaplasia; Lupus Erythematosus, Systemic; Nonalcoholic Steatohepatitis; Steatohepatitis; Platelet mean volume determination (procedure); Obesity; Fatty Liver; Metaplasia; Hyperlipidemia; Adenocarcinoma, Endometrioid",0.0034602840073026; 0.0149002095788623; 0.0149315928814189; 0.0155921563748247; 0.0228075668512991; 0.0739788831250619; 0.0745502070959292; 0.0991201145654548; 0.1193558174333938; 0.2714542429024338; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.4213286052188015; 0.4335751357405352; 0.4906258721078565; 0.4981941174985421; 0.5140447474168605; 0.533913711453195; 0.5710095678317721; 0.6035970790768342; 0.625027955184583,Colorectal Cancer,0.4286813331685578,Galactose mutarotase deficiency ORPHA:570422; Acatalasemia ORPHA:926; Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia ORPHA:572428; Marfan syndrome type 2 ORPHA:284973; Proteasome-associated autoinflammatory syndrome ORPHA:324977; Imerslund-Grasbeck syndrome ORPHA:35858; Coffin-Lowry syndrome ORPHA:192; Symptomatic form of Coffin-Lowry syndrome in female carriers ORPHA:276630; Adenosine monophosphate deaminase deficiency ORPHA:45; Hereditary renal hypouricemia ORPHA:94088; Thyroid hypoplasia ORPHA:95720; Squamous cell carcinoma of the esophagus ORPHA:99977,0.1590470395003315; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,In vitro,0.35,chemical synthesis,Homo sapiens
ACTA2,"Mammary Neoplasms; Breast Carcinoma; Adenocarcinoma; Malignant neoplasm of breast; Mammary Neoplasms, Human; Neoplasm Metastasis; Renal Cell Carcinoma; AORTIC VALVE DISEASE 2; Liver Cirrhosis, Experimental; Liver Cirrhosis; Osteosarcoma; Chronic Lymphocytic Leukemia; Brain Aneurysm; Dilatation of the cerebral artery; Nephrogenic Fibrosing Dermopathy; Cholestasis, Extrahepatic; Myocardial Infarction; Colonic Neoplasms; Marfan Syndrome; Intracranial Aneurysm; Systemic Scleroderma; Seizures; Connective Tissue Diseases; Malignant tumor of colon; Bicuspid aortic valve; Aortic Aneurysm, Thoracic; Heart Septal Defects; Ehlers-Danlos Syndrome; Ischemic stroke; Aortic root dilatation; Metastatic malignant neoplasm to brain; Endometriosis; Pulmonary arterial hypertension; Cakut; Cerebrovascular Disorders; Fetal Growth Retardation; Kidney Diseases; Cerebral arterial aneurysm; Hypertensive disease; Aortic aneurysm and dissection; Mydriasis; Aortic Aneurysm, Thoracoabdominal; Ascending aorta dilatation; Fibrosis, Liver; Coronary heart disease; acute aortic dissection; Aortic Aneurysm; Telangiectasis; Moyamoya disease 1; Focal glomerulosclerosis; Dupuytren Contracture; Epilepsy; Meningitis, Cryptococcal; Abnormality of the cerebral vasculature; Dyspnea on exertion; Moyamoya Disease; Ischemia; Endometrioma; Cerebral Aneurysm; Congenital aneurysm of ascending aorta; Copper-Overload Cirrhosis; Cerebrovascular accident; Ascending aortic dissection; Cystic medial necrosis of aorta; Descending aortic dissection; Patent ductus arteriosus - persisting type; Vascular Diseases; Dyspnea, Paroxysmal; Abnormality of the iris; Obstructive Ureterocele; Arteriopathic disease; Adenocarcinoma of lung, stage IV; Dilated ventricles (finding); Psoriasis; Impaired left ventricular function; Spider Veins; Cryptogenic Chronic Hepatitis; Dupuytren's Disease; Aneurysm; Aortic Diseases; Chronic active hepatitis; Tachypnea; Cardiomyopathy, Familial Idiopathic; Hyalinosis, Segmental Glomerular; Atrial Septal Defects; Myopathies, Nemaline; Chronic Persistent Hepatitis; Congenital malrotation of intestine; Increase in blood pressure; Crohn Disease; Ulcerative Colitis; Coronary Arteriosclerosis; Adenocarcinoma of lung (disorder); Dull intelligence; Low intelligence; Familial (FPAH); Congenital Heart Defects; Dissection of aorta; Left-Sided Heart Failure; Poor school performance; Cutis marmorata; Idiopathic pulmonary arterial hypertension; Aortic Valve Insufficiency; Mental deficiency; Mental Retardation; Cardiomegaly; Patent ductus arteriosus; Ankylosing spondylitis; Cardiomyopathy, Hypertrophic, Familial; Chest Pain; Cardiomyopathies; Coronary Artery Disease; Liver diseases; Cryptorchidism; Cholangitis, Sclerosing; Intellectual Disability; Hepatitis, Chronic; Hypertrophic Cardiomyopathy; Liver Dysfunction",0.0034602840073026; 0.0042545616049287; 0.0155921563748247; 0.0191435238361999; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0745502070959292; 0.0747863377072194; 0.0773771948186562; 0.1029977559100099; 0.1147307578771389; 0.1253114324938153; 0.1254380558571286; 0.1254380558571286; 0.13167400689206; 0.1352936728187231; 0.1454373331146953; 0.1735868515093891; 0.1735868515093891; 0.1900258729042946; 0.2053083986145698; 0.2139814021986384; 0.223747154820789; 0.2687300999130421; 0.2980670559114652; 0.3044782497745498; 0.3283839486480793; 0.3486533561309259; 0.3508665345292502; 0.3638414818541592; 0.383941725017158; 0.3925783478421996; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.4028066164685291; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.425419812815905; 0.425992946703162; 0.4304973629098372; 0.4396723023384634; 0.4459714599189374; 0.4459714599189374; 0.4506578937113162; 0.4561717689698902; 0.4564472886428772; 0.4615352570710579; 0.4615352570710579; 0.4704594475773637; 0.4753011022966241; 0.4757083758251088; 0.4906258721078565; 0.4906258721078565; 0.4906258721078565; 0.4923669467696064; 0.4981941174985421; 0.5001612228394569; 0.5140447474168605; 0.51550637274795; 0.5300976305939776; 0.5300976305939776; 0.533913711453195; 0.533913711453195; 0.5393787854381349; 0.5568517196017908; 0.5610226870913673; 0.5619299124666532; 0.5655222348249326; 0.5683976277847906; 0.6035970790768342; 0.6319938293757544; 0.6332132835539771; 0.6334536292962906; 0.6446807314576214; 0.655573080043894; 0.6656356363792992; 0.6989462176022242; 0.7240930522443176; 0.7337030585693298; 0.7417321496240817; 0.8244780048843707; 0.8352623613787349; 0.8867784885819414; 0.89450044231149; 0.9114432287644624,"Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Lymphocytic Leukemia; Pulmonary Fibrosis; Alveolitis; Thoracic Aortic Aneurysm And Aortic Dissection; Endometriosis; Nasopharyngeal Carcinoma; Subarachnoid Hemorrhage; Cholestasis; Connective Tissue Disease; Liver Cirrhosis; Glomerular Hyalinosis; Pulmonary Arterial Hypertension; Aortic Valve Insufficiency; Ischemic Stroke; Lung Cancer; Lung Carcinoma; Aortic Aneurysm; Copper-Overload Cirrhosis; Transient Ischemic Attack; Liver Fibrosis; Nephrosclerosis; Descending Aortic Dissection; Dyspnea, Paroxysmal; Hypertension; Bicuspid Aortic Valve; Congenital Malrotation Of Intestine; Colonic Neoplasms; Scoliosis; Coronary Arteriosclerosis; Peripheral Arterial Stenosis; Endometrioma; Scleroderma; Arachnodactyly; Moyamoya Disease; Myocardial Infarction; Glomerulosclerosis; Kidney Disease; Patent Ductus Arteriosus; Ulcerative Colitis; Cholangitis; Ankylosing Spondylitis; Cutis Marmorata; Psoriasis; Crohn Disease; Mental Retardation; Cryptorchidism",0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0487679768343083; 0.0654534781440596; 0.1025546857843372; 0.1641294276675242; 0.2187610616307245; 0.2278592962769385; 0.2627224344149009; 0.336287627428424; 0.425341435586089; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4402141802500753; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4646409362700993; 0.4809179010794786; 0.4875380732267193; 0.4875380732267193; 0.4968320901822731; 0.5036845352940079; 0.5162067638232762; 0.525214105372123; 0.555382961603519; 0.5632819212593052; 0.5924794904332197; 0.6420878824691651; 0.6596918765832213; 0.6990462534407934; 0.6999859437625926; 0.7049836926927165; 0.7083841747135766; 0.7184623115342476; 0.7414460416900516; 0.7729545590606223; 0.776786668801341,"Familial thoracic aortic aneurysm and aortic dissection ORPHA:91387; Arthrochalasia Ehlers-Danlos syndrome ORPHA:1899; Ehlers-Danlos/osteogenesis imperfecta syndrome ORPHA:230857; Osteogenesis imperfecta type 1 ORPHA:216796; Periodontal Ehlers-Danlos syndrome ORPHA:75392; Acrogeria ORPHA:2500; Familial abdominal aortic aneurysm ORPHA:86; Familial retinal arterial macroaneurysm ORPHA:284247; Familial visceral myopathy ORPHA:2604; Myopathic intestinal pseudoobstruction ORPHA:104077; Pycnodysostosis ORPHA:763; Vascular Ehlers-Danlos syndrome ORPHA:286; Familial calcium pyrophosphate deposition ORPHA:1416; Isolated ectopia lentis ORPHA:1885; Congenital glaucoma ORPHA:98976; Cardiac-valvular Ehlers-Danlos syndrome ORPHA:230851; EMILIN-1-related connective tissue disease ORPHA:485418; LIMS2-related limb-girdle muscular dystrophy ORPHA:466801; Primary dystonia, DYT27 type ORPHA:464440; Autosomal dominant cutis laxa ORPHA:90348; Geleophysic dysplasia ORPHA:2623; Weill-Marchesani syndrome ORPHA:3449; Familial cerebral saccular aneurysm ORPHA:231160; Autosomal recessive cutis laxa type 1 ORPHA:90349; Acroosteolysis-keloid-like lesions-premature aging syndrome ORPHA:363665; Chronic myeloproliferative disease, unclassifiable ORPHA:86830; Dermatosparaxis Ehlers-Danlos syndrome ORPHA:1901; Familial episodic pain syndrome with predominantly upper body involvement ORPHA:391389; Lethal arteriopathy syndrome due to fibulin-4 deficiency ORPHA:314718; Multisystemic smooth muscle dysfunction syndrome ORPHA:404463; Myeloid/lymphoid neoplasm associated with PDGFRA rearrangement ORPHA:168947; Myeloid/lymphoid neoplasm associated with PDGFRB rearrangement ORPHA:168950; Pyle disease ORPHA:3005; Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome ORPHA:477831; Juvenile glaucoma ORPHA:98977; Hereditary hemorrhagic telangiectasia ORPHA:774; Primary hypereosinophilic syndrome ORPHA:314950; Alpha-sarcoglycan-related  limb-girdle muscular dystrophy R3 ORPHA:62; Congenital cornea plana ORPHA:53691; Congenital stromal corneal dystrophy ORPHA:101068; Delta-sarcoglycan-related  limb-girdle muscular dystrophy R6 ORPHA:219; Desminopathy ORPHA:98909; Familial aortic dissection ORPHA:229; Hereditary sensorimotor neuropathy with hyperelastic skin ORPHA:280598; Holt-Oram syndrome ORPHA:392; Keutel syndrome ORPHA:85202; Megacystis-microcolon-intestinal hypoperistalsis syndrome ORPHA:2241; Multiple epiphyseal dysplasia type 1 ORPHA:93308; NON RARE IN EUROPE: Patent arterial duct ORPHA:706; Neurogenic scapuloperoneal syndrome, Kaeser type ORPHA:85146; Pseudoachondroplasia ORPHA:750; Supravalvular aortic stenosis ORPHA:3193; Moyamoya disease ORPHA:2573",0.0902044104910482; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3826134188846508; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.6279395134845649; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Salivirus NG-J1 3D; Ectromelia virus ERPV profilin-like protein; Variola virus hypothetical protein (gene: A47R); Monkeypox virus profilin-like protein; Monkeypox virus Zaire-96-I-16 A42R (gene: A42R); Horsepox virus HSPV164 (Profilin); Vaccinia virus profilin-like protein (gene: A42R); Vaccinia virus Ankara Profilin-1-like; Cowpox virus CPXV179 protein (gene: CPXV179 CDS); Human T-cell leukemia virus type I p21 TM (gene: env); Human immunodeficiency virus envelope glycoprotein (gene: env); Human alphaherpesvirus 2 tegument protein VP22 (gene: UL49); Human alphaherpesvirus 1 tegument protein VP22 (gene: UL49),0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597,Homo sapiens HEK293 embryonic kidney cell;In vitro;yeasx,0.35;0.37,Dengue virus 2;Homo sapiens;chemical synthesis;hhv11,Homo sapiens;Yersinia pestis
ADAM15,Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Epithelioma; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Malignant neoplasm of prostate; Neoplasm Metastasis; Degenerative polyarthritis; inflammatory joint disease; Prostate carcinoma; Stage IV Bladder Cancer AJCC v6; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Colon Carcinoma; Carcinoma of bladder; Rheumatoid Arthritis; Prostatic Neoplasms; Metastasis from malignant tumor of prostate; Chondrosarcoma; Metastatic Prostate Carcinoma; Malignant Squamous Cell Neoplasm; Carcinoma of lung; Cardiac dilatation; Genitourinary Cancer; Inflammatory Bowel Diseases; Anaplasia; Atrial Fibrillation; Pathologic Neovascularization; Osteophyte; Arteriosclerosis; Atherosclerosis; Bloom Syndrome,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0569142010728473; 0.0648809611869375; 0.0739788831250619; 0.0745502070959292; 0.0773771948186562; 0.084286432100041; 0.084286432100041; 0.0891725280554336; 0.1062239757831962; 0.13167400689206; 0.1537760235124317; 0.223747154820789; 0.2454426921531692; 0.2643145809900195; 0.2643145809900195; 0.3104232675696299; 0.3663130598151661; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.3941558617476422; 0.4192169590514327; 0.4459714599189374; 0.5019670090704682; 0.5393787854381349; 0.6802335864704374,Lupus Erythematosus,0.5087473896242481,"Microduplication Xp11.22p11.23 syndrome ORPHA:217377; Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome ORPHA:397933; Early-onset autosomal dominant Alzheimer disease ORPHA:1020; 5-oxoprolinase deficiency ORPHA:33572; Autosomal dominant Charcot-Marie-Tooth disease type 2V ORPHA:447964; CLN10 disease ORPHA:228337; Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome ORPHA:508476; Fetal Gaucher disease ORPHA:85212; Gaucher disease type 2 ORPHA:77260; Gaucher disease type 3 ORPHA:77261; Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome ORPHA:2072; Glycogen storage disease due to acid maltase deficiency, infantile onset ORPHA:308552; Glycogen storage disease due to acid maltase deficiency, late-onset ORPHA:420429; Glycogen storage disease due to muscle and heart glycogen synthase deficiency ORPHA:137625; NON RARE IN EUROPE: Parkinson disease ORPHA:319705; Naxos disease ORPHA:34217; Sanfilippo syndrome type B ORPHA:79270; Gaucher disease type 1 ORPHA:77259; NON RARE IN EUROPE: Paget disease of bone ORPHA:280110; Idiopathic pulmonary fibrosis ORPHA:2032; Autosomal recessive spastic paraplegia type 76 ORPHA:488594; Connective tissue disorder due to lysyl hydroxylase-3 deficiency ORPHA:300284; Intellectual disability-seizures-hypophosphatasia-ophthalmic-skeletal anomalies syndrome ORPHA:369837; Jalili syndrome ORPHA:1873; MAN1B1-CDG ORPHA:397941; Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome ORPHA:300333; Neurogenic arthrogryposis multiplex congenita ORPHA:1143; Oxoglutaric aciduria ORPHA:31; Severe congenital hypochromic anemia with ringed sideroblasts ORPHA:300298; Very long chain acyl-CoA dehydrogenase deficiency ORPHA:26793; Autosomal recessive progressive external ophthalmoplegia ORPHA:254886; Epidermolysis bullosa simplex with pyloric atresia ORPHA:158684; Multiple endocrine neoplasia type 1 ORPHA:652; Acyl-CoA dehydrogenase 9 deficiency ORPHA:99901; Epidermolysis bullosa simplex with muscular dystrophy ORPHA:257; PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement ORPHA:79401; Plectin-related  limb-girdle muscular dystrophy R17 ORPHA:254361",0.1590470395003315; 0.1590470395003315; 0.1739455566145445; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.43936148647173; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6279395134845649; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,yeasx,0.37,Homo sapiens,Bacillus anthracis
ADAMTS14,"Colorectal Carcinoma; Colorectal Cancer; Degenerative polyarthritis; Liver carcinoma; Multiple Sclerosis; EHLERS-DANLOS SYNDROME, DERMATOSPARAXIS TYPE; Asthma",0.0034602840073026; 0.0149315928814189; 0.0739788831250619; 0.095319386034013; 0.2835142372342932; 0.3933196962529684; 0.3933196962529684,Asthma,0.504364324740411,Hereditary sensory and autonomic neuropathy type 5 ORPHA:64752,0.3762014630157917,,,,,,
ADAMTS15,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Degenerative polyarthritis; Colon Carcinoma; Intracranial Aneurysm; Malignant tumor of colon; Prostatic Neoplasms; Airway Obstruction,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0739788831250619; 0.1062239757831962; 0.1735868515093891; 0.223747154820789; 0.223747154820789; 0.5655222348249326,Colorectal Cancer,0.4286813331685578,"SIX2-related frontonasal dysplasia ORPHA:488437; Peters anomaly ORPHA:708; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Early-onset nuclear cataract ORPHA:98991; Craniosynostosis, Boston type ORPHA:1541; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Parietal foramina with clavicular hypoplasia ORPHA:251290; Congenital cataract microcornea with corneal opacity ORPHA:289499; Dermatofibrosarcoma protuberans ORPHA:31112; Tetralogy of Fallot ORPHA:3303; Microphthalmia with brain and digit anomalies ORPHA:139471; Autosomal recessive Robinow syndrome ORPHA:1507; Postaxial polydactyly type B ORPHA:93335; Familial isolated restrictive cardiomyopathy ORPHA:75249; Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:136; Lateral meningocele syndrome ORPHA:2789; Enlarged parietal foramina ORPHA:60015; Hyperostosis corticalis generalisata ORPHA:3416; Acrocallosal syndrome ORPHA:36; NON RARE IN EUROPE: Ventricular septal defect ORPHA:1480; Brachydactyly type B1 ORPHA:572385; Familial bicuspid aortic valve ORPHA:402075; Early-onset posterior polar cataract ORPHA:98993; Craniofrontonasal dysplasia ORPHA:1520",0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0277610005156803; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0640416108792758; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3775879467205478; 0.4045231980457672; 0.6239678957896782,,,,,,
ADPRHL1,,,,,"Familial isolated restrictive cardiomyopathy ORPHA:75249; Amish nemaline myopathy ORPHA:98902; Cataract-glaucoma syndrome ORPHA:162; Familial progressive cardiac conduction defect ORPHA:871; Adenylosuccinate synthetase-like 1-related distal myopathy ORPHA:482601; Congenital fiber-type disproportion myopathy ORPHA:2020; Fetal akinesia deformation sequence ORPHA:994; NON RARE IN EUROPE: Familial isolated hypertrophic cardiomyopathy ORPHA:155; Familial isolated dilated cardiomyopathy ORPHA:154; Congenital myopathy with excess of thin filaments ORPHA:98904; Distal myopathy, Tateyama type ORPHA:488650; Isolated asymptomatic elevation of creatine phosphokinase ORPHA:206599; Late-onset distal myopathy, Markesbery-Griggs type ORPHA:98912; Progressive scapulohumeroperoneal distal myopathy ORPHA:447977; Rippling muscle disease ORPHA:97238; Zebra body myopathy ORPHA:97240; Glycogen storage disease due to muscle phosphorylase kinase deficiency ORPHA:715; Rigid spine syndrome ORPHA:97244; Childhood-onset nemaline myopathy ORPHA:171439",0.0640416108792758; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.6239678957896782; 0.6279395134845649; 0.6279395134845649; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
AFAP1L2,Colorectal Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Malignant neoplasm of stomach; Carcinogenesis; Squamous cell carcinoma of esophagus; Malignant neoplasm of large intestine; Neoplasms; Malignant neoplasm of lung; Carcinoma of lung; Thyroid Neoplasm; Primary malignant neoplasm of lung; Papillary thyroid carcinoma; Thyroid carcinoma; Chronic Obstructive Airway Disease,0.0034602840073026; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991; 0.0919714360040484; 0.13167400689206; 0.2714542429024338; 0.2714542429024338; 0.3663130598151661; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3941558617476422; 0.5049674142533507,Carcinoma,0.0534520155998091,Bilateral frontoparietal polymicrogyria ORPHA:101070,0.0586579655822394,,,,,,
ALDH3B1,"Renal Cell Carcinoma; Hallucinations; Diabetes Mellitus, Non-Insulin-Dependent; Schizophrenia; Paranoid Schizophrenia",0.0648809611869375; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.5090214163899865,Schizophrenia; Paranoid Schizophrenia,0.0531117779464085; 0.4560460337187313,"Mucopolysaccharidosis type 4A ORPHA:309297; Carnitine palmitoyl transferase 1A deficiency ORPHA:156; Cathepsin A-related arteriopathy-strokes-leukoencephalopathy ORPHA:575553; Galactosialidosis ORPHA:351; Hypocalcemic vitamin D-resistant rickets ORPHA:93160; Embryonal rhabdomyosarcoma ORPHA:99757; Mitochondrial DNA depletion syndrome, myopathic form ORPHA:254875; Overgrowth-macrocephaly-facial dysmorphism syndrome ORPHA:137634; Tumor necrosis factor receptor 1 associated periodic syndrome ORPHA:32960; Glycogen storage disease due to liver glycogen phosphorylase deficiency ORPHA:369; Multiple sulfatase deficiency ORPHA:585; NON RARE IN EUROPE: Hemochromatosis type 1 ORPHA:139498; Sporadic porphyria cutanea tarda ORPHA:443057; Symptomatic form of hemochromatosis type 1 ORPHA:465508",0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782,,,Homo sapiens HEK293T embryonic kidney cell;Homo sapiens HepaRG hepatoma cell;yeasx,0.35;0.4;0.56,Hepatitis delta virus;Homo sapiens;SARS-CoV-2,Homo sapiens
ALKBH6,,,,,Autosomal dominant spondylocostal dysostosis ORPHA:1797,0.7068064785325423,,,,,,
AMOTL2,Glioblastoma; Colon Carcinoma; Malignant tumor of colon,0.0745502070959292; 0.1062239757831962; 0.223747154820789,,,"Atrial septal defect, ostium primum type ORPHA:99106; Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; SIX2-related frontonasal dysplasia ORPHA:488437; Auriculocondylar syndrome ORPHA:137888; Peters anomaly ORPHA:708; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; Severe generalized junctional epidermolysis bullosa ORPHA:79404; 20p12.3 microdeletion syndrome ORPHA:261295; Chondrosarcoma ORPHA:55880; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Greig cephalopolysyndactyly syndrome ORPHA:380; Isolated hyperchlorhidrosis ORPHA:542657; Kindler epidermolysis bullosa ORPHA:2908; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Ulnar-mammary syndrome ORPHA:3138; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Branchiootic syndrome ORPHA:52429; Myelodysplastic syndrome ORPHA:52688; Papillary renal cell carcinoma ORPHA:319298; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Rieger anomaly ORPHA:91483; Brachydactyly type A2 ORPHA:93396; Unverricht-Lundborg disease ORPHA:308; Waardenburg syndrome type 2 ORPHA:895; Early-onset nuclear cataract ORPHA:98991; Bruck syndrome ORPHA:2771; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; CHST3-related skeletal dysplasia ORPHA:263463; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Craniosynostosis, Boston type ORPHA:1541; Diaphanospondylodysostosis ORPHA:66637; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; Hereditary neuropathy with liability to pressure palsies ORPHA:640; Hereditary papillary renal cell carcinoma ORPHA:47044; Ischiovertebral syndrome ORPHA:85200; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Mandibulofacial dysostosis with alopecia ORPHA:443995; Myopathic Ehlers-Danlos syndrome ORPHA:536516; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Nance-Horan syndrome ORPHA:627; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Oculocutaneous albinism type 3 ORPHA:79433; Osteofibrous dysplasia ORPHA:488265; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Parietal foramina with clavicular hypoplasia ORPHA:251290; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Primary CD59 deficiency ORPHA:169464; Retinal arterial tortuosity ORPHA:75326; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; X-linked osteoporosis with fractures ORPHA:391330; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Congenital cataract microcornea with corneal opacity ORPHA:289499; Congenital diaphragmatic hernia ORPHA:2140; Dermatofibrosarcoma protuberans ORPHA:31112; Hypoplastic left heart syndrome ORPHA:2248; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Matthew-Wood syndrome ORPHA:2470; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402; Posterior hypospadias ORPHA:95706; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721; Trichorhinophalangeal syndrome type 2 ORPHA:502; BOR syndrome ORPHA:107; Erythrokeratodermia variabilis ORPHA:317; Tetralogy of Fallot ORPHA:3303; Classical Ehlers-Danlos syndrome ORPHA:287; Multiple osteochondromas ORPHA:321; X-linked Alport syndrome-diffuse leiomyomatosis ORPHA:1018; 15q14 microdeletion syndrome ORPHA:261190; Alagille syndrome due to 20p12 microdeletion ORPHA:261600; Alagille syndrome due to a JAG1 point mutation ORPHA:261619; Alopecia universalis ORPHA:701; Atrichia with papular lesions ORPHA:86819; Autosomal dominant palmoplantar keratoderma and congenital alopecia ORPHA:1010; Autosomal dominant slowed nerve conduction velocity ORPHA:140481; Caffey disease ORPHA:1310; Cerebral autosomal recessive arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:199354; Childhood-onset benign chorea with striatal involvement ORPHA:494541; Chronic enteropathy associated with SLCO2A1 gene ORPHA:468641; Distal myopathy with posterior leg and anterior hand involvement ORPHA:63273; Epidermolysis bullosa simplex due to BP230 deficiency ORPHA:412181; Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome ORPHA:412022; Familial generalized lentiginosis ORPHA:231040; HTRA1-related autosomal dominant cerebral small vessel disease ORPHA:482077; Helicoid peripapillary chorioretinal degeneration ORPHA:86813; Hereditary sensory and autonomic neuropathy type 6 ORPHA:314381; Infantile-onset generalized dyskinesia with orofacial involvement ORPHA:494526; Kuskokwim syndrome ORPHA:1149; Lethal hydranencephaly-diaphragmatic hernia syndrome ORPHA:480528; Lymphedema-distichiasis syndrome ORPHA:33001; Microphthalmia with brain and digit anomalies ORPHA:139471; Monoamine oxidase A deficiency ORPHA:3057; Multiple paragangliomas associated with polycythemia ORPHA:324299; Muscle filaminopathy ORPHA:171445; NON RARE IN EUROPE: Autosomal dominant ichthyosis vulgaris ORPHA:462; NON RARE IN EUROPE: Benign familial hematuria ORPHA:97562; Non-immune hydrops fetalis ORPHA:363999; Oculodentodigital dysplasia ORPHA:2710; Optic atrophy-intellectual disability syndrome ORPHA:401777; Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome ORPHA:447961; Syndactyly type 3 ORPHA:93404; X-linked Alport syndrome ORPHA:88917; Autosomal recessive Robinow syndrome ORPHA:1507; Lacrimoauriculodentodigital syndrome ORPHA:2363; Malignant peripheral nerve sheath tumor ORPHA:3148; Non-seminomatous germ cell tumor of testis ORPHA:363494; Phakomatosis cesioflammea ORPHA:79483; Sclerosteosis ORPHA:3152; Brachydactyly type A1 ORPHA:93388; Distal hereditary motor neuropathy type 2 ORPHA:139525; Familial isolated restrictive cardiomyopathy ORPHA:75249; Osteogenesis imperfecta type 3 ORPHA:216812; Hirschsprung disease ORPHA:388; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form ORPHA:293899; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form ORPHA:293888; ABeta amyloidosis, Arctic type ORPHA:324723; ABeta amyloidosis, Dutch type ORPHA:100006; ABeta amyloidosis, Iowa type ORPHA:324708; ABeta amyloidosis, Italian type ORPHA:324713; ABetaA21G amyloidosis ORPHA:324718; ABetaL34V amyloidosis ORPHA:324703; Allan-Herndon-Dudley syndrome ORPHA:59; Autosomal dominant osteopetrosis type 1 ORPHA:2783; Branchio-oculo-facial syndrome ORPHA:1297; Campomelic dysplasia ORPHA:140; Carbamoyl-phosphate synthetase 1 deficiency ORPHA:147; Carvajal syndrome ORPHA:65282; Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:136; Colobomatous macrophthalmia-microcornea syndrome ORPHA:468672; Dicarboxylic aminoaciduria ORPHA:2195; Dyssegmental dysplasia, Silverman-Handmaker type ORPHA:1865; Endosteal hyperostosis, Worth type ORPHA:2790; Erythrokeratodermia-cardiomyopathy syndrome ORPHA:476096; Fibronectin glomerulopathy ORPHA:84090; Glutaric acidemia type 3 ORPHA:35706; Hot water reflex epilepsy ORPHA:166412; Hypopigmentation-punctate palmoplantar keratoderma syndrome ORPHA:324561; Isolated Pierre Robin syndrome ORPHA:718; LRP5-related primary osteoporosis ORPHA:498481; Lateral meningocele syndrome ORPHA:2789; Lymphedema-posterior choanal atresia syndrome ORPHA:99141; Multiple myeloma ORPHA:29073; Osteoporosis-pseudoglioma syndrome ORPHA:2788; Osteosclerosis-developmental delay-craniosynostosis syndrome ORPHA:178377; Progressive familial intrahepatic cholestasis type 4 ORPHA:480483; Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome ORPHA:228012; Ring dermoid of cornea ORPHA:91481; Schwartz-Jampel syndrome ORPHA:800; Skin fragility-woolly hair-palmoplantar keratoderma syndrome ORPHA:293165; Split hand-split foot-deafness syndrome ORPHA:71271; Stuve-Wiedemann syndrome ORPHA:3206; Trehalase deficiency ORPHA:103909; Acromesomelic dysplasia, Grebe type ORPHA:2098; Autosomal recessive hypophosphatemic rickets ORPHA:289176; Brachydactyly type C ORPHA:93384; Enlarged parietal foramina ORPHA:60015; Familial patent arterial duct ORPHA:466729; Fibular aplasia-complex brachydactyly syndrome ORPHA:2639; Hyperostosis corticalis generalisata ORPHA:3416; Pfeiffer syndrome type 1 ORPHA:93258; Silver-Russell syndrome due to 11p15 microduplication ORPHA:231144; Silver-Russell syndrome due to an imprinting defect of 11p15 ORPHA:231140; Spondylometaphyseal dysplasia, 'corner fracture' type ORPHA:93315; Acrocallosal syndrome ORPHA:36; Beckwith-Wiedemann syndrome due to imprinting defect of 11p15 ORPHA:231117; Butterfly-shaped pigment dystrophy ORPHA:99001; Complete atrioventricular septal defect with ventricular hypoplasia ORPHA:99067; Isolated aniridia ORPHA:250923; Isolated hemihyperplasia ORPHA:2128; Mutilating palmoplantar keratoderma with periorificial keratotic plaques ORPHA:659; Partial atrioventricular septal defect ORPHA:1330; Persistent hyperplastic primary vitreous ORPHA:91495; Retinopathy of prematurity ORPHA:90050; Epithelioid hemangioendothelioma ORPHA:157791; Familial progressive cardiac conduction defect ORPHA:871; Isolated brachycephaly ORPHA:35099; Isolated plagiocephaly ORPHA:35098; Autosomal dominant polycystic kidney disease ORPHA:730; Colobomatous microphthalmia ORPHA:98938; Familial isolated arrhythmogenic ventricular dysplasia, right dominant form ORPHA:293910; Autosomal dominant non-syndromic sensorineural deafness type DFNA ORPHA:90635; Action myoclonus-renal failure syndrome ORPHA:163696; Acute neonatal citrullinemia type I ORPHA:247546; Adult-onset citrullinemia type I ORPHA:247573; Arterial tortuosity syndrome ORPHA:3342; Atelosteogenesis type I ORPHA:1190; Atelosteogenesis type III ORPHA:56305; Autosomal dominant generalized dystrophic epidermolysis bullosa ORPHA:231568; Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form ORPHA:89842; Autosomal recessive omodysplasia ORPHA:93329; Autosomal spastic paraplegia type 58 ORPHA:397946; Beta-sarcoglycan-related  limb-girdle muscular dystrophy R4 ORPHA:119; Boomerang dysplasia ORPHA:1263; Charcot-Marie-Tooth disease type 2R ORPHA:397968; Craniofacial dysplasia-osteopenia syndrome ORPHA:314555; Curry-Jones syndrome ORPHA:1553; Dystrophic epidermolysis bullosa pruriginosa ORPHA:89843; Frank-Ter Haar syndrome ORPHA:137834; Goldberg-Shprintzen megacolon syndrome ORPHA:66629; Growth delay due to insulin-like growth factor I resistance ORPHA:73273; Hartsfield syndrome ORPHA:2117; Isolated biliary atresia ORPHA:30391; Isolated congenital breast hypoplasia/aplasia ORPHA:180188; Larsen syndrome ORPHA:503; Legius syndrome ORPHA:137605; Localized dystrophic epidermolysis bullosa, acral form ORPHA:158673; Localized dystrophic epidermolysis bullosa, nails only ORPHA:158676; Localized dystrophic epidermolysis bullosa, pretibial form ORPHA:79410; Malignant epithelial tumor of salivary glands ORPHA:276145; Metopic ridging-ptosis-facial dysmorphism syndrome ORPHA:502430; Multiple epiphyseal dysplasia type 5 ORPHA:93311; Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement ORPHA:168953; Osteoglosphonic dysplasia ORPHA:2645; Pierson syndrome ORPHA:2670; Recessive dystrophic epidermolysis bullosa inversa ORPHA:79409; Scalp-ear-nipple syndrome ORPHA:2036; Self-improving dystrophic epidermolysis bullosa ORPHA:79411; Sjogren-Larsson syndrome ORPHA:816; Spondyloepimetaphyseal dysplasia, matrilin-3 type ORPHA:156728; Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A ORPHA:308386; Autosomal recessive polycystic kidney disease ORPHA:731; Alopecia-intellectual disability syndrome ORPHA:2850; Complete atrioventricular septal defect-tetralogy of Fallot ORPHA:99068; Hereditary diffuse gastric cancer ORPHA:26106; Hypomyelination neuropathy-arthrogryposis syndrome ORPHA:2680; Milroy disease ORPHA:79452; NON RARE IN EUROPE: Infantile capillary hemangioma ORPHA:464293; Saethre-Chotzen syndrome ORPHA:794; Aplasia cutis congenita ORPHA:1114; Familial exudative vitreoretinopathy ORPHA:891; Renal agenesis, unilateral ORPHA:93100; Early-onset posterior polar cataract ORPHA:98993; Cleft lip/palate ORPHA:199306; Midline interhemispheric variant of holoprosencephaly ORPHA:93926; Septopreoptic holoprosencephaly ORPHA:280195; Aarskog-Scott syndrome ORPHA:915; Achondroplasia ORPHA:15; Alpha-dystroglycan-related  limb-girdle muscular dystrophy R16 ORPHA:280333; Autosomal dominant adult-onset proximal spinal muscular atrophy ORPHA:209335; Autosomal recessive intermediate Charcot-Marie-Tooth disease type C ORPHA:369867; Autosomal recessive lower motor neuron disease with childhood onset ORPHA:206580; Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency ORPHA:91135; Camptodactyly-tall stature-scoliosis-hearing loss syndrome ORPHA:85164; Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation ORPHA:300570; Crouzon syndrome-acanthosis nigricans syndrome ORPHA:93262; Dent disease type 2 ORPHA:93623; Familial hypocalciuric hypercalcemia type 2 ORPHA:101049; Hypochondroplasia ORPHA:429; Hypodontia-dysplasia of nails syndrome ORPHA:2228; Keipert syndrome ORPHA:2662; LAMA5-related multisystemic syndrome ORPHA:521450; Microcystic stromal tumor ORPHA:569248; Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome ORPHA:476126; Monosomy 22q13.3 ORPHA:48652; Muenke syndrome ORPHA:53271; Multiple epiphyseal dysplasia, Al-Gazali type ORPHA:166024; Muscle-eye-brain disease with bilateral multicystic leucodystrophy ORPHA:370997; Muscular dystrophy, Selcen type ORPHA:199340; Neurodegenerative syndrome due to cerebral folate transport deficiency ORPHA:217382; OBSOLETE: Alpha-1-antichymotrypsin deficiency ORPHA:93594; Oculocerebrorenal syndrome of Lowe ORPHA:534; PGM1-CDG ORPHA:319646; Phakomatosis cesiomarmorata ORPHA:79484; Pilomatrixoma ORPHA:91414; Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome ORPHA:477673; Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa ORPHA:436274; Severe achondroplasia-developmental delay-acanthosis nigricans syndrome ORPHA:85165; Severe intellectual disability-progressive spastic diplegia syndrome ORPHA:404473; Thanatophoric dysplasia type 1 ORPHA:1860; Thanatophoric dysplasia type 2 ORPHA:93274; Vein of Galen aneurysmal malformation ORPHA:1053; Wolfram-like syndrome ORPHA:411590; 3M syndrome ORPHA:2616; Brachydactyly type E ORPHA:93387; Familial avascular necrosis of femoral head ORPHA:86820; Progressive myoclonic epilepsy type 5 ORPHA:402082; Spondyloepimetaphyseal dysplasia with joint laxity ORPHA:93359; 46,XX testicular disorder of sex development ORPHA:393; Periventricular nodular heterotopia ORPHA:98892; Oligodontia ORPHA:99798; Lobar holoprosencephaly ORPHA:93924; Microform holoprosencephaly ORPHA:280200; Total early-onset cataract ORPHA:98994; Autosomal dominant neovascular inflammatory vitreoretinopathy ORPHA:329211; Autosomal recessive dopa-responsive dystonia ORPHA:101150; Desmosterolosis ORPHA:35107; Dystonia-parkinsonism-hypermanganesemia syndrome ORPHA:521406; Familial congenital nasolacrimal duct obstruction ORPHA:451612; Familial cortical myoclonus ORPHA:319189; Glycogen storage disease due to muscle phosphofructokinase deficiency ORPHA:371; POMT2-related  limb-girdle muscular dystrophy R14 ORPHA:206559; Pyruvate carboxylase deficiency, benign type ORPHA:353320; Pyruvate carboxylase deficiency, infantile type ORPHA:353308; Pyruvate carboxylase deficiency, severe neonatal type ORPHA:353314; X-linked external auditory canal atresia-dilated internal auditory canal-facial dysmorphism syndrome ORPHA:500188; X-linked intellectual disability, Najm type ORPHA:163937; Autosomal dominant hypocalcemia ORPHA:428; Carpenter syndrome ORPHA:65759; 46,XX ovotesticular disorder of sex development ORPHA:2138; Familial hypercholanemia ORPHA:238475; Juvenile nephronophthisis ORPHA:93592; Walker-Warburg syndrome ORPHA:899",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0083744975290613; 0.0092060390928213; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111; 0.0277610005156803; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.0621182671032116; 0.0640416108792758; 0.0683063362547733; 0.0706635700002548; 0.0783959336694202; 0.0783959336694202; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.1614487935928034; 0.1614487935928034; 0.1614487935928034; 0.1697334635963512; 0.1782034488938806; 0.1981653781243822; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.3900898302534297; 0.3969770464111636; 0.4045231980457672; 0.4101640425710954; 0.43936148647173; 0.43936148647173; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6279395134845649; 0.639029370164481; 0.6723027000992685; 0.6787273931204523; 0.6857161253678724; 0.7002194990845196; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7072638369101406; 0.7195544063051836,,,yeasx,0.37;0.56,Homo sapiens,Homo sapiens;Saccharomyces cerevisiae
APOBEC3B,"Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Stomach Carcinoma; Retroviridae Infections; melanoma; Adenocarcinoma; Squamous cell carcinoma; Malignant mesothelioma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Epithelial ovarian cancer; Mammary Neoplasms, Human; Neoplasm Metastasis; Renal Cell Carcinoma; Malignant neoplasm of pancreas; Lymphoma; Pancreatic carcinoma; Squamous cell carcinoma of the head and neck; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Liver carcinoma; Malignant Neoplasms; Clear-cell metastatic renal cell carcinoma; Solid Neoplasm; Sickle Cell Dactylitis; Palmar-plantar erythrodysesthesia syndrome; Neck Neoplasms; cervical cancer; Malignant Head and Neck Neoplasm; Malignant neoplasm of liver; Neoplasms; Conventional (Clear Cell) Renal Cell Carcinoma; Head and Neck Neoplasms; Primary malignant neoplasm; Human papilloma virus infection; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Uterine Cervical Neoplasm; Non-Small Cell Lung Carcinoma; Infection caused by Helicobacter pylori; Leukemia, Myelocytic, Acute; HIV Infections; Malaria, Falciparum; Liver and Intrahepatic Biliary Tract Carcinoma; Neoplastic Processes; Down Syndrome; Stromal Neoplasm; Benign Neoplasm; leukemia; Upper Aerodigestive Tract Neoplasms; Head Neoplasms; Cancer of Head; Cancer of Neck; Coinfection; Adenocarcinoma of lung (disorder); Malaria; Xeroderma Pigmentosum, Complementation Group D; Malnutrition; Hepatitis B, Chronic; Hepatitis C; Hepatitis B",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0387439397151409; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0726340460169901; 0.0739788831250619; 0.0745502070959292; 0.0775520919998773; 0.084286432100041; 0.0891725280554336; 0.095319386034013; 0.0991201145654548; 0.13167400689206; 0.1413782599148022; 0.1602092191314262; 0.1602092191314262; 0.1614820148711231; 0.2050045461627939; 0.2522264785494494; 0.2643145809900195; 0.2714542429024338; 0.2980670559114652; 0.3412203844672238; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.4028066164685291; 0.4126392832024548; 0.4213286052188015; 0.4213286052188015; 0.4588513406515081; 0.4753011022966241; 0.4753011022966241; 0.4790179402069343; 0.4790179402069343; 0.489336365264797; 0.51550637274795; 0.5655222348249326; 0.5885228491254589; 0.5916904943304121; 0.6150955455771212; 0.7169459458481418; 0.9169959402964138,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Carcinoma; Cervical Cancer; Uterine Cervix Neoplasm; Benign Neoplasm; Neoplasms; Bladder Neoplasm; Upper Aerodigestive Tract Neoplasms; Head Neoplasms; Neoplasm Of Head; Urinary Bladder Cancer; Neck Neoplasms; Neck Cancer; Head And Neck Neoplasms; Malignant Neoplasm; Head And Neck Cancer; Lung Adenocarcinoma,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0534520155998091; 0.4402141802500753; 0.4541466895915311; 0.4624858551053053; 0.4646409362700993; 0.4723647227028846; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.5632819212593052; 0.5973360026714207; 0.6003406542362493; 0.7979764766391754,Athabaskan brainstem dysgenesis syndrome ORPHA:69739; Bosley-Salih-Alorainy syndrome ORPHA:69737,0.3762014630157917; 0.3762014630157917,,,,,,
APOLD1,Adenocarcinoma; Birth Weight,0.0155921563748247; 0.3933196962529684,Cardiovascular Diseases; Prostate Cancer,0.554079268109006; 0.6104715460837368,,,,,,,,
ARL2BP,"Stomach Carcinoma; Carcinogenesis; Carcinoma; Neoplasm Metastasis; Malignant neoplasm of pancreas; Pancreatic carcinoma; Cataract; Burkitt Lymphoma; Glaucoma; Nasopharyngeal carcinoma; Secondary malignant neoplasm of liver; Lens Opacities; Obesity; Dull intelligence; Low intelligence; Poor school performance; Mental deficiency; Broad flat nasal bridge; Pallor of optic disc; Nasal bridge wide; Mental Retardation; Keratoconus; Retinal pigment epithelial abnormality; Abnormality of retinal pigmentation; Congenital anomaly of testis; Progressive night blindness; Sensorineural Hearing Loss (disorder); Abnormality of the retinal vasculature; Congenital hypoplasia of penis; Atypical scarring of skin; Retinitis Pigmentosa; Reduced visual acuity; Optic Atrophy; Hyperinsulinism; Electroretinogram abnormal; Ophthalmoplegia; Intellectual Disability; Anteverted nostril; Blindness, Legal; Blindness; Retinal Dystrophies; Conductive hearing loss; Photodysphoria; Photophobia; Hypogonadism; Nystagmus",0.0149315928814189; 0.0228075668512991; 0.0593779966354549; 0.0648809611869375; 0.0726340460169901; 0.0745502070959292; 0.223747154820789; 0.2521987644415915; 0.3105909001629992; 0.3933196962529684; 0.3933196962529684; 0.4213286052188015; 0.5140447474168605; 0.5300976305939776; 0.5300976305939776; 0.5610226870913673; 0.6035970790768342; 0.6196470808426647; 0.6222451141623291; 0.6238969878903416; 0.6319938293757544; 0.652707626880454; 0.6545439509404224; 0.6545439509404224; 0.6691893635307453; 0.6691893635307453; 0.6891882956008074; 0.6959870102453846; 0.6974821940437801; 0.7045203904267408; 0.7352133686428474; 0.7577323833810212; 0.809878589520458; 0.8245140009975604; 0.8257883659984262; 0.8306551823873084; 0.8352623613787349; 0.8472019892490944; 0.8515974315972522; 0.8612829843327843; 0.8815334766742503; 0.8849686999768298; 0.8849686999768298; 0.8921715172820168; 0.9100787832273576; 0.926001913794773,Hereditary Retinal Dystrophy; Glaucoma; Anetoderma; Hearing Loss; Congenital Hypoplasia Of Penis; Cataract; Optic Atrophy; Rod-cone Dystrophy; Mental Retardation; Keratoconus; Hypogonadism; Hyperinsulinism; Retinal Dystrophy; Nystagmus; Retinitis Pigmentosa; Obesity; Diabetes Mellitus,0.4541466895915311; 0.4646409362700993; 0.4875380732267193; 0.5632819212593052; 0.6572113517052336; 0.6660731887258019; 0.675936313627625; 0.7062235569782704; 0.7729545590606223; 0.7893608212024619; 0.8536040084512244; 0.8570285304674955; 0.8570285304674955; 0.9146877763175152; 0.9538309557027852; 0.9568083835980838; 0.9683912711598086,"X-linked myotubular myopathy-abnormal genitalia syndrome ORPHA:456328; Autosomal dominant Charcot-Marie-Tooth disease type 2B ORPHA:99936; Hemolytic anemia due to diphosphoglycerate mutase deficiency ORPHA:714; Hyperbiliverdinemia ORPHA:276405; X-linked intellectual disability, Nascimento type ORPHA:163956; Retinitis pigmentosa ORPHA:791",0.3762014630157917; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.8578236036529228,,,yeasx,0.56,Homo sapiens,Homo sapiens
ARRDC4,"Congenital diaphragmatic hernia; Enterovirus Infections; Acidosis, Lactic",0.4790179402069343; 0.5019670090704682; 0.8867784885819414,,,Familial multiple nevi flammei ORPHA:624; Sturge-Weber syndrome ORPHA:3205; Congenital brain dysgenesis due to glutamine synthetase deficiency ORPHA:71278,0.0180064224283883; 0.0180064224283883; 0.6239678957896782,,,,,,
B3GLCT,"Biliary tract abnormality; Biliary Tract Diseases; Clouding of corneal stroma; Seizures; Corneal Opacity; Cataract; Heart Septal Defects; Proximal placement of thumb; Glaucoma; Round face; Round, full face; Abnormality of the skull; Fetal Growth Retardation; Hydrocephalus; Anomalous pulmonary artery; Polio and Post-Polio Syndrome; Popliteal pterygium syndrome; Infant, Small for Gestational Age; Intrauterine retardation; Craniosynostosis; Birth length less than 3rd percentile; Anemia; Epilepsy; Broad neck; Autism Spectrum Disorders; Single transverse palmar crease; Bulging forehead; Prominent forehead; Conical incisor; Limited elbow movement; Peg shaped front tooth; Pointed front tooth; Pointed incisor; Umbilical hernia; Short columella; Hypoplasia of columella; Agenesis of corpus callosum; Polyhydramnios; Cleft palate with cleft lip; Pulmonary Stenosis; Double ureter; Short palpebral fissure; Brachycephaly; Lens Opacities; Rudimentary vagina; Hypoplasia of vagina; Narrowing of ear canal; Aortopulmonary Septal Defect; Dilated ventricles (finding); Stenosis of external auditory canal; Diastasis recti; Supratentorial atrophy; Irido-corneo-trabecular dysgenesis (disorder); Reduced fetal movement; Skin tag on the posterior cheek; Ventricular Septal Defects; Syndactyly; Preauricular skin tag; Postnatal growth retardation; Curvature of little finger; Clinodactyly of the 5th finger; Micromelia; Weight decreased; Small labia majora; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Atrial Septal Defects; Aplasia/Hypoplasia of the mandible; Degenerative brain disorder; Micrognathism; Cleft upper lip; Clitoral hypoplasia; Small head; Short metatarsal; Preauricular Fistulae, Congenital; Congenital preauricular sinus; Disproportionate short-limb short stature; Preauricular dimple; Underweight; Hypoplastic feet; Acquired scoliosis; Penile hypospadias; Congenital hemivertebra; Fundus coloboma; Infantile uterus; Weight less than 3rd percentile; Myopia; Short toe; Rhizomelia; Dull intelligence; Low intelligence; Hypospadias; exudative macular degeneration; Wide skull shape; Broad cranium shape; Brachydactyly; Thin upper lip vermilion; Abnormality of the cornea; Poor school performance; Neck webbing; Frontal bossing; Pectus excavatum; Geographic Atrophy; Curvature of spine; Mental deficiency; Wide anterior fontanel; Coloboma of iris; Short metacarpal; Syndactyly of the toes; Cerebral atrophy; Wide spaced nipples; Mental Retardation; Decreased corneal diameter; Microcornea; Protruding ear; Uranostaphyloschisis; Prominent ear; Short palm; Joint laxity; Cryptorchidism; Big calvaria; Increased size of skull; Increased head circumference; Hydronephrosis; Feeding difficulties in infancy; Congenital Disorders of Glycosylation; Upward slant of palpebral fissure; Congenital pes cavus; Orbital separation excessive; Age related macular degeneration; Intellectual Disability; Long philtrum; Mental and motor retardation; Cognitive delay; Nystagmus; Global developmental delay; Blepharoptosis",0.0745502070959292; 0.0775520919998773; 0.1859959283872542; 0.2053083986145698; 0.2085938372806741; 0.223747154820789; 0.3044782497745498; 0.3099246715197673; 0.3105909001629992; 0.3706856725676674; 0.3706856725676674; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3986414839122469; 0.4028066164685291; 0.4028066164685291; 0.4103119460235835; 0.4115056600660309; 0.4186011760974318; 0.4186011760974318; 0.4192169590514327; 0.4209380602168584; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.425992946703162; 0.4304973629098372; 0.4335751357405352; 0.4381343267935581; 0.4459714599189374; 0.4459714599189374; 0.4506578937113162; 0.4564472886428772; 0.4564472886428772; 0.4564472886428772; 0.4615352570710579; 0.4635211539849193; 0.4675904598629673; 0.4714226702518064; 0.472444704048021; 0.472444704048021; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4757083758251088; 0.4790179402069343; 0.4790179402069343; 0.479747709091007; 0.4850576707687362; 0.4852430673532381; 0.4906258721078565; 0.4923669467696064; 0.4923669467696064; 0.4923669467696064; 0.4923669467696064; 0.4923669467696064; 0.4981941174985421; 0.4990401620718274; 0.5019670090704682; 0.5019670090704682; 0.5019670090704682; 0.5140447474168605; 0.5140447474168605; 0.5188223685230745; 0.5239792328442205; 0.5251317541886066; 0.5299466034567416; 0.5300976305939776; 0.5300976305939776; 0.533913711453195; 0.5359212109443033; 0.5462489630068115; 0.5462489630068115; 0.549941235475765; 0.5557519470957561; 0.5568517196017908; 0.5610226870913673; 0.5655222348249326; 0.5710095678317721; 0.5956632182199403; 0.6002127202571572; 0.6035970790768342; 0.6035970790768342; 0.6035970790768342; 0.6196470808426647; 0.625027955184583; 0.6274540883972485; 0.6294837700416086; 0.6304655343580164; 0.6319938293757544; 0.6588479076808555; 0.6656356363792992; 0.672336954961104; 0.6784817526917547; 0.6802335864704374; 0.7096959691931399; 0.717484976234209; 0.7417321496240817; 0.7484342194688707; 0.7484342194688707; 0.7511668779991656; 0.7651930135295156; 0.7797826088609066; 0.7891530777939482; 0.7935206698366561; 0.8065625879493252; 0.8157137944879093; 0.8304052766033214; 0.8352623613787349; 0.8943302762243359; 0.897310588550617; 0.9238745269736108; 0.926001913794773; 0.9327689937867868; 0.9781217366509172,Anomalous Pulmonary Artery; Hydrocephalus; Craniosynostosis; Hypoplastic Left Heart Syndrome; Pulmonary Stenosis; Mental Depression; Hypopituitarism; Frontal Bossing; Brachycephaly; Hypoplasia Of Vagina; Spina Bifida Occulta; Multicystic Renal Dysplasia; Glaucoma; Accessory Kidney; Anterior Segment Dysgenesis; Spade-Like Hand; Renal Hypoplasia; Stenosis Of External Auditory Canal; Scoliosis; Double Ureter; Syndactyly; Microcephaly; Talipes Transversoplanus; Cerebral Atrophy; Cerebral Cortical Atrophy; Micrognathism; Congenital Hypothyroidism; Posteriorly Rotated Ear; Micromelia; Atrial Septal Defect; Hypoplasia Of The Maxilla; Hearing Loss; Geographic Atrophy; Exudative Macular Degeneration; Microcornea; Brachydactyly; Agenesis Of Corpus Callosum; Congenital Exomphalos; Fundus Coloboma; Heart Septal Defects; Retinal Coloboma; Rhizomelia; Congenital Coloboma Of Iris; Patent Ductus Arteriosus; Cataract; Optic Atrophy; Neck Webbing; Camptodactyly Of Fingers; Myopia; Hydronephrosis; Ventricular Septal Defect; Mental Retardation; Disorder Of Eye; Cryptorchidism; Macrocephaly; Imperforate Anus; Ptosis; Congenital Pectus Excavatum; Macrostomia; Hypospadias; Syndactyly Of The Toes; Nystagmus; Developmental Delay,0.0075861267486594; 0.3657224783929353; 0.4286813331685578; 0.4402141802500753; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4602028929328057; 0.4646409362700993; 0.4646409362700993; 0.4646409362700993; 0.4646409362700993; 0.4867879381749835; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.4968320901822731; 0.5123947823327547; 0.5123947823327547; 0.5127628024019304; 0.5129298662020659; 0.5129298662020659; 0.5234357475824973; 0.5234357475824973; 0.5248691614865011; 0.525214105372123; 0.5254133486377646; 0.5576425853515448; 0.5632819212593052; 0.5796489603182782; 0.6003406542362493; 0.6030919130927346; 0.6198128018123746; 0.6252040071965056; 0.6270755162143985; 0.6329251700753155; 0.6340319940404294; 0.6340319940404294; 0.6340319940404294; 0.6572113517052336; 0.6596918765832213; 0.6660731887258019; 0.675936313627625; 0.7112499273451761; 0.7328159476505643; 0.7405519560111998; 0.7412420740397021; 0.7729545590606223; 0.7729545590606223; 0.7729545590606223; 0.776786668801341; 0.800821840688695; 0.8225549273532161; 0.8357787380041017; 0.8407264689819682; 0.8569751017318014; 0.8570285304674955; 0.9096190669068288; 0.9146877763175152; 0.96477535147595,Christianson syndrome ORPHA:85278; Peters plus syndrome ORPHA:709,0.3762014630157917; 0.6239678957896782,,,,,,
BBC3,"Colorectal Carcinoma; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Hematopoietic Neoplasms; Epithelial ovarian cancer; Malignant neoplasm of prostate; Central neuroblastoma; Renal Cell Carcinoma; Neuroblastoma; Malignant neoplasm of pancreas; Glioma; Degenerative polyarthritis; Lymphoma; Glioblastoma; Pancreatic carcinoma; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Colorectal Neoplasms; Liver carcinoma; Colon Carcinoma; Chronic Lymphocytic Leukemia; Hyperactive behavior; Liver neoplasms; Rheumatoid Arthritis; cervical cancer; Malignant tumor of colon; Burkitt Lymphoma; Malignant Head and Neck Neoplasm; B-Cell Lymphomas; Malignant neoplasm of liver; Malignant tumor of cervix; Malignant neoplasm of lung; Cervix carcinoma; Pancreatic Ductal Adenocarcinoma; Head and Neck Neoplasms; Leukemogenesis; African Burkitt's lymphoma; Amyloidosis; Gallbladder Carcinoma; Fulminant hepatitis; Leukemia, Myelocytic, Acute; Cystadenocarcinoma, Serous; Lip and Oral Cavity Carcinoma; Alcoholic Steatohepatitis; refractory plasma cell neoplasm; Liver Neoplasms, Experimental; Experimental Hepatoma; AICARDI-GOUTIERES SYNDROME 1; Multiple Myeloma; Hepatoma, Novikoff; Retinoblastoma; Hepatoma, Morris; SPHEROCYTOSIS, TYPE 1 (disorder); Malignant neoplasm of mouth; Addictive Behavior; Pulmonary Fibrosis; Machado-Joseph Disease; Choriocarcinoma; Intermittent Claudication; Steatohepatitis; Hepatitis A; Malignant neoplasm of oropharynx; Ewings sarcoma; Lymphoma, Follicular; Malignant neoplasm of gallbladder; Infection; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Silicosis; Oropharyngeal Carcinoma; Other specified transient cerebral ischemias; Sepsis; Brain Ischemia; Van der Woude syndrome; Transient Ischemic Attack; Hepatitis; Septicemia; Cerebral Ischemia",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0334891258932371; 0.0387439397151409; 0.0569142010728473; 0.0593779966354549; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0775520919998773; 0.0827744840860166; 0.095319386034013; 0.1062239757831962; 0.1147307578771389; 0.1387448809655294; 0.1454373331146953; 0.1537760235124317; 0.2050045461627939; 0.223747154820789; 0.2521987644415915; 0.2522264785494494; 0.2522264785494494; 0.2643145809900195; 0.2714542429024338; 0.2714542429024338; 0.2834835531038365; 0.3018974726133723; 0.3412203844672238; 0.3510063969122338; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.4028066164685291; 0.4100742336915555; 0.4100742336915555; 0.4100901006059349; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4213286052188015; 0.4314759856195063; 0.4335751357405352; 0.4335751357405352; 0.4564472886428772; 0.4753011022966241; 0.4906258721078565; 0.5090214163899865; 0.5140447474168605; 0.5251317541886066; 0.533913711453195; 0.5496357724684553; 0.5959654688257199; 0.6035970790768342; 0.6035970790768342; 0.610971999959321; 0.6274540883972485; 0.6395767498329145; 0.6592493193460769; 0.6910672612216457; 0.7061487180640408; 0.7484342194688707; 0.8064248359603999; 0.839057838231319,Esophagus Neoplasm; African Burkitt`s Lymphoma; Burkitt`s Lymphoma; Cerebral Ischemia,0.0102679590519094; 0.2960946950751588; 0.4541466895915311; 0.6798971073653743,Oculootodental syndrome ORPHA:99806; Peutz-Jeghers syndrome ORPHA:2869; Multiple endocrine neoplasia type 1 ORPHA:652; Primary familial polycythemia ORPHA:90042,0.3762014630157917; 0.6239678957896782; 0.6279395134845649; 0.7068064785325423,"Human gammaherpesvirus 4 hypothetical protein (gene: BHRF1); Human herpesvirus 4 type 2 BHRF1; Yaba monkey tumor virus anti-apoptotic membrane protein; Monkeypox virus Zaire-96-I-16 Hypothetical protein (gene: C7L); Vaccinia virus Ankara apoptosis inhibitor; Yaba monkey tumor virus putative transmembrane protein; Horsepox virus HSPV032 (putative alpha aminitin-sensitive protein, provisional); Human gammaherpesvirus 4 hypothetical BALF1 protein (gene: BALF1); Human herpesvirus 4 type 2 BALF1; Variola virus hypothetical protein (gene: D9L); Yaba-like disease virus 16L protein (gene: 16L); Yaba-like disease virus 3L protein (gene: 3L); Cowpox virus CPXV190 protein (gene: CPXV190 CDS); Vaccinia virus Toll/IL-receptor-like protein (gene: A52R); Vaccinia virus Ankara Toll/IL1-receptor signalling inhibitor; Horsepox virus HSPV174 (Toll/IL-receptor-like protein; Provisional); Yaba-like disease virus 139R protein (gene: 139R); Monkeypox virus virokine protein; Monkeypox virus Zaire-96-I-16 putative virulence factor (gene: P1L); Ectromelia virus ERPV virokine/NFKb inhibitor; Variola virus putative virulence factor (gene: P1L); Cowpox virus CPXV037 protein (gene: CPXV037 CDS); Human gammaherpesvirus 8 ORF16 (gene: ORF16); Ectromelia virus ERPV apoptosis inhibitor; Yaba monkey tumor virus hypothetical protein; Variola virus hypothetical protein (gene: C5L); Cowpox virus CPXV048 (gene: CPXV048 CDS); Horsepox virus HSPV041 (Hypothetical protein); Vaccinia virus Hypothetical protein (gene: F1L); Monkeypox virus unknown protein",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597,,,,
BFSP1,Cataract; Nuclear cataract; Bilateral cataracts (disorder); Cortical cataract; Nuclear non-senile cataract,0.223747154820789; 0.3933196962529684; 0.4028066164685291; 0.4126392832024548; 0.4790179402069343,Cortical Cataract; Congenital Cataract; Cataract,0.4286813331685578; 0.6340319940404294; 0.6660731887258019,"Early-onset nuclear cataract ORPHA:98991; Craniosynostosis, Boston type ORPHA:1541; Parietal foramina with clavicular hypoplasia ORPHA:251290; Idiopathic juvenile osteoporosis ORPHA:85193",0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.1590470395003315,,,,,,
BMF,"Colorectal Carcinoma; Colorectal Cancer; Liver Cirrhosis, Experimental; Colon Carcinoma; Chronic Lymphocytic Leukemia; Malignant tumor of colon; Diabetes; Hodgkin Disease; B-Cell Lymphomas; Diabetes Mellitus; Childhood Acute Lymphoblastic Leukemia; Non-Small Cell Lung Carcinoma; Multiple Myeloma; Leukemia, B-Cell",0.0034602840073026; 0.0149315928814189; 0.0747863377072194; 0.1062239757831962; 0.1147307578771389; 0.223747154820789; 0.2277108302018961; 0.2454476567103779; 0.2522264785494494; 0.2522264785494494; 0.3099246715197673; 0.3933196962529684; 0.4103119460235835; 0.5359212109443033,Lymphocytic Leukemia; Hodgkin Disease; Multiple Myeloma,0.0487679768343083; 0.2627224344149009; 0.4560460337187313,,,Human gammaherpesvirus 4 hypothetical protein (gene: BHRF1); Human herpesvirus 4 type 2 BHRF1; Human gammaherpesvirus 4 hypothetical BALF1 protein (gene: BALF1); Human herpesvirus 4 type 2 BALF1,0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597,,,,
C11ORF71,,,,,Isobutyryl-CoA dehydrogenase deficiency ORPHA:79159; Mitochondrial pyruvate carrier deficiency ORPHA:447784,0.7068064785325423; 0.7068064785325423,,,,,,
C1QL1,"Breast Carcinoma; Malignant neoplasm of breast; Central neuroblastoma; Neoplasm Metastasis; Neuroblastoma; Liver carcinoma; Small cell carcinoma of lung; Unipolar Depression; Hyperactive behavior; Liver neoplasms; Major Depressive Disorder; hiv-infection/aids; Alzheimer's Disease; Anxiety Disorders; Adenoma; Focal glomerulosclerosis; Mental Depression; Pituitary Neoplasms; Depressive disorder; Chronic Kidney Diseases; Familial hematuria; Anxiety; Mood Disorders; Precocious Puberty; Addictive Behavior; Choriocarcinoma; Chronic kidney disease stage 5; Anorexia Nervosa; Bulimia; Coinfection; Kidney Failure, Chronic; Adrenal Cushing's syndrome; Cushing Syndrome; Renal Insufficiency",0.0042545616049287; 0.0191435238361999; 0.0593779966354549; 0.0648809611869375; 0.0688152422187159; 0.095319386034013; 0.1193558174333938; 0.13167400689206; 0.1387448809655294; 0.1454373331146953; 0.21122597829463; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4115056600660309; 0.4192169590514327; 0.4209380602168584; 0.4314759856195063; 0.4564472886428772; 0.4704594475773637; 0.4790179402069343; 0.4852430673532381; 0.489336365264797; 0.5299466034567416; 0.5710095678317721; 0.6319938293757544; 0.658736510383757,,,"X-linked adrenal hypoplasia congenita ORPHA:95702; WAGR syndrome ORPHA:893; Partial pancreatic agenesis ORPHA:2805; Autosomal spastic paraplegia type 72 ORPHA:401849; Hydrocephalus with stenosis of the aqueduct of Sylvius ORPHA:2182; MASA syndrome ORPHA:2466; X-linked complicated corpus callosum dysgenesis ORPHA:1497; X-linked complicated spastic paraplegia type 1 ORPHA:306617; Aarskog-Scott syndrome ORPHA:915; Anterior segment developmental anomaly ORPHA:88632; Atrial septal defect-atrioventricular conduction defects syndrome ORPHA:1479; Congenital primary aphakia ORPHA:83461; Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation ORPHA:300570; Oculoauricular syndrome, Schorderet type ORPHA:157962; Renal coloboma syndrome ORPHA:1475; Spondylo-megaepiphyseal-metaphyseal dysplasia ORPHA:228387; 9q33.3q34.11 microdeletion syndrome ORPHA:495818; Autosomal recessive spastic paraplegia type 26 ORPHA:101006; Mazabraud syndrome ORPHA:57782; McCune-Albright syndrome ORPHA:562; Monostotic fibrous dysplasia ORPHA:93277; Polyostotic fibrous dysplasia ORPHA:93276; Progressive myoclonic epilepsy type 8 ORPHA:424027; Progressive osseous heteroplasia ORPHA:2762; Pseudohypoparathyroidism type 1A ORPHA:79443; Pseudohypoparathyroidism type 1C ORPHA:79444; Pseudopseudohypoparathyroidism ORPHA:79445; Right sided atrial isomerism ORPHA:97548; Paroxysmal exertion-induced dyskinesia ORPHA:98811; Autosomal recessive spondylocostal dysostosis ORPHA:2311; Coloboma of choroid and retina ORPHA:98942; Coloboma of iris ORPHA:98944; Myoclonus-dystonia syndrome ORPHA:36899",0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens A549 lung carcinoma cell,0.35,Human SARS coronavirus;SARS-CoV-2,Homo sapiens
C6ORF141,,,,,Nail-patella syndrome ORPHA:2614; Nail-patella-like renal disease ORPHA:2613,0.6239678957896782; 0.6239678957896782,,,,,,
CA11,Breast Carcinoma; Stomach Carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; cervical cancer; Malignant tumor of cervix; Cervix carcinoma; Gastrointestinal Stromal Tumors; Malaria; Febrile Convulsions; Granulocyte count; Neutrophil count (procedure); Eosinophil count procedure; Eosinophil count result; Blood basophil count (lab test),0.0042545616049287; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.2050045461627939; 0.2714542429024338; 0.2834835531038365; 0.3199171478489988; 0.5655222348249326; 0.625027955184583; 0.6841967398409226; 0.7631684472516962; 0.905697116584928; 0.905697116584928; 0.9263023523923462,,,"Primary dystonia, DYT4 type ORPHA:98805; Benign Samaritan congenital myopathy ORPHA:324581; Central core disease ORPHA:597; Congenital multicore myopathy with external ophthalmoplegia ORPHA:98905; Congenital myopathy with myasthenic-like onset ORPHA:424107; Exercise-induced malignant hyperthermia ORPHA:466650; King-Denborough syndrome ORPHA:99741; Moderate multiminicore disease with hand involvement ORPHA:178145; PRKAR1B-related neurodegenerative dementia with intermediate filaments ORPHA:412066",0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Vaccinia virus Ankara IMV chondroitin-binding membrane protein; Variola virus hypothetical protein (gene: F8L); Horsepox virus HSPV114 (Eukaryotic-type carbonic anhydrase),0.6362779693488597; 0.6362779693488597; 0.6362779693488597,,,,
CA2,"Breast Carcinoma; melanoma; Adenocarcinoma; Malignant neoplasm of stomach; Central neuroblastoma; Neoplasm Metastasis; Renal Cell Carcinoma; Neuroblastoma; Pancreatic Neoplasm; Osteoporosis; Pancreatic carcinoma; Malignant neoplasm of urinary bladder; Squamous cell carcinoma of esophagus; Liver carcinoma; Colon Carcinoma; Peroxisome Biogenesis Disorder, Complementation Group C; Rheumatoid Arthritis; TARSAL-CARPAL COALITION SYNDROME; Malignant tumor of colon; Diabetes Mellitus; Distal Renal Tubular Acidosis; Malignant neoplasm of lung; Diabetes Mellitus, Insulin-Dependent; Basal ganglia calcification; Sjogren's Syndrome; Glaucoma; Post-Traumatic Osteoporosis; Leukemogenesis; Osteoporosis, Senile; Endometriosis; ST segment elevation myocardial infarction; Bone necrosis; Bipolar Disorder; Columnar Cell Change of the Breast; Fibrillation; High altitude pulmonary edema; Kidney Diseases; Schizophrenia; Osteoporosis, Age-Related; OSTEOPETROSIS, AUTOSOMAL RECESSIVE 3; Extramedullary erythropoiesis; Cystadenocarcinoma, Serous; Alzheimer's Disease; Stomach Neoplasms; Coronary heart disease; Compression of optic nerve; Atypical Teratoid Rhabdoid Tumor; Thick skull bones; Cranial hyperostosis; Enlargement of skull bones; Excessive growth of skull bones; Hypertrophy of cranial bones; Periodic hypokalemic paresis; Anemia; Abnormality of the renal tubule; Premature coronary artery disease; Aseptic necrosis; Bone infarction; Bone pain; Aseptic Necrosis of Bone; Hemoglobin low; Hepatosplenomegaly; Splenomegaly; Cerebral calcification; Abnormal mental state; Phobic anxiety disorder; Osteopetrosis; Down Syndrome; Angle class 2 malocclusion; Angle class 3 malocclusion; Thrombocytopenia; Knee joint valgus deformity; Malocclusion; Varying degree of multiple fractures; Frequent fractures; Increased fracture rate; Fractures, Multiple; Psoriasis; Adenocarcinoma of pancreas; Neuropathy; Mental handicap; Carcinoid Tumor; Short stature; Abnormal vision; Camurati-Engelmann Syndrome; Hepatomegaly; Decreased platelet count; Extramedullary Hematopoiesis (disorder); Rotting teeth; Dental caries; Acute interstitial pneumonia; Metabolic Bone Disorder; Cholangitis; Ulcerative Colitis; Coronary Arteriosclerosis; Renal tubular acidosis; Dull intelligence; Low intelligence; Carcinoma, Cribriform; Carcinoma, Granular Cell; Adenocarcinoma, Basal Cell; Reduced bone mineral density; Tooth Abnormalities; Acute intermittent porphyria; Adenocarcinoma, Oxyphilic; Adenocarcinoma, Tubular; Poor school performance; beta^+^ Thalassemia; Hereditary Diffuse Gastric Cancer; Peripheral Neuropathy; Malnutrition; Abnormality of epiphysis morphology; Mental deficiency; Cystic Fibrosis; Mental Retardation; Migraine with Aura; Inborn Errors of Metabolism; Dermatitis, Atopic; Developmental delay (disorder); Hypertrophy of lower jaw; mandibular excess (physical finding); Mandibular hyperplasia; Increased size of the mandible; Class III malocclusion; Encephalopathies; Eczema; Intellectual Disability; Mental and motor retardation; Cognitive delay; Global developmental delay; Undergrowth; Failure to gain weight; Pediatric failure to thrive; Pancreatitis",0.0042545616049287; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0593779966354549; 0.0648809611869375; 0.0648809611869375; 0.0688152422187159; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.084286432100041; 0.0919714360040484; 0.095319386034013; 0.1062239757831962; 0.1254380558571286; 0.1537760235124317; 0.1906413554467301; 0.223747154820789; 0.2522264785494494; 0.2643145809900195; 0.2714542429024338; 0.2714542429024338; 0.286740104053178; 0.3099246715197673; 0.3105909001629992; 0.3233418869346274; 0.3510063969122338; 0.3544355608905275; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4209380602168584; 0.4209380602168584; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.4297858918260954; 0.4304973629098372; 0.4325044517055656; 0.4335751357405352; 0.4335751357405352; 0.4381343267935581; 0.439389586518055; 0.4396723023384634; 0.4459714599189374; 0.4506578937113162; 0.4561717689698902; 0.4675904598629673; 0.4790179402069343; 0.4852430673532381; 0.4852430673532381; 0.4923669467696064; 0.4981941174985421; 0.5001612228394569; 0.5140447474168605; 0.5140447474168605; 0.5300976305939776; 0.5300976305939776; 0.5337853752290136; 0.5337853752290136; 0.5359212109443033; 0.5359212109443033; 0.5393787854381349; 0.5393787854381349; 0.549941235475765; 0.5557519470957561; 0.5610226870913673; 0.563120546412355; 0.5696906826730043; 0.5851527280548257; 0.5916904943304121; 0.6002127202571572; 0.6035970790768342; 0.6124306570512981; 0.6319938293757544; 0.6355866602993508; 0.655573080043894; 0.7045203904267408; 0.7096959691931399; 0.7433468668038986; 0.7433468668038986; 0.7433468668038986; 0.7484342194688707; 0.7577323833810212; 0.7815030391631113; 0.7893058450619891; 0.8352623613787349; 0.897310588550617; 0.9238745269736108; 0.9327689937867868; 0.9401531131388324; 0.9449543840411656; 0.9465829057944656; 0.95412990454283,Esophagus Neoplasm; Liver Carcinoma; Carcinoma; Osteopetrosis; Autism Spectrum Disorder; Distal Renal Tubular Acidosis; Diaphyseal Dysplasia; Periodic Hypokalemic Paresis; Osteoporosis; Renal Tubular Acidosis; Anemia; Adenocarcinoma; Dwarfism; Nervous System Diseases; Gastric Cancer; Malocclusion; Stomach Neoplasms; Optic Atrophy; Mental Retardation; Developmental Delay,0.0102679590519094; 0.0520696613701797; 0.0534520155998091; 0.336287627428424; 0.425341435586089; 0.4402141802500753; 0.4541466895915311; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4780231573499264; 0.4780231573499264; 0.5796489603182782; 0.6420878824691651; 0.6524705037929849; 0.6564901877271138; 0.669817442578862; 0.675936313627625; 0.7729545590606223; 0.96477535147595,McLeod neuroacanthocytosis syndrome ORPHA:59306; Osteopetrosis with renal tubular acidosis ORPHA:2785,0.6239678957896782; 0.7068064785325423,Vaccinia virus Ankara IMV chondroitin-binding membrane protein; Variola virus hypothetical protein (gene: F8L); Vaccinia virus Ankara Haemagglutinin; Cowpox virus CPXV125 protein (gene: CPV125 CDS); Ectromelia virus ERPV carbonic anhydrase; Horsepox virus HSPV177 (Immunoglobulin like),0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.691145768348025,yeasx,0.37,Homo sapiens,coxbu
CALHM3,Endometriosis,0.383941725017158,Endometriosis,0.2187610616307245,,,,,,,,
CASP7,"Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of prostate; Mammary Neoplasms, Human; Neoplasm Metastasis; Glioma; Osteoporosis; Lymphoma; Glioblastoma; Liver Cirrhosis, Experimental; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Liver carcinoma; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Myocardial Infarction; Liver neoplasms; Rheumatoid Arthritis; Acute Myeloid Leukemia (AML-M2); cervical cancer; Prostatic Neoplasms; Adenocarcinoma Of Esophagus; Malignant tumor of cervix; Malignant neoplasm of lung; Cervix carcinoma; Endometrial Carcinoma; Leukoplakia; Carcinoma of lung; Primary malignant neoplasm of lung; Spinocerebellar Ataxia Type 7; Diabetes Mellitus, Non-Insulin-Dependent; Non-Small Cell Lung Carcinoma; Leukemia, Myelocytic, Acute; Alzheimer's Disease; Lip and Oral Cavity Carcinoma; Stomach Neoplasms; Glioblastoma Multiforme; Luminal A Breast Carcinoma; Gastric Adenocarcinoma; Acute Myeloid Leukemia, M1; Refractory anemias; Malignant neoplasm of mouth; Breast adenocarcinoma; Myocardial Reperfusion Injury; Vitiligo",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0569142010728473; 0.064548079316548; 0.0648809611869375; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0747863377072194; 0.0773771948186562; 0.0775520919998773; 0.095319386034013; 0.13167400689206; 0.1328002618052838; 0.1352936728187231; 0.1454373331146953; 0.1537760235124317; 0.2050045461627939; 0.2050045461627939; 0.223747154820789; 0.2679411586077776; 0.2714542429024338; 0.2714542429024338; 0.2834835531038365; 0.3044782497745498; 0.333745294913745; 0.3663130598151661; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3975960596292668; 0.4028066164685291; 0.4100742336915555; 0.421267417774367; 0.4213286052188015; 0.4810435657134442; 0.6980473696540115; 0.7965733310657268,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Myeloid Leukemia; Vitiligo; Leukemia,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.525214105372123; 0.5576425853515448; 0.7167438233451096,Carnitine palmitoyl transferase 1A deficiency ORPHA:156; Hypocalcemic vitamin D-resistant rickets ORPHA:93160; Chondrodysplasia-disorder of sex development syndrome ORPHA:1422; Herpes simplex virus encephalitis ORPHA:1930; B4GALT1-CDG ORPHA:79332; USP18 deficiency ORPHA:481665; Juvenile-onset diabetes mellitus-central and peripheral neurodegeneration syndrome ORPHA:445062,0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3826134188846508; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423,Human papillomavirus 201 E7 (gene: E7); Human papillomavirus type 147 transforming protein (gene: E7); Horsepox virus HSPV020e (ankyrin repeats); Horsepox virus HSPV011a; Vaccinia virus hypothetical protein; Variola virus hypothetical protein (gene: B21R); Cowpox virus VHR1 or CPXV025 protein (gene: VHR1); Horsepox virus HSPV011c (ankyrin repeats); Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Horsepox virus HSPV194 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Monkeypox virus ankyrin-like protein; Cowpox virus CPXV016 protein (gene: CPXV016 CDS); Vaccinia virus Ankara CP77 host range protein f2; Cowpox virus CPXV213 protein (gene: CPXV213 CDS); Vaccinia virus Ankara 54.4k ankyrin repeat protein f2; Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Cowpox virus CPXV211 protein (gene: CPXV211 CDS); Cowpox virus CPXV011 protein (gene: CPXV011 CDS); Horsepox virus HSPV033c (ankyrin repeats); Vaccinia virus ankyrin-like protein; Vaccinia virus ankyrin-like protein (gene: C9L); Horsepox virus HSPV005c (Ankyrin repeats); Yaba-like disease virus 148R protein (gene: 148R); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Yaba-like disease virus 8L protein (gene: 8L); Vaccinia virus Ankara CP77 host range protein f4; Horsepox virus HSPV196 (ankyrin-like protein; Provisional); Ectromelia virus ERPV ankyrin; Cowpox virus CPXV039 (gene: CPXV039 CDS); Vaccinia virus Ankara CP77 Host range protein f1; Yaba-like disease virus 146R protein (gene: 146R); Vaccinia virus ankyin-like protein (gene: M1L); Orf virus ORF008 ankyrin repeat protein; Monkeypox virus Zaire-96-I-16 J3L (gene: J3L); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D7L); Cowpox virus CPXV017 protein (gene: CPXV017 CDS); Monkeypox virus Zaire-96-I-16 B17R (gene: B17R); Horsepox virus HSPV005b (ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D9L); Cowpox virus CPXV019 protein (gene: CPXV019 CDS); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D1L); Horsepox virus HSPV181 (ankyrin repeats); Vaccinia virus ankyrin-like protein (gene: B4R); Variola virus hypothetical protein (gene: B19R); Vaccinia virus Ankara 67.9k ankyrin repeat protein; Cowpox virus CPXV008 protein (gene: CPXV008 CDS); Yaba monkey tumor virus ankyrin repeat protein; Horsepox virus HSPV014c (ankyrin repeats); Vaccinia virus ankyrin-like protein (gene: B18R); Vaccinia virus Ankara 72.4k ankyrin repeat protein f2; Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Horsepox virus HSPV033b (Ankyrin repeats); Variola virus hypothetical protein (gene: G3R); Variola virus hypothetical protein (gene: D6L); Orf virus ORF129 ankyrin repeat protein; Vaccinia virus Ankara 54.4k ankyrin repeat protein f1; Horsepox virus HSPV201a (ankyrin repeats); Yaba-like disease virus 147R protein (gene: 147R); Variola virus ankyin-like protein (gene: O1L); Vaccinia virus Ankara Host range protein; Monkeypox virus Zaire-96-I-16 ankyin-like protein (gene: O1L); Yaba-like disease virus 11L protein (gene: 11L); Cowpox virus CPXV027 protein (gene: CPXV027 CDS); Cowpox virus CPXV006 protein (gene: CPXV006 CDS); Horsepox virus HSPV012 (ankyrin-like protein; Provisional); Orf virus ORF128 ankyrin repeat protein; Orf virus ORF126 ankyrin repeat protein; Horsepox virus HSPV022 (ankyrin-like protein; Provisional); Horsepox virus HSPV020b (ankyrin repeats); Variola virus hypothetical protein (gene: B6R); Horsepox virus HSPV004 (ankyrin repeats); Horsepox virus HSPV014b (ankyrin repeats); Cowpox virus CPXV220 protein (gene: CPXV220 CDS); Vaccinia virus Ankara 72.4k ankyrin repeat protein f1; Yaba monkey tumor virus ankyrin-like protein,0.6362779693488597; 0.6362779693488597; 0.7079503198328393; 0.776311155917498; 0.7975886343350181; 0.7988086321880973; 0.8031136315766868; 0.830387084488226; 0.8315214238833722; 0.8320620882218038; 0.8390943852085586; 0.8426793553344071; 0.8507994162096807; 0.8509394234802752; 0.8565042041973229; 0.8665950357166999; 0.876049415394169; 0.8784689389733535; 0.8826243651582266; 0.8826243651582266; 0.8912506515619287; 0.8962695058306248; 0.9005654634109755; 0.9055720084468104; 0.9097056179628632; 0.9102852214746716; 0.9135411983375344; 0.9195586782304176; 0.9199249371723298; 0.920189880588384; 0.920189880588384; 0.924238809115565; 0.9271250260824724; 0.9285312497152513; 0.9285312497152513; 0.9317407101292444; 0.9394149990743936; 0.9407405842467907; 0.945966103627342; 0.9475760000797028; 0.9475760000797028; 0.9475760000797028; 0.9517968639566384; 0.9518028028273808; 0.9566905696255492; 0.9566905696255492; 0.9566905696255492; 0.960637237597315; 0.960637237597315; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9676678660011035; 0.9687365967836944; 0.9695158706192956; 0.970789305792858; 0.9776389019841476; 0.9782376397065295; 0.9784209964188774; 0.9810164003109842; 0.986358730247118,In vitro,0.4;0.44,Homo sapiens;chemical synthesis,Homo sapiens
CCN2,,,Carcinoma; Pulmonary Fibrosis; Alveolitis; Cholestasis; Liver Cirrhosis; Glomerular Hyalinosis; Pulmonary Arterial Hypertension; Aortic Valve Insufficiency; Diffuse Cutaneous Systemic Sclerosis; Limited Systemic Sclerosis; CREST Syndrome; Lung Cancer; Arthritis; Lung Neoplasms; Rheumatoid Arthritis; Liver Fibrosis; Lung Diseases; Hypertension; Posterolateral Diaphragmatic Hernia; Morgagni Diaphragmatic Hernia; Gastroesophageal Reflux Disease; Adenocarcinoma; Dysphagia; Lymphoblastic Leukemia; Scleroderma; Congenital Diaphragmatic Hernia; Subfertility; Dermatitis; Myocardial Infarction; Glomerulosclerosis; Renal Insufficiency; Heart Failure; Congestive Heart Failure; Malabsorption Syndrome,0.0534520155998091; 0.0654534781440596; 0.1025546857843372; 0.336287627428424; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4402141802500753; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4646409362700993; 0.4742592264758768; 0.4780231573499264; 0.5127628024019304; 0.5129298662020659; 0.5162067638232762; 0.5162067638232762; 0.5207800595599322; 0.525214105372123; 0.5632819212593052; 0.5924794904332197; 0.7112499273451761; 0.7360789997461612; 0.7532174466905212; 0.8934893385336675,Diffuse cutaneous systemic sclerosis ORPHA:220393; Limited cutaneous systemic sclerosis ORPHA:220402,0.6279395134845649; 0.6340773186521831,,,In vitro;Saccharomyces cerevisiae;yeasx,0.35;0.37,Homo sapiens;chemical synthesis,Bacillus anthracis;Homo sapiens;hcvco
CCND1,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Retroviridae Infections; melanoma; Adenocarcinoma; Proliferative vitreoretinopathy; Squamous cell carcinoma; Esophageal Neoplasms; Malignant mesothelioma; Pre B-cell acute lymphoblastic leukemia; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Urologic Neoplasms; Hematopoietic Neoplasms; Medulloblastoma; Epithelial ovarian cancer; Brain Tumor, Primary; Skin carcinoma; Cancer of Urinary Tract; Malignant neoplasm of prostate; Carcinoma; Central neuroblastoma; Cervical intraepithelial neoplasia grade 1; Well Differentiated Oligodendroglioma; Carcinomatosis; Primary malignant neoplasm of brain; Mammary Neoplasms, Human; Brain Neoplasms; Neoplasm Metastasis; Barrett Esophagus; Mucoepidermoid Carcinoma; Renal Cell Carcinoma; oligodendroglioma; Neuroblastoma; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Glioma; Squamous cell carcinoma of penis; Osteoporosis; Lymphoma; Endometrial Neoplasms; Glioblastoma; Pancreatic carcinoma; Carcinoma breast stage IV; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Adenoid cystic carcinoma of salivary gland; Genomic Instability; Colorectal Neoplasms; Anaplastic carcinoma; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Adult Acute Lymphocytic Leukemia; Squamous cell carcinoma of esophagus; Anus Neoplasms; Liver carcinoma; Malignant Neoplasms; Osteosarcoma; Colon Carcinoma; Adenocarcinoma of colon; Ganglioneuroma; Skin toxicity; Cardiac Carcinoma; Chondromyxoid fibroma; Chronic Lymphocytic Leukemia; Small cell carcinoma of lung; Hematologic Neoplasms; MYELODYSPLASTIC SYNDROME; Esophageal carcinoma; Ductal Breast Carcinoma; Hamman-Rich syndrome; Tumor Initiation; Undifferentiated carcinoma; Clear-cell metastatic renal cell carcinoma; Carcinoma, Transitional Cell; Oral Cavity Carcinoma; Malignant neoplasm of large intestine; Carcinoma of bladder; Malignant neoplasm of endometrium; Papillary serous cystadenocarcinoma; Unipolar Depression; Uterine Corpus Cancer; Myocardial Infarction; Mammary Carcinoma, Animal; Animal Mammary Neoplasms; Solid Neoplasm; Colonic Neoplasms; Jaw Keratocyst; Mixed Salivary Gland Tumor; Liver neoplasms; Chromophobe Renal Cell Carcinoma; Rheumatoid Arthritis; Sarcoma; Benign neoplasm of brain, unspecified; Breast Cancer, Familial; Invasive Carcinoma; Neck Neoplasms; Chronic leukemia (category); Visual seizure; Comedone; Testicular Germ Cell Tumor; Head and Neck Carcinoma; Recurrent Brain Neoplasm; Benign Ovarian Neoplasm; Low Grade Cervical Squamous Intraepithelial Neoplasia; TARSAL-CARPAL COALITION SYNDROME; Cervical intraepithelial neoplasia grade 2; cervical cancer; Seizures; Lung Neoplasms; Osteosarcoma of bone; Major Depressive Disorder; Malignant tumor of colon; Prostatic Neoplasms; Hodgkin Disease; Anoxia; Burkitt Lymphoma; Hepatoblastoma; Malignant Head and Neck Neoplasm; B-Cell Lymphomas; B-CELL MALIGNANCY, LOW-GRADE; Thymus Hyperplasia; Primary Cutaneous Anaplastic Large Cell Lymphoma; MIXED LINEAGE LEUKEMIA; Malignant neoplasm of liver; Small Lymphocytic Lymphoma; Chondrosarcoma; Squamous cell carcinoma of vulva; Adenocarcinoma Of Esophagus; Malignant tumor of cervix; Malignant neoplasm of lung; Kidney Neoplasm; Peyronie Disease; Cervix carcinoma; Multiple Sclerosis; Fibroid Tumor; Neoplasms, Intracranial; Conventional (Clear Cell) Renal Cell Carcinoma; Triple Negative Breast Neoplasms; Myeloid Leukemia; Pancreatic Ductal Adenocarcinoma; Endometrial Carcinoma; Idiopathic Pulmonary Fibrosis; Hemangioma; Childhood Acute Lymphoblastic Leukemia; Malignant Squamous Cell Neoplasm; Embryonal Carcinoma; Anaplastic Oligodendroglioma; Cervical Squamous Cell Carcinoma; Gastrointestinal Stromal Tumors; Epithelial hyperplasia of skin; Cholangiocarcinoma; Hairy Cell Leukemia; Head and Neck Neoplasms; Blast Phase; Mammary Neoplasms, Experimental; Ataxia Telangiectasia; Pathological fracture; Leukemogenesis; Uterine Cancer; Severe Combined Immunodeficiency; Cutaneous lymphoma; Carcinoma of lung; Pheochromocytoma; Anaplastic astrocytoma; Adenomatous polyp of colon; Human papilloma virus infection; Endometriosis; Thyroid Neoplasm; Cardiac Lymphoma; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Uterine Fibroids; Noninfiltrating Intraductal Carcinoma; Primary malignant neoplasm of lung; Chromosome 8, trisomy; Von Hippel-Lindau Syndrome; Secondary malignant neoplasm of lymph node; Epstein-Barr Virus Infections; Dysplastic Nevus; Peripheral T-Cell Lymphoma; Adenocarcinoma of large intestine; Cerebrovascular Disorders; Verrucous carcinoma; Hamartoma; Uterine Cervical Neoplasm; Laryngeal Squamous Cell Carcinoma; Pancreatitis, Chronic; Kidney Diseases; Nasopharyngeal carcinoma; Parathyroid Adenoma; Papillary thyroid carcinoma; Hereditary Nonpolyposis Colorectal Cancer; Nephroblastoma; Schizophrenia; Malignant Glioma; Non-Small Cell Lung Carcinoma; Gastroesophageal reflux disease; Hypertensive disease; Secondary malignant neoplasm of liver; Leukemia, Myelocytic, Acute; Inflammatory Myofibroblastic Tumor; Large cell neuroendocrine carcinoma; Lichen Sclerosus et Atrophicus; Skin Carcinogenesis; Bone Marrow Diseases; Abnormality of bone marrow cell morphology; Virchow's node (disorder); Adrenal incidentaloma; Cecal Neoplasms; Centrocytic lymphoma; Intermediate Grade Ductal Breast Carcinoma In Situ; Lentigo maligna melanoma; Malignant neoplasm of cecum; Milroy Disease; Skin Neoplasms; Urothelial Carcinoma; Carcinoma, Papillary; Hurthle Cell Tumor; Stage 4S neuroblastoma; Astrocytoma; Lymphoma, T-Cell, Cutaneous; Aplasia Cutis Congenita; Hemangiosarcoma; Osteoarthritis of the hand; Arthritis, Psoriatic; Alzheimer's Disease; Anxiety Disorders; Peroxisome Biogenesis Disorder, Complementation Group H; Heart Neoplasm; impaired motor coordination; Non-small cell lung cancer stage III; Papillary cystic tumor; Endometrioid carcinoma ovary; Intestinal Polyps; Prolymphocytic Leukemia; Bronchioloalveolar Adenocarcinoma; Liver and Intrahepatic Biliary Tract Carcinoma; Thrombocythemia, Essential; Generalized osteopenia; Lymphoma, Non-Hodgkin; Prolactinoma; Acute lymphocytic leukemia; Lip and Oral Cavity Carcinoma; High Grade Lymphoma (neoplasm); Primary Carcinoma; Stomach Neoplasms; Adenoid Cystic Carcinoma; Inflammatory Bowel Diseases; Endometrial stromal sarcoma, high grade; Transitional Cell Neoplasm; Adenomyoma; Endometrial Stromal Tumors; CARCINOMA OF VULVA; Atypical Teratoid Rhabdoid Tumor; Cerebral Amyloid Angiopathy; Mammary adenocarcinoma; Squamous cell carcinoma of tongue; Adenoma; Basal Cell Nevus Syndrome; Malignant neoplasm of male breast; Glioblastoma Multiforme; synovial sarcoma; Renal medullary carcinoma; Atypical polypoid adenomyoma; Burkitt-like lymphoma; psychosocial stressor; Carcinoma in situ of uterine cervix; Disseminated neuroblastoma; Anaplasia; Anemia; Malignant neoplasm of kidney; Neoplasm, Residual; keratoacanthoma; Familial multiple trichoepitheliomata; Stage 0 Skin Melanoma; stage, endometrial cancer; Epithelioid and spindle cell nevus; Pilomatrixoma; Renal carcinoma; Thyroid carcinoma; androgen independent prostate cancer; Pituitary Adenoma; Ki-1+ Anaplastic Large Cell Lymphoma; Drug abuse; Pituitary Neoplasms; Lymphocytic infiltration; Malignant neoplasm of brain; Serum creatinine raised; Nevus, Blue; extranodal lymphoma; HYPERPARATHYROIDISM 3; Malignant tumor of parathyroid gland; Alcohol abuse; Hyperparathyroidism, Primary; Waldenstrom Macroglobulinemia; Fibrosis; Senile Plaques; Luminal A Breast Carcinoma; Bone pain; Lymphoma, Lymphocytic, Intermediate; hyperparathyroid; HYPERPARATHYROIDISM 1; Papillary Thyroid Microcarcinoma; Multiple Endocrine Neoplasia Type 1; HER2 gene amplification; Merkel cell carcinoma; Pituitary Diseases; Meningioma, benign, no ICD-O subtype; Kidney Failure, Acute; Mammary Tumorigenesis; Neuroectodermal Tumor, Primitive; leiomyosarcoma; Carcinoma of larynx; Hemoglobin low; Intrahepatic Cholangiocarcinoma; Gastric Adenocarcinoma; Carcinoma of Male Breast; Liver Neoplasms, Experimental; Experimental Hepatoma; Fibromatosis, Aggressive; Squamous cell carcinoma of mouth; AICARDI-GOUTIERES SYNDROME 1; Splenomegaly; Acute myocardial infarction; Agenesis of corpus callosum; Multiple Myeloma; Nephrotic Syndrome; Trisomy 11; Hypochondroplasia (disorder); Anxiety; Hepatoma, Novikoff; Retinoblastoma; MYELOPROLIFERATIVE SYNDROME, TRANSIENT; Ulcer; Phyllodes Tumor; Hepatoma, Morris; Leukemia, Prolymphocytic, B-Cell; Triglyceride storage disease with ichthyosis; Group B streptococcal pneumonia; Malignant melanoma of ciliary body; Metaphyseal chondrodysplasia; Nevi and Melanomas; Familial Alzheimer Disease (FAD); Malignant Peripheral Nerve Sheath Tumor; Down Syndrome; Adenoma of large intestine; Melanocytic nevus of skin; HYPERTRICHOSIS, CONGENITAL GENERALIZED; Benign neurologic neoplasms; Lepidic Predominant Adenocarcinoma; premalignant lesion; stage, non-small cell lung cancer; SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME; Mature B-Cell Non-Hodgkin Lymphoma; Malignant neoplasm of larynx; Refractory anemias; Immunologic Deficiency Syndromes; Malignant neoplasm of salivary gland; Mouth Neoplasms; Smoldering myeloma; Coxsackievirus Infections; Hyperlipoproteinemia Type I; Papillomatosis; Malignant neoplasm of mouth; Rhabdoid Tumor; Splenic Marginal Zone B-Cell Lymphoma; Melanocytic nevus; Mycoses; Neurilemmoma; Benign melanocytic nevus; Papilloma, Squamous Cell; Apert syndrome; Carcinoma of extrahepatic bile duct; Parathyroid hyperplasia; Papilloma; Follicular adenoma; Rectal Carcinoma; Squamous cell carcinoma of skin; Marginal Zone B-Cell Lymphoma; Solitary fibrous tumor; Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; Vulval intraepithelial neoplasia; Carcinoma ex pleomorphic adenoma; malignant neoplasm of breast staging; Malignant neoplasm of thyroid; Adenocarcinoma of pancreas; Breast Fibrocystic Disease; Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Trisomy; Germ cell tumor; Neurofibromatosis 1; Early-Stage Breast Carcinoma; Squamous cell carcinoma of lung; Oncocytoma, renal; Fibrolamellar Hepatocellular Carcinoma; Nodular Goiter; Peripheral Vascular Diseases; Meningioma; Squamous cell carcinoma of tonsil; Pancreatic carcinoma, familial; Fibromyxosarcoma; Adenocarcinoma of prostate; Luminal B Breast Carcinoma; Monosomy; Squamous Cell Neoplasms; Superficial spreading malignant melanoma of skin; Hemimegalencephaly; Peptic Ulcer; Precancerous Conditions; Salivary Gland Neoplasms; Malignant neoplasm of tongue; Status Epilepticus; Myocardial Ischemia; Lymphoma, Large-Cell, Follicular; Gardner Syndrome; Ovarian Diseases; Cicatrix, Hypertrophic; Malignant lymphoma - lymphoplasmacytic; leukemia; Generalized muscle weakness; Cyclic neutropenia; Malignant neoplasm of skin; Intestinal Neoplasms; Cardiovascular Diseases; Promyelocytic leukemia; Hereditary Leiomyomatosis and Renal Cell Cancer; Premenopausal breast cancer; Primary amyloidosis; Cardiomyopathy, Familial Idiopathic; Weight decreased; Uveal melanoma; Myeloid Leukemia, Chronic; Plasma cell dyscrasia; Adenomatous Polyposis Coli; Acute kidney injury; XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C; Lymphoid hyperplasia; Transitional cell carcinoma of bladder; Thymic Carcinoma; TUBEROUS SCLEROSIS 2 (disorder); Lymphoid neoplasm; Kaposi Sarcoma; ESTROGEN RESISTANCE; Plasma Cell Neoplasm; Steatohepatitis; Hyperglycemia; Osteopenia; Epithelial hyperplasia; Anaplastic thyroid carcinoma; Richter's syndrome; Parathyroid Gland Adenocarcinoma; Metastatic melanoma; Ulcerative Colitis; Neuroendocrine Tumors; Deficiency of glucose-6-phosphate dehydrogenase; Chronic Obstructive Airway Disease; Obesity; ACTH-Secreting Pituitary Adenoma; Adenocarcinoma of lung (disorder); Keratosis; Ewings sarcoma; Carcinoma, Cribriform; Carcinoma, Granular Cell; Pancreatic intraepithelial neoplasia; Laryngeal neoplasm; Monoclonal B-Cell Lymphocytosis; Lymphoma, Follicular; Hepatocarcinogenesis; Fatty Liver; Condition, Preneoplastic; Adenocarcinoma, Basal Cell; Carcinoma, Small Cell; Leukemia, B-Cell; Tuberous Sclerosis; Erectile dysfunction; Precursor Cell Lymphoblastic Leukemia Lymphoma; Sarcoma, Epithelioid; Cardiac Arrest; Adenocarcinoma, Oxyphilic; Leukemia, Plasma Cell; Liposarcoma, Dedifferentiated; Endometrial Stromal Sarcoma; Hyperplasia; Thymoma; Adult Diffuse Large B-Cell Lymphoma; Childhood Diffuse Large B-Cell Lymphoma; Adenocarcinoma, Tubular; Peripheral Arterial Diseases; Ataxia; Colorectal cancer metastatic; Metabolic Syndrome X; Hemangioblastoma; Hyperparathyroidism; Kidney damage; liposarcoma; Female Breast Carcinoma; Multiple Endocrine Neoplasia; Aortic Valve Insufficiency; Hereditary Diffuse Gastric Cancer; Lymphoproliferative Disorders; Neoplastic Cell Transformation; Atypical Ductal Breast Hyperplasia; Carcinosarcoma; Erythroblastosis; Giant Cell Tumors; Cutaneous Melanoma; precancerous lesions; Breast Diseases; Malignant neoplasm of female breast; Cerebellar Ataxia; Decreased antibody level in blood; Invasive Lobular Breast Carcinoma; Interstitial Cystitis; Diffuse Large B-Cell Lymphoma; Laryngeal Diseases; Parathyroid Neoplasms; Pituitary-dependent Cushing's disease; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Malignant neoplasm of colon stage IV; Ductal Carcinoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Congenital chromosomal disease; Precursor cell lymphoblastic lymphoma; Sezary Syndrome; Lymphocytosis; Tongue Carcinoma; Sporadic Breast Carcinoma; Persistent infection; Leukoplakia, Oral; invasive cancer; Familial primary gastric lymphoma; Retinal Diseases; ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1; Acoustic Neuroma; Fever; Leukemia, T-Cell; Prostatic Intraepithelial Neoplasias; Mucosa-Associated Lymphoid Tissue Lymphoma; Neoplasms, Experimental; Hypogammaglobulinemia; Hashimoto Disease; polyps; Nevus; Hemophilia A; Lymphadenopathy; Coronary Artery Disease; Leukoencephalopathy, Progressive Multifocal; Plasmacytoma; Fatigue; Anorexia; Familial M??ni??re disease; Thyroid Gland Follicular Adenoma; Hyperinsulinism; Mycosis Fungoides; Hepatitis C, Chronic; Adult T-Cell Lymphoma/Leukemia; Monoclonal Gammopathy of Undetermined Significance; Dwarfism; Familial lichen amyloidosis",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0189794808441368; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0308703957553632; 0.0314665934969085; 0.0334891258932371; 0.0354767239335874; 0.0387439397151409; 0.044151975756427; 0.0482468351695405; 0.0492766532827251; 0.0569142010728473; 0.0593779966354549; 0.0593779966354549; 0.0593779966354549; 0.0617471306652618; 0.0617471306652618; 0.064548079316548; 0.064548079316548; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0775520919998773; 0.0775520919998773; 0.0775520919998773; 0.0827744840860166; 0.084286432100041; 0.084286432100041; 0.0891725280554336; 0.0919714360040484; 0.0919714360040484; 0.095319386034013; 0.095319386034013; 0.0991201145654548; 0.1029977559100099; 0.1062239757831962; 0.1112281755580192; 0.1138051695421299; 0.1138051695421299; 0.1138051695421299; 0.1138051695421299; 0.1147307578771389; 0.1193558174333938; 0.1253114324938153; 0.1254380558571286; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1352936728187231; 0.1352936728187231; 0.1352936728187231; 0.1413782599148022; 0.1454373331146953; 0.1454373331146953; 0.1454373331146953; 0.1454373331146953; 0.1461248774859792; 0.1537760235124317; 0.1537760235124317; 0.1602092191314262; 0.1602092191314262; 0.1602092191314262; 0.1614820148711231; 0.1653491983554358; 0.1735868515093891; 0.1735868515093891; 0.1735868515093891; 0.1735868515093891; 0.1770067065899052; 0.1770067065899052; 0.1897991423047819; 0.1906413554467301; 0.2050045461627939; 0.2050045461627939; 0.2053083986145698; 0.2062010908869036; 0.2109483801368481; 0.21122597829463; 0.223747154820789; 0.223747154820789; 0.2454476567103779; 0.2462384927636234; 0.2521987644415915; 0.2522264785494494; 0.2522264785494494; 0.2522264785494494; 0.2522264785494494; 0.2522264785494494; 0.2522264785494494; 0.2605479444258003; 0.2643145809900195; 0.2643145809900195; 0.2643145809900195; 0.2643145809900195; 0.2679411586077776; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2834835531038365; 0.2835142372342932; 0.290158730291654; 0.290158730291654; 0.2980670559114652; 0.2980670559114652; 0.2980670559114652; 0.3018974726133723; 0.3044782497745498; 0.3099246715197673; 0.3099246715197673; 0.3099246715197673; 0.3104232675696299; 0.3112516166225269; 0.3176684185973055; 0.3199171478489988; 0.3199171478489988; 0.333745294913745; 0.340892538685018; 0.3412203844672238; 0.3412203844672238; 0.3494455519738624; 0.3508665345292502; 0.3508665345292502; 0.3508665345292502; 0.3510063969122338; 0.3544355608905275; 0.3553621627681198; 0.3638414818541592; 0.3663130598151661; 0.3712878513813393; 0.3763374964032415; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3925783478421996; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.39623320406434; 0.39623320406434; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3986414839122469; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4100742336915555; 0.4100742336915555; 0.4100901006059349; 0.4100901006059349; 0.4100901006059349; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4186011760974318; 0.4192169590514327; 0.4192169590514327; 0.4192169590514327; 0.421267417774367; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425992946703162; 0.4269926086051838; 0.429029854971378; 0.4297858918260954; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4307603335611732; 0.4325044517055656; 0.4330362522463816; 0.4330362522463816; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4396723023384634; 0.4396723023384634; 0.4396723023384634; 0.4396723023384634; 0.4396723023384634; 0.4421745246585178; 0.4459714599189374; 0.4459714599189374; 0.4459714599189374; 0.4459714599189374; 0.4459714599189374; 0.4459714599189374; 0.4479115285676636; 0.4506578937113162; 0.4506578937113162; 0.4506578937113162; 0.4506578937113162; 0.4506578937113162; 0.4506578937113162; 0.4506578937113162; 0.4564472886428772; 0.4564472886428772; 0.4588513406515081; 0.4615352570710579; 0.4615352570710579; 0.466957409863091; 0.4675904598629673; 0.4675904598629673; 0.4675904598629673; 0.4675904598629673; 0.4675904598629673; 0.4675904598629673; 0.4704594475773637; 0.472444704048021; 0.472444704048021; 0.472444704048021; 0.472444704048021; 0.4749780675672355; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4790179402069343; 0.4790179402069343; 0.4790179402069343; 0.4790179402069343; 0.4851378030288289; 0.4852430673532381; 0.4852430673532381; 0.4906258721078565; 0.4906258721078565; 0.4923669467696064; 0.4923669467696064; 0.4952592576151974; 0.4981941174985421; 0.4981941174985421; 0.5001612228394569; 0.5001612228394569; 0.5017066790423467; 0.5019670090704682; 0.5049674142533507; 0.5140447474168605; 0.5140447474168605; 0.51550637274795; 0.5188223685230745; 0.5251317541886066; 0.5337853752290136; 0.5337853752290136; 0.5337853752290136; 0.5337853752290136; 0.5337853752290136; 0.533913711453195; 0.533913711453195; 0.533913711453195; 0.533913711453195; 0.5359212109443033; 0.5359212109443033; 0.5359212109443033; 0.5359212109443033; 0.5393787854381349; 0.5393787854381349; 0.5393787854381349; 0.5453394612016188; 0.549941235475765; 0.549941235475765; 0.549941235475765; 0.549941235475765; 0.5514573300659174; 0.5523521032803237; 0.553002957824355; 0.553002957824355; 0.5557519470957561; 0.5557519470957561; 0.5568517196017908; 0.5568517196017908; 0.5568517196017908; 0.5568517196017908; 0.5568517196017908; 0.5568517196017908; 0.5655222348249326; 0.5655222348249326; 0.5655222348249326; 0.5683976277847906; 0.5696906826730043; 0.5696906826730043; 0.5696906826730043; 0.5696906826730043; 0.5696906826730043; 0.5696906826730043; 0.5696906826730043; 0.5710095678317721; 0.5710095678317721; 0.5710095678317721; 0.5710095678317721; 0.5754799679683854; 0.5768212166102149; 0.5768212166102149; 0.582492855487907; 0.5913651925298382; 0.5956632182199403; 0.5956632182199403; 0.5956632182199403; 0.6002127202571572; 0.6002127202571572; 0.6002127202571572; 0.6035970790768342; 0.6035970790768342; 0.6196470808426647; 0.6248356417853507; 0.6274540883972485; 0.6319938293757544; 0.6332132835539771; 0.6355866602993508; 0.6447029562500783; 0.652707626880454; 0.652707626880454; 0.655573080043894; 0.655573080043894; 0.6588479076808555; 0.6677140893034832; 0.6691893635307453; 0.6693434807212948; 0.6740259274935673; 0.6841967398409226; 0.6959870102453846; 0.6962828901009075; 0.6974821940437801; 0.701831040553294; 0.7068844070911514; 0.7129583530027284; 0.7240930522443176; 0.7511652060995492; 0.7651930135295156; 0.7658980225613361; 0.7796824214131131; 0.7961936196098257; 0.8148412516612868; 0.8245140009975604; 0.827626149232917; 0.8343509960860942; 0.8367216325123092; 0.839057838231319; 0.8405066264419017; 0.8441962785769224,"Breast Carcinoma; Esophagus Neoplasm; Urinary Tract Cancer; Marfan Syndrome; Mammary Neoplasms; Anaplastic Carcinoma; Breast Cancer; Lymphocytic Leukemia; Liver Carcinoma; Schizophrenia; Carcinoma; Urologic Neoplasms; Brain Neoplasms; Intracranial Neoplasm; Nasopharyngeal Carcinoma; Kidney Cancer; Kidney Neoplasm; Polycythemia; Endometrial Carcinoma; Amyloidosis; Carcinoma Of The Head And Neck; Colorectal Cancer; Papillary Cystadenoma Of The Epididymis; Lung Cancer; Cervical Cancer; Renal Carcinoma; Paraproteinemia; Uterine Cervix Neoplasm; Lung Neoplasms; Osteopenia; Multiple Myeloma; Mental Depression; Lymphoma, Lymphocytic, Intermediate; Papillomatosis; Myocardial Ischemia; Hypercalcemia; Capillary Hemangioma Of Retina; Hypertension; Malignant Lymphoma, Lymphocytic, Intermediate Differentiation; Spinal Cord Compression; Melanoma; Paraganglioma; Hemangiosarcoma; Liver Cancer; Anemia; Adenocarcinoma; Colonic Neoplasms; Pheochromocytoma; Pancreatic Cyst; Prostatic Neoplasms; Endometrial Neoplasms; Hyperparathyroidism; Papilloma; Liver Neoplasms; B-Cell Lymphoma; Hearing Loss; Multiple Renal Cysts; Malignant Neoplasm Of Salivary Gland; Malignant Neoplasm; Prostate Cancer; Thyroid Gland Follicular Adenoma; Salivary Gland Neoplasm; Kidney Disease; Pancreatic Neoplasm; Pleural Effusion; Gastric Cancer; Thyroid Neoplasm; Stomach Neoplasms; Leukemia; Thyroid Carcinoma; Anorexia; Nephrotic Syndrome",0.0075861267486594; 0.0102679590519094; 0.0102679590519094; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0402286636010764; 0.0487679768343083; 0.0520696613701797; 0.0531117779464085; 0.0534520155998091; 0.0839188440969517; 0.1534453668959814; 0.2038801271174535; 0.2278592962769385; 0.3094716280561038; 0.336287627428424; 0.3528591516609595; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4402141802500753; 0.4402141802500753; 0.4541466895915311; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4646409362700993; 0.4646409362700993; 0.4723647227028846; 0.4723647227028846; 0.4723647227028846; 0.4780231573499264; 0.4780231573499264; 0.4809179010794786; 0.4867879381749835; 0.4875380732267193; 0.4875380732267193; 0.4931425946912698; 0.504364324740411; 0.5127628024019304; 0.5129298662020659; 0.5576425853515448; 0.5632819212593052; 0.5681293104170607; 0.5940503504528969; 0.5973360026714207; 0.6104715460837368; 0.6198254949034767; 0.6252040071965056; 0.6420878824691651; 0.6508151871447407; 0.6508151871447407; 0.6524705037929849; 0.6524705037929849; 0.669817442578862; 0.7167438233451096; 0.7414460416900516; 0.8373515856057342; 0.8825528876115188,"Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Auriculocondylar syndrome ORPHA:137888; Chondrosarcoma ORPHA:55880; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Isolated hyperchlorhidrosis ORPHA:542657; Kindler epidermolysis bullosa ORPHA:2908; Ulnar-mammary syndrome ORPHA:3138; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Rieger anomaly ORPHA:91483; Unverricht-Lundborg disease ORPHA:308; Early-onset nuclear cataract ORPHA:98991; Bruck syndrome ORPHA:2771; CHST3-related skeletal dysplasia ORPHA:263463; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Craniosynostosis, Boston type ORPHA:1541; Hereditary papillary renal cell carcinoma ORPHA:47044; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Osteofibrous dysplasia ORPHA:488265; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Parietal foramina with clavicular hypoplasia ORPHA:251290; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; X-linked osteoporosis with fractures ORPHA:391330; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Dermatofibrosarcoma protuberans ORPHA:31112; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402; BOR syndrome ORPHA:107; Multiple osteochondromas ORPHA:321; Alagille syndrome due to 20p12 microdeletion ORPHA:261600; Alagille syndrome due to a JAG1 point mutation ORPHA:261619; Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome ORPHA:412022; Helicoid peripapillary chorioretinal degeneration ORPHA:86813; Kuskokwim syndrome ORPHA:1149; Microphthalmia with brain and digit anomalies ORPHA:139471; Juvenile Paget disease ORPHA:2801; Non-seminomatous germ cell tumor of testis ORPHA:363494; ABeta amyloidosis, Arctic type ORPHA:324723; ABeta amyloidosis, Dutch type ORPHA:100006; ABeta amyloidosis, Iowa type ORPHA:324708; ABeta amyloidosis, Italian type ORPHA:324713; ABetaA21G amyloidosis ORPHA:324718; ABetaL34V amyloidosis ORPHA:324703; Autosomal dominant osteopetrosis type 1 ORPHA:2783; Branchio-oculo-facial syndrome ORPHA:1297; Campomelic dysplasia ORPHA:140; Carvajal syndrome ORPHA:65282; Dyssegmental dysplasia, Silverman-Handmaker type ORPHA:1865; Endosteal hyperostosis, Worth type ORPHA:2790; Erythrokeratodermia-cardiomyopathy syndrome ORPHA:476096; Hypopigmentation-punctate palmoplantar keratoderma syndrome ORPHA:324561; Isolated Pierre Robin syndrome ORPHA:718; LRP5-related primary osteoporosis ORPHA:498481; Multiple myeloma ORPHA:29073; Osteoporosis-pseudoglioma syndrome ORPHA:2788; Osteosclerosis-developmental delay-craniosynostosis syndrome ORPHA:178377; Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome ORPHA:228012; Schwartz-Jampel syndrome ORPHA:800; Skin fragility-woolly hair-palmoplantar keratoderma syndrome ORPHA:293165; Autosomal recessive hypophosphatemic rickets ORPHA:289176; Hyperostosis corticalis generalisata ORPHA:3416; Complete atrioventricular septal defect with ventricular hypoplasia ORPHA:99067; Mutilating palmoplantar keratoderma with periorificial keratotic plaques ORPHA:659; Partial atrioventricular septal defect ORPHA:1330; Retinopathy of prematurity ORPHA:90050; Epithelioid hemangioendothelioma ORPHA:157791; Autosomal dominant non-syndromic sensorineural deafness type DFNA ORPHA:90635; Atelosteogenesis type I ORPHA:1190; Atelosteogenesis type III ORPHA:56305; Autosomal spastic paraplegia type 58 ORPHA:397946; Boomerang dysplasia ORPHA:1263; Craniofacial dysplasia-osteopenia syndrome ORPHA:314555; Frank-Ter Haar syndrome ORPHA:137834; Isolated biliary atresia ORPHA:30391; Isolated congenital breast hypoplasia/aplasia ORPHA:180188; Larsen syndrome ORPHA:503; Legius syndrome ORPHA:137605; Multiple epiphyseal dysplasia type 5 ORPHA:93311; Pierson syndrome ORPHA:2670; Spondyloepimetaphyseal dysplasia, matrilin-3 type ORPHA:156728; Complete atrioventricular septal defect-tetralogy of Fallot ORPHA:99068; Aplasia cutis congenita ORPHA:1114; Familial exudative vitreoretinopathy ORPHA:891; Early-onset posterior polar cataract ORPHA:98993; Giant cell glioblastoma ORPHA:251579; Gliosarcoma ORPHA:251576; Alpha-dystroglycan-related  limb-girdle muscular dystrophy R16 ORPHA:280333; Autosomal dominant Charcot-Marie-Tooth disease type 2C ORPHA:99937; Autosomal dominant brachyolmia ORPHA:93304; Autosomal dominant congenital benign spinal muscular atrophy ORPHA:1216; Dent disease type 2 ORPHA:93623; Dopa-responsive dystonia due to sepiapterin reductase deficiency ORPHA:70594; Familial digital arthropathy-brachydactyly ORPHA:85169; Familial hypocalciuric hypercalcemia type 2 ORPHA:101049; LAMA5-related multisystemic syndrome ORPHA:521450; Metatropic dysplasia ORPHA:2635; Muscle-eye-brain disease with bilateral multicystic leucodystrophy ORPHA:370997; Muscular dystrophy, Selcen type ORPHA:199340; Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome ORPHA:300333; Oculocerebrorenal syndrome of Lowe ORPHA:534; Parastremmatic dwarfism ORPHA:2646; Phakomatosis cesiomarmorata ORPHA:79484; Scapuloperoneal spinal muscular atrophy ORPHA:431255; Severe congenital hypochromic anemia with ringed sideroblasts ORPHA:300298; Spondyloepiphyseal dysplasia, Maroteaux type ORPHA:263482; Spondylometaphyseal dysplasia, Kozlowski type ORPHA:93314; Vein of Galen aneurysmal malformation ORPHA:1053; Wolfram-like syndrome ORPHA:411590; Spondyloepimetaphyseal dysplasia with joint laxity ORPHA:93359; Periventricular nodular heterotopia ORPHA:98892; B-cell chronic lymphocytic leukemia ORPHA:67038; Atypical Werner syndrome ORPHA:79474; Autosomal dominant Charcot-Marie-Tooth disease type 2F ORPHA:99940; Autosomal recessive Emery-Dreifuss muscular dystrophy ORPHA:98855; Autosomal semi-dominant severe lipodystrophic laminopathy ORPHA:280365; Charcot-Marie-Tooth disease type 2B1 ORPHA:98856; Congenital hereditary endothelial dystrophy type II ORPHA:293603; Congenital muscular dystrophy due to LMNA mutation ORPHA:157973; Corneal dystrophy-perceptive deafness syndrome ORPHA:1490; Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome ORPHA:2229; Familial dilated cardiomyopathy with conduction defect due to LMNA mutation ORPHA:300751; Familial partial lipodystrophy, Dunnigan type ORPHA:2348; Familial partial lipodystrophy, Kobberling type ORPHA:79084; Heart-hand syndrome, Slovenian type ORPHA:168796; LMNA-related cardiocutaneous progeria syndrome ORPHA:363618; Mandibuloacral dysplasia with type A lipodystrophy ORPHA:90153; Hutchinson-Gilford progeria syndrome ORPHA:740; Restrictive dermopathy ORPHA:1662; Mantle cell lymphoma ORPHA:52416; Osteogenesis imperfecta ORPHA:666",0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.3900898302534297; 0.4045231980457672; 0.433039750392822; 0.433039750392822; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.639029370164481; 0.6581690778726346; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,"Trichodysplasia spinulosa-associated polyomavirus large T antigen (gene: T); Human polyomavirus 10 large T Antigen; WU Polyomavirus large T antigen; Yaba-like disease virus 142R protein (gene: 142R); Vaccinia virus ser/thr kinase (gene: B1R); Vaccinia virus Ankara Serine/threonine-protein kinase; Horsepox virus HSPV179 (Serine/Threonine protein kinase, Vaccinia Related Kinase); Human polyomavirus 6 large T antigen; Human polyomavirus 9 large T antigen; Human polyomavirus IPPyV large T antigen protein (gene: large T antigen); BK polyomavirus large T antigen; Variola virus hypothetical protein (gene: B1R); Monkeypox virus ser/thr protein kinase-like protein; Monkeypox virus Zaire-96-I-16 B3R (gene: B3R); Banna virus strain JKT-6423 Vp7; Monkeypox virus Zaire-96-I-16 B11R (gene: B11R); MW polyomavirus large T antigen; MX polyomavirus large T-antigen; Horsepox virus HSPV189 (Serine/threonine protein kinase); JC polyomavirus hypothetical protein; Orf virus ORF130 putative serine/threonine protein kinase; Molluscum contagiosum virus subtype 1 MC017L (gene: MC017L); Vaccinia virus ser/thr protein kinase-like protein (gene: B12R); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); KI polyomavirus Stockholm 350 large T antigen; Cowpox virus CPXV206 protein (gene: CPXV206 CDS); KI polyomavirus large T antigen; Human betaherpesvirus 6B Phosphotransferase (gene: U69); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human gammaherpesvirus 8 ORF72; Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Yaba monkey tumor virus 142R; Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Ectromelia virus ERPV serine/threonine kinase; Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Monkeypox virus ser/thr kinase; Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Monkeypox virus Zaire-96-I-16 Ser/Thr kinase (gene: C16L); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Variola virus Ser/Thr kinase (gene: C14L); Vaccinia virus Ser/Thr kinase (gene: F10L); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Human gammaherpesvirus 8 ORF36 (gene: ORF36); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3)",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.664689610422691; 0.6761714078632568; 0.691145768348025; 0.6920622798772148; 0.6980058392556946; 0.7054555693277184; 0.7108466056279036; 0.7108466056279036; 0.7553529087917877; 0.7975886343350181; 0.8090912655264054; 0.8090912655264054; 0.8164631368980444; 0.8400145987535752; 0.8412554142619568; 0.8458935424065495; 0.8567113603862105; 0.8623814598290633; 0.8826243651582266; 0.9049668877841942; 0.9320456693098416; 0.93590945176733; 0.960637237597315; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9624639844306644; 0.9624639844306644; 0.9658028592930472; 0.9687365967836944; 0.9782376397065295; 0.9782376397065295; 0.978680518510813; 0.985687915361386; 0.9867877113290736; 0.988150003801932; 0.9886132556795868; 0.9886132556795868,,,,
CCSAP,,,,,Christianson syndrome ORPHA:85278; Alkaline ceramidase 3 deficiency ORPHA:502444; Distal 22q11.2 microdeletion syndrome ORPHA:261330; Aniridia-cerebellar ataxia-intellectual disability syndrome ORPHA:1065,0.3762014630157917; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423,,,,,,
CD22,"Neoplasm Metastasis; Lymphoma; Liver carcinoma; Chronic Lymphocytic Leukemia; Hematologic Neoplasms; MYELODYSPLASTIC SYNDROME; Systemic Scleroderma; Connective Tissue Diseases; Burkitt Lymphoma; B-Cell Lymphomas; Small Lymphocytic Lymphoma; Malignant neoplasm of lung; Acute leukemia; Myeloid Leukemia; Childhood Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Hairy Cell Leukemia; Cutaneous lymphoma; Carcinoma of lung; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Primary malignant neoplasm of lung; Chromosome 8, trisomy; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Acute lymphocytic leukemia; High Grade Lymphoma (neoplasm); Lymphoid leukemia; Neoplasm, Residual; Waldenstrom Macroglobulinemia; Multiple Myeloma; Hemolytic-Uremic Syndrome; Mental disorders; Lupus Erythematosus, Systemic; Splenic Marginal Zone B-Cell Lymphoma; Trisomy; Monosomy; Infant Leukemia; leukemia; Precursor Cell Lymphoblastic Leukemia Lymphoma; Precursor B-cell lymphoblastic leukemia; Autoimmune Diseases; Diffuse Large B-Cell Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Bullous pemphigoid; Vasculitis; High density lipoprotein measurement",0.0648809611869375; 0.0739788831250619; 0.095319386034013; 0.1147307578771389; 0.1253114324938153; 0.1254380558571286; 0.1900258729042946; 0.2139814021986384; 0.2521987644415915; 0.2522264785494494; 0.2643145809900195; 0.2714542429024338; 0.2835142372342932; 0.2980670559114652; 0.3099246715197673; 0.3105909001629992; 0.3412203844672238; 0.3638414818541592; 0.3663130598151661; 0.383941725017158; 0.3902116649640871; 0.3925783478421996; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3975960596292668; 0.4103119460235835; 0.4115056600660309; 0.4126392832024548; 0.4213286052188015; 0.425419812815905; 0.4335751357405352; 0.4459714599189374; 0.4506578937113162; 0.4588513406515081; 0.5393787854381349; 0.5451009374855866; 0.5512224939896888; 0.5913651925298382; 0.6035970790768342; 0.610971999959321; 0.8178117518835931; 0.8913309410682808,,,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency ORPHA:404499; NON RARE IN EUROPE: Immunoglobulin A deficiency ORPHA:69127; Short stature due to growth hormone qualitative anomaly ORPHA:629,0.3762014630157917; 0.7068064785325423; 0.7068064785325423,,,,,,
CEACAM19,Breast Carcinoma; Malignant neoplasm of breast,0.0042545616049287; 0.0191435238361999,Alzheimer Disease,0.4560460337187313,,,"Molluscum contagiosum virus subtype 1 MC157R (gene: MC157R); Vaccinia virus Ankara Haemagglutinin; Human alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Human adenovirus 41 E3 31.6K; Human adenovirus 23 CR1 b protein (gene: E3); Papiine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Vaccinia virus hemagglutinin (gene: A56R); Human gammaherpesvirus 8 K14; Molluscum contagiosum virus subtype 1 MC162R (gene: MC162R); Human adenovirus 52 E3 CR1-beta1 (gene: E3); Cercopithecine betaherpesvirus 5 membrane protein RL11M (gene: RL11M); Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Human alphaherpesvirus 1 envelope glycoprotein C (gene: UL44); Horsepox virus HSPV177 (Immunoglobulin like); Cowpox virus CPXV209 protein (gene: CPXV209 CDS); Human adenovirus 64 E3 48.9 kDa protein; Cowpox virus CPXV194 protein (gene: CPXV194 CDS); Cercopithecine betaherpesvirus 5 membrane protein RL11Q (gene: RL11Q); Variola virus hypothetical protein (gene: J9R); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Molluscum contagiosum virus subtype 1 MC080R (gene: MC080R); Human betaherpesvirus 5 membrane glycoprotein UL7 (gene: UL7); Human mastadenovirus A E3 CR1-beta1; Vaccinia virus IL-beta-binding protein (gene: VACWR-B15R); Monkeypox virus bifunctional hemagglutinin/type-I membrane glycoprotein; Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta); Human adenovirus 61 E3 CR1 beta; Human betaherpesvirus 5 membrane protein UL6 (gene: UL6); Yaba-like disease virus 141R protein (gene: 141R); Human betaherpesvirus 5 envelope glycoprotein UL4 (gene: UL4); Vaccinia virus Ankara Interleukin-1 beta receptor; Horsepox virus HSPV192 (IL-beta-binding protein; Provisional); Yaba monkey tumor virus Ig domain OX-2-like protein; Human mastadenovirus F membrane glycoprotein E3 CR1-beta (gene: E3A); Human mastadenovirus A E3 CR1-alpha1; Human adenovirus 18 CR1-beta protein (gene: E3); Human gammaherpesvirus 4 BARF1 protein (gene: BARF1); Human herpesvirus 4 type 2 BARF1; Human betaherpesvirus 7 membrane glycoprotein UL119 (gene: U85); Human betaherpesvirus 6B glycoprotein (gene: U85)",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6386053036162835; 0.6462089477181691; 0.6621265548536891; 0.6743504588964037; 0.6806291584193672; 0.6806291584193672; 0.6859529108680942; 0.691145768348025; 0.6920622798772148; 0.7184028158722842; 0.7212352368560536; 0.7286961934616806; 0.7651942752688915; 0.776311155917498; 0.8071041616616108; 0.8205168751208474; 0.8285661572509389; 0.8498604215998952; 0.870986154363754; 0.875442055263636; 0.8784689389733535; 0.8826243651582266; 0.8884451411763671; 0.8981524065835117; 0.9097056179628632; 0.9188516474257704; 0.920189880588384; 0.9353779004188908; 0.9353779004188908; 0.9445347004229157; 0.9621839893030432; 0.9646199311883896; 0.9646199311883896; 0.988150003801932,,,,
CENPE,"Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; melanoma; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of prostate; Central neuroblastoma; Neuroblastoma; Prostate carcinoma; Liver carcinoma; Breast Cancer, Familial; Carcinoma testes; Absent earlobe; Testicular Germ Cell Tumor; Systemic Scleroderma; Seizures; Partial or complete agenesis of corpus callosum; Partial agenesis of corpus callosum; Triple Negative Breast Neoplasms; Glaucoma; Round face; Round, full face; Recurrent tumor; Abnormality of the skull; Chronic myeloproliferative disorder; Fetal Growth Retardation; Metaphyseal sclerosis; Defective tooth enamel; Dystrophic tooth enamel; Infant, Small for Gestational Age; Intrauterine retardation; Craniosynostosis; Cachexia; Abnormality of dental enamel; Epilepsy; Microcephaly; Pituitary Diseases; Mild global developmental delay; Short stature; Psychomotor retardation, mild; Sloping forehead; Hip Dislocation, Congenital; Prematurely aged appearance; Cortical gyral simplification; Curvature of little finger; Clinodactyly of the 5th finger; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Aplasia/Hypoplasia of the mandible; Micrognathism; Reduced number of teeth; Small head; Hypoplastic feet; Sandal gap; Tooth agenesis; Seckel syndrome; Cone-shaped epiphysis; Dull intelligence; Low intelligence; Joint hyperflexibility; Hyperplasia of nose; Hypertrophy of nose; Large nose; Poor school performance; Convex nasal ridge; Mental deficiency; Sparse scalp hair; Thin face; Narrow face; Small hand; Mental Retardation; Delayed bone age; Developmental delay (disorder); Downward slant of palpebral fissure; Primary microcephaly; Impaired cognition; Cerebellar Hypoplasia; Intellectual Disability; Mental impairment; Global developmental delay",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991; 0.0569142010728473; 0.0593779966354549; 0.0688152422187159; 0.0773771948186562; 0.095319386034013; 0.1602092191314262; 0.1653491983554358; 0.1735868515093891; 0.1735868515093891; 0.1900258729042946; 0.2053083986145698; 0.2062010908869036; 0.222537307875512; 0.2980670559114652; 0.3105909001629992; 0.3706856725676674; 0.3706856725676674; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3975960596292668; 0.4028066164685291; 0.4335751357405352; 0.439389586518055; 0.4396723023384634; 0.4561717689698902; 0.4564472886428772; 0.4564472886428772; 0.4615352570710579; 0.4635211539849193; 0.4675904598629673; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4790179402069343; 0.479747709091007; 0.4852430673532381; 0.4906258721078565; 0.4990401620718274; 0.5019670090704682; 0.5019670090704682; 0.5090214163899865; 0.5140447474168605; 0.5300976305939776; 0.5300976305939776; 0.5305233935923577; 0.5393787854381349; 0.5393787854381349; 0.5393787854381349; 0.5610226870913673; 0.5710095678317721; 0.6035970790768342; 0.6196470808426647; 0.6222451141623291; 0.6222451141623291; 0.6274540883972485; 0.6319938293757544; 0.6910672612216457; 0.7096959691931399; 0.7634367398642647; 0.7756460653898786; 0.8000044931629623; 0.8306551823873084; 0.8352623613787349; 0.8861753047262128; 0.9327689937867868,Liver Carcinoma; Partial Agenesis Of Corpus Callosum; Testicular Neoplasms; Craniosynostosis; Testicular Germ Cell Tumor; Glaucoma; Seckel Syndrome; Scoliosis; Microcephaly; Micrognathism; Myeloproliferative Disorder; Dwarfism; Camptodactyly Of Fingers; Mental Retardation; Impaired Cognition; Cardiomyopathy; Cerebellar Hypoplasia; Nystagmus,0.0520696613701797; 0.2187610616307245; 0.4286813331685578; 0.4286813331685578; 0.4560460337187313; 0.4646409362700993; 0.4875380732267193; 0.4875380732267193; 0.5123947823327547; 0.5234357475824973; 0.5681293104170607; 0.5796489603182782; 0.7328159476505643; 0.7729545590606223; 0.781505274734613; 0.8407264689819682; 0.9055059991400024; 0.9146877763175152,"Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Roberts syndrome ORPHA:3103; Stromme syndrome ORPHA:506307; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; Hereditary site-specific ovarian cancer syndrome ORPHA:213524; Bloom syndrome ORPHA:125; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Primary peritoneal carcinoma ORPHA:168829; VACTERL with hydrocephalus ORPHA:3412; Mosaic variegated aneuploidy syndrome ORPHA:1052; Osteosarcoma ORPHA:668; Seckel syndrome ORPHA:808; Fanconi anemia ORPHA:84; Autosomal recessive primary microcephaly ORPHA:2512; Combined immunodeficiency with granulomatosis ORPHA:157949; Pleomorphic salivary gland adenoma ORPHA:454821; Severe combined immunodeficiency due to complete RAG1/2 deficiency ORPHA:331206; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; DNA2-related mitochondrial DNA deletion syndrome ORPHA:352470; Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations ORPHA:319462; Jawad syndrome ORPHA:313795; Microcephaly-complex motor and sensory axonal neuropathy syndrome ORPHA:423894; Hereditary breast and ovarian cancer syndrome ORPHA:145; Familial prostate cancer ORPHA:1331; Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome ORPHA:314404; Chudley-McCullough syndrome ORPHA:314597; Hereditary sensory neuropathy-deafness-dementia syndrome ORPHA:456318; ICF syndrome ORPHA:2268; Weaver syndrome ORPHA:3447; Familial pancreatic carcinoma ORPHA:1333; Nephroblastoma ORPHA:654; Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome ORPHA:504476; Charcot-Marie-Tooth disease type 4B1 ORPHA:99955; X-linked intellectual disability, Van Esch type ORPHA:163976; X-linked reticulate pigmentary disorder ORPHA:85453; Neuroendocrine tumor of stomach ORPHA:100075; Borjeson-Forssman-Lehmann syndrome ORPHA:127; Severe combined immunodeficiency due to DNA-PKcs deficiency ORPHA:317425; NON RARE IN EUROPE: FG syndrome phenotypic spectrum ORPHA:323; Juvenile myelomonocytic leukemia ORPHA:86834; Genetic steroid-resistant nephrotic syndrome ORPHA:656",0.0083045131203191; 0.0106988445340883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.0599424746210022; 0.0683063362547733; 0.0930156564388357; 0.1026843275212335; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1936858543871029; 0.1981653781243822; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.3775879467205478; 0.4101640425710954; 0.4101640425710954; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.765572103905398,,,,,,
CHST1,Cataract; Parkinson Disease; Bilateral cataracts (disorder); Osteochondrodysplasias,0.223747154820789; 0.3933196962529684; 0.4028066164685291; 0.4561717689698902,,,"Female restricted epilepsy with intellectual disability ORPHA:101039; 46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome ORPHA:168563; Familial dyskinesia and facial myokymia ORPHA:324588; Anterior maxillary protrusion-strabismus-intellectual disability syndrome ORPHA:562559; NON RARE IN EUROPE: Dementia with Lewy body ORPHA:1648",0.1590470395003315; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423,,,,,,
CHST11,Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Tumor Progression; Malignant neoplasm of breast; Malignant neoplasm of ovary; Neoplasm Metastasis; Degenerative polyarthritis; Chronic Lymphocytic Leukemia; Costello syndrome (disorder); Schizophrenia; Calcification of coronary artery,0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0191435238361999; 0.0277695594716545; 0.0648809611869375; 0.0739788831250619; 0.1147307578771389; 0.1253114324938153; 0.3933196962529684; 0.6881884194440517,Schizophrenia; Hypoplasia Of Thumb; Scoliosis; Brachydactyly,0.0531117779464085; 0.3094716280561038; 0.4875380732267193; 0.6198128018123746,Early-onset Lafora body disease ORPHA:324290; Autosomal dominant intermediate Charcot-Marie-Tooth disease type F ORPHA:352670; Combined immunodeficiency due to Moesin deficiency ORPHA:504530; Noonan syndrome-like disorder with juvenile myelomonocytic leukemia ORPHA:363972; Temtamy preaxial brachydactyly syndrome ORPHA:363417; Angiocentric glioma ORPHA:251671,0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782,,,,,,
CLSPN,"Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Malignant neoplasm of breast; Carcinogenesis; Neoplasm Metastasis; Malignant Neoplasms; Solid Neoplasm; Breast Cancer, Familial; cervical cancer; Malignant tumor of cervix; Malignant neoplasm of lung; Cervix carcinoma; Ataxia Telangiectasia; Metastatic malignant neoplasm to brain; Carcinoma of lung; Primary malignant neoplasm; Primary malignant neoplasm of lung",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0191435238361999; 0.0228075668512991; 0.0648809611869375; 0.0991201145654548; 0.1413782599148022; 0.1602092191314262; 0.2050045461627939; 0.2714542429024338; 0.2714542429024338; 0.2834835531038365; 0.3508665345292502; 0.3638414818541592; 0.3663130598151661; 0.383941725017158; 0.3902116649640871,Breast Cancer,0.0402286636010764,"Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Roberts syndrome ORPHA:3103; Stromme syndrome ORPHA:506307; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; Hereditary site-specific ovarian cancer syndrome ORPHA:213524; Bloom syndrome ORPHA:125; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Primary peritoneal carcinoma ORPHA:168829; VACTERL with hydrocephalus ORPHA:3412; Mosaic variegated aneuploidy syndrome ORPHA:1052; Osteosarcoma ORPHA:668; Seckel syndrome ORPHA:808; Fanconi anemia ORPHA:84; Autosomal recessive primary microcephaly ORPHA:2512; Pleomorphic salivary gland adenoma ORPHA:454821; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Combined immunodeficiency due to GINS1 deficiency ORPHA:505227; DNA2-related mitochondrial DNA deletion syndrome ORPHA:352470; Denys-Drash syndrome ORPHA:220; Frasier syndrome ORPHA:347; Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations ORPHA:319462; Jawad syndrome ORPHA:313795; Meacham syndrome ORPHA:3097; Microcephaly-complex motor and sensory axonal neuropathy syndrome ORPHA:423894; Xeroderma pigmentosum variant ORPHA:90342; Li-Fraumeni syndrome ORPHA:524; Ear-patella-short stature syndrome ORPHA:2554; Hereditary breast and ovarian cancer syndrome ORPHA:145; Familial prostate cancer ORPHA:1331; Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome ORPHA:314404; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; Hereditary sensory neuropathy-deafness-dementia syndrome ORPHA:456318; Combined immunodeficiency with faciooculoskeletal anomalies ORPHA:221139; ICF syndrome ORPHA:2268; Weaver syndrome ORPHA:3447; Familial pancreatic carcinoma ORPHA:1333; Nephroblastoma ORPHA:654; Adult-onset autosomal dominant leukodystrophy ORPHA:99027; Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome ORPHA:504476; Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency ORPHA:75391; Retinitis pigmentosa-hearing loss-premature aging-short stature-facial dysmorphism syndrome ORPHA:494439; X-linked intellectual disability, Van Esch type ORPHA:163976; X-linked reticulate pigmentary disorder ORPHA:85453; Neuroendocrine tumor of stomach ORPHA:100075; Hypothyroidism due to deficient transcription factors involved in pituitary development or function ORPHA:226307; 46,XX gonadal dysgenesis ORPHA:243; Facial dysmorphism-immunodeficiency-livedo-short stature syndrome ORPHA:352712; Acute myeloid leukemia with t(6;9)(p23;q34) ORPHA:402014; Autosomal recessive chorioretinopathy-microcephaly syndrome ORPHA:2518",0.0083045131203191; 0.0106988445340883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.0599424746210022; 0.0683063362547733; 0.0930156564388357; 0.1026843275212335; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.1659988674007724; 0.1936858543871029; 0.1981653781243822; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.3775879467205478; 0.4101640425710954; 0.4101640425710954; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6279395134845649; 0.6522156347158065; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
CNTNAP1,"Breast Carcinoma; Pre B-cell acute lymphoblastic leukemia; Carcinogenesis; Well Differentiated Oligodendroglioma; Flexion contracture of the knee; Neoplasm Metastasis; oligodendroglioma; Malignant neoplasm of pancreas; Glioma; Lymphoma; Pancreatic carcinoma; Adult Acute Lymphocytic Leukemia; Hematologic Neoplasms; MYELODYSPLASTIC SYNDROME; Chronic leukemia (category); Leukemia, Myeloid, Chronic-Phase; Acute leukemia; Childhood Acute Lymphoblastic Leukemia; Blast Phase; Leukemogenesis; Undifferentiated leukemia; Leukemia, Myelocytic, Acute; Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Malaria, Falciparum; Acute lymphocytic leukemia; Lymphoid leukemia; Congenital hypomyelinating neuropathy; Neoplasm, Residual; B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1; Reduced tendon reflexes; Primary Myelofibrosis; Facial diplegia; Oropharyngeal Dysphagia; Polyhydramnios; Dyspnea; Early severe fetal akinesia sequence; secondary acute myeloid leukemia; Electromyogram abnormal; Pena-Shokeir syndrome type I; leukemia; Myeloid Leukemia, Chronic; Monocytosis; Respiratory distress; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelomonocytic, Chronic; Cerebellar atrophy; Deglutition Disorders; Precursor Cell Lymphoblastic Leukemia Lymphoma; Neurodevelopmental Disorders; Absent tendon reflex; Reflex, Deep Tendon, Absent; Absent reflex; Limitation of joint mobility; Philadelphia chromosome-positive acute lymphoblastic leukemia; Leukodystrophy; Arthrogryposis; Generalized hypotonia; Muscle hypotonia; Autistic Disorder",0.0042545616049287; 0.0189794808441368; 0.0228075668512991; 0.0617471306652618; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0919714360040484; 0.1253114324938153; 0.1254380558571286; 0.1653491983554358; 0.1662487420178625; 0.2835142372342932; 0.3099246715197673; 0.3494455519738624; 0.3510063969122338; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4126392832024548; 0.4192169590514327; 0.425419812815905; 0.4396723023384634; 0.4459714599189374; 0.4588513406515081; 0.472444704048021; 0.4981941174985421; 0.5019670090704682; 0.5090214163899865; 0.5140447474168605; 0.5251317541886066; 0.5284231402423694; 0.5393787854381349; 0.5568517196017908; 0.5768212166102149; 0.586007951376766; 0.586007951376766; 0.6274540883972485; 0.6447029562500783; 0.7309076068378124; 0.7317475852509061; 0.7631684472516962; 0.7965733310657268; 0.8064248359603999,Breast Carcinoma; Hydrocephalus; Congenital Muscular Dystrophy; Mental Depression; Lethal Congenital Contracture Syndrome; Frontal Bossing; Atrophy Of Corpus Callosum; Hemangioma; Gastroesophageal Reflux Disease; Distal Arthrogryposis; Spinal Muscular Atrophy; Hypotonia; Microcephaly; Pena Shokeir Syndrome; Dysphagia; Cerebral Atrophy; Cerebral Cortical Atrophy; Neuropathy; Oropharyngeal Dysphagia; Micrognathism; Bulbar Palsy; Optic Atrophy; Cerebellar Atrophy; Congenital Epicanthus; Ptosis; Arthrogryposis Multiplex Congenita; Myopathy; Dolichocephaly; High Palate; Hypoplasia Of Corpus Callosum,0.0075861267486594; 0.3657224783929353; 0.4286813331685578; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4723647227028846; 0.4742592264758768; 0.4867879381749835; 0.5087473896242481; 0.5087473896242481; 0.5123947823327547; 0.5127628024019304; 0.5127628024019304; 0.5129298662020659; 0.5129298662020659; 0.5129298662020659; 0.5129298662020659; 0.5234357475824973; 0.5875654081009305; 0.675936313627625; 0.7112499273451761; 0.7729545590606223; 0.8357787380041017; 0.8536040084512244; 0.8607543198108836; 0.8646787810763381; 0.9334417262711258; 0.9807964358467072,"Shprintzen-Goldberg syndrome ORPHA:2462; Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome ORPHA:508533; Fibrochondrogenesis ORPHA:2021; Hypomyelination neuropathy-arthrogryposis syndrome ORPHA:2680; Acromesomelic dysplasia, Maroteaux type ORPHA:40; Spinocerebellar ataxia type 21 ORPHA:98773; Tall stature-scoliosis-macrodactyly of the great toes syndrome ORPHA:329191; Freeman-Sheldon syndrome ORPHA:2053; Potocki-Shaffer syndrome ORPHA:52022; Congenital muscular dystrophy without intellectual disability ORPHA:370980; Otospondylomegaepiphyseal dysplasia ORPHA:1427; Gorlin syndrome ORPHA:377; Myoclonic-astatic epilepsy ORPHA:1942",0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.7068064785325423; 0.7068064785325423; 0.7072638369101406,,,Homo sapiens,0.35,Human papillomavirus type 11;Human papillomavirus type 6b;ebvb9,Homo sapiens
CNTNAP2,"Well Differentiated Oligodendroglioma; oligodendroglioma; Glioma; Liver Cirrhosis; Small cell carcinoma of lung; Unipolar Depression; Hyperactive behavior; Visual seizure; Seizures; Major Depressive Disorder; Mental Disorders, Severe; Language Disorders; Multiple Sclerosis; Cirrhosis; Apraxia, Developmental Verbal; Diagnosis, Psychiatric; Bipolar Disorder; Hyperkinesia, Generalized; Schizophrenia; Androgen-Insensitivity Syndrome; Hypertensive disease; Social Communication Disorder; High-functioning autism; Behavior Disorders; Epilepsies, Partial; Epilepsy; Apraxia, Verbal; Stuttering; Stuttering, Developmental; Autism Spectrum Disorders; Isaacs syndrome; NEUROTICISM; Reduced tendon reflexes; Schizoaffective Disorder; Auditory Processing Disorder, Central; Semantic-Pragmatic Disorder; Social Anxiety; Language Development Disorders; Limbic Encephalitis; Aura; Awakening Epilepsy; Epilepsy, Cryptogenic; Cortical Dysplasia; Mental disorders; Rhabdoid Tumor; Substance Use Disorders; Encephalitis; Psychosis, Brief Reactive; Benign Rolandic Epilepsy; Dyslexia; Exfoliation Syndrome; Specific language impairment; Schizophreniform Disorders; Psychotic Disorders; Epilepsy, Rolandic; Alcoholic Intoxication, Chronic; Gross motor development delay; nervous system disorder; Dull intelligence; Low intelligence; Obsessive-Compulsive Disorder; Neurodevelopmental Disorders; Poor school performance; Pervasive Development Disorder; Autistic behavior; Mental deficiency; Mental Retardation; Brain Diseases; Calcification of coronary artery; Pachygyria; Gilles de la Tourette syndrome; Malformations of Cortical Development; Severe mental retardation (I.Q. 20-34); Impaired cognition; Autistic Disorder; Intellectual Disability; Attention deficit hyperactivity disorder; Decreased tendon reflex; Epileptic encephalopathy; Language Delay; Hepatitis B; Speech Delay; Abnormal behavior",0.0617471306652618; 0.0648809611869375; 0.0739788831250619; 0.0773771948186562; 0.1193558174333938; 0.13167400689206; 0.1387448809655294; 0.1735868515093891; 0.2053083986145698; 0.21122597829463; 0.2714542429024338; 0.2747883228704706; 0.2835142372342932; 0.2923761731100008; 0.340892538685018; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.39623320406434; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4118266358241932; 0.4126392832024548; 0.4126392832024548; 0.425419812815905; 0.4381343267935581; 0.4396723023384634; 0.4396723023384634; 0.4396723023384634; 0.4459714599189374; 0.4459714599189374; 0.4564472886428772; 0.4615352570710579; 0.4753011022966241; 0.4906258721078565; 0.5097818625871164; 0.5188223685230745; 0.5276472086074249; 0.5300976305939776; 0.5300976305939776; 0.5305233935923577; 0.5568517196017908; 0.5610226870913673; 0.5655222348249326; 0.5885228491254589; 0.6035970790768342; 0.6319938293757544; 0.6319938293757544; 0.6881884194440517; 0.7240930522443176; 0.7294281406818208; 0.7347935459099629; 0.7668324850675137; 0.8000044931629623; 0.8064248359603999; 0.8352623613787349; 0.8600100703665297; 0.8997473146038651; 0.905697116584928; 0.9109170915079636; 0.9169959402964138; 0.9170233981501684; 0.9274396272108874,Schizophrenia; Language Disorders; Epilepsy; Autism Spectrum Disorder; Mental Disorders; Lung Carcinoma; Pulmonary Stenosis; Mental Depression; Language Development Disorders; Alzheimer Disease; Psychosis; Auditory Processing Disorder; Frontal Bossing; Brachycephaly; Glaucoma; Speech Delay; Gastroesophageal Reflux Disease; Social Communication Disorder; Bipolar Disorder; Scoliosis; Dementia; Tricuspid Valve Insufficiency; Dysphagia; Cerebral Cortical Atrophy; Seizure; Celiac Disease; Malocclusion; Plagiocephaly; Precocious Puberty; Ventricular Septal Defect; Mental Retardation; Cryptorchidism; Stereotyped Behavior; Strabismus; Epileptic Encephalopathy; Developmental Delay; Autism,0.0531117779464085; 0.3094716280561038; 0.3449614869411272; 0.425341435586089; 0.4286813331685578; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4723647227028846; 0.4742592264758768; 0.4867879381749835; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.5127628024019304; 0.5127628024019304; 0.5129298662020659; 0.5576425853515448; 0.6485812088066297; 0.6564901877271138; 0.7015979603136192; 0.7328159476505643; 0.7729545590606223; 0.7729545590606223; 0.776786668801341; 0.8374871697490577; 0.9568083835980838; 0.9589164573822424; 0.96477535147595; 0.9783327858636056,"NON RARE IN EUROPE: Non rare obesity ORPHA:521399; ANK3-related intellectual disability-sleep disturbance syndrome ORPHA:356996; Donnai-Barrow syndrome ORPHA:2143; Syndromic microphthalmia type 5 ORPHA:178364; X-linked central congenital hypothyroidism with late-onset testicular enlargement ORPHA:329235; PEHO syndrome ORPHA:2836; Pitt-Hopkins-like syndrome ORPHA:221150; Autosomal dominant focal dystonia, DYT25 type ORPHA:329466; Autosomal recessive congenital cerebellar ataxia due to GRID2 deficiency ORPHA:363432; Cortical dysplasia-focal epilepsy syndrome ORPHA:163681; Gamma-aminobutyric acid transaminase deficiency ORPHA:2066; Hyperprolinemia type 1 ORPHA:419; Prune belly syndrome ORPHA:2970; CHARGE syndrome ORPHA:138; Isolated congenitally uncorrected transposition of the great arteries ORPHA:216718; Spinocerebellar ataxia type 37 ORPHA:363710; Usher syndrome type 2 ORPHA:231178; Lennox-Gastaut syndrome ORPHA:2382; Situs ambiguus ORPHA:157769; NON RARE IN EUROPE: Autism ORPHA:106",0.1590470395003315; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7072638369101406; 0.7120423847116372; 0.7277121423170946,,,yeasx,0.37,Homo sapiens,Bacillus anthracis
COL12A1,"Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Malignant mesothelioma; Malignant neoplasm of breast; Flexion contracture of the knee; Liver Cirrhosis, Experimental; Chondromyxoid fibroma; contracture of elbow; Flexion contracture - elbow; Ehlers-Danlos Syndrome; Endometriosis; Exostoses; Adducted thumb; Increased endomysial connective tissue; Diaphragmatic paresis; Diminished diaphragmatic motion; Cachexia; Flexion contracture of proximal interphalangeal joint; Slender finger; Valgus deformities of feet; Bethlem myopathy; Long toe; Scleroatonic muscular dystrophy; Electromyogram abnormal; Reduced fetal movement; Spinal rigidity; Frequent falls; Generalized muscle weakness; Spasmodic torticollis; Abnormality of the palate; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Torticollis; Generalized amyotrophy; Aplasia/Hypoplasia of the mandible; Increased variability in muscle fiber diameter; Overlap syndrome; Micrognathism; Acquired scoliosis; Cervical Dystonia; Respiratory Failure; Congenital myopathy (disorder); Esotropia; Joint stiffness; EMG: myopathic abnormalities; Short neck; Absent tendon reflex; Range of joint movement increased; Reflex, Deep Tendon, Absent; Absent reflex; Curvature of spine; Elevated creatine kinase; Hip Dislocation; Congenital muscular dystrophy (disorder); Creatine phosphokinase serum increased; Contracture; Respiratory function loss; Respiratory Insufficiency; Kyphoscoliosis deformity of spine; Facial muscle weakness of muscles innervated by CN VII; Bell Palsy; Facial Paresis; Arthrogryposis; Generalized hypotonia; Muscle hypotonia; Flexion contractures of joints; Flexion contracture; Contracture of joint; Byzanthine arch palate; Hyperkyphosis; Kyphosis deformity of spine; Muscle Weakness; No development of motor milestones; Motor delay; Myopathy",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.064548079316548; 0.0747863377072194; 0.1138051695421299; 0.2522264785494494; 0.2714542429024338; 0.3283839486480793; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4192169590514327; 0.4396723023384634; 0.4459714599189374; 0.4506578937113162; 0.4564472886428772; 0.4615352570710579; 0.4615352570710579; 0.4615352570710579; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4790179402069343; 0.4790179402069343; 0.4790179402069343; 0.479747709091007; 0.5019670090704682; 0.5019670090704682; 0.5140447474168605; 0.5188223685230745; 0.5251317541886066; 0.5359212109443033; 0.5359212109443033; 0.549941235475765; 0.5768212166102149; 0.5768212166102149; 0.586007951376766; 0.586007951376766; 0.6035970790768342; 0.6294837700416086; 0.6304655343580164; 0.6319938293757544; 0.6332132835539771; 0.652707626880454; 0.6606366664484469; 0.6891882956008074; 0.6925751397474874; 0.7045203904267408; 0.7156410971578294; 0.7156410971578294; 0.7317475852509061; 0.7631684472516962; 0.7965733310657268; 0.8163430347375975; 0.8178117518835931; 0.8244780048843707; 0.8441962785769224; 0.8499037334512025; 0.8675929025638992; 0.9042453170318407; 0.930169779950098; 0.932126049986882; 0.9503327807211356,Endometriosis; Congenital Muscular Dystrophy; Elbow Flexion Contracture; Respiratory Failure; Alzheimer Disease; Phrynoderma; Scoliosis; Hypotonia; Micrognathism; Malignant Mesothelioma; Facial Paralysis; Amyotrophy; Muscular Dystrophy; Esotropia; Motor Delay; Acquired Kyphoscoliosis; Congenital Kyphoscoliosis; Myopathy; High Palate,0.2187610616307245; 0.4286813331685578; 0.4286813331685578; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4875380732267193; 0.5087473896242481; 0.5234357475824973; 0.555382961603519; 0.696610260564548; 0.6999859437625926; 0.7112499273451761; 0.817609416385332; 0.8371848756758566; 0.8374871697490577; 0.8388613222538848; 0.8607543198108836; 0.9334417262711258,"Atrial septal defect, ostium primum type ORPHA:99106; Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; SIX2-related frontonasal dysplasia ORPHA:488437; Auriculocondylar syndrome ORPHA:137888; Peters anomaly ORPHA:708; Familial porencephaly ORPHA:99810; Severe generalized junctional epidermolysis bullosa ORPHA:79404; 20p12.3 microdeletion syndrome ORPHA:261295; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Chondrosarcoma ORPHA:55880; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Greig cephalopolysyndactyly syndrome ORPHA:380; Isolated hyperchlorhidrosis ORPHA:542657; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Ulnar-mammary syndrome ORPHA:3138; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Congenital short bowel syndrome ORPHA:2301; Myelodysplastic syndrome ORPHA:52688; Papillary renal cell carcinoma ORPHA:319298; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Rieger anomaly ORPHA:91483; Brachydactyly type A2 ORPHA:93396; Waardenburg syndrome type 2 ORPHA:895; Bruck syndrome ORPHA:2771; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; Autosomal recessive brachyolmia ORPHA:448242; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; CHST3-related skeletal dysplasia ORPHA:263463; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; Diaphanospondylodysostosis ORPHA:66637; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial drusen ORPHA:75376; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; Hereditary neuropathy with liability to pressure palsies ORPHA:640; Hereditary papillary renal cell carcinoma ORPHA:47044; Ischiovertebral syndrome ORPHA:85200; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Mandibulofacial dysostosis with alopecia ORPHA:443995; Myopathic Ehlers-Danlos syndrome ORPHA:536516; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Nance-Horan syndrome ORPHA:627; Oculocutaneous albinism type 3 ORPHA:79433; Osteofibrous dysplasia ORPHA:488265; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Primary CD59 deficiency ORPHA:169464; Retinal arterial tortuosity ORPHA:75326; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; X-linked osteoporosis with fractures ORPHA:391330; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Congenital cataract microcornea with corneal opacity ORPHA:289499; Congenital diaphragmatic hernia ORPHA:2140; Dermatofibrosarcoma protuberans ORPHA:31112; Familial primary localized cutaneous amyloidosis ORPHA:353220; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402; Piebaldism ORPHA:2884; Posterior hypospadias ORPHA:95706; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721; Trichorhinophalangeal syndrome type 2 ORPHA:502; Erythrokeratodermia variabilis ORPHA:317; Ondine syndrome ORPHA:661; Classical Ehlers-Danlos syndrome ORPHA:287; Multiple osteochondromas ORPHA:321; X-linked Alport syndrome-diffuse leiomyomatosis ORPHA:1018; Alopecia universalis ORPHA:701; Alpha-B crystallin-related late-onset myopathy ORPHA:399058; Atrichia with papular lesions ORPHA:86819; Autosomal dominant palmoplantar keratoderma and congenital alopecia ORPHA:1010; Autosomal dominant slowed nerve conduction velocity ORPHA:140481; Caffey disease ORPHA:1310; Cerebral autosomal recessive arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:199354; Chronic enteropathy associated with SLCO2A1 gene ORPHA:468641; Congenital alveolar capillary dysplasia ORPHA:210122; Distal myopathy with posterior leg and anterior hand involvement ORPHA:63273; Epidermolysis bullosa simplex due to BP230 deficiency ORPHA:412181; Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome ORPHA:412022; Familial generalized lentiginosis ORPHA:231040; Fatal infantile hypertonic myofibrillar myopathy ORPHA:280553; Glaucoma secondary to spherophakia/ectopia lentis and megalocornea ORPHA:238763; HTRA1-related autosomal dominant cerebral small vessel disease ORPHA:482077; Helicoid peripapillary chorioretinal degeneration ORPHA:86813; Hereditary sensory and autonomic neuropathy type 6 ORPHA:314381; Kuskokwim syndrome ORPHA:1149; Lethal hydranencephaly-diaphragmatic hernia syndrome ORPHA:480528; Lymphedema-distichiasis syndrome ORPHA:33001; Microphthalmia with brain and digit anomalies ORPHA:139471; Multiple paragangliomas associated with polycythemia ORPHA:324299; Muscle filaminopathy ORPHA:171445; NON RARE IN EUROPE: Autosomal dominant ichthyosis vulgaris ORPHA:462; NON RARE IN EUROPE: Benign familial hematuria ORPHA:97562; Non-immune hydrops fetalis ORPHA:363999; Oculodentodigital dysplasia ORPHA:2710; Optic atrophy-intellectual disability syndrome ORPHA:401777; Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome ORPHA:447961; Posterior urethral valve ORPHA:93110; Syndactyly type 3 ORPHA:93404; X-linked Alport syndrome ORPHA:88917; Autosomal recessive Robinow syndrome ORPHA:1507; Griscelli syndrome type 3 ORPHA:79478; Juvenile Paget disease ORPHA:2801; Malignant peripheral nerve sheath tumor ORPHA:3148; Non-seminomatous germ cell tumor of testis ORPHA:363494; Postaxial polydactyly type B ORPHA:93335; Brachydactyly type A1 ORPHA:93388; Hennekam syndrome ORPHA:2136; Distal hereditary motor neuropathy type 2 ORPHA:139525; Osteogenesis imperfecta type 3 ORPHA:216812; Hirschsprung disease ORPHA:388; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form ORPHA:293899; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form ORPHA:293888; Familial thoracic aortic aneurysm and aortic dissection ORPHA:91387; Arthrochalasia Ehlers-Danlos syndrome ORPHA:1899; Ehlers-Danlos/osteogenesis imperfecta syndrome ORPHA:230857; Osteogenesis imperfecta type 1 ORPHA:216796; Periodontal Ehlers-Danlos syndrome ORPHA:75392; Ablepharon macrostomia syndrome ORPHA:920; Acrogeria ORPHA:2500; Acromesomelic dysplasia, Hunter-Thompson type ORPHA:968; Adenocarcinoma of ovary ORPHA:213504; Allan-Herndon-Dudley syndrome ORPHA:59; Angel-shaped phalango-epiphyseal dysplasia ORPHA:63442; Barber-Say syndrome ORPHA:1231; Carbamoyl-phosphate synthetase 1 deficiency ORPHA:147; Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:136; Colobomatous macrophthalmia-microcornea syndrome ORPHA:468672; Complete androgen insensitivity syndrome ORPHA:99429; Dicarboxylic aminoaciduria ORPHA:2195; Dyssegmental dysplasia, Silverman-Handmaker type ORPHA:1865; Familial abdominal aortic aneurysm ORPHA:86; Familial visceral myopathy ORPHA:2604; Fibronectin glomerulopathy ORPHA:84090; Focal facial dermal dysplasia type III ORPHA:1807; Glutaric acidemia type 3 ORPHA:35706; Hot water reflex epilepsy ORPHA:166412; Hypopigmentation-punctate palmoplantar keratoderma syndrome ORPHA:324561; Kennedy disease ORPHA:481; Lateral meningocele syndrome ORPHA:2789; Lipoid proteinosis ORPHA:530; Lymphedema-posterior choanal atresia syndrome ORPHA:99141; Multiple myeloma ORPHA:29073; Myopathic intestinal pseudoobstruction ORPHA:104077; Partial androgen insensitivity syndrome ORPHA:90797; Ring dermoid of cornea ORPHA:91481; Schwartz-Jampel syndrome ORPHA:800; Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome ORPHA:93358; Stuve-Wiedemann syndrome ORPHA:3206; Trehalase deficiency ORPHA:103909; Vascular Ehlers-Danlos syndrome ORPHA:286; Acromesomelic dysplasia, Grebe type ORPHA:2098; Autosomal recessive hypophosphatemic rickets ORPHA:289176; Brachydactyly type C ORPHA:93384; Familial calcium pyrophosphate deposition ORPHA:1416; Fibular aplasia-complex brachydactyly syndrome ORPHA:2639; Hereditary mixed polyposis syndrome ORPHA:157794; Isolated ectopia lentis ORPHA:1885; Shprintzen-Goldberg syndrome ORPHA:2462; Mutilating palmoplantar keratoderma with periorificial keratotic plaques ORPHA:659; Congenital glaucoma ORPHA:98976; Epithelioid hemangioendothelioma ORPHA:157791; Autosomal dominant polycystic kidney disease ORPHA:730; NON RARE IN EUROPE: Age-related macular degeneration ORPHA:279; Heritable pulmonary arterial hypertension ORPHA:275777; Familial isolated arrhythmogenic ventricular dysplasia, right dominant form ORPHA:293910; Bethlem myopathy ORPHA:610; Congenital muscular dystrophy, Ullrich type ORPHA:75840; Multicentric osteolysis-nodulosis-arthropathy spectrum ORPHA:371428; Arterial tortuosity syndrome ORPHA:3342; Autosomal dominant generalized dystrophic epidermolysis bullosa ORPHA:231568; Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form ORPHA:89842; Autosomal spastic paraplegia type 58 ORPHA:397946; Brachydactyly type B1 ORPHA:572385; Cardiac-valvular Ehlers-Danlos syndrome ORPHA:230851; Congenital vertical talus, bilateral ORPHA:295203; Congenital vertical talus, unilateral ORPHA:295201; Dystrophic epidermolysis bullosa pruriginosa ORPHA:89843; Glaucoma-ectopia lentis-microspherophakia-stiff joints-short stature syndrome ORPHA:2084; High bone mass osteogenesis imperfecta ORPHA:314029; Isolated biliary atresia ORPHA:30391; Laminin subunit alpha 2-related congenital muscular dystrophy ORPHA:258; Localized dystrophic epidermolysis bullosa, acral form ORPHA:158673; Localized dystrophic epidermolysis bullosa, nails only ORPHA:158676; Localized dystrophic epidermolysis bullosa, pretibial form ORPHA:79410; Marfan syndrome type 1 ORPHA:284963; Microcephaly-facial dysmorphism-ocular anomalies-multiple congenital anomalies syndrome ORPHA:521445; Multiple epiphyseal dysplasia type 5 ORPHA:93311; Neonatal Marfan syndrome ORPHA:284979; Pelviscapular dysplasia ORPHA:93333; Pierson syndrome ORPHA:2670; Primary dystonia, DYT27 type ORPHA:464440; Progeroid and marfanoid aspect-lipodystrophy syndrome ORPHA:300382; Recessive dystrophic epidermolysis bullosa inversa ORPHA:79409; Self-improving dystrophic epidermolysis bullosa ORPHA:79411; Spondyloepimetaphyseal dysplasia, matrilin-3 type ORPHA:156728; Stiff skin syndrome ORPHA:2833; X-linked spondyloepimetaphyseal dysplasia ORPHA:93349; Acromicric dysplasia ORPHA:969; Autosomal recessive polycystic kidney disease ORPHA:731; Craniometaphyseal dysplasia ORPHA:1522; Autosomal dominant cutis laxa ORPHA:90348; Geleophysic dysplasia ORPHA:2623; Milroy disease ORPHA:79452; Weill-Marchesani syndrome ORPHA:3449; Osteogenesis imperfecta type 2 ORPHA:216804; Osteogenesis imperfecta type 4 ORPHA:216820; Autosomal recessive intermediate Charcot-Marie-Tooth disease type C ORPHA:369867; Autosomal recessive lower motor neuron disease with childhood onset ORPHA:206580; Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency ORPHA:91135; Branchioskeletogenital syndrome ORPHA:1299; Generalized epilepsy-paroxysmal dyskinesia syndrome ORPHA:79137; Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency ORPHA:300179; Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome ORPHA:476126; Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa ORPHA:436274; Cap myopathy ORPHA:171881; Infantile myofibromatosis ORPHA:2591; Punctate palmoplantar keratoderma type 1 ORPHA:79501; NON RARE IN EUROPE: Primary adult open-angle glaucoma ORPHA:353225",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0092060390928213; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.020072786018028; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.0599424746210022; 0.0621182671032116; 0.0683063362547733; 0.0706635700002548; 0.0783959336694202; 0.0783959336694202; 0.0902044104910482; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.1614487935928034; 0.1697334635963512; 0.1739455566145445; 0.1782034488938806; 0.1981653781243822; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3826134188846508; 0.4101640425710954; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6340773186521831,Ectromelia virus ERPV hemagglutinin; Vaccinia virus Ankara Haemagglutinin; Human adenovirus 41 E3 31.6K; Vaccinia virus hemagglutinin (gene: A56R); Human gammaherpesvirus 8 K14; Horsepox virus HSPV177 (Immunoglobulin like); Variola virus hypothetical protein (gene: J9R); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta); Human adenovirus 61 E3 CR1 beta; Human adenovirus 18 CR1-beta protein (gene: E3); Human betaherpesvirus 7 membrane glycoprotein UL119 (gene: U85),0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6386053036162835; 0.691145768348025; 0.7651942752688915; 0.776311155917498; 0.875442055263636; 0.8784689389733535; 0.9445347004229157; 0.9646199311883896,yeasx,0.37,Homo sapiens;Yersinia pestis,Bacillus anthracis;Homo sapiens;den27
COL5A2,"Colorectal Carcinoma; Colorectal Cancer; Carcinogenesis; Degenerative polyarthritis; Liver Cirrhosis, Experimental; Liver Cirrhosis; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Malignant Neoplasms; Carcinoma of bladder; Myocardial Infarction; Neoplasms; Atrophic scar; Aortic Aneurysm, Thoracic; Ehlers-Danlos Syndrome; Aortic root dilatation; Ectopia Lentis; Primary malignant neoplasm; Noninfiltrating Intraductal Carcinoma; Hernia, Inguinal; Gastroesophageal reflux disease; Bat ear; Cigarette-paper scars; Bowel diverticula; Bowel diverticulosis; Ehlers-Danlos syndrome type 1; Molluscoid pseudotumors; Fibrosis, Liver; Blue sclera; Aortic Aneurysm; eyelids (symptom); Poor wound healing; Hernia, Femoral; Abortion, Tubal; Umbilical hernia; Congenital aneurysm of ascending aorta; Hyperextensibility of the finger joints; Genu recurvatum; Thin skin; Spontaneous abortion; Soft skin; Velvety skin; Congenital pectus carinatum; Short stature; Fragile skin; Infantile muscular hypotonia; Myocardial Ischemia; Lens dislocation; Increased tendency to bruise; Cardiovascular Diseases; Cardiomyopathy, Familial Idiopathic; Congenital diaphragmatic hernia; Hallux Valgus; Bunion; Acquired scoliosis; Myopia; Dislocations; Joint hyperflexibility; Hyperextensible skin; Metabolic Syndrome X; Acid reflux; Pectus excavatum; Curvature of spine; Mitral Valve Prolapse Syndrome; Heartburn; Varicosity; Acquired flat foot; Flatfoot; Congenital Epicanthus",0.0034602840073026; 0.0149315928814189; 0.0228075668512991; 0.0739788831250619; 0.0747863377072194; 0.0773771948186562; 0.084286432100041; 0.0891725280554336; 0.0991201145654548; 0.13167400689206; 0.1352936728187231; 0.2714542429024338; 0.286740104053178; 0.2980670559114652; 0.3283839486480793; 0.3508665345292502; 0.3638414818541592; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3986414839122469; 0.4028066164685291; 0.4103119460235835; 0.4192169590514327; 0.4209380602168584; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4335751357405352; 0.439389586518055; 0.4396723023384634; 0.4396723023384634; 0.4506578937113162; 0.4506578937113162; 0.4564472886428772; 0.4675904598629673; 0.4704594475773637; 0.4790179402069343; 0.4852430673532381; 0.4906258721078565; 0.5019670090704682; 0.5239792328442205; 0.5251317541886066; 0.5305233935923577; 0.5359212109443033; 0.5568517196017908; 0.5936773368594411; 0.5956632182199403; 0.6035970790768342; 0.625027955184583; 0.641532117799187; 0.6656356363792992; 0.7484342194688707; 0.7577323833810212; 0.8152796510476865,Thoracic Aortic Aneurysm And Aortic Dissection; Blood Coagulation Disorders; Connective Tissue Disease; Liver Cirrhosis; Classical-Like Ehlers-Danlos Syndrome; Arthritis; Shagreen Patch; Aortic Aneurysm; Miscarriage; Autoimmune Lymphoproliferative Disorder; Liver Fibrosis; Tricuspid Valve Prolapse; Venous Insufficiency; Migraine; Hypertension; Ehlers-Danlos Syndrome; Spina Bifida Occulta; Glaucoma; Atrophy; Retinal Detachment; Corneal Dystrophy; Scoliosis; Asthma; Ectopia Lentis; Hiatal Hernia; Arachnodactyly; Atrial Septal Defect; Congenital Keratoglobus; Dwarfism; Microcornea; Congenital Pectus Carinatum; Congenital Exomphalos; Urticaria; Eczema; Mitral Valve Prolapse; Myopia; Congenital Epicanthus; Microdontia; Impaired Cognition,0.1641294276675242; 0.3094716280561038; 0.425341435586089; 0.4286813331685578; 0.4402141802500753; 0.4541466895915311; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4646409362700993; 0.4646409362700993; 0.4867879381749835; 0.4875380732267193; 0.4875380732267193; 0.504364324740411; 0.5087473896242481; 0.5129298662020659; 0.525214105372123; 0.5254133486377646; 0.5681293104170607; 0.5796489603182782; 0.6030919130927346; 0.6104715460837368; 0.6270755162143985; 0.6420878824691651; 0.6899894525110877; 0.7112499273451761; 0.7405519560111998; 0.7729545590606223; 0.7729545590606223; 0.781505274734613,"Atrial septal defect, ostium primum type ORPHA:99106; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; 20p12.3 microdeletion syndrome ORPHA:261295; Chondrosarcoma ORPHA:55880; Greig cephalopolysyndactyly syndrome ORPHA:380; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Tibial hemimelia ORPHA:93322; Congenital short bowel syndrome ORPHA:2301; Brachydactyly type A2 ORPHA:93396; Bruck syndrome ORPHA:2771; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Diaphanospondylodysostosis ORPHA:66637; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial drusen ORPHA:75376; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; Ischiovertebral syndrome ORPHA:85200; Mandibulofacial dysostosis with alopecia ORPHA:443995; Myopathic Ehlers-Danlos syndrome ORPHA:536516; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Retinal arterial tortuosity ORPHA:75326; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Dermatofibrosarcoma protuberans ORPHA:31112; Hypoplastic left heart syndrome ORPHA:2248; Matthew-Wood syndrome ORPHA:2470; Piebaldism ORPHA:2884; Posterior hypospadias ORPHA:95706; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721; Ondine syndrome ORPHA:661; Tetralogy of Fallot ORPHA:3303; Classical Ehlers-Danlos syndrome ORPHA:287; Multiple osteochondromas ORPHA:321; Alpha-B crystallin-related late-onset myopathy ORPHA:399058; Autosomal dominant palmoplantar keratoderma and congenital alopecia ORPHA:1010; Caffey disease ORPHA:1310; Cerebral autosomal recessive arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:199354; Congenital alveolar capillary dysplasia ORPHA:210122; Distal myopathy with posterior leg and anterior hand involvement ORPHA:63273; Fatal infantile hypertonic myofibrillar myopathy ORPHA:280553; Glaucoma secondary to spherophakia/ectopia lentis and megalocornea ORPHA:238763; HTRA1-related autosomal dominant cerebral small vessel disease ORPHA:482077; Kuskokwim syndrome ORPHA:1149; Lethal hydranencephaly-diaphragmatic hernia syndrome ORPHA:480528; Lymphedema-distichiasis syndrome ORPHA:33001; Muscle filaminopathy ORPHA:171445; Non-immune hydrops fetalis ORPHA:363999; Oculodentodigital dysplasia ORPHA:2710; Posterior urethral valve ORPHA:93110; Syndactyly type 3 ORPHA:93404; Malignant peripheral nerve sheath tumor ORPHA:3148; Postaxial polydactyly type B ORPHA:93335; Sclerosteosis ORPHA:3152; Hennekam syndrome ORPHA:2136; Distal hereditary motor neuropathy type 2 ORPHA:139525; Osteogenesis imperfecta type 3 ORPHA:216812; Hirschsprung disease ORPHA:388; Familial thoracic aortic aneurysm and aortic dissection ORPHA:91387; Arthrochalasia Ehlers-Danlos syndrome ORPHA:1899; Ehlers-Danlos/osteogenesis imperfecta syndrome ORPHA:230857; Osteogenesis imperfecta type 1 ORPHA:216796; Periodontal Ehlers-Danlos syndrome ORPHA:75392; Ablepharon macrostomia syndrome ORPHA:920; Acrogeria ORPHA:2500; Allan-Herndon-Dudley syndrome ORPHA:59; Barber-Say syndrome ORPHA:1231; Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:136; Complete androgen insensitivity syndrome ORPHA:99429; Dyssegmental dysplasia, Silverman-Handmaker type ORPHA:1865; Familial abdominal aortic aneurysm ORPHA:86; Familial visceral myopathy ORPHA:2604; Fibronectin glomerulopathy ORPHA:84090; Focal facial dermal dysplasia type III ORPHA:1807; Glutaric acidemia type 3 ORPHA:35706; Kennedy disease ORPHA:481; Lateral meningocele syndrome ORPHA:2789; Myopathic intestinal pseudoobstruction ORPHA:104077; Partial androgen insensitivity syndrome ORPHA:90797; Schwartz-Jampel syndrome ORPHA:800; Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome ORPHA:93358; Vascular Ehlers-Danlos syndrome ORPHA:286; Hereditary mixed polyposis syndrome ORPHA:157794; Isolated ectopia lentis ORPHA:1885; Shprintzen-Goldberg syndrome ORPHA:2462; Silver-Russell syndrome due to 11p15 microduplication ORPHA:231144; Silver-Russell syndrome due to an imprinting defect of 11p15 ORPHA:231140; Spondylometaphyseal dysplasia, 'corner fracture' type ORPHA:93315; Acrocallosal syndrome ORPHA:36; Beckwith-Wiedemann syndrome due to imprinting defect of 11p15 ORPHA:231117; Isolated hemihyperplasia ORPHA:2128; Congenital glaucoma ORPHA:98976; Isolated brachycephaly ORPHA:35099; Isolated plagiocephaly ORPHA:35098; Autosomal dominant polycystic kidney disease ORPHA:730; Bilateral striopallidodentate calcinosis ORPHA:1980; NON RARE IN EUROPE: Age-related macular degeneration ORPHA:279; Colobomatous microphthalmia ORPHA:98938; Heritable pulmonary arterial hypertension ORPHA:275777; Bethlem myopathy ORPHA:610; Congenital muscular dystrophy, Ullrich type ORPHA:75840; Multicentric osteolysis-nodulosis-arthropathy spectrum ORPHA:371428; Arterial tortuosity syndrome ORPHA:3342; Arthrogryposis-oculomotor limitation-electroretinal anomalies syndrome ORPHA:1154; Autosomal recessive omodysplasia ORPHA:93329; Beta-sarcoglycan-related  limb-girdle muscular dystrophy R4 ORPHA:119; Butyrylcholinesterase deficiency ORPHA:132; Cardiac-valvular Ehlers-Danlos syndrome ORPHA:230851; Curry-Jones syndrome ORPHA:1553; EMILIN-1-related connective tissue disease ORPHA:485418; Glaucoma-ectopia lentis-microspherophakia-stiff joints-short stature syndrome ORPHA:2084; Gordon syndrome ORPHA:376; Hartsfield syndrome ORPHA:2117; High bone mass osteogenesis imperfecta ORPHA:314029; Laminin subunit alpha 2-related congenital muscular dystrophy ORPHA:258; Malignant epithelial tumor of salivary glands ORPHA:276145; Marden-Walker syndrome ORPHA:2461; Marfan syndrome type 1 ORPHA:284963; Microcephaly-facial dysmorphism-ocular anomalies-multiple congenital anomalies syndrome ORPHA:521445; Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement ORPHA:168953; Neonatal Marfan syndrome ORPHA:284979; Osteoglosphonic dysplasia ORPHA:2645; Pelviscapular dysplasia ORPHA:93333; Primary dystonia, DYT27 type ORPHA:464440; Progeroid and marfanoid aspect-lipodystrophy syndrome ORPHA:300382; Stiff skin syndrome ORPHA:2833; Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A ORPHA:308386; X-linked spondyloepimetaphyseal dysplasia ORPHA:93349; Acromicric dysplasia ORPHA:969; Craniometaphyseal dysplasia ORPHA:1522; Fibrochondrogenesis ORPHA:2021; Autosomal dominant cutis laxa ORPHA:90348; Ellis Van Creveld syndrome ORPHA:289; Geleophysic dysplasia ORPHA:2623; Milroy disease ORPHA:79452; NON RARE IN EUROPE: Infantile capillary hemangioma ORPHA:464293; Weill-Marchesani syndrome ORPHA:3449; Familial cerebral saccular aneurysm ORPHA:231160; Osteogenesis imperfecta type 2 ORPHA:216804; Osteogenesis imperfecta type 4 ORPHA:216820; Acrofacial dysostosis, Weyers type ORPHA:952; Autosomal recessive cutis laxa type 1 ORPHA:90349; Acromesomelic dysplasia, Maroteaux type ORPHA:40; Acroosteolysis-keloid-like lesions-premature aging syndrome ORPHA:363665; Aplasia of lacrimal and salivary glands ORPHA:86815; Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ORPHA:440354; Blue rubber bleb nevus ORPHA:1059; Branchioskeletogenital syndrome ORPHA:1299; Chronic myeloproliferative disease, unclassifiable ORPHA:86830; Dermatosparaxis Ehlers-Danlos syndrome ORPHA:1901; Generalized epilepsy-paroxysmal dyskinesia syndrome ORPHA:79137; Late-onset retinal degeneration ORPHA:67042; Lethal arteriopathy syndrome due to fibulin-4 deficiency ORPHA:314718; Marshall syndrome ORPHA:560; Mucocutaneous venous malformations ORPHA:2451; Multisystemic smooth muscle dysfunction syndrome ORPHA:404463; Myeloid/lymphoid neoplasm associated with PDGFRA rearrangement ORPHA:168947; Myeloid/lymphoid neoplasm associated with PDGFRB rearrangement ORPHA:168950; Myosclerosis ORPHA:289380; Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome ORPHA:477831; Stickler syndrome type 2 ORPHA:90654; Tall stature-scoliosis-macrodactyly of the great toes syndrome ORPHA:329191; 3M syndrome ORPHA:2616; Agnathia-holoprosencephaly-situs inversus syndrome ORPHA:990; Infantile myofibromatosis ORPHA:2591; Isolated trigonocephaly ORPHA:3366; Punctate palmoplantar keratoderma type 1 ORPHA:79501; Generalized juvenile polyposis/juvenile polyposis coli ORPHA:329971; Isolated Klippel-Feil syndrome ORPHA:2345; Primary hypereosinophilic syndrome ORPHA:314950; Skeletal Ewing sarcoma ORPHA:319; Classical-like Ehlers-Danlos syndrome type 2 ORPHA:536532; Congenital factor X deficiency ORPHA:328; Isolated Dandy-Walker malformation ORPHA:217; Cerebrofacioarticular syndrome ORPHA:314679; X-linked hypohidrotic ectodermal dysplasia ORPHA:181",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.020072786018028; 0.0277610005156803; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.0621182671032116; 0.0683063362547733; 0.0706635700002548; 0.0902044104910482; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.1614487935928034; 0.1614487935928034; 0.1697334635963512; 0.1697334635963512; 0.1739455566145445; 0.1782034488938806; 0.1782034488938806; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3826134188846508; 0.3826134188846508; 0.4101640425710954; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6279395134845649; 0.6279395134845649; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,In vitro,0.35,chemical synthesis,Homo sapiens
CORO1A,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Carcinoma; Carcinomatosis; Neoplasm Metastasis; Lymphoma; Anaplastic carcinoma; Adult Acute Lymphocytic Leukemia; Liver carcinoma; Malignant Neoplasms; Colon Carcinoma; Undifferentiated carcinoma; Malignant neoplasm of large intestine; Mammary Carcinoma, Animal; Animal Mammary Neoplasms; Hyperactive behavior; Hydatidiform Mole, Partial; Malignant tumor of colon; Neoplasms; Childhood Acute Lymphoblastic Leukemia; Severe Combined Immunodeficiency; Tuberculosis; Primary malignant neoplasm; Complete hydatidiform mole; Nephroblastoma; Hydrocephalus; Triploidy syndrome; HYDATIDIFORM MOLE, RECURRENT, 1; Cerebellar malformation; Lupus Erythematosus, Systemic; Immunologic Deficiency Syndromes; Lupus Vulgaris; Epidermodysplasia Verruciformis; Hydatidiform Mole; leukemia; Lupus Erythematosus; Lupus Erythematosus, Discoid; Gestational Trophoblastic Neoplasms; Lymphoma, Follicular; Lymphopenia; Primary immune deficiency disorder; insulinoma; Muscular Dystrophy, Duchenne; Recurrent respiratory infections; Attention deficit hyperactivity disorder; Mental and motor retardation; Cognitive delay; Global developmental delay; Virus Diseases",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0308703957553632; 0.0593779966354549; 0.0617471306652618; 0.0648809611869375; 0.0739788831250619; 0.084286432100041; 0.0919714360040484; 0.095319386034013; 0.0991201145654548; 0.1062239757831962; 0.13167400689206; 0.13167400689206; 0.1352936728187231; 0.1352936728187231; 0.1387448809655294; 0.1897991423047819; 0.223747154820789; 0.2714542429024338; 0.3099246715197673; 0.3553621627681198; 0.3706856725676674; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.4126392832024548; 0.4213286052188015; 0.4213286052188015; 0.4335751357405352; 0.4396723023384634; 0.4506578937113162; 0.4588513406515081; 0.4615352570710579; 0.4675904598629673; 0.5337853752290136; 0.533913711453195; 0.586007951376766; 0.6841967398409226; 0.6875373888914498; 0.7045203904267408; 0.7484342194688707; 0.8600100703665297; 0.897310588550617; 0.9238745269736108; 0.9327689937867868; 0.9692165430561782,Anaplastic Carcinoma; Carcinoma; Omenn Syndrome; Lymphopenia; Immunodeficiency; Severe Combined Immunodeficiency Disease; Immunologic Deficiency Syndromes; Developmental Delay,0.0402286636010764; 0.0534520155998091; 0.4646409362700993; 0.4780231573499264; 0.6899894525110877; 0.6952142233667052; 0.903598527417506; 0.96477535147595,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency ORPHA:404499; Congenital non-communicating hydrocephalus ORPHA:269510; Spinocerebellar ataxia type 40 ORPHA:423275; Coats plus syndrome ORPHA:313838; Autosomal dominant spastic ataxia type 1 ORPHA:251282; BENTA disease ORPHA:464336; Combined immunodeficiency due to CD27 deficiency ORPHA:238505; Combined immunodeficiency-enteropathy spectrum ORPHA:436252; Multiple intestinal atresia ORPHA:2300; Neutrophil immunodeficiency syndrome ORPHA:183707; Persistent polyclonal B-cell lymphocytosis ORPHA:300324; Predisposition to severe viral infection due to IRF7 deficiency ORPHA:574918; Severe combined immunodeficiency due to CARD11 deficiency ORPHA:357237; Severe combined immunodeficiency due to LCK deficiency ORPHA:280142; Cystic leukoencephalopathy without megalencephaly ORPHA:85136; Recurrent infection due to specific granule deficiency ORPHA:169142; Epidermodysplasia verruciformis ORPHA:302; Aicardi-Goutieres syndrome ORPHA:51; Narcolepsy type 1 ORPHA:2073; Primary biliary cholangitis ORPHA:186; Precursor B-cell acute lymphoblastic leukemia ORPHA:99860; Acute encephalopathy with biphasic seizures and late reduced diffusion ORPHA:363549; Autosomal dominant Charcot-Marie-Tooth disease type 2I ORPHA:99942; Autosomal dominant Charcot-Marie-Tooth disease type 2J ORPHA:99943; Autosomal dominant intermediate Charcot-Marie-Tooth disease type D ORPHA:100046; Autosomal dominant intermediate Charcot-Marie-Tooth disease with neuropathic pain ORPHA:324585; Bleeding disorder due to CalDAG-GEFI deficiency ORPHA:420566; Charcot-Marie-Tooth disease type 1B ORPHA:101082; Combined immunodeficiency due to IL21R deficiency ORPHA:357329; Combined immunodeficiency due to OX40 deficiency ORPHA:431149; Combined immunodeficiency due to ZAP70 deficiency ORPHA:911; DOCK2 deficiency ORPHA:447737; Grange syndrome ORPHA:79094; Hermansky-Pudlak syndrome type 7 ORPHA:231531; Hyperinsulinism due to UCP2 deficiency ORPHA:276556; Hyperzincemia and hypercalprotectinemia ORPHA:251523; LIPE-related familial partial lipodystrophy ORPHA:435660; Leukocyte adhesion deficiency type I ORPHA:99842; Leukocyte adhesion deficiency type III ORPHA:99844; NON RARE IN EUROPE: Psoriatic arthritis ORPHA:40050; Nephrogenic syndrome of inappropriate antidiuresis ORPHA:93606; Pancytopenia due to IKZF1 mutations ORPHA:317473; Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome ORPHA:500533; Pyogenic arthritis-pyoderma gangrenosum-acne syndrome ORPHA:69126; Severe combined immunodeficiency due to CARMIL2 deficiency ORPHA:542301; Severe combined immunodeficiency due to CORO1A deficiency ORPHA:228003; T-B+ severe combined immunodeficiency due to JAK3 deficiency ORPHA:35078; T-B+ severe combined immunodeficiency due to gamma chain deficiency ORPHA:276; WHIM syndrome ORPHA:51636; X-linked severe congenital neutropenia ORPHA:86788; X-linked thrombocytopenia with normal platelets ORPHA:852; Acute basophilic leukemia ORPHA:86849; Familial isolated pituitary adenoma ORPHA:314777; Stevens-Johnson syndrome ORPHA:36426; Wiskott-Aldrich syndrome ORPHA:906; Familial focal epilepsy with variable foci ORPHA:98820; Immunodeficiency by defective expression of MHC class II ORPHA:572; Autosomal dominant severe congenital neutropenia ORPHA:486; Autosomal recessive malignant osteopetrosis ORPHA:667; Complete hydatidiform mole ORPHA:254688; Familial hemophagocytic lymphohistiocytosis ORPHA:540; Narcolepsy type 2 ORPHA:83465; Autosomal agammaglobulinemia ORPHA:33110; Common variable immunodeficiency ORPHA:1572,0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.639029370164481; 0.64564126367818; 0.64564126367818; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7143653415082738,,,Homo sapiens HepaRG hepatoma cell;yeasx,0.35;0.37,Hepatitis delta virus;Homo sapiens,Homo sapiens;Yersinia pestis
CPA4,"Malignant neoplasm of prostate; Prostate carcinoma; Eosinophilic esophagitis; Asthma; Mastocytosis; Nasal Polyps; Pulmonary Eosinophilia; Prostate Cancer, Hereditary, 7; Russell-Silver syndrome",0.0569142010728473; 0.0773771948186562; 0.2085938372806741; 0.3933196962529684; 0.4126392832024548; 0.4459714599189374; 0.4852430673532381; 0.5019670090704682; 0.5916904943304121,Rheumatoid Arthritis,0.4560460337187313,"Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Bamforth-Lazarus syndrome ORPHA:1226; Familial primary localized cutaneous amyloidosis ORPHA:353220; NON RARE IN EUROPE: Autosomal dominant ichthyosis vulgaris ORPHA:462; Athyreosis ORPHA:95713; X-linked hypophosphatemia ORPHA:89936; Charcot-Marie-Tooth disease type 4C ORPHA:99949; Familial isolated trichomegaly ORPHA:411788; Palmoplantar keratoderma, Nagashima type ORPHA:140966; Proximal symphalangism ORPHA:3250",0.00518481975049; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0640416108792758; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917,,,In vitro,0.62,Sabellastarte magnifica,Homo sapiens
CPEB4,"Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Adenocarcinoma; Malignant neoplasm of breast; Neoplasm Metastasis; Liver Cirrhosis; Malignant Neoplasms; Hypertension, Portal; Malignant neoplasm of liver; Cirrhosis; Pancreatic Ductal Adenocarcinoma; Gallbladder Carcinoma; Chronic liver disease; Astrocytoma; Liver and Intrahepatic Biliary Tract Carcinoma; Inflammatory Bowel Diseases; Mean Corpuscular Volume (result); Crohn Disease; Diastolic blood pressure; Body mass index; Finding of body mass index; Waist-Hip Ratio; Smoking Behaviors; Waist Circumference; Liver diseases; Red cell distribution width determination; RDW - Red blood cell distribution width result; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0648809611869375; 0.0773771948186562; 0.0991201145654548; 0.1328002618052838; 0.2643145809900195; 0.2923761731100008; 0.3018974726133723; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.4192169590514327; 0.4981941174985421; 0.5359212109443033; 0.5496357724684553; 0.5496357724684553; 0.549941235475765; 0.5580691945487462; 0.7129583530027284; 0.7337030585693298; 0.7577323833810212; 0.7577323833810212; 0.8352423037513227; 0.8352423037513227,Ulcerative Colitis; Cholangitis; Ankylosing Spondylitis; Psoriasis; Crohn Disease; Inflammatory Bowel Disease,0.6990462534407934; 0.6999859437625926; 0.7049836926927165; 0.7184623115342476; 0.7414460416900516; 0.7662135194687344,Spinocerebellar ataxia type 1 ORPHA:98755; Peroxisomal acyl-CoA oxidase deficiency ORPHA:2971; Acrodysostosis ORPHA:950; Acrodysostosis with multiple hormone resistance ORPHA:280651; Primary pigmented nodular adrenocortical disease ORPHA:189439; Charcot-Marie-Tooth disease type 4H ORPHA:99954; Complex lethal osteochondrodysplasia ORPHA:457378; Gingival fibromatosis-hypertrichosis syndrome ORPHA:2026; Chylomicron retention disease ORPHA:71; Intermediate epidermolysis bullosa simplex with cardiomyopathy ORPHA:508529; PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation ORPHA:438216; Severe neonatal hypotonia-seizures-encephalopathy syndrome due to 5q31.3 microdeletion ORPHA:314655,0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Human adenovirus 7d2 100 kDa hexon assembly-associated protein (gene: L4); Human adenovirus 66 100 kDa hexon assembly-associated protein (gene: L4); Human adenovirus 7 100K; Human adenovirus 68 100 kDa hexon assembly-associated protein (gene: L4); Titi monkey adenovirus ECC-2011 100K; Human mastadenovirus B hexon assembly protein 100K (gene: L4); Human adenovirus B3 L4 100-kDa protein (gene: L4); Human adenovirus 21a 100 kDa hexon-assembly associated protein (gene: L4); Cercopithecine betaherpesvirus 5 tegument protein UL37 (gene: UL47),0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6520551900793279; 0.7477109270664255; 0.8031136315766868; 0.8031136315766868; 0.8656146801545769; 0.9591706521139316,Xenopus laevis,0.4,Homo sapiens,Homo sapiens
CTSD,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Central neuroblastoma; Neoplasm Metastasis; Barrett Esophagus; Renal Cell Carcinoma; Neuroblastoma; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Glioma; Degenerative polyarthritis; Glioblastoma; Pancreatic carcinoma; Prostate carcinoma; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Liver carcinoma; Malignant Neoplasms; Osteosarcoma; Colon Carcinoma; Secondary malignant neoplasm of bone; Carcinoma of bladder; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Myocardial Infarction; Liver neoplasms; Chromophobe Renal Cell Carcinoma; Rheumatoid Arthritis; Seizures; Prostatic Neoplasms; Diabetes Mellitus; Adenocarcinoma Of Esophagus; Neoplasms; Malignant neoplasm of lung; Secondary malignant neoplasm of lung; Diabetic Retinopathy; Conventional (Clear Cell) Renal Cell Carcinoma; Endometrial Carcinoma; Sjogren's Syndrome; Cervical Squamous Cell Carcinoma; Carcinoma of lung; Anaplastic astrocytoma; Primary malignant neoplasm; Acquired CJD; Primary malignant neoplasm of lung; Muscle Rigidity; Secondary malignant neoplasm of lymph node; Amyloidosis; Spinocerebellar Ataxia Type 7; Dysplastic Nevus; Plaque, Amyloid; Harlequin Fetus; Neuronal loss in central nervous system; Kidney Diseases; Nasopharyngeal carcinoma; Sarcomatoid Renal Cell Carcinoma; Non-Small Cell Lung Carcinoma; Oculocerebrorenal Syndrome; Amyotrophic Lateral Sclerosis, Sporadic; HIV Infections; Collecting Duct Carcinoma of the Kidney; Astrocytoma; Alzheimer's Disease; Creutzfeldt-Jakob disease; Adenoid Cystic Carcinoma; Parkinson Disease; Increased neuronal autofluorescent lipopigment; Neuronal lipopigments; AMYOTROPHIC LATERAL SCLEROSIS 1; Craniosynostosis; Asthma; Ovarian cancer stage III; Epilepsy; Lafora Disease; Diabetic macular edema; Mental deterioration; Amyotrophic Lateral Sclerosis; Papillary Renal Cell Carcinoma; Senile Plaques; Microcephaly; Weight Gain; Exaggerated startle response; Refractory cancer; Cerebral Amyloid Angiopathy, Hereditary; Epilepsy, Temporal Lobe; Neoplasm Invasiveness; Alzheimer Disease, Late Onset; Familial Alzheimer Disease (FAD); Adult Neuronal Ceroid Lipofuscinosis; Nephropathic cystinosis; Late-Infantile Neuronal Ceroid Lipfuscinosis; Melanocytic nevus; Mycoses; Amyloid angiopathy; Atrophic retina; Dent's disease; Other Creutzfeldt-Jakob disease; Apnea; Neurodegenerative Disorders; Supratentorial atrophy; Abnormal vision; Adenocarcinoma of prostate; Prion Diseases; Cholesteatoma; Status Epilepticus; Sloping forehead; Type II Mucolipidosis; Retinal Degeneration; Osteoarthrosis Deformans; Creutzfeldt-Jakob Disease, Sporadic; Adult Fanconi syndrome; Juvenile Neuronal Ceroid Lipofuscinosis; Degenerative brain disorder; Welts; Small head; Obesity; Respiratory Failure; Adenocarcinoma of lung (disorder); Cerebellar atrophy; Neuronal Ceroid-Lipofuscinoses; Bacterial Infections; Cardiac Arrest; Intellectual disability, progressive; Low set ears; Barrett Epithelium; Endometrial adenocarcinoma; Cerebellar Ataxia; Lymphopenia; Frontotemporal dementia; Broad flat nasal bridge; Nasal bridge wide; Primary Effusion Lymphoma; Abnormality of metabolism/homeostasis; Cerebral atrophy; Infratentorial atrophy; MYOTONIC DYSTROPHY 1; Dementia, Vascular; Cardiomyopathies; Cerebellar degeneration; Lung diseases; Retinitis Pigmentosa; Tumor Promotion; Severe mental retardation (I.Q. 20-34); Cholera; Urticaria; Gingival Diseases; Muscle Spasticity; Nodule; Autistic Disorder; Periodontal Diseases; Intellectual Disability; Epileptic encephalopathy",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0569142010728473; 0.0593779966354549; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.084286432100041; 0.0891725280554336; 0.095319386034013; 0.0991201145654548; 0.1029977559100099; 0.1062239757831962; 0.1253114324938153; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1352936728187231; 0.1454373331146953; 0.1461248774859792; 0.1537760235124317; 0.2053083986145698; 0.223747154820789; 0.2522264785494494; 0.2679411586077776; 0.2714542429024338; 0.2714542429024338; 0.2723545094624877; 0.2723545094624877; 0.2980670559114652; 0.3044782497745498; 0.3099246715197673; 0.3199171478489988; 0.3663130598151661; 0.3763374964032415; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.39623320406434; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4213286052188015; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.4304973629098372; 0.4330362522463816; 0.4335751357405352; 0.4381343267935581; 0.4396723023384634; 0.4421745246585178; 0.4459714599189374; 0.4459714599189374; 0.4506578937113162; 0.4561717689698902; 0.4564472886428772; 0.4675904598629673; 0.4675904598629673; 0.472444704048021; 0.4753011022966241; 0.4753011022966241; 0.4790179402069343; 0.4790179402069343; 0.4906258721078565; 0.5140447474168605; 0.5140447474168605; 0.51550637274795; 0.5251317541886066; 0.5251317541886066; 0.5337853752290136; 0.5453394612016188; 0.5453394612016188; 0.5578737381206628; 0.5619299124666532; 0.5655222348249326; 0.5754799679683854; 0.586007951376766; 0.6064571148125548; 0.6196470808426647; 0.6238969878903416; 0.6248356417853507; 0.6274540883972485; 0.6294837700416086; 0.6545439509404224; 0.6627865715415371; 0.6802335864704374; 0.6989462176022242; 0.7096959691931399; 0.7128284704851243; 0.7352133686428474; 0.7577323833810212; 0.7668324850675137; 0.7670529315163258; 0.7706351321777464; 0.7706351321777464; 0.7965501584766118; 0.7977380842181487; 0.8064248359603999; 0.8195255693608234; 0.8352623613787349; 0.905697116584928,Liver Carcinoma; Chromophobe Carcinoma; Papillary Renal Carcinoma; Arthritis; Renal Carcinoma; Rheumatoid Arthritis; Respiratory Failure; Lateral Sclerosis; Prostatic Neoplasms; Osteoarthrosis Deformans; Microcephaly; Cerebral Atrophy; Prostate Cancer; Kidney Disease; Status Epilepticus; Rod-cone Dystrophy; Cerebellar Atrophy; Mental Retardation; Disorder Of Eye,0.0520696613701797; 0.4286813331685578; 0.4286813331685578; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4867879381749835; 0.4875380732267193; 0.5087473896242481; 0.5123947823327547; 0.5129298662020659; 0.6104715460837368; 0.6420878824691651; 0.7049836926927165; 0.7062235569782704; 0.7112499273451761; 0.7729545590606223; 0.7729545590606223,"AGel amyloidosis ORPHA:85448; Keratolytic winter erythema ORPHA:50943; Mucopolysaccharidosis type 4A ORPHA:309297; Carnitine palmitoyl transferase 1A deficiency ORPHA:156; Cathepsin A-related arteriopathy-strokes-leukoencephalopathy ORPHA:575553; Galactosialidosis ORPHA:351; Sanfilippo syndrome type D ORPHA:79272; Tay-Sachs disease, B variant, adult form ORPHA:309192; Tay-Sachs disease, B variant, infantile form ORPHA:309178; Tay-Sachs disease, B variant, juvenile form ORPHA:309185; Tay-Sachs disease, B1 variant ORPHA:309239; Early-onset autosomal dominant Alzheimer disease ORPHA:1020; 5-oxoprolinase deficiency ORPHA:33572; ACys amyloidosis ORPHA:100008; Autosomal dominant Charcot-Marie-Tooth disease type 2V ORPHA:447964; CLN10 disease ORPHA:228337; Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency ORPHA:95699; Congenital bile acid synthesis defect type 1 ORPHA:79301; Embryonal rhabdomyosarcoma ORPHA:99757; Fetal Gaucher disease ORPHA:85212; Gaucher disease type 2 ORPHA:77260; Gaucher disease type 3 ORPHA:77261; Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome ORPHA:2072; Glycogen storage disease due to acid maltase deficiency, infantile onset ORPHA:308552; Glycogen storage disease due to acid maltase deficiency, late-onset ORPHA:420429; NON RARE IN EUROPE: Parkinson disease ORPHA:319705; Neutral lipid storage myopathy ORPHA:98908; Sanfilippo syndrome type B ORPHA:79270; Triglyceride deposit cardiomyovasculopathy ORPHA:565612; Tumor necrosis factor receptor 1 associated periodic syndrome ORPHA:32960; Gaucher disease type 1 ORPHA:77259; Niemann-Pick disease type C, adult neurologic onset ORPHA:216986; Niemann-Pick disease type C, juvenile neurologic onset ORPHA:216981; Niemann-Pick disease type C, late infantile neurologic onset ORPHA:216978; Niemann-Pick disease type C, severe early infantile neurologic onset ORPHA:216975; Niemann-Pick disease type C, severe perinatal form ORPHA:216972; Dysosteosclerosis ORPHA:1782; NON RARE IN EUROPE: Paget disease of bone ORPHA:280110; Autosomal dominant Charcot-Marie-Tooth disease type 2C ORPHA:99937; Autosomal dominant brachyolmia ORPHA:93304; Autosomal dominant congenital benign spinal muscular atrophy ORPHA:1216; Autosomal recessive spastic paraplegia type 76 ORPHA:488594; CLN11 disease ORPHA:314629; Charcot-Marie-Tooth disease type 4D ORPHA:99950; Clear cell renal carcinoma ORPHA:319276; Familial digital arthropathy-brachydactyly ORPHA:85169; Fucosidosis ORPHA:349; GM2 gangliosidosis, AB variant ORPHA:309246; Infantile nephropathic cystinosis ORPHA:411629; Juvenile nephropathic cystinosis ORPHA:411634; Metatropic dysplasia ORPHA:2635; Mucolipidosis type III gamma ORPHA:423470; NON RARE IN EUROPE: Pseudoarylsulfatase A deficiency ORPHA:751; Niemann-Pick disease type A ORPHA:77292; Niemann-Pick disease type B ORPHA:77293; Ocular cystinosis ORPHA:411641; Parastremmatic dwarfism ORPHA:2646; Polyneuropathy-hearing loss-ataxia-retinitis pigmentosa-cataract syndrome ORPHA:171848; Sanfilippo syndrome type A ORPHA:79269; Scapuloperoneal spinal muscular atrophy ORPHA:431255; Short chain acyl-CoA dehydrogenase deficiency ORPHA:26792; Spondyloepiphyseal dysplasia, Maroteaux type ORPHA:263482; Spondylometaphyseal dysplasia, Kozlowski type ORPHA:93314; Transcobalamin deficiency ORPHA:859; Very long chain acyl-CoA dehydrogenase deficiency ORPHA:26793; Rare isolated myopia ORPHA:98619; Systemic-onset juvenile idiopathic arthritis ORPHA:85414; Semantic dementia ORPHA:100069; Behavioral variant of frontotemporal dementia ORPHA:275864; Metachromatic leukodystrophy, adult form ORPHA:309271; Metachromatic leukodystrophy, juvenile form ORPHA:309263; Metachromatic leukodystrophy, late infantile form ORPHA:309256; Atypical Gaucher disease due to saposin C deficiency ORPHA:309252; Cerebrotendinous xanthomatosis ORPHA:909; Cholesteryl ester storage disease ORPHA:75234; Encephalopathy due to prosaposin deficiency ORPHA:139406; FTH1-related iron overload ORPHA:247790; Genetic hyperferritinemia without iron overload ORPHA:254704; Heme oxygenase-1 deficiency ORPHA:562509; Hereditary hyperferritinemia-cataract syndrome ORPHA:163; Hereditary thrombocytopenia with early-onset myelofibrosis ORPHA:480851; L-ferritin deficiency ORPHA:440731; Neuroferritinopathy ORPHA:157846; Prolidase deficiency ORPHA:742; Wolman disease ORPHA:75233; CADDS ORPHA:369942; Infantile Krabbe disease ORPHA:206436; Pediatric systemic lupus erythematosus ORPHA:93552; Congenital generalized lipodystrophy ORPHA:528; Progressive non-fluent aphasia ORPHA:100070",0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1739455566145445; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.639029370164481; 0.6522156347158065; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7100092263364535,Human adenovirus 41 E4 hypothetical protein 3; Human mastadenovirus F control protein E4orf3 (gene: E4); Human immunodeficiency virus 2 full_polyprotein 1..1550 (gene: gag-pol),0.6362779693488597; 0.6362779693488597; 0.6481498905276316,Homo sapiens QGY7703 hepatocellular carcinoma cell;In vitro;yeasx,0.35;0.37;0.44;0.56,Homo sapiens;Yersinia pestis;canen;chemical synthesis,Homo sapiens;chemical synthesis
CYP24A1,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; melanoma; Adenocarcinoma; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Mammary Neoplasms, Human; Neoplasm Metastasis; Renal Cell Carcinoma; Malignant neoplasm of pancreas; Osteoporosis; Pancreatic carcinoma; Prostate carcinoma; Colorectal Neoplasms; Liver carcinoma; Malignant Neoplasms; Colon Carcinoma; Esophageal carcinoma; Ductal Breast Carcinoma; Malignant neoplasm of large intestine; Solid Neoplasm; Liver neoplasms; Lung Neoplasms; Malignant tumor of colon; Prostatic Neoplasms; Diabetes; Diabetes Mellitus; Malignant neoplasm of lung; Diabetes Mellitus, Insulin-Dependent; Tumor-Associated Vasculature; Multiple Sclerosis; Wasting; Post-Traumatic Osteoporosis; Cholangiocarcinoma; Osteoporosis, Senile; Carcinoma of lung; Primary malignant neoplasm; Primary malignant neoplasm of lung; Secondary malignant neoplasm of lymph node; Amyloidosis; Pancreatitis, Chronic; Kidney Diseases; Papillary thyroid carcinoma; Non-Small Cell Lung Carcinoma; Osteoporosis, Age-Related; Hypercalcemia, Infantile; Vitamin D-resistant rickets; Abnormality of the eye; Deficiency of monooxygenase; Lymphoma, Non-Hodgkin; Acute anterior uveitis; Cutaneous Mastocytosis; Asthma; Diabetic Nephropathy; Thyroid carcinoma; Bone Diseases; Elfin facies; Abortion, Tubal; Multiple Endocrine Neoplasia Type 1; Chronic Kidney Diseases; Calcium measurement; Milk-Alkali Syndrome; Ulcer; Melanocytic nevus of skin; Pulmonary Stenosis; Arteriopathic disease; Cleft palate, isolated; Aortic Valve Stenosis; Disorder of eye; Melanocytic nevus; Infant, Premature; Spontaneous abortion; Psoriasis; Hypophosphatemic Rickets; Malignant neoplasm of thyroid; Thick lower lip vermilion; Full lower lip; Adult Rickets; Cerebral Palsy; Chronic kidney disease stage 5; Dehydration; Weight decreased; Familial Hypophosphatemic Rickets; Alport Syndrome; Hypophosphatemic Rickets, X-Linked Dominant; Osteomalacia; Rickets; Multinodular goiter; Polyuria; Obesity; Increased calcium level in kidney; Adenocarcinoma of lung (disorder); Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Dull intelligence; Low intelligence; Autoimmune Diseases; Poor school performance; Uveitis; Hypercalciuria; Mental deficiency; Nephrocalcinosis; Kidney Calculi; Mental Retardation; Ankylosing spondylitis; Behcet Syndrome; Renal Insufficiency; Uveomeningoencephalitic Syndrome; Vomiting; Muscle Cramp; Dermatitis, Atopic; Hypercalcemia; Nephrolithiasis; Lethargy; Generalized hypotonia; Eczema; Age related macular degeneration; Hepatitis C, Chronic; Intellectual Disability; Undergrowth; Failure to gain weight; Pediatric failure to thrive; Kidney Failure",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0569142010728473; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0726340460169901; 0.0739788831250619; 0.0745502070959292; 0.0773771948186562; 0.0827744840860166; 0.095319386034013; 0.0991201145654548; 0.1062239757831962; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.1413782599148022; 0.1454373331146953; 0.2062010908869036; 0.223747154820789; 0.223747154820789; 0.2277108302018961; 0.2522264785494494; 0.2714542429024338; 0.2714542429024338; 0.2747883228704706; 0.2835142372342932; 0.2980670559114652; 0.3233418869346274; 0.340892538685018; 0.3544355608905275; 0.3663130598151661; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3986414839122469; 0.4028066164685291; 0.4028066164685291; 0.4103119460235835; 0.4115056600660309; 0.4126392832024548; 0.4186011760974318; 0.4192169590514327; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4307603335611732; 0.4396723023384634; 0.4396723023384634; 0.4396723023384634; 0.4675904598629673; 0.4704594475773637; 0.4714226702518064; 0.472444704048021; 0.472444704048021; 0.4753011022966241; 0.4852430673532381; 0.4923669467696064; 0.4981941174985421; 0.5019670090704682; 0.5019670090704682; 0.5140447474168605; 0.5140447474168605; 0.51550637274795; 0.5188223685230745; 0.5299466034567416; 0.5300976305939776; 0.5300976305939776; 0.5512224939896888; 0.5610226870913673; 0.5682392297191953; 0.5696906826730043; 0.6035970790768342; 0.6084642888478995; 0.6222451141623291; 0.6319938293757544; 0.6446807314576214; 0.6496433426951205; 0.658736510383757; 0.6588479076808555; 0.6980473696540115; 0.6980473696540115; 0.7045203904267408; 0.7317475852509061; 0.7347935459099629; 0.7631684472516962; 0.7631684472516962; 0.7893058450619891; 0.8304052766033214; 0.8343509960860942; 0.8352623613787349; 0.9401531131388324; 0.9449543840411656; 0.9465829057944656; 0.9661303320799302,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Aortic Valve Sclerosis; Lung Cancer; Pulmonary Stenosis; Osteoporosis; Lung Neoplasms; Miscarriage; Milk-Alkali Syndrome; Hypercalcemia; Nephrolithiasis; Nephrocalcinosis; Kidney Failure; Renal Insufficiency; Mental Retardation,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.3182746822082389; 0.4402141802500753; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4875380732267193; 0.6792162876553974; 0.6899894525110877; 0.7112499273451761; 0.7729545590606223,Autosomal recessive infantile hypercalcemia ORPHA:300547; Bamforth-Lazarus syndrome ORPHA:1226; Athyreosis ORPHA:95713; Aneurysm-osteoarthritis syndrome ORPHA:284984; Monilethrix ORPHA:573; Idiopathic juvenile osteoporosis ORPHA:85193,0.0083045131203191; 0.0180064224283883; 0.0640416108792758; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315,,,,,,
CYP4F2,Ovarian Carcinoma; Malignant neoplasm of ovary; Liver carcinoma; Myocardial Infarction; Pancreatic Ductal Adenocarcinoma; Ischemic stroke; Hypertensive disease; Vitamin E Assay; Celiac Disease; Cerebrovascular accident; Vascular Diseases; response to anticoagulant; Hypercholesterolemia; Crohn Disease; Metabolic Syndrome X; Non-alcoholic Fatty Liver Disease; Patent ductus arteriosus; Calcification of coronary artery; Low density lipoprotein cholesterol measurement; Essential Hypertension; Cerebral Infarction,0.0034602840073026; 0.0277695594716545; 0.095319386034013; 0.1352936728187231; 0.3018974726133723; 0.3486533561309259; 0.3933196962529684; 0.3941558617476422; 0.4028066164685291; 0.4115056600660309; 0.4126392832024548; 0.4335751357405352; 0.4755217870653703; 0.4981941174985421; 0.5568517196017908; 0.625027955184583; 0.6334536292962906; 0.6881884194440517; 0.6941270729825465; 0.8418436641268439; 0.8472019892490944,,,Peroxisomal acyl-CoA oxidase deficiency ORPHA:2971; Dominant hypophosphatemia with nephrolithiasis or osteoporosis ORPHA:244305; Dubin-Johnson syndrome ORPHA:234; Alkaptonuria ORPHA:56; Cystinuria type B ORPHA:93613; Hemolytic anemia due to red cell pyruvate kinase deficiency ORPHA:766; Hereditary fructose intolerance ORPHA:469; Ornithine transcarbamylase deficiency ORPHA:664; Progressive familial intrahepatic cholestasis type 5 ORPHA:480476; Renin-angiotensin-aldosterone system-blocker-induced angioedema ORPHA:100057; Severe hereditary thrombophilia due to congenital protein C deficiency ORPHA:745; Cholesterol-ester transfer protein deficiency ORPHA:79506; Hartnup disease ORPHA:2116; Phosphoenolpyruvate carboxykinase deficiency ORPHA:2880,0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,yeasx,0.56,Homo sapiens,Homo sapiens
DEPDC1B,Lip and Oral Cavity Carcinoma; Malignant neoplasm of mouth; Intelligence,0.3933196962529684; 0.4213286052188015; 0.5683976277847906,Liver Carcinoma,0.0520696613701797,"Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Roberts syndrome ORPHA:3103; Stromme syndrome ORPHA:506307; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; Hereditary site-specific ovarian cancer syndrome ORPHA:213524; Bloom syndrome ORPHA:125; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Primary peritoneal carcinoma ORPHA:168829; VACTERL with hydrocephalus ORPHA:3412; Mosaic variegated aneuploidy syndrome ORPHA:1052; Osteosarcoma ORPHA:668; Seckel syndrome ORPHA:808; Fanconi anemia ORPHA:84; Autosomal recessive primary microcephaly ORPHA:2512; Combined immunodeficiency with granulomatosis ORPHA:157949; Severe combined immunodeficiency due to complete RAG1/2 deficiency ORPHA:331206; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Combined immunodeficiency due to GINS1 deficiency ORPHA:505227; DNA2-related mitochondrial DNA deletion syndrome ORPHA:352470; Jawad syndrome ORPHA:313795; Microcephaly-complex motor and sensory axonal neuropathy syndrome ORPHA:423894; Ear-patella-short stature syndrome ORPHA:2554; Chudley-McCullough syndrome ORPHA:314597; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome ORPHA:544488; ICF syndrome ORPHA:2268; Nephroblastoma ORPHA:654; 3-phosphoserine phosphatase deficiency, infantile/juvenile form ORPHA:79350; Acute myeloid leukemia with NPM1 somatic mutations ORPHA:402026; Adult-onset autosomal dominant leukodystrophy ORPHA:99027; Autosomal dominant spastic paraplegia type 13 ORPHA:100994; Citrullinemia type II ORPHA:247585; Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome ORPHA:415; Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome ORPHA:137898; Neonatal intrahepatic cholestasis due to citrin deficiency ORPHA:247598; PCNA-related progressive neurodegenerative photosensitivity syndrome ORPHA:438134; Pelizaeus-Merzbacher-like disease due to HSPD1 mutation ORPHA:280288; Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency ORPHA:75391; Progressive external ophthalmoplegia-myopathy-emaciation syndrome ORPHA:352447; Severe combined immunodeficiency due to CTPS1 deficiency ORPHA:420573; Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome ORPHA:314394; Intrauterine growth restriction-congenital multiple cafe-au-lait macules-increased sister chromatid exchange syndrome ORPHA:508512; Small cell lung cancer ORPHA:70573; 46,XY complete gonadal dysgenesis ORPHA:242; Hereditary orotic aciduria ORPHA:30; Muir-Torre syndrome ORPHA:587",0.0083045131203191; 0.0106988445340883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.0599424746210022; 0.0683063362547733; 0.0930156564388357; 0.1026843275212335; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1659988674007724; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.4101640425710954; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6581690778726346; 0.7068064785325423; 0.7068064785325423,,,,,,
DMBX1,"Proliferative vitreoretinopathy; Seizures; Cataract; Hyperopia; Muscle hypotonia; Hearing Loss, Partial; Mental and motor retardation; Strabismus",0.0182265588252201; 0.2053083986145698; 0.223747154820789; 0.6959870102453846; 0.7965733310657268; 0.8209296131179464; 0.897310588550617; 0.9894915051452228,Epilepsy; Hyperopia; Strabismus; Developmental Delay,0.3449614869411272; 0.8323347200926986; 0.9568083835980838; 0.96477535147595,Nail-patella syndrome ORPHA:2614; Nail-patella-like renal disease ORPHA:2613,0.6239678957896782; 0.6239678957896782,Yaba monkey tumor virus 72L; Machupo mammarenavirus L protein; Lassa mammarenavirus L protein; Human immunodeficiency virus envelope glycoprotein (gene: env); Human alphaherpesvirus 2 tegument protein VP22 (gene: UL49); Human alphaherpesvirus 1 tegument protein VP22 (gene: UL49); Junin mammarenavirus L protein; Guanarito mammarenavirus L protein,0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597,,,,
DNHD1,Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Conventional (Clear Cell) Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Collecting Duct Carcinoma of the Kidney; Papillary Renal Cell Carcinoma,0.0648809611869375; 0.1461248774859792; 0.2980670559114652; 0.3933196962529684; 0.3933196962529684; 0.3975960596292668,Chromophobe Carcinoma; Papillary Renal Carcinoma; Renal Carcinoma,0.4286813331685578; 0.4286813331685578; 0.4541466895915311,Coats plus syndrome ORPHA:313838; 2q37 microdeletion syndrome ORPHA:1001; Adult-onset dystonia-parkinsonism ORPHA:199351; Autosomal dominant multiple pterygium syndrome ORPHA:65743; Autosomal dominant spastic ataxia type 1 ORPHA:251282; Birt-Hogg-Dube syndrome ORPHA:122; Familial spontaneous pneumothorax ORPHA:2903; Infantile neuroaxonal dystrophy ORPHA:35069; Huntington disease ORPHA:399; Autosomal recessive multiple pterygium syndrome ORPHA:2990; 17q21.31 microdeletion syndrome ORPHA:363958; Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons ORPHA:401964; Autosomal recessive spastic paraplegia type 15 ORPHA:100996; Combined malonic and methylmalonic acidemia ORPHA:289504; Immunodeficiency due to MASP-2 deficiency ORPHA:331187; Koolen-De Vries syndrome due to a point mutation ORPHA:363965; NEK9-related lethal skeletal dysplasia ORPHA:464366; Nevus comedonicus syndrome ORPHA:64754; Perlman syndrome ORPHA:2849; Deafness-enamel hypoplasia-nail defects syndrome ORPHA:3220; Kabuki syndrome ORPHA:2322,0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
DOCK11,"Breast Carcinoma; Neoplasm Metastasis; Chronic Lymphocytic Leukemia; Diabetes Mellitus; Wasting; Pheochromocytoma; pseudohermaphrodite (non-specific); West Nile viral infection; Tumor Necrosis Factor Receptor 1-Associated Periodic Syndrome; Graves Disease; Penile hypospadias; Familial medullary thyroid carcinoma; Hypospadias; Encephalitis, St. Louis; beta^+^ Thalassemia; alpha^+^ Thalassemia; Intellectual Disability",0.0042545616049287; 0.0648809611869375; 0.1147307578771389; 0.2522264785494494; 0.2980670559114652; 0.3712878513813393; 0.3933196962529684; 0.425419812815905; 0.4459714599189374; 0.4981941174985421; 0.5019670090704682; 0.5090214163899865; 0.533913711453195; 0.553002957824355; 0.563120546412355; 0.652707626880454; 0.8352623613787349,,,"Autosomal dominant intermediate Charcot-Marie-Tooth disease type F ORPHA:352670; Combined immunodeficiency due to Moesin deficiency ORPHA:504530; Fried syndrome ORPHA:85335; Mowat-Wilson syndrome due to a ZEB2 point mutation ORPHA:261552; Mowat-Wilson syndrome due to monosomy 2q22 ORPHA:261537; X-linked intellectual disability-Dandy-Walker malformation-basal ganglia disease-seizures syndrome ORPHA:1568; X-linked intellectual disability-hypotonia-facial dysmorphism-aggressive behavior syndrome ORPHA:85329; Noonan syndrome-like disorder with juvenile myelomonocytic leukemia ORPHA:363972; XYLT1-CDG ORPHA:370930; Angiocentric glioma ORPHA:251671; Huntington disease ORPHA:399; Loeys-Dietz syndrome ORPHA:60030; Bilateral parasagittal parieto-occipital polymicrogyria ORPHA:208441; Charcot-Marie-Tooth disease type 4J ORPHA:139515; Microcephalic primordial dwarfism, Dauber type ORPHA:319675; Multiple self-healing squamous epithelioma ORPHA:65748; Acute promyelocytic leukemia ORPHA:520",0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7224251630156712,,,,,,
DRAXIN,,,,,"15q13.3 microdeletion syndrome ORPHA:199318; Lissencephaly type 1 due to doublecortin gene mutation ORPHA:2148; CLN8 disease ORPHA:228354; Familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement ORPHA:2196; Focal facial dermal dysplasia type IV ORPHA:398189; Progressive epilepsy-intellectual disability syndrome, Finnish type ORPHA:1947; Tatton-Brown-Rahman syndrome ORPHA:404443",0.1590470395003315; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
E2F7,"Breast Carcinoma; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Squamous cell carcinoma of the head and neck; Liver carcinoma; Chronic Lymphocytic Leukemia; Leukemogenesis; Leukemia, Myelocytic, Acute",0.0042545616049287; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0775520919998773; 0.095319386034013; 0.1147307578771389; 0.3510063969122338; 0.3933196962529684,Lung Carcinoma,0.4541466895915311,"Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Stromme syndrome ORPHA:506307; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; Combined pituitary hormone deficiencies, genetic forms ORPHA:95494; Combined immunodeficiency with granulomatosis ORPHA:157949; Pleomorphic salivary gland adenoma ORPHA:454821; Severe combined immunodeficiency due to complete RAG1/2 deficiency ORPHA:331206; Branchio-oculo-facial syndrome ORPHA:1297; Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome ORPHA:306542; Jawad syndrome ORPHA:313795; Xeroderma pigmentosum variant ORPHA:90342; Li-Fraumeni syndrome ORPHA:524; Familial atypical multiple mole melanoma syndrome ORPHA:404560; Melanoma and neural system tumor syndrome ORPHA:252206; Autosomal dominant Charcot-Marie-Tooth disease type 2D ORPHA:99938; Charcot-Marie-Tooth disease type 4B1 ORPHA:99955; Combined immunodeficiency due to partial RAG1 deficiency ORPHA:231154; Spondylo-megaepiphyseal-metaphyseal dysplasia ORPHA:228387; 12q14 microdeletion syndrome ORPHA:94063; Large congenital melanocytic nevus ORPHA:626; Small cell lung cancer ORPHA:70573; 46,XX gonadal dysgenesis ORPHA:243; 46,XY complete gonadal dysgenesis ORPHA:242; Classic glucose transporter type 1 deficiency syndrome ORPHA:71277; Hereditary cryohydrocytosis with reduced stomatin ORPHA:168577; Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity ORPHA:53583; Geroderma osteodysplastica ORPHA:2078; Hydrolethalus ORPHA:2189",0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111; 0.0683063362547733; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6522156347158065; 0.6581690778726346; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens U2OS osteosarcoma cell;In vitro,0.35;0.54,Homo sapiens,Homo sapiens
EFR3B,"Breast Carcinoma; Diabetes Mellitus, Insulin-Dependent; Schizophrenia; Body mass index; Finding of body mass index; Body Height",0.0042545616049287; 0.2714542429024338; 0.3933196962529684; 0.5496357724684553; 0.5496357724684553; 0.5936773368594411,Breast Carcinoma; Schizophrenia; Diabetes Mellitus,0.0075861267486594; 0.0531117779464085; 0.9683912711598086,"NON RARE IN EUROPE: Non rare obesity ORPHA:521399; Autosomal spastic paraplegia type 72 ORPHA:401849; Male infertility with teratozoospermia due to single gene mutation ORPHA:399808; Bradyopsia ORPHA:75374; Autosomal recessive cerebellar ataxia-psychomotor delay syndrome ORPHA:284271; Cerebellar ataxia, Cayman type ORPHA:94122; DOORS syndrome ORPHA:79500; Donnai-Barrow syndrome ORPHA:2143; Focal epilepsy-intellectual disability-cerebro-cerebellar malformation ORPHA:352587; Microcornea-myopic chorioretinal atrophy-telecanthus syndrome ORPHA:369970; Progressive myoclonic epilepsy with dystonia ORPHA:352596; Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome ORPHA:163727; X-linked central congenital hypothyroidism with late-onset testicular enlargement ORPHA:329235; 9q33.3q34.11 microdeletion syndrome ORPHA:495818; PEHO syndrome ORPHA:2836; Acquired schizencephaly ORPHA:485275; Subcortical band heterotopia ORPHA:99796; Thyrotoxic periodic paralysis ORPHA:79102; Autosomal dominant non-syndromic intellectual disability ORPHA:178469; Isolated Dandy-Walker malformation with hydrocephalus ORPHA:269212; Isolated Dandy-Walker malformation without hydrocephalus ORPHA:269215; Autosomal dominant Charcot-Marie-Tooth disease type 2A1 ORPHA:99946; Autosomal dominant primary microcephaly ORPHA:2514; Autosomal dominant spastic paraplegia type 73 ORPHA:444099; Classic progressive supranuclear palsy syndrome ORPHA:240071; Corpus callosum agenesis-abnormal genitalia syndrome ORPHA:2508; Infant acute respiratory distress syndrome ORPHA:70587; Infantile epileptic-dyskinetic encephalopathy ORPHA:364063; Isolated oxycephaly ORPHA:63440; Partington syndrome ORPHA:94083; Pigmented paravenous retinochoroidal atrophy ORPHA:251295; Progressive essential tremor-speech impairment-facial dysmorphism-intellectual disability-abnormal behavior syndrome ORPHA:457212; Progressive supranuclear palsy-corticobasal syndrome ORPHA:240103; Progressive supranuclear palsy-parkinsonism syndrome ORPHA:240085; Progressive supranuclear palsy-progressive non-fluent aphasia syndrome ORPHA:240112; Progressive supranuclear palsy-pure akinesia with gait freezing syndrome ORPHA:240094; Spinocerebellar ataxia type 42 ORPHA:458803; X-linked lissencephaly with abnormal genitalia ORPHA:452; X-linked spasticity-intellectual disability-epilepsy syndrome ORPHA:3175; Idiopathic ventricular fibrillation, non Brugada type ORPHA:228140; Occipital pachygyria and polymicrogyria ORPHA:280640; Atypical Rett syndrome ORPHA:3095; Nanophthalmos ORPHA:35612",0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
EHF,"Ovarian Carcinoma; Tumor Progression; Stomach Carcinoma; Malignant mesothelioma; Malignant neoplasm of stomach; Carcinogenesis; Epithelial ovarian cancer; Malignant neoplasm of prostate; Prostate carcinoma; Squamous cell carcinoma of esophagus; Prostatic Neoplasms; Inflammation; Ovarian Serous Adenocarcinoma; Asthma; Aortic Aneurysm, Abdominal; response to risperidone; Cystic Fibrosis; Lung diseases; airway disease",0.0034602840073026; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0387439397151409; 0.0569142010728473; 0.0773771948186562; 0.0919714360040484; 0.223747154820789; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.4335751357405352; 0.6124306570512981; 0.7128284704851243; 0.721596134343186,Prostatic Neoplasms; Prostate Cancer,0.4875380732267193; 0.6104715460837368,"Severe generalized junctional epidermolysis bullosa ORPHA:79404; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Autosomal recessive infantile hypercalcemia ORPHA:300547; Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Intermediate generalized junctional epidermolysis bullosa ORPHA:79402; Localized junctional epidermolysis bullosa ORPHA:251393; AA amyloidosis ORPHA:85445; Bartsocas-Papas syndrome ORPHA:1234; Benign familial mesial temporal lobe epilepsy ORPHA:163717; Bilateral frontoparietal polymicrogyria ORPHA:101070; CHAND syndrome ORPHA:1401; Epithelial recurrent erosion dystrophy ORPHA:293381; Familial mesial temporal lobe epilepsy with febrile seizures ORPHA:165805; Glutamate-cysteine ligase deficiency ORPHA:33574; Late-onset junctional epidermolysis bullosa ORPHA:79406; Metaphyseal chondrodysplasia, Spahr type ORPHA:2501; Neuropathy with hearing impairment ORPHA:139512; Spondyloepimetaphyseal dysplasia, Missouri type ORPHA:93356; Marie Unna hereditary hypotrichosis ORPHA:444; Progressive familial intrahepatic cholestasis type 1 ORPHA:79306; White sponge nevus ORPHA:171723; Cholangiocarcinoma ORPHA:70567; Familial expansile osteolysis ORPHA:85195; Harlequin ichthyosis ORPHA:457; High myopia-sensorineural deafness syndrome ORPHA:363396; Keratoderma hereditarium mutilans ORPHA:494; Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome ORPHA:2698; Osteopetrosis-hypogammaglobulinemia syndrome ORPHA:178389; Porokeratotic eccrine ostial and dermal duct nevus ORPHA:166286; Xanthinuria type I ORPHA:93601; Blepharo-cheilo-odontic syndrome ORPHA:1997; Palmoplantar keratoderma-deafness syndrome ORPHA:2202; Severe dermatitis-multiple allergies-metabolic wasting syndrome ORPHA:369992; Hypoplastic amelogenesis imperfecta ORPHA:100031; Autosomal recessive spastic paraplegia type 35 ORPHA:171629; Congenital hereditary endothelial dystrophy type I ORPHA:98975; Epidermolysis bullosa simplex with circinate migratory erythema ORPHA:158681; Fatty acid hydroxylase-associated neurodegeneration ORPHA:329308; Gelatinous drop-like corneal dystrophy ORPHA:98957; Genetic transient congenital hypothyroidism ORPHA:226316; Glucose-galactose malabsorption ORPHA:35710; MUC1-related autosomal dominant tubulointerstitial kidney disease ORPHA:88949; MYO5B-related progressive familial intrahepatic cholestasis ORPHA:480491; RFVT3-related riboflavin transporter deficiency ORPHA:572550; Microvillus inclusion disease ORPHA:2290; Cleft lip and alveolus ORPHA:141291; Hypocalcified amelogenesis imperfecta ORPHA:100032; Isolated cleft lip ORPHA:199302; Posterior polymorphous corneal dystrophy ORPHA:98973; Generalized pseudohypoaldosteronism type 1 ORPHA:171876; KID syndrome ORPHA:477; Liddle syndrome ORPHA:526; Van der Woude syndrome ORPHA:888; Autosomal dominant popliteal pterygium syndrome ORPHA:1300; Autosomal recessive cerebral atrophy ORPHA:363969; Ectodermal dysplasia-syndactyly syndrome ORPHA:247820; Familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis without severe ocular involvement ORPHA:31043; Familial steroid-resistant nephrotic syndrome with adrenal insufficiency ORPHA:506334; Ichthyosis-hypotrichosis syndrome ORPHA:91132; Idiopathic bronchiectasis ORPHA:60033; Lethal congenital contracture syndrome type 2 ORPHA:137776; Mullerian aplasia and hyperandrogenism ORPHA:247768; Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome ORPHA:423454; Non-epidermolytic palmoplantar keratoderma ORPHA:2337; REN-related autosomal dominant tubulointerstitial kidney disease ORPHA:217330; SERKAL syndrome ORPHA:139466; Syndromic congenital sodium diarrhea ORPHA:563708; Systemic primary carnitine deficiency ORPHA:158; Diffuse panbronchiolitis ORPHA:171700; Hypotrichosis simplex ORPHA:55654; Epidermolysis bullosa simplex due to exophilin 5 deficiency ORPHA:412189; Microcytic anemia with liver iron overload ORPHA:83642; Acrodermatitis continua of Hallopeau ORPHA:163931; Generalized pustular psoriasis ORPHA:247353; Neonatal severe primary hyperparathyroidism ORPHA:417; Pustulosis palmaris et plantaris ORPHA:163927",0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1697334635963512; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.3775879467205478; 0.3775879467205478; 0.3826134188846508; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.639029370164481; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Horsepox virus HSPV020e (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Monkeypox virus ankyrin-like protein; Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Ectromelia virus ERPV ankyrin; Orf virus ORF008 ankyrin repeat protein; Horsepox virus HSPV181 (ankyrin repeats); Vaccinia virus ankyrin-like protein (gene: B4R); Yaba monkey tumor virus ankyrin repeat protein; Yaba-like disease virus 11L protein (gene: 11L),0.7079503198328393; 0.8390943852085586; 0.8426793553344071; 0.876049415394169; 0.9097056179628632; 0.9199249371723298; 0.9285312497152513; 0.9517968639566384; 0.9518028028273808; 0.960637237597315; 0.9624639844306644,In vitro,0.54,Homo sapiens,Homo sapiens
ELFN2,,,,,Brain-lung-thyroid syndrome ORPHA:209905; Hydrocephalus with stenosis of the aqueduct of Sylvius ORPHA:2182; MASA syndrome ORPHA:2466; X-linked complicated corpus callosum dysgenesis ORPHA:1497; X-linked complicated spastic paraplegia type 1 ORPHA:306617,0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917,,,,,,
ENC1,"Colorectal Carcinoma; Mammary Neoplasms; Carcinogenesis; Central neuroblastoma; Brain Neoplasms; Neuroblastoma; Liver Cirrhosis, Experimental; Colon Carcinoma; Malignant tumor of colon; Nervous System Neoplasms; Hairy Cell Leukemia; Hurthle Cell Tumor; Adenoma; Multiple Myeloma; Non-Functioning Pituitary Gland Neoplasm; Adrenal Cortical Adenoma",0.0034602840073026; 0.0034602840073026; 0.0228075668512991; 0.0593779966354549; 0.064548079316548; 0.0688152422187159; 0.0747863377072194; 0.1062239757831962; 0.223747154820789; 0.2569222032997501; 0.3412203844672238; 0.3933196962529684; 0.3933196962529684; 0.4103119460235835; 0.4192169590514327; 0.7156410971578294,,,Pyruvate dehydrogenase phosphatase deficiency ORPHA:79246,0.6239678957896782,"Yaba-like disease virus 140R protein (gene: 140R); Yaba monkey tumor virus kelch-like protein; Vaccinia virus Ankara 64.7k Kelch-like protein f1; Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Horsepox virus HSPV008; Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Horsepox virus HSPV176 (kelch-like protein; Provisional); Yaba-like disease virus 19L protein (gene: 19L); Horsepox virus HSPV043 (Kelch-like protein; Provisional); Vaccinia virus kelch-like protein (gene: A55R); Cowpox virus CPXV215 Protein (gene: CPXV215 CDS); Cowpox virus CPXV050 (gene: CPXV050 CDS); Horsepox virus HSPV197 (Hypothetical protein); Monkeypox virus Zaire-96-I-16 B18R (gene: B18R); Monkeypox virus Zaire-96-I-16 B1R (gene: B1R); Vaccinia virus Ankara Kelch-like protein, modulator of inflammation; Cowpox virus CPXV013 protein (gene: CPXV013 CDS); Cowpox virus CPXV193 protein (gene: CPXV193 CDS); Vaccinia virus Ankara 64.7k Kelch-like protein f2; Monkeypox virus kelch-like protein; Horsepox virus HSPV029 (kelch-like protein; Provisional); Ectromelia virus ERPV kelch-like protein; Monkeypox virus Zaire-96-I-16 D15L (gene: D15L); Cowpox virus CPXV035 protein (gene: CPXV035 CDS); Vaccinia virus kelch-like protein (gene: C2L); Monkeypox virus Zaire-96-I-16 D17L (gene: D17L); Variola virus hypothetical protein (gene: J8R); Variola virus hypothetical protein (gene: D13L); Vaccinia virus Ankara 18.9k Kelch-like protein; Cowpox virus CPXV204 protein (gene: CPXV204 CDS); Variola virus hypothetical protein (gene: C7L); Variola virus hypothetical protein (gene: B24R); Variola virus hypothetical protein (gene: J7R); Horsepox virus HSPV187 (kelch-like protein; Provisional); Monkeypox virus Zaire-96-I-16 D16L (gene: D16L); Vaccinia virus hypothetical protein",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6624448726460891; 0.7648879200949484; 0.776311155917498; 0.7975886343350181,,,,
ENG,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Epithelial ovarian cancer; Malignant neoplasm of prostate; Neoplasm Metastasis; Barrett Esophagus; Mucoepidermoid Carcinoma; Renal Cell Carcinoma; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Glioma; Degenerative polyarthritis; Endometrial Neoplasms; Glioblastoma; Pancreatic carcinoma; Carcinoma breast stage IV; AORTIC VALVE DISEASE 2; Liver Cirrhosis; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Colorectal Neoplasms; Squamous cell carcinoma of esophagus; Liver carcinoma; Osteosarcoma; Colon Carcinoma; Hematologic Neoplasms; MYELODYSPLASTIC SYNDROME; Esophageal carcinoma; Carcinoma, Transitional Cell; Hypertension, Portal; Myocardial Infarction; Solid Neoplasm; Colonic Neoplasms; Mixed Salivary Gland Tumor; Rheumatoid Arthritis; Sarcoma; Renal fibrosis; Intracranial Aneurysm; Systemic Scleroderma; cervical cancer; Seizures; Gastrointestinal Neoplasms; Lung Neoplasms; Osteosarcoma of bone; Prostatic Neoplasms; Metastasis from malignant tumor of prostate; Anoxia; Malignant neoplasm of liver; Chondrosarcoma; Metastatic Prostate Carcinoma; Arteriovenous Malformations, Cerebral; Adenocarcinoma Of Esophagus; Bicuspid aortic valve; Malignant tumor of cervix; Malignant neoplasm of lung; Diabetes Mellitus, Insulin-Dependent; Secondary malignant neoplasm of lung; Diabetic Retinopathy; Tumor-Associated Vasculature; Cervix carcinoma; Adult Hepatocellular Carcinoma; Aortic Aneurysm, Thoracic; Hemangioma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Gastrointestinal Stromal Tumors; Ischemic stroke; Ataxia Telangiectasia; Severe Combined Immunodeficiency; Carcinoma of lung; Uterine Fibroids; Primary malignant neoplasm of lung; Pulmonary arterial hypertension; Secondary malignant neoplasm of lymph node; Chronic myeloproliferative disorder; Cerebrovascular Disorders; Generalized seizures; Interstitial lung fibrosis; Kidney Diseases; Papillary thyroid carcinoma; Hereditary Nonpolyposis Colorectal Cancer; tumor vasculature; Cerebral arterial aneurysm; Hypertensive disease; Juvenile rheumatoid arthritis; Bronchopulmonary Dysplasia; Skin Carcinogenesis; Hemorrhage; Refractory cytopenia with multilineage dysplasia; Saccular Aneurysm; Dural Arteriovenous Fistula; OSLER-RENDU-WEBER SYNDROME 2; Urothelial Carcinoma; Aplasia Cutis Congenita; Associated Pulmonary Arterial Hypertension; Liver and Intrahepatic Biliary Tract Carcinoma; Acute lymphocytic leukemia; Adenoid Cystic Carcinoma; Fibrosis, Liver; Grade III Chondrosarcoma; Mammary adenocarcinoma; Telangiectasis; Spontaneous hematomas; Familial pulmonary arterial hypertension; Polyglobulia; Anaplasia; Diabetic Nephropathy; Anemia; Malignant neoplasm of kidney; Familial multiple trichoepitheliomata; Epilepsy; Pulmonary Veno-Occlusive Disease (disorder); Renal carcinoma; Abnormality of brainstem morphology; Cerebral abscess; Amyotrophic Lateral Sclerosis; Senile Plaques; Brain Abscess; Intracranial Arteriovenous Malformation; Plaque build-up in arteries; Glomerulosclerosis (disorder); Hemoglobin low; Erythrocytosis; Extramedullary Plasmacytoma; Cholestasis; Agenesis of corpus callosum; Multiple Myeloma; Primary Myelofibrosis; Cerebrovascular accident; Clubbing; Conjunctival telangiectasis; Hematochezia; Dyspnea; Vascular Diseases; Visceral angiomatosis; Congenital arteriovenous malformation; Triglycerides measurement; Lupus Erythematosus, Systemic; Myoma; Congestive heart failure; Cholecystitis; Heart failure; Squamous cell carcinoma of lung; Meningioma; Migraine Disorders; Salivary Gland Neoplasms; Signs and Symptoms, Respiratory; Familial primary pulmonary hypertension; Aneurysm; Choriocarcinoma; Hemangioma, Cavernous; Cyanosis; Menkes Kinky Hair Syndrome; Cardiovascular Diseases; Vascular anomaly; Visual field defects; Congenital vascular anomaly; Hereditary hemorrhagic telangiectasia; Intermittent migraine headaches; Brain hemorrhage; Thrombosis; Juvenile polyposis syndrome; Increase in blood pressure; Central Diabetes Insipidus; Iron-Refractory Iron Deficiency Anemia; Ulcerative Colitis; Scleroderma; Arteriosclerosis; Borderline Personality Disorder; Arteriovenous hemangioma; Ewings sarcoma; Congenital Abnormality; Congenital Heart Defects; Atherosclerosis; Transient Cerebral Ischemia; Telangiectasia of the skin; Hereditary Diseases; Idiopathic pulmonary arterial hypertension; Angioimmunoblastic Lymphadenopathy; Epistaxis; Frequent nosebleeds; Ureteral obstruction; Infection; Vascular inflammations; Hemiparesis; Multiple polyps; Tumor Angiogenesis; Pre-Eclampsia; Polyp of large intestine; Cerebral Hemorrhage; Polycythemia; Blood Coagulation Disorders; polyps; Lung diseases; Subarachnoid Hemorrhage; Idiopathic pulmonary hypertension; Endothelial dysfunction; Hepatitis C, Chronic; Eclampsia; Trichohepatoenteric Syndrome",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0308703957553632; 0.0387439397151409; 0.0569142010728473; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0773771948186562; 0.0775520919998773; 0.0827744840860166; 0.0919714360040484; 0.095319386034013; 0.1029977559100099; 0.1062239757831962; 0.1253114324938153; 0.1254380558571286; 0.1254380558571286; 0.13167400689206; 0.1328002618052838; 0.1352936728187231; 0.1413782599148022; 0.1454373331146953; 0.1454373331146953; 0.1537760235124317; 0.1537760235124317; 0.1602092191314262; 0.1735868515093891; 0.1900258729042946; 0.2050045461627939; 0.2053083986145698; 0.2062010908869036; 0.2062010908869036; 0.2109483801368481; 0.223747154820789; 0.2454426921531692; 0.2462384927636234; 0.2643145809900195; 0.2643145809900195; 0.2643145809900195; 0.2643145809900195; 0.2679411586077776; 0.2687300999130421; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2723545094624877; 0.2723545094624877; 0.2747883228704706; 0.2834835531038365; 0.290158730291654; 0.2980670559114652; 0.3099246715197673; 0.3105909001629992; 0.3199171478489988; 0.3486533561309259; 0.3508665345292502; 0.3553621627681198; 0.3663130598151661; 0.383941725017158; 0.3902116649640871; 0.3925783478421996; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.3938591532700354; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4100901006059349; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4186011760974318; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.425419812815905; 0.4304973629098372; 0.4335751357405352; 0.4396723023384634; 0.4450743762496232; 0.4506578937113162; 0.4506578937113162; 0.4506578937113162; 0.4561717689698902; 0.4564472886428772; 0.4564472886428772; 0.4564472886428772; 0.4615352570710579; 0.4675904598629673; 0.4675904598629673; 0.4675904598629673; 0.4675904598629673; 0.4753011022966241; 0.4790179402069343; 0.4790179402069343; 0.4906258721078565; 0.4906258721078565; 0.4923669467696064; 0.4923669467696064; 0.4923669467696064; 0.5001612228394569; 0.5019670090704682; 0.5019670090704682; 0.5188223685230745; 0.5188223685230745; 0.5251317541886066; 0.5305233935923577; 0.533913711453195; 0.5393787854381349; 0.5393787854381349; 0.553002957824355; 0.553002957824355; 0.5655222348249326; 0.5710095678317721; 0.5710095678317721; 0.5710095678317721; 0.589345563575654; 0.5959654688257199; 0.5995952178307736; 0.6150955455771212; 0.6196470808426647; 0.6218520979526325; 0.6222451141623291; 0.625027955184583; 0.6319938293757544; 0.6627865715415371; 0.6631086714705082; 0.6974821940437801; 0.7128284704851243; 0.717484976234209; 0.726789939981526; 0.82379775978369; 0.8343509960860942; 0.898753604719554; 0.9533233478887546,"Anomalous Pulmonary Artery; Thoracic Aortic Aneurysm And Aortic Dissection; Subarachnoid Hemorrhage; Blood Coagulation Disorders; Retinal Telangiectasia; Oculomotor Nerve Palsy; Polycythemia; Esophageal Varix; Pulmonary Arterial Hypertension; Hematomas; Ischemic Stroke; Lactose Intolerance; Cerebral Saccular Aneurysm; Encephalomalacia; Rectal Polyp; Cerebral Arteriovenous Malformation; Gastric Polyposis; Heritable Pulmonary Arterial Hypertension; Cystic Fibrosis Of Pancreas; Pulmonary Cystic Fibrosis; Osteopenia; Intracranial Aneurysm; Portal Hypertension; Transient Ischemic Attack; Bronchiectasis; Lung Diseases; Migraine; Hypertension; Cholecystitis; Visceral Angiomatosis; Pulmonary Hypertension; Conjunctival Telangiectasis; Cystic Fibrosis; Anemia; Nephrolithiasis; Cirrhosis; Lupus Erythematosus; Aortic Dissection; Hemangioma, Cavernous; Liver Failure; Intestinal Polyposis; Eczema; Cholelithiasis; Atherosclerosis; Stroke; Leukopenia; Congestive Heart Failure",0.0075861267486594; 0.1641294276675242; 0.2627224344149009; 0.3094716280561038; 0.336287627428424; 0.336287627428424; 0.3528591516609595; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4541466895915311; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4602028929328057; 0.4646409362700993; 0.4646409362700993; 0.4646409362700993; 0.4780231573499264; 0.4875380732267193; 0.4875380732267193; 0.5087473896242481; 0.5129298662020659; 0.5129298662020659; 0.5162067638232762; 0.5498080544456183; 0.6899894525110877; 0.7167438233451096; 0.7300866884650863; 0.7429124769329748; 0.7472134648605725; 0.7532174466905212,AGel amyloidosis ORPHA:85448; Keratolytic winter erythema ORPHA:50943; Cathepsin A-related arteriopathy-strokes-leukoencephalopathy ORPHA:575553; Epithelial basement membrane dystrophy ORPHA:98956; Familial cavitary optic disc anomaly ORPHA:464760; Familial retinal arterial macroaneurysm ORPHA:284247; Galactosialidosis ORPHA:351; Granular corneal dystrophy type I ORPHA:98962; Granular corneal dystrophy type II ORPHA:98963; Lattice corneal dystrophy type I ORPHA:98964; Lipoid proteinosis ORPHA:530; Pycnodysostosis ORPHA:763; Reis-Bucklers corneal dystrophy ORPHA:98961; Thiel-Behnke corneal dystrophy ORPHA:98960; Isolated ectopia lentis ORPHA:1885; Solitary fibrous tumor/hemangiopericytoma ORPHA:2126; Heritable pulmonary arterial hypertension ORPHA:275777; Amyloidosis cutis dyschromia ORPHA:319635; EMILIN-1-related connective tissue disease ORPHA:485418; LIMS2-related limb-girdle muscular dystrophy ORPHA:466801; Truncus arteriosus ORPHA:3384; Familial cerebral saccular aneurysm ORPHA:231160; Hyperandrogenism due to cortisone reductase deficiency ORPHA:168588; Diencephalic-mesencephalic junction dysplasia ORPHA:319192; Marfan syndrome type 2 ORPHA:284973; NON RARE IN EUROPE: Berger disease ORPHA:34145; Niemann-Pick disease type A ORPHA:77292; Niemann-Pick disease type B ORPHA:77293; Sanfilippo syndrome type C ORPHA:79271; Roussy-Levy syndrome ORPHA:3115; Generalized juvenile polyposis/juvenile polyposis coli ORPHA:329971; Dejerine-Sottas syndrome ORPHA:64748; Hereditary hemorrhagic telangiectasia ORPHA:774; Systemic-onset juvenile idiopathic arthritis ORPHA:85414; Adams-Oliver syndrome ORPHA:974; CLN13 disease ORPHA:352709; CLN2 disease ORPHA:228349; Childhood-onset autosomal recessive slowly progressive spinocerebellar ataxia ORPHA:284324; Paternal uniparental disomy of chromosome 6 ORPHA:96191; Chronic myelomonocytic leukemia ORPHA:98823,0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1782034488938806; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3826134188846508; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.6268296504510718; 0.6268296504510718; 0.6340773186521831; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens;Homo sapiens HEK293 embryonic kidney cell;Homo sapiens HeLa S3 epitheloid cervical carcinoma cell;yeasx,0.35;0.37;0.4;0.5,Bacillus anthracis;Homo sapiens;Human papillomavirus type 11;Human papillomavirus type 6b;ade05;chemical synthesis;ebvb9,Homo sapiens
ESCO2,"Stomach Carcinoma; Malignant neoplasm of stomach; Carcinogenesis; Flexion contracture of the knee; Biliary tract abnormality; Biliary Tract Diseases; Absent earlobe; Seizures; Cataract; contracture of elbow; Neoplasms; Flexion contracture - elbow; Kidney Neoplasm; Proximal placement of thumb; Abnormality of the skull; Fetal Growth Retardation; Hydrocephalus; Talipes Equinovalgus; Equinovalgus deformity; Phocomelia; Hypoplasia of thumb; Cloudy cornea; Corneal stromal opacities; Roberts-SC phocomelia syndrome; Complete duplication of thumb phalanx; Flexion contracture - wrist; Birthmark; Blue sclera; Infant, Small for Gestational Age; Cafe-au-Lait Spots; Intrauterine retardation; Craniosynostosis; Malignant neoplasm of kidney; Epilepsy; Absent finger; Accessory spleen; Increased size of penis; Ectromelia; Polycystic Kidney - body part; Fair hair; Blonde hair; Polyhydramnios; Aplasia/Hypoplasia of the thumb; Polycystic Kidney Diseases; Ankle contracture; Bicornuate uterus; Cranial nerve palsies; Aortic Valve Stenosis; Brachycephaly; Lens Opacities; Shallow orbits; absence of radius and ulna; Absent radius; Radial aplasia; Coloboma of eyelid; Short stature; Flexion contracture of hip; Congenital ear anomaly NOS (disorder); Ventricular Septal Defects; Syndactyly; Postnatal growth retardation; Curvature of little finger; Clinodactyly of the 5th finger; Hypotrophic malar bone; Malar flattening; Radial ray hypoplasia; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Lymphangioma, Cystic; Congenital hypoplasia of radius; Atrial Septal Defects; Aplasia/Hypoplasia of the mandible; Cornelia De Lange Syndrome; Horseshoe Kidney; Micrognathism; Cleft upper lip; Small head; Penile hypospadias; Abnormality of the metacarpal bones; Radioulnar Synostosis; Dull intelligence; Low intelligence; Bowing of the long bones; Hypospadias; Congenital Heart Defects; Radial deviation of finger; Wide skull shape; Broad cranium shape; Short neck; Brachydactyly; Abnormality of the outer ear; Low set ears; Poor school performance; Underdeveloped brows; Underdeveloped supraorbital ridges; Microphthalmos; Hypertrophy of clitoris; Mental deficiency; Abnormally small eyeball; Decreased size of eyeball; Radial club hand; Broad flat nasal bridge; Nasal bridge wide; Mental Retardation; Abnormality of cardiovascular system morphology; Patent ductus arteriosus; Underdeveloped nasal alae; Uranostaphyloschisis; Curvature of digit; Congenital clinodactyly; Sparse hair; Thin, sparse hair; Cryptorchidism; Downward slant of palpebral fissure; Posteriorly rotated ear; Premature Birth; Orbital separation excessive; Prominent eyes; Protruding eyes; Prominent globes; Exophthalmos; Intellectual Disability; Byzanthine arch palate; Craniofacial Abnormalities; Mental and motor retardation; Cognitive delay; Global developmental delay",0.0149315928814189; 0.0191435238361999; 0.0228075668512991; 0.064548079316548; 0.0745502070959292; 0.0775520919998773; 0.1735868515093891; 0.2053083986145698; 0.223747154820789; 0.2522264785494494; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.3099246715197673; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.39623320406434; 0.3975960596292668; 0.4028066164685291; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.425419812815905; 0.4304973629098372; 0.4304973629098372; 0.4335751357405352; 0.439389586518055; 0.4396723023384634; 0.4459714599189374; 0.4564472886428772; 0.4564472886428772; 0.4615352570710579; 0.4635211539849193; 0.4675904598629673; 0.4704594475773637; 0.4704594475773637; 0.472444704048021; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4757083758251088; 0.4790179402069343; 0.4790179402069343; 0.4790179402069343; 0.479747709091007; 0.4850576707687362; 0.4906258721078565; 0.5019670090704682; 0.5019670090704682; 0.5188223685230745; 0.5300976305939776; 0.5300976305939776; 0.5337853752290136; 0.533913711453195; 0.533913711453195; 0.5393787854381349; 0.5462489630068115; 0.5462489630068115; 0.549941235475765; 0.549941235475765; 0.5568517196017908; 0.5578737381206628; 0.5610226870913673; 0.5619299124666532; 0.5619299124666532; 0.5839588826096398; 0.6002127202571572; 0.6035970790768342; 0.6064571148125548; 0.6064571148125548; 0.6084642888478995; 0.6196470808426647; 0.6238969878903416; 0.6319938293757544; 0.6319938293757544; 0.6334536292962906; 0.6403143122455015; 0.6784817526917547; 0.6980473696540115; 0.7068844070911514; 0.726789939981526; 0.726789939981526; 0.7417321496240817; 0.7634367398642647; 0.7706351321777464; 0.7815030391631113; 0.8157137944879093; 0.8195255693608234; 0.8195255693608234; 0.8228582885461879; 0.827626149232917; 0.8352623613787349; 0.8441962785769224; 0.8913309410682808; 0.897310588550617; 0.9238745269736108; 0.9327689937867868,Kidney Cancer; Hypoplasia Of Thumb; Aortic Valve Sclerosis; Kidney Neoplasm; Hydrocephalus; Craniosynostosis; Elbow Flexion Contracture; Talipes Equinovalgus; Phocomelia; Horseshoe Kidney; Brachycephaly; Flexion Contracture Of Wrist; Radioulnar Synostosis; Polycystic Kidney Disease; Glaucoma; Cranial Nerve Paralysis; Syndactyly; Microcephaly; Micrognathism; Hip Contracture; Posteriorly Rotated Ear; Atrial Septal Defect; Congenital Hypoplasia Of Radius; Cystic Hygroma; Dwarfism; Brachydactyly; Hypertrophy Of Clitoris; Patent Ductus Arteriosus; Cataract; Congenital Ocular Coloboma; Camptodactyly Of Fingers; Proptosis; Ventricular Septal Defect; Mental Retardation; Cryptorchidism; Microphthalmos; Hypospadias; Clinodactyly; Syndactyly Of Fingers; Nystagmus; High Palate; Developmental Delay,0.3094716280561038; 0.3094716280561038; 0.3182746822082389; 0.336287627428424; 0.3657224783929353; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4646409362700993; 0.4867879381749835; 0.5123947823327547; 0.5123947823327547; 0.5234357475824973; 0.5234357475824973; 0.5248691614865011; 0.5254133486377646; 0.5414559855274098; 0.5498080544456183; 0.5796489603182782; 0.6198128018123746; 0.6524705037929849; 0.6596918765832213; 0.6660731887258019; 0.6883874961919009; 0.7328159476505643; 0.7558828942158288; 0.7729545590606223; 0.7729545590606223; 0.776786668801341; 0.7875494303517502; 0.8570285304674955; 0.8876319700740651; 0.8988523790817545; 0.9146877763175152; 0.9334417262711258; 0.96477535147595,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Roberts syndrome ORPHA:3103; Stromme syndrome ORPHA:506307; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Hereditary site-specific ovarian cancer syndrome ORPHA:213524; Bloom syndrome ORPHA:125; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; Primary peritoneal carcinoma ORPHA:168829; VACTERL with hydrocephalus ORPHA:3412; Osteosarcoma ORPHA:668; Seckel syndrome ORPHA:808; Fanconi anemia ORPHA:84; Autosomal recessive primary microcephaly ORPHA:2512; Combined immunodeficiency due to GINS1 deficiency ORPHA:505227; DNA2-related mitochondrial DNA deletion syndrome ORPHA:352470; Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations ORPHA:319462; Microcephaly-complex motor and sensory axonal neuropathy syndrome ORPHA:423894; Xeroderma pigmentosum variant ORPHA:90342; Li-Fraumeni syndrome ORPHA:524; Ear-patella-short stature syndrome ORPHA:2554; Hereditary breast and ovarian cancer syndrome ORPHA:145; Familial prostate cancer ORPHA:1331; Chudley-McCullough syndrome ORPHA:314597; Weaver syndrome ORPHA:3447; Familial pancreatic carcinoma ORPHA:1333; Male infertility with azoospermia or oligozoospermia due to single gene mutation ORPHA:399805; Retinitis pigmentosa-hearing loss-premature aging-short stature-facial dysmorphism syndrome ORPHA:494439; Combined oxidative phosphorylation defect type 13 ORPHA:319514; Congenital lactase deficiency ORPHA:53690; Posterior column ataxia-retinitis pigmentosa syndrome ORPHA:88628,0.0083045131203191; 0.0106988445340883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.0683063362547733; 0.0930156564388357; 0.1026843275212335; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.1659988674007724; 0.1936858543871029; 0.1981653781243822; 0.3762014630157917; 0.3775879467205478; 0.4101640425710954; 0.4548046963946745; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
FAM111B,"Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Conventional (Clear Cell) Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Collecting Duct Carcinoma of the Kidney; Diminished sweating; Hypohidrosis; Erythrokeratodermia variabilis; Papillary Renal Cell Carcinoma; Poikiloderma; Pulmonary Fibrosis; Hepatomegaly; Rothmund-Thomson syndrome; Congenital myopathy (disorder); Elevated creatine kinase; Creatine phosphokinase serum increased; Contracture; Arthrogryposis; Skeletal muscle atrophy; Neurogenic muscle atrophy, especially in the lower limbs; Alopecia; Neurogenic Muscular Atrophy; Muscle degeneration; Intellectual Disability",0.0648809611869375; 0.1461248774859792; 0.2980670559114652; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3975960596292668; 0.4304973629098372; 0.4335751357405352; 0.4506578937113162; 0.4675904598629673; 0.5188223685230745; 0.6294837700416086; 0.6332132835539771; 0.652707626880454; 0.7317475852509061; 0.7511668779991656; 0.7511668779991656; 0.7533159919746161; 0.7720422491171346; 0.8198848943907875; 0.8352623613787349,Liver Carcinoma; Pulmonary Fibrosis; Myositis; Chromophobe Carcinoma; Papillary Renal Carcinoma; Renal Carcinoma; Hypohidrosis; Poikiloderma; Alopecia,0.0520696613701797; 0.0654534781440596; 0.425341435586089; 0.4286813331685578; 0.4286813331685578; 0.4541466895915311; 0.4560460337187313; 0.4602028929328057; 0.7167438233451096,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043,0.0083045131203191,,,yeasx,0.56,Homo sapiens,Homo sapiens
FAM219A,,,,,Microduplication Xp11.22p11.23 syndrome ORPHA:217377; Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome ORPHA:397933; Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome ORPHA:508533; Global developmental delay-neuro-ophthalmological abnormalities-seizures-intellectual disability syndrome ORPHA:488613; Spinocerebellar ataxia type 21 ORPHA:98773; Autosomal dominant spastic paraplegia type 12 ORPHA:100993; Autosomal recessive spastic paraplegia type 44 ORPHA:320401; DNAJB2-related Charcot-Marie-Tooth disease type 2 ORPHA:443950; Pelizaeus-Merzbacher-like disease due to GJC2 mutation ORPHA:280282; Perry syndrome ORPHA:178509; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha ORPHA:566231; Young adult-onset distal hereditary motor neuropathy ORPHA:314485; Lethal congenital contracture syndrome type 3 ORPHA:137783; Miller-Dieker syndrome ORPHA:531,0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens HEK293T embryonic kidney cell,0.27,SARS-CoV-2,Homo sapiens
FAM234B,,,,,Autosomal dominant Charcot-Marie-Tooth disease type 2K ORPHA:99944; Autosomal recessive Charcot-Marie-Tooth disease with hoarseness ORPHA:101097; Autosomal recessive intermediate Charcot-Marie-Tooth disease type A ORPHA:217055; Charcot-Marie-Tooth disease type 2H ORPHA:101102; Charcot-Marie-Tooth disease type 4A ORPHA:99948; DOORS syndrome ORPHA:79500; Focal epilepsy-intellectual disability-cerebro-cerebellar malformation ORPHA:352587; Progressive myoclonic epilepsy with dystonia ORPHA:352596; Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome ORPHA:163727; Mulibrey nanism ORPHA:2576; Congenital neutropenia-myelofibrosis-nephromegaly syndrome ORPHA:369852,0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens HEK293T embryonic kidney cell,0.35,Homo sapiens,Homo sapiens
FAM43A,"Liver Cirrhosis, Experimental; Autistic Disorder",0.0747863377072194; 0.8064248359603999,,,"Atrial septal defect, sinus venosus type ORPHA:99105",0.3762014630157917,,,,,,
FGF19,"Breast Carcinoma; Tumor Progression; Squamous cell carcinoma; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of prostate; Liver Cirrhosis; Prostate carcinoma; Squamous cell carcinoma of esophagus; Liver carcinoma; Malignant Neoplasms; Colon Carcinoma; Adenocarcinoma of colon; Colonic Neoplasms; Liver neoplasms; Malignant tumor of colon; Diabetes; Metastasis from malignant tumor of prostate; Diabetes Mellitus; Malignant neoplasm of liver; Metastatic Prostate Carcinoma; Neoplasms; Cirrhosis; Pancreatic Ductal Adenocarcinoma; Diabetes Mellitus, Non-Insulin-Dependent; Chronic liver disease; Liver and Intrahepatic Biliary Tract Carcinoma; Fibrosis, Liver; Retinal defect; Osteoporosis with pseudoglioma; Cholestasis of pregnancy; Insulin Sensitivity; Cholestasis; Squamous cell carcinoma of lung; Insulin Resistance; Steatohepatitis; Diarrhea; Primary biliary cirrhosis; Obesity; Colitis; Pancreatic intraepithelial neoplasia; Polycystic Ovary Syndrome; Hepatocarcinogenesis; Fatty Liver; Metabolic Syndrome X; Necrosis; Hypertriglyceridemia; Irritable Bowel Syndrome; Crohn's disease of large bowel; Liver diseases; Metabolic Diseases; Lipodystrophy",0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0569142010728473; 0.0773771948186562; 0.0773771948186562; 0.0919714360040484; 0.095319386034013; 0.0991201145654548; 0.1062239757831962; 0.1112281755580192; 0.1454373331146953; 0.1454373331146953; 0.223747154820789; 0.2277108302018961; 0.2454426921531692; 0.2522264785494494; 0.2643145809900195; 0.2643145809900195; 0.2714542429024338; 0.2923761731100008; 0.3018974726133723; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3975960596292668; 0.4100901006059349; 0.4335751357405352; 0.4459714599189374; 0.4906258721078565; 0.4923669467696064; 0.4923669467696064; 0.5140447474168605; 0.5323590634832615; 0.5337853752290136; 0.5337853752290136; 0.533913711453195; 0.533913711453195; 0.5568517196017908; 0.6002127202571572; 0.6304655343580164; 0.6545439509404224; 0.672336954961104; 0.7337030585693298; 0.750779529196619; 0.7683326132740758,Liver Carcinoma,0.0520696613701797,"Combined pituitary hormone deficiencies, genetic forms ORPHA:95494; Partial pancreatic agenesis ORPHA:2805; Oculootodental syndrome ORPHA:99806; Midline interhemispheric variant of holoprosencephaly ORPHA:93926; Septopreoptic holoprosencephaly ORPHA:280195; Semilobar holoprosencephaly ORPHA:220386; Anterior segment developmental anomaly ORPHA:88632; Congenital primary aphakia ORPHA:83461; Deafness with labyrinthine aplasia, microtia, and microdontia ORPHA:90024; Otodental syndrome ORPHA:2791; Alobar holoprosencephaly ORPHA:93925; Acro-renal-ocular syndrome ORPHA:959; Congenital hereditary facial paralysis-variable hearing loss syndrome ORPHA:306530; IVIC syndrome ORPHA:2307; Infantile dystonia-parkinsonism ORPHA:238455; Okihiro syndrome due to 20q13 microdeletion ORPHA:261638; Okihiro syndrome due to a point mutation ORPHA:261647; 17q12 microdeletion syndrome ORPHA:261265",0.0683063362547733; 0.3762014630157917; 0.3762014630157917; 0.43936148647173; 0.43936148647173; 0.4470672161388242; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6787273931204523; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
FHIT,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant mesothelioma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Urologic Neoplasms; Hematopoietic Neoplasms; Medulloblastoma; Epithelial ovarian cancer; Brain Tumor, Primary; Skin carcinoma; Cancer of Urinary Tract; Malignant neoplasm of prostate; Cervical Squamous Intraepithelial Neoplasia 1; Carcinoma; Cervical intraepithelial neoplasia grade 1; Carcinomatosis; Brain Neoplasms; Neoplasm Metastasis; Barrett Esophagus; Mucoepidermoid Carcinoma; Renal Cell Carcinoma; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Squamous cell carcinoma of penis; Lymphoma; Endometrial Neoplasms; Pancreatic carcinoma; Liver Cirrhosis; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Adenoid cystic carcinoma of salivary gland; Colorectal Neoplasms; Anaplastic carcinoma; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Adult Acute Lymphocytic Leukemia; Squamous cell carcinoma of esophagus; Anus Neoplasms; Liver carcinoma; Malignant Neoplasms; Colon Carcinoma; Adenocarcinoma of colon; Chronic Lymphocytic Leukemia; Small cell carcinoma of lung; Hematologic Neoplasms; Brain Aneurysm; MYELODYSPLASTIC SYNDROME; Esophageal carcinoma; Ductal Breast Carcinoma; Hamman-Rich syndrome; Undifferentiated carcinoma; Clear-cell metastatic renal cell carcinoma; Carcinoma, Transitional Cell; Oral Cavity Carcinoma; Carcinoma of bladder; Malignant neoplasm of endometrium; Unipolar Depression; Uterine Corpus Cancer; Solid Neoplasm; Colonic Neoplasms; Liver neoplasms; Breast Cancer, Familial; Invasive Carcinoma; Testicular Germ Cell Tumor; Head and Neck Carcinoma; Benign Ovarian Neoplasm; Low Grade Cervical Squamous Intraepithelial Neoplasia; TARSAL-CARPAL COALITION SYNDROME; Cervical intraepithelial neoplasia grade 2; cervical cancer; Gastrointestinal Neoplasms; Lung Neoplasms; Malignant tumor of colon; Prostatic Neoplasms; Hodgkin Disease; Burkitt Lymphoma; Malignant Head and Neck Neoplasm; B-Cell Lymphomas; Malignant neoplasm of liver; Adenocarcinoma Of Esophagus; Malignant tumor of cervix; Malignant ascites; Malignant neoplasm of lung; Kidney Neoplasm; Cervix carcinoma; Acute leukemia; Adult Hepatocellular Carcinoma; Conventional (Clear Cell) Renal Cell Carcinoma; Breast cancer, lobular; Myeloid Leukemia; Pancreatic Ductal Adenocarcinoma; Endometrial Carcinoma; Idiopathic Pulmonary Fibrosis; Childhood Acute Lymphoblastic Leukemia; Malignant Squamous Cell Neoplasm; Cervical Squamous Cell Carcinoma; Penis carcinoma; Leukoplakia; Cholangiocarcinoma; Blast Phase; Leukemogenesis; Mammary Ductal Carcinoma; Carcinoma of lung; Tuberculosis; Classical Hodgkin's Lymphoma; Adenomatous polyp of colon; Thyroid Neoplasm; Tuberculosis, Pulmonary; Teratoma; Noninfiltrating Intraductal Carcinoma; Primary malignant neoplasm of lung; Von Hippel-Lindau Syndrome; Secondary malignant neoplasm of lymph node; Gallbladder Carcinoma; Epstein-Barr Virus Infections; Adenocarcinoma of large intestine; Uterine Cervical Neoplasm; Diabetes Mellitus, Non-Insulin-Dependent; Nasopharyngeal carcinoma; Non-small cell lung cancer stage I; Infant Acute Lymphoblastic Leukemia; Schizophrenia; Non-Small Cell Lung Carcinoma; Infection caused by Helicobacter pylori; Leukemia, Myelocytic, Acute; HIV Infections; Urothelial Carcinoma; Chordoma; Anxiety Disorders; Torre-Muir syndrome; Bronchioloalveolar Adenocarcinoma; Liver and Intrahepatic Biliary Tract Carcinoma; Acute lymphocytic leukemia; Lip and Oral Cavity Carcinoma; Stomach Neoplasms; Inflammatory Bowel Diseases; Coronary heart disease; Familial renal cell carcinoma; Hereditary Clear Cell Renal Cell Carcinoma; Hereditary Renal Cell Carcinoma; Krukenberg Tumor; Non-small cell lung cancer stage II; Adenoma; Anemia; Malignant neoplasm of kidney; Familial multiple trichoepitheliomata; Autism Spectrum Disorders; Renal carcinoma; Cervical Squamous Intraepithelial Neoplasia; Thyroid carcinoma; Drug abuse; Progressive Neoplastic Disease; Fibrosis; Progressive cGVHD; Physical Activity Measurement; Merkel cell carcinoma; Drug Dependence; Intrahepatic Cholangiocarcinoma; Squamous cell carcinoma of mouth; Multiple Myeloma; ALZHEIMER DISEASE 5; Anxiety; Phyllodes Tumor; Breast Fibrocystic Change, Proliferative Type; Acute Coronary Syndrome; High-Grade Squamous Intraepithelial Lesions; Adenoma of large intestine; Focal Nodular Hyperplasia; Non-small cell carcinoma; Immunologic Deficiency Syndromes; Mouth Neoplasms; Disease due to Papilloma virus; Malignant neoplasm of mouth; Papilloma; Autosomal dominant compelling helio ophthalmic outburst syndrome; Malignant neoplasm of thyroid; Breast Fibrocystic Disease; Germ cell tumor; Amphetamine-Related Disorders; Amphetamine Abuse; Squamous cell carcinoma of lung; Amphetamine Addiction; Substance Use Disorders; Carcinoid Tumor; Personality Traits; Precancerous Conditions; Malignant neoplasm of tongue; bilateral breast cancer; Dyspepsia; Perianal Squamous Intraepithelial Neoplasia; leukemia; Substance abuse problem; Chronic active hepatitis; MOHR-TRANEBJAERG SYNDROME; Mesothelioma; Myeloid Leukemia, Chronic; Adenomatous Polyposis Coli; Treatment related leukaemia; Transitional cell carcinoma of bladder; Follicular thyroid carcinoma; High grade serous carcinoma; PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE; Sebaceous Adenocarcinoma; Bowen's Disease; Cervical high grade squamous intraepithelial lesion; Pleural Tuberculosis; Crohn Disease; Ulcerative Colitis; Neuroendocrine Tumors; Low Grade Squamous Intraepithelial Neoplasia; Squamous intraepithelial lesion; Organic Mental Disorders, Substance-Induced; Prescription Drug Abuse; Carcinoma, Small Cell; Precursor Cell Lymphoblastic Leukemia Lymphoma; Drug Use Disorders; Precursor B-cell lymphoblastic leukemia; Body mass index; Finding of body mass index; Substance-Related Disorders; Thymoma; Cervical Intraepithelial Neoplasia; Hypoalbuminemia; Congenital hypoplasia of lung; Smoking Behaviors; Hereditary Diffuse Gastric Cancer; precancerous lesions; Drug habituation; Diffuse Large B-Cell Lymphoma; Substance Dependence; Infection; Seminoma; Ductal Carcinoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Congenital chromosomal disease; Primary Effusion Lymphoma; Sporadic Breast Carcinoma; Carcinoma, Large Cell; Tracheal Diseases; Narcolepsy; invasive cancer; Systemic arterial pressure; Blood Pressure; Blood pressure finding; Fanconi Anemia; Hepatitis C; Pleural effusion disorder; Exanthema; Gastrointestinal Carcinoid Tumor; Systolic Pressure; Gastritis, Atrophic; FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0308703957553632; 0.0314665934969085; 0.0334891258932371; 0.0354767239335874; 0.0387439397151409; 0.044151975756427; 0.0482468351695405; 0.0492766532827251; 0.0569142010728473; 0.0593779966354549; 0.0593779966354549; 0.0593779966354549; 0.0617471306652618; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0773771948186562; 0.0775520919998773; 0.0775520919998773; 0.0827744840860166; 0.084286432100041; 0.084286432100041; 0.0891725280554336; 0.0919714360040484; 0.0919714360040484; 0.095319386034013; 0.095319386034013; 0.0991201145654548; 0.1062239757831962; 0.1112281755580192; 0.1147307578771389; 0.1193558174333938; 0.1253114324938153; 0.1253114324938153; 0.1254380558571286; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1413782599148022; 0.1454373331146953; 0.1454373331146953; 0.1602092191314262; 0.1602092191314262; 0.1735868515093891; 0.1735868515093891; 0.1770067065899052; 0.1897991423047819; 0.1906413554467301; 0.2050045461627939; 0.2050045461627939; 0.2062010908869036; 0.2062010908869036; 0.223747154820789; 0.223747154820789; 0.2454476567103779; 0.2521987644415915; 0.2522264785494494; 0.2522264785494494; 0.2643145809900195; 0.2679411586077776; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2834835531038365; 0.2835142372342932; 0.290158730291654; 0.2980670559114652; 0.2980670559114652; 0.2980670559114652; 0.3018974726133723; 0.3044782497745498; 0.3099246715197673; 0.3099246715197673; 0.3104232675696299; 0.3199171478489988; 0.3220099003872086; 0.333745294913745; 0.340892538685018; 0.3494455519738624; 0.3510063969122338; 0.3638414818541592; 0.3663130598151661; 0.3706856725676674; 0.3763374964032415; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.3986414839122469; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4100901006059349; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4118266358241932; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.425992946703162; 0.4304973629098372; 0.4307603335611732; 0.4330362522463816; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4352815161963393; 0.4381343267935581; 0.4381343267935581; 0.4396723023384634; 0.4479115285676636; 0.4506578937113162; 0.4506578937113162; 0.4564472886428772; 0.4564472886428772; 0.4588513406515081; 0.4615352570710579; 0.4615352570710579; 0.4615352570710579; 0.4635211539849193; 0.472444704048021; 0.4749780675672355; 0.4753011022966241; 0.4790179402069343; 0.4790179402069343; 0.4790179402069343; 0.4840863724482356; 0.4852430673532381; 0.4906258721078565; 0.4906258721078565; 0.4923669467696064; 0.4981941174985421; 0.5001612228394569; 0.5017066790423467; 0.5019670090704682; 0.5090214163899865; 0.533913711453195; 0.533913711453195; 0.5359212109443033; 0.5393787854381349; 0.5393787854381349; 0.5451009374855866; 0.5496357724684553; 0.5496357724684553; 0.5514573300659174; 0.5523521032803237; 0.5523521032803237; 0.553002957824355; 0.5557519470957561; 0.5580691945487462; 0.5696906826730043; 0.5710095678317721; 0.589345563575654; 0.5913651925298382; 0.5936773368594411; 0.5959654688257199; 0.5990568578129436; 0.6002127202571572; 0.6035970790768342; 0.6035970790768342; 0.6248356417853507; 0.6332132835539771; 0.6355866602993508; 0.6496433426951205; 0.6496433426951205; 0.652707626880454; 0.6656356363792992; 0.6656356363792992; 0.6656356363792992; 0.7053337831155875; 0.7169459458481418; 0.7564787632115322; 0.7674304683279349; 0.7674304683279349; 0.7796824214131131; 0.8000044931629623; 0.8064248359603999,Urinary Tract Cancer; Anaplastic Carcinoma; Schizophrenia; Carcinoma; Urologic Neoplasms; Development Disorder; Lung Cancer; Hereditary Renal Carcinoma; Lung Carcinoma; Lip And Oral Cavity Carcinoma; Lung Neoplasms; Intracranial Aneurysm; Mental Depression; Coronary Syndrome; Colorectal Neoplasms; Liver Cancer; Narcolepsy; Prostatic Neoplasms; Achoo Syndrome; Liver Neoplasms; Mesothelioma; Prostate Cancer; Gastric Cancer; Stomach Neoplasms; Leukemia; Coronary Heart Disease,0.0102679590519094; 0.0402286636010764; 0.0531117779464085; 0.0534520155998091; 0.0839188440969517; 0.4372065554432662; 0.4402141802500753; 0.4402141802500753; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4723647227028846; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.5129298662020659; 0.5796489603182782; 0.6104715460837368; 0.6524705037929849; 0.669817442578862; 0.7167438233451096; 0.7726217084209973,Hereditary clear cell renal cell carcinoma ORPHA:422526,0.639029370164481,,,In vitro;yeasx,0.95,Homo sapiens,Homo sapiens
FRAT2,Stomach Carcinoma; Malignant neoplasm of stomach; Carcinogenesis; MIXED LINEAGE LEUKEMIA; leukemia,0.0149315928814189; 0.0191435238361999; 0.0228075668512991; 0.2605479444258003; 0.4588513406515081,,,Acute myeloid leukemia with CEBPA somatic mutations ORPHA:319480; Recurrent infection due to specific granule deficiency ORPHA:169142; Squamous cell carcinoma of salivary glands ORPHA:500481; Squamous cell carcinoma of the hypopharynx ORPHA:494547; Squamous cell carcinoma of the larynx ORPHA:494550; Squamous cell carcinoma of the lip ORPHA:502366; Squamous cell carcinoma of the nasal cavity and paranasal sinuses ORPHA:500464; Squamous cell carcinoma of the oral cavity ORPHA:502363; Squamous cell carcinoma of the oropharynx ORPHA:500478; Congenital dyserythropoietic anemia type IV ORPHA:293825,0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423,,,,,,
FRMD8,,,Leukemia,0.7167438233451096,Mucopolysaccharidosis type 4A ORPHA:309297; Solitary fibrous tumor/hemangiopericytoma ORPHA:2126; Hydranencephaly ORPHA:2177; NDE1-related microhydranencephaly ORPHA:443162; Dehydrated hereditary stomatocytosis ORPHA:3202; Autosomal recessive spastic paraplegia type 48 ORPHA:306511; Infantile nephropathic cystinosis ORPHA:411629; Juvenile nephropathic cystinosis ORPHA:411634; MYH9-related disease ORPHA:182050; Ocular cystinosis ORPHA:411641; Combined immunodeficiency due to ORAI1 deficiency ORPHA:317428; Hermansky-Pudlak syndrome type 8 ORPHA:231537; Spondylometaphyseal dysplasia-cone-rod dystrophy syndrome ORPHA:85167; Ependymoma ORPHA:251636; RELA fusion-positive ependymoma ORPHA:530792; Stormorken-Sjaastad-Langslet syndrome ORPHA:3204,0.0586579655822394; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Yaba monkey tumor virus kelch-like protein; Crimean-Congo hemorrhagic fever virus full_polyprotein 1..3945 (gene: RdRp); SARS coronavirus excised_polyprotein 1..4369 (gene: orf1ab); SARS coronavirus P2 full_polyprotein 1..4382; SARS coronavirus Tor2 replicase 1AB; SARS coronavirus P2 full_polyprotein 1..7073; Vaccinia virus Ankara serine proteinase inhibitor / SPI-2 f2; SARS coronavirus nsp3-pp1a/pp1ab (gene: orf1ab); Dugbe virus L protein,0.6362779693488597; 0.6433049303988263; 0.7568193074461791; 0.7651942752688915; 0.7988086321880973; 0.8020079067482934; 0.8220964101663402; 0.8220964101663402; 0.875442055263636,,,,
FZD1,"Breast Carcinoma; Invasive carcinoma of breast; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of esophagus; Medulloblastoma; Central neuroblastoma; Neoplasm Metastasis; Neuroblastoma; Osteosarcoma; Colon Carcinoma; Esophageal carcinoma; Osteosarcoma of bone; Malignant tumor of colon; Smith-Lemli-Opitz Syndrome; Triple Negative Breast Neoplasms; Idiopathic Pulmonary Fibrosis; Adenomatous polyp of colon; Thyroid Neoplasm; Parathyroid Adenoma; Nephroblastoma; Non-Small Cell Lung Carcinoma; NAIL DISORDER, NONSYNDROMIC CONGENITAL, 9; Mental Depression; Teratocarcinoma; Hyperparathyroidism, Primary; Depressive disorder; Refractory cancer; Familial Exudative Vitreoretinopathy; Nail dysplasia; Follicular thyroid carcinoma; Rhabdoid Tumor of the Kidney; Ulcerative Colitis; Williams Syndrome",0.0042545616049287; 0.0149002095788623; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0248454592431097; 0.0354767239335874; 0.0593779966354549; 0.0648809611869375; 0.0688152422187159; 0.1029977559100099; 0.1062239757831962; 0.1254380558571286; 0.2109483801368481; 0.223747154820789; 0.2522264785494494; 0.2980670559114652; 0.3099246715197673; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.39623320406434; 0.3975960596292668; 0.4028066164685291; 0.4103119460235835; 0.4192169590514327; 0.4790179402069343; 0.4981941174985421; 0.5001612228394569; 0.6403143122455015,,,"Unverricht-Lundborg disease ORPHA:308; 19p13.3 microduplication syndrome ORPHA:447980; Malan overgrowth syndrome ORPHA:420179; Marshall-Smith syndrome ORPHA:561; Sanfilippo syndrome type D ORPHA:79272; Atrial septal defect, sinus venosus type ORPHA:99105; Chondrodysplasia-disorder of sex development syndrome ORPHA:1422; Lethal osteosclerotic bone dysplasia ORPHA:1832",0.0083744975290613; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782,,,,,,
GABRQ,Liver carcinoma; Liver neoplasms; Malignant neoplasm of lung; Carcinoma of lung; Primary malignant neoplasm of lung; Asthma; Essential Tremor; Migraine Disorders; Tremor; Intellectual Disability,0.095319386034013; 0.1454373331146953; 0.2714542429024338; 0.3663130598151661; 0.3902116649640871; 0.3933196962529684; 0.425419812815905; 0.4450743762496232; 0.4564472886428772; 0.8352623613787349,Schizophrenia; Autism Spectrum Disorder; Migraine; Atrial Septal Defect,0.0531117779464085; 0.425341435586089; 0.4560460337187313; 0.5254133486377646,Neuroblastoma ORPHA:635; Thyrotoxic periodic paralysis ORPHA:79102; Anonychia congenita totalis ORPHA:94150,0.3969770464111636; 0.6239678957896782; 0.7068064785325423,Ectromelia virus ERPV hemagglutinin; Vaccinia virus Ankara Haemagglutinin; Vaccinia virus hemagglutinin (gene: A56R); Horsepox virus HSPV177 (Immunoglobulin like); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R),0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.691145768348025; 0.776311155917498,,,,
GAL,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Proliferative vitreoretinopathy; Squamous cell carcinoma; Malignant mesothelioma; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Central neuroblastoma; Brain Neoplasms; Renal Cell Carcinoma; Neuroblastoma; Glioma; Glioblastoma; Squamous cell carcinoma of the head and neck; Lysosomal Storage Diseases; Colorectal Neoplasms; Liver carcinoma; Colon Carcinoma; Adenocarcinoma of colon; Ganglioneuroma; Small cell carcinoma of lung; Unipolar Depression; Head and Neck Carcinoma; Seizures; Major Depressive Disorder; Malignant tumor of colon; Diabetes; Neuroblastic tumors; Malignant Head and Neck Neoplasm; Diabetes Mellitus; MIXED LINEAGE LEUKEMIA; Opiate Addiction; Neoplasms; Malignant ascites; Diabetes Mellitus, Insulin-Dependent; Multiple Sclerosis; Embryonal Carcinoma; Acute pancreatitis; Apraxia, Developmental Verbal; Marijuana Abuse; Pheochromocytoma; Classical Hodgkin's Lymphoma; Rat Insulinoma; Complex partial seizures; Amyloidosis; Bipolar Disorder; Plaque, Amyloid; Inflammation; Seizures, Focal; Hypertensive disease; Alzheimer's Disease; Anxiety Disorders; Fabry Disease; Epilepsy; Intrauterine infection; Mental Depression; Pituitary Adenoma; Drug abuse; Pituitary Neoplasms; Alcohol abuse; Mechanical Allodynia; Depressive disorder; Nicotine withdrawal; Drug Dependence; Epilepsy, Temporal Lobe; Drug-induced depressive state; Anxiety; Complex partial seizure with impairment of consciousness; Neuralgia, Atypical; Neuralgia, Iliohypogastric Nerve; Neuralgia, Ilioinguinal; Neuralgia, Perineal; Neuralgia, Stump; Neuralgia, Supraorbital; Neuralgia, Vidian; Paroxysmal Nerve Pain; Mood Disorders; Nerve Pain; Cleft palate, isolated; Lupus Erythematosus, Systemic; Tachyarrhythmia; Galactosemias; Encephalomyelitis; Psychosis, Involutional; Involutional Depression; Involutional paraphrenia; Addictive Behavior; Central Nervous System Neoplasms; Myxoid cyst; Classical galactosemia; PANIC DISORDER 1; Herpes zoster disease; Migraine Disorders; Mild cognitive disorder; Hyperalgesia, Secondary; Allodynia; Hyperalgesia, Primary; leukemia; Diabetic Neuropathies; Tactile Allodynia; Cerebral Palsy; Panic Disorder; Pain; Neuralgia; Ovarian Failure, Premature; Alcoholic Intoxication, Chronic; Obesity; Hyperalgesia, Thermal; Syncope; Hyperalgesia; Autoimmune Diseases; Encephalitis, St. Louis; Hirschsprung Disease; Tachycardia; Graft-vs-Host Disease; Premature Menopause; Stress, Psychological; Hypertriglyceridemia; Sepsis; Brain Ischemia; Gastric ulcer; T-Cell Lymphoma; Nicotine Dependence",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0593779966354549; 0.064548079316548; 0.0648809611869375; 0.0688152422187159; 0.0739788831250619; 0.0745502070959292; 0.0775520919998773; 0.0798053340865682; 0.0827744840860166; 0.095319386034013; 0.1062239757831962; 0.1112281755580192; 0.1138051695421299; 0.1193558174333938; 0.13167400689206; 0.1735868515093891; 0.2053083986145698; 0.21122597829463; 0.223747154820789; 0.2277108302018961; 0.2522264785494494; 0.2522264785494494; 0.2522264785494494; 0.2605479444258003; 0.2643145809900195; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2835142372342932; 0.3112516166225269; 0.3220099003872086; 0.340892538685018; 0.3418217363648192; 0.3712878513813393; 0.3763374964032415; 0.3778347117514905; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.39623320406434; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.4192169590514327; 0.4192169590514327; 0.4213286052188015; 0.425419812815905; 0.425419812815905; 0.4254307049060398; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4314759856195063; 0.4330362522463816; 0.4335751357405352; 0.4335751357405352; 0.4352815161963393; 0.4396723023384634; 0.4450743762496232; 0.4506578937113162; 0.4561717689698902; 0.4561717689698902; 0.4564472886428772; 0.4588513406515081; 0.4615352570710579; 0.4675904598629673; 0.4675904598629673; 0.4753011022966241; 0.4871698998714747; 0.4923669467696064; 0.4923669467696064; 0.5097818625871164; 0.5140447474168605; 0.5178072301085912; 0.5299466034567416; 0.5393787854381349; 0.5512224939896888; 0.553002957824355; 0.5794721015064842; 0.582492855487907; 0.5922440535658843; 0.625112405383346; 0.6274540883972485; 0.6304655343580164; 0.6395767498329145; 0.6592493193460769; 0.7240930522443176; 0.7577323833810212; 0.7935206698366561,Hodgkin Disease; Epilepsy; Mental Depression; Psychosis; Hypertension; Mood Disorder; Hirschsprung Disease; Involutional Depression; Involutional Paraphrenia; Bipolar Disorder; Huntington Disease; Seizure; Dyscognitive Seizures,0.2627224344149009; 0.3449614869411272; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.5576425853515448; 0.5632819212593052,Deafness-lymphedema-leukemia syndrome ORPHA:3226; Monocytopenia with susceptibility to infections ORPHA:228423; Blepharophimosis-ptosis-epicanthus inversus syndrome plus ORPHA:572333; Blepharophimosis-ptosis-epicanthus inversus syndrome type 1 ORPHA:572354; Blepharophimosis-ptosis-epicanthus inversus syndrome type 2 ORPHA:572361,0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782,,,,,,
GANAB,"Degenerative polyarthritis; Lymphoma; Brain Aneurysm; Dilatation of the cerebral artery; Intracranial Aneurysm; Cerebral arterial aneurysm; Polycystic Kidney, Type 1 Autosomal Dominant Disease; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney - body part; Cerebral Aneurysm; Physical Activity Measurement; Polycystic kidney disease, type 2; Polycystic Kidney Diseases; Polycystic liver disease; Liver cyst",0.0739788831250619; 0.0739788831250619; 0.1253114324938153; 0.1254380558571286; 0.1735868515093891; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.39623320406434; 0.3975960596292668; 0.3986414839122469; 0.4028066164685291; 0.4126392832024548; 0.4192169590514327; 0.4459714599189374,Liver Cyst; Polycystic Kidney Disease; Polycystic Liver Disease,0.4560460337187313; 0.4646409362700993; 0.4875380732267193,"Autosomal dominant osteopetrosis type 1 ORPHA:2783; Endosteal hyperostosis, Worth type ORPHA:2790; LRP5-related primary osteoporosis ORPHA:498481; Osteoporosis-pseudoglioma syndrome ORPHA:2788; Osteosclerosis-developmental delay-craniosynostosis syndrome ORPHA:178377; Autosomal dominant polycystic kidney disease ORPHA:730; Autosomal dominant Charcot-Marie-Tooth disease type 2V ORPHA:447964; Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome ORPHA:508476; Glycogen storage disease due to muscle and heart glycogen synthase deficiency ORPHA:137625; Sanfilippo syndrome type B ORPHA:79270; Giant cell glioblastoma ORPHA:251579; Gliosarcoma ORPHA:251576; Idiopathic pulmonary fibrosis ORPHA:2032; Adult-onset distal myopathy due to VCP mutation ORPHA:329478; Autosomal dominant Charcot-Marie-Tooth disease type 2N ORPHA:228174; Autosomal dominant Charcot-Marie-Tooth disease type 2Y ORPHA:435387; Autosomal recessive spastic paraplegia type 62 ORPHA:401785; Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome ORPHA:436174; Connective tissue disorder due to lysyl hydroxylase-3 deficiency ORPHA:300284; DDOST-CDG ORPHA:300536; Global developmental delay-neuro-ophthalmological abnormalities-seizures-intellectual disability syndrome ORPHA:488613; Intellectual disability-seizures-hypophosphatasia-ophthalmic-skeletal anomalies syndrome ORPHA:369837; Jalili syndrome ORPHA:1873; MAN1B1-CDG ORPHA:397941; Neurogenic arthrogryposis multiplex congenita ORPHA:1143; Oxoglutaric aciduria ORPHA:31; Polyneuropathy-hearing loss-ataxia-retinitis pigmentosa-cataract syndrome ORPHA:171848; STT3A-CDG ORPHA:370921; Schimke immuno-osseous dysplasia ORPHA:1830; Smith-Lemli-Opitz syndrome ORPHA:818; Spastic paraplegia-Paget disease of bone syndrome ORPHA:329475; Spinocerebellar ataxia type 4 ORPHA:98765; Caudal regression sequence ORPHA:3027; Frontometaphyseal dysplasia ORPHA:1826; Progressive myoclonic epilepsy type 5 ORPHA:402082; Lujan-Fryns syndrome ORPHA:776; Myxofibrosarcoma ORPHA:79105; Potocki-Shaffer syndrome ORPHA:52022; Congenital muscular dystrophy without intellectual disability ORPHA:370980; Familial multiple meningioma ORPHA:263662; Meningioma ORPHA:2495; Total early-onset cataract ORPHA:98994; ALDH18A1-related De Barsy syndrome ORPHA:35664; Autoimmune interstitial lung disease-arthritis syndrome ORPHA:444092; Autosomal dominant Charcot-Marie-Tooth disease type 2A2 ORPHA:99947; Autosomal dominant Charcot-Marie-Tooth disease type 2DD ORPHA:521414; Autosomal dominant spastic paraplegia type 9A ORPHA:447753; Autosomal dominant spastic paraplegia type 9B ORPHA:447757; Autosomal recessive severe congenital neutropenia due to G6PC3 deficiency ORPHA:331176; Autosomal recessive spastic paraplegia type 18 ORPHA:209951; Autosomal recessive spastic paraplegia type 9B ORPHA:447760; COG4-CDG ORPHA:263501; DPAGT1-CDG ORPHA:86309; Diffuse cerebral and cerebellar atrophy-intractable seizures-progressive microcephaly syndrome ORPHA:404437; Distal hereditary motor neuropathy, Jerash type ORPHA:139552; FLNA-related X-linked myxomatous valvular dysplasia ORPHA:555877; Frontorhiny ORPHA:391474; Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome ORPHA:480898; Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib ORPHA:79259; Hereditary motor and sensory neuropathy type 5 ORPHA:64751; Infantile-onset X-linked spinal muscular atrophy ORPHA:1145; Intellectual disability-macrocephaly-hypotonia-behavioral abnormalities syndrome ORPHA:457279; Isolated sedoheptulokinase deficiency ORPHA:440713; Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency ORPHA:1900; MOGS-CDG ORPHA:79330; Melnick-Needles syndrome ORPHA:2484; Microcephalic osteodysplastic dysplasia, Saul-Wilson type ORPHA:85172; Microcephaly-short stature-intellectual disability-facial dysmorphism syndrome ORPHA:423306; Multiple symmetric lipomatosis ORPHA:2398; Neuronal intestinal pseudoobstruction ORPHA:99811; Opsismodysplasia ORPHA:2746; Orofaciodigital syndrome type 4 ORPHA:2753; Otopalatodigital syndrome type 1 ORPHA:90650; Otopalatodigital syndrome type 2 ORPHA:90652; POMGNT1-related  limb-girdle muscular dystrophy R15 ORPHA:206564; Recessive intellectual disability-motor dysfunction-multiple joint contractures syndrome ORPHA:280384; Rhizomelic chondrodysplasia punctata type 5 ORPHA:468717; Seizures-scoliosis-macrocephaly syndrome ORPHA:466926; Severe early-onset axonal neuropathy due to MFN2 deficiency ORPHA:90118; Spinocerebellar ataxia type 26 ORPHA:101112; Terminal osseous dysplasia-pigmentary defects syndrome ORPHA:88630; X-linked Ehlers-Danlos syndrome ORPHA:75497; X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome ORPHA:482606; Cole-Carpenter syndrome ORPHA:2050; MEDNIK syndrome ORPHA:171851; Schneckenbecken dysplasia ORPHA:3144; Syndromic diarrhea ORPHA:84064; Isolated polycystic liver disease ORPHA:2924; Triple A syndrome ORPHA:869; Juvenile amyotrophic lateral sclerosis ORPHA:300605; Extraskeletal myxoid chondrosarcoma ORPHA:209916; Cervical spina bifida aperta ORPHA:268392; Cervical spina bifida cystica ORPHA:268762; Cervicothoracic spina bifida aperta ORPHA:268397; Cervicothoracic spina bifida cystica ORPHA:268766; Lumbosacral spina bifida aperta ORPHA:268388; Lumbosacral spina bifida cystica ORPHA:268758; Muscle-eye-brain disease ORPHA:588; Perrault syndrome ORPHA:2855; Thoracolumbosacral spina bifida aperta ORPHA:268384; Thoracolumbosacral spina bifida cystica ORPHA:268752; Total spina bifida aperta ORPHA:268377; Total spina bifida cystica ORPHA:268748; Upper thoracic spina bifida aperta ORPHA:268740; Upper thoracic spina bifida cystica ORPHA:268770; Frontotemporal dementia with motor neuron disease ORPHA:275872; MiT family translocation renal cell carcinoma ORPHA:319308; Williams syndrome ORPHA:904; Amyotrophic lateral sclerosis ORPHA:803; Autosomal recessive non-syndromic intellectual disability ORPHA:88616",0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1697334635963512; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.433039750392822; 0.433039750392822; 0.43936148647173; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.6279395134845649; 0.6581690778726346; 0.7002194990845196; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7072638369101406; 0.7072638369101406; 0.7522711230011014; 0.7851555354466673; 0.7919417912871124,Human betaherpesvirus 5 membrane glycoprotein UL18 (gene: UL18),0.6906952981256558,Homo sapiens HEK293 embryonic kidney cell;Homo sapiens HuH-7.5 hepatocyte carcinoma cell;In vitro,0.35;0.4;0.44,Homo sapiens;chemical synthesis;hcvjf,Homo sapiens;chemical synthesis
GLI2,"Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive Ductal Breast Carcinoma; Tumor Progression; Stomach Carcinoma; melanoma; Squamous cell carcinoma; Malignant mesothelioma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Medulloblastoma; Skin carcinoma; Malignant neoplasm of prostate; Central neuroblastoma; Neoplasm Metastasis; Neuroblastoma; Glioma; Glioblastoma; Carcinoma breast stage IV; Liver Cirrhosis; Prostate carcinoma; Stage IV Bladder Cancer AJCC v6; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Liver carcinoma; Osteosarcoma; Colon Carcinoma; Secondary malignant neoplasm of bone; Tumor Initiation; Carcinoma, Transitional Cell; Carcinoma of bladder; Colonic Neoplasms; Jaw Keratocyst; Liver neoplasms; Renal fibrosis; Seizures; Partial or complete agenesis of corpus callosum; Osteosarcoma of bone; Partial agenesis of corpus callosum; Malignant tumor of colon; Prostatic Neoplasms; B-Cell Lymphomas; Chondrosarcoma; Cirrhosis; Pancreatic Ductal Adenocarcinoma; Idiopathic Pulmonary Fibrosis; Gastrointestinal Stromal Tumors; Rhabdomyosarcoma; Undifferentiated leukemia; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Muscle Rigidity; Non-Small Cell Lung Carcinoma; Infection caused by Helicobacter pylori; Hydrocephalus; Short palate; HIV Infections; Skin Neoplasms; Anxiety Disorders; SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR; Pituitary Hormone Deficiency, Combined, 1; Prominent antihelix; Generalized osteopenia; Acute Promyelocytic Leukemia; Parkinson Disease; Childhood Medulloblastoma; Abnormality of secondary sexual hair; Anterior pituitary agenesis; Cleft palate and bilateral cleft lip; Basal Cell Nevus Syndrome; Chronic schizophrenia; Epilepsy; Abnormal prolactin level; androgen independent prostate cancer; Ectopic posterior pituitary; Hereditary hemochromatosis; Waldenstrom Macroglobulinemia; Abnormal cortical gyration; Pituitary Diseases; Chronic Kidney Diseases; Spondylarthropathies; Axenfeld-Rieger syndrome; Anxiety; Reiter Syndrome; Anterior pituitary hypoplasia; Aplasia/Hypoplasia of the breasts; Congenital Foot Deformity; Decreased circulating ACTH level; Alobar Holoprosencephaly; Mood Disorders; Semilobar Holoprosencephaly; Split foot; Cleft palate, isolated; Angle class 2 malocclusion; Angle class 3 malocclusion; Immunologic Deficiency Syndromes; PACHYONYCHIA CONGENITA 3; Malocclusion; Hypoplasia of the pituitary gland; Arhinencephaly; Short stature; bone destruction; Secondary hypothyroidism; Septo-Optic Dysplasia; Ectrodactyly; Abnormality of the skeletal system; Malignant neoplasm of skin; Hypotrophic malar bone; Malar flattening; Esophageal atresia with or without tracheoesophageal fistula; Pigmented Basal Cell Carcinoma; Hypoplasia of the optic nerve; Small head; POLYDACTYLY, POSTAXIAL; Lobar Holoprosencephaly; Osteopenia; Split-Hand/Foot Malformation; Chronic graft-versus-host disease; Alcoholic Intoxication, Chronic; Arthritis, Reactive; Pituitary dwarfism; Orbital separation diminished; Concave bridge of nose; Depressed nasal root/bridge; Depressed nasal bridge; Split hand foot deformity 1; Hypopituitarism; Panhypopituitarism; Childhood Osteosarcoma; Amenorrhea; Tardive Dyskinesia; Drug-induced tardive dyskinesia; Microphthalmos; Anophthalmos; Body Height; Holoprosencephaly; Congenital chromosomal disease; Abnormally small eyeball; Decreased size of eyeball; Gastrointestinal Stromal Sarcoma; Disorders of Sex Development; Idiopathic hypogonadotropic hypogonadism; Shigella Infections; Small midface; Decreased projection of midface; Hypotrophic midface; Midface retrusion; Isolated somatotropin deficiency; Infertility; Acute Undifferentiated Leukemia; Ulnar polydactyly of fingers; Uranostaphyloschisis; Depressed nasal ridge; Retrusion of upper jaw bones; Short philtrum; Decreased projection of maxilla; Deficiency of upper jaw bones; Hypoplasia of the maxilla; Hypotrophic maxilla; Maxillary retrognathia; Congenital hypoplasia of penis; Hypotension; Osteogenesis Imperfecta; Cryptorchidism; Benign Prostatic Hyperplasia; Biliary Atresia; Basal cell carcinoma; Small testicle; Fatigue; Cleft Palate; Hypogonadism, Isolated Hypogonadotropic; Hypoglycemia; Hypogonadotropic hypogonadism; Large auricle; Large pinnae; Macrotia; Intellectual Disability; Polydactyly; Dwarfism; Mental and motor retardation; Cognitive delay; Global developmental delay; Medullary carcinoma of thyroid; Experimental Organism Basal Cell Carcinoma; Genetic Diseases, Inborn",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0354767239335874; 0.0482468351695405; 0.0569142010728473; 0.0593779966354549; 0.0648809611869375; 0.0688152422187159; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0773771948186562; 0.084286432100041; 0.084286432100041; 0.0891725280554336; 0.095319386034013; 0.1029977559100099; 0.1062239757831962; 0.1253114324938153; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1454373331146953; 0.1454373331146953; 0.1454373331146953; 0.1602092191314262; 0.2053083986145698; 0.2062010908869036; 0.2109483801368481; 0.222537307875512; 0.223747154820789; 0.223747154820789; 0.2522264785494494; 0.2643145809900195; 0.2923761731100008; 0.3018974726133723; 0.3099246715197673; 0.3199171478489988; 0.3510063969122338; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4192169590514327; 0.4192169590514327; 0.4192169590514327; 0.4192169590514327; 0.4209380602168584; 0.4209380602168584; 0.4213286052188015; 0.424575176503444; 0.425419812815905; 0.4304973629098372; 0.4335751357405352; 0.439389586518055; 0.4506578937113162; 0.4506578937113162; 0.4615352570710579; 0.4615352570710579; 0.466957409863091; 0.466957409863091; 0.4704594475773637; 0.4704594475773637; 0.472444704048021; 0.4753011022966241; 0.4790179402069343; 0.4906258721078565; 0.4906258721078565; 0.4906258721078565; 0.4923669467696064; 0.5019670090704682; 0.5090214163899865; 0.5097818625871164; 0.5188223685230745; 0.5188223685230745; 0.5251317541886066; 0.5337853752290136; 0.5337853752290136; 0.533913711453195; 0.5453394612016188; 0.549941235475765; 0.549941235475765; 0.553002957824355; 0.5655222348249326; 0.5710095678317721; 0.5710095678317721; 0.5839588826096398; 0.5916904943304121; 0.5936773368594411; 0.5956632182199403; 0.6035970790768342; 0.6064571148125548; 0.6064571148125548; 0.610971999959321; 0.6150955455771212; 0.6222451141623291; 0.6304655343580164; 0.6319938293757544; 0.6319938293757544; 0.6319938293757544; 0.6319938293757544; 0.652707626880454; 0.655573080043894; 0.6656356363792992; 0.6691893635307453; 0.6784817526917547; 0.6802335864704374; 0.6925751397474874; 0.6925751397474874; 0.6925751397474874; 0.6925751397474874; 0.6925751397474874; 0.6925751397474874; 0.6925751397474874; 0.6974821940437801; 0.7068844070911514; 0.7309076068378124; 0.7417321496240817; 0.7491018580851883; 0.7511652060995492; 0.7564787632115322; 0.7631684472516962; 0.7658980225613361; 0.7670529315163258; 0.7780887836634591; 0.7790800975250889; 0.7977380842181487; 0.8148412516612868; 0.8148412516612868; 0.8148412516612868; 0.8352623613787349; 0.8352623613787349; 0.8405066264419017; 0.897310588550617; 0.9238745269736108; 0.9327689937867868; 0.9368645815921308; 0.9601817390493856; 0.9781572866315434,Carcinoma; Partial Agenesis Of Corpus Callosum; Hydrocephalus; Ectopic Anterior Pituitary Gland; Skin Neoplasms; Pituitary Hormone Deficiency; Osteopenia; Cleft Palate And Bilateral Cleft Lip; Hypopituitarism; Basal Cell Neoplasm; Septopreoptic Holoprosencephaly; Midline Interhemispheric Variant Of Holoprosencephaly; Osteoporosis Of Vertebrae; Alobar Holoprosencephaly; Microform Holoprosencephaly; Semilobar Holoprosencephaly; Cyclocephaly; Septo-Optic Dysplasia; Fused Incisors; Hemangioma; Pituitary Dwarfism; Panhypopituitarism; Scoliosis; Ambiguous Genitalia; Asthma; Microcephaly; Renal Agenesis; Lobar Holoprosencephaly; Arrhinencephaly; Duodenal Atresia; Hypoplasia Of The Maxilla; Dwarfism; Promyelocytic Leukemia; Agenesis Of Corpus Callosum; Hypogonadotropic Hypogonadism; Hypoplasia Of The Optic Nerve; Holoprosencephaly; Skin Cancer; Congenital Coloboma Of Iris; Congenital Hypoplasia Of Penis; Gastrointestinal Stromal Tumor; Syndromic Microphthalmia; Somatotropin Deficiency; Isolated Somatotropin Deficiency; Postaxial Hand Polydactyly; Penis Agenesis; Mental Retardation; Choanal Atresia; Cryptorchidism; Microphthalmos; Hypothyroidism; Multiple Congenital Anomalies; Hypogonadism; Tetralogy Of Fallot; Polydactyly; Macrotia; Hypoglycemia; Dysmorphic Features; Strabismus; Developmental Delay,0.0534520155998091; 0.2187610616307245; 0.3657224783929353; 0.4402141802500753; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4646409362700993; 0.4646409362700993; 0.4646409362700993; 0.4723647227028846; 0.4809179010794786; 0.4867879381749835; 0.4875380732267193; 0.5021774953934145; 0.504364324740411; 0.5123947823327547; 0.5207800595599322; 0.5234357475824973; 0.5316139823120088; 0.5414559855274098; 0.5576425853515448; 0.5796489603182782; 0.6030919130927346; 0.6252040071965056; 0.6325735973587235; 0.6340319940404294; 0.6400187225075934; 0.6524705037929849; 0.6572113517052336; 0.6572113517052336; 0.669025484259299; 0.6798971073653743; 0.7049836926927165; 0.7378537370641419; 0.7472134648605725; 0.7662135194687344; 0.7729545590606223; 0.7729545590606223; 0.776786668801341; 0.7875494303517502; 0.7921294370722203; 0.836331547891711; 0.8536040084512244; 0.8570285304674955; 0.8938134940770912; 0.9055059991400024; 0.9096190669068288; 0.91146174923533; 0.9568083835980838; 0.96477535147595,"SIX2-related frontonasal dysplasia ORPHA:488437; Peters anomaly ORPHA:708; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; Greig cephalopolysyndactyly syndrome ORPHA:380; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Branchiootic syndrome ORPHA:52429; Congenital short bowel syndrome ORPHA:2301; Rieger anomaly ORPHA:91483; Early-onset nuclear cataract ORPHA:98991; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; CHST3-related skeletal dysplasia ORPHA:263463; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Nance-Horan syndrome ORPHA:627; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Retinal arterial tortuosity ORPHA:75326; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Congenital cataract microcornea with corneal opacity ORPHA:289499; Hypoplastic left heart syndrome ORPHA:2248; Matthew-Wood syndrome ORPHA:2470; Piebaldism ORPHA:2884; BOR syndrome ORPHA:107; Ondine syndrome ORPHA:661; Tetralogy of Fallot ORPHA:3303; Classical Ehlers-Danlos syndrome ORPHA:287; Autosomal dominant palmoplantar keratoderma and congenital alopecia ORPHA:1010; Autosomal dominant slowed nerve conduction velocity ORPHA:140481; Caffey disease ORPHA:1310; Childhood-onset benign chorea with striatal involvement ORPHA:494541; Congenital alveolar capillary dysplasia ORPHA:210122; Distal myopathy with posterior leg and anterior hand involvement ORPHA:63273; Infantile-onset generalized dyskinesia with orofacial involvement ORPHA:494526; Kuskokwim syndrome ORPHA:1149; Lethal hydranencephaly-diaphragmatic hernia syndrome ORPHA:480528; Lymphedema-distichiasis syndrome ORPHA:33001; Muscle filaminopathy ORPHA:171445; Oculodentodigital dysplasia ORPHA:2710; Posterior urethral valve ORPHA:93110; Syndactyly type 3 ORPHA:93404; Autosomal recessive Robinow syndrome ORPHA:1507; Postaxial polydactyly type B ORPHA:93335; Sclerosteosis ORPHA:3152; Hennekam syndrome ORPHA:2136; Familial isolated restrictive cardiomyopathy ORPHA:75249; Combined pituitary hormone deficiencies, genetic forms ORPHA:95494; Osteogenesis imperfecta type 3 ORPHA:216812; Ablepharon macrostomia syndrome ORPHA:920; Barber-Say syndrome ORPHA:1231; Focal facial dermal dysplasia type III ORPHA:1807; Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome ORPHA:306542; Lymphedema-posterior choanal atresia syndrome ORPHA:99141; Ring dermoid of cornea ORPHA:91481; X-linked adrenal hypoplasia congenita ORPHA:95702; Enlarged parietal foramina ORPHA:60015; Hereditary mixed polyposis syndrome ORPHA:157794; Pfeiffer syndrome type 1 ORPHA:93258; Spondylometaphyseal dysplasia, 'corner fracture' type ORPHA:93315; Acrocallosal syndrome ORPHA:36; Butterfly-shaped pigment dystrophy ORPHA:99001; NON RARE IN EUROPE: Ventricular septal defect ORPHA:1480; WAGR syndrome ORPHA:893; Isolated brachycephaly ORPHA:35099; Isolated plagiocephaly ORPHA:35098; Colobomatous microphthalmia ORPHA:98938; Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome ORPHA:370022; Brachydactyly type B1 ORPHA:572385; Congenital vertical talus, bilateral ORPHA:295203; Congenital vertical talus, unilateral ORPHA:295201; Craniodiaphyseal dysplasia ORPHA:1513; Curry-Jones syndrome ORPHA:1553; Frontonasal dysplasia-alopecia-genital anomalies syndrome ORPHA:228390; Hartsfield syndrome ORPHA:2117; Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement ORPHA:168953; Osteoglosphonic dysplasia ORPHA:2645; Congenital ptosis ORPHA:91411; Fibrochondrogenesis ORPHA:2021; Hereditary sensory and autonomic neuropathy type 5 ORPHA:64752; Renal hypoplasia, bilateral ORPHA:97362; Ellis Van Creveld syndrome ORPHA:289; Familial bicuspid aortic valve ORPHA:402075; Midline interhemispheric variant of holoprosencephaly ORPHA:93926; Septopreoptic holoprosencephaly ORPHA:280195; Semilobar holoprosencephaly ORPHA:220386; Atrial septal defect-atrioventricular conduction defects syndrome ORPHA:1479; Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ORPHA:440354; Blepharophimosis-ptosis-epicanthus inversus syndrome plus ORPHA:572333; Blepharophimosis-ptosis-epicanthus inversus syndrome type 1 ORPHA:572354; Blepharophimosis-ptosis-epicanthus inversus syndrome type 2 ORPHA:572361; Congenital contractural arachnodactyly ORPHA:115; Craniofacial-deafness-hand syndrome ORPHA:1529; Marshall syndrome ORPHA:560; Multiple epiphyseal dysplasia, Al-Gazali type ORPHA:166024; Palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome ORPHA:85112; Stickler syndrome type 2 ORPHA:90654; Waardenburg syndrome type 1 ORPHA:894; Waardenburg syndrome type 3 ORPHA:896; Agnathia-holoprosencephaly-situs inversus syndrome ORPHA:990; Encephalocraniocutaneous lipomatosis ORPHA:2396; Isolated Klippel-Feil syndrome ORPHA:2345; Myxofibrosarcoma ORPHA:79105; Silver-Russell syndrome due to a point mutation ORPHA:397590; 46,XX testicular disorder of sex development ORPHA:393; Alobar holoprosencephaly ORPHA:93925; Lobar holoprosencephaly ORPHA:93924; Microform holoprosencephaly ORPHA:280200; Classic Bartter syndrome ORPHA:93605; Townes-Brocks syndrome ORPHA:857; Pituitary stalk interruption syndrome ORPHA:95496",0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.020072786018028; 0.0277610005156803; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.0640416108792758; 0.0683063362547733; 0.0683063362547733; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.1614487935928034; 0.1782034488938806; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.43936148647173; 0.43936148647173; 0.4470672161388242; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.6279395134845649; 0.6787273931204523; 0.6787273931204523; 0.6857161253678724; 0.7068064785325423; 0.7068064785325423; 0.7072638369101406,Human papillomavirus type 6 E5B (gene: E5B),0.9829721238496356,,,,
GPNMB,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Colorectal Cancer; Tumor Progression; melanoma; Adenocarcinoma; Squamous cell carcinoma; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Mammary Neoplasms, Human; Brain Neoplasms; Neoplasm Metastasis; Renal Cell Carcinoma; Malignant neoplasm of pancreas; Glioma; Degenerative polyarthritis; Glioblastoma; Pancreatic carcinoma; Carcinoma breast stage IV; Liver Cirrhosis, Experimental; Liver Cirrhosis; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Colorectal Neoplasms; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Liver carcinoma; Malignant Neoplasms; Osteosarcoma; Hematologic Neoplasms; Secondary malignant neoplasm of bone; Carcinoma of bladder; Hyperactive behavior; Solid Neoplasm; Liver neoplasms; Osteosarcoma of bone; Metastasis from malignant tumor of prostate; Metastatic Prostate Carcinoma; Squamous cell carcinoma of vulva; Secondary malignant neoplasm of lung; Cervix carcinoma; Cirrhosis; Triple Negative Breast Neoplasms; Ataxia Telangiectasia; Primary malignant neoplasm; Endometriosis; Secondary malignant neoplasm of lymph node; Amyloidosis; Fulminant hepatitis; Malignant Glioma; Bronchopulmonary Dysplasia; Skin Carcinogenesis; Pigment dispersion syndrome (disorder); HIV Infections; Alzheimer's Disease; Parkinson Disease; Glioblastoma Multiforme; Malignant epithelioma; Malignant neoplasm of kidney; Polycystic Kidney, Autosomal Dominant; Renal carcinoma; Pituitary Adenoma; Amyotrophic Lateral Sclerosis; Kidney Failure, Acute; Hemolytic-Uremic Syndrome; Alzheimer Disease, Late Onset; Down Syndrome; Immunologic Deficiency Syndromes; Encephalomyelitis; Neurodegenerative Disorders; leukemia; Motor neuron atrophy; Acute kidney injury; LEOPARD Syndrome; Cyst; Diarrhea; Metastatic melanoma; Obesity; Bacterial Infections; Human immunodeficiency virus, type 2 [HIV-2] infection in conditions classified elsewhere and of unspecified site; Disseminated Malignant Neoplasm; Autoimmune Diseases; Cutaneous Melanoma; Turner Syndrome, Male; Microphthalmos; Noonan Syndrome; Lymphangioleiomyomatosis; Brain Ischemia; Myasthenia Gravis; Acute Kidney Insufficiency; Muscular Dystrophies, Limb-Girdle; Muscular Dystrophy; Liver Failure, Acute; Cerebral Ischemia; Cerebral Infarction",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0569142010728473; 0.064548079316548; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0747863377072194; 0.0773771948186562; 0.0773771948186562; 0.0775520919998773; 0.0827744840860166; 0.084286432100041; 0.0891725280554336; 0.095319386034013; 0.0991201145654548; 0.1029977559100099; 0.1253114324938153; 0.1253114324938153; 0.13167400689206; 0.1387448809655294; 0.1413782599148022; 0.1454373331146953; 0.2109483801368481; 0.2454426921531692; 0.2643145809900195; 0.2643145809900195; 0.2723545094624877; 0.2834835531038365; 0.2923761731100008; 0.2980670559114652; 0.3508665345292502; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.4028066164685291; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4213286052188015; 0.4254307049060398; 0.4335751357405352; 0.4588513406515081; 0.4714226702518064; 0.4753011022966241; 0.4753011022966241; 0.4850576707687362; 0.4923669467696064; 0.5001612228394569; 0.5140447474168605; 0.5337853752290136; 0.5337853752290136; 0.533913711453195; 0.5512224939896888; 0.5710095678317721; 0.582492855487907; 0.5839588826096398; 0.6150955455771212; 0.6222451141623291; 0.6592493193460769; 0.6821087736355662; 0.7068844070911514; 0.717484976234209; 0.7294281406818208; 0.7840911880051142; 0.839057838231319; 0.8472019892490944,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Endometriosis; Amyloidosis; Colorectal Cancer; Colorectal Neoplasms; Liver Failure; Kidney Failure; Acute Kidney Insufficiency,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.2187610616307245; 0.4286813331685578; 0.4286813331685578; 0.4560460337187313; 0.5162067638232762; 0.6899894525110877; 0.7729545590606223,"AGel amyloidosis ORPHA:85448; Keratolytic winter erythema ORPHA:50943; Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome ORPHA:447997; Griscelli syndrome type 3 ORPHA:79478; Familial cavitary optic disc anomaly ORPHA:464760; Lipoid proteinosis ORPHA:530; MITF-related melanoma and renal cell carcinoma predisposition syndrome ORPHA:293822; Pycnodysostosis ORPHA:763; Tay-Sachs disease, B variant, adult form ORPHA:309192; Tay-Sachs disease, B variant, infantile form ORPHA:309178; Tay-Sachs disease, B variant, juvenile form ORPHA:309185; Tay-Sachs disease, B1 variant ORPHA:309239; Tietz syndrome ORPHA:42665; Familial calcium pyrophosphate deposition ORPHA:1416; Amyloidosis cutis dyschromia ORPHA:319635; Aromatase deficiency ORPHA:91; Aromatase excess syndrome ORPHA:178345; Complement component 3 deficiency ORPHA:280133; Congenital bile acid synthesis defect type 1 ORPHA:79301; Atypical hemolytic uremic syndrome with complement gene abnormality ORPHA:544472; Niemann-Pick disease type C, adult neurologic onset ORPHA:216986; Niemann-Pick disease type C, juvenile neurologic onset ORPHA:216981; Niemann-Pick disease type C, late infantile neurologic onset ORPHA:216978; Niemann-Pick disease type C, severe early infantile neurologic onset ORPHA:216975; Niemann-Pick disease type C, severe perinatal form ORPHA:216972; Keratosis follicularis spinulosa decalvans ORPHA:2340; Hyperandrogenism due to cortisone reductase deficiency ORPHA:168588; Ocular albinism with congenital sensorineural deafness ORPHA:352740; Dysbetalipoproteinemia ORPHA:412; Familial episodic pain syndrome with predominantly upper body involvement ORPHA:391389; GM2 gangliosidosis, AB variant ORPHA:309246; Lipoprotein glomerulopathy ORPHA:329481; Sea-blue histiocytosis ORPHA:158029; Juvenile glaucoma ORPHA:98977; Semantic dementia ORPHA:100069; Immunodeficiency due to a classical component pathway complement deficiency ORPHA:169147; Minimal pigment oculocutaneous albinism type 1 ORPHA:352734; Oculocutaneous albinism type 1A ORPHA:79431; Oculocutaneous albinism type 1B ORPHA:79434; Temperature-sensitive oculocutaneous albinism type 1 ORPHA:352737; NON RARE IN EUROPE: Barrett esophagus ORPHA:1232",0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.639029370164481; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
GPR137C,,,,,Familial primary hypomagnesemia with normocalciuria and normocalcemia ORPHA:34527; 15q13.3 microdeletion syndrome ORPHA:199318; NON RARE IN EUROPE: Non rare obesity ORPHA:521399; Bradyopsia ORPHA:75374; Autosomal recessive cerebellar ataxia-psychomotor delay syndrome ORPHA:284271; Colobomatous microphthalmia-rhizomelic dysplasia syndrome ORPHA:424099; Goldmann-Favre syndrome ORPHA:53540; NON RARE IN EUROPE: Isolated keratoconus ORPHA:2335; ALG9-CDG ORPHA:79328; CDKL5-related epileptic encephalopathy ORPHA:505652; Episodic ataxia type 5 ORPHA:211067; GNB5-related intellectual disability-cardiac arrhythmia syndrome ORPHA:542306; Keppen-Lubinsky syndrome ORPHA:435628; MEGDEL syndrome ORPHA:352328; Spastic paraplegia-severe developmental delay-epilepsy syndrome ORPHA:464282; X-linked intellectual disability-cerebellar hypoplasia syndrome ORPHA:137831; Hypotonia-speech impairment-severe cognitive delay syndrome ORPHA:371364; Otofaciocervical syndrome ORPHA:2792; Autosomal dominant epilepsy with auditory features ORPHA:101046; Progressive cone dystrophy ORPHA:1871; Juvenile myoclonic epilepsy ORPHA:307; Leber congenital amaurosis ORPHA:65,0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7100092263364535; 0.7443958988603572,,,yeasx,0.37,Homo sapiens,coxbu
GPR15,Barrett Esophagus; Rheumatoid Arthritis; Colitis,0.0648809611869375; 0.1537760235124317; 0.5323590634832615,,,Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944; Combined immunodeficiency due to MALT1 deficiency ORPHA:397964,0.0180064224283883; 0.0180064224283883; 0.7068064785325423,,,,,,
GPR37,"melanoma; Malignant mesothelioma; Chronic Lymphocytic Leukemia; Parkinson Disease; Autism Spectrum Disorders; PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE; Pervasive Development Disorder; Cutaneous Melanoma; Autistic Disorder",0.0149315928814189; 0.0182265588252201; 0.1147307578771389; 0.3933196962529684; 0.3941558617476422; 0.4840863724482356; 0.5655222348249326; 0.5710095678317721; 0.8064248359603999,Lymphocytic Leukemia; Malignant Melanoma Of Skin; Melanoma; Malignant Mesothelioma,0.0487679768343083; 0.4286813331685578; 0.4646409362700993; 0.555382961603519,Oculocutaneous albinism type 3 ORPHA:79433; Congenital cataract microcornea with corneal opacity ORPHA:289499; X-linked adrenal hypoplasia congenita ORPHA:95702; Persistent hyperplastic primary vitreous ORPHA:91495; Butyrylcholinesterase deficiency ORPHA:132; Scalp-ear-nipple syndrome ORPHA:2036; Tetraamelia-multiple malformations syndrome ORPHA:3301; Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome ORPHA:522077; Microphthalmia with limb anomalies ORPHA:1106; Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome ORPHA:477673; NON RARE IN EUROPE: Idiopathic infantile nystagmus ORPHA:651; Distal hereditary motor neuropathy type 5 ORPHA:139536; Spectrin-associated autosomal recessive cerebellar ataxia ORPHA:352403; Spinocerebellar ataxia type 5 ORPHA:98766; X-linked recessive ocular albinism ORPHA:54; Atypical glycine encephalopathy ORPHA:289863; Infantile glycine encephalopathy ORPHA:289860,0.0180064224283883; 0.0180064224283883; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens A549 lung carcinoma cell;yeasx,0.35;0.37;0.56,Homo sapiens;SARS-CoV-2,Homo sapiens
GRAMD1B,"Chronic Lymphocytic Leukemia; Hodgkin Disease; Diabetes Mellitus, Insulin-Dependent; Bipolar Disorder; Schizophrenia; Nasopharyngeal Neoplasms; Multiple Myeloma",0.1147307578771389; 0.2454476567103779; 0.2714542429024338; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.4103119460235835,Breast Carcinoma; Lymphocytic Leukemia; Schizophrenia; Nasopharyngeal Carcinoma; Hodgkin Disease; B-Cell Neoplasm; Development Disorder; Multiple Myeloma; Erectile Dysfunction; Bipolar Disorder; Lymphoma,0.0075861267486594; 0.0487679768343083; 0.0531117779464085; 0.2278592962769385; 0.2627224344149009; 0.4286813331685578; 0.4372065554432662; 0.4560460337187313; 0.4602028929328057; 0.4875380732267193; 0.8794964218770293,Pseudohypoaldosteronism type 2D ORPHA:300525,0.6239678957896782,,,,,,
H2AX,,,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Schizophrenia; Giant Cell Glioblastoma; Glioblastoma,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0531117779464085; 0.4875380732267193; 0.4875380732267193,,,,,Homo sapiens;Homo sapiens CACO2 Caucasian colon adenocarcinoma cell;Homo sapiens HEK293T embryonic kidney cell;Homo sapiens SW480 adenocarcinoma cell;In vitro,0.35;0.4;0.46,Homo sapiens;SARS-CoV-2,Homo sapiens
HABP4,,,,,Autosomal recessive spastic paraplegia type 56 ORPHA:320411,0.6239678957896782,Molluscum contagiosum virus subtype 1 MC080R (gene: MC080R),0.8071041616616108,,,,
HPSE,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Retroviridae Infections; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant mesothelioma; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Medulloblastoma; Epithelial ovarian cancer; Malignant neoplasm of prostate; Central neuroblastoma; Well Differentiated Oligodendroglioma; Mammary Neoplasms, Human; Brain Neoplasms; Neoplasm Metastasis; Barrett Esophagus; Renal Cell Carcinoma; oligodendroglioma; Neuroblastoma; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Glioma; Degenerative polyarthritis; Osteoporosis; Lymphoma; Endometrial Neoplasms; Glioblastoma; Pancreatic carcinoma; Carcinoma breast stage IV; Liver Cirrhosis, Experimental; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Colorectal Neoplasms; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Squamous cell carcinoma of esophagus; Liver carcinoma; Colon Carcinoma; Adenocarcinoma of colon; Ameloblastoma; Hematologic Neoplasms; Secondary malignant neoplasm of bone; MYELODYSPLASTIC SYNDROME; Esophageal carcinoma; Tumor Initiation; Carcinoma of bladder; Unipolar Depression; Myocardial Infarction; Solid Neoplasm; Liver neoplasms; Rheumatoid Arthritis; Sarcoma; Renal fibrosis; Invasive Carcinoma; Comedone; Head and Neck Carcinoma; Benign Ovarian Neoplasm; von Willebrand Disease, Type 1; Lung Neoplasms; Desmoplastic; Major Depressive Disorder; Malignant tumor of colon; Prostatic Neoplasms; Diabetes; Hodgkin Disease; Hepatoblastoma; Malignant Head and Neck Neoplasm; Diabetes Mellitus; Malignant neoplasm of liver; Neoplasms; Malignant neoplasm of lung; Diabetes Mellitus, Insulin-Dependent; Diabetic Retinopathy; Cervix carcinoma; Acute leukemia; Neonatal Alloimmune Thrombocytopenia; Cholangiocarcinoma; Head and Neck Neoplasms; Coronary Thrombosis; Rhabdomyosarcoma; Severe Combined Immunodeficiency; Metastatic malignant neoplasm to brain; Carcinoma of lung; Tuberculosis; Anaplastic astrocytoma; Endometriosis; Thyroid Neoplasm; Recurrent tumor; Exostoses; Noninfiltrating Intraductal Carcinoma; Primary malignant neoplasm of lung; Secondary malignant neoplasm of lymph node; Amyloidosis; Bipolar Disorder; Cerebrovascular Disorders; Verrucous carcinoma; Diabetes Mellitus, Non-Insulin-Dependent; Laryngeal Squamous Cell Carcinoma; Renal glomerular disease; Non-Small Cell Lung Carcinoma; Secondary malignant neoplasm of liver; Leukemia, Myelocytic, Acute; Carcinoma, Papillary; Astrocytoma; Alzheimer's Disease; Liver and Intrahepatic Biliary Tract Carcinoma; Thrombocythemia, Essential; Acute lymphocytic leukemia; Lip and Oral Cavity Carcinoma; Stomach Neoplasms; Inflammatory Bowel Diseases; Coronary heart disease; Glioblastoma Multiforme; synovial sarcoma; Anaplasia; Diabetic Nephropathy; Aortic Aneurysm, Abdominal; Thyroid carcinoma; Rabies (disorder); Bone Diseases; Pituitary Neoplasms; Depressive episode, unspecified; Tuberculosis of intestines; Depressive disorder; IGA Glomerulonephritis; Kidney Failure, Acute; Carcinoma of larynx; Dengue Fever; Acute myocardial infarction; Multiple Myeloma; Nephrotic Syndrome; Neoplasm Invasiveness; Cerebrovascular accident; Neonatal thrombocytopenia (disorder); Vascular Diseases; Steroid-sensitive nephrotic syndrome; Malignant neoplasm of larynx; Immunologic Deficiency Syndromes; Thrombocytopenia; Hyperlipoproteinemia Type III; Malignant neoplasm of mouth; PACHYONYCHIA CONGENITA 3; Benign melanocytic nevus; Encephalomyelitis; Follicular adenoma; Psoriasis; Malignant neoplasm of thyroid; Adenocarcinoma of pancreas; External exotoses; Hereditary Multiple Exostoses; Lymphatic Metastasis; Sicca Syndrome; Migraine Disorders; bone destruction; Choriocarcinoma; Hepatic Veno-Occlusive Disease; Embryonal Rhabdomyosarcoma; Myeloid Leukemia, Chronic; Chronic colitis; Acute GVH disease; Membranous glomerulonephritis; Breast adenocarcinoma; Steroid Sulfatase Deficiency Disease; Hyperglycemia; Crohn Disease; Secondary malignant neoplasm of pancreas; Ichthyosis, X-Linked; Metastatic melanoma; Neuroendocrine Tumors; Arteriosclerosis; Carotid Atherosclerosis; Chronic graft-versus-host disease; Coronary Arteriosclerosis; Secondary Neoplasm; Obesity; Respiratory Failure; Adenocarcinoma of lung (disorder); Sweet Syndrome; Disseminated Malignant Neoplasm; Atherosclerosis; Autoimmune Diseases; Thrombasthenia; Thromboangiitis Obliterans; Nephrosis; Graft-vs-Host Disease; Tumor Angiogenesis; Chronic Fatigue Syndrome; Sepsis; Inflammatory dermatosis; Retinal Diseases; Myeloproliferative disease; Proliferative diabetic retinopathy; Blood Coagulation Disorders; Stable angina; Proteinuria; Dermatitis; Inflammatory disorder; Mucinous Adenocarcinoma; Coronary Artery Disease; Benign Prostatic Hyperplasia; Septicemia; Melanoma, B16; Malignant Pleural Mesothelioma; Immune thrombocytopenic purpura; Hepatitis B; Anemia, Sickle Cell",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0354767239335874; 0.0387439397151409; 0.0569142010728473; 0.0593779966354549; 0.0617471306652618; 0.064548079316548; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0747863377072194; 0.0773771948186562; 0.0775520919998773; 0.0827744840860166; 0.084286432100041; 0.0891725280554336; 0.0919714360040484; 0.095319386034013; 0.1062239757831962; 0.1112281755580192; 0.1208020277850109; 0.1253114324938153; 0.1253114324938153; 0.1254380558571286; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1352936728187231; 0.1413782599148022; 0.1454373331146953; 0.1537760235124317; 0.1537760235124317; 0.1602092191314262; 0.1602092191314262; 0.1735868515093891; 0.1735868515093891; 0.1770067065899052; 0.1897991423047819; 0.2062010908869036; 0.2085938372806741; 0.21122597829463; 0.223747154820789; 0.223747154820789; 0.2277108302018961; 0.2454476567103779; 0.2522264785494494; 0.2522264785494494; 0.2522264785494494; 0.2643145809900195; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2723545094624877; 0.2834835531038365; 0.2835142372342932; 0.3099246715197673; 0.340892538685018; 0.3412203844672238; 0.3508665345292502; 0.3510063969122338; 0.3553621627681198; 0.3638414818541592; 0.3663130598151661; 0.3706856725676674; 0.3763374964032415; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.3938591532700354; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.424575176503444; 0.425419812815905; 0.4254307049060398; 0.4269926086051838; 0.4304973629098372; 0.4307603335611732; 0.4325044517055656; 0.4335751357405352; 0.4335751357405352; 0.4342056919538745; 0.4396723023384634; 0.4450743762496232; 0.4506578937113162; 0.4564472886428772; 0.4564472886428772; 0.472444704048021; 0.472444704048021; 0.472444704048021; 0.4790179402069343; 0.4790179402069343; 0.4810435657134442; 0.4840863724482356; 0.4906258721078565; 0.4981941174985421; 0.4981941174985421; 0.4990401620718274; 0.5001612228394569; 0.5017066790423467; 0.5019670090704682; 0.504136641473215; 0.5090214163899865; 0.5140447474168605; 0.5140447474168605; 0.5140447474168605; 0.5140447474168605; 0.51550637274795; 0.5251317541886066; 0.533913711453195; 0.5393787854381349; 0.5512224939896888; 0.553002957824355; 0.5655222348249326; 0.5696906826730043; 0.5922440535658843; 0.6218520979526325; 0.625027955184583; 0.6395767498329145; 0.6447029562500783; 0.655573080043894; 0.6592493193460769; 0.6627865715415371; 0.6631086714705082; 0.6656356363792992; 0.6925751397474874; 0.7045203904267408; 0.7075286941606513; 0.717484976234209; 0.7240930522443176; 0.7491018580851883; 0.8064248359603999; 0.8178117518835931; 0.8209296131179464; 0.8867784885819414; 0.9169959402964138; 0.931585270977292,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Liver Carcinoma; Mental Depression; Nephrosis; Melanoma; Glomerulonephritis,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0520696613701797; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.8277709367020475,Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome ORPHA:566175; Hypocalcemic vitamin D-resistant rickets ORPHA:93160; Haim-Munk syndrome ORPHA:2342; Papillon-Lefevre ORPHA:678,0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917,,,Homo sapiens diploid fibroblast;In vitro,0.35;0.4;0.44,chemical synthesis,Homo sapiens
HS3ST1,Tumor Progression; Malignant neoplasm of pancreas; Pancreatic carcinoma; Chondrosarcoma; Alzheimer's Disease; Arteriosclerosis; Atherosclerosis; Herpes Simplex Infections; Coronary Artery Disease,0.0149315928814189; 0.0726340460169901; 0.0745502070959292; 0.2643145809900195; 0.3933196962529684; 0.5019670090704682; 0.5393787854381349; 0.610971999959321; 0.7240930522443176,Arteriosclerosis; Coronary Artery Disease,0.4723647227028846; 0.7729545590606223,,,,,,,,
HSDL2,"Glioma; Glioblastoma; Liver neoplasms; Malignant neoplasm of liver; Creatinine measurement, serum (procedure)",0.0739788831250619; 0.0745502070959292; 0.1454373331146953; 0.2643145809900195; 0.383941725017158,Liver Cancer; Liver Neoplasms,0.4723647227028846; 0.5129298662020659,Peroxisomal acyl-CoA oxidase deficiency ORPHA:2971; Mild hemophilia A ORPHA:169808; Moderately severe hemophilia A ORPHA:169805; PGM1-CDG ORPHA:319646; Severe hemophilia A ORPHA:169802; Symptomatic form of hemophilia A in female carriers ORPHA:177926; Bifunctional enzyme deficiency ORPHA:300; Mitochondrial trifunctional protein deficiency ORPHA:746; 3-methylglutaconic aciduria type 1 ORPHA:67046; Beta-ketothiolase deficiency ORPHA:134; Congenital bile acid synthesis defect type 4 ORPHA:79095; Proximal myopathy with extrapyramidal signs ORPHA:401768; Vitamin B12-unresponsive methylmalonic acidemia type mut- ORPHA:79312; Vitamin B12-unresponsive methylmalonic acidemia type mut0 ORPHA:289916; Classic maple syrup urine disease ORPHA:268145; Intermittent maple syrup urine disease ORPHA:268173; Thiamine-responsive maple syrup urine disease ORPHA:268184,0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Ectromelia virus ERPV hydroxysteroid dehydrogenase; Monkeypox virus bifunctional hydroxysteroid dehydrogenase/deletion attenuates intradermal lesion in VAC-mouse model; Cowpox virus CPXV182 protein (gene: CPXV182 CDS); Monkeypox virus Zaire-96-I-16 A45L (gene: A45L); Vaccinia virus hydroxysteroid dehydrogenase (gene: A44L); Horsepox virus HSPV166 (Rossmann-fold NAD(P)(+)-binding proteins); Vaccinia virus Ankara 3 beta-hydroxysteroid dehydrogenase; Molluscum contagiosum virus subtype 1 MC152R (gene: MC152R); Yaba-like disease virus 133L protein (gene: 133L),0.6362779693488597; 0.6947065917563796; 0.7017760963861425; 0.7054555693277184; 0.7108466056279036; 0.7108466056279036; 0.7148278327249904; 0.7398997088314572; 0.7477109270664255,Homo sapiens;Homo sapiens HEK293flp-in embryonic kidney cell;Homo sapiens Huh7 hepatoma cell;In vitro,0.27;0.35,chemical synthesis;cioin;hcvjf;povbk,Homo sapiens
HTATIP2,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; melanoma; Squamous cell carcinoma; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of prostate; Neoplasm Metastasis; Malignant neoplasm of pancreas; Glioma; Pancreatic carcinoma; Prostate carcinoma; Squamous cell carcinoma of esophagus; Liver carcinoma; Small cell carcinoma of lung; ADENOMAS AND ADENOCARCINOMAS; Esophageal carcinoma; Lung Neoplasms; Prostatic Neoplasms; Hepatoblastoma; Malignant neoplasm of lung; Secondary malignant neoplasm of lung; Multiple Sclerosis; Pancreatic Ductal Adenocarcinoma; Carcinoma of lung; Primary malignant neoplasm of lung; Secondary malignant neoplasm of lymph node; Non-Small Cell Lung Carcinoma; Stomach Neoplasms; Mammary Tumorigenesis; Immunologic Deficiency Syndromes; Adenocarcinoma of lung (disorder); Hepatocarcinogenesis,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0569142010728473; 0.0648809611869375; 0.0726340460169901; 0.0739788831250619; 0.0745502070959292; 0.0773771948186562; 0.0919714360040484; 0.095319386034013; 0.1193558174333938; 0.1193558174333938; 0.1254380558571286; 0.2062010908869036; 0.223747154820789; 0.2522264785494494; 0.2714542429024338; 0.2723545094624877; 0.2835142372342932; 0.3018974726133723; 0.3663130598151661; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.4028066164685291; 0.4213286052188015; 0.51550637274795; 0.533913711453195,Liver Carcinoma,0.0520696613701797,Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome ORPHA:566175,0.1590470395003315,,,Homo sapiens A549 lung carcinoma cell,0.35,Human SARS coronavirus;SARS-CoV-2,Homo sapiens
HYAL1,Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Tumor Progression; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of ovary; Epithelial ovarian cancer; Malignant neoplasm of prostate; Neoplasm Metastasis; Glioma; Degenerative polyarthritis; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Lysosomal Storage Diseases; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Small cell carcinoma of lung; Clear-cell metastatic renal cell carcinoma; Carcinoma of bladder; Neck Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Metastatic Prostate Carcinoma; Malignant neoplasm of lung; Endometrial Carcinoma; Metastatic malignant neoplasm to brain; Carcinoma of lung; Primary malignant neoplasm of lung; Non-Small Cell Lung Carcinoma; Juvenile rheumatoid arthritis; Heparan sulfate excretion in urine; Pulmonary Hypertension; Allergic sensitization; Hyperammonemia; Juvenile arthritis; Submucous clefting; Recurrent otitis media; Short stature; Submucous cleft of hard palate; Dermatologic disorders; Concave bridge of nose; Depressed nasal root/bridge; Depressed nasal bridge; Cleft uvula; Skin Abnormalities; Intellectual Disability,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0277695594716545; 0.0387439397151409; 0.0569142010728473; 0.0648809611869375; 0.0739788831250619; 0.0739788831250619; 0.0773771948186562; 0.0775520919998773; 0.0798053340865682; 0.084286432100041; 0.0891725280554336; 0.1193558174333938; 0.13167400689206; 0.13167400689206; 0.1614820148711231; 0.2062010908869036; 0.223747154820789; 0.2643145809900195; 0.2714542429024338; 0.3044782497745498; 0.3638414818541592; 0.3663130598151661; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.4115056600660309; 0.4126392832024548; 0.425419812815905; 0.4352815161963393; 0.439389586518055; 0.4396723023384634; 0.4906258721078565; 0.5337853752290136; 0.5337853752290136; 0.533913711453195; 0.5393787854381349; 0.6084642888478995; 0.8352623613787349,Dwarfism; Submucosal Cleft Palate; Otitis Media,0.5796489603182782; 0.6420878824691651; 0.7979559493902503,Adenylosuccinate synthetase-like 1-related distal myopathy ORPHA:482601; Hawkinsinuria ORPHA:2118; Isolated sulfite oxidase deficiency ORPHA:99731; Transient infantile hypertriglyceridemia and hepatosteatosis ORPHA:300293; Tyrosinemia type 3 ORPHA:69723; Autosomal dominant secondary polycythemia ORPHA:247511; Congenital alpha2-antiplasmin deficiency ORPHA:79; Hyaluronidase deficiency ORPHA:67041; Immunodeficiency due to ficolin3 deficiency ORPHA:331190,0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
ICA1,"Colorectal Carcinoma; Colorectal Cancer; Malignant neoplasm of prostate; Central neuroblastoma; Neuroblastoma; Prostate carcinoma; Rheumatoid Arthritis; Diabetes; Metastasis from malignant tumor of prostate; Diabetes Mellitus; Diabetes Mellitus, Insulin-Dependent; Multiple Sclerosis; Sjogren's Syndrome; Glaucoma; Inflammatory Bowel Diseases; Autism Spectrum Disorders; Lupus Erythematosus, Systemic; Primary Sj??gren's syndrome; Graves Disease; Autoimmune Diseases; Autoimmune thyroid disease",0.0034602840073026; 0.0149315928814189; 0.0569142010728473; 0.0593779966354549; 0.0688152422187159; 0.0773771948186562; 0.1537760235124317; 0.2277108302018961; 0.2454426921531692; 0.2522264785494494; 0.2714542429024338; 0.2835142372342932; 0.3099246715197673; 0.3105909001629992; 0.3933196962529684; 0.3941558617476422; 0.4213286052188015; 0.451408428170596; 0.4981941174985421; 0.5512224939896888; 0.5710095678317721,Lupus Erythematosus,0.5087473896242481,Isolated sulfite oxidase deficiency ORPHA:99731,0.6239678957896782,,,yeasx,0.37,Bacillus anthracis,Homo sapiens
ID2,"Ovarian Carcinoma; Epithelioma; Squamous cell carcinoma; ovarian neoplasm; Carcinogenesis; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Central neuroblastoma; Neuroblastoma; Malignant neoplasm of pancreas; Glioma; Glioblastoma; Pancreatic carcinoma; Liver Cirrhosis, Experimental; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Liver carcinoma; Colon Carcinoma; Small cell carcinoma of lung; Arsenic Poisoning, Inorganic; Nervous System, Organic Arsenic Poisoning; Arsenic Encephalopathy; Arsenic Induced Polyneuropathy; Arsenic Poisoning; Myocardial Infarction; Sarcoma; Acute Myeloid Leukemia (AML-M2); Lung Neoplasms; Prostatic Neoplasms; Hodgkin Disease; B-Cell Lymphomas; Primary Cutaneous Anaplastic Large Cell Lymphoma; Diabetes Mellitus, Insulin-Dependent; Diabetic Retinopathy; Classical Hodgkin's Lymphoma; Peripheral T-Cell Lymphoma; Renal glomerular disease; Hypertensive disease; Leukemia, Myelocytic, Acute; Acute Promyelocytic Leukemia; Diabetic Nephropathy; Polycystic Kidney, Autosomal Dominant; Ki-1+ Anaplastic Large Cell Lymphoma; Acute Myeloid Leukemia, M1; Multiple Myeloma; Retinoblastoma; Congestive heart failure; Heart failure; Myxoid cyst; Restenosis; Dyslipidemias; Intestinal Diseases; Chronic kidney disease stage 5; T-Cell Prolymphocytic Leukemia; Dermatologic disorders; Ovarian Failure, Premature; Kidney Failure, Chronic; Proliferative retinopathy; Thyroid Diseases; Hyperlipidemia; T-Cell Lymphoma; Impaired cognition; Rett Syndrome; Turner Syndrome; Pneumonia",0.0034602840073026; 0.0149002095788623; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0569142010728473; 0.0593779966354549; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0747863377072194; 0.0773771948186562; 0.0775520919998773; 0.095319386034013; 0.1062239757831962; 0.1193558174333938; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1352936728187231; 0.1537760235124317; 0.2050045461627939; 0.2062010908869036; 0.223747154820789; 0.2454476567103779; 0.2522264785494494; 0.2522264785494494; 0.2714542429024338; 0.2723545094624877; 0.3763374964032415; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.3941558617476422; 0.3941558617476422; 0.4100742336915555; 0.4103119460235835; 0.4115056600660309; 0.425419812815905; 0.4304973629098372; 0.4335751357405352; 0.4396723023384634; 0.4421745246585178; 0.4459714599189374; 0.4704594475773637; 0.4753011022966241; 0.4906258721078565; 0.4923669467696064; 0.5299466034567416; 0.5393787854381349; 0.5936773368594411; 0.6035970790768342; 0.7577323833810212; 0.8000044931629623; 0.8048897980514186; 0.8552002762584644; 0.924303335582991,Arsenic Encephalopathy; Dermatologic Disorders; Lung Carcinoma; Thyroid Diseases; Myeloid Leukemia; Leukemia,0.185736315425117; 0.2895940391390291; 0.4541466895915311; 0.4560460337187313; 0.525214105372123; 0.7167438233451096,,,,,Homo sapiens;yeasx,0.4;0.55;0.56,Homo sapiens;Saccharomyces cerevisiae,Homo sapiens;Saccharomyces cerevisiae
IL22RA1,"Colorectal Carcinoma; Colorectal Cancer; Lymphoma, T-Cell, Cutaneous; Nasal Polyps; Colitis",0.0034602840073026; 0.0149315928814189; 0.3933196962529684; 0.4459714599189374; 0.5323590634832615,,,Severe generalized junctional epidermolysis bullosa ORPHA:79404; Kindler epidermolysis bullosa ORPHA:2908; Autosomal recessive infantile hypercalcemia ORPHA:300547; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Intermediate generalized junctional epidermolysis bullosa ORPHA:79402; Localized junctional epidermolysis bullosa ORPHA:251393; AA amyloidosis ORPHA:85445; Bartsocas-Papas syndrome ORPHA:1234; Benign familial mesial temporal lobe epilepsy ORPHA:163717; CHAND syndrome ORPHA:1401; Epithelial recurrent erosion dystrophy ORPHA:293381; Familial mesial temporal lobe epilepsy with febrile seizures ORPHA:165805; Late-onset junctional epidermolysis bullosa ORPHA:79406; Neuropathy with hearing impairment ORPHA:139512; Marie Unna hereditary hypotrichosis ORPHA:444; Cholangiocarcinoma ORPHA:70567; Familial expansile osteolysis ORPHA:85195; Keratoderma hereditarium mutilans ORPHA:494; Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome ORPHA:2698; Monilethrix ORPHA:573; Osteopetrosis-hypogammaglobulinemia syndrome ORPHA:178389; Porokeratotic eccrine ostial and dermal duct nevus ORPHA:166286; Xanthinuria type I ORPHA:93601; Palmoplantar keratoderma-deafness syndrome ORPHA:2202; Severe dermatitis-multiple allergies-metabolic wasting syndrome ORPHA:369992; Hypoplastic amelogenesis imperfecta ORPHA:100031; Apparent mineralocorticoid excess ORPHA:320; Genetic transient congenital hypothyroidism ORPHA:226316; Glucose-galactose malabsorption ORPHA:35710; Xanthinuria type II ORPHA:93602; Meesmann corneal dystrophy ORPHA:98954; Alopecia-intellectual disability syndrome ORPHA:2850; Pachydermoperiostosis ORPHA:2796; Acrocapitofemoral dysplasia ORPHA:63446; CIDEC-related familial partial lipodystrophy ORPHA:435651; Early-onset anterior polar cataract ORPHA:98988,0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1697334635963512; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
IQCG,Myeloid Leukemia; Leukemogenesis,0.2980670559114652; 0.3510063969122338,Diamond-Blackfan Anemia; Anemia,0.4646409362700993; 0.4780231573499264,Primary ciliary dyskinesia ORPHA:244; Situs inversus totalis ORPHA:101063; Meckel syndrome ORPHA:564; Non-syndromic male infertility due to sperm motility disorder ORPHA:276234,0.7068064785325423; 0.7120423847116372; 0.7166448869866529; 0.7249187045096473,,,yeasx,0.56,Homo sapiens,Homo sapiens
IQGAP2,"Ovarian Carcinoma; Stomach Carcinoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Brain Tumor, Primary; Malignant neoplasm of prostate; Primary malignant neoplasm of brain; Brain Neoplasms; Prostate carcinoma; Liver carcinoma; Malignant Neoplasms; Liver neoplasms; Benign neoplasm of brain, unspecified; Recurrent Brain Neoplasm; Neoplasms, Intracranial; Adult Hepatocellular Carcinoma; Stomach Neoplasms; Inflammatory Bowel Diseases; Malignant neoplasm of brain; Platelet distribution width measurement; Platelet distribution width result; Reticulocyte count (procedure); Rectal Carcinoma; Platelet mean volume determination (procedure); Colitis; Prostatic Intraepithelial Neoplasias; Venous Thromboembolism; Platelet Count measurement; hearing impairment",0.0034602840073026; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.044151975756427; 0.0569142010728473; 0.064548079316548; 0.064548079316548; 0.0773771948186562; 0.095319386034013; 0.0991201145654548; 0.1454373331146953; 0.1602092191314262; 0.1770067065899052; 0.290158730291654; 0.290158730291654; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.4115056600660309; 0.4115056600660309; 0.425419812815905; 0.429029854971378; 0.4981941174985421; 0.5323590634832615; 0.6693434807212948; 0.6925751397474874; 0.7061487180640408; 0.8612168330350624,Liver Carcinoma; Schizophrenia; Brain Neoplasms; Intracranial Neoplasm,0.0520696613701797; 0.0531117779464085; 0.1534453668959814; 0.2038801271174535,Galactose mutarotase deficiency ORPHA:570422; Congenital non-communicating hydrocephalus ORPHA:269510; Spinocerebellar ataxia type 40 ORPHA:423275; Cranio-osteoarthropathy ORPHA:1525; Isolated congenital digital clubbing ORPHA:217059; Brain dopamine-serotonin vesicular transport disease ORPHA:352649,0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423,,,In vitro;yeasx,0.35;0.37;0.46,Bacillus anthracis;Homo sapiens;chemical synthesis,Homo sapiens;ebvg;hcvjf
ISL1,"Breast Carcinoma; Stomach Carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Central neuroblastoma; Neuroblastoma; Lymphoma; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Ameloblastoma; Carcinoma of bladder; Rheumatoid Arthritis; Gastrointestinal Neoplasms; Diabetes; Hodgkin Disease; Diabetes Mellitus; Triple Negative Breast Neoplasms; Rat Insulinoma; Secondary malignant neoplasm of lymph node; Bipolar Disorder; Hernia, Inguinal; Diabetes Mellitus, Non-Insulin-Dependent; Truncus Arteriosus, Persistent; Congenital atresia of pulmonary valve; Lymphoma, Non-Hodgkin; Coronary heart disease; Epispadias, male (disorder); Abnormality of the anus; Anemia; Bladder Exstrophy; Umbilical hernia; Pituitary Diseases; Gastric Adenocarcinoma; Down Syndrome; Congenital atresia of pulmonary artery; Congestive heart failure; Heart failure; Myxoid cyst; Maturity onset diabetes mellitus in young; Ventricular Septal Defects; Conotruncal defect; Muscular Dystrophy, Emery-Dreifuss; Obesity; Neoplasm Recurrence, Local; Congenital Abnormality; Arrhythmogenic Right Ventricular Dysplasia; Congenital heart disease; Biliary Tract Cancer; Congenital hypoplasia of penis; Recurrent urinary tract infection; Agenesis; Vesico-Ureteral Reflux",0.0042545616049287; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0593779966354549; 0.0688152422187159; 0.0739788831250619; 0.084286432100041; 0.0891725280554336; 0.1208020277850109; 0.13167400689206; 0.1537760235124317; 0.2062010908869036; 0.2277108302018961; 0.2454476567103779; 0.2522264785494494; 0.2980670559114652; 0.3778347117514905; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3986414839122469; 0.4028066164685291; 0.4028066164685291; 0.4126392832024548; 0.4192169590514327; 0.425419812815905; 0.4304973629098372; 0.4335751357405352; 0.4506578937113162; 0.4564472886428772; 0.4675904598629673; 0.4923669467696064; 0.5140447474168605; 0.5299466034567416; 0.5305233935923577; 0.5359212109443033; 0.549941235475765; 0.563120546412355; 0.6974821940437801; 0.6980473696540115; 0.7240930522443176; 0.7577323833810212,Bladder Exstrophy; Congenital Malrotation Of Intestine; Vesicoureteral Reflux; Bladder Neoplasm; Urinary Bladder Cancer; Epispadias; Neuroblastoma; Bowel Incontinence; Congenital Exomphalos; Congenital Hypoplasia Of Penis; Congenital Omphalocele,0.4541466895915311; 0.4646409362700993; 0.4714699023601434; 0.4723647227028846; 0.4875380732267193; 0.4875380732267193; 0.5127628024019304; 0.6130153808924363; 0.6270755162143985; 0.6572113517052336; 0.6712925710975606,"Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome ORPHA:306542; Split hand-split foot-deafness syndrome ORPHA:71271; Bladder exstrophy ORPHA:93930; Partial pancreatic agenesis ORPHA:2805; Brain-lung-thyroid syndrome ORPHA:209905; Brachydactyly-syndactyly, Zhao type ORPHA:93409; Hirschsprung disease-ganglioneuroblastoma syndrome ORPHA:2151; Hypoplastic pancreas-intestinal atresia-hypoplastic gallbladder syndrome ORPHA:293864; NON RARE IN EUROPE: Brachydactyly type D ORPHA:93385; Syndactyly type 5 ORPHA:93406; Synpolydactyly type 1 ORPHA:295195; VACTERL/VATER association ORPHA:887; Zygodactyly type 3 ORPHA:295191",0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Vaccinia virus hemagglutinin (gene: A56R); Variola virus hypothetical protein (gene: B21R); Cowpox virus VHR1 or CPXV025 protein (gene: VHR1); Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Horsepox virus HSPV194 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Monkeypox virus ankyrin-like protein; Cowpox virus CPXV016 protein (gene: CPXV016 CDS); Vaccinia virus Ankara 54.4k ankyrin repeat protein f2; Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Cowpox virus CPXV211 protein (gene: CPXV211 CDS); Horsepox virus HSPV005c (Ankyrin repeats); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Yaba-like disease virus 8L protein (gene: 8L); Ectromelia virus ERPV ankyrin; Cowpox virus CPXV039 (gene: CPXV039 CDS); Vaccinia virus ankyin-like protein (gene: M1L); Orf virus ORF008 ankyrin repeat protein; Monkeypox virus Zaire-96-I-16 J3L (gene: J3L); Horsepox virus HSPV181 (ankyrin repeats); Vaccinia virus ankyrin-like protein (gene: B4R); Yaba monkey tumor virus ankyrin repeat protein; Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Orf virus ORF129 ankyrin repeat protein; Yaba-like disease virus 11L protein (gene: 11L); Orf virus ORF128 ankyrin repeat protein; Orf virus ORF126 ankyrin repeat protein; Variola virus hypothetical protein (gene: B6R),0.6362779693488597; 0.7988086321880973; 0.8031136315766868; 0.8315214238833722; 0.8320620882218038; 0.8390943852085586; 0.8426793553344071; 0.8507994162096807; 0.8665950357166999; 0.876049415394169; 0.8784689389733535; 0.9005654634109755; 0.9097056179628632; 0.9102852214746716; 0.9199249371723298; 0.920189880588384; 0.9271250260824724; 0.9285312497152513; 0.9285312497152513; 0.9517968639566384; 0.9518028028273808; 0.960637237597315; 0.9621839893030432; 0.9621839893030432; 0.9624639844306644; 0.9624639844306644; 0.9676678660011035; 0.970789305792858,,,,
ITGA2,"Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Malignant neoplasm of ovary; Medulloblastoma; Malignant neoplasm of prostate; Central neuroblastoma; Neoplasm Metastasis; Neuroblastoma; Pancreatic Neoplasm; Degenerative polyarthritis; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Malignant Neoplasms; Osteosarcoma; Adenocarcinoma of colon; Ameloblastoma; Secondary malignant neoplasm of bone; Myocardial Infarction; Colonic Neoplasms; Rheumatoid Arthritis; Renal fibrosis; von Willebrand Disease, Type 1; Systemic Scleroderma; Lung Neoplasms; Osteosarcoma of bone; Prostatic Neoplasms; Parasitic Diseases; Malignant neoplasm of lung; Diabetic Retinopathy; Fibroid Tumor; Idiopathic Pulmonary Fibrosis; Neonatal Alloimmune Thrombocytopenia; Ischemic stroke; Coronary Thrombosis; Rhabdomyosarcoma; Carcinoma of lung; Endometriosis; Collagen Diseases; Uterine Fibroids; Primary malignant neoplasm of lung; Secondary malignant neoplasm of lymph node; Diabetes Mellitus, Non-Insulin-Dependent; Nasopharyngeal carcinoma; Non-Small Cell Lung Carcinoma; Hypertensive disease; Coronary heart disease; Glomerulonephritis; FNAITP; Cardiac fibrosis; Arthritis, Bacterial; Atrial Fibrillation; Endometrioma; Mechanical Allodynia; Arthritis, Infectious; Glomerulosclerosis (disorder); Chronic Kidney Diseases; Acute myocardial infarction; Cerebrovascular accident; Triglycerides measurement; Lupus Erythematosus, Systemic; Thrombocytopenia; Mouth Neoplasms; Alloimmunisation; Destructive Arthritis; Retinal Vein Occlusion; Decreased platelet count; Hyperalgesia, Secondary; Allodynia; Hyperalgesia, Primary; Increased tendency to bruise; Astrocytosis; Tactile Allodynia; Myeloid Leukemia, Chronic; von Willebrand Disease; Placental Insufficiency; Acute GVH disease; Thrombosis; Coronary Arteriosclerosis; Hyperalgesia, Thermal; Skin Erosion; Rheumatic Heart Disease; Ewings sarcoma-primitive neuroectodermal tumor (PNET); Hyperalgesia; Arthritis; Osteomyelitis; Behcet Syndrome; Superficial ulcer; Gliosis; Coronary Artery Disease; Neurologic Symptoms",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0277695594716545; 0.0354767239335874; 0.0569142010728473; 0.0593779966354549; 0.0648809611869375; 0.0688152422187159; 0.0739788831250619; 0.0739788831250619; 0.0773771948186562; 0.0775520919998773; 0.0991201145654548; 0.1029977559100099; 0.1112281755580192; 0.1208020277850109; 0.1253114324938153; 0.1352936728187231; 0.1454373331146953; 0.1537760235124317; 0.1602092191314262; 0.1897991423047819; 0.1900258729042946; 0.2062010908869036; 0.2109483801368481; 0.223747154820789; 0.2714542429024338; 0.2714542429024338; 0.2723545094624877; 0.290158730291654; 0.3099246715197673; 0.3099246715197673; 0.3486533561309259; 0.3508665345292502; 0.3510063969122338; 0.3663130598151661; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4103119460235835; 0.4115056600660309; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.4304973629098372; 0.4459714599189374; 0.4561717689698902; 0.4561717689698902; 0.4561717689698902; 0.4564472886428772; 0.4564472886428772; 0.4564472886428772; 0.4675904598629673; 0.472444704048021; 0.472444704048021; 0.472444704048021; 0.4790179402069343; 0.4906258721078565; 0.5140447474168605; 0.5178072301085912; 0.5252711504839724; 0.5337853752290136; 0.5359212109443033; 0.5393787854381349; 0.553002957824355; 0.6196470808426647; 0.6496433426951205; 0.6691893635307453; 0.6761967139251879; 0.7240930522443176; 0.7840911880051142,Endometriosis; Subarachnoid Hemorrhage; Hematomas; Fetal And Neonatal Alloimmune Thrombocytopenia; Retinal Vein Occlusion; Alloimmune Thrombocytopenia; Endometrioma; Cerebral Palsy; Sensorineural Hearing Loss; Developmental Delay,0.2187610616307245; 0.2627224344149009; 0.4286813331685578; 0.4286813331685578; 0.4402141802500753; 0.4560460337187313; 0.5036845352940079; 0.6340319940404294; 0.7559892870751337; 0.96477535147595,"Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Auriculocondylar syndrome ORPHA:137888; Severe generalized junctional epidermolysis bullosa ORPHA:79404; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Isolated hyperchlorhidrosis ORPHA:542657; Kindler epidermolysis bullosa ORPHA:2908; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Myelodysplastic syndrome ORPHA:52688; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Hereditary papillary renal cell carcinoma ORPHA:47044; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Osteofibrous dysplasia ORPHA:488265; PPARG-related familial partial lipodystrophy ORPHA:79083; Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Familial primary localized cutaneous amyloidosis ORPHA:353220; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402; Erythrokeratodermia variabilis ORPHA:317; Intermediate generalized junctional epidermolysis bullosa ORPHA:79402; Localized junctional epidermolysis bullosa ORPHA:251393; Benign familial mesial temporal lobe epilepsy ORPHA:163717; Epithelial recurrent erosion dystrophy ORPHA:293381; Familial mesial temporal lobe epilepsy with febrile seizures ORPHA:165805; Late-onset junctional epidermolysis bullosa ORPHA:79406; Metaphyseal chondrodysplasia, Spahr type ORPHA:2501; Spondyloepimetaphyseal dysplasia, Missouri type ORPHA:93356; Griscelli syndrome type 3 ORPHA:79478; Juvenile Paget disease ORPHA:2801; Progressive familial intrahepatic cholestasis type 1 ORPHA:79306; Athyreosis ORPHA:95713; Aneurysm-osteoarthritis syndrome ORPHA:284984; Progressive familial intrahepatic cholestasis type 4 ORPHA:480483; X-linked hypophosphatemia ORPHA:89936; Charcot-Marie-Tooth disease type 4C ORPHA:99949; Palmoplantar keratoderma, Nagashima type ORPHA:140966; Xanthinuria type II ORPHA:93602; Fetal and neonatal alloimmune thrombocytopenia ORPHA:853; Cystic fibrosis ORPHA:586; Achondrogenesis type 1B ORPHA:93298; Atelosteogenesis type II ORPHA:56304; Diastrophic dwarfism ORPHA:628; Multiple epiphyseal dysplasia type 4 ORPHA:93307",0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0640416108792758; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3826134188846508; 0.6279395134845649; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,"Ectromelia virus ERPV hemagglutinin; Vaccinia virus Ankara Haemagglutinin; Human adenovirus 41 E3 31.6K; Papiine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Vaccinia virus hemagglutinin (gene: A56R); Human adenovirus 52 E3 CR1-beta1 (gene: E3); Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Horsepox virus HSPV177 (Immunoglobulin like); Cowpox virus CPXV194 protein (gene: CPXV194 CDS); Variola virus hypothetical protein (gene: J9R); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Human mastadenovirus A E3 CR1-beta1; Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta); Human adenovirus 61 E3 CR1 beta; Human mastadenovirus F membrane glycoprotein E3 CR1-beta (gene: E3A); Human adenovirus 18 CR1-beta protein (gene: E3)",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6621265548536891; 0.6806291584193672; 0.6806291584193672; 0.691145768348025; 0.7212352368560536; 0.7651942752688915; 0.776311155917498; 0.8285661572509389; 0.875442055263636; 0.8784689389733535; 0.9353779004188908; 0.9445347004229157,In vitro;ecoli;yeasx,0.35;0.37;0.44;0.56;0.59,Homo sapiens;Mus musculus;chemical synthesis;chick;rat;rots1,Echis multisquamatus;Homo sapiens;Mus musculus;bovin;coxbu
KAT2B,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Colorectal Cancer; Stomach Carcinoma; Pre B-cell acute lymphoblastic leukemia; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Medulloblastoma; Malignant neoplasm of prostate; Neoplasm Metastasis; Glioma; Glioblastoma; Prostate carcinoma; Malignant neoplasm of urinary bladder; Squamous cell carcinoma of esophagus; Liver carcinoma; Malignant Neoplasms; Colon Carcinoma; Carcinoma, Transitional Cell; Carcinoma of bladder; Malignant tumor of colon; Diabetes; Anoxia; Diabetes Mellitus; Neoplasms; Diabetes Mellitus, Insulin-Dependent; Conventional (Clear Cell) Renal Cell Carcinoma; Ataxia Telangiectasia; Rhabdomyosarcoma; Primary malignant neoplasm; Secondary malignant neoplasm of lymph node; Spinocerebellar Ataxia Type 7; Kidney Diseases; Secondary malignant neoplasm of liver; Urothelial Carcinoma; Acute lymphocytic leukemia; Stomach Neoplasms; Coronary heart disease; Asthma; Aortic Aneurysm, Abdominal; Atrial Fibrillation; Drug Dependence; Bulbo-Spinal Atrophy, X-Linked; Mean Corpuscular Volume (result); Mood Disorders; stage, gastric cancer; Central Nervous System Neoplasms; Neurodegenerative Disorders; Impaired glucose tolerance; Hyperglycemia; Mean blood pressure; Secondary Neoplasm; Obesity; Adenocarcinoma of lung (disorder); Alcohol consumption; Precursor Cell Lymphoblastic Leukemia Lymphoma; Vascular inflammations; Paroxysmal atrial fibrillation; Leukemia, T-Cell; Metabolic Diseases; Pilocytic Astrocytoma; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0189794808441368; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0354767239335874; 0.0569142010728473; 0.0648809611869375; 0.0739788831250619; 0.0745502070959292; 0.0773771948186562; 0.084286432100041; 0.0919714360040484; 0.095319386034013; 0.0991201145654548; 0.1062239757831962; 0.13167400689206; 0.13167400689206; 0.223747154820789; 0.2277108302018961; 0.2462384927636234; 0.2522264785494494; 0.2714542429024338; 0.2714542429024338; 0.2980670559114652; 0.3508665345292502; 0.3510063969122338; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.4028066164685291; 0.4118266358241932; 0.4192169590514327; 0.4192169590514327; 0.4304973629098372; 0.4330362522463816; 0.4335751357405352; 0.4900770016856776; 0.4906258721078565; 0.4923669467696064; 0.5140447474168605; 0.5140447474168605; 0.51550637274795; 0.5251317541886066; 0.5393787854381349; 0.5995952178307736; 0.6304655343580164; 0.6691893635307453; 0.750779529196619; 0.7891530777939482; 0.8352423037513227; 0.8352423037513227,Mood Disorder,0.4646409362700993,"Generalized glucocorticoid resistance syndrome ORPHA:786; Spinocerebellar ataxia type 1 ORPHA:98755; Attenuated Chediak-Higashi syndrome ORPHA:352723; Calpain-3-related  limb-girdle muscular dystrophy R1 ORPHA:267; Chediak-Higashi syndrome ORPHA:167; GM3 synthase deficiency ORPHA:370933; Renal pseudohypoaldosteronism type 1 ORPHA:171871; Acrodysostosis ORPHA:950; Acrodysostosis with multiple hormone resistance ORPHA:280651; X-linked myotubular myopathy-abnormal genitalia syndrome ORPHA:456328; Bietti crystalline dystrophy ORPHA:41751; Complex lethal osteochondrodysplasia ORPHA:457378; External auditory canal aplasia/hypoplasia ORPHA:141074; Gingival fibromatosis-hypertrichosis syndrome ORPHA:2026; Mild hemophilia A ORPHA:169808; Moderately severe hemophilia A ORPHA:169805; Multiple endocrine neoplasia type 4 ORPHA:276152; Nicolaides-Baraitser syndrome ORPHA:3051; PDE4D haploinsufficiency syndrome ORPHA:439822; Severe hemophilia A ORPHA:169802; Symptomatic form of hemophilia A in female carriers ORPHA:177926; Autosomal recessive ataxia, Beauce type ORPHA:88644; Autosomal recessive myogenic arthrogryposis multiplex congenita ORPHA:319332; Estrogen resistance syndrome ORPHA:785; Methylmalonic acidemia with homocystinuria type cblF ORPHA:79284; Polycythemia vera ORPHA:729; SHORT syndrome ORPHA:3163; Familial thrombocytosis ORPHA:71493",0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,"Human papillomavirus type 48 regulatory protein E2 (gene: E2); Trichodysplasia spinulosa-associated polyomavirus large T antigen (gene: T); Human papillomavirus 116 E2 protein; Reston ebolavirus spike glycoprotein (gene: GP); Ebola virus - Mayinga, Zaire, 1976 virion spike glycoprotein precursor (gene: GP); Zaire ebolavirus spike glycoprotein (gene: GP); Modoc virus non-structural protein 2A; Human alphaherpesvirus 2 multifunctional expression regulator (gene: UL54); Tai Forest ebolavirus spike glycoprotein (gene: GP); BK polyomavirus large T antigen; Human adenovirus 11a IVa2; Human coronavirus HKU1 small membrane protein (gene: E); Human papillomavirus type 128 E2 (gene: E2); Monkeypox virus sulfhydryl oxidase; Horsepox virus HSPV067 (sulfhydryl oxidase); Hendra henipavirus phosphoprotein P (gene: P/V/C); Nipah henipavirus P phosphoprotein",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6761714078632568; 0.8919745352546131; 0.9511894303546532,Homo sapiens CD4+ T-cell;Homo sapiens HeLa epitheloid cervical carcinoma cell;Homo sapiens LNCaP caucasian prostate adenocarcinoma cell;Homo sapiens M059JK glioblastoma cell;Homo sapiens U2OS osteosarcoma cell;In vitro;Saccharomyces cerevisiae,0.35;0.4;0.44;0.51;0.66,Homo sapiens;ade05,-;Homo sapiens;ade05;chemical synthesis
KBTBD8,Malignant neoplasm of breast; Mandibulofacial Dysostosis,0.0191435238361999; 0.2643145809900195,Breast Cancer,0.0402286636010764,Fried syndrome ORPHA:85335; X-linked intellectual disability-Dandy-Walker malformation-basal ganglia disease-seizures syndrome ORPHA:1568; X-linked intellectual disability-hypotonia-facial dysmorphism-aggressive behavior syndrome ORPHA:85329; Fetal encasement syndrome ORPHA:465824,0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782,"Yaba-like disease virus 140R protein (gene: 140R); Yaba monkey tumor virus kelch-like protein; Vaccinia virus Ankara 64.7k Kelch-like protein f1; Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Horsepox virus HSPV008; Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Horsepox virus HSPV176 (kelch-like protein; Provisional); Yaba-like disease virus 19L protein (gene: 19L); Horsepox virus HSPV043 (Kelch-like protein; Provisional); Vaccinia virus kelch-like protein (gene: A55R); Cowpox virus CPXV215 Protein (gene: CPXV215 CDS); Cowpox virus CPXV050 (gene: CPXV050 CDS); Horsepox virus HSPV197 (Hypothetical protein); Monkeypox virus Zaire-96-I-16 B1R (gene: B1R); Vaccinia virus Ankara Kelch-like protein, modulator of inflammation; Cowpox virus CPXV193 protein (gene: CPXV193 CDS); Vaccinia virus Ankara 64.7k Kelch-like protein f2; Monkeypox virus kelch-like protein; Horsepox virus HSPV029 (kelch-like protein; Provisional); Ectromelia virus ERPV kelch-like protein; Monkeypox virus Zaire-96-I-16 D15L (gene: D15L); Cowpox virus CPXV035 protein (gene: CPXV035 CDS); Vaccinia virus kelch-like protein (gene: C2L); Monkeypox virus Zaire-96-I-16 D17L (gene: D17L); Variola virus hypothetical protein (gene: J8R); Variola virus hypothetical protein (gene: D13L); Vaccinia virus Ankara 18.9k Kelch-like protein; Cowpox virus CPXV204 protein (gene: CPXV204 CDS); Variola virus hypothetical protein (gene: C7L); Variola virus hypothetical protein (gene: B24R); Vaccinia virus hypothetical protein",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.7975886343350181,,,,
KCNN4,"Breast Carcinoma; Malignant neoplasm of prostate; Malignant neoplasm of pancreas; Glioma; Endometrial Neoplasms; Pancreatic carcinoma; Prostate carcinoma; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Endometrial Carcinoma; Non-Small Cell Lung Carcinoma; Anisopoikilocytosis; Inflammatory Bowel Diseases; Increased mean corpuscular volume; Xerocytosis; Acanthocytosis; Splenomegaly; Mean Corpuscular Volume (result); Hepatomegaly; Reticulocytosis; Cardiovascular Diseases; Hemoglobin measurement; Increased bilirubin level (finding); Crohn Disease; Hamartoma Syndrome, Multiple; Cystic Fibrosis; Icterus; Monocyte count procedure; Monocyte count result; Mean corpuscular hemoglobin concentration determination; Anemia, Hemolytic",0.0042545616049287; 0.0569142010728473; 0.0726340460169901; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.13167400689206; 0.1328002618052838; 0.3044782497745498; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3975960596292668; 0.4103119460235835; 0.4192169590514327; 0.4506578937113162; 0.4615352570710579; 0.4675904598629673; 0.4852430673532381; 0.4906258721078565; 0.4981941174985421; 0.589345563575654; 0.6124306570512981; 0.625112405383346; 0.6274540883972485; 0.6274540883972485; 0.7412504828119304; 0.7796824214131131,Breast Carcinoma; Hyperbilirubinemia; Abetalipoproteinemia; Anemia,0.0075861267486594; 0.3094716280561038; 0.4560460337187313; 0.4780231573499264,Combined immunodeficiency due to CD70 deficiency ORPHA:538958; Hypocalcemic vitamin D-resistant rickets ORPHA:93160; Solitary fibrous tumor/hemangiopericytoma ORPHA:2126; Dehydrated hereditary stomatocytosis ORPHA:3202; Dysosteosclerosis ORPHA:1782; Herpes simplex virus encephalitis ORPHA:1930; Combined immunodeficiency-enteropathy spectrum ORPHA:436252; Deficiency in anterior pituitary function-variable immunodeficiency syndrome ORPHA:293978; Multiple intestinal atresia ORPHA:2300,0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3826134188846508; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782,,,,,,
KITLG,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Malignant neoplasm of prostate; Carcinoma; Central neuroblastoma; Carcinomatosis; Neoplasm Metastasis; Renal Cell Carcinoma; Neuroblastoma; Malignant neoplasm of pancreas; Glioblastoma; Pancreatic carcinoma; Colorectal Neoplasms; Anaplastic carcinoma; Liver carcinoma; Osteosarcoma; Colon Carcinoma; Premature canities; MYELODYSPLASTIC SYNDROME; Waardenburg Syndrome Type 2; Undifferentiated carcinoma; Mammary Carcinoma, Animal; Animal Mammary Neoplasms; Colonic Neoplasms; Rheumatoid Arthritis; Sarcoma; Heterochromia iridis; Carcinoma testes; Leukemia, Myeloid, Chronic-Phase; White forelock; Testicular Germ Cell Tumor; cervical cancer; Lung Neoplasms; Eosinophilic esophagitis; Osteosarcoma of bone; Adverse reaction to drug; Drug toxicity; Diabetes; Anoxia; Neuroblastic tumors; Diabetes Mellitus; Malignant neoplasm of liver; Malignant neoplasm of lung; Mastocytoma; Piebaldism; Benign Mastocytoma; Pancreatic Ductal Adenocarcinoma; Endometrial Carcinoma; Gastrointestinal Stromal Tumors; Mammary Neoplasms, Experimental; Mast Cell Neoplasm; Rhabdomyosarcoma; Carcinoma of lung; Endometriosis; Teratoma; Primary malignant neoplasm of lung; Chronic myeloproliferative disorder; Nasopharyngeal carcinoma; Non-Small Cell Lung Carcinoma; Leukemia, Myelocytic, Acute; Germ Cell Cancer; Large cell neuroendocrine carcinoma; Tumor of Rete Testis; Nasopharyngeal Neoplasms; Liver and Intrahepatic Biliary Tract Carcinoma; Acute lymphocytic leukemia; Glomerulonephritis; Birthmark; Cafe-au-Lait Spots; Cachexia; Cardiac fibrosis; Cutaneous Mastocytosis; Asthma; synovial sarcoma; Anaplasia; Renal carcinoma; Thyroid carcinoma; Drug abuse; Progressive Neoplastic Disease; Amyotrophic Lateral Sclerosis; Progressive cGVHD; Menstrual spotting; Multiple lentigines; Merkel cell carcinoma; Multiple Myeloma; Urticaria Pigmentosa; Pigmented lesions; Mastocytosis; Cancer, Embryonal and Mixed; Neoplasms, Embryonal and Mixed; Hyperkeratosis; Oxyphilic Adenoma; Histiocytosis, Langerhans-Cell; Cancer, Embryonal; Hypopigmentation disorder; hypopigmented skin patch; Malignant neoplasm of thyroid; Germ cell tumor; Neurofibromatosis 1; Machado-Joseph Disease; Neurodegenerative Disorders; Nasal Polyps; Myocardial Ischemia; Senile lentigo; Leukemia, Mast-Cell; leukemia; Mesothelioma; Non-obstructive azoospermia; Cardiomyopathy, Familial Idiopathic; Huntington Disease; Myeloid Leukemia, Chronic; Myelodysplasia; ALBINOIDISM, OCULOCUTANEOUS, AUTOSOMAL DOMINANT; Ovarian Failure, Premature; Chromosome 5, trisomy 5q; Adult Acute Myeloblastic Leukemia; Myelodysplastic Syndrome with Isolated del(5q); Metastatic melanoma; Neoplasms, Germ Cell and Embryonal; 5q-syndrome; Leukemia, Myelomonocytic, Chronic; Obesity; Oligospermia; Synovitis; Anemia, severe; Polycystic Ovary Syndrome; Lymphoma, Follicular; Arthritis; Embryonal Neoplasm; Hyperpigmentation; Seminoma; Congenital chromosomal disease; Hepatitis, Toxic; Chemical and Drug Induced Liver Injury; Chemically-Induced Liver Toxicity; Drug-Induced Acute Liver Injury; Hepatitis, Drug-Induced; Premature Menopause; Anemia, Diamond-Blackfan; Myeloproliferative disease; Gastritis; Sensorineural Hearing Loss (disorder); Testicular Neoplasms; Drug-Induced Liver Disease; Dermatitis, Atopic; Left Ventricular Hypertrophy; Muscular Dystrophy; Leigh Disease; Malignant Testicular Germ Cell Tumor; Gastrointestinal Carcinoid Tumor; Vitiligo; VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding); Cardiomyopathy, Dilated; Malignant neoplasm of testis; Polycythemia Vera; Male infertility",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0308703957553632; 0.0569142010728473; 0.0593779966354549; 0.0593779966354549; 0.0617471306652618; 0.0648809611869375; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0745502070959292; 0.0745502070959292; 0.0827744840860166; 0.084286432100041; 0.095319386034013; 0.1029977559100099; 0.1062239757831962; 0.1193558174333938; 0.1254380558571286; 0.1254380558571286; 0.13167400689206; 0.1352936728187231; 0.1352936728187231; 0.1454373331146953; 0.1537760235124317; 0.1537760235124317; 0.1602092191314262; 0.1653491983554358; 0.1662487420178625; 0.1735868515093891; 0.1735868515093891; 0.2050045461627939; 0.2062010908869036; 0.2085938372806741; 0.2109483801368481; 0.223747154820789; 0.223747154820789; 0.2277108302018961; 0.2462384927636234; 0.2522264785494494; 0.2522264785494494; 0.2643145809900195; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2980670559114652; 0.3018974726133723; 0.3044782497745498; 0.3199171478489988; 0.3508665345292502; 0.3508665345292502; 0.3510063969122338; 0.3663130598151661; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.4297858918260954; 0.4297858918260954; 0.4307603335611732; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4459714599189374; 0.4506578937113162; 0.4506578937113162; 0.4506578937113162; 0.4588513406515081; 0.4635211539849193; 0.4675904598629673; 0.4704594475773637; 0.4704594475773637; 0.472444704048021; 0.4790179402069343; 0.4790179402069343; 0.4923669467696064; 0.4923669467696064; 0.4981941174985421; 0.4981941174985421; 0.5001612228394569; 0.5019670090704682; 0.5090214163899865; 0.5140447474168605; 0.5140447474168605; 0.5178072301085912; 0.5252711504839724; 0.5299466034567416; 0.5337853752290136; 0.533913711453195; 0.553002957824355; 0.5619299124666532; 0.5710095678317721; 0.5990568578129436; 0.6035970790768342; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.6189532555846575; 0.625112405383346; 0.6447029562500783; 0.6592493193460769; 0.6875373888914498; 0.6891882956008074; 0.6910672612216457; 0.6910672612216457; 0.7045203904267408; 0.7294281406818208; 0.7294281406818208; 0.7347935459099629; 0.7533159919746161; 0.7674304683279349; 0.7965733310657268; 0.8646232927091104; 0.8670707879649133; 0.8891038160665995; 0.9114432287644624; 0.9513218044829236,Anomalous Pulmonary Artery; Anaplastic Carcinoma; Carcinoma; Nasopharyngeal Carcinoma; Testicular Neoplasms; Tumor Of Rete Testis; Malignant Testicular Germ Cell Tumor; Testicular Germ Cell Tumor; Malignant Neoplasm Of Testis; Melanosis; Myocardial Ischemia; Multiple Lentigines; Embryonal Neoplasm; Nasal Polyposis; Tumor; Multicystic Renal Dysplasia; Neoplasm; Hirschsprung Disease; Hyperkeratosis; Hearing Loss; Nonsyndromic Deafness; Non-Syndromic Sensorineural Deafness; Ptosis; Deafness,0.0075861267486594; 0.0402286636010764; 0.0534520155998091; 0.2278592962769385; 0.4286813331685578; 0.4286813331685578; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4602028929328057; 0.4646409362700993; 0.4646409362700993; 0.4875380732267193; 0.4875380732267193; 0.5632819212593052; 0.7273481622222765; 0.7820056260843418; 0.8357787380041017; 0.8371848756758566,"Atrial septal defect, ostium primum type ORPHA:99106; Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; SIX2-related frontonasal dysplasia ORPHA:488437; Auriculocondylar syndrome ORPHA:137888; Peters anomaly ORPHA:708; 20p12.3 microdeletion syndrome ORPHA:261295; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Isolated hyperchlorhidrosis ORPHA:542657; Kindler epidermolysis bullosa ORPHA:2908; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Ulnar-mammary syndrome ORPHA:3138; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Papillary renal cell carcinoma ORPHA:319298; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Rieger anomaly ORPHA:91483; Brachydactyly type A2 ORPHA:93396; Unverricht-Lundborg disease ORPHA:308; Waardenburg syndrome type 2 ORPHA:895; Early-onset nuclear cataract ORPHA:98991; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; Autosomal recessive brachyolmia ORPHA:448242; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Craniosynostosis, Boston type ORPHA:1541; Hereditary neuropathy with liability to pressure palsies ORPHA:640; Hereditary papillary renal cell carcinoma ORPHA:47044; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Myopathic Ehlers-Danlos syndrome ORPHA:536516; Nance-Horan syndrome ORPHA:627; Osteofibrous dysplasia ORPHA:488265; PPARG-related familial partial lipodystrophy ORPHA:79083; Parietal foramina with clavicular hypoplasia ORPHA:251290; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; X-linked osteoporosis with fractures ORPHA:391330; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402; X-linked Alport syndrome-diffuse leiomyomatosis ORPHA:1018; Alagille syndrome due to 20p12 microdeletion ORPHA:261600; Alagille syndrome due to a JAG1 point mutation ORPHA:261619; Alopecia universalis ORPHA:701; Atrichia with papular lesions ORPHA:86819; Epidermolysis bullosa simplex due to BP230 deficiency ORPHA:412181; Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome ORPHA:412022; Familial generalized lentiginosis ORPHA:231040; Helicoid peripapillary chorioretinal degeneration ORPHA:86813; Hereditary sensory and autonomic neuropathy type 6 ORPHA:314381; Microphthalmia with brain and digit anomalies ORPHA:139471; Monoamine oxidase A deficiency ORPHA:3057; Optic atrophy-intellectual disability syndrome ORPHA:401777; Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome ORPHA:447961; X-linked Alport syndrome ORPHA:88917; Juvenile Paget disease ORPHA:2801; Non-seminomatous germ cell tumor of testis ORPHA:363494; Phakomatosis cesioflammea ORPHA:79483; Brachydactyly type A1 ORPHA:93388; ABeta amyloidosis, Arctic type ORPHA:324723; ABeta amyloidosis, Dutch type ORPHA:100006; ABeta amyloidosis, Iowa type ORPHA:324708; ABeta amyloidosis, Italian type ORPHA:324713; ABetaA21G amyloidosis ORPHA:324718; ABetaL34V amyloidosis ORPHA:324703; Campomelic dysplasia ORPHA:140; Dicarboxylic aminoaciduria ORPHA:2195; Hot water reflex epilepsy ORPHA:166412; Isolated Pierre Robin syndrome ORPHA:718; Multiple myeloma ORPHA:29073; Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome ORPHA:228012; Persistent hyperplastic primary vitreous ORPHA:91495; Retinopathy of prematurity ORPHA:90050; Autosomal dominant non-syndromic sensorineural deafness type DFNA ORPHA:90635; Action myoclonus-renal failure syndrome ORPHA:163696; Acute neonatal citrullinemia type I ORPHA:247546; Adult-onset citrullinemia type I ORPHA:247573; Aromatase deficiency ORPHA:91; Aromatase excess syndrome ORPHA:178345; Frank-Ter Haar syndrome ORPHA:137834; Goldberg-Shprintzen megacolon syndrome ORPHA:66629; Legius syndrome ORPHA:137605; Sjogren-Larsson syndrome ORPHA:816; Familial exudative vitreoretinopathy ORPHA:891; Keipert syndrome ORPHA:2662; Microcystic stromal tumor ORPHA:569248; Pilomatrixoma ORPHA:91414; Severe intellectual disability-progressive spastic diplegia syndrome ORPHA:404473",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0083744975290613; 0.0092060390928213; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3900898302534297; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782,,,In vitro,0.44,Homo sapiens,Homo sapiens
KRT13,Breast Carcinoma; Tumor Progression; Adenocarcinoma; Squamous cell carcinoma; Malignant neoplasm of breast; Neoplasm Metastasis; Squamous cell carcinoma of esophagus; Oral Cavity Carcinoma; Adenocarcinoma Of Esophagus; Cervical Squamous Cell Carcinoma; Leukoplakia; Lip and Oral Cavity Carcinoma; Waisman syndrome; Hyperkeratosis; Acanthosis; Intraepithelial Neoplasia,0.0042545616049287; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0648809611869375; 0.0919714360040484; 0.13167400689206; 0.2679411586077776; 0.3199171478489988; 0.333745294913745; 0.3933196962529684; 0.4028066164685291; 0.4192169590514327; 0.5019670090704682; 0.717484976234209,Esophagus Neoplasm,0.0102679590519094,"Autosomal recessive infantile hypercalcemia ORPHA:300547; Bamforth-Lazarus syndrome ORPHA:1226; Metaphyseal chondrodysplasia, Spahr type ORPHA:2501; Neuropathy with hearing impairment ORPHA:139512; Spondyloepimetaphyseal dysplasia, Missouri type ORPHA:93356; White sponge nevus ORPHA:171723; Bladder exstrophy ORPHA:93930; Uncombable hair syndrome ORPHA:1410; Hypoplastic amelogenesis imperfecta ORPHA:100031; Epidermolysis bullosa simplex with circinate migratory erythema ORPHA:158681; Gelatinous drop-like corneal dystrophy ORPHA:98957; Sebocystomatosis ORPHA:841; Bifid uvula ORPHA:99771; Cleft hard palate ORPHA:101023; Cleft velum ORPHA:99772; Meesmann corneal dystrophy ORPHA:98954; Submucosal cleft palate ORPHA:155878; Hypocalcified amelogenesis imperfecta ORPHA:100032; Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form ORPHA:79399; Autosomal dominant generalized epidermolysis bullosa simplex, severe form ORPHA:79396; Epidermolysis bullosa simplex with mottled pigmentation ORPHA:79397; Localized epidermolysis bullosa simplex ORPHA:79400; Pachyonychia congenita ORPHA:2309; ADULT syndrome ORPHA:978; Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome ORPHA:1071; EEC syndrome ORPHA:1896; Limb-mammary syndrome ORPHA:69085",0.0083045131203191; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1697334635963512; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782,,,In vitro;yeasx,0.35;0.56,Homo sapiens;chemical synthesis,Homo sapiens
KRT23,Colorectal Carcinoma; Colorectal Cancer; Adenocarcinoma; Malignant neoplasm of pancreas; Pancreatic carcinoma; Colon Carcinoma; Malignant neoplasm of large intestine; Malignant tumor of colon; Steatohepatitis,0.0034602840073026; 0.0149315928814189; 0.0155921563748247; 0.0726340460169901; 0.0745502070959292; 0.1062239757831962; 0.13167400689206; 0.223747154820789; 0.4906258721078565,,,Bilateral frontoparietal polymicrogyria ORPHA:101070; Uncombable hair syndrome ORPHA:1410; Glycogen storage disease due to liver glycogen phosphorylase deficiency ORPHA:369; Hypohidrosis-electrolyte imbalance-lacrimal gland dysfunction-ichthyosis-xerostomia syndrome ORPHA:528105; Autosomal dominant Charcot-Marie-Tooth disease type 2 due to DGAT2 mutation ORPHA:487814,0.0586579655822394; 0.1590470395003315; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423,,,,,,
LAMA3,"Mammary Neoplasms; Ovarian Carcinoma; Stomach Carcinoma; Adenocarcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Epithelial ovarian cancer; Malignant neoplasm of prostate; Neoplasm Metastasis; Glioblastoma; Squamous cell carcinoma of the head and neck; Myocardial Infarction; Cataract; Atrophic scar; EPIDERMOLYSIS BULLOSA, JUNCTIONAL, LOCALISATA VARIANT (disorder); Adult junctional epidermolysis bullosa (disorder); Epidermolysis Bullosa Progressiva; Herlitz Disease; Hoarse cry; JEB-I; Palmar hyperhidrosis; Abnormality of the eye; Aplasia Cutis Congenita; Congenital localized absence of skin; Epidermolysis bullosa inversa dystrophica; Junctional split; Laryngismus; Plantar hyperkeratosis; Pyloric Atresia; Adenoma; Ovarian Serous Adenocarcinoma; Late-onset muscular dystrophy; Anemia; Laryngostenosis; Cervical Squamous Intraepithelial Neoplasia; Hoarseness; Oral mucosal blisters; Amyotrophic Lateral Sclerosis; Flexion contracture of proximal interphalangeal joint; Paronychia Inflammation; Hemoglobin low; Junctional Epidermolysis Bullosa; Scarring alopecia of scalp; Dyspnea; Nail dysplasia; Disorder of eye; Congenital scar; Reticulocyte count (procedure); Research-Related Injuries; Traumatic injury; Wounds and Injuries; Fragile nails; Injury wounds; Milium Cyst; Esophageal Stenosis; Weak cry; Prion Diseases; Skin Ulcer; ANONYCHIA; Dehydration; Rotting teeth; Dental caries; Dermatologic disorders; Abnormal pigmentation; Epidermolysis Bullosa; Skin Erosion; Nail Diseases; Thin dental enamel; Defective enamel matrix; Dysplasia of tooth enamel; Amelogenesis Imperfecta; Cervical Intraepithelial Neoplasia; Pyloric Stenosis; Sparse body hair; Dental Enamel Hypoplasia; Skin blisters; Abnormal blistering of the skin; Skin bullae; Dystrophia unguium; Death in infancy; Death in early childhood; Hypodontia; Feeding difficulties; Allergic rhinitis (disorder); Undergrowth; Failure to gain weight; Pediatric failure to thrive",0.0034602840073026; 0.0034602840073026; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0191435238361999; 0.0387439397151409; 0.0569142010728473; 0.0648809611869375; 0.0745502070959292; 0.0775520919998773; 0.1352936728187231; 0.223747154820789; 0.286740104053178; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4103119460235835; 0.4115056600660309; 0.4126392832024548; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.4335751357405352; 0.4396723023384634; 0.4459714599189374; 0.4561717689698902; 0.4615352570710579; 0.4714226702518064; 0.4790179402069343; 0.4852430673532381; 0.4906258721078565; 0.5019670090704682; 0.5019670090704682; 0.5252711504839724; 0.5359212109443033; 0.5393787854381349; 0.5393787854381349; 0.5393787854381349; 0.5453394612016188; 0.5523521032803237; 0.553002957824355; 0.5655222348249326; 0.5655222348249326; 0.6319938293757544; 0.6319938293757544; 0.6355866602993508; 0.6355866602993508; 0.7467090191923123; 0.7484342194688707; 0.7867131318906807; 0.7900704408991807; 0.8600100703665297; 0.9401531131388324; 0.9449543840411656; 0.9465829057944656,Junctional Epidermolysis Bullosa Gravis Of Herlitz; Junctional Split; Congenital Localized Absence Of Skin; Junctional Epidermolysis Bullosa; Osteoporosis; Paronychia Inflammation; Laryngostenosis; Respiratory Failure; Ovarian Serous Adenocarcinoma; Allergic Rhinitis; Esophageal Stricture; Ankyloglossia; Onycholysis; Skin Erosion; Epidermolysis Bullosa; Anemia; Anonychia; Amelogenesis Imperfecta; Aplasia Cutis Congenita; Myocardial Infarction; Skin Carcinoma; Laryngospasm; Dental Enamel Hypoplasia; Nail Diseases; Nail Dysplasia; Nail Dystrophy; Alopecia; Amyotrophic Lateral Sclerosis; Ovarian Neoplasm; Cardiomyopathy; Palmoplantar Keratoderma; Microstomia; Hypodontia,0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4402141802500753; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4780231573499264; 0.5087473896242481; 0.5234357475824973; 0.5316139823120088; 0.5632819212593052; 0.5764868917478859; 0.6098159321331; 0.6564901877271138; 0.696610260564548; 0.696610260564548; 0.7112499273451761; 0.7167438233451096; 0.7506125843857363; 0.7921294370722203; 0.8407264689819682; 0.8536040084512244; 0.8880601774083273; 0.903750316592452,"Atrial septal defect, ostium primum type ORPHA:99106; Autosomal recessive nail dysplasia ORPHA:280654; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Severe generalized junctional epidermolysis bullosa ORPHA:79404; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Isolated hyperchlorhidrosis ORPHA:542657; Kindler epidermolysis bullosa ORPHA:2908; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Myelodysplastic syndrome ORPHA:52688; Papillary renal cell carcinoma ORPHA:319298; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Bamforth-Lazarus syndrome ORPHA:1226; Hereditary papillary renal cell carcinoma ORPHA:47044; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Osteofibrous dysplasia ORPHA:488265; PPARG-related familial partial lipodystrophy ORPHA:79083; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Erythrokeratodermia variabilis ORPHA:317; Intermediate generalized junctional epidermolysis bullosa ORPHA:79402; Localized junctional epidermolysis bullosa ORPHA:251393; AA amyloidosis ORPHA:85445; Alagille syndrome due to 20p12 microdeletion ORPHA:261600; Alagille syndrome due to a JAG1 point mutation ORPHA:261619; Alopecia universalis ORPHA:701; Atrichia with papular lesions ORPHA:86819; Bartsocas-Papas syndrome ORPHA:1234; Benign familial mesial temporal lobe epilepsy ORPHA:163717; CHAND syndrome ORPHA:1401; Chronic enteropathy associated with SLCO2A1 gene ORPHA:468641; Epithelial recurrent erosion dystrophy ORPHA:293381; Familial mesial temporal lobe epilepsy with febrile seizures ORPHA:165805; Late-onset junctional epidermolysis bullosa ORPHA:79406; Metaphyseal chondrodysplasia, Spahr type ORPHA:2501; Monoamine oxidase A deficiency ORPHA:3057; Multiple paragangliomas associated with polycythemia ORPHA:324299; NON RARE IN EUROPE: Autosomal dominant ichthyosis vulgaris ORPHA:462; Neuropathy with hearing impairment ORPHA:139512; Spondyloepimetaphyseal dysplasia, Missouri type ORPHA:93356; Juvenile Paget disease ORPHA:2801; Marie Unna hereditary hypotrichosis ORPHA:444; Progressive familial intrahepatic cholestasis type 1 ORPHA:79306; Athyreosis ORPHA:95713; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form ORPHA:293899; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form ORPHA:293888; Branchio-oculo-facial syndrome ORPHA:1297; Carvajal syndrome ORPHA:65282; Cholangiocarcinoma ORPHA:70567; Erythrokeratodermia-cardiomyopathy syndrome ORPHA:476096; Familial expansile osteolysis ORPHA:85195; Harlequin ichthyosis ORPHA:457; High myopia-sensorineural deafness syndrome ORPHA:363396; Keratoderma hereditarium mutilans ORPHA:494; Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome ORPHA:2698; Osteopetrosis-hypogammaglobulinemia syndrome ORPHA:178389; Porokeratotic eccrine ostial and dermal duct nevus ORPHA:166286; Progressive familial intrahepatic cholestasis type 4 ORPHA:480483; Skin fragility-woolly hair-palmoplantar keratoderma syndrome ORPHA:293165; Xanthinuria type I ORPHA:93601; Bladder exstrophy ORPHA:93930; Blepharo-cheilo-odontic syndrome ORPHA:1997; Palmoplantar keratoderma-deafness syndrome ORPHA:2202; Severe dermatitis-multiple allergies-metabolic wasting syndrome ORPHA:369992; Mutilating palmoplantar keratoderma with periorificial keratotic plaques ORPHA:659; Autosomal dominant non-syndromic sensorineural deafness type DFNA ORPHA:90635; Lethal acantholytic erosive disorder ORPHA:158687; Acute neonatal citrullinemia type I ORPHA:247546; Adult-onset citrullinemia type I ORPHA:247573; Atelosteogenesis type I ORPHA:1190; Atelosteogenesis type III ORPHA:56305; Boomerang dysplasia ORPHA:1263; Larsen syndrome ORPHA:503; MYO5B-related progressive familial intrahepatic cholestasis ORPHA:480491; Sebocystomatosis ORPHA:841; Sjogren-Larsson syndrome ORPHA:816; Xanthinuria type II ORPHA:93602; Hereditary diffuse gastric cancer ORPHA:26106; Aplasia cutis congenita ORPHA:1114; Cleft lip and alveolus ORPHA:141291; Isolated cleft lip ORPHA:199302; Posterior polymorphous corneal dystrophy ORPHA:98973; Cleft lip/palate ORPHA:199306; Ectodermal dysplasia-skin fragility syndrome ORPHA:158668; Systemic primary carnitine deficiency ORPHA:158",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0640416108792758; 0.0783959336694202; 0.0783959336694202; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.3775879467205478; 0.3775879467205478; 0.3826134188846508; 0.4101640425710954; 0.6239678957896782; 0.6239678957896782,,,Homo sapiens;Homo sapiens HEK293 embryonic kidney cell,0.35;0.4,Homo sapiens;ebvb9,Homo sapiens
LAMP3,"Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Malignant neoplasm of ovary; Epithelial ovarian cancer; Neoplasm Metastasis; Colorectal Neoplasms; Squamous cell carcinoma of esophagus; Chronic Lymphocytic Leukemia; Solid Neoplasm; Rheumatoid Arthritis; cervical cancer; Malignant tumor of cervix; Cervix carcinoma; Tuberculosis; Tuberculosis, Pulmonary; Bipolar Disorder; Uterine Cervical Neoplasm; Schizophrenia; Glycogen Storage Disease Type IIb; Parkinson Disease; Adenoma; Sialuria; IGA Glomerulonephritis; Dengue Fever; Cerebrovascular accident; Sialic Acid Storage Disease, Finnish Type (disorder); Mucolipidosis Type IV; Multiple Chronic Conditions; Gastroenteritis; Hemorrhagic Fevers, Viral; African Trypanosomiasis; Rubella; Adenocarcinoma of lung (disorder); Chikungunya Fever; Malaria; Gaucher Disease; Influenza; Hepatitis C; Virus Diseases",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0191435238361999; 0.0277695594716545; 0.0387439397151409; 0.0648809611869375; 0.0827744840860166; 0.0919714360040484; 0.1147307578771389; 0.1413782599148022; 0.1537760235124317; 0.2050045461627939; 0.2714542429024338; 0.2834835531038365; 0.3706856725676674; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3975960596292668; 0.4028066164685291; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.4675904598629673; 0.4790179402069343; 0.4906258721078565; 0.5140447474168605; 0.51550637274795; 0.5337853752290136; 0.5655222348249326; 0.7096959691931399; 0.7149953523738256; 0.7169459458481418; 0.9692165430561782,Schizophrenia; Bipolar Disorder,0.0531117779464085; 0.4875380732267193,Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944; Autosomal recessive hypohidrotic ectodermal dysplasia ORPHA:248; USP18 deficiency ORPHA:481665,0.0180064224283883; 0.0180064224283883; 0.3775879467205478; 0.6239678957896782,,,Homo sapiens HEK293T embryonic kidney cell,0.35,Homo sapiens,Homo sapiens
LIFR,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Medulloblastoma; Malignant neoplasm of prostate; Central neuroblastoma; Flexion contracture of the knee; Neoplasm Metastasis; Neuroblastoma; Osteoporosis; Glioblastoma; Squamous cell carcinoma of esophagus; Liver carcinoma; Colon Carcinoma; Skin toxicity; Myocardial Infarction; Mixed Salivary Gland Tumor; Liver neoplasms; Systemic Scleroderma; Malignant tumor of colon; Prostatic Neoplasms; contracture of elbow; Flexion contracture - elbow; Pathological fracture; Rhabdomyosarcoma; Pulmonary arterial hypertension; Cakut; Amyloidosis; Fetal Growth Retardation; Adducted thumb; Schizophrenia; Adrenocortical carcinoma; Leukemia, Myelocytic, Acute; Crisponi syndrome; Lacrimation abnormality; Alzheimer's Disease; Thickened cortex of long bones; Enlarged joints; Prominent joints; Cloudy cornea; Corneal stromal opacities; Generalized osteopenia; Defective tooth enamel; Dystrophic tooth enamel; Prolactinoma; Parkinson Disease; Infant, Small for Gestational Age; Diminished sweating; Intrauterine retardation; Abnormality of dental enamel; Hypohidrosis; Asthma; Flexion contracture of toe; Hypomenorrhea; Decrease in jaw opening; Limited jaw mobility; Limited jaw opening; Single transverse palmar crease; Hoarseness; Congenital Pain Insensitivity; Flexion contracture of proximal interphalangeal joint; Short tibia; Trismus; Myotonia; Achromatopsia 1; Dyspnea; Oligohydramnios; Achromatopsia; Hereditary Sensory and Autonomic Neuropathies; Short palpebral fissure; Thin skin; Knee joint valgus deformity; Congestive heart failure; Varying degree of multiple fractures; Frequent fractures; Increased fracture rate; Intermittent fever; Fractures, Multiple; Heart failure; Apnea; Short stature; Abnormal skeletal development; Osteochondrodysplasias; Ulnar deviation of the fingers; leukemia; Thin rib; Tibial bowing; Malignant neoplasm of skin; Flared metaphysis; Hypotrophic malar bone; Malar flattening; Micromelia; Reactive airway disease; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Aplasia/Hypoplasia of the mandible; Femoral bowing; Micrognathism; Impaired pain sensation; Osteopenia; Metaphyseal widening; Dysautonomia; Acquired scoliosis; Respiratory distress; Talipes foot deformities; Deglutition Disorders; Talipes; Congenital Abnormality; Polycystic Ovary Syndrome; Short phalanx of finger; Autonomic nervous system disorders; Short neck; Arthritis; Congenital hypoplasia of lung; Low set ears; Paresthesia; Idiopathic pulmonary arterial hypertension; Abnormality of vision; Frontal bossing; Curvature of spine; Maternal oligohydramnios; Hypernasal voice; Nasal voice; Skeletal dysplasia; Small midface; Decreased projection of midface; Hypotrophic midface; Midface retrusion; Sclerocystic Ovaries; Respiratory function loss; Respiratory Insufficiency; Sweating; Hyperhidrosis disorder; Increased sweating; Osteogenesis Imperfecta; Generalized hypotonia; Feeding difficulties in infancy; Feeding difficulties; Cardiomyopathy, Dilated; Small nose; Short nose; Congenital clubfoot",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0354767239335874; 0.0569142010728473; 0.0593779966354549; 0.064548079316548; 0.0648809611869375; 0.0688152422187159; 0.0739788831250619; 0.0745502070959292; 0.0919714360040484; 0.095319386034013; 0.1062239757831962; 0.1138051695421299; 0.1352936728187231; 0.1454373331146953; 0.1454373331146953; 0.1900258729042946; 0.223747154820789; 0.223747154820789; 0.2522264785494494; 0.2714542429024338; 0.3508665345292502; 0.3510063969122338; 0.3925783478421996; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4103119460235835; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4209380602168584; 0.4209380602168584; 0.4213286052188015; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.4297858918260954; 0.4304973629098372; 0.4330362522463816; 0.439389586518055; 0.4396723023384634; 0.4561717689698902; 0.4564472886428772; 0.4588513406515081; 0.4615352570710579; 0.4615352570710579; 0.466957409863091; 0.4675904598629673; 0.4704594475773637; 0.4704594475773637; 0.4714226702518064; 0.472444704048021; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4790179402069343; 0.4790179402069343; 0.479747709091007; 0.4852430673532381; 0.4923669467696064; 0.4923669467696064; 0.4981941174985421; 0.5019670090704682; 0.5019670090704682; 0.5251317541886066; 0.5284231402423694; 0.5299466034567416; 0.5305233935923577; 0.5337853752290136; 0.5359212109443033; 0.5453394612016188; 0.549941235475765; 0.553002957824355; 0.5557519470957561; 0.5578737381206628; 0.5619299124666532; 0.5655222348249326; 0.5655222348249326; 0.5710095678317721; 0.6035970790768342; 0.6035970790768342; 0.6150955455771212; 0.6150955455771212; 0.6304655343580164; 0.6319938293757544; 0.6319938293757544; 0.6319938293757544; 0.6319938293757544; 0.652707626880454; 0.6606366664484469; 0.6891882956008074; 0.7294281406818208; 0.7294281406818208; 0.7294281406818208; 0.7309076068378124; 0.7631684472516962; 0.7797826088609066; 0.7900704408991807; 0.8670707879649133; 0.8789568302467123; 0.882794167859443; 0.903232380243832,Congenital Anomalies Of Kidney And Urinary Tract; Liver Carcinoma; Schizophrenia; Elbow Flexion Contracture; Pulmonary Arterial Hypertension; Colorectal Cancer; Hemophagocytic Lymphohistiocytosis; Osteoporosis; Osteopenia; Frontal Bossing; Hypohidrosis; Trismus; Scoliosis; Prostatic Neoplasms; Asthma; Dysphagia; Micrognathism; Micromelia; Dwarfism; Skeletal Dysplasia; Osteochondrodysplasia; Prostate Cancer; Sclerocystic Ovaries; Talipes; Dysautonomia; Polycystic Ovary Syndrome; Pulmonary Hypoplasia; Hypothyroidism; Congenital Clubfoot,0.0075861267486594; 0.0520696613701797; 0.0531117779464085; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4402141802500753; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4875380732267193; 0.4875380732267193; 0.504364324740411; 0.5127628024019304; 0.5234357475824973; 0.525214105372123; 0.5796489603182782; 0.5796489603182782; 0.5878255556245724; 0.6104715460837368; 0.6508151871447407; 0.696610260564548; 0.7414460416900516; 0.7729545590606223; 0.7893608212024619; 0.7921294370722203; 0.950211794897412,"Atrial septal defect, ostium primum type ORPHA:99106; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Greig cephalopolysyndactyly syndrome ORPHA:380; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Ulnar-mammary syndrome ORPHA:3138; Branchiootic syndrome ORPHA:52429; Myelodysplastic syndrome ORPHA:52688; Brachydactyly type A2 ORPHA:93396; Waardenburg syndrome type 2 ORPHA:895; Bruck syndrome ORPHA:2771; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; CHST3-related skeletal dysplasia ORPHA:263463; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Diaphanospondylodysostosis ORPHA:66637; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial drusen ORPHA:75376; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; Hereditary neuropathy with liability to pressure palsies ORPHA:640; Ischiovertebral syndrome ORPHA:85200; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Mandibulofacial dysostosis with alopecia ORPHA:443995; Myopathic Ehlers-Danlos syndrome ORPHA:536516; Oculocutaneous albinism type 3 ORPHA:79433; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Retinal arterial tortuosity ORPHA:75326; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; X-linked osteoporosis with fractures ORPHA:391330; Congenital cataract microcornea with corneal opacity ORPHA:289499; Congenital diaphragmatic hernia ORPHA:2140; Hypoplastic left heart syndrome ORPHA:2248; Matthew-Wood syndrome ORPHA:2470; Piebaldism ORPHA:2884; Posterior hypospadias ORPHA:95706; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721; BOR syndrome ORPHA:107; Tetralogy of Fallot ORPHA:3303; X-linked Alport syndrome-diffuse leiomyomatosis ORPHA:1018; 15q14 microdeletion syndrome ORPHA:261190; Alpha-B crystallin-related late-onset myopathy ORPHA:399058; Autosomal dominant palmoplantar keratoderma and congenital alopecia ORPHA:1010; Autosomal dominant slowed nerve conduction velocity ORPHA:140481; Childhood-onset benign chorea with striatal involvement ORPHA:494541; Chronic enteropathy associated with SLCO2A1 gene ORPHA:468641; Distal myopathy with posterior leg and anterior hand involvement ORPHA:63273; Epidermolysis bullosa simplex due to BP230 deficiency ORPHA:412181; Familial generalized lentiginosis ORPHA:231040; Fatal infantile hypertonic myofibrillar myopathy ORPHA:280553; Helicoid peripapillary chorioretinal degeneration ORPHA:86813; Hereditary sensory and autonomic neuropathy type 6 ORPHA:314381; Infantile-onset generalized dyskinesia with orofacial involvement ORPHA:494526; Monoamine oxidase A deficiency ORPHA:3057; Muscle filaminopathy ORPHA:171445; NON RARE IN EUROPE: Benign familial hematuria ORPHA:97562; Oculodentodigital dysplasia ORPHA:2710; Optic atrophy-intellectual disability syndrome ORPHA:401777; Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome ORPHA:447961; Syndactyly type 3 ORPHA:93404; X-linked Alport syndrome ORPHA:88917; Autosomal recessive Robinow syndrome ORPHA:1507; Lacrimoauriculodentodigital syndrome ORPHA:2363; Non-seminomatous germ cell tumor of testis ORPHA:363494; Phakomatosis cesioflammea ORPHA:79483; Sclerosteosis ORPHA:3152; Brachydactyly type A1 ORPHA:93388; Hennekam syndrome ORPHA:2136; Hirschsprung disease ORPHA:388; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form ORPHA:293899; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form ORPHA:293888; 1p31p32 microdeletion syndrome ORPHA:401986; Allan-Herndon-Dudley syndrome ORPHA:59; Brachydactyly-arterial hypertension syndrome ORPHA:1276; Campomelic dysplasia ORPHA:140; Carbamoyl-phosphate synthetase 1 deficiency ORPHA:147; Complete androgen insensitivity syndrome ORPHA:99429; Dicarboxylic aminoaciduria ORPHA:2195; Female restricted epilepsy with intellectual disability ORPHA:101039; Hot water reflex epilepsy ORPHA:166412; Hypopigmentation-punctate palmoplantar keratoderma syndrome ORPHA:324561; Isolated Pierre Robin syndrome ORPHA:718; Kennedy disease ORPHA:481; Partial androgen insensitivity syndrome ORPHA:90797; Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome ORPHA:228012; Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome ORPHA:93358; Stuve-Wiedemann syndrome ORPHA:3206; Trehalase deficiency ORPHA:103909; Acromesomelic dysplasia, Grebe type ORPHA:2098; Autosomal recessive hypophosphatemic rickets ORPHA:289176; Brachydactyly type C ORPHA:93384; Familial patent arterial duct ORPHA:466729; Fibular aplasia-complex brachydactyly syndrome ORPHA:2639; Pfeiffer syndrome type 1 ORPHA:93258; Silver-Russell syndrome due to 11p15 microduplication ORPHA:231144; Silver-Russell syndrome due to an imprinting defect of 11p15 ORPHA:231140; Spondylometaphyseal dysplasia, 'corner fracture' type ORPHA:93315; Beckwith-Wiedemann syndrome due to imprinting defect of 11p15 ORPHA:231117; Butterfly-shaped pigment dystrophy ORPHA:99001; Complete atrioventricular septal defect with ventricular hypoplasia ORPHA:99067; Isolated aniridia ORPHA:250923; Isolated hemihyperplasia ORPHA:2128; Partial atrioventricular septal defect ORPHA:1330; Persistent hyperplastic primary vitreous ORPHA:91495; Retinopathy of prematurity ORPHA:90050; Epithelioid hemangioendothelioma ORPHA:157791; Isolated brachycephaly ORPHA:35099; Isolated plagiocephaly ORPHA:35098; Bilateral striopallidodentate calcinosis ORPHA:1980; Colobomatous microphthalmia ORPHA:98938; Familial isolated arrhythmogenic ventricular dysplasia, right dominant form ORPHA:293910; Arthrogryposis-oculomotor limitation-electroretinal anomalies syndrome ORPHA:1154; Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome ORPHA:370022; Autosomal recessive omodysplasia ORPHA:93329; Becker muscular dystrophy ORPHA:98895; Butyrylcholinesterase deficiency ORPHA:132; Charcot-Marie-Tooth disease type 2R ORPHA:397968; Frontonasal dysplasia-alopecia-genital anomalies syndrome ORPHA:228390; Gordon syndrome ORPHA:376; Isolated congenital breast hypoplasia/aplasia ORPHA:180188; Malignant epithelial tumor of salivary glands ORPHA:276145; Marden-Walker syndrome ORPHA:2461; Metopic ridging-ptosis-facial dysmorphism syndrome ORPHA:502430; Spinocerebellar ataxia type 27 ORPHA:98764; Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A ORPHA:308386; Symptomatic form of muscular dystrophy of Duchenne and Becker in female carriers ORPHA:206546; Autosomal recessive polycystic kidney disease ORPHA:731; Congenital ptosis ORPHA:91411; Renal hypoplasia, bilateral ORPHA:97362; Tetraamelia-multiple malformations syndrome ORPHA:3301; Complete atrioventricular septal defect-tetralogy of Fallot ORPHA:99068; Familial vesicoureteral reflux ORPHA:289365; Hypomyelination neuropathy-arthrogryposis syndrome ORPHA:2680; NON RARE IN EUROPE: Infantile capillary hemangioma ORPHA:464293; Saethre-Chotzen syndrome ORPHA:794; Renal agenesis, bilateral ORPHA:1848; Severe early-childhood-onset retinal dystrophy ORPHA:364055; Renal agenesis, unilateral ORPHA:93100; Brugada syndrome ORPHA:130; Autosomal recessive non-syndromic sensorineural deafness type DFNB ORPHA:90636; Achondroplasia ORPHA:15; Autosomal dominant spastic paraplegia type 31 ORPHA:101011; BNAR syndrome ORPHA:217266; Camptodactyly-tall stature-scoliosis-hearing loss syndrome ORPHA:85164; Crouzon syndrome-acanthosis nigricans syndrome ORPHA:93262; Hypochondroplasia ORPHA:429; Lissencephaly syndrome, Norman-Roberts type ORPHA:89844; Microphthalmia with limb anomalies ORPHA:1106; Monosomy 22q13.3 ORPHA:48652; Muenke syndrome ORPHA:53271; Obesity due to prohormone convertase I deficiency ORPHA:71528; Oculotrichoanal syndrome ORPHA:2717; Pontocerebellar hypoplasia type 3 ORPHA:97249; Severe achondroplasia-developmental delay-acanthosis nigricans syndrome ORPHA:85165; Severe hereditary thrombophilia due to congenital protein S deficiency ORPHA:743; Short rib-polydactyly syndrome, Saldino-Noonan type ORPHA:93270; Thanatophoric dysplasia type 1 ORPHA:1860; Thanatophoric dysplasia type 2 ORPHA:93274; Cenani-Lenz syndrome ORPHA:3258; Congenital communicating hydrocephalus ORPHA:269505; Duchenne muscular dystrophy ORPHA:98896; Isolated trigonocephaly ORPHA:3366; Hereditary hyperekplexia ORPHA:3197; Stargardt disease ORPHA:827; 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency ORPHA:168558; Autosomal dominant striatal neurodegeneration ORPHA:228169; Blomstrand lethal chondrodysplasia ORPHA:50945; Drug- or toxin-induced pulmonary arterial hypertension ORPHA:275786; Eiken syndrome ORPHA:79106; Hyperlysinemia ORPHA:2203; Inherited isolated adrenal insufficiency due to partial CYP11A1 deficiency ORPHA:289548; Metaphyseal chondrodysplasia, Jansen type ORPHA:33067; Primary failure of tooth eruption ORPHA:412206; Saccharopinuria ORPHA:3124; Wilson disease ORPHA:905; Benign hereditary chorea ORPHA:1429",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0092060390928213; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0277610005156803; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.0599424746210022; 0.0706635700002548; 0.0783959336694202; 0.0783959336694202; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.1614487935928034; 0.1614487935928034; 0.1697334635963512; 0.1782034488938806; 0.1981653781243822; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.3775879467205478; 0.3969770464111636; 0.5145066480201691; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6279395134845649; 0.6279395134845649; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,"Human adenovirus 41 E3 31.6K; Vaccinia virus hemagglutinin (gene: A56R); Human adenovirus 52 E3 CR1-beta1 (gene: E3); Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Human mastadenovirus A E3 CR1-beta1; Monkeypox virus bifunctional hemagglutinin/type-I membrane glycoprotein; Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta); Human adenovirus 18 CR1-beta protein (gene: E3)",0.6362779693488597; 0.6362779693488597; 0.6621265548536891; 0.6806291584193672; 0.6806291584193672; 0.8285661572509389; 0.870986154363754; 0.875442055263636; 0.9445347004229157,Homo sapiens,0.35,ebvb9,Homo sapiens
LINC02331,,,Endometrial Carcinoma,0.4286813331685578,,,,,,,,
LPAR5,melanoma; Fibrosarcoma; Neoplasm Metastasis; Osteosarcoma; Sarcoma; Osteosarcoma of bone; Secondary malignant neoplasm of lung; Epstein-Barr Virus Infections; Nasopharyngeal carcinoma,0.0149315928814189; 0.0191435238361999; 0.0648809611869375; 0.1029977559100099; 0.1537760235124317; 0.2109483801368481; 0.2723545094624877; 0.3933196962529684; 0.3933196962529684,,,Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944; Serrated polyposis syndrome ORPHA:157798,0.0180064224283883; 0.0180064224283883; 0.1590470395003315,,,,,,
LRIG1,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Squamous cell carcinoma; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Well Differentiated Oligodendroglioma; Neoplasm Metastasis; Renal Cell Carcinoma; oligodendroglioma; Glioma; Glioblastoma; Prostate carcinoma; Colorectal Neoplasms; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Chronic Lymphocytic Leukemia; Carcinoma of bladder; Solid Neoplasm; Malignant Head and Neck Neoplasm; Malignant neoplasm of lung; Kidney Neoplasm; Epithelial hyperplasia of skin; Carcinoma of lung; Primary malignant neoplasm of lung; Nasopharyngeal carcinoma; Malignant Glioma; Skin Neoplasms; Malignant Central Nervous System Neoplasm; Adenoma; Antibody measurement (procedure); Mean Corpuscular Volume (result); HIV-1 infection; QRS complex feature; Peripheral Neuropathy; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0569142010728473; 0.0617471306652618; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0739788831250619; 0.0745502070959292; 0.0773771948186562; 0.0827744840860166; 0.084286432100041; 0.0891725280554336; 0.1147307578771389; 0.13167400689206; 0.1413782599148022; 0.2522264785494494; 0.2714542429024338; 0.2714542429024338; 0.333745294913745; 0.3663130598151661; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.4192169590514327; 0.4506578937113162; 0.5140447474168605; 0.5851527280548257; 0.8352423037513227; 0.8352423037513227,Colorectal Cancer; Central Nervous System Neoplasms; Colorectal Neoplasms; Glioma; Colonic Neoplasms; Paroxysmal Atrial Fibrillation; Hyperuricemia; Atrial Fibrillation; Kidney Failure,0.4286813331685578; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4809179010794786; 0.5082542877462781; 0.6329251700753155; 0.6792162876553974; 0.6899894525110877,Renal pseudohypoaldosteronism type 1 ORPHA:171871; Autism spectrum disorder due to AUTS2 deficiency ORPHA:352490; Autosomal recessive spastic paraplegia type 56 ORPHA:320411; AXIN2-related attenuated familial adenomatous polyposis ORPHA:401911; Oligodontia-cancer predisposition syndrome ORPHA:300576,0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423,Human adenovirus 41 E3 31.6K; Human mastadenovirus A fiber; Human adenovirus 12 fiber protein; Monkeypox virus bifunctional IL-1-beta-inhibitor; Orf virus ORF132 vascular endothelial growth factor-like protein,0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.8154217170310376; 0.8507994162096807,,,,
LZTS1,"Colorectal Carcinoma; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Neoplasm Metastasis; Prostate carcinoma; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Esophageal carcinoma; Carcinoma, Transitional Cell; Carcinoma of bladder; TARSAL-CARPAL COALITION SYNDROME; Prostatic Neoplasms; Malignant neoplasm of lung; Malignant Squamous Cell Neoplasm; Carcinoma of lung; Recurrent tumor; Primary malignant neoplasm of lung; Secondary malignant neoplasm of lymph node; Benign neoplasm of esophagus; Carcinoma in situ of esophagus; Squamous cell carcinoma of skin; Uveal melanoma",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0248454592431097; 0.0277695594716545; 0.0569142010728473; 0.0648809611869375; 0.0773771948186562; 0.084286432100041; 0.0891725280554336; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.1906413554467301; 0.223747154820789; 0.2714542429024338; 0.3104232675696299; 0.3663130598151661; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.4297858918260954; 0.472444704048021,Esophagus Neoplasm; Carcinoma; Benign Neoplasm Of Esophagus; Prostatic Neoplasms; Esophageal Carcinoma; Prostate Cancer,0.0102679590519094; 0.0534520155998091; 0.4286813331685578; 0.4875380732267193; 0.5087473896242481; 0.6104715460837368,"Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome ORPHA:508533; Peripheral demyelinating neuropathy-central dysmyelinating leukodystrophy-Waardenburg syndrome-Hirschsprung disease ORPHA:163746; Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome ORPHA:83473; Familial osteochondritis dissecans ORPHA:251262; Oculocutaneous albinism type 4 ORPHA:79435; Oculocutaneous albinism type 6 ORPHA:370097; Porencephaly-microcephaly-bilateral congenital cataract syndrome ORPHA:306547; Short stature-advanced bone age-early-onset osteoarthritis syndrome ORPHA:435804; Spondyloepimetaphyseal dysplasia, aggrecan type ORPHA:171866; Spondyloepiphyseal dysplasia, Kimberley type ORPHA:93283; Autosomal recessive Stickler syndrome ORPHA:250984",0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
MBNL3,Liver carcinoma; Blast Phase; Intellectual Disability,0.095319386034013; 0.3494455519738624; 0.8352623613787349,,,,,,,,,,
ME1,"Breast Carcinoma; Colorectal Cancer; Carcinogenesis; Epithelial ovarian cancer; Neoplasm Metastasis; Glioma; Glioblastoma; Liver carcinoma; Malignant Neoplasms; Colon Carcinoma; Sarcoma; Uterine Corpus Sarcoma; Malignant tumor of colon; Carcinoma of lung; Primary malignant neoplasm of lung; Diabetes Mellitus, Non-Insulin-Dependent; Weight Gain; MRSA - Methicillin resistant Staphylococcus aureus infection; Obesity",0.0042545616049287; 0.0149315928814189; 0.0228075668512991; 0.0387439397151409; 0.0648809611869375; 0.0739788831250619; 0.0745502070959292; 0.095319386034013; 0.0991201145654548; 0.1062239757831962; 0.1537760235124317; 0.222537307875512; 0.223747154820789; 0.3663130598151661; 0.3902116649640871; 0.3933196962529684; 0.3975960596292668; 0.4506578937113162; 0.5140447474168605,Liver Carcinoma; Obesity,0.0520696613701797; 0.9568083835980838,Papillary renal cell carcinoma ORPHA:319298; Unverricht-Lundborg disease ORPHA:308; PPARG-related familial partial lipodystrophy ORPHA:79083; MITF-related melanoma and renal cell carcinoma predisposition syndrome ORPHA:293822; Tietz syndrome ORPHA:42665,0.0083045131203191; 0.0083744975290613; 0.0180064224283883; 0.1590470395003315; 0.1590470395003315,,,In vitro;yeasx,0.35;0.68,Homo sapiens,Homo sapiens;chemical synthesis
MED12L,"Usher Syndrome, Type III; Triglycerides measurement; Smoking Behaviors",0.4028066164685291; 0.4192169590514327; 0.5580691945487462,Platelet-type Bleeding Disorder; Alzheimer Disease; Diverticular Diseases; Non-Syndromic Intellectual Disability; Mental Retardation; Motor Delay,0.3940072377207739; 0.4560460337187313; 0.4560460337187313; 0.7015979603136192; 0.7729545590606223; 0.8371848756758566,Familial primary hypomagnesemia with normocalciuria and normocalcemia ORPHA:34527; FRAXE intellectual disability ORPHA:100973; Autosomal dominant non-syndromic intellectual disability ORPHA:178469; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to WWOX deficiency ORPHA:284282; Early-onset parkinsonism-intellectual disability syndrome ORPHA:2379,0.0586579655822394; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
MICB,"Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Malignant neoplasm of breast; Cervical Squamous Intraepithelial Neoplasia 1; Cervical intraepithelial neoplasia grade 1; Neoplasm Metastasis; Malignant neoplasm of pancreas; Glioma; Pancreatic carcinoma; Liver carcinoma; Malignant Neoplasms; Osteosarcoma; Rheumatoid Arthritis; cervical cancer; Osteosarcoma of bone; Hodgkin Disease; Thymus Hyperplasia; Neoplasms; Malignant tumor of cervix; Diabetes Mellitus, Insulin-Dependent; Cervix carcinoma; Multiple Sclerosis; Classical Hodgkin's Lymphoma; Addison's disease due to autoimmunity; hiv-infection/aids; Schizophrenia; Non-Small Cell Lung Carcinoma; Lymphoma, T-Cell, Cutaneous; DOSAGE-SENSITIVE SEX REVERSAL; Arthritis, Psoriatic; Inflammatory Bowel Diseases; Polybrominated biphenyl measurement; Asthma; Autoimmune Primary Adrenal Insufficiency; Communicable Diseases; Dengue Shock Syndrome; Dengue Fever; Gastric Adenocarcinoma; Severe Dengue; Multiple Myeloma; Ductal Carcinoma In Situ with Microinvasion; Lupus Erythematosus, Systemic; Leprosy, Paucibacillary; HIV-1 infection; Dejerine-Sottas Disease (disorder); Forced expiratory volume function; Crohn Disease; Ulcerative Colitis; Respiratory Syncytial Virus Infections; Thymoma; Primary sclerosing cholangitis; Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site; Infection; Myositis; Herpes Simplex Infections; Addison Disease; Immune System Diseases; Behcet Syndrome; Mucosa-Associated Lymphoid Tissue Lymphoma; Herpes NOS; Hepatitis C; Leprosy",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0593779966354549; 0.0593779966354549; 0.0648809611869375; 0.0726340460169901; 0.0739788831250619; 0.0745502070959292; 0.095319386034013; 0.0991201145654548; 0.1029977559100099; 0.1537760235124317; 0.2050045461627939; 0.2109483801368481; 0.2454476567103779; 0.2522264785494494; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2834835531038365; 0.2835142372342932; 0.3763374964032415; 0.3778347117514905; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4103119460235835; 0.4115056600660309; 0.4213286052188015; 0.4213286052188015; 0.4506578937113162; 0.4753011022966241; 0.4929829683479762; 0.4981941174985421; 0.5001612228394569; 0.533913711453195; 0.5523521032803237; 0.5682392297191953; 0.5710095678317721; 0.5959654688257199; 0.601753535647179; 0.610971999959321; 0.6304655343580164; 0.6319938293757544; 0.6496433426951205; 0.6740259274935673; 0.6980473696540115; 0.7169459458481418; 0.8297144684182294,Schizophrenia; Hodgkin Disease; Myositis; Rheumatoid Arthritis; Mental Depression; Asthma; Lupus Erythematosus; Behcet Syndrome; Myasthenia Gravis; Diabetes Mellitus,0.0531117779464085; 0.2627224344149009; 0.425341435586089; 0.4560460337187313; 0.4560460337187313; 0.504364324740411; 0.5087473896242481; 0.555382961603519; 0.7049836926927165; 0.9683912711598086,Combined immunodeficiency due to CD70 deficiency ORPHA:538958; Hydranencephaly ORPHA:2177; NDE1-related microhydranencephaly ORPHA:443162; Combined immunodeficiency with faciooculoskeletal anomalies ORPHA:221139; Congenital generalized hypercontractile muscle stiffness syndrome ORPHA:476406; Hermansky-Pudlak syndrome without pulmonary fibrosis ORPHA:231512; Amish lethal microcephaly ORPHA:99742; Autosomal recessive cerebellar ataxia due to CWF19L1 deficiency ORPHA:453521; Progressive polyneuropathy with bilateral striatal necrosis ORPHA:217396; Purine nucleoside phosphorylase deficiency ORPHA:760; Severe combined immunodeficiency due to adenosine deaminase deficiency ORPHA:277; Alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome ORPHA:86818,0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Human betaherpesvirus 5 membrane glycoprotein UL16 (gene: UL16); Human adenovirus 54 17.6 kDa protein; Human adenovirus 23 gp 19K protein (gene: E3); Human betaherpesvirus 5 membrane glycoprotein UL18 (gene: UL18); Molluscum contagiosum virus subtype 1 MC080R (gene: MC080R); Human betaherpesvirus 5 membrane glycoprotein UL142 (gene: UL142); Yaba-like disease virus 123R protein (gene: 123R); Yaba monkey tumor virus IEV and EEV membrane glycoprotein,0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6906952981256558; 0.8071041616616108; 0.8205168751208474; 0.8884451411763671; 0.945966103627342,,,,
MIR100HG,"Breast Carcinoma; Malignant neoplasm of breast; Medulloblastoma; Central neuroblastoma; Neuroblastoma; Myeloid Leukemia; Childhood Medulloblastoma; Acute Megakaryocytic Leukemias; Adult Medulloblastoma; Myopia, Degenerative",0.0042545616049287; 0.0191435238361999; 0.0354767239335874; 0.0593779966354549; 0.0688152422187159; 0.2980670559114652; 0.3933196962529684; 0.4115056600660309; 0.4126392832024548; 0.4459714599189374,Schizophrenia; Myopia; Stroke,0.0531117779464085; 0.7405519560111998; 0.7429124769329748,,,,,,,,
MIR17HG,"Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Hematopoietic Neoplasms; Medulloblastoma; Malignant neoplasm of prostate; Central neuroblastoma; Brain Neoplasms; Neoplasm Metastasis; Barrett Esophagus; Renal Cell Carcinoma; Neuroblastoma; Malignant neoplasm of pancreas; Glioma; Lymphoma; Glioblastoma; Pancreatic carcinoma; Carcinoma breast stage IV; Liver Cirrhosis; Prostate carcinoma; Squamous cell carcinoma of esophagus; Liver carcinoma; Malignant Neoplasms; Osteosarcoma; Colon Carcinoma; Chronic Lymphocytic Leukemia; Small cell carcinoma of lung; Hematologic Neoplasms; MYELODYSPLASTIC SYNDROME; Esophageal carcinoma; Solid Neoplasm; Colonic Neoplasms; Liver neoplasms; Rheumatoid Arthritis; cervical cancer; Gastrointestinal Neoplasms; Osteosarcoma of bone; Malignant tumor of colon; Hodgkin Disease; Burkitt Lymphoma; B-Cell Lymphomas; MIXED LINEAGE LEUKEMIA; Malignant neoplasm of liver; Adenocarcinoma Of Esophagus; Neoplasms; Malignant tumor of cervix; Malignant neoplasm of lung; Secondary malignant neoplasm of lung; Cervix carcinoma; Acute leukemia; Cirrhosis; Conventional (Clear Cell) Renal Cell Carcinoma; Triple Negative Breast Neoplasms; Pancreatic Ductal Adenocarcinoma; Gastrointestinal Stromal Tumors; Cholangiocarcinoma; Blast Phase; Ataxia Telangiectasia; Leukemogenesis; Rhabdomyosarcoma; Severe Combined Immunodeficiency; Carcinoma of lung; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Primary malignant neoplasm of lung; Diabetes Mellitus, Non-Insulin-Dependent; Nasopharyngeal carcinoma; Non-Small Cell Lung Carcinoma; Hypertensive disease; Leukemia, Myelocytic, Acute; Ulnar-mammary syndrome; Astrocytoma; Aplasia Cutis Congenita; Hemangiosarcoma; Hypoplasia of thumb; Lymphoma, Non-Hodgkin; Adenoid Cystic Carcinoma; Coronary heart disease; Glioblastoma Multiforme; Malignant neoplasm of kidney; Atrial Fibrillation; Acute Erythroblastic Leukemia; Renal carcinoma; Ki-1+ Anaplastic Large Cell Lymphoma; Microcephaly; Agenesis of corpus callosum; Multiple Myeloma; Hashimoto's encephalitis; Retinoblastoma; Adenoma of large intestine; Lupus Erythematosus, Systemic; Short middle phalanx of finger; Primary cutaneous B-cell lymphoma; Squamous cell carcinoma of skin; Lupus Vulgaris; Sinus Node Dysfunction (disorder); Short stature; Restenosis; leukemia; Lupus Erythematosus; Lupus Erythematosus, Discoid; Myeloid Leukemia, Chronic; Kaposi Sarcoma; Small head; Severe Congenital Microcephaly; Microlissencephaly; Anaplastic thyroid carcinoma; Growth Disorders; Dull intelligence; Low intelligence; Congenital Abnormality; Hepatocarcinogenesis; Limb Deformities, Congenital; Brachydactyly; Autoimmune Diseases; Poor school performance; Lymphoproliferative Disorders; Diffuse Large B-Cell Lymphoma; Bone Diseases, Developmental; Mental deficiency; Tumor Angiogenesis; Sezary Syndrome; Mental Retardation; Alveolar rhabdomyosarcoma; Marinesco-Sjogren syndrome; Malignant neoplasm of gastrointestinal tract; Intellectual Disability",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0334891258932371; 0.0354767239335874; 0.0569142010728473; 0.0593779966354549; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0773771948186562; 0.0919714360040484; 0.095319386034013; 0.0991201145654548; 0.1029977559100099; 0.1062239757831962; 0.1147307578771389; 0.1193558174333938; 0.1253114324938153; 0.1254380558571286; 0.1254380558571286; 0.1413782599148022; 0.1454373331146953; 0.1454373331146953; 0.1537760235124317; 0.2050045461627939; 0.2062010908869036; 0.2109483801368481; 0.223747154820789; 0.2454476567103779; 0.2521987644415915; 0.2522264785494494; 0.2605479444258003; 0.2643145809900195; 0.2679411586077776; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2723545094624877; 0.2834835531038365; 0.2835142372342932; 0.2923761731100008; 0.2980670559114652; 0.2980670559114652; 0.3018974726133723; 0.3199171478489988; 0.340892538685018; 0.3494455519738624; 0.3508665345292502; 0.3510063969122338; 0.3510063969122338; 0.3553621627681198; 0.3663130598151661; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4126392832024548; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4297858918260954; 0.4335751357405352; 0.4335751357405352; 0.439389586518055; 0.4396723023384634; 0.4588513406515081; 0.4615352570710579; 0.4675904598629673; 0.472444704048021; 0.4851378030288289; 0.4906258721078565; 0.4923669467696064; 0.4923669467696064; 0.4952592576151974; 0.5251317541886066; 0.5300976305939776; 0.5300976305939776; 0.5305233935923577; 0.533913711453195; 0.549941235475765; 0.549941235475765; 0.5512224939896888; 0.5610226870913673; 0.5696906826730043; 0.5913651925298382; 0.5916904943304121; 0.6035970790768342; 0.6218520979526325; 0.6248356417853507; 0.6319938293757544; 0.6355866602993508; 0.672336954961104; 0.8245140009975604; 0.8352623613787349,Hypoplasia Of Thumb; Congenital Anomaly Of Limb; Microcephaly; Microlissencephaly; Bone Disease; Dwarfism; Brachydactyly; Congenital Microcephaly; Coronary Heart Disease; Mental Retardation; Diabetes Mellitus,0.3094716280561038; 0.4602028929328057; 0.5123947823327547; 0.525214105372123; 0.5576425853515448; 0.5796489603182782; 0.6198128018123746; 0.657896505422784; 0.7726217084209973; 0.7729545590606223; 0.9683912711598086,,,,,,,,
MKNK2,Breast Carcinoma; Malignant neoplasm of breast; Medulloblastoma; Pancolitis; Pancreatic Ductal Adenocarcinoma; Cleft upper lip; Ulcerative Colitis; Diffuse Large B-Cell Lymphoma,0.0042545616049287; 0.0191435238361999; 0.0354767239335874; 0.2980670559114652; 0.3018974726133723; 0.4850576707687362; 0.5001612228394569; 0.5913651925298382,,,Neutral lipid storage myopathy ORPHA:98908; Triglyceride deposit cardiomyovasculopathy ORPHA:565612; Autosomal dominant Charcot-Marie-Tooth disease type 2M ORPHA:228179; Autosomal dominant intermediate Charcot-Marie-Tooth disease type B ORPHA:100044; Fetal akinesia-cerebral and retinal hemorrhage syndrome ORPHA:363409; Congenital chronic diarrhea with protein-losing enteropathy ORPHA:329242; Proteus syndrome ORPHA:744; Gray platelet syndrome ORPHA:721; Tubular aggregate myopathy ORPHA:2593; Autosomal dominant centronuclear myopathy ORPHA:169189,0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,"Yaba-like disease virus 142R protein (gene: 142R); Vaccinia virus ser/thr kinase (gene: B1R); Vaccinia virus Ankara Serine/threonine-protein kinase; Horsepox virus HSPV179 (Serine/Threonine protein kinase, Vaccinia Related Kinase); Variola virus hypothetical protein (gene: B1R); Monkeypox virus Zaire-96-I-16 B3R (gene: B3R); Molluscum contagiosum virus subtype 1 MC017L (gene: MC017L); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human gammaherpesvirus 8 ORF72; Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Yaba monkey tumor virus 142R; Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Ectromelia virus ERPV serine/threonine kinase; Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Monkeypox virus ser/thr kinase; Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3)",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.691145768348025; 0.6980058392556946; 0.7553529087917877; 0.8090912655264054; 0.8090912655264054; 0.8164631368980444; 0.8315214238833722; 0.8400145987535752; 0.8412554142619568; 0.8458935424065495; 0.8567113603862105; 0.8826243651582266; 0.960637237597315; 0.9782376397065295; 0.978680518510813; 0.9867877113290736; 0.988150003801932; 0.9886132556795868; 0.9886132556795868,yeasx,0.37,Homo sapiens,Homo sapiens
MRM1,,,,,Combined immunodeficiency due to CD70 deficiency ORPHA:538958; Auditory neuropathy-optic atrophy syndrome ORPHA:542585; Lipoyl transferase 2 deficiency ORPHA:447795; Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome ORPHA:543470; Schimke immuno-osseous dysplasia ORPHA:1830; Spinocerebellar ataxia type 4 ORPHA:98765; ALG1-CDG ORPHA:79327; Bjornstad syndrome ORPHA:123; GRACILE syndrome ORPHA:53693; Glutaryl-CoA dehydrogenase deficiency ORPHA:25; Hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome ORPHA:363694; NTHL1-related attenuated familial adenomatous polyposis ORPHA:454840; PYCR2-related microcephaly-progressive leukoencephalopathy ORPHA:481152; Renal tubulopathy-encephalopathy-liver failure syndrome ORPHA:254902; Testicular regression syndrome ORPHA:983; Hyperphosphatasia-intellectual disability syndrome ORPHA:247262; Hoyeraal-Hreidarsson syndrome ORPHA:3322,0.1590470395003315; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,In vitro;yeasx,0.35;0.56,Homo sapiens;chemical synthesis,Homo sapiens
MT1E,"Mammary Neoplasms; Breast Carcinoma; Invasive Ductal Breast Carcinoma; Malignant neoplasm of breast; Renal Cell Carcinoma; Glioma; Glioblastoma; Carcinoma breast stage IV; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Liver carcinoma; Carcinoma of bladder; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Solid Neoplasm; Colonic Neoplasms; Diabetes; Diabetes Mellitus; Neoplasms; Hyperbilirubinemia; Endometrial Carcinoma; Tuberculosis; Androgen-Insensitivity Syndrome; Non-Small Cell Lung Carcinoma; Amyotrophic Lateral Sclerosis, Sporadic; HIV Infections; Creutzfeldt-Jakob disease; Parkinson Disease; Epilepsy; Bronchiectasis; Substance abuse problem; Huntington Disease; Stage IV Breast Cancer AJCC v6 and v7; Lymphoma, Diffuse; Pneumonia",0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0191435238361999; 0.0648809611869375; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.084286432100041; 0.0891725280554336; 0.095319386034013; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1413782599148022; 0.1454373331146953; 0.2277108302018961; 0.2522264785494494; 0.2714542429024338; 0.2980670559114652; 0.3044782497745498; 0.3706856725676674; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.4028066164685291; 0.4615352570710579; 0.4704594475773637; 0.4753011022966241; 0.5916904943304121; 0.924303335582991,Liver Carcinoma,0.0520696613701797,Hereditary arterial and articular multiple calcification syndrome ORPHA:289601,0.00518481975049,,,,,,
MYBL1,Glioma; Lymphoma; Adenoid cystic carcinoma of salivary gland; Mixed Salivary Gland Tumor; Acute Myeloid Leukemia (AML-M2); B-Cell Lymphomas; Malignant Glioma; Aplasia Cutis Congenita; Adenoid Cystic Carcinoma; Agenesis of corpus callosum; Polycystic Ovary Syndrome; Diffuse Astrocytoma; Sclerocystic Ovaries; mixed gliomas,0.0739788831250619; 0.0739788831250619; 0.0775520919998773; 0.1454373331146953; 0.2050045461627939; 0.2522264785494494; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.4103119460235835; 0.5337853752290136; 0.6304655343580164; 0.652707626880454; 0.655573080043894,Glioma; Adenocarcinoma; Sclerocystic Ovaries; Polycystic Ovary Syndrome,0.4560460337187313; 0.4780231573499264; 0.6508151871447407; 0.7729545590606223,Brachydactyly type B2 ORPHA:140908; Stapes ankylosis with broad thumbs and toes ORPHA:140917; Tarsal-carpal coalition syndrome ORPHA:1412,0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
MYO15B,,,,,"Acute myeloid leukemia with CEBPA somatic mutations ORPHA:319480; Calpain-3-related  limb-girdle muscular dystrophy R1 ORPHA:267; 2q37 microdeletion syndrome ORPHA:1001; Adult-onset dystonia-parkinsonism ORPHA:199351; Birt-Hogg-Dube syndrome ORPHA:122; Diencephalic-mesencephalic junction dysplasia ORPHA:319192; Familial spontaneous pneumothorax ORPHA:2903; Infantile neuroaxonal dystrophy ORPHA:35069; NON RARE IN EUROPE: Berger disease ORPHA:34145; Congenital chronic diarrhea with protein-losing enteropathy ORPHA:329242; Imerslund-Grasbeck syndrome ORPHA:35858; NON RARE IN EUROPE: Alzheimer disease ORPHA:238616; Cherubism ORPHA:184; Craniosynostosis-dental anomalies ORPHA:284149; Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome ORPHA:352530; Malonic aciduria ORPHA:943; Megaconial congenital muscular dystrophy ORPHA:280671; Methylmalonic acidemia with homocystinuria, type cblJ ORPHA:369955; Proximal myopathy with focal depletion of mitochondria ORPHA:521305; X-linked dominant chondrodysplasia, Chassaing-Lacombe type ORPHA:163966; Congenital sodium diarrhea ORPHA:103908; Hereditary diffuse leukoencephalopathy with axonal spheroids and pigmented glia ORPHA:313808; Nephrogenic diabetes insipidus ORPHA:223; Primary sclerosing cholangitis ORPHA:171; Autosomal systemic lupus erythematosus ORPHA:300345",0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Papiine alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5); Monkeypox virus ankyrin-like protein,0.6362779693488597; 0.8426793553344071,,,,
NCALD,Diabetic Nephropathy,0.3938591532700354,Mental Depression; Cardiovascular Diseases,0.4560460337187313; 0.554079268109006,Megalencephalic leukoencephalopathy with subcortical cysts ORPHA:2478; Acquired schizencephaly ORPHA:485275; Autosomal dominant hypophosphatemic rickets ORPHA:89937; Primary hyperaldosteronism-seizures-neurological abnormalities syndrome ORPHA:369929; Sinoatrial node dysfunction and deafness ORPHA:324321; Macrocephaly-intellectual disability-autism syndrome ORPHA:210548; NON RARE IN EUROPE: Tourette syndrome ORPHA:856,0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
NCEH1,Parkinson Disease; Arteriosclerosis; Atherosclerosis,0.3933196962529684; 0.5019670090704682; 0.5393787854381349,Leukemia,0.7167438233451096,"PPARG-related familial partial lipodystrophy ORPHA:79083; Recessive X-linked ichthyosis ORPHA:461; Syndromic recessive X-linked ichthyosis ORPHA:281090; Pyridoxal phosphate-responsive seizures ORPHA:79096; Pyruvate dehydrogenase phosphatase deficiency ORPHA:79246; Sandhoff disease, adult form ORPHA:309169; Sandhoff disease, infantile form ORPHA:309155; Sandhoff disease, juvenile form ORPHA:309162; Familial Alzheimer-like prion disease ORPHA:280397; Fatal familial insomnia ORPHA:466; Gerstmann-Straussler-Scheinker syndrome ORPHA:356; Huntington disease-like 1 ORPHA:157941; Inherited Creutzfeldt-Jakob disease ORPHA:282166; Kuru ORPHA:454745; PrP systemic amyloidosis ORPHA:397606; Sporadic fatal insomnia ORPHA:586130",0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Yaba monkey tumor virus monoglyceride lipase,0.6362779693488597,Homo sapiens;Homo sapiens A549 lung carcinoma cell;Homo sapiens HEK293T embryonic kidney cell;Homo sapiens QGY7703 hepatocellular carcinoma cell;In vitro,0.35;0.53,Homo sapiens;Human SARS coronavirus;Human coronavirus 229E;Human papillomavirus type 11;Human papillomavirus type 6b;SARS-CoV-2;ade05;canen;chltr;ebvb9,Homo sapiens
NEU1,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Epithelioma; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Adenocarcinoma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Epithelial ovarian cancer; Malignant neoplasm of prostate; Neoplasm Metastasis; Renal Cell Carcinoma; Glioblastoma; Carcinoma breast stage IV; Prostate carcinoma; Lysosomal Storage Diseases; Osteosarcoma; Ductal Breast Carcinoma; Carcinoma, Transitional Cell; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Invasive Carcinoma; Comedone; Clouding of corneal stroma; TARSAL-CARPAL COALITION SYNDROME; Seizures; Corneal Opacity; Osteosarcoma of bone; Cataract; Nervous System Neoplasms; Malignant neoplasm of lung; Secondary malignant neoplasm of lung; Triple Negative Breast Neoplasms; Endometrial Carcinoma; Cholangiocarcinoma; Pfaundler-Hurler Syndrome; Carcinoma of lung; Noninfiltrating Intraductal Carcinoma; Primary malignant neoplasm of lung; Secondary malignant neoplasm of lymph node; Plaque, Amyloid; Adenocarcinoma of large intestine; Hernia, Inguinal; Non-small cell lung cancer stage I; Malignant Glioma; Non-Small Cell Lung Carcinoma; Skin Diseases, Vascular; Bone-marrow foam cells; Carcinoma, Papillary; Astrocytoma; Cystadenocarcinoma, Serous; Alzheimer's Disease; beta-Galactosidase Deficiency; Type I Mucolipidosis; Cerebral cortex myoclonus; Secondary malignant neoplasm of axilla; Vacuolated lymphocytes; Cherry red spot of the macula; Epilepsy; Ewing's sarcoma of bone; Nephritis; Senile Plaques; IGA Glomerulonephritis; Adenocarcinoma of the gastroesophageal junction; Breast cancer stage II; GALACTOSIALIDOSIS; Gangliosidosis GM1; HER2 gene amplification; Pituitary Diseases; Mammary Tumorigenesis; Mucolipidoses; Splenomegaly; Hyperammonemia; Hyperkeratosis; Lens Opacities; Thrombocytopenia; Storage disease; Atypical Inclusion-Body Disease; Biotin-Responsive Encephalopathy; Familial Progressive Myoclonic Epilepsy; May-White Syndrome; Ovarian adenocarcinoma; Neurilemmoma; Slurred speech; Action Myoclonus-Renal Failure Syndrome; Congenital pectus carinatum; Short stature; Thick lower lip vermilion; Abnormal skeletal development; Full lower lip; Precancerous Conditions; Hepatomegaly; Hydrops Fetalis, Non-Immune; Osteochondrodysplasias; Tremor; Stippled epiphyses; Paget Disease Extramammary; Transitional cell carcinoma of bladder; Hyperglycemia; Unverricht-Lundborg Syndrome; Hydrops Fetalis; Acquired scoliosis; Paget Disease; Short thorax; Dull intelligence; Low intelligence; Congenital Abnormality; Eye Abnormalities; Hernia; Abnormal form of the vertebral bodies; Ascites; Spasmodic movement; Involuntary jerking movements; Poor school performance; Abnormal urinary amino-acid findings; Biliary Tract Cancer; Endometrial adenocarcinoma; Frontal bossing; Cerebellar Ataxia; Aminoaciduria; Decreased nerve conduction velocity; Progressive visual loss; Decreased visual acuity, progressive; Ductal Carcinoma; Curvature of spine; Mental deficiency; Broad flat nasal bridge; Thickened facial skin with coarse facial features; Coarse facial features; Nasal bridge wide; Myoclonus; Dentatorubral-Pallidoluysian Atrophy; Mental Retardation; Cardiomegaly; Retinal Diseases; Osteitis Deformans; Cerebellar Dysmetria; Sensorineural Hearing Loss (disorder); Delayed bone age; Proteinuria; Cardiomyopathies; Myoclonic Epilepsies, Progressive; Gait abnormality; Speech Disorders; Skeletal muscle atrophy; Neurogenic muscle atrophy, especially in the lower limbs; Generalized hypotonia; Neurogenic Muscular Atrophy; Muscle hypotonia; Visual Impairment; Muscle degeneration; Low Vision; Electroencephalogram abnormal; Intellectual Disability; Hyperreflexia; Muscle Weakness; Nystagmus",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0387439397151409; 0.0569142010728473; 0.0648809611869375; 0.0648809611869375; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0798053340865682; 0.1029977559100099; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1602092191314262; 0.1735868515093891; 0.1859959283872542; 0.1906413554467301; 0.2053083986145698; 0.2085938372806741; 0.2109483801368481; 0.223747154820789; 0.2569222032997501; 0.2714542429024338; 0.2723545094624877; 0.2980670559114652; 0.3044782497745498; 0.340892538685018; 0.3508665345292502; 0.3663130598151661; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4103119460235835; 0.4115056600660309; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.425419812815905; 0.4304973629098372; 0.4335751357405352; 0.439389586518055; 0.4396723023384634; 0.4396723023384634; 0.4396723023384634; 0.4479115285676636; 0.4506578937113162; 0.4506578937113162; 0.4561717689698902; 0.4564472886428772; 0.4753011022966241; 0.4753011022966241; 0.4790179402069343; 0.4906258721078565; 0.4906258721078565; 0.4990401620718274; 0.5019670090704682; 0.5140447474168605; 0.5299466034567416; 0.5300976305939776; 0.5300976305939776; 0.5305233935923577; 0.5359212109443033; 0.5359212109443033; 0.5453394612016188; 0.549941235475765; 0.5514573300659174; 0.5514573300659174; 0.5610226870913673; 0.5619299124666532; 0.563120546412355; 0.5655222348249326; 0.5710095678317721; 0.5754799679683854; 0.5768212166102149; 0.5768212166102149; 0.5768212166102149; 0.5916904943304121; 0.6002127202571572; 0.6035970790768342; 0.6035970790768342; 0.6196470808426647; 0.6207008101484466; 0.6222451141623291; 0.6238969878903416; 0.625112405383346; 0.6304655343580164; 0.6319938293757544; 0.6332132835539771; 0.655573080043894; 0.6761967139251879; 0.6878314377608323; 0.6891882956008074; 0.6910672612216457; 0.6925751397474874; 0.6989462176022242; 0.7045203904267408; 0.7138331851025355; 0.717484976234209; 0.7511668779991656; 0.7511668779991656; 0.7631684472516962; 0.7720422491171346; 0.7965733310657268; 0.8098594112577364; 0.8198848943907875; 0.8225089178916923; 0.8257883659984262; 0.8352623613787349; 0.869420268668135; 0.9042453170318407; 0.926001913794773,"Schizophrenia; Pfaundler-Hurler Syndrome; Mucolipidosis; Skin Diseases, Vascular; Frontal Bossing; Inclusion-Body Disease; May-White Syndrome; Dentatorubral Pallidoluysian Atrophy; Action Myoclonus-Renal Failure Syndrome; Scoliosis; Hyperkeratosis; Vitiligo; Hearing Loss; Dwarfism; Skeletal Dysplasia; Osteochondrodysplasia; Myoclonic Epilepsy; Congenital Pectus Carinatum; Speech Disorders; Retinal Diseases; Cataract; Hydrops Fetalis; Mental Retardation; Cardiomyopathy; Nystagmus",0.0531117779464085; 0.3940072377207739; 0.4286813331685578; 0.4560460337187313; 0.4560460337187313; 0.4602028929328057; 0.4602028929328057; 0.4602028929328057; 0.4646409362700993; 0.4875380732267193; 0.4875380732267193; 0.5576425853515448; 0.5632819212593052; 0.5796489603182782; 0.5796489603182782; 0.5878255556245724; 0.6098159321331; 0.6104715460837368; 0.6239791345488227; 0.6329251700753155; 0.6660731887258019; 0.7378537370641419; 0.7729545590606223; 0.8407264689819682; 0.9146877763175152,"Tay-Sachs disease, B variant, adult form ORPHA:309192; Tay-Sachs disease, B variant, infantile form ORPHA:309178; Tay-Sachs disease, B variant, juvenile form ORPHA:309185; Tay-Sachs disease, B1 variant ORPHA:309239; Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency ORPHA:95699; Fetal Gaucher disease ORPHA:85212; Free sialic acid storage disease, infantile form ORPHA:309324; Gaucher disease type 2 ORPHA:77260; Gaucher disease type 3 ORPHA:77261; Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome ORPHA:2072; Intermediate severe Salla disease ORPHA:309331; NON RARE IN EUROPE: Parkinson disease ORPHA:319705; Salla disease ORPHA:309334; Niemann-Pick disease type C, adult neurologic onset ORPHA:216986; Niemann-Pick disease type C, juvenile neurologic onset ORPHA:216981; Niemann-Pick disease type C, late infantile neurologic onset ORPHA:216978; Niemann-Pick disease type C, severe early infantile neurologic onset ORPHA:216975; Niemann-Pick disease type C, severe perinatal form ORPHA:216972; Fucosidosis ORPHA:349; Sandhoff disease, adult form ORPHA:309169; Sandhoff disease, infantile form ORPHA:309155; Sandhoff disease, juvenile form ORPHA:309162; Behavioral variant of frontotemporal dementia ORPHA:275864; Biotinidase deficiency ORPHA:79241; Congenital sialidosis type 2 ORPHA:93400; GM1 gangliosidosis type 1 ORPHA:79255; GM1 gangliosidosis type 2 ORPHA:79256; GM1 gangliosidosis type 3 ORPHA:79257; Juvenile sialidosis type 2 ORPHA:93399; Mucopolysaccharidosis type 4B ORPHA:309310; Sialidosis type 1 ORPHA:812; NON RARE IN EUROPE: Hidradenitis suppurativa ORPHA:387",0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6522156347158065; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens HEK293T embryonic kidney cell;In vitro,0.35;0.53,Homo sapiens;SARS-CoV-2;chemical synthesis,Homo sapiens
NGFR,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Epithelioma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Squamous cell carcinoma; Malignant mesothelioma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Medulloblastoma; Epithelial ovarian cancer; Malignant neoplasm of prostate; Central neuroblastoma; Neoplasm Metastasis; Neuroblastoma; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Glioma; Pancreatic carcinoma; Liver Cirrhosis; Prostate carcinoma; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Squamous cell carcinoma of esophagus; Liver carcinoma; Chronic Lymphocytic Leukemia; Small cell carcinoma of lung; Carcinoma of bladder; Unipolar Depression; Hypertension, Portal; Sarcoma; Visual seizure; Seizures; Major Depressive Disorder; Prostatic Neoplasms; Diabetes; Hodgkin Disease; Diabetes Mellitus; Nervous System Neoplasms; Clear cell sarcoma of kidney; Mastocytoma; Secondary malignant neoplasm of lung; Acute leukemia; Cirrhosis; Benign Mastocytoma; Neuroepithelioma; Glaucoma; Epithelial hyperplasia of skin; Mast Cell Neoplasm; Complex partial seizures; Childhood Brain Neoplasm; Amyloidosis; Myelomonocytic leukemia; Fibrillation; Hamartoma; Generalized seizures; Pancreatitis, Chronic; Kidney Diseases; Papillary thyroid carcinoma; Schizophrenia; Seizures, Focal; Chronic liver disease; Hypertensive disease; RIPPLING MUSCLE DISEASE 1; Other specified senile psychotic conditions; Soft Tissue Neoplasms; Astrocytoma; Alzheimer's Disease; Rippling muscle disease; Myelolipoma; Prolactinoma; Acute lymphocytic leukemia; Triploidy syndrome; Stomach Neoplasms; Fibrosis, Liver; Acute Promyelocytic Leukemia; Amyloid Neuropathies; Granulomatous Disease, Chronic, X-Linked; Glioblastoma Multiforme; Hypopharyngeal Cancer; Single Seizure; Seizures, Auditory; Seizures, Clonic; Seizures, Sensory; Seizures, Somatosensory; Vertiginous seizure; Atonic Absence Seizures; Generalized Absence Seizures; Gustatory seizure; Jacksonian Seizure; Non-epileptic convulsion; Nonepileptic Seizures; Olfactory seizure; Autism Spectrum Disorders; Epileptic Seizures; Mental Depression; Tonic Seizures; Ischemia; Rabies (disorder); HSAN Type IV; Myeloid neoplasm; Amyotrophic Lateral Sclerosis; Convulsive Seizures; Depressive disorder; IGA Glomerulonephritis; Neuroectodermal Tumor, Primitive; Epileptic drop attack; Convulsions; Absence Seizures; Malignant Peripheral Nerve Sheath Tumor; Cervical Disc Degenerative Disorder; Congenital Hypothyroidism; Hypopharyngeal Carcinoma; Immunologic Deficiency Syndromes; Central Nervous System Embryonal Tumor, Not Otherwise Specified; Congestive heart failure; Heart failure; Leukaemia recurrent; Myxoid cyst; Neurofibromatosis 1; Neurodegenerative Disorders; Neuropathy; Adenocarcinoma of prostate; Endemic Cretinism; leukemia; Diabetic Neuropathies; Myoclonic Seizures; Charcot-Marie-Tooth Disease, Type Ia (disorder); Pain; Tonic - clonic seizures; Memory impairment; Erythema; Degenerative Diseases, Spinal Cord; Polycystic Ovary Syndrome; Respiratory Syncytial Virus Infections; Degenerative Diseases, Central Nervous System; Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site; Peripheral Neuropathy; Body Height; Cystitis; Lichen Planus, Oral; Other specified transient cerebral ischemias; Hereditary pancreatitis; Keratoconus; Dermatitis, Atopic; Fanconi Anemia; Transient Ischemic Attack; Sciatic Neuropathy; Liver diseases; Infarction, Middle Cerebral Artery; Eczema; FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder); Nerve Degeneration",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0354767239335874; 0.0387439397151409; 0.0569142010728473; 0.0593779966354549; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0773771948186562; 0.0773771948186562; 0.084286432100041; 0.0891725280554336; 0.0919714360040484; 0.095319386034013; 0.1147307578771389; 0.1193558174333938; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1537760235124317; 0.1735868515093891; 0.2053083986145698; 0.21122597829463; 0.223747154820789; 0.2277108302018961; 0.2454476567103779; 0.2522264785494494; 0.2569222032997501; 0.2714542429024338; 0.2714542429024338; 0.2723545094624877; 0.2835142372342932; 0.2923761731100008; 0.2980670559114652; 0.3099246715197673; 0.3105909001629992; 0.333745294913745; 0.3508665345292502; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.39623320406434; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4037249857069285; 0.4103119460235835; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.4304973629098372; 0.4304973629098372; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4421745246585178; 0.4506578937113162; 0.4588513406515081; 0.4615352570710579; 0.4615352570710579; 0.4753011022966241; 0.4871698998714747; 0.4919605488358906; 0.5188223685230745; 0.5299466034567416; 0.5299466034567416; 0.5337853752290136; 0.533913711453195; 0.5359212109443033; 0.5710095678317721; 0.5851527280548257; 0.5936773368594411; 0.5956632182199403; 0.6222451141623291; 0.6274540883972485; 0.6447029562500783; 0.652707626880454; 0.7045203904267408; 0.7053337831155875; 0.7061487180640408; 0.7240930522443176; 0.7337030585693298; 0.7815030391631113; 0.7893058450619891; 0.8064248359603999; 0.8326859687569312,"Schizophrenia; Mental Depression; Prostatic Neoplasms; Jacksonian Seizure; Seizure; Neurodegenerative Disorders; Degenerative Diseases, Central Nervous System; Clonic Seizures; Prostate Cancer; Hypotonic Seizures",0.0531117779464085; 0.4560460337187313; 0.4875380732267193; 0.5234357475824973; 0.5576425853515448; 0.5576425853515448; 0.5576425853515448; 0.5762801672039276; 0.6104715460837368; 0.6344671175966539,Familial avascular necrosis of femoral head ORPHA:86820,0.6239678957896782,Papiine alphaherpesvirus 2 envelope glycoprotein D (gene: US6); Cercopithecine alphaherpesvirus 2 envelope glycoprotein D (gene: US6); Cercopithecine betaherpesvirus 5 membrane glycoprotein UL144 (gene: UL144); Human betaherpesvirus 5 membrane protein UL14 (gene: UL14); Human alphaherpesvirus 1 envelope glycoprotein D (gene: US6); Macacine alphaherpesvirus 1 envelope glycoprotein D (gene: US6),0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6462089477181691; 0.7444198880830654,,,,
NOLC1,Colorectal Carcinoma; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; Squamous cell carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Epithelial ovarian cancer; Malignant neoplasm of prostate; Neoplasm Metastasis; Lymphoma; Glioblastoma; Prostate carcinoma; Liver carcinoma; Small cell carcinoma of lung; Rheumatoid Arthritis; Seizures; Mandibulofacial Dysostosis; Embryonal Carcinoma; Nasopharyngeal carcinoma; Retinoblastoma; Refractory anemias; Papilloma; Cardiac Arrest; Herpes Simplex Infections,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0387439397151409; 0.0569142010728473; 0.0648809611869375; 0.0739788831250619; 0.0745502070959292; 0.0773771948186562; 0.095319386034013; 0.1193558174333938; 0.1537760235124317; 0.2053083986145698; 0.2643145809900195; 0.3112516166225269; 0.3933196962529684; 0.4115056600660309; 0.421267417774367; 0.425992946703162; 0.5453394612016188; 0.610971999959321,,,"Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome ORPHA:544488; Acute myeloid leukemia with NPM1 somatic mutations ORPHA:402026; Autosomal dominant Charcot-Marie-Tooth disease type 2N ORPHA:228174; Autosomal dominant spastic paraplegia type 13 ORPHA:100994; Burkitt lymphoma ORPHA:543; Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome ORPHA:391376; Hyper-IgM syndrome type 5 ORPHA:101092; Mutilating hereditary sensory neuropathy with spastic paraplegia ORPHA:139578; Pelizaeus-Merzbacher-like disease due to HSPD1 mutation ORPHA:280288; Reticular dysgenesis ORPHA:33355; Severe combined immunodeficiency due to CTPS1 deficiency ORPHA:420573; Dubowitz syndrome ORPHA:235; Lujan-Fryns syndrome ORPHA:776; 1q44 microdeletion syndrome ORPHA:238769; AICA-ribosiduria ORPHA:250977; Autosomal dominant intermediate Charcot-Marie-Tooth disease type C ORPHA:100045; Autosomal recessive spastic ataxia with leukoencephalopathy ORPHA:314603; Brain calcification, Rajab type ORPHA:178506; Combined oxidative phosphorylation defect type 25 ORPHA:447954; EVEN-plus syndrome ORPHA:496751; Exercise-induced hyperinsulinism ORPHA:165991; Growth delay-intellectual disability-hepatopathy syndrome ORPHA:541423; Hereditary North American Indian childhood cirrhosis ORPHA:168583; Hereditary sensory and autonomic neuropathy type 8 ORPHA:478664; Hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome ORPHA:528091; Ketoacidosis due to monocarboxylate transporter-1 deficiency ORPHA:438075; Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome ORPHA:314051; Metabolic myopathy due to lactate transporter defect ORPHA:171690; Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome ORPHA:477993; Phosphoserine aminotransferase deficiency, infantile/juvenile form ORPHA:284417; Spinal muscular atrophy with respiratory distress type 2 ORPHA:404521; Spinocerebellar ataxia type 36 ORPHA:276198; Autosomal recessive sideroblastic anemia ORPHA:260305; Desmoplastic small round cell tumor ORPHA:83469; Inclusion body myopathy with Paget disease of bone and frontotemporal dementia ORPHA:52430; Microphthalmia, Lenz type ORPHA:568; Wilson-Turner syndrome ORPHA:3459; Familial isolated hyperparathyroidism ORPHA:99879; Hypomyelination-hypogonadotropic hypogonadism-hypodontia syndrome ORPHA:88637; Clear cell sarcoma of kidney ORPHA:457246",0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens CACO2 Caucasian colon adenocarcinoma cell;In vitro,0.35,SARS-CoV-2;chemical synthesis,Homo sapiens
NR4A2,"Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Malignant neoplasm of prostate; Central neuroblastoma; Mucoepidermoid Carcinoma; Neuroblastoma; inflammatory joint disease; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Colorectal Neoplasms; Bladder Neoplasm; Liver carcinoma; Colon Carcinoma; MYELODYSPLASTIC SYNDROME; Arsenic Poisoning, Inorganic; Nervous System, Organic Arsenic Poisoning; Arsenic Encephalopathy; Arsenic Induced Polyneuropathy; Arsenic Poisoning; Unipolar Depression; Hyperactive behavior; Rheumatoid Arthritis; Seizures; Major Depressive Disorder; Malignant tumor of colon; Neuroblastic tumors; Opiate Addiction; Malignant neoplasm of lung; Language Disorders; Cervix carcinoma; Multiple Sclerosis; Sjogren's Syndrome; Postural instability; Carcinoma of lung; Mask-like facies; Primary malignant neoplasm of lung; Muscle Rigidity; Secondary malignant neoplasm of lymph node; Bipolar Disorder; Neuronal loss in central nervous system; Schizophrenia; Adrenocortical carcinoma; Secondary malignant neoplasm of liver; Neurobehavioral Manifestations; Arthritis, Psoriatic; Alzheimer's Disease; Short stepped shuffling gait; Intestinal Polyps; Parkinson Disease; Adenoma; Voice Fatigue; Hypophonia; Depressive disorder; Parkinsonian tremor; Gastric Adenocarcinoma; Bradykinesia; Cerebrovascular accident; Juvenile arthritis; Cortical Dysplasia; Cocaine Abuse; Precocious Puberty; Progressive supranuclear palsy; Lewy Body Disease; Encephalomyelitis; Psoriasis; Urgency frequency syndrome; Restenosis; Resting Tremor; Chronic arthritis; Dystonic disease; Urgency of micturition; Overactive Bladder; Overactive bladder syndrome; Personality change; Cardiovascular Diseases; Juvenile psoriatic arthritis; Juvenile-Onset Still Disease; Dermatologic disorders; Sleep disturbances; Parkinson Disease, Familial, Type 1; Alcoholic Intoxication, Chronic; Memory impairment; Deglutition Disorders; Autoimmune Diseases; Arthritis; Psychotic symptom; Tauopathies; Parkinsonian Disorders; Other specified types of schizophrenia, unspecified; Adenosquamous carcinoma; SCHIZOPHRENIA 1 (disorder); Angelman Syndrome; Tumor Angiogenesis; Dystonia; Dementia; Sepsis; PARKINSON DISEASE, LATE-ONSET; Septicemia; Dysarthria; Attention deficit hyperactivity disorder; Developmental Disabilities; Dyschezia; Constipation",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0191435238361999; 0.0569142010728473; 0.0593779966354549; 0.0648809611869375; 0.0688152422187159; 0.0745502070959292; 0.0773771948186562; 0.0775520919998773; 0.0827744840860166; 0.0891725280554336; 0.095319386034013; 0.1062239757831962; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1387448809655294; 0.1537760235124317; 0.2053083986145698; 0.21122597829463; 0.223747154820789; 0.2522264785494494; 0.2643145809900195; 0.2714542429024338; 0.2747883228704706; 0.2834835531038365; 0.2835142372342932; 0.3099246715197673; 0.3220099003872086; 0.3663130598151661; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.4209380602168584; 0.4213286052188015; 0.424575176503444; 0.4254307049060398; 0.4304973629098372; 0.4335751357405352; 0.4396723023384634; 0.4396723023384634; 0.4459714599189374; 0.4459714599189374; 0.4564472886428772; 0.4615352570710579; 0.4615352570710579; 0.4615352570710579; 0.4675904598629673; 0.472444704048021; 0.4810435657134442; 0.4906258721078565; 0.4929829683479762; 0.4981941174985421; 0.5097818625871164; 0.5188223685230745; 0.5284231402423694; 0.5512224939896888; 0.553002957824355; 0.5619299124666532; 0.5682392297191953; 0.5683976277847906; 0.582492855487907; 0.5916904943304121; 0.6035970790768342; 0.610971999959321; 0.6218520979526325; 0.6334536292962906; 0.6364853529519863; 0.6395767498329145; 0.717484976234209; 0.8064248359603999; 0.8464957591845941; 0.8600100703665297; 0.8701913670211346; 0.8815334766742503; 0.9122550445311894,"Schizophrenia; Arsenic Encephalopathy; Dermatologic Disorders; Language Disorders; Parkinson Disease; Colorectal Cancer; Arthritis; Mental Depression; Colorectal Neoplasms; Juvenile Arthritis; Polyarthritis, Rheumatoid Factor Positive; Seronegative Polyarthritis; Bipolar Disorder; Dementia; Still Disease; Dysphagia; Psoriatic Arthritis; Mental Retardation; Dyssomnia; Sleep Disorders; Dysarthria; Autism",0.0531117779464085; 0.185736315425117; 0.2895940391390291; 0.3094716280561038; 0.4286813331685578; 0.4286813331685578; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4646409362700993; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.504364324740411; 0.5127628024019304; 0.6130153808924363; 0.7729545590606223; 0.8849119011111558; 0.9055059991400024; 0.9724404706118156; 0.9783327858636056,Charcot-Marie-Tooth disease type 1D ORPHA:101084; Charcot-Marie-Tooth disease type 4E ORPHA:99951,0.7068064785325423; 0.7068064785325423,Human papillomavirus type 72b E7 protein (gene: E7),0.6362779693488597,yeasx,0.37,Homo sapiens,Homo sapiens
NRGN,Malignant neoplasm of prostate; Central neuroblastoma; Neuroblastoma; Glioma; Prostate carcinoma; Unipolar Depression; Visual seizure; Major Depressive Disorder; Amyloidosis; Bipolar Disorder; Schizophrenia; Alzheimer's Disease; Glioblastoma Multiforme; Autism Spectrum Disorders; Jacobsen Distal 11q Deletion Syndrome; Mental disorders; Cocaine Abuse; Congenital Hypothyroidism; Dyslexia; Psychotic Disorders; Nonorganic psychosis; Hypothyroidism,0.0569142010728473; 0.0593779966354549; 0.0688152422187159; 0.0739788831250619; 0.0773771948186562; 0.13167400689206; 0.1735868515093891; 0.21122597829463; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.4115056600660309; 0.4126392832024548; 0.4192169590514327; 0.4192169590514327; 0.4459714599189374; 0.4753011022966241; 0.578835730221474; 0.8306551823873084,Schizophrenia; Development Disorder; Bipolar Disorder,0.0531117779464085; 0.4372065554432662; 0.4875380732267193,Deafness-lymphedema-leukemia syndrome ORPHA:3226; Monocytopenia with susceptibility to infections ORPHA:228423; Fetal and neonatal alloimmune thrombocytopenia ORPHA:853; Autosomal recessive spastic paraplegia type 63 ORPHA:401805; Polymicrogyria with optic nerve hypoplasia ORPHA:250972; Pontocerebellar hypoplasia type 9 ORPHA:369920; Bernard-Soulier syndrome ORPHA:274,0.3762014630157917; 0.3762014630157917; 0.3826134188846508; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423,,,In vitro,0.44,Homo sapiens,Homo sapiens
NRIP1,"Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Adenocarcinoma; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of ovary; Mammary Neoplasms, Human; Osteoporosis; Endometrial Neoplasms; Liver carcinoma; Colon Carcinoma; Chronic Lymphocytic Leukemia; Hematologic Neoplasms; Secondary malignant neoplasm of bone; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Myocardial Infarction; Solid Neoplasm; Rheumatoid Arthritis; Malignant tumor of colon; Endometrial Carcinoma; Embryonal Carcinoma; Noninfiltrating Intraductal Carcinoma; Schizophrenia; Birth Weight; Platelet distribution width measurement; Platelet distribution width result; Refractory anemias; Congestive heart failure; Heart failure; Germ cell tumor; Steatohepatitis; Fatty Liver; Left-Sided Heart Failure; Osteoporosis, Postmenopausal; Heart Diseases; Heart Decompensation; Metabolic Diseases; Heart Failure, Right-Sided; Myocardial Failure",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0155921563748247; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.064548079316548; 0.0739788831250619; 0.0745502070959292; 0.095319386034013; 0.1062239757831962; 0.1147307578771389; 0.1253114324938153; 0.1253114324938153; 0.13167400689206; 0.1328002618052838; 0.1352936728187231; 0.1413782599148022; 0.1537760235124317; 0.223747154820789; 0.3044782497745498; 0.3112516166225269; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.4115056600660309; 0.4115056600660309; 0.421267417774367; 0.425419812815905; 0.4304973629098372; 0.4335751357405352; 0.4906258721078565; 0.533913711453195; 0.5568517196017908; 0.5916904943304121; 0.610971999959321; 0.7433468668038986; 0.750779529196619; 0.7533159919746161; 0.7577323833810212,Congenital Anomalies Of Kidney And Urinary Tract; Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Schizophrenia; Endometrial Carcinoma; Ectopic Kidney; Vesicoureteral Reflux; Endometrial Neoplasms; Myocardial Infarction; Renal Cyst; Heart Failure; Hydronephrosis; Congestive Heart Failure,0.0075861267486594; 0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0531117779464085; 0.4286813331685578; 0.4402141802500753; 0.4714699023601434; 0.4931425946912698; 0.5632819212593052; 0.7167438233451096; 0.7360789997461612; 0.7412420740397021; 0.7532174466905212,Familial multiple nevi flammei ORPHA:624; Sturge-Weber syndrome ORPHA:3205,0.0180064224283883; 0.0180064224283883,,,,,,
OGFR,Ovarian Carcinoma; Tumor Progression; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Pancreatic carcinoma; Squamous cell carcinoma of the head and neck; Colonic Neoplasms; Malignant neoplasm of liver; Ataxia Telangiectasia; Papillary thyroid carcinoma; Thyroid carcinoma; Malignant neoplasm of thyroid,0.0034602840073026; 0.0149315928814189; 0.0277695594716545; 0.0726340460169901; 0.0739788831250619; 0.0745502070959292; 0.0775520919998773; 0.1454373331146953; 0.2643145809900195; 0.3508665345292502; 0.3933196962529684; 0.3941558617476422; 0.4307603335611732,,,"Mucopolysaccharidosis type 4A ORPHA:309297; Solitary fibrous tumor/hemangiopericytoma ORPHA:2126; Early-onset autosomal dominant Alzheimer disease ORPHA:1020; Glycogen storage disease due to acid maltase deficiency, infantile onset ORPHA:308552; Glycogen storage disease due to acid maltase deficiency, late-onset ORPHA:420429; Neutral lipid storage myopathy ORPHA:98908; Triglyceride deposit cardiomyovasculopathy ORPHA:565612; NON RARE IN EUROPE: Paget disease of bone ORPHA:280110; Adrenomyeloneuropathy ORPHA:139399; Autosomal dominant Charcot-Marie-Tooth disease type 2M ORPHA:228179; Autosomal dominant intermediate Charcot-Marie-Tooth disease type B ORPHA:100044; Autosomal recessive spastic paraplegia type 48 ORPHA:306511; Autosomal recessive spastic paraplegia type 63 ORPHA:401805; Basel-Vanagaite-Smirin-Yosef syndrome ORPHA:464738; Deficiency in anterior pituitary function-variable immunodeficiency syndrome ORPHA:293978; Fetal akinesia-cerebral and retinal hemorrhage syndrome ORPHA:363409; Peutz-Jeghers syndrome ORPHA:2869; Polyglucosan body myopathy type 1 ORPHA:397937; Pontocerebellar hypoplasia type 9 ORPHA:369920; X-linked cerebral adrenoleukodystrophy ORPHA:139396; Alveolar soft tissue sarcoma ORPHA:163699; Autosomal recessive progressive external ophthalmoplegia ORPHA:254886; Proteus syndrome ORPHA:744; Charcot-Marie-Tooth disease type 2B2 ORPHA:101101; Albers Schonberg osteopetrosis ORPHA:53; Alpers-Huttenlocher syndrome ORPHA:726; Alpha-mannosidosis, adult form ORPHA:309288; Alpha-mannosidosis, infantile form ORPHA:309282; Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome ORPHA:69088; Ataxia-hypogonadism-choroidal dystrophy syndrome ORPHA:1180; Ataxia-oculomotor apraxia type 4 ORPHA:459033; Autosomal recessive spastic paraplegia type 39 ORPHA:139480; CLN4B disease ORPHA:228343; Charcot-Marie-Tooth disease type 2P ORPHA:300319; Charcot-Marie-Tooth disease type 2S ORPHA:443073; Combined oxidative phosphorylation defect type 27 ORPHA:477774; Congenital cataracts-facial dysmorphism-neuropathy syndrome ORPHA:48431; Hurler syndrome ORPHA:93473; Hurler-Scheie syndrome ORPHA:93476; Idiopathic CD4 lymphocytopenia ORPHA:228000; Incontinentia pigmenti ORPHA:464; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression ORPHA:391316; Laurence-Moon syndrome ORPHA:2377; Lethal neonatal spasticity-epileptic encephalopathy syndrome ORPHA:435845; Microcephalic primordial dwarfism due to ZNF335 deficiency ORPHA:329228; Neuralgic amyotrophy ORPHA:2901; Predisposition to invasive fungal disease due to CARD9 deficiency ORPHA:457088; Recessive mitochondrial ataxia syndrome ORPHA:94125; Scheie syndrome ORPHA:93474; Spinal muscular atrophy with respiratory distress type 1 ORPHA:98920; Spinocerebellar ataxia with epilepsy ORPHA:254881; Susceptibility to infection due to TYK2 deficiency ORPHA:331226; Trichomegaly-retina pigmentary degeneration-dwarfism syndrome ORPHA:3363; X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency ORPHA:319612; Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis ORPHA:329173; Cerebellar ataxia-hypogonadism syndrome ORPHA:1173; Intermediate osteopetrosis ORPHA:210110; Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome ORPHA:70595; Mitochondrial neurogastrointestinal encephalomyopathy ORPHA:298; Prolactinoma ORPHA:2965",0.0586579655822394; 0.1590470395003315; 0.1739455566145445; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
OIP5,Breast Carcinoma; Stomach Carcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Glioblastoma; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Liver carcinoma; Malignant Neoplasms; Esophageal carcinoma; Carcinoma of bladder; Malignant neoplasm of lung; Primary malignant neoplasm; Obesity,0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0745502070959292; 0.084286432100041; 0.0891725280554336; 0.095319386034013; 0.0991201145654548; 0.1254380558571286; 0.13167400689206; 0.2714542429024338; 0.383941725017158; 0.5140447474168605,,,"Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Mosaic variegated aneuploidy syndrome ORPHA:1052; Amish nemaline myopathy ORPHA:98902; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome ORPHA:544488; 3-phosphoserine phosphatase deficiency, infantile/juvenile form ORPHA:79350; Adenylosuccinate lyase deficiency ORPHA:46; Autosomal recessive Kenny-Caffey syndrome ORPHA:93324; Combined oxidative phosphorylation defect type 2 ORPHA:254920; Deafness-encephaloneuropathy-obesity-valvulopathy syndrome ORPHA:254898; Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome ORPHA:496756; Hereditary coproporphyria ORPHA:79273; Hyper-IgM syndrome type 5 ORPHA:101092; Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome ORPHA:415; Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome ORPHA:137898; Lipoyl transferase 2 deficiency ORPHA:447795; Mohr-Tranebjaerg syndrome ORPHA:52368; Multiple system atrophy, cerebellar type ORPHA:227510; Multiple system atrophy, parkinsonian type ORPHA:98933; Mutilating hereditary sensory neuropathy with spastic paraplegia ORPHA:139578; PCNA-related progressive neurodegenerative photosensitivity syndrome ORPHA:438134; Progressive external ophthalmoplegia-myopathy-emaciation syndrome ORPHA:352447; Reticular dysgenesis ORPHA:33355; Sanjad-Sakati syndrome ORPHA:2323; Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome ORPHA:314394; Intrauterine growth restriction-congenital multiple cafe-au-lait macules-increased sister chromatid exchange syndrome ORPHA:508512; ALG8-CDG ORPHA:79325; Acute intermittent porphyria ORPHA:79276; Brody myopathy ORPHA:53347; Combined oxidative phosphorylation defect type 24 ORPHA:444458; Cutis marmorata telangiectatica congenita ORPHA:1556; Hemolytic anemia due to glutathione reductase deficiency ORPHA:90030; Spondyloepimetaphyseal dysplasia with multiple dislocations ORPHA:93360; X-linked intellectual disability, Snyder type ORPHA:3063; Anaplastic oligodendroglioma ORPHA:251630; Oligodendroglioma ORPHA:251627",0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens HEK293T embryonic kidney cell;Saccharomyces cerevisiae;yeasx,0.35;0.56;0.67,Homo sapiens,Homo sapiens
OSTM1,Lysosomal Storage Diseases; Hamartoma; Hydrocephalus; Bone Diseases; Teratocarcinoma; Infantile malignant osteopetrosis; Osteopetrosis; Neurodegenerative Disorders; Stillbirth; Fetal Death; Abnormality of metabolism/homeostasis; Optic Atrophy,0.0798053340865682; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.4028066164685291; 0.4126392832024548; 0.4335751357405352; 0.4335751357405352; 0.472444704048021; 0.6274540883972485; 0.809878589520458,Partial Agenesis Of Corpus Callosum; Blood Coagulation Disorders; Hyperbilirubinemia; Osteopetrosis; Hydrocephalus; Hyperostosis Of Skull; Hypoplastic Hippocampus; Mental Depression; Respiratory Failure; Anemia; Cranial Nerve Paralysis; Microcephaly; Cerebral Atrophy; Liver Failure; Micrognathism; Pancytopenia; Seizure; Hearing Loss; Dwarfism; Nervous System Diseases; Optic Atrophy; Spastic Quadriplegia; Nystagmus; Developmental Delay,0.2187610616307245; 0.3094716280561038; 0.3094716280561038; 0.336287627428424; 0.3657224783929353; 0.4286813331685578; 0.4286813331685578; 0.4560460337187313; 0.4560460337187313; 0.4780231573499264; 0.4867879381749835; 0.5123947823327547; 0.5129298662020659; 0.5162067638232762; 0.5234357475824973; 0.5234357475824973; 0.5576425853515448; 0.5632819212593052; 0.5796489603182782; 0.6420878824691651; 0.675936313627625; 0.7167438233451096; 0.9146877763175152; 0.96477535147595,"Autosomal dominant intermediate Charcot-Marie-Tooth disease type F ORPHA:352670; Free sialic acid storage disease, infantile form ORPHA:309324; Fried syndrome ORPHA:85335; Intermediate severe Salla disease ORPHA:309331; Salla disease ORPHA:309334; X-linked intellectual disability-Dandy-Walker malformation-basal ganglia disease-seizures syndrome ORPHA:1568; X-linked intellectual disability-hypotonia-facial dysmorphism-aggressive behavior syndrome ORPHA:85329; Ocular albinism with congenital sensorineural deafness ORPHA:352740; Alkaline ceramidase 3 deficiency ORPHA:502444; Glycogen storage disease due to LAMP-2 deficiency ORPHA:34587; Infantile osteopetrosis with neuroaxonal dysplasia ORPHA:85179; Mucopolysaccharidosis type 6, rapidly progressing ORPHA:276212; Mucopolysaccharidosis type 6, slowly progressing ORPHA:276223; TOR1AIP1-related limb-girdle muscular dystrophy ORPHA:424261; X-linked intellectual disability, Hedera type ORPHA:93952; X-linked parkinsonism-spasticity syndrome ORPHA:363654; Autosomal recessive cutis laxa type 2, classic type ORPHA:357074",0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens,0.35,ebvb9,Homo sapiens
P2RX7,"Mammary Neoplasms; Breast Carcinoma; Colorectal Cancer; Tumor Progression; melanoma; Adenocarcinoma; Malignant neoplasm of breast; Carcinogenesis; Hematopoietic Neoplasms; Malignant neoplasm of prostate; Central neuroblastoma; Brain Neoplasms; Neoplasm Metastasis; Neuroblastoma; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Glioma; Degenerative polyarthritis; Osteoporosis; Lymphoma; Pancreatic carcinoma; Prostate carcinoma; Liver carcinoma; Osteosarcoma; Chronic Lymphocytic Leukemia; Secondary malignant neoplasm of bone; MYELODYSPLASTIC SYNDROME; Unipolar Depression; Hyperactive behavior; Solid Neoplasm; Liver neoplasms; Rheumatoid Arthritis; Head and Neck Carcinoma; Osteosarcoma of bone; Major Depressive Disorder; Diabetes; Metastasis from malignant tumor of prostate; Malignant Head and Neck Neoplasm; Diabetes Mellitus; B-CELL MALIGNANCY, LOW-GRADE; Small Lymphocytic Lymphoma; Metastatic Prostate Carcinoma; Multiple Sclerosis; Myeloid Leukemia; Sjogren's Syndrome; Acute pancreatitis; Ischemic stroke; Tuberculosis; Thyroid Neoplasm; Tuberculosis, Pulmonary; Amyloidosis; Bipolar Disorder; Diabetes Mellitus, Non-Insulin-Dependent; Pancreatitis, Chronic; Papillary thyroid carcinoma; Schizophrenia; Gastroesophageal reflux disease; Hypertensive disease; Bronchopulmonary Dysplasia; Chronic esophagitis; Neurobehavioral Manifestations; Skin Neoplasms; Astrocytoma; Alzheimer's Disease; Anxiety Disorders; Lymphoma, Non-Hodgkin; Inflammatory Bowel Diseases; Glomerulonephritis; manic symptom; Asthma; Spinal Cord Contusion; Spinal Cord Injuries; Spinal Cord Laceration; Spinal Cord transection injury; Post-Traumatic Myelopathy; Polycystic Kidney, Autosomal Dominant; Mental Depression; Bone Diseases; NEUROTICISM; Amyotrophic Lateral Sclerosis; Mechanical Allodynia; Depressive disorder; Chronic Kidney Diseases; Musculoskeletal Diseases; Acute myocardial infarction; Multiple Myeloma; Epilepsy, Temporal Lobe; Tuberculosis, Multidrug-Resistant; Hemophagocytic Syndrome; Primary gout; Polycystic Kidney Diseases; Mood Disorders; Lupus Erythematosus, Systemic; Congestive heart failure; Adult Non-Hodgkin Lymphoma; Agoraphobia; Encephalomyelitis; Heart failure; Hypophosphatasia; Trisomy; Neurodegenerative Disorders; Lupus Vulgaris; Lymphatic Metastasis; Tuberculosis, extrapulmonary; Depressive Symptoms; Bone Cysts, Aneurysmal; Childhood Non-Hodgkin Lymphoma; Fleck corneal dystrophy; Myocardial Ischemia; Epilepsy, Benign Psychomotor, Childhood; Uncinate Epilepsy; Primary Sj??gren's syndrome; leukemia; Lupus Erythematosus; Epilepsy, Lateral Temporal; Lupus Erythematosus, Discoid; Huntington Disease; Uveal melanoma; Malignant Bone Neoplasm; Recurrent major depressive episodes; Acute GVH disease; Pain; Impaired glucose tolerance; Osteopenia; Neuralgia; Crohn Disease; Chronic Obstructive Airway Disease; Borderline Personality Disorder; Colitis; Familial (FPAH); intracranial glioma; Multiple Sclerosis, Acute Fulminating; Mixed anxiety and depressive disorder; Hyperplasia; Arthritis; Metabolic Syndrome X; Chronic pain; Lymphohistiocytosis, Hemophagocytic; Graft-vs-Host Disease; Chlamydia Infections; MAJOR AFFECTIVE DISORDER 8; MAJOR AFFECTIVE DISORDER 9; Cystic Fibrosis; MAJOR AFFECTIVE DISORDER 7; Brain Diseases; Bipolar I disorder; Sepsis; Narcolepsy; Hyperuricemia; MAJOR AFFECTIVE DISORDER 4; MAJOR AFFECTIVE DISORDER 6; MAJOR AFFECTIVE DISORDER 1; Inflammatory pain; aggressive cancer; Chagas Disease; Bacteremia; Lung diseases; MAJOR AFFECTIVE DISORDER 2; Severe Sepsis; Post-Traumatic Stress Disorder; Infectious disease of lung; Septicemia; Hyperinsulinism; Age related macular degeneration",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0228075668512991; 0.0334891258932371; 0.0569142010728473; 0.0593779966354549; 0.064548079316548; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0773771948186562; 0.095319386034013; 0.1029977559100099; 0.1147307578771389; 0.1253114324938153; 0.1254380558571286; 0.13167400689206; 0.1387448809655294; 0.1413782599148022; 0.1454373331146953; 0.1537760235124317; 0.1735868515093891; 0.2109483801368481; 0.21122597829463; 0.2277108302018961; 0.2454426921531692; 0.2522264785494494; 0.2522264785494494; 0.2522264785494494; 0.2643145809900195; 0.2643145809900195; 0.2835142372342932; 0.2980670559114652; 0.3099246715197673; 0.3220099003872086; 0.3486533561309259; 0.3706856725676674; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.39623320406434; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4126392832024548; 0.4192169590514327; 0.4213286052188015; 0.425419812815905; 0.425419812815905; 0.425419812815905; 0.4254307049060398; 0.4304973629098372; 0.4304973629098372; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4342056919538745; 0.4396723023384634; 0.4459714599189374; 0.4459714599189374; 0.4459714599189374; 0.4459714599189374; 0.4506578937113162; 0.4506578937113162; 0.4506578937113162; 0.451408428170596; 0.4588513406515081; 0.4615352570710579; 0.4615352570710579; 0.4675904598629673; 0.4704594475773637; 0.472444704048021; 0.472444704048021; 0.4753011022966241; 0.4790179402069343; 0.4871698998714747; 0.4900770016856776; 0.4923669467696064; 0.4923669467696064; 0.4981941174985421; 0.5049674142533507; 0.5188223685230745; 0.5323590634832615; 0.533913711453195; 0.5393787854381349; 0.5453394612016188; 0.5453394612016188; 0.5514573300659174; 0.553002957824355; 0.5568517196017908; 0.5568517196017908; 0.5710095678317721; 0.5922440535658843; 0.6035970790768342; 0.610971999959321; 0.610971999959321; 0.6124306570512981; 0.6150955455771212; 0.6319938293757544; 0.6319938293757544; 0.6395767498329145; 0.6496433426951205; 0.652707626880454; 0.652707626880454; 0.652707626880454; 0.6588479076808555; 0.6656356363792992; 0.6691893635307453; 0.7068844070911514; 0.7096959691931399; 0.7128284704851243; 0.726789939981526; 0.7467090191923123; 0.7631684472516962; 0.7670529315163258; 0.8064248359603999; 0.8245140009975604; 0.8304052766033214,Lymphocytic Leukemia; Epilepsy; Colorectal Cancer; Mental Depression; Mood Disorder; Bipolar Disorder; Multiple Sclerosis,0.0487679768343083; 0.3449614869411272; 0.4286813331685578; 0.4560460337187313; 0.4646409362700993; 0.4875380732267193; 0.880175848034561,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome ORPHA:447997; Spinocerebellar ataxia type 1 ORPHA:98755; Attenuated Chediak-Higashi syndrome ORPHA:352723; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency ORPHA:404499; Calpain-3-related  limb-girdle muscular dystrophy R1 ORPHA:267; Chediak-Higashi syndrome ORPHA:167; GM3 synthase deficiency ORPHA:370933; Mowat-Wilson syndrome due to a ZEB2 point mutation ORPHA:261552; Mowat-Wilson syndrome due to monosomy 2q22 ORPHA:261537; Bietti crystalline dystrophy ORPHA:41751; Spinocerebellar ataxia type 15/16 ORPHA:98769; Spinocerebellar ataxia type 29 ORPHA:208513; Megalencephalic leukoencephalopathy with subcortical cysts ORPHA:2478; Hereditary clear cell renal cell carcinoma ORPHA:422526; Narcolepsy type 1 ORPHA:2073; B-cell chronic lymphocytic leukemia ORPHA:67038; 5q14.3 microdeletion syndrome ORPHA:228384; Autosomal dominant vitreoretinochoroidopathy ORPHA:3086; Autosomal recessive bestrophinopathy ORPHA:139455; Best vitelliform macular dystrophy ORPHA:1243; MRCS syndrome ORPHA:263347; X-linked intellectual disability-cardiomegaly-congestive heart failure syndrome ORPHA:324410; Andersen-Tawil syndrome ORPHA:37553; Idiopathic achalasia ORPHA:930,0.0586579655822394; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.639029370164481; 0.64564126367818; 0.6581690778726346; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
P3H2,Breast Carcinoma; melanoma; Malignant neoplasm of breast; Brain Neoplasms; Hyperactive behavior; Marfan Syndrome; Cataract; Ectopia Lentis; Lens Opacities; Severe myopia; Myopia; Exanthema,0.0042545616049287; 0.0149315928814189; 0.0191435238361999; 0.064548079316548; 0.1387448809655294; 0.1735868515093891; 0.223747154820789; 0.3638414818541592; 0.4213286052188015; 0.5140447474168605; 0.5239792328442205; 0.7674304683279349,Breast Cancer; Cataract; Myopia,0.0402286636010764; 0.6660731887258019; 0.7405519560111998,20p12.3 microdeletion syndrome ORPHA:261295; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; Craniodiaphyseal dysplasia ORPHA:1513; Congenital contractural arachnodactyly ORPHA:115; Rare isolated myopia ORPHA:98619,0.0083045131203191; 0.0180064224283883; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782,,,yeasx,0.37,Bacillus anthracis;Homo sapiens,Bacillus anthracis;Homo sapiens
PADI3,Malignant neoplasm of breast; Carcinogenesis; Rheumatoid Arthritis; Pili canaliculi; White hair; Rough hair texture; Coarse hair; Dry hair; Wooly hair; Afro-textured hair; Kinky hair texture; Nappy hair texture; Forced expiratory volume function; Smell Perception,0.0191435238361999; 0.0228075668512991; 0.1537760235124317; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4929829683479762; 0.5568517196017908,Breast Cancer; Alopecia Areata,0.0402286636010764; 0.5234357475824973,Autosomal recessive infantile hypercalcemia ORPHA:300547; Bamforth-Lazarus syndrome ORPHA:1226; White sponge nevus ORPHA:171723; Amish nemaline myopathy ORPHA:98902; Harlequin ichthyosis ORPHA:457; Monilethrix ORPHA:573; Uncombable hair syndrome ORPHA:1410; Idiopathic juvenile osteoporosis ORPHA:85193; Bifid uvula ORPHA:99771; Cleft hard palate ORPHA:101023; Cleft velum ORPHA:99772; Submucosal cleft palate ORPHA:155878; Autosomal recessive distal renal tubular acidosis ORPHA:402041; Pure hair and nail ectodermal dysplasia ORPHA:69084,0.0083045131203191; 0.0180064224283883; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.7068064785325423,,,yeasx,0.67,Homo sapiens,Homo sapiens
PBX1,"Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Stomach Carcinoma; Retroviridae Infections; melanoma; Squamous cell carcinoma; Pre B-cell acute lymphoblastic leukemia; ovarian neoplasm; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of ovary; Hematopoietic Neoplasms; Malignant neoplasm of prostate; Central neuroblastoma; Neoplasm Metastasis; Neuroblastoma; Malignant neoplasm of pancreas; Lymphoma; Pancreatic carcinoma; Prostate carcinoma; Adult Acute Lymphocytic Leukemia; Ganglioneuroma; Hematologic Neoplasms; Hyperactive behavior; Adrenal Gland Diseases; Lung Neoplasms; Prostatic Neoplasms; Diabetes; Burkitt Lymphoma; Diabetes Mellitus; Acute leukemia; Myeloid Leukemia; Childhood Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemogenesis; Chromosome 8, trisomy; African Burkitt's lymphoma; Cakut; Diabetes Mellitus, Non-Insulin-Dependent; Nephroblastoma; Androgen-Insensitivity Syndrome; Non-Small Cell Lung Carcinoma; Leukemia, Myelocytic, Acute; Truncus Arteriosus, Persistent; Acute lymphocytic leukemia; Acute Promyelocytic Leukemia; Lymphoid leukemia; Neoplasm, Residual; androgen independent prostate cancer; Drug abuse; Pituitary Neoplasms; Rous Sarcoma; Childhood Pre-B Acute Lymphoblastic Leukemia; Lymphoblastic leukemia in children; Drug Dependence; Myoepithelioma; Lupus Erythematosus, Systemic; Congenital absence of spleen; Infant, Premature; Rokitansky Kuster Hauser syndrome; Lupus Vulgaris; Substance Use Disorders; leukemia; Substance abuse problem; Lupus Erythematosus; Lupus Erythematosus, Discoid; Promyelocytic leukemia; Adenocarcinoma in Situ; Hyperdiploid B Acute Lymphoblastic Leukemia; Adrenal gland hypofunction; Common acute lymphoblastic leukemia; Congenital Abnormality; Obsessive-Compulsive Disorder; Organic Mental Disorders, Substance-Induced; Prescription Drug Abuse; Precursor Cell Lymphoblastic Leukemia Lymphoma; Drug Use Disorders; Precursor B-cell lymphoblastic leukemia; Substance-Related Disorders; Tetralogy of Fallot; Drug habituation; Substance Dependence; Congenital chromosomal disease; Hematological Disease; Childhood Leukemia; Metabolic Diseases; Intellectual Disability",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0189794808441368; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0334891258932371; 0.0569142010728473; 0.0593779966354549; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0745502070959292; 0.0773771948186562; 0.0919714360040484; 0.1138051695421299; 0.1253114324938153; 0.1387448809655294; 0.1735868515093891; 0.2062010908869036; 0.223747154820789; 0.2277108302018961; 0.2521987644415915; 0.2522264785494494; 0.2835142372342932; 0.2980670559114652; 0.3099246715197673; 0.3105909001629992; 0.3510063969122338; 0.3925783478421996; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.39623320406434; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4192169590514327; 0.4213286052188015; 0.425419812815905; 0.4304973629098372; 0.4304973629098372; 0.4335751357405352; 0.4381343267935581; 0.4588513406515081; 0.4615352570710579; 0.4615352570710579; 0.4675904598629673; 0.4675904598629673; 0.4852430673532381; 0.4852430673532381; 0.5090214163899865; 0.5188223685230745; 0.5305233935923577; 0.5305233935923577; 0.533913711453195; 0.533913711453195; 0.5393787854381349; 0.5393787854381349; 0.5451009374855866; 0.5514573300659174; 0.5557519470957561; 0.589345563575654; 0.5936773368594411; 0.6035970790768342; 0.610971999959321; 0.656104947944719; 0.750779529196619; 0.8352623613787349,Congenital Anomalies Of Kidney And Urinary Tract; African Burkitt`s Lymphoma; Bilateral Renal Hypoplasia; Ectopic Kidney; Burkitt`s Lymphoma; Horseshoe Kidney; Vesicoureteral Reflux; Renal Hypoplasia; Ambiguous Genitalia; Lymphoblastic Leukemia; Congenital Diaphragmatic Hernia; Renal Agenesis; Renal Dysplasia; Renal Insufficiency; Leukemia; Penis Agenesis; Congenital Epicanthus; Cryptorchidism; Microtia; Motor Delay; Strabismus,0.0075861267486594; 0.2960946950751588; 0.4286813331685578; 0.4402141802500753; 0.4541466895915311; 0.4560460337187313; 0.4714699023601434; 0.4875380732267193; 0.5021774953934145; 0.5129298662020659; 0.5162067638232762; 0.5207800595599322; 0.657896505422784; 0.7112499273451761; 0.7167438233451096; 0.7662135194687344; 0.7729545590606223; 0.776786668801341; 0.8273480078036296; 0.8371848756758566; 0.9568083835980838,"Nance-Horan syndrome ORPHA:627; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Matthew-Wood syndrome ORPHA:2470; NON RARE IN EUROPE: Benign familial hematuria ORPHA:97562; Familial primary hypomagnesemia with normocalciuria and normocalcemia ORPHA:34527; Lacrimoauriculodentodigital syndrome ORPHA:2363; 1p31p32 microdeletion syndrome ORPHA:401986; Brachydactyly-arterial hypertension syndrome ORPHA:1276; Complete androgen insensitivity syndrome ORPHA:99429; Female restricted epilepsy with intellectual disability ORPHA:101039; Kennedy disease ORPHA:481; Partial androgen insensitivity syndrome ORPHA:90797; Familial patent arterial duct ORPHA:466729; Pfeiffer syndrome type 1 ORPHA:93258; Butterfly-shaped pigment dystrophy ORPHA:99001; Growth delay due to insulin-like growth factor I resistance ORPHA:73273; Renal hypoplasia, bilateral ORPHA:97362; Renal agenesis, bilateral ORPHA:1848; Posterior polymorphous corneal dystrophy ORPHA:98973; Renal agenesis, unilateral ORPHA:93100; Brugada syndrome ORPHA:130; Autosomal recessive non-syndromic sensorineural deafness type DFNB ORPHA:90636; ANK3-related intellectual disability-sleep disturbance syndrome ORPHA:356996; Apert syndrome ORPHA:87; Autism spectrum disorder due to AUTS2 deficiency ORPHA:352490; Autosomal dominant spastic paraplegia type 31 ORPHA:101011; Autosomal recessive extra-oral halitosis ORPHA:562538; Colobomatous microphthalmia-rhizomelic dysplasia syndrome ORPHA:424099; Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome ORPHA:1555; FGFR2-related bent bone dysplasia ORPHA:313855; Familial scaphocephaly syndrome, McGillivray type ORPHA:168624; Fraser syndrome ORPHA:2052; Goldmann-Favre syndrome ORPHA:53540; Hyperinsulinism due to INSR deficiency ORPHA:263458; Insulin-resistance syndrome type A ORPHA:2297; Jackson-Weiss syndrome ORPHA:1540; Kaposiform hemangioendothelioma ORPHA:2122; Leprechaunism ORPHA:508; Palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome ORPHA:85112; Pfeiffer syndrome type 2 ORPHA:93259; Pfeiffer syndrome type 3 ORPHA:93260; Rabson-Mendenhall syndrome ORPHA:769; Tufted angioma ORPHA:1063; Stargardt disease ORPHA:827; Precursor B-cell acute lymphoblastic leukemia ORPHA:99860; Complete cryptophthalmia ORPHA:98949; Infantile Bartter syndrome with sensorineural deafness ORPHA:89938; Intellectual disability-expressive aphasia-facial dysmorphism syndrome ORPHA:436151; Retinal macular dystrophy type 2 ORPHA:319640; Schinzel-Giedion syndrome ORPHA:798; Congenital bilateral absence of vas deferens ORPHA:48; Alveolar rhabdomyosarcoma ORPHA:99756; Duane retraction syndrome ORPHA:233",0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.3826134188846508; 0.3969770464111636; 0.5145066480201691; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6279395134845649; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,"Reston ebolavirus spike glycoprotein (gene: GP); Louping ill virus nonstructural protein NS3; Sudan ebolavirus spike glycoprotein (gene: GP); Sudan ebolavirus - Nakisamata structural glycoprotein (gene: GP); Tai Forest ebolavirus spike glycoprotein (gene: GP); Cercopithecine betaherpesvirus 5 large tegument protein (gene: UL48); Human immunodeficiency virus envelope glycoprotein (gene: env); Lake Victoria marburgvirus - Leiden glycoprotein (gene: GP); Marburg virus - Musoke, Kenya, 1980 glycoprotein (gene: GP); Marburg marburgvirus glycoprotein (gene: GP); Vaccinia virus Ankara 150k A-type inclusion protein (ATI) f1",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6386053036162835; 0.6481498905276316; 0.6761714078632568; 0.853754994225345,,,,
PCDH7,Bladder Neoplasm; Epilepsy,0.0891725280554336; 0.3941558617476422,Schizophrenia; Epilepsy; Ischemic Stroke,0.0531117779464085; 0.3449614869411272; 0.4286813331685578,"Atrial septal defect, ostium primum type ORPHA:99106; Peters anomaly ORPHA:708; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Greig cephalopolysyndactyly syndrome ORPHA:380; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Branchiootic syndrome ORPHA:52429; Brachydactyly type A2 ORPHA:93396; Waardenburg syndrome type 2 ORPHA:895; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Mandibulofacial dysostosis with alopecia ORPHA:443995; Nance-Horan syndrome ORPHA:627; Oculocutaneous albinism type 3 ORPHA:79433; Hypoplastic left heart syndrome ORPHA:2248; Matthew-Wood syndrome ORPHA:2470; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721; X-linked Alport syndrome-diffuse leiomyomatosis ORPHA:1018; 15q14 microdeletion syndrome ORPHA:261190; Autosomal dominant slowed nerve conduction velocity ORPHA:140481; Childhood-onset benign chorea with striatal involvement ORPHA:494541; Epidermolysis bullosa simplex due to BP230 deficiency ORPHA:412181; Hereditary sensory and autonomic neuropathy type 6 ORPHA:314381; Infantile-onset generalized dyskinesia with orofacial involvement ORPHA:494526; Optic atrophy-intellectual disability syndrome ORPHA:401777; X-linked Alport syndrome ORPHA:88917; Lacrimoauriculodentodigital syndrome ORPHA:2363; Sclerosteosis ORPHA:3152; Hirschsprung disease ORPHA:388; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form ORPHA:293899; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form ORPHA:293888; Female restricted epilepsy with intellectual disability ORPHA:101039; High myopia-sensorineural deafness syndrome ORPHA:363396; Split hand-split foot-deafness syndrome ORPHA:71271; Stuve-Wiedemann syndrome ORPHA:3206; Familial patent arterial duct ORPHA:466729; Isolated aniridia ORPHA:250923; Familial isolated arrhythmogenic ventricular dysplasia, right dominant form ORPHA:293910; Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome ORPHA:370022; Charcot-Marie-Tooth disease type 2R ORPHA:397968; Metopic ridging-ptosis-facial dysmorphism syndrome ORPHA:502430; Scalp-ear-nipple syndrome ORPHA:2036; Congenital ptosis ORPHA:91411; Rolandic epilepsy ORPHA:1945; Saethre-Chotzen syndrome ORPHA:794; Renal agenesis, bilateral ORPHA:1848; Severe early-childhood-onset retinal dystrophy ORPHA:364055; Apert syndrome ORPHA:87; Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome ORPHA:1555; FGFR2-related bent bone dysplasia ORPHA:313855; Familial scaphocephaly syndrome, McGillivray type ORPHA:168624; Fraser syndrome ORPHA:2052; Jackson-Weiss syndrome ORPHA:1540; Pfeiffer syndrome type 2 ORPHA:93259; Pfeiffer syndrome type 3 ORPHA:93260; Pontocerebellar hypoplasia type 3 ORPHA:97249; Short rib-polydactyly syndrome, Saldino-Noonan type ORPHA:93270; 7q31 microdeletion syndrome ORPHA:251061; Childhood apraxia of speech ORPHA:209908; Congenital lethal myopathy, Compton-North type ORPHA:210163",0.0040361447187818; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0092060390928213; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0706635700002548; 0.0783959336694202; 0.0783959336694202; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1981653781243822; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.3775879467205478; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
PDE4B,"Colorectal Carcinoma; Colorectal Cancer; Lymphoma; Chronic Lymphocytic Leukemia; Arsenic Poisoning, Inorganic; Nervous System, Organic Arsenic Poisoning; Arsenic Encephalopathy; Arsenic Induced Polyneuropathy; Arsenic Poisoning; Phototoxicity; Unipolar Depression; Dermatitis, Phototoxic; Acute Myeloid Leukemia (AML-M2); Major Depressive Disorder; B-Cell Lymphomas; Bipolar Disorder; Schizophrenia; Leukemia, Myelocytic, Acute; Anxiety Disorders; Fibrosis, Liver; Asthma; Mental Depression; Alcohol abuse; Depressive disorder; Acute Myeloid Leukemia, M1; Anxiety; Depression, Bipolar; Mental disorders; Latent Autoimmune Diabetes in Adults; Triglycerides measurement; Psoriasis; Amphetamine-Related Disorders; Amphetamine Abuse; Amphetamine Addiction; PANIC DISORDER 1; Myocardial Ischemia; Manic; Panic Disorder; Staphylococcus aureus infection; Dermatologic disorders; Neutropenia; Alcoholic Intoxication, Chronic; Manic Disorder; Autoimmune thyroid disease; Tachycardia, Ventricular; Diffuse Large B-Cell Lymphoma; Ventricular arrhythmia; Leukopenia; Narcolepsy; Respiration Disorders; Low density lipoprotein cholesterol measurement; Alcohol Use Disorder; Allergic asthma; Autistic Disorder; Serum total cholesterol measurement; Abnormal behavior",0.0034602840073026; 0.0149315928814189; 0.0739788831250619; 0.1147307578771389; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1897991423047819; 0.2050045461627939; 0.21122597829463; 0.2522264785494494; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.39623320406434; 0.3975960596292668; 0.4100742336915555; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.4304973629098372; 0.4335751357405352; 0.4335751357405352; 0.4352815161963393; 0.4352815161963393; 0.4506578937113162; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4906258721078565; 0.498994845947585; 0.5097818625871164; 0.5619299124666532; 0.5710095678317721; 0.5710095678317721; 0.5913651925298382; 0.610971999959321; 0.6274540883972485; 0.6496433426951205; 0.6656356363792992; 0.6941270729825465; 0.7045203904267408; 0.717484976234209; 0.8064248359603999; 0.8758099322635008; 0.9274396272108874,Schizophrenia; Arsenic Encephalopathy; Dermatologic Disorders; Mental Depression; Stress Disorder; Myocardial Ischemia; Mood Disorder; Gastroesophageal Reflux Disease; Narcolepsy; Bipolar Disorder; Asthma; Myeloid Leukemia; Manic Disorder; Leukemia; Anxiety Disorder; Autism,0.0531117779464085; 0.185736315425117; 0.2895940391390291; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4742592264758768; 0.4875380732267193; 0.4875380732267193; 0.504364324740411; 0.525214105372123; 0.7112499273451761; 0.7167438233451096; 0.947453223782586; 0.9783327858636056,"Early-onset Lafora body disease ORPHA:324290; GM3 synthase deficiency ORPHA:370933; Mowat-Wilson syndrome due to a ZEB2 point mutation ORPHA:261552; Mowat-Wilson syndrome due to monosomy 2q22 ORPHA:261537; PDE4D haploinsufficiency syndrome ORPHA:439822; XYLT1-CDG ORPHA:370930; Mucopolysaccharidosis type 2, attenuated form ORPHA:217093; Mucopolysaccharidosis type 2, severe form ORPHA:217085",0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423,,,,,,
PDGFB,"Mammary Neoplasms; Breast Carcinoma; melanoma; Malignant mesothelioma; ovarian neoplasm; Fibrosarcoma; Medulloblastoma; Skin carcinoma; Malignant neoplasm of prostate; Brain Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasm; Glioma; Glioblastoma; Liver Cirrhosis; Prostate carcinoma; Colorectal Neoplasms; Liver carcinoma; Osteosarcoma; Hamman-Rich syndrome; Sarcoma; Neck Neoplasms; Visual seizure; Clouding of corneal stroma; Systemic Scleroderma; Seizures; Lung Neoplasms; Corneal Opacity; Osteosarcoma of bone; Anoxia; Mannose-Binding Protein Deficiency; Basal ganglia calcification; Cirrhosis; Myeloid Leukemia; Idiopathic Pulmonary Fibrosis; Anaplastic Oligodendroglioma; Postural instability; Carcinoma of lung; Thyroid Neoplasm; Mask-like facies; Muscle Rigidity; Myelomonocytic leukemia; Inflammation; Fetal Growth Retardation; Schizophrenia; Malignant Glioma; Hypertensive disease; Leukemia, Myelocytic, Acute; HIV Infections; Skin Neoplasms; Soft Tissue Neoplasms; Carcinoma, Papillary; Malformations of Cortical Development, Group II; Astrocytoma; Alzheimer's Disease; Spinal Neoplasms; Uncoordinated limb movement; Fahr's syndrome (disorder); Fibrosis of bile duct; Intraspinal Neoplasm; Limb dysmetria; Microcalcification; Thrombocythemia, Essential; Other ureteric obstruction; Inflammatory Bowel Diseases; Glomerulonephritis; Adult Fibrosarcoma; Familial meningioma; Tumoral calcinosis; Infant, Small for Gestational Age; Pulmonary Hypertension; Intrauterine retardation; Asthma; Anemia; Acute Erythroblastic Leukemia; Epilepsy; Thrombocytosis, Autosomal Dominant; Calcinosis; Nephritis; Subcutaneous hemorrhage; Mental deterioration; Fibrosis; Dizziness; Depressive disorder; IGA Glomerulonephritis; Vertigo; Meningioma, benign, no ICD-O subtype; Celiac Disease; Spinal Cord Neoplasms; Laryngeal dystonia; Lenticulostriate Disorders; Monosomy 22; Extrapyramidal Disorders; Cholestasis; Fibromatosis, Aggressive; Forgetful; Cerebral calcification; Primary Myelofibrosis; Anxiety; Bradykinesia; Brain Infarction; Ulcer; Acute Megakaryocytic Leukemias; Oligohydramnios; Down Syndrome; Dermatofibrosarcoma; Mesangial proliferative glomerulonephritis; Histiocytosis, Langerhans-Cell; Thrombocytopenia; Dilated ventricles (finding); Follicular adenoma; Basal Ganglia Diseases; Cutaneous Fibrous Histiocytoma; Malignant Fibrous Histiocytoma; Pulmonary Fibrosis; Meningiomas, Multiple; Meningioma; Encephalitis; Migraine Disorders; Nasal Polyps; Athetosis; Dystonic disease; Hepatomegaly; Decreased platelet count; Skin Ulcer; Tremor; leukemia; Mesothelioma; Malignant neoplasm of skin; Apathy; Myeloid Leukemia, Chronic; Adenomatous Polyposis Coli; Diffusely thickened skin; Psychotic Disorders; Intermittent migraine headaches; Kaposi Sarcoma; Thick skin; Small head; Dermatofibrosarcoma Protuberans; Giant Cell Fibroblastoma; HIV encephalitis; Primary biliary cirrhosis; Dysdiadochokinesis; Arteriosclerosis; Mesenchymal Cell Neoplasm; Memory impairment; nervous system disorder; Erythema; Choreatic disease; Malignant Meningioma; Atherosclerosis; Memory Loss; Parkinsonian Disorders; Gingival Hyperplasia; Infection; Urinary Incontinence; Low grade glioma; Lung Diseases, Interstitial; Multiple, subcutaneous nodules; Subcutaneous nodule; Dystonia; Dementia; Retinal Diseases; Chorea; Dyskinetic syndrome; Gait abnormality; Henoch-Schoenlein Purpura; Lupus Nephritis; Impaired cognition; Intellectual Disability; Dysarthria; Anxiety disease; Hyperreflexia",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0354767239335874; 0.0482468351695405; 0.0569142010728473; 0.064548079316548; 0.0648809611869375; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0773771948186562; 0.0773771948186562; 0.0827744840860166; 0.095319386034013; 0.1029977559100099; 0.13167400689206; 0.1537760235124317; 0.1614820148711231; 0.1735868515093891; 0.1859959283872542; 0.1900258729042946; 0.2053083986145698; 0.2062010908869036; 0.2085938372806741; 0.2109483801368481; 0.2462384927636234; 0.2643145809900195; 0.286740104053178; 0.2923761731100008; 0.2980670559114652; 0.3099246715197673; 0.3176684185973055; 0.3220099003872086; 0.3663130598151661; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.39623320406434; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4100901006059349; 0.4100901006059349; 0.4100901006059349; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.425992946703162; 0.4269926086051838; 0.4304973629098372; 0.4304973629098372; 0.4330362522463816; 0.4335751357405352; 0.4335751357405352; 0.4396723023384634; 0.4396723023384634; 0.4450743762496232; 0.4459714599189374; 0.4459714599189374; 0.4459714599189374; 0.4506578937113162; 0.4561717689698902; 0.4561717689698902; 0.4564472886428772; 0.4588513406515081; 0.4635211539849193; 0.466957409863091; 0.4675904598629673; 0.472444704048021; 0.4749780675672355; 0.4753011022966241; 0.4753011022966241; 0.4790179402069343; 0.4851378030288289; 0.4852430673532381; 0.4906258721078565; 0.4906258721078565; 0.4906258721078565; 0.4906258721078565; 0.4923669467696064; 0.4923669467696064; 0.5019670090704682; 0.5090214163899865; 0.5188223685230745; 0.5276472086074249; 0.5299466034567416; 0.5337853752290136; 0.5337853752290136; 0.5393787854381349; 0.5568517196017908; 0.5683976277847906; 0.5710095678317721; 0.5959654688257199; 0.6084642888478995; 0.6196470808426647; 0.6207008101484466; 0.6274540883972485; 0.6274540883972485; 0.6334536292962906; 0.6364853529519863; 0.655573080043894; 0.655573080043894; 0.672336954961104; 0.7138331851025355; 0.7317475852509061; 0.7433468668038986; 0.8000044931629623; 0.8352623613787349; 0.8464957591845941; 0.8499037334512025; 0.869420268668135,Liver Carcinoma; Pulmonary Fibrosis; Alveolitis; Brain Neoplasms; Tumoral Calcinosis; Oculomotor Nerve Palsy; Hydrocephalus; Parkinson Disease; Hypothalamic Hypothyroidism; Multiple Meningioma; Fahr`s Syndrome; Bilateral Striopallidodentate Calcinosis; Fibrosarcoma; Brain Stem Compression; Skin Neoplasms; Neurofibroma; Mental Depression; Growth Hormone Deficiency; Basal Ganglia Diseases; Lenticulostriate Disorders; Extrapyramidal Disease; Psychosis; Subcutaneous Hemorrhage; Thrombocythemia; Spinal Meningioma; Migraine; Papilledema; Erectile Dysfunction; Intracranial Meningioma; Trigeminal Neuralgia; Tongue Neoplasms; Cirrhosis; Dementia; Microcephaly; Amnesia; Thrombocytosis; Meningioma; Speech Disorders; Hypogonadotropic Hypogonadism; Retinal Diseases; Facial Paralysis; Proptosis; Malformation Of Cortical Development; Hypothyroidism; Mood Swings; Dyskinetic Syndrome; Anxiety Disorder; Obesity; Dysarthria,0.0520696613701797; 0.0654534781440596; 0.1025546857843372; 0.1534453668959814; 0.2954316182315451; 0.336287627428424; 0.3657224783929353; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4402141802500753; 0.4402141802500753; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4602028929328057; 0.4602028929328057; 0.4602028929328057; 0.4646409362700993; 0.4875380732267193; 0.4875380732267193; 0.5123947823327547; 0.5129298662020659; 0.525214105372123; 0.5498080544456183; 0.6239791345488227; 0.6325735973587235; 0.6329251700753155; 0.696610260564548; 0.7558828942158288; 0.776786668801341; 0.7921294370722203; 0.8369864135373719; 0.9082935011758586; 0.947453223782586; 0.9568083835980838; 0.9724404706118156,Dermatofibrosarcoma protuberans ORPHA:31112; Bilateral frontoparietal polymicrogyria ORPHA:101070; Bilateral striopallidodentate calcinosis ORPHA:1980; Familial multiple meningioma ORPHA:263662; Meningioma ORPHA:2495,0.0180064224283883; 0.0586579655822394; 0.1697334635963512; 0.6279395134845649; 0.6581690778726346,"Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Cowpox virus CPXV209 protein (gene: CPXV209 CDS)",0.6806291584193672; 0.6806291584193672; 0.6920622798772148,Escherichia coli;Homo sapiens HEK293T embryonic kidney cell;In vitro,0.35;0.73,Homo sapiens,Homo sapiens
PIR,"melanoma; Secondary malignant neoplasm of lymph node; Leukemia, Myelocytic, Acute; Acute Promyelocytic Leukemia; Contact hypersensitivity; Contact Dermatitis; Promyelocytic leukemia",0.0149315928814189; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.425419812815905; 0.4615352570710579; 0.4675904598629673,Osteoporosis; Dermatitis,0.4541466895915311; 0.525214105372123,Glutamate-cysteine ligase deficiency ORPHA:33574; Aromatase deficiency ORPHA:91; Aromatase excess syndrome ORPHA:178345; Citrullinemia type II ORPHA:247585; Dopa-responsive dystonia due to sepiapterin reductase deficiency ORPHA:70594; Neonatal intrahepatic cholestasis due to citrin deficiency ORPHA:247598; Congenital cataract-severe neonatal hepatopathy-global developmental delay syndrome ORPHA:521432; Dyschromatosis universalis hereditaria ORPHA:241; Familial pseudohyperkalemia ORPHA:90044; Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria ORPHA:99646; SRD5A3-CDG ORPHA:324737,0.0586579655822394; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
PLEKHD1,,,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,NON RARE IN EUROPE: Isolated keratoconus ORPHA:2335; Deafness-infertility syndrome ORPHA:94064; Occult macular dystrophy ORPHA:247834; Spinocerebellar ataxia type 31 ORPHA:217012; Oguchi disease ORPHA:75382; Female infertility due to zona pellucida defect ORPHA:404466; Usher syndrome type 3 ORPHA:231183; Congenital stationary night blindness ORPHA:215,0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7120423847116372,,,,,,
PLK2,"Ovarian Carcinoma; Tumor Progression; Adenocarcinoma; Squamous cell carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Epithelial ovarian cancer; Carcinoma; Carcinomatosis; Malignant neoplasm of pancreas; Lymphoma; Glioblastoma; Pancreatic carcinoma; Anaplastic carcinoma; Liver carcinoma; Osteosarcoma; Chronic Lymphocytic Leukemia; Hematologic Neoplasms; MYELODYSPLASTIC SYNDROME; Undifferentiated carcinoma; Mammary Carcinoma, Animal; Animal Mammary Neoplasms; Sarcoma; Lung Neoplasms; Osteosarcoma of bone; Adverse reaction to drug; Drug toxicity; Burkitt Lymphoma; Malignant neoplasm of liver; Ischemic stroke; Mammary Neoplasms, Experimental; Laryngeal Squamous Cell Carcinoma; Non-Small Cell Lung Carcinoma; Leukemia, Myelocytic, Acute; Hydroa Vacciniforme; Alzheimer's Disease; Endometrioid carcinoma ovary; Liver and Intrahepatic Biliary Tract Carcinoma; Parkinson Disease; Myeloid neoplasm; Carcinoma of larynx; Multiple Myeloma; Juvenile arthritis; Malignant neoplasm of larynx; Lewy Body Disease; Mild cognitive disorder; Juvenile psoriatic arthritis; Juvenile-Onset Still Disease; Ulcerative Colitis; Adenocarcinoma of lung (disorder); Childhood Osteosarcoma; Irritable Bowel Syndrome",0.0034602840073026; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0228075668512991; 0.0277695594716545; 0.0308703957553632; 0.0387439397151409; 0.0593779966354549; 0.0617471306652618; 0.0726340460169901; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.084286432100041; 0.095319386034013; 0.1029977559100099; 0.1147307578771389; 0.1253114324938153; 0.1254380558571286; 0.13167400689206; 0.1352936728187231; 0.1352936728187231; 0.1537760235124317; 0.2062010908869036; 0.2109483801368481; 0.223747154820789; 0.223747154820789; 0.2521987644415915; 0.2643145809900195; 0.3486533561309259; 0.3508665345292502; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.39623320406434; 0.4028066164685291; 0.4103119460235835; 0.4126392832024548; 0.4192169590514327; 0.424575176503444; 0.4506578937113162; 0.472444704048021; 0.4810435657134442; 0.5001612228394569; 0.51550637274795; 0.553002957824355; 0.6545439509404224,"Anaplastic Carcinoma; Carcinoma; Arthritis; Juvenile Arthritis; Polyarthritis, Rheumatoid Factor Positive; Ovarian Endometrioid Carcinoma; Seronegative Polyarthritis; Still Disease; Lung Adenocarcinoma",0.0402286636010764; 0.0534520155998091; 0.4541466895915311; 0.4646409362700993; 0.4646409362700993; 0.4875380732267193; 0.4875380732267193; 0.504364324740411; 0.7979764766391754,"Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Auriculocondylar syndrome ORPHA:137888; Chondrosarcoma ORPHA:55880; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402; Trichorhinophalangeal syndrome type 2 ORPHA:502; Alagille syndrome due to 20p12 microdeletion ORPHA:261600; Alagille syndrome due to a JAG1 point mutation ORPHA:261619; Griscelli syndrome type 3 ORPHA:79478; ABeta amyloidosis, Arctic type ORPHA:324723; ABeta amyloidosis, Dutch type ORPHA:100006; ABeta amyloidosis, Iowa type ORPHA:324708; ABeta amyloidosis, Italian type ORPHA:324713; ABetaA21G amyloidosis ORPHA:324718; ABetaL34V amyloidosis ORPHA:324703; Colobomatous macrophthalmia-microcornea syndrome ORPHA:468672; Chondrodysplasia-disorder of sex development syndrome ORPHA:1422; NON RARE IN EUROPE: Idiopathic infantile nystagmus ORPHA:651",0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.6239678957896782,"Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Horsepox virus HSPV020e (ankyrin repeats); Cowpox virus CPXV206 protein (gene: CPXV206 CDS); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Horsepox virus HSPV011a; Vaccinia virus hypothetical protein; Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Variola virus hypothetical protein (gene: B21R); Cowpox virus VHR1 or CPXV025 protein (gene: VHR1); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human gammaherpesvirus 8 ORF72; Horsepox virus HSPV011c (ankyrin repeats); Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Horsepox virus HSPV194 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Monkeypox virus ankyrin-like protein; Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Cowpox virus CPXV016 protein (gene: CPXV016 CDS); Cowpox virus CPXV213 protein (gene: CPXV213 CDS); Ectromelia virus ERPV serine/threonine kinase; Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Vaccinia virus Ankara 54.4k ankyrin repeat protein f2; Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Cowpox virus CPXV211 protein (gene: CPXV211 CDS); Cowpox virus CPXV011 protein (gene: CPXV011 CDS); Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Horsepox virus HSPV033c (ankyrin repeats); Vaccinia virus ankyrin-like protein; Horsepox virus HSPV005c (Ankyrin repeats); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Yaba-like disease virus 148R protein (gene: 148R); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Yaba-like disease virus 8L protein (gene: 8L); Horsepox virus HSPV196 (ankyrin-like protein; Provisional); Ectromelia virus ERPV ankyrin; Cowpox virus CPXV039 (gene: CPXV039 CDS); Vaccinia virus Ankara CP77 Host range protein f1; Yaba-like disease virus 146R protein (gene: 146R); Vaccinia virus ankyin-like protein (gene: M1L); Monkeypox virus Zaire-96-I-16 J3L (gene: J3L); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D7L); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Cowpox virus CPXV017 protein (gene: CPXV017 CDS); Monkeypox virus Zaire-96-I-16 B17R (gene: B17R); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D9L); Cowpox virus CPXV019 protein (gene: CPXV019 CDS); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D1L); Horsepox virus HSPV181 (ankyrin repeats); Vaccinia virus ankyrin-like protein (gene: B4R); Variola virus hypothetical protein (gene: B19R); Vaccinia virus Ankara 67.9k ankyrin repeat protein; Cowpox virus CPXV008 protein (gene: CPXV008 CDS); Yaba monkey tumor virus ankyrin repeat protein; Horsepox virus HSPV014c (ankyrin repeats); Vaccinia virus ankyrin-like protein (gene: B18R); Vaccinia virus Ankara 72.4k ankyrin repeat protein f2; Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Horsepox virus HSPV011b (ankyrin repeats); Variola virus hypothetical protein (gene: G3R); Variola virus hypothetical protein (gene: D6L); Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Orf virus ORF129 ankyrin repeat protein; Vaccinia virus Ankara 54.4k ankyrin repeat protein f1; Yaba-like disease virus 147R protein (gene: 147R); Variola virus ankyin-like protein (gene: O1L); Monkeypox virus Zaire-96-I-16 ankyin-like protein (gene: O1L); Yaba-like disease virus 11L protein (gene: 11L); Cowpox virus CPXV006 protein (gene: CPXV006 CDS); Horsepox virus HSPV012 (ankyrin-like protein; Provisional); Orf virus ORF128 ankyrin repeat protein; Orf virus ORF126 ankyrin repeat protein; Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Cowpox virus CPXV220 protein (gene: CPXV220 CDS); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Yaba monkey tumor virus ankyrin-like protein; Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3)",0.6980058392556946; 0.7079503198328393; 0.7108466056279036; 0.7553529087917877; 0.776311155917498; 0.7975886343350181; 0.7975886343350181; 0.7988086321880973; 0.8031136315766868; 0.8090912655264054; 0.8090912655264054; 0.8164631368980444; 0.830387084488226; 0.8315214238833722; 0.8320620882218038; 0.8390943852085586; 0.8426793553344071; 0.8458935424065495; 0.8507994162096807; 0.8565042041973229; 0.8567113603862105; 0.8623814598290633; 0.8665950357166999; 0.876049415394169; 0.8784689389733535; 0.8826243651582266; 0.8826243651582266; 0.8826243651582266; 0.8912506515619287; 0.9005654634109755; 0.9049668877841942; 0.9055720084468104; 0.9097056179628632; 0.9102852214746716; 0.9195586782304176; 0.9199249371723298; 0.920189880588384; 0.920189880588384; 0.924238809115565; 0.9271250260824724; 0.9285312497152513; 0.9317407101292444; 0.9320456693098416; 0.93590945176733; 0.9394149990743936; 0.9407405842467907; 0.9475760000797028; 0.9475760000797028; 0.9475760000797028; 0.9517968639566384; 0.9518028028273808; 0.9566905696255492; 0.9566905696255492; 0.9566905696255492; 0.960637237597315; 0.960637237597315; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9624639844306644; 0.9676678660011035; 0.9782376397065295; 0.9784209964188774; 0.978680518510813; 0.985687915361386; 0.986358730247118; 0.9867877113290736; 0.988150003801932; 0.9886132556795868; 0.9886132556795868,Homo sapiens HeLa epitheloid cervical carcinoma cell,0.4,Homo sapiens,Mus musculus
PLSCR4,Lymphoma; Small cell carcinoma of lung; Embryonal Carcinoma; Teratoma; Schizophrenia; Teratocarcinoma; Down Syndrome; Trisomy,0.0739788831250619; 0.1193558174333938; 0.3112516166225269; 0.383941725017158; 0.3933196962529684; 0.3941558617476422; 0.4126392832024548; 0.4335751357405352,Schizophrenia; Lung Carcinoma,0.0531117779464085; 0.4541466895915311,"Atrial septal defect, ostium primum type ORPHA:99106; Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; 20p12.3 microdeletion syndrome ORPHA:261295; Papillary renal cell carcinoma ORPHA:319298; Waardenburg syndrome type 2 ORPHA:895; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Autosomal recessive brachyolmia ORPHA:448242; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Diaphanospondylodysostosis ORPHA:66637; Familial drusen ORPHA:75376; Hereditary neuropathy with liability to pressure palsies ORPHA:640; Ischiovertebral syndrome ORPHA:85200; Primary CD59 deficiency ORPHA:169464; RIN2 syndrome ORPHA:217335; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; Congenital diaphragmatic hernia ORPHA:2140; Piebaldism ORPHA:2884; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721; 19p13.3 microduplication syndrome ORPHA:447980; Alpha-B crystallin-related late-onset myopathy ORPHA:399058; Cerebral autosomal recessive arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:199354; Chronic enteropathy associated with SLCO2A1 gene ORPHA:468641; Congenital alveolar capillary dysplasia ORPHA:210122; Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome ORPHA:412022; Familial generalized lentiginosis ORPHA:231040; Fatal infantile hypertonic myofibrillar myopathy ORPHA:280553; HTRA1-related autosomal dominant cerebral small vessel disease ORPHA:482077; Malan overgrowth syndrome ORPHA:420179; Marshall-Smith syndrome ORPHA:561; Monoamine oxidase A deficiency ORPHA:3057; Multiple paragangliomas associated with polycythemia ORPHA:324299; NON RARE IN EUROPE: Benign familial hematuria ORPHA:97562; Non-immune hydrops fetalis ORPHA:363999; Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome ORPHA:447961; Recessive X-linked ichthyosis ORPHA:461; Syndromic recessive X-linked ichthyosis ORPHA:281090; Malignant peripheral nerve sheath tumor ORPHA:3148; Phakomatosis cesioflammea ORPHA:79483; Familial thoracic aortic aneurysm and aortic dissection ORPHA:91387; Periodontal Ehlers-Danlos syndrome ORPHA:75392; 1p31p32 microdeletion syndrome ORPHA:401986; Brachydactyly-arterial hypertension syndrome ORPHA:1276; Familial retinal arterial macroaneurysm ORPHA:284247; MITF-related melanoma and renal cell carcinoma predisposition syndrome ORPHA:293822; Tietz syndrome ORPHA:42665; Trehalase deficiency ORPHA:103909; Familial calcium pyrophosphate deposition ORPHA:1416; Silver-Russell syndrome due to 11p15 microduplication ORPHA:231144; Silver-Russell syndrome due to an imprinting defect of 11p15 ORPHA:231140; Beckwith-Wiedemann syndrome due to imprinting defect of 11p15 ORPHA:231117; Isolated hemihyperplasia ORPHA:2128; Congenital glaucoma ORPHA:98976; NON RARE IN EUROPE: Age-related macular degeneration ORPHA:279; Heritable pulmonary arterial hypertension ORPHA:275777; Autosomal recessive spastic paraplegia type 5A ORPHA:100986; Complement component 3 deficiency ORPHA:280133; Congenital bile acid synthesis defect type 3 ORPHA:79302; Fibrodysplasia ossificans progressiva ORPHA:337; Laminin subunit alpha 2-related congenital muscular dystrophy ORPHA:258; Spinocerebellar ataxia type 27 ORPHA:98764; X-linked spondyloepimetaphyseal dysplasia ORPHA:93349; Acromicric dysplasia ORPHA:969; Atypical hemolytic uremic syndrome with complement gene abnormality ORPHA:544472; Craniometaphyseal dysplasia ORPHA:1522; Familial vesicoureteral reflux ORPHA:289365; De novo thrombotic microangiopathy after kidney transplantation ORPHA:244275; ANGPT1-related hereditary angioedema with normal C1Inh ORPHA:537891; Autosomal recessive extra-oral halitosis ORPHA:562538; Blue rubber bleb nevus ORPHA:1059; Immunodeficiency with factor H anomaly ORPHA:200421; Immunodeficiency with factor I anomaly ORPHA:200418; Kaposiform hemangioendothelioma ORPHA:2122; Late-onset retinal degeneration ORPHA:67042; Mucocutaneous venous malformations ORPHA:2451; OBSOLETE: Alpha-1-antichymotrypsin deficiency ORPHA:93594; Pyle disease ORPHA:3005; Severe hereditary thrombophilia due to congenital protein S deficiency ORPHA:743; Tufted angioma ORPHA:1063; X-linked intellectual disability, Stocco Dos Santos type ORPHA:85288; HELLP syndrome ORPHA:244242; Autosomal dominant secondary polycythemia ORPHA:247511; Inherited congenital spastic tetraplegia ORPHA:210141; Autosomal recessive proximal renal tubular acidosis ORPHA:93607; Brachytelephalangic chondrodysplasia punctata ORPHA:79345; Obesity due to leptin receptor gene deficiency ORPHA:179494; Dense deposit disease ORPHA:93571; Renal tubular dysgenesis of genetic origin ORPHA:97369",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0092060390928213; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0902044104910482; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.1739455566145445; 0.1782034488938806; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,yeasx,0.37;0.56,Bacillus anthracis;Homo sapiens,Homo sapiens
PPP1R14B,melanoma; Acquired CJD; Parasitemia,0.0149315928814189; 0.383941725017158; 0.4192169590514327,Melanoma,0.4646409362700993,"Amish nemaline myopathy ORPHA:98902; Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome ORPHA:508476; Oculootodental syndrome ORPHA:99806; Adult-onset distal myopathy due to VCP mutation ORPHA:329478; Auditory neuropathy-optic atrophy syndrome ORPHA:542585; Autosomal dominant Charcot-Marie-Tooth disease type 2Y ORPHA:435387; Autosomal recessive ataxia due to PEX10 deficiency ORPHA:247815; B3GALT6-related spondylodysplastic Ehlers-Danlos syndrome ORPHA:536467; DDOST-CDG ORPHA:300536; Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome ORPHA:543470; Smith-Lemli-Opitz syndrome ORPHA:818; Spastic paraplegia-Paget disease of bone syndrome ORPHA:329475; Caudal regression sequence ORPHA:3027; Acquired partial lipodystrophy ORPHA:79087; Autosomal dominant omodysplasia ORPHA:93328; Autosomal recessive cutis laxa type 2B ORPHA:357064; Autosomal recessive epidermolytic ichthyosis ORPHA:512103; Cerebrocostomandibular syndrome ORPHA:1393; Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome ORPHA:330054; Costello syndrome ORPHA:3071; D,L-2-hydroxyglutaric aciduria ORPHA:356978; Erythrocyte galactose epimerase deficiency ORPHA:308473; FADD-related immunodeficiency ORPHA:306550; Familial hypocalciuric hypercalcemia type 3 ORPHA:101050; Generalized galactose epimerase deficiency ORPHA:308487; Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom ORPHA:500159; Ocular anomalies-axonal neuropathy-developmental delay syndrome ORPHA:496790; PYCR1-related De Barsy syndrome ORPHA:293633; Phakomatosis pigmentokeratotica ORPHA:2874; Progressive myoclonic epilepsy type 9 ORPHA:457265; RFVT2-related riboflavin transporter deficiency ORPHA:572543; S-adenosylhomocysteine hydrolase deficiency ORPHA:88618; Woolly hair nevus ORPHA:79414; Familial melanoma ORPHA:618",0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7166448869866529,,,,,,
PRMT6,"Mammary Neoplasms; Breast Carcinoma; Tumor Progression; melanoma; Malignant neoplasm of breast; Carcinogenesis; Neoplasm Metastasis; Osteosarcoma; Osteosarcoma of bone; Severe Combined Immunodeficiency; Malformations of Cortical Development, Group II; Bulbo-Spinal Atrophy, X-Linked; Cocaine Abuse; Non-obstructive azoospermia; Obesity; Oligospermia; Cocaine Dependence; Cocaine-Related Disorders",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991; 0.0648809611869375; 0.1029977559100099; 0.2109483801368481; 0.3553621627681198; 0.3933196962529684; 0.4118266358241932; 0.4192169590514327; 0.4675904598629673; 0.5140447474168605; 0.5178072301085912; 0.6304655343580164; 0.7683326132740758,,,,,,,Homo sapiens HEK293T embryonic kidney cell;In vitro;yeasx,0.35;0.52;0.56,Homo sapiens;hhv8,Homo sapiens;chemical synthesis
PRR15,Colorectal Carcinoma; Colorectal Cancer; Gastrointestinal Neoplasms; Intestinal Neoplasms,0.0034602840073026; 0.0149315928814189; 0.2062010908869036; 0.4675904598629673,,,Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Bartsocas-Papas syndrome ORPHA:1234; CHAND syndrome ORPHA:1401; Marie Unna hereditary hypotrichosis ORPHA:444; Progressive familial intrahepatic cholestasis type 1 ORPHA:79306; Blepharo-cheilo-odontic syndrome ORPHA:1997; Lethal acantholytic erosive disorder ORPHA:158687; Apparent mineralocorticoid excess ORPHA:320; Autosomal recessive spastic paraplegia type 35 ORPHA:171629; Congenital hereditary endothelial dystrophy type I ORPHA:98975; Fatty acid hydroxylase-associated neurodegeneration ORPHA:329308; MUC1-related autosomal dominant tubulointerstitial kidney disease ORPHA:88949; Naxos disease ORPHA:34217; RFVT3-related riboflavin transporter deficiency ORPHA:572550; Microvillus inclusion disease ORPHA:2290; Congenital tufting enteropathy ORPHA:92050; Hereditary hypercarotenemia and vitamin A deficiency ORPHA:199285; Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) ORPHA:402020,0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423,,,In vitro;yeasx,0.35;0.44;0.56,HCV77;Homo sapiens;chemical synthesis,Homo sapiens
PRSS23,Breast Carcinoma; Tumor Progression; melanoma; Malignant neoplasm of breast; Exudative vitreoretinopathy 1,0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.3933196962529684,Retinopathy; Exudative Vitreoretinopathy; Exudative Retinopathy; Melanoma; Retinal Detachment; Retinal Dysplasia; Hearing Loss,0.4286813331685578; 0.4541466895915311; 0.4560460337187313; 0.4646409362700993; 0.4867879381749835; 0.4875380732267193; 0.5632819212593052,"Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; Auriculocondylar syndrome ORPHA:137888; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Autosomal recessive brachyolmia ORPHA:448242; Primary CD59 deficiency ORPHA:169464; RIN2 syndrome ORPHA:217335; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; Familial primary localized cutaneous amyloidosis ORPHA:353220; Trichorhinophalangeal syndrome type 2 ORPHA:502; Aneurysm-osteoarthritis syndrome ORPHA:284984; Colobomatous macrophthalmia-microcornea syndrome ORPHA:468672; X-linked hypophosphatemia ORPHA:89936; Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome ORPHA:444138; Autosomal dominant Emery-Dreifuss muscular dystrophy ORPHA:98853",0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.6239678957896782; 0.6268296504510718,,,,,,
PSMB9,"Epithelioma; melanoma; ovarian neoplasm; Malignant neoplasm of prostate; Renal Cell Carcinoma; Lymphoma; Glioblastoma; Carcinoma breast stage IV; Liver Cirrhosis, Experimental; Prostate carcinoma; Squamous cell carcinoma of esophagus; Colonic Neoplasms; Rheumatoid Arthritis; Hydatidiform Mole, Partial; cervical cancer; Hodgkin Disease; Malignant tumor of cervix; Diabetes Mellitus, Insulin-Dependent; Cervix carcinoma; Multiple Sclerosis; Fibroid Tumor; Sjogren's Syndrome; Ataxia Telangiectasia; Leukemogenesis; Tuberculosis; Human papilloma virus infection; Collagen Diseases; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Uterine Fibroids; Epstein-Barr Virus Infections; Complete hydatidiform mole; Nasopharyngeal carcinoma; Juvenile rheumatoid arthritis; Alzheimer's Disease; Lymphoma, Non-Hodgkin; Acute anterior uveitis; HYDATIDIFORM MOLE, RECURRENT, 1; Acquired hypothyroidism; Spondylarthropathies; Juvenile arthritis; Lupus Erythematosus, Systemic; Disorder of eye; West Nile viral infection; Psoriasis; Niemann-Pick Disease, Type C; Hydatidiform Mole; Primary Sj??gren's syndrome; Extrinsic allergic alveolitis; Rheumatism; Coinfection; Toeing-in; Crohn Disease; Graves Disease; Leiomyosarcoma of uterus; Hepatitis A; Infectious Mononucleosis; Erectile dysfunction; LATERAL MENINGOCELE SYNDROME; Autoimmune Diseases; Arthritis; Peptic Esophagitis; Arthropathy; LIMB-MAMMARY SYNDROME; Uveitis; Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site; Ankylosing spondylitis; Spondylarthritis; Hashimoto Disease; Hypothyroidism; Complete atrioventricular block",0.0149002095788623; 0.0149315928814189; 0.0191435238361999; 0.0569142010728473; 0.0648809611869375; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0747863377072194; 0.0773771948186562; 0.0919714360040484; 0.1454373331146953; 0.1537760235124317; 0.1897991423047819; 0.2050045461627939; 0.2454476567103779; 0.2714542429024338; 0.2714542429024338; 0.2834835531038365; 0.2835142372342932; 0.290158730291654; 0.3099246715197673; 0.3508665345292502; 0.3510063969122338; 0.3706856725676674; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.4028066164685291; 0.4126392832024548; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.4304973629098372; 0.4352815161963393; 0.4506578937113162; 0.451408428170596; 0.472444704048021; 0.4790179402069343; 0.489336365264797; 0.4923669467696064; 0.4981941174985421; 0.4981941174985421; 0.5019670090704682; 0.5090214163899865; 0.5188223685230745; 0.5393787854381349; 0.549941235475765; 0.5512224939896888; 0.553002957824355; 0.553002957824355; 0.5557519470957561; 0.5568517196017908; 0.5682392297191953; 0.5710095678317721; 0.6446807314576214; 0.6588479076808555; 0.6962828901009075; 0.8306551823873084; 0.8701913670211346,Schizophrenia; Myositis; Proteasome-associated Autoinflammatory Syndrome; Development Disorder; Arthritis; Rheumatoid Arthritis; Panniculitis; Anemia; Lymphopenia; Oral Ulcer; Narcolepsy; Dermatitis; Acanthosis Nigricans; Sinusitis; Conjunctivitis; Crohn Disease; Lipodystrophy; Diabetes Mellitus,0.0531117779464085; 0.425341435586089; 0.4286813331685578; 0.4372065554432662; 0.4541466895915311; 0.4560460337187313; 0.4646409362700993; 0.4780231573499264; 0.4780231573499264; 0.4809179010794786; 0.4875380732267193; 0.525214105372123; 0.555382961603519; 0.5576425853515448; 0.6304164862793252; 0.7414460416900516; 0.7833015488163313; 0.9683912711598086,Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944; Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome ORPHA:566175; Galactose mutarotase deficiency ORPHA:570422; Generalized glucocorticoid resistance syndrome ORPHA:786; Acatalasemia ORPHA:926; Haim-Munk syndrome ORPHA:2342; Overgrowth-macrocephaly-facial dysmorphism syndrome ORPHA:137634; Papillon-Lefevre ORPHA:678; Autoimmune lymphoproliferative syndrome with recurrent viral infections ORPHA:275517; Cleidocranial dysplasia ORPHA:1452; Familial normophosphatemic tumoral calcinosis ORPHA:306658; Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia ORPHA:572428; MIRAGE syndrome ORPHA:494433; Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ORPHA:2504; Neutrophil immunodeficiency syndrome ORPHA:183707; Predisposition to severe viral infection due to IRF7 deficiency ORPHA:574918; Proteasome-associated autoinflammatory syndrome ORPHA:324977; Cystic leukoencephalopathy without megalencephaly ORPHA:85136; Epidermodysplasia verruciformis ORPHA:302; Diffuse cutaneous systemic sclerosis ORPHA:220393; Limited cutaneous systemic sclerosis ORPHA:220402; Aicardi-Goutieres syndrome ORPHA:51; Primary biliary cholangitis ORPHA:186; Immunodeficiency by defective expression of MHC class I ORPHA:34592; Singleton-Merten dysplasia ORPHA:85191; 1p21.3 microdeletion syndrome ORPHA:293948; Ataxia-pancytopenia syndrome ORPHA:2585; Autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome ORPHA:391487; Autosomal dominant Kenny-Caffey syndrome ORPHA:93325; Autosomal dominant hyper-IgE syndrome ORPHA:2314; Bacterial susceptibility due to TLR signaling pathway deficiency ORPHA:183713; Birdshot chorioretinopathy ORPHA:179; Charcot-Marie-Tooth disease type 1C ORPHA:101083; Chronic lymphoproliferative disorder of natural killer cells ORPHA:512017; Dihydropyrimidine dehydrogenase deficiency ORPHA:1675; Griscelli syndrome type 2 ORPHA:79477; Hepatic veno-occlusive disease-immunodeficiency syndrome ORPHA:79124; Hereditary pediatric Behcet-like disease ORPHA:476102; Hyper-IgM syndrome type 3 ORPHA:101090; Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency ORPHA:70592; Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency ORPHA:319563; Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency ORPHA:319595; NIK deficiency ORPHA:447731; NON RARE IN EUROPE: Ankylosing spondylitis ORPHA:825; Nasopharyngeal carcinoma ORPHA:150; Osteocraniostenosis ORPHA:2763; Pulmonary arterial hypertension associated with connective tissue disease ORPHA:275798; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations ORPHA:247691; STAT3-related early-onset multisystem autoimmune disease ORPHA:438159; STING-associated vasculopathy with onset in infancy ORPHA:425120; Susceptibility to viral and mycobacterial infections due to STAT1 deficiency ORPHA:391311; T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency ORPHA:169154; T-cell large granular lymphocyte leukemia ORPHA:86872; Variant ABeta2M amyloidosis ORPHA:314652; Waldenstrom macroglobulinemia ORPHA:33226; Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection ORPHA:431166; Vogt-Koyanagi-Harada disease ORPHA:3437; Familial Chilblain lupus ORPHA:481662; Takayasu arteritis ORPHA:3287; Giant cell arteritis ORPHA:397; MALT lymphoma ORPHA:52417; Chronic mucocutaneous candidiasis ORPHA:1334; Behcet disease ORPHA:117,0.0180064224283883; 0.0180064224283883; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.6279395134845649; 0.6340773186521831; 0.639029370164481; 0.64564126367818; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7249187045096473,Norovirus Hu/Norwalk/10074/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20047/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CBNU2/2007/KR capsid protein; Norovirus Hu/Norwalk/10247/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH13/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/Norwalk/10051/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10116/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10183/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10236/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH02/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH03/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH04/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH06/2006/TW major viral capsid protein; Norovirus Hu/GII-4/CGMH07/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH09/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH12/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH17/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/SGU-110421/KOR/2011 VP1; Norovirus Hu/GII-4/CGMH05/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH08/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/GZ2010-L26/Guangzhou/CHN/2010 major viral capsid protein (gene: VP1); Norovirus Hu/GII/Shanghai/SH2/2008/CHN VP1; Norovirus Hu/Shanghai/SH5/2009/CHN VP1; Norovirus Hu/GII-4/CGMH14/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH15/2007/TW major viral capsid protein; Norovirus Hu/Norwalk/20123/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH10/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH22/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Miranda/NSW850K/2011/AU VP1; Norovirus Hu/GII-4/CGMH18/2008/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH28/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Guangzhou/GZ2010-L88/CHN/2011 major viral capsid protein; Norovirus Hu/GII.4/Guangzhou/GZ2010-L91/CHN/2011 major viral capsid protein; Human calicivirus Hu/NLV/GII/MD145-12/1987/US capsid protein; Lordsdale virus capsid protein (gene: orf2); Norovirus Hu/GII.4/CHDC3967/1988/US VP1; Norovirus Hu/GII.4/20199/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20033/2009/VNM capsid protein VP1 (gene: VP1),0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597,Homo sapiens HEK293T embryonic kidney cell;Saccharomyces cerevisiae,0.37;0.51,Homo sapiens;hcvco,Homo sapiens;hcvco
PURPL,Colorectal Carcinoma; Colorectal Cancer; Malignant neoplasm of large intestine,0.0034602840073026; 0.0149315928814189; 0.13167400689206,,,,,,,,,,
RBM24,"Dysautonomia, Familial",0.553002957824355,,,"Atrial septal defect, ostium secundum type ORPHA:99103; Branchiootic syndrome ORPHA:52429; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; Posterior hypospadias ORPHA:95706; Distal hereditary motor neuropathy type 2 ORPHA:139525; Familial isolated restrictive cardiomyopathy ORPHA:75249; Cataract-glaucoma syndrome ORPHA:162; NON RARE IN EUROPE: Ventricular septal defect ORPHA:1480; Familial progressive cardiac conduction defect ORPHA:871; BVES-related limb-girdle muscular dystrophy ORPHA:476084; Beta-sarcoglycan-related  limb-girdle muscular dystrophy R4 ORPHA:119; Goldberg-Shprintzen megacolon syndrome ORPHA:66629; Left ventricular noncompaction ORPHA:54260; Hemolytic anemia due to adenylate kinase deficiency ORPHA:86817; Atrial standstill ORPHA:1344; Congenital fiber-type disproportion myopathy ORPHA:2020; Fetal akinesia deformation sequence ORPHA:994; NON RARE IN EUROPE: Primary adult open-angle glaucoma ORPHA:353225; NON RARE IN EUROPE: Familial isolated hypertrophic cardiomyopathy ORPHA:155; Familial isolated dilated cardiomyopathy ORPHA:154; Familial sick sinus syndrome ORPHA:166282; Gamma-sarcoglycan-related  limb-girdle muscular dystrophy R5 ORPHA:353; X-linked non-syndromic sensorineural deafness type DFN ORPHA:90625; Typical nemaline myopathy ORPHA:171436; Postsynaptic congenital myasthenic syndromes ORPHA:98913",0.00518481975049; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0621182671032116; 0.0640416108792758; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.4177534028018127; 0.6239678957896782; 0.6239678957896782; 0.6279395134845649; 0.6279395134845649; 0.6340773186521831; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7166448869866529,"Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human herpesvirus 3 strain Dumas serine-threonine protein kinase",0.6980058392556946; 0.7553529087917877; 0.7975886343350181; 0.8090912655264054; 0.8090912655264054; 0.8458935424065495; 0.9782376397065295,,,,
RGL1,Malignant neoplasm of breast; Reticulocyte count (procedure); Calcification of coronary artery,0.0191435238361999; 0.425419812815905; 0.6881884194440517,Breast Cancer,0.0402286636010764,Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; RIN2 syndrome ORPHA:217335; Recessive X-linked ichthyosis ORPHA:461; Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome ORPHA:447997; Syndromic recessive X-linked ichthyosis ORPHA:281090; Amyloidosis cutis dyschromia ORPHA:319635; Autosomal recessive spastic paraplegia type 5A ORPHA:100986; Congenital bile acid synthesis defect type 3 ORPHA:79302; Keratosis follicularis spinulosa decalvans ORPHA:2340; Tangier disease ORPHA:31150; Transcobalamin deficiency ORPHA:859; Adams-Oliver syndrome ORPHA:974; Episodic ataxia type 6 ORPHA:209967,0.00518481975049; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6340773186521831; 0.7068064785325423,,,,,,
RGS6,"Mammary Neoplasms; Breast Carcinoma; Tumor Progression; Malignant neoplasm of breast; Carcinogenesis; Well Differentiated Oligodendroglioma; Neoplasm Metastasis; oligodendroglioma; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Small cell carcinoma of lung; Costello syndrome (disorder); Tumor Initiation; Carcinoma of bladder; Hyperactive behavior; Leukemia, Myeloid, Chronic-Phase; Malignant neoplasm of lung; Carcinoma of lung; Pheochromocytoma; Childhood Brain Neoplasm; Primary malignant neoplasm of lung; Schizophrenia; Non-Small Cell Lung Carcinoma; Astrocytoma; Neurofibromatosis-Noonan syndrome; Atrial Fibrillation; Autism Spectrum Disorders; Schizoaffective Disorder; Microcephaly; Malignant Peripheral Nerve Sheath Tumor; Mood Disorders; Laryngeal cleft; Psoriasis; Neurofibromatosis 1; Tremor; Abnormality of the skeletal system; Myeloid Leukemia, Chronic; heart rate; Primary angle-closure glaucoma; Angle Closure Glaucoma; Acquired scoliosis; Obesity; Tuberous Sclerosis; Tetralogy of Fallot; Ataxia; Cerebellar Ataxia; RESTING HEART RATE; Scoliosis, unspecified; Familial aplasia of the vermis; Mental Retardation; Cardiomyopathies; Influenza; Congenital cataract; Intellectual Disability",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991; 0.0617471306652618; 0.0648809611869375; 0.0648809611869375; 0.084286432100041; 0.0891725280554336; 0.1193558174333938; 0.1253114324938153; 0.13167400689206; 0.13167400689206; 0.1387448809655294; 0.1662487420178625; 0.2714542429024338; 0.3663130598151661; 0.3712878513813393; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.4126392832024548; 0.4192169590514327; 0.4192169590514327; 0.4304973629098372; 0.4335751357405352; 0.4564472886428772; 0.466957409863091; 0.472444704048021; 0.4790179402069343; 0.4923669467696064; 0.4981941174985421; 0.5019670090704682; 0.5140447474168605; 0.5359212109443033; 0.5557519470957561; 0.5568517196017908; 0.5754799679683854; 0.582492855487907; 0.5916904943304121; 0.6222451141623291; 0.6319938293757544; 0.6989462176022242; 0.7149953523738256; 0.7651930135295156; 0.8352623613787349,Schizophrenia; Development Disorder; Duchenne Muscular Dystrophy; Mood Disorder; Schizoaffective Disorder; Psoriasis,0.0531117779464085; 0.4372065554432662; 0.4560460337187313; 0.4646409362700993; 0.6712925710975606; 0.7184623115342476,McLeod neuroacanthocytosis syndrome ORPHA:59306; Polymicrogyria with optic nerve hypoplasia ORPHA:250972; 8p11.2 deletion syndrome ORPHA:251066,0.6239678957896782; 0.6239678957896782; 0.7068064785325423,,,,,,
RHOBTB3,Tumor Progression; Malnutrition,0.0149315928814189; 0.5916904943304121,,,Myelodysplastic syndrome ORPHA:52688; Congenital diaphragmatic hernia ORPHA:2140; 15q14 microdeletion syndrome ORPHA:261190; Isolated aniridia ORPHA:250923; 2q32q33 microdeletion syndrome ORPHA:251019; Autosomal dominant adult-onset proximal spinal muscular atrophy ORPHA:209335; SATB2-associated syndrome due to a chromosomal rearrangement ORPHA:251028; SATB2-associated syndrome due to a pathogenic variant ORPHA:576283; Early-onset epileptic encephalopathy-cortical blindness-intellectual disability-facial dysmorphism syndrome ORPHA:411986; PGM3-CDG ORPHA:443811,0.0083045131203191; 0.0180064224283883; 0.0586579655822394; 0.1590470395003315; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423,Yaba-like disease virus 140R protein (gene: 140R); Yaba monkey tumor virus kelch-like protein; Vaccinia virus Ankara 64.7k Kelch-like protein f1; Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Horsepox virus HSPV008; Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Horsepox virus HSPV176 (kelch-like protein; Provisional); Yaba-like disease virus 19L protein (gene: 19L); Horsepox virus HSPV043 (Kelch-like protein; Provisional); Vaccinia virus kelch-like protein (gene: A55R); Cowpox virus CPXV215 Protein (gene: CPXV215 CDS); Cowpox virus CPXV050 (gene: CPXV050 CDS); Horsepox virus HSPV197 (Hypothetical protein); Cowpox virus CPXV013 protein (gene: CPXV013 CDS); Ectromelia virus ERPV kelch-like protein,0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597,In vitro,0.44,Homo sapiens;chemical synthesis,Homo sapiens;chemical synthesis
RHOU,"Mammary Neoplasms; Stomach Carcinoma; Malignant neoplasm of stomach; Carcinogenesis; Kidney Neoplasm; Uterine Cancer; Congestive heart failure; Heart failure; Cardiomyopathy, Familial Idiopathic; Ischemic cardiomyopathy",0.0034602840073026; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991; 0.2714542429024338; 0.3544355608905275; 0.425419812815905; 0.4304973629098372; 0.4704594475773637; 0.7756460653898786,Lymphocytic Leukemia,0.0487679768343083,Familial multiple nevi flammei ORPHA:624; Sturge-Weber syndrome ORPHA:3205; Congenital brain dysgenesis due to glutamine synthetase deficiency ORPHA:71278,0.0180064224283883; 0.0180064224283883; 0.6239678957896782,Monkeypox virus Zaire-96-I-16 B2R (gene: B2R),0.776311155917498,In vitro,0.44,Homo sapiens,chemical synthesis
RPSAP52,"Diabetes Mellitus, Non-Insulin-Dependent",0.3933196962529684,Diabetes Mellitus,0.9683912711598086,"Arnold-Chiari malformation type I ORPHA:268882; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; Pleomorphic salivary gland adenoma ORPHA:454821; Acromesomelic dysplasia, Hunter-Thompson type ORPHA:968; Angel-shaped phalango-epiphyseal dysplasia ORPHA:63442; Bilateral microtia-deafness-cleft palate syndrome ORPHA:140963; Familial isolated trichomegaly ORPHA:411788; Microtia ORPHA:83463; Proximal symphalangism ORPHA:3250; Quebec platelet disorder ORPHA:220436; 12q14 microdeletion syndrome ORPHA:94063; Silver-Russell syndrome due to a point mutation ORPHA:397590; Thyroid ectopia ORPHA:95712; Cold-induced sweating syndrome ORPHA:157820",0.00518481975049; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.7068064785325423; 0.7068064785325423,,,,,,
RTKN2,"Breast Carcinoma; Rheumatoid Arthritis; Adenocarcinoma of large intestine; Schizophrenia; Lupus Erythematosus, Systemic; Idiopathic Interstitial Pneumonias",0.0042545616049287; 0.1537760235124317; 0.3933196962529684; 0.3933196962529684; 0.4213286052188015; 0.4675904598629673,Breast Carcinoma; Schizophrenia; Colorectal Cancer; Rheumatoid Arthritis; Lupus Erythematosus,0.0075861267486594; 0.0531117779464085; 0.4286813331685578; 0.4560460337187313; 0.5087473896242481,,,Human papillomavirus type 90 putative regulatory protein E2 (gene: E2),0.6362779693488597,,,,
S100A14,Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Tumor Progression; Stomach Carcinoma; Squamous cell carcinoma; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Neoplasm Metastasis; Squamous cell carcinoma of esophagus; Esophageal carcinoma; Oral Cavity Carcinoma; Malignant neoplasm of lung; Carcinoma of lung; Primary malignant neoplasm of lung; Non-Small Cell Lung Carcinoma; Lip and Oral Cavity Carcinoma; Non-small cell lung cancer metastatic; Progressive Neoplastic Disease; Progressive cGVHD; Malignant neoplasm of mouth; Psoriasis; Huntington Disease; EPIDERMAL DIFFERENTIATION COMPLEX; Adenocarcinoma of lung (disorder); Metastatic Neoplasm,0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0648809611869375; 0.0919714360040484; 0.1254380558571286; 0.13167400689206; 0.2714542429024338; 0.3663130598151661; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3975960596292668; 0.4213286052188015; 0.4304973629098372; 0.4704594475773637; 0.4923669467696064; 0.51550637274795; 0.8757716428200738,,,"Severe generalized junctional epidermolysis bullosa ORPHA:79404; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Kindler epidermolysis bullosa ORPHA:2908; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Autosomal recessive infantile hypercalcemia ORPHA:300547; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Erythrokeratodermia variabilis ORPHA:317; Intermediate generalized junctional epidermolysis bullosa ORPHA:79402; Localized junctional epidermolysis bullosa ORPHA:251393; AA amyloidosis ORPHA:85445; Alopecia universalis ORPHA:701; Atrichia with papular lesions ORPHA:86819; Bartsocas-Papas syndrome ORPHA:1234; Benign familial mesial temporal lobe epilepsy ORPHA:163717; CHAND syndrome ORPHA:1401; Epithelial recurrent erosion dystrophy ORPHA:293381; Familial mesial temporal lobe epilepsy with febrile seizures ORPHA:165805; Glutamate-cysteine ligase deficiency ORPHA:33574; Late-onset junctional epidermolysis bullosa ORPHA:79406; Metaphyseal chondrodysplasia, Spahr type ORPHA:2501; Neuropathy with hearing impairment ORPHA:139512; Spondyloepimetaphyseal dysplasia, Missouri type ORPHA:93356; Marie Unna hereditary hypotrichosis ORPHA:444; Progressive familial intrahepatic cholestasis type 1 ORPHA:79306; White sponge nevus ORPHA:171723; Carvajal syndrome ORPHA:65282; Cholangiocarcinoma ORPHA:70567; Erythrokeratodermia-cardiomyopathy syndrome ORPHA:476096; Familial expansile osteolysis ORPHA:85195; Harlequin ichthyosis ORPHA:457; High myopia-sensorineural deafness syndrome ORPHA:363396; Keratoderma hereditarium mutilans ORPHA:494; Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome ORPHA:2698; Monilethrix ORPHA:573; Osteopetrosis-hypogammaglobulinemia syndrome ORPHA:178389; Porokeratotic eccrine ostial and dermal duct nevus ORPHA:166286; Progressive familial intrahepatic cholestasis type 4 ORPHA:480483; Skin fragility-woolly hair-palmoplantar keratoderma syndrome ORPHA:293165; Xanthinuria type I ORPHA:93601; Bladder exstrophy ORPHA:93930; Blepharo-cheilo-odontic syndrome ORPHA:1997; Palmoplantar keratoderma-deafness syndrome ORPHA:2202; Severe dermatitis-multiple allergies-metabolic wasting syndrome ORPHA:369992; Uncombable hair syndrome ORPHA:1410; Hypoplastic amelogenesis imperfecta ORPHA:100031; Lethal acantholytic erosive disorder ORPHA:158687; Apparent mineralocorticoid excess ORPHA:320; Autosomal recessive spastic paraplegia type 35 ORPHA:171629; Congenital hereditary endothelial dystrophy type I ORPHA:98975; Epidermolysis bullosa simplex with circinate migratory erythema ORPHA:158681; Fatty acid hydroxylase-associated neurodegeneration ORPHA:329308; Gelatinous drop-like corneal dystrophy ORPHA:98957; Genetic transient congenital hypothyroidism ORPHA:226316; Glucose-galactose malabsorption ORPHA:35710; MUC1-related autosomal dominant tubulointerstitial kidney disease ORPHA:88949; MYO5B-related progressive familial intrahepatic cholestasis ORPHA:480491; Naxos disease ORPHA:34217; RFVT3-related riboflavin transporter deficiency ORPHA:572550; Sebocystomatosis ORPHA:841; Bifid uvula ORPHA:99771; Cleft hard palate ORPHA:101023; Cleft velum ORPHA:99772; Meesmann corneal dystrophy ORPHA:98954; Microvillus inclusion disease ORPHA:2290; Submucosal cleft palate ORPHA:155878; Alopecia-intellectual disability syndrome ORPHA:2850; Hereditary diffuse gastric cancer ORPHA:26106; Cleft lip and alveolus ORPHA:141291; Hypocalcified amelogenesis imperfecta ORPHA:100032; Isolated cleft lip ORPHA:199302; Cleft lip/palate ORPHA:199306; Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form ORPHA:79399; Autosomal dominant generalized epidermolysis bullosa simplex, severe form ORPHA:79396; Autosomal recessive distal renal tubular acidosis ORPHA:402041; Epidermolysis bullosa simplex with mottled pigmentation ORPHA:79397; Generalized pseudohypoaldosteronism type 1 ORPHA:171876; KID syndrome ORPHA:477; Liddle syndrome ORPHA:526; Localized epidermolysis bullosa simplex ORPHA:79400; Pachyonychia congenita ORPHA:2309; Van der Woude syndrome ORPHA:888; ADULT syndrome ORPHA:978; Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome ORPHA:1071; Autosomal dominant popliteal pterygium syndrome ORPHA:1300; Autosomal recessive cerebral atrophy ORPHA:363969; Congenital tufting enteropathy ORPHA:92050; EEC syndrome ORPHA:1896; Ectodermal dysplasia-skin fragility syndrome ORPHA:158668; Ectodermal dysplasia-syndactyly syndrome ORPHA:247820; Familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis without severe ocular involvement ORPHA:31043; Familial steroid-resistant nephrotic syndrome with adrenal insufficiency ORPHA:506334; Hypomaturation-hypoplastic amelogenesis imperfecta with taurodontism ORPHA:100034; Ichthyosis-hypotrichosis syndrome ORPHA:91132; Idiopathic bronchiectasis ORPHA:60033; Lethal congenital contracture syndrome type 2 ORPHA:137776; Limb-mammary syndrome ORPHA:69085; Mullerian aplasia and hyperandrogenism ORPHA:247768; Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome ORPHA:423454; Neurodegenerative syndrome due to cerebral folate transport deficiency ORPHA:217382; Non-epidermolytic palmoplantar keratoderma ORPHA:2337; REN-related autosomal dominant tubulointerstitial kidney disease ORPHA:217330; SERKAL syndrome ORPHA:139466; Syndromic congenital sodium diarrhea ORPHA:563708; Tricho-dento-osseous syndrome ORPHA:3352; Diffuse panbronchiolitis ORPHA:171700; Epidermolysis bullosa simplex with pyloric atresia ORPHA:158684; Pachydermoperiostosis ORPHA:2796; Hypotrichosis simplex ORPHA:55654; Oligodontia ORPHA:99798; Autosomal recessive generalized epidermolysis bullosa simplex ORPHA:89838; Congenital intrauterine infection-like syndrome ORPHA:1229; Dermatopathia pigmentosa reticularis ORPHA:86920; EEM syndrome ORPHA:1897; Hypotrichosis with juvenile macular degeneration ORPHA:1573; Low isolated anorectal malformation ORPHA:171215; Naegeli-Franceschetti-Jadassohn syndrome ORPHA:69087; Netherton syndrome ORPHA:634; Peeling skin syndrome type B ORPHA:263553; Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome ORPHA:397744; Seborrhea-like dermatitis with psoriasiform elements ORPHA:168606; Severe combined immunodeficiency due to FOXN1 deficiency ORPHA:169095; Antley-Bixler syndrome ORPHA:83; Isolated focal non-epidermolytic palmoplantar keratoderma ORPHA:448264; Striate palmoplantar keratoderma ORPHA:50942; Progressive symmetric erythrokeratodermia ORPHA:316; NON RARE IN EUROPE: Hypodontia ORPHA:2227",0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1697334635963512; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.3775879467205478; 0.3775879467205478; 0.4101640425710954; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.639029370164481; 0.6723027000992685; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7143653415082738,,,,,,
SCG2,"melanoma; Adenocarcinoma; Central neuroblastoma; Neuroblastoma; Degenerative polyarthritis; Myocardial Infarction; Rheumatoid Arthritis; Diabetes; Diabetes Mellitus; Multiple Sclerosis; Tuberculosis; Pheochromocytoma; Hypertensive disease; Pheochromocytoma, malignant; Amyotrophic Lateral Sclerosis; Multiple Endocrine Neoplasia Type 1; Celiac Disease; Congestive heart failure; Heart failure; Myocardial Ischemia; Hypercholesterolemia; Pain; Neuroendocrine Tumors; Arteriosclerosis; Coronary Arteriosclerosis; Ewings sarcoma; Atherosclerosis; Fibromyalgia; Limb ischemia; Prader-Willi Syndrome",0.0149315928814189; 0.0155921563748247; 0.0593779966354549; 0.0688152422187159; 0.0739788831250619; 0.1352936728187231; 0.1537760235124317; 0.2277108302018961; 0.2522264785494494; 0.2835142372342932; 0.3706856725676674; 0.3712878513813393; 0.3933196962529684; 0.3941558617476422; 0.3975960596292668; 0.3986414839122469; 0.4028066164685291; 0.425419812815905; 0.4304973629098372; 0.4506578937113162; 0.4755217870653703; 0.4871698998714747; 0.5017066790423467; 0.5019670090704682; 0.5140447474168605; 0.5251317541886066; 0.5393787854381349; 0.5696906826730043; 0.7240930522443176; 0.7815030391631113,,,Ondine syndrome ORPHA:661; X-linked adrenal hypoplasia congenita ORPHA:95702; WAGR syndrome ORPHA:893; Hydrocephalus with stenosis of the aqueduct of Sylvius ORPHA:2182; MASA syndrome ORPHA:2466; Spinocerebellar ataxia type 27 ORPHA:98764; X-linked complicated corpus callosum dysgenesis ORPHA:1497; X-linked complicated spastic paraplegia type 1 ORPHA:306617; Tetraamelia-multiple malformations syndrome ORPHA:3301; Rolandic epilepsy ORPHA:1945; Congenital limbs-face contractures-hypotonia-developmental delay syndrome ORPHA:562528; Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome ORPHA:522077; Obesity due to prohormone convertase I deficiency ORPHA:71528; Temple-Baraitser syndrome ORPHA:420561; Tubulinopathy-associated dysgyria ORPHA:467166; Distal hereditary motor neuropathy type 5 ORPHA:139536; Autosomal dominant spastic paraplegia type 3 ORPHA:100984; Obesity due to melanocortin 4 receptor deficiency ORPHA:71529; Congenital fibrosis of extraocular muscles ORPHA:45358; Presynaptic congenital myasthenic syndromes ORPHA:98914,0.020072786018028; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7143653415082738,,,,,,
SCHIP1,Chromophobe Renal Cell Carcinoma; Conventional (Clear Cell) Renal Cell Carcinoma; Adenomatous Polyposis Coli,0.1461248774859792; 0.2980670559114652; 0.4749780675672355,Oral Ulcer,0.4809179010794786,Ondine syndrome ORPHA:661; 15q14 microdeletion syndrome ORPHA:261190; Childhood-onset benign chorea with striatal involvement ORPHA:494541; Infantile-onset generalized dyskinesia with orofacial involvement ORPHA:494526; WAGR syndrome ORPHA:893; Arthrogryposis-oculomotor limitation-electroretinal anomalies syndrome ORPHA:1154; BVES-related limb-girdle muscular dystrophy ORPHA:476084; Becker muscular dystrophy ORPHA:98895; Charcot-Marie-Tooth disease type 4C ORPHA:99949; Gordon syndrome ORPHA:376; Male infertility with teratozoospermia due to single gene mutation ORPHA:399808; Marden-Walker syndrome ORPHA:2461; Symptomatic form of muscular dystrophy of Duchenne and Becker in female carriers ORPHA:206546; Rolandic epilepsy ORPHA:1945; Severe early-childhood-onset retinal dystrophy ORPHA:364055; Left ventricular noncompaction ORPHA:54260; Congenital limbs-face contractures-hypotonia-developmental delay syndrome ORPHA:562528; Microcornea-myopic chorioretinal atrophy-telecanthus syndrome ORPHA:369970; Temple-Baraitser syndrome ORPHA:420561; Cenani-Lenz syndrome ORPHA:3258; Freeman-Sheldon syndrome ORPHA:2053; Subcortical band heterotopia ORPHA:99796; Hereditary hyperekplexia ORPHA:3197; Infantile-onset ascending hereditary spastic paralysis ORPHA:293168,0.020072786018028; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.4177534028018127; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6279395134845649; 0.7068064785325423,,,In vitro;yeasx,0.56;0.59,Homo sapiens,Homo sapiens
SCML2,Medulloblastoma; Childhood Medulloblastoma; Adult Medulloblastoma; Medullomyoblastoma; Melanotic medulloblastoma; Desmoplastic Medulloblastoma,0.0354767239335874; 0.3933196962529684; 0.4126392832024548; 0.5453394612016188; 0.5453394612016188; 0.5768212166102149,Medullomyoblastoma; Medulloblastoma,0.5796489603182782; 0.675936313627625,"Combined pituitary hormone deficiencies, genetic forms ORPHA:95494; Combined immunodeficiency with granulomatosis ORPHA:157949; Severe combined immunodeficiency due to complete RAG1/2 deficiency ORPHA:331206; Denys-Drash syndrome ORPHA:220; Frasier syndrome ORPHA:347; Meacham syndrome ORPHA:3097; Hypothyroidism due to deficient transcription factors involved in pituitary development or function ORPHA:226307; 46,XY partial gonadal dysgenesis ORPHA:251510; Persistent Mullerian duct syndrome ORPHA:2856",0.0683063362547733; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.6279395134845649; 0.665250072408594; 0.7068064785325423,Human gammaherpesvirus 4 EBNA-2 nuclear protein (gene: BYRF1); Human herpesvirus 4 type 2 EBNA-2,0.6362779693488597; 0.6362779693488597,,,,
SETD7,"Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Stomach Carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of prostate; Prostate carcinoma; Liver carcinoma; Cholestasis, Extrahepatic; Diabetes; Diabetes Mellitus; MIXED LINEAGE LEUKEMIA; Diabetes Mellitus, Insulin-Dependent; Diabetes Mellitus, Non-Insulin-Dependent; Inflammation; Hyperglycemia; Chronic Obstructive Airway Disease; Diastolic blood pressure; Influenza; Hepatitis C",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0569142010728473; 0.0773771948186562; 0.095319386034013; 0.13167400689206; 0.2277108302018961; 0.2522264785494494; 0.2605479444258003; 0.2714542429024338; 0.3933196962529684; 0.3933196962529684; 0.4906258721078565; 0.5049674142533507; 0.5359212109443033; 0.7149953523738256; 0.7169459458481418,Alzheimer Disease,0.4560460337187313,"19p13.3 microduplication syndrome ORPHA:447980; Malan overgrowth syndrome ORPHA:420179; Marshall-Smith syndrome ORPHA:561; Recessive X-linked ichthyosis ORPHA:461; Syndromic recessive X-linked ichthyosis ORPHA:281090; Griscelli syndrome type 3 ORPHA:79478; Alagille syndrome due to a NOTCH2 point mutation ORPHA:261629; Hajdu-Cheney syndrome ORPHA:955; Chondrodysplasia with joint dislocations, gPAPP type ORPHA:280586; Craniosynostosis-microretrognathia-severe intellectual disability syndrome ORPHA:565858",0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.7068064785325423,,,In vitro,0.44,Homo sapiens,-;chemical synthesis
SHCBP1,"Tumor Progression; melanoma; Carcinogenesis; Neoplasm Metastasis; Liver Cirrhosis, Experimental; Rheumatoid Arthritis; Dysplastic Nevus; synovial sarcoma; Adult Synovial Sarcoma; Childhood Synovial Sarcoma; Melanocytic nevus; Erythema Chronicum Migrans; Glossitis, Benign Migratory; Hyperphenylalaninaemia; Conn Syndrome; Ankylosing spondylitis; Influenza; Metastatic Neoplasm",0.0149315928814189; 0.0149315928814189; 0.0228075668512991; 0.0648809611869375; 0.0747863377072194; 0.1537760235124317; 0.3933196962529684; 0.3933196962529684; 0.4115056600660309; 0.4126392832024548; 0.425419812815905; 0.4335751357405352; 0.4506578937113162; 0.4506578937113162; 0.6084642888478995; 0.6446807314576214; 0.7149953523738256; 0.8757716428200738,Synovial Sarcoma,0.4286813331685578,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Roberts syndrome ORPHA:3103; Stromme syndrome ORPHA:506307; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; Hereditary site-specific ovarian cancer syndrome ORPHA:213524; Bloom syndrome ORPHA:125; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Primary peritoneal carcinoma ORPHA:168829; VACTERL with hydrocephalus ORPHA:3412; Mosaic variegated aneuploidy syndrome ORPHA:1052; Osteosarcoma ORPHA:668; Seckel syndrome ORPHA:808; Fanconi anemia ORPHA:84; Autosomal recessive primary microcephaly ORPHA:2512; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Combined immunodeficiency due to GINS1 deficiency ORPHA:505227; Denys-Drash syndrome ORPHA:220; Frasier syndrome ORPHA:347; Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations ORPHA:319462; Meacham syndrome ORPHA:3097; Xeroderma pigmentosum variant ORPHA:90342; Li-Fraumeni syndrome ORPHA:524; Ear-patella-short stature syndrome ORPHA:2554; Hereditary breast and ovarian cancer syndrome ORPHA:145; Familial prostate cancer ORPHA:1331; Athabaskan brainstem dysgenesis syndrome ORPHA:69739; Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome ORPHA:314404; Bosley-Salih-Alorainy syndrome ORPHA:69737; Hereditary sensory neuropathy-deafness-dementia syndrome ORPHA:456318; Combined immunodeficiency with faciooculoskeletal anomalies ORPHA:221139; Deafness-encephaloneuropathy-obesity-valvulopathy syndrome ORPHA:254898; Combined immunodeficiency due to TFRC deficiency ORPHA:476113,0.0083045131203191; 0.0106988445340883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.0599424746210022; 0.0683063362547733; 0.0930156564388357; 0.1026843275212335; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.1659988674007724; 0.1936858543871029; 0.1981653781243822; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.7068064785325423,,,Homo sapiens HeLa epitheloid cervical carcinoma cell,0.4,Mus musculus,Homo sapiens
SIX2,"Breast Carcinoma; Malignant neoplasm of breast; Carcinogenesis; Neoplasm Metastasis; Renal Cell Carcinoma; Tumor Initiation; Kidney Neoplasm; Von Hippel-Lindau Syndrome; Kidney Diseases; Nephroblastoma; Amyotrophic Lateral Sclerosis, Sporadic; Brenner Tumor; AMYOTROPHIC LATERAL SCLEROSIS 1; Squamous cell carcinoma of tongue; Frontonasal dysplasia; Bilateral Wilms Tumor; Renal dysplasia; Cystadenoma",0.0042545616049287; 0.0191435238361999; 0.0228075668512991; 0.0648809611869375; 0.0648809611869375; 0.13167400689206; 0.2714542429024338; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.4790179402069343; 0.5696906826730043; 0.5710095678317721,Congenital Anomalies Of Kidney And Urinary Tract; Metopic Synostosis; Frontonasal Dysplasia; Frontal Bossing; Lateral Sclerosis; Wilms Tumor; Posteriorly Rotated Ear; Dwarfism; Kidney Disease; Nephroblastoma; Macrocephaly; Ptosis,0.0075861267486594; 0.425341435586089; 0.4402141802500753; 0.4560460337187313; 0.4867879381749835; 0.5087473896242481; 0.5248691614865011; 0.5796489603182782; 0.6420878824691651; 0.6883874961919009; 0.800821840688695; 0.8357787380041017,SIX2-related frontonasal dysplasia ORPHA:488437; Peters anomaly ORPHA:708; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Branchiootic syndrome ORPHA:52429; Rieger anomaly ORPHA:91483; Bamforth-Lazarus syndrome ORPHA:1226; BOR syndrome ORPHA:107; Athyreosis ORPHA:95713; Cataract-glaucoma syndrome ORPHA:162; Brain-lung-thyroid syndrome ORPHA:209905; Craniofacial dysplasia-osteopenia syndrome ORPHA:314555; 22q11.2 duplication syndrome ORPHA:1727; Hypomaturation-hypoplastic amelogenesis imperfecta with taurodontism ORPHA:100034; Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ORPHA:397623; Tricho-dento-osseous syndrome ORPHA:3352; Familial clubfoot due to 5q31 microdeletion ORPHA:293144; Familial clubfoot due to PITX1 point mutation ORPHA:293150; Mirror-image polydactyly ORPHA:498494; Brachydactyly-elbow wrist dysplasia syndrome ORPHA:1275,0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0183145313768111; 0.0640416108792758; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Yaba monkey tumor virus 72L; Machupo mammarenavirus L protein; Lassa mammarenavirus L protein; Cercopithecine betaherpesvirus 5 large tegument protein (gene: UL48),0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597,Homo sapiens HEK293T embryonic kidney cell;yeasx,0.37;0.4,Homo sapiens,Homo sapiens
SKAP1,Ovarian Carcinoma; ovarian neoplasm; Malignant neoplasm of ovary; Epithelial ovarian cancer; Hairy Cell Leukemia; Classical Hodgkin's Lymphoma; Peripheral T-Cell Lymphoma; Ovarian Serous Adenocarcinoma; Ki-1+ Anaplastic Large Cell Lymphoma; Body mass index; Finding of body mass index; Intelligence,0.0034602840073026; 0.0191435238361999; 0.0277695594716545; 0.0387439397151409; 0.3412203844672238; 0.3763374964032415; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.5496357724684553; 0.5496357724684553; 0.5683976277847906,Endometriosis; Endometrial Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Neoplasm; Ovarian Cancer,0.2187610616307245; 0.4286813331685578; 0.4560460337187313; 0.7921294370722203; 0.8876319700740651,Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944; Galactose mutarotase deficiency ORPHA:570422; Serrated polyposis syndrome ORPHA:157798; Congenital non-communicating hydrocephalus ORPHA:269510; Spinocerebellar ataxia type 40 ORPHA:423275; Autosomal recessive hypohidrotic ectodermal dysplasia ORPHA:248; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency ORPHA:477857; BENTA disease ORPHA:464336; Combined immunodeficiency due to CD27 deficiency ORPHA:238505; Cranio-osteoarthropathy ORPHA:1525; Isolated congenital digital clubbing ORPHA:217059; Persistent polyclonal B-cell lymphocytosis ORPHA:300324; Severe combined immunodeficiency due to CARD11 deficiency ORPHA:357237; Severe combined immunodeficiency due to LCK deficiency ORPHA:280142; Autosomal dominant dopa-responsive dystonia ORPHA:98808; C syndrome ORPHA:1308; Fatal post-viral neurodegenerative disorder ORPHA:391343; GTP cyclohydrolase I deficiency ORPHA:2102; Hypoparathyroidism-sensorineural deafness-renal disease syndrome ORPHA:2237; Susceptibility to respiratory infections associated with CD8alpha chain mutation ORPHA:169085; Female infertility due to oocyte meiotic arrest ORPHA:488191; Autosomal dominant hypohidrotic ectodermal dysplasia ORPHA:1810; Idiopathic aplastic anemia ORPHA:88,0.0180064224283883; 0.0180064224283883; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Human immunodeficiency virus 2 nef protein; Human immunodeficiency virus 1 Pol (gene: gag-pol); Human papillomavirus type 90 putative regulatory protein E2 (gene: E2); Human papillomavirus type 10 envelope protein (gene: E2); Human immunodeficiency virus nef protein (gene: nef); Human papillomavirus 117 E2; Monkeypox virus ankyrin-like protein,0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6386053036162835; 0.7795229132668053; 0.7954342107380572; 0.8426793553344071,,,,
SKIL,"melanoma; Squamous cell carcinoma; Malignant neoplasm of prostate; Central neuroblastoma; Barrett Esophagus; Neuroblastoma; Prostate carcinoma; Colorectal Neoplasms; Hamman-Rich syndrome; Arsenic Poisoning, Inorganic; Nervous System, Organic Arsenic Poisoning; Arsenic Encephalopathy; Arsenic Induced Polyneuropathy; Arsenic Poisoning; Hyperactive behavior; Creatinine measurement, serum (procedure); Non-Small Cell Lung Carcinoma; Alzheimer's Disease; Other ureteric obstruction; Parkinson Disease; Adenoma; Glomerular filtration rate finding; Pulmonary Fibrosis; Dermatologic disorders; Obstructive nephropathy",0.0149315928814189; 0.0182265588252201; 0.0569142010728473; 0.0593779966354549; 0.0648809611869375; 0.0688152422187159; 0.0773771948186562; 0.0827744840860166; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1387448809655294; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.4126392832024548; 0.4335751357405352; 0.4906258721078565; 0.553002957824355,Pulmonary Fibrosis; Alveolitis; Arsenic Encephalopathy; Dermatologic Disorders,0.0654534781440596; 0.1025546857843372; 0.185736315425117; 0.2895940391390291,,,Human T-lymphotropic virus 3 polymerase (gene: pol); Human immunodeficiency virus 2 full_polyprotein 1..1550 (gene: gag-pol); Human T-cell leukemia virus type I p15NC-p14PR-p95RT/IN (gene: gag-pro-pol); Human T-cell leukemia virus type I Pr gag-pro-pol (gene: gag-pro-pol); Human betacoronavirus 2c EMC/2012 ORF4a (gene: orf4a); Middle East respiratory syndrome-related coronavirus NS4A protein (gene: orf4a); Adult diarrheal rotavirus strain J19 NSP1; Human T-lymphotropic virus 2 full_polyprotein 1..982; Human T-lymphotropic virus 2 Gag-Pro-Pol; Monkeypox virus ankyrin-like protein,0.6362779693488597; 0.6481498905276316; 0.6920622798772148; 0.6949711755793786; 0.7245718814666527; 0.7245718814666527; 0.7879984651860477; 0.8390943852085586; 0.8415830684989161; 0.8426793553344071,yeasx,0.56,Homo sapiens,Homo sapiens
SLC16A6,Endometriosis; Endometrioma,0.383941725017158; 0.3941558617476422,Endometriosis; Endometrioma,0.2187610616307245; 0.5036845352940079,,,,,Homo sapiens A549 lung carcinoma cell,0.35,Human coronavirus 229E;SARS-CoV-2,Homo sapiens
SLC22A18,"Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of esophagus; Mammary Neoplasms, Human; Barrett Esophagus; Glioma; Glioblastoma; Squamous cell carcinoma of esophagus; Liver carcinoma; Esophageal carcinoma; Myocardial Infarction; Breast Cancer, Familial; Lung Neoplasms; Eosinophilic esophagitis; Hepatoblastoma; Smith-Lemli-Opitz Syndrome; Adenocarcinoma Of Esophagus; Neoplasms; Malignant neoplasm of lung; Rhabdomyosarcoma; Carcinoma of lung; Recurrent tumor; Amyloidosis; Interstitial lung fibrosis; Nephroblastoma; Non-Small Cell Lung Carcinoma; Gastroesophageal reflux disease; Childhood Hepatocellular Carcinoma; Bronchioloalveolar Adenocarcinoma; Glioblastoma Multiforme; Familial multiple trichoepitheliomata; Erosive esophagitis; Bilirubin measurement; Embryonal Rhabdomyosarcoma; Barrett's Adenocarcinoma; Alcoholic Intoxication, Chronic; Adenocarcinoma of lung (disorder); Malaria; Factor V Leiden mutation; Beckwith-Wiedemann Syndrome",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.064548079316548; 0.0648809611869375; 0.0739788831250619; 0.0745502070959292; 0.0919714360040484; 0.095319386034013; 0.1254380558571286; 0.1352936728187231; 0.1602092191314262; 0.2062010908869036; 0.2085938372806741; 0.2522264785494494; 0.2522264785494494; 0.2679411586077776; 0.2714542429024338; 0.2714542429024338; 0.3510063969122338; 0.3663130598151661; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.4615352570710579; 0.472444704048021; 0.5090214163899865; 0.5097818625871164; 0.51550637274795; 0.5655222348249326; 0.610971999959321; 0.6304655343580164,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Lung Cancer; Lung Carcinoma; Embryonal Rhabdomyosarcoma; Hereditary Breast Cancer; Lung Neoplasms; Rhabdomyosarcoma; Lung Adenocarcinoma,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.4402141802500753; 0.4541466895915311; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4875380732267193; 0.7979764766391754,Hereditary breast cancer ORPHA:227535; Mucopolysaccharidosis type 4A ORPHA:309297; Cathepsin A-related arteriopathy-strokes-leukoencephalopathy ORPHA:575553; Galactosialidosis ORPHA:351; 5-oxoprolinase deficiency ORPHA:33572; CLN10 disease ORPHA:228337; Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency ORPHA:95699; Congenital bile acid synthesis defect type 1 ORPHA:79301; Embryonal rhabdomyosarcoma ORPHA:99757; Tumor necrosis factor receptor 1 associated periodic syndrome ORPHA:32960; Dominant hypophosphatemia with nephrolithiasis or osteoporosis ORPHA:244305; Dysosteosclerosis ORPHA:1782; 3-hydroxy-3-methylglutaric aciduria ORPHA:20; Acrodermatitis enteropathica ORPHA:37; CLN11 disease ORPHA:314629; Clear cell renal carcinoma ORPHA:319276; Mucolipidosis type III gamma ORPHA:423470; Mucopolysaccharidosis type 7 ORPHA:584; NON RARE IN EUROPE: Pseudoarylsulfatase A deficiency ORPHA:751; Polyglucosan body myopathy type 1 ORPHA:397937; Sanfilippo syndrome type A ORPHA:79269; Argininosuccinic aciduria ORPHA:23; CLN3 disease ORPHA:228346; D-glyceric aciduria ORPHA:941; Gamma-glutamyl transpeptidase deficiency ORPHA:33573; Hyperammonemia due to N-acetylglutamate synthase deficiency ORPHA:927,0.0106988445340883; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens;In vitro,0.35,Homo sapiens;Human papillomavirus type 11;Human papillomavirus type 6b;ebvb9,Homo sapiens
SLC26A7,Distal Renal Tubular Acidosis; Schizophrenia; Alzheimer's Disease; Hereditary spherocytosis; Hypokalemia; Tauopathies,0.2643145809900195; 0.3933196962529684; 0.3933196962529684; 0.472444704048021; 0.5299466034567416; 0.5682392297191953,Schizophrenia,0.0531117779464085,,,,,,,,
SLC4A8,Alzheimer's Disease; Prediabetes syndrome,0.3933196962529684; 0.6878314377608323,Alzheimer Disease,0.4560460337187313,"15q13.3 microdeletion syndrome ORPHA:199318; Cerebellar ataxia, Cayman type ORPHA:94122; Lissencephaly due to TUBA1A mutation ORPHA:171680; Lissencephaly type 1 due to doublecortin gene mutation ORPHA:2148; FRAXE intellectual disability ORPHA:100973; ALK-positive anaplastic large cell lymphoma ORPHA:300895; ALK-positive large B-cell lymphoma ORPHA:364043; Benign paroxysmal torticollis of infancy ORPHA:71518; Familial paroxysmal ataxia ORPHA:97; Griscelli syndrome type 1 ORPHA:79476; Hyperekplexia-epilepsy syndrome ORPHA:163985; Neuroectodermal melanolysosomal disease ORPHA:33445; Spinocerebellar ataxia type 6 ORPHA:98758",0.1590470395003315; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
SMAD6,"Ovarian Carcinoma; Squamous cell carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Glioma; Lymphoma; AORTIC VALVE DISEASE 2; Bicuspid aortic valve; Malignant neoplasm of lung; Aortic Aneurysm, Thoracic; Metastatic malignant neoplasm to brain; Carcinoma of lung; Primary malignant neoplasm of lung; Renal glomerular disease; Non-Small Cell Lung Carcinoma; Hypertensive disease; Dilatation of the aortic arch; Pulmonary Hypertension; Craniosynostosis; Nephritis; Hereditary hemochromatosis; Osteitis Fibrosa Disseminata; Synostotic Anterior Plagiocephaly; Aortic Valve Stenosis; Brachycephaly; Heart murmur; Synostotic Posterior Plagiocephaly; Acrocephaly; Iron Overload; Metopic synostosis; Aortic valve disorder; Aortic valve calcification; Increase in blood pressure; Fibrous Dysplasia; Trigonocephaly; Chronic Obstructive Airway Disease; Scaphycephaly; Body mass index; Finding of body mass index; Waist-Hip Ratio; Aortic coarctation; Aortic Valve Insufficiency",0.0034602840073026; 0.0182265588252201; 0.0228075668512991; 0.0277695594716545; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.2687300999130421; 0.2714542429024338; 0.2980670559114652; 0.3638414818541592; 0.3663130598151661; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.4028066164685291; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4506578937113162; 0.4564472886428772; 0.466957409863091; 0.4675904598629673; 0.472444704048021; 0.4906258721078565; 0.4923669467696064; 0.4923669467696064; 0.4981941174985421; 0.5049674142533507; 0.5090214163899865; 0.5496357724684553; 0.5496357724684553; 0.549941235475765; 0.5655222348249326; 0.5683976277847906,Thoracic Aortic Aneurysm And Aortic Dissection; Aortic Valve Sclerosis; Metopic Synostosis; Craniosynostosis; Aortic Valve Insufficiency; Aortic Valve Disease; Colorectal Cancer; Hypoplastic Left Heart Syndrome; Aortic Aneurysm; Carpal Tunnel Syndrome; Aortic Valve Calcification; Brachycephaly; Radioulnar Synostosis; Colorectal Neoplasms; Hypertension; Colorectal Adenoma; Synostotic Anterior Plagiocephaly; Bicuspid Aortic Valve; Aneurysm Of Aortic Arch; Synostotic Posterior Plagiocephaly; Colonic Neoplasms; Scaphocephaly; Acrocephaly; Trigonocephaly; Aortic Coarctation,0.1641294276675242; 0.3182746822082389; 0.425341435586089; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4402141802500753; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4646409362700993; 0.4723647227028846; 0.4809179010794786; 0.5234357475824973; 0.5316139823120088; 0.6030919130927346; 0.6712925710975606,"Atrial septal defect, ostium secundum type ORPHA:99103; Ulnar-mammary syndrome ORPHA:3138; Myelodysplastic syndrome ORPHA:52688; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; Tetralogy of Fallot ORPHA:3303; Autosomal dominant osteopetrosis type 1 ORPHA:2783; Endosteal hyperostosis, Worth type ORPHA:2790; LRP5-related primary osteoporosis ORPHA:498481; Osteoporosis-pseudoglioma syndrome ORPHA:2788; Osteosclerosis-developmental delay-craniosynostosis syndrome ORPHA:178377; Enlarged parietal foramina ORPHA:60015; Hyperostosis corticalis generalisata ORPHA:3416; Complete atrioventricular septal defect with ventricular hypoplasia ORPHA:99067; NON RARE IN EUROPE: Ventricular septal defect ORPHA:1480; Partial atrioventricular septal defect ORPHA:1330; Familial progressive cardiac conduction defect ORPHA:871; Deafness-lymphedema-leukemia syndrome ORPHA:3226; Frontonasal dysplasia-alopecia-genital anomalies syndrome ORPHA:228390; Monocytopenia with susceptibility to infections ORPHA:228423; Truncus arteriosus ORPHA:3384; Familial bicuspid aortic valve ORPHA:402075; Giant cell glioblastoma ORPHA:251579; Gliosarcoma ORPHA:251576; 2q32q33 microdeletion syndrome ORPHA:251019; Hypodontia-dysplasia of nails syndrome ORPHA:2228; Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome ORPHA:69735; SATB2-associated syndrome due to a chromosomal rearrangement ORPHA:251028; SATB2-associated syndrome due to a pathogenic variant ORPHA:576283; 8p23.1 microdeletion syndrome ORPHA:251071; Guttmacher syndrome ORPHA:2957; Hand-foot-genital syndrome ORPHA:2438; Isolated scaphocephaly ORPHA:35093",0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0277610005156803; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1614487935928034; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.433039750392822; 0.433039750392822; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,Human gammaherpesvirus 8 vIRF-3 (gene: vIRF-3),0.6362779693488597,Chlorocebus aethiops;Homo sapiens;Homo sapiens HEK293T embryonic kidney cell;Saccharomyces cerevisiae,0.35;0.4;0.51,Homo sapiens;Mus musculus,Homo sapiens
SMAD7,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Retroviridae Infections; melanoma; Proliferative vitreoretinopathy; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Epithelial ovarian cancer; Malignant neoplasm of prostate; Neoplasm Metastasis; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Glioma; Degenerative polyarthritis; Endometrial Neoplasms; Pancreatic carcinoma; Prostate carcinoma; Colorectal Neoplasms; Squamous cell carcinoma of esophagus; Liver carcinoma; Osteosarcoma; Colon Carcinoma; Adenocarcinoma of colon; Chronic Lymphocytic Leukemia; Secondary malignant neoplasm of bone; MYELODYSPLASTIC SYNDROME; Hamman-Rich syndrome; Malignant neoplasm of large intestine; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Hyperactive behavior; Renal fibrosis; Invasive Carcinoma; Systemic Scleroderma; Osteosarcoma of bone; Malignant tumor of colon; Prostatic Neoplasms; Hepatoblastoma; Malignant neoplasm of lung; Diabetes Mellitus, Insulin-Dependent; 5,10-Methylenetetrahydrofolate reductase deficiency; Peyronie Disease; Secondary malignant neoplasm of lung; Multiple Sclerosis; Fibroid Tumor; Triple Negative Breast Neoplasms; Pancreatic Ductal Adenocarcinoma; Endometrial Carcinoma; Acute pancreatitis; Ataxia Telangiectasia; Carcinoma of lung; Thyroid Neoplasm; Uterine Fibroids; Primary malignant neoplasm of lung; Gallbladder Carcinoma; Epstein-Barr Virus Infections; Adenocarcinoma of large intestine; Diabetes Mellitus, Non-Insulin-Dependent; Inflammation; Renal glomerular disease; Kidney Diseases; Non-Small Cell Lung Carcinoma; Infection caused by Helicobacter pylori; Secondary malignant neoplasm of liver; Lichen disease; Nasopharyngeal Neoplasms; Acute lymphocytic leukemia; Inflammatory Bowel Diseases; Fibrosis, Liver; Coronary heart disease; Pulmonary Hypertension; Asthma; Focal glomerulosclerosis; Diabetic Nephropathy; Acute Erythroblastic Leukemia; Nephritis; Pituitary Adenoma; Hereditary hemochromatosis; Glomerulosclerosis (disorder); Chronic Kidney Diseases; Kidney Failure, Acute; Celiac Disease; Necrotizing Enterocolitis; Biliary stricture; Immunologic Deficiency Syndromes; Choroid Plexus Carcinoma; Rectal Carcinoma; Nonalcoholic Steatohepatitis; Pulmonary Fibrosis; Lymphatic Metastasis; Gastrointestinal inflammation; Ventricular Septal Defects; Cicatrix, Hypertrophic; leukemia; Iron Overload; Intestinal Neoplasms; Localized scleroderma; Periodontitis, Juvenile; Membranous glomerulonephritis; Hemoglobin measurement; Crohn Disease; Scleroderma; Arteriosclerosis; Varicose Ulcer; Chronic Obstructive Airway Disease; Lipoid nephrosis; Fibrodysplasia Ossificans Progressiva; Congenital Abnormality; Colitis; Hepatocarcinogenesis; Precursor Cell Lymphoblastic Leukemia Lymphoma; Atherosclerosis; Congenital heart disease; Seminoma; Non-alcoholic Fatty Liver Disease; HEMOCHROMATOSIS, TYPE 1; Pustulosis of Palms and Soles; Necrotizing enterocolitis in fetus OR newborn; Hemochromatosis; Liver diseases; Hematocrit procedure; Lupus Nephritis; Pulmonary Emphysema; Red Blood Cell Count measurement; Sleep Apnea, Obstructive; Adult T-Cell Lymphoma/Leukemia; Keloid",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0387439397151409; 0.0569142010728473; 0.0648809611869375; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0827744840860166; 0.0919714360040484; 0.095319386034013; 0.1029977559100099; 0.1062239757831962; 0.1112281755580192; 0.1147307578771389; 0.1253114324938153; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1387448809655294; 0.1602092191314262; 0.1602092191314262; 0.1900258729042946; 0.2109483801368481; 0.223747154820789; 0.223747154820789; 0.2522264785494494; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2723545094624877; 0.2835142372342932; 0.290158730291654; 0.2980670559114652; 0.3018974726133723; 0.3044782497745498; 0.3220099003872086; 0.3508665345292502; 0.3663130598151661; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4118266358241932; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.429029854971378; 0.4335751357405352; 0.4335751357405352; 0.4342056919538745; 0.4396723023384634; 0.4564472886428772; 0.4564472886428772; 0.4588513406515081; 0.466957409863091; 0.4675904598629673; 0.4675904598629673; 0.4714226702518064; 0.4790179402069343; 0.4852430673532381; 0.4981941174985421; 0.5019670090704682; 0.5019670090704682; 0.5019670090704682; 0.5049674142533507; 0.5188223685230745; 0.5299466034567416; 0.5305233935923577; 0.5323590634832615; 0.533913711453195; 0.5393787854381349; 0.5393787854381349; 0.549941235475765; 0.5990568578129436; 0.625027955184583; 0.6274540883972485; 0.6319938293757544; 0.6588479076808555; 0.6925751397474874; 0.7337030585693298; 0.7412504828119304; 0.7433468668038986; 0.7674304683279349; 0.7796824214131131; 0.8109066403528201; 0.8367216325123092; 0.8716042675435699,Pulmonary Fibrosis; Alveolitis; Nasopharyngeal Carcinoma; Colorectal Cancer; Colorectal Neoplasms; Colorectal Adenoma; Colonic Neoplasms; Paroxysmal Atrial Fibrillation; Atrial Fibrillation; Eczema,0.0654534781440596; 0.1025546857843372; 0.2278592962769385; 0.4286813331685578; 0.4560460337187313; 0.4560460337187313; 0.4809179010794786; 0.5082542877462781; 0.6792162876553974; 0.6899894525110877,"Atrial septal defect, sinus venosus type ORPHA:99105",0.3762014630157917,Lujo mammarenavirus multifunctional matrix-like protein; Guanarito mammarenavirus Z protein; Human gammaherpesvirus 8 vIRF-3 (gene: vIRF-3); Chapare mammarenavirus Z protein; Junin mammarenavirus Z protein; Lassa mammarenavirus Z protein; Pichinde mammarenavirus Z protein (gene: Z); Machupo mammarenavirus Z protein; Sabia mammarenavirus Z protein,0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597,Homo sapiens,0.4,Homo sapiens,Homo sapiens
SMIM13,,,,,"Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome ORPHA:447997; Christianson syndrome ORPHA:85278; Male infertility with teratozoospermia due to single gene mutation ORPHA:399808; Chondrodysplasia with joint dislocations, gPAPP type ORPHA:280586; Peters plus syndrome ORPHA:709; Hypomyelination with atrophy of basal ganglia and cerebellum ORPHA:139441; Autosomal dominant spastic paraplegia type 6 ORPHA:100988; Severe myopia-generalized joint laxity-short stature syndrome ORPHA:527450",0.0586579655822394; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423,,,,,,
SNAI2,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Epithelioma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Epithelial ovarian cancer; Skin carcinoma; Malignant neoplasm of prostate; Central neuroblastoma; Mammary Neoplasms, Human; Neoplasm Metastasis; Renal Cell Carcinoma; Neuroblastoma; Glioma; Glioblastoma; Carcinoma breast stage IV; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Colorectal Neoplasms; Liver carcinoma; Malignant Neoplasms; Osteosarcoma; Colon Carcinoma; Premature canities; Secondary malignant neoplasm of bone; Costello syndrome (disorder); Waardenburg Syndrome Type 2; Ductal Breast Carcinoma; Hamman-Rich syndrome; Tumor Initiation; Rheumatoid Arthritis; Heterochromia iridis; White forelock; Systemic Scleroderma; Osteosarcoma of bone; Malignant tumor of colon; Prostatic Neoplasms; Metastasis from malignant tumor of prostate; Metastatic Prostate Carcinoma; Neoplasms; Malignant neoplasm of lung; Piebaldism; Secondary malignant neoplasm of lung; Triple Negative Breast Neoplasms; Idiopathic Pulmonary Fibrosis; Gastrointestinal Stromal Tumors; Cholangiocarcinoma; Mammary Ductal Carcinoma; Carcinoma of lung; Pheochromocytoma; Primary malignant neoplasm; Recurrent tumor; Primary malignant neoplasm of lung; Secondary malignant neoplasm of lymph node; Papillary thyroid carcinoma; Non-Small Cell Lung Carcinoma; Carcinoma, Papillary; Chordoma; White eyebrow; Blonde eyebrow; Grey eyebrow; Squamous cell carcinoma of tongue; White eyelashes; Grey eyelashes; Rash and Dermatitis Adverse Event Associated with Chemoradiation; Thyroid carcinoma; Luminal A Breast Carcinoma; leiomyosarcoma; Germinoma; Neoplasm Invasiveness; Uterine Corpus Carcinosarcoma; Hypopigmentation disorder; hypopigmented skin patch; Basal-Like Breast Carcinoma; Macule; Congenital ear anomaly NOS (disorder); Uterine Carcinosarcoma; Mesothelioma; Congenital sensorineural hearing loss; Megacolon; Nonnuclear polymorphic congenital cataract; Arteriosclerosis; Obesity; Atherosclerosis; Hirschsprung Disease; Familial Nonmedullary Thyroid Cancer; Multiple malignancy; Malignancy; Non-medullary thyroid carcinoma; Sensorineural Hearing Loss (disorder); Telecanthus; Neural Tube Defects",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0387439397151409; 0.0482468351695405; 0.0569142010728473; 0.0593779966354549; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0688152422187159; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0775520919998773; 0.0827744840860166; 0.095319386034013; 0.0991201145654548; 0.1029977559100099; 0.1062239757831962; 0.1193558174333938; 0.1253114324938153; 0.1253114324938153; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1537760235124317; 0.1602092191314262; 0.1735868515093891; 0.1900258729042946; 0.2109483801368481; 0.223747154820789; 0.223747154820789; 0.2454426921531692; 0.2643145809900195; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2723545094624877; 0.2980670559114652; 0.3099246715197673; 0.3199171478489988; 0.340892538685018; 0.3638414818541592; 0.3663130598151661; 0.3712878513813393; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.4028066164685291; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4297858918260954; 0.4297858918260954; 0.4396723023384634; 0.4459714599189374; 0.4459714599189374; 0.4564472886428772; 0.4635211539849193; 0.4753011022966241; 0.4923669467696064; 0.4981941174985421; 0.5019670090704682; 0.5140447474168605; 0.5393787854381349; 0.5794721015064842; 0.6274540883972485; 0.6740259274935673; 0.6761967139251879; 0.6878314377608323; 0.6891882956008074; 0.726789939981526; 0.8600100703665297,Anomalous Pulmonary Artery; Breast Carcinoma; Esophagus Neoplasm; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Tumoral Calcinosis; Waardenburg Syndrome; Skin Neoplasms; Piebaldism; Neoplasms; Multicystic Renal Dysplasia; Hirschsprung Disease; Microcephaly; Hearing Loss; Congenital Sensorineural Hearing Loss; Nonmedullary Thyroid Carcinoma; Thyroid Cancer; Papillary Thyroid Carcinoma; Mental Retardation; Synophrys; Ptosis,0.0075861267486594; 0.0075861267486594; 0.0102679590519094; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.2954316182315451; 0.4286813331685578; 0.4541466895915311; 0.4541466895915311; 0.4646409362700993; 0.4646409362700993; 0.4875380732267193; 0.5123947823327547; 0.5632819212593052; 0.6130153808924363; 0.6883874961919009; 0.7015979603136192; 0.768479933091106; 0.7729545590606223; 0.7893608212024619; 0.8357787380041017,"Atrial septal defect, ostium primum type ORPHA:99106; Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; SIX2-related frontonasal dysplasia ORPHA:488437; Peters anomaly ORPHA:708; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; 20p12.3 microdeletion syndrome ORPHA:261295; Chondrosarcoma ORPHA:55880; Greig cephalopolysyndactyly syndrome ORPHA:380; Isolated hyperchlorhidrosis ORPHA:542657; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Ulnar-mammary syndrome ORPHA:3138; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Branchiootic syndrome ORPHA:52429; Congenital short bowel syndrome ORPHA:2301; Papillary renal cell carcinoma ORPHA:319298; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Rieger anomaly ORPHA:91483; Brachydactyly type A2 ORPHA:93396; Unverricht-Lundborg disease ORPHA:308; Waardenburg syndrome type 2 ORPHA:895; Early-onset nuclear cataract ORPHA:98991; Bruck syndrome ORPHA:2771; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; CHST3-related skeletal dysplasia ORPHA:263463; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; Diaphanospondylodysostosis ORPHA:66637; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial drusen ORPHA:75376; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; Ischiovertebral syndrome ORPHA:85200; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Mandibulofacial dysostosis with alopecia ORPHA:443995; Myopathic Ehlers-Danlos syndrome ORPHA:536516; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Oculocutaneous albinism type 3 ORPHA:79433; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Primary CD59 deficiency ORPHA:169464; Retinal arterial tortuosity ORPHA:75326; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; X-linked osteoporosis with fractures ORPHA:391330; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Congenital diaphragmatic hernia ORPHA:2140; Familial primary localized cutaneous amyloidosis ORPHA:353220; Hypoplastic left heart syndrome ORPHA:2248; Piebaldism ORPHA:2884; Posterior hypospadias ORPHA:95706; Trichorhinophalangeal syndrome type 2 ORPHA:502; BOR syndrome ORPHA:107; Erythrokeratodermia variabilis ORPHA:317; Ondine syndrome ORPHA:661; Classical Ehlers-Danlos syndrome ORPHA:287; Multiple osteochondromas ORPHA:321; AA amyloidosis ORPHA:85445; Caffey disease ORPHA:1310; Cerebral autosomal recessive arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:199354; Congenital alveolar capillary dysplasia ORPHA:210122; Glaucoma secondary to spherophakia/ectopia lentis and megalocornea ORPHA:238763; HTRA1-related autosomal dominant cerebral small vessel disease ORPHA:482077; Lethal hydranencephaly-diaphragmatic hernia syndrome ORPHA:480528; Lymphedema-distichiasis syndrome ORPHA:33001; NON RARE IN EUROPE: Autosomal dominant ichthyosis vulgaris ORPHA:462; Non-immune hydrops fetalis ORPHA:363999; Posterior urethral valve ORPHA:93110; Malignant peripheral nerve sheath tumor ORPHA:3148; Postaxial polydactyly type B ORPHA:93335; Brachydactyly type A1 ORPHA:93388; Hennekam syndrome ORPHA:2136; Distal hereditary motor neuropathy type 2 ORPHA:139525; Osteogenesis imperfecta type 3 ORPHA:216812; Familial thoracic aortic aneurysm and aortic dissection ORPHA:91387; Arthrochalasia Ehlers-Danlos syndrome ORPHA:1899; Ehlers-Danlos/osteogenesis imperfecta syndrome ORPHA:230857; Osteogenesis imperfecta type 1 ORPHA:216796; Ablepharon macrostomia syndrome ORPHA:920; Acrogeria ORPHA:2500; Acromesomelic dysplasia, Hunter-Thompson type ORPHA:968; Adenocarcinoma of ovary ORPHA:213504; Angel-shaped phalango-epiphyseal dysplasia ORPHA:63442; Barber-Say syndrome ORPHA:1231; Carbamoyl-phosphate synthetase 1 deficiency ORPHA:147; Familial abdominal aortic aneurysm ORPHA:86; Familial visceral myopathy ORPHA:2604; Fibronectin glomerulopathy ORPHA:84090; Focal facial dermal dysplasia type III ORPHA:1807; Glutaric acidemia type 3 ORPHA:35706; Lipoid proteinosis ORPHA:530; Lymphedema-posterior choanal atresia syndrome ORPHA:99141; Myopathic intestinal pseudoobstruction ORPHA:104077; Ring dermoid of cornea ORPHA:91481; Split hand-split foot-deafness syndrome ORPHA:71271; Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome ORPHA:93358; Vascular Ehlers-Danlos syndrome ORPHA:286; Acromesomelic dysplasia, Grebe type ORPHA:2098; Brachydactyly type C ORPHA:93384; Fibular aplasia-complex brachydactyly syndrome ORPHA:2639; NON RARE IN EUROPE: Age-related macular degeneration ORPHA:279; Bethlem myopathy ORPHA:610; Congenital muscular dystrophy, Ullrich type ORPHA:75840; Multicentric osteolysis-nodulosis-arthropathy spectrum ORPHA:371428; Autosomal dominant generalized dystrophic epidermolysis bullosa ORPHA:231568; Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form ORPHA:89842; Bilateral microtia-deafness-cleft palate syndrome ORPHA:140963; Congenital vertical talus, bilateral ORPHA:295203; Congenital vertical talus, unilateral ORPHA:295201; Craniodiaphyseal dysplasia ORPHA:1513; Dystrophic epidermolysis bullosa pruriginosa ORPHA:89843; Glaucoma-ectopia lentis-microspherophakia-stiff joints-short stature syndrome ORPHA:2084; High bone mass osteogenesis imperfecta ORPHA:314029; Localized dystrophic epidermolysis bullosa, acral form ORPHA:158673; Localized dystrophic epidermolysis bullosa, nails only ORPHA:158676; Localized dystrophic epidermolysis bullosa, pretibial form ORPHA:79410; Marfan syndrome type 1 ORPHA:284963; Microcephaly-facial dysmorphism-ocular anomalies-multiple congenital anomalies syndrome ORPHA:521445; Microtia ORPHA:83463; Neonatal Marfan syndrome ORPHA:284979; Palmoplantar keratoderma, Nagashima type ORPHA:140966; Pelviscapular dysplasia ORPHA:93333; Progeroid and marfanoid aspect-lipodystrophy syndrome ORPHA:300382; Recessive dystrophic epidermolysis bullosa inversa ORPHA:79409; Self-improving dystrophic epidermolysis bullosa ORPHA:79411; Stiff skin syndrome ORPHA:2833; Hereditary sensory and autonomic neuropathy type 5 ORPHA:64752; Ellis Van Creveld syndrome ORPHA:289; Osteogenesis imperfecta type 2 ORPHA:216804; Osteogenesis imperfecta type 4 ORPHA:216820; Acrofacial dysostosis, Weyers type ORPHA:952; Craniofacial-deafness-hand syndrome ORPHA:1529; Craniofrontonasal dysplasia ORPHA:1520; Waardenburg syndrome type 1 ORPHA:894; Waardenburg syndrome type 3 ORPHA:896; Brachydactyly type E ORPHA:93387",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0083744975290613; 0.0092060390928213; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111; 0.020072786018028; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0599424746210022; 0.0599424746210022; 0.0621182671032116; 0.0683063362547733; 0.0902044104910482; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1739455566145445; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3826134188846508; 0.4101640425710954; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782,,,Homo sapiens MDA-MB-468 mammary gland adenocarcinoma cell,0.35,Homo sapiens,Homo sapiens
SNCG,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Squamous cell carcinoma; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Epithelial ovarian cancer; Carcinoma; Carcinomatosis; Mammary Neoplasms, Human; Neoplasm Metastasis; Malignant neoplasm of pancreas; Pancreatic carcinoma; Liver Cirrhosis; Colorectal Neoplasms; Anaplastic carcinoma; Bladder Neoplasm; Liver carcinoma; Esophageal carcinoma; Undifferentiated carcinoma; Malignant neoplasm of endometrium; Papillary serous cystadenocarcinoma; Uterine Corpus Cancer; Mammary Carcinoma, Animal; Animal Mammary Neoplasms; Hyperactive behavior; Solid Neoplasm; Liver neoplasms; Lung Neoplasms; Malignant neoplasm of liver; Neoplasms; Malignant neoplasm of lung; Endometrial Carcinoma; Glaucoma; Mammary Neoplasms, Experimental; Carcinoma of lung; Endometriosis; Noninfiltrating Intraductal Carcinoma; Primary malignant neoplasm of lung; Secondary malignant neoplasm of lymph node; Amyloidosis; Hyperkinesia, Generalized; Secondary malignant neoplasm of liver; Amyotrophic Lateral Sclerosis, Sporadic; Alzheimer's Disease; Liver and Intrahepatic Biliary Tract Carcinoma; Parkinson Disease; AMYOTROPHIC LATERAL SCLEROSIS 1; Mental Depression; Lafora Disease; Mammary Tumorigenesis; Retinoblastoma; Familial Alzheimer Disease (FAD); Lewy Body Disease; Neurodegenerative Disorders; AMYOTROPHIC LATERAL SCLEROSIS 1, AUTOSOMAL RECESSIVE; Cyst; Endometriosis of ovary; Obesity; Hepatocarcinogenesis; Ependymoma; Motor Neuron Disease",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0308703957553632; 0.0387439397151409; 0.0593779966354549; 0.0617471306652618; 0.064548079316548; 0.0648809611869375; 0.0726340460169901; 0.0745502070959292; 0.0773771948186562; 0.0827744840860166; 0.084286432100041; 0.0891725280554336; 0.095319386034013; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1352936728187231; 0.1352936728187231; 0.1387448809655294; 0.1413782599148022; 0.1454373331146953; 0.2062010908869036; 0.2643145809900195; 0.2714542429024338; 0.2714542429024338; 0.3044782497745498; 0.3105909001629992; 0.3508665345292502; 0.3663130598151661; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.4028066164685291; 0.4115056600660309; 0.4126392832024548; 0.424575176503444; 0.4335751357405352; 0.472444704048021; 0.4850576707687362; 0.5090214163899865; 0.5140447474168605; 0.533913711453195; 0.563120546412355; 0.8163430347375975,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Anaplastic Carcinoma; Breast Cancer; Carcinoma,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0402286636010764; 0.0534520155998091,"Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; 46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome ORPHA:168563; Hemolytic anemia due to adenylate kinase deficiency ORPHA:86817; Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome ORPHA:69735",0.0180064224283883; 0.0180064224283883; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782,,,Homo sapiens HEK293 embryonic kidney cell,0.4,Homo sapiens,Homo sapiens
SORBS1,"Colorectal Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Colorectal Cancer; Malignant neoplasm of breast; Epithelial ovarian cancer; Liver carcinoma; Colon Carcinoma; Liver neoplasms; Malignant tumor of colon; Diabetes; Diabetes Mellitus; Mannose-Binding Protein Deficiency; Diabetes Mellitus, Insulin-Dependent; Diabetic Retinopathy; Ischemic stroke; Tuberculosis; Plaque, Amyloid; Diabetes Mellitus, Non-Insulin-Dependent; Schizophrenia; Hypertensive disease; HIV Infections; Stinging Sensation; Asthma; Diabetic Nephropathy; Perry Syndrome; Rous Sarcoma; Viremia; Brain Infarction; Cerebrovascular accident; High-Grade Squamous Intraepithelial Lesions; Empyema; Hereditary persistence of fetal hemoglobin thalassemia; Infarction, Lacunar; Infant, Premature; Precocious pubarche; Huntington Disease; Motor neuron atrophy; Chronic Obstructive Airway Disease; Invasive Streptococcus pneumoniae disease; Obesity; Polycystic Ovary Syndrome; Anaphylaxis (non medication); Colorectal cancer metastatic; Clostridium; difficile (disorder); Hyperandrogenism; Hay fever; Hepatitis C; Cytomegalovirus Infections; Hepatitis B; Allergic disposition",0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0191435238361999; 0.0387439397151409; 0.095319386034013; 0.1062239757831962; 0.1454373331146953; 0.223747154820789; 0.2277108302018961; 0.2522264785494494; 0.2643145809900195; 0.2714542429024338; 0.2723545094624877; 0.3486533561309259; 0.3706856725676674; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.3941558617476422; 0.39623320406434; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4213286052188015; 0.4304973629098372; 0.4506578937113162; 0.4704594475773637; 0.4714226702518064; 0.5049674142533507; 0.5090214163899865; 0.5140447474168605; 0.5337853752290136; 0.5359212109443033; 0.5568517196017908; 0.5696906826730043; 0.5956632182199403; 0.6910672612216457; 0.7169459458481418; 0.8335660382047895; 0.9169959402964138; 0.9373303308937144,Breast Cancer; Cardiovascular Diseases; Diabetic Nephropathy; Leukemia; Diabetes Mellitus,0.0402286636010764; 0.554079268109006; 0.7049836926927165; 0.7167438233451096; 0.9683912711598086,"Alpha-B crystallin-related late-onset myopathy ORPHA:399058; Fatal infantile hypertonic myofibrillar myopathy ORPHA:280553; Lacrimoauriculodentodigital syndrome ORPHA:2363; 1p31p32 microdeletion syndrome ORPHA:401986; Brachydactyly-arterial hypertension syndrome ORPHA:1276; Bilateral striopallidodentate calcinosis ORPHA:1980; Autosomal recessive spastic paraplegia type 5A ORPHA:100986; Becker muscular dystrophy ORPHA:98895; Congenital bile acid synthesis defect type 3 ORPHA:79302; Symptomatic form of muscular dystrophy of Duchenne and Becker in female carriers ORPHA:206546; Familial vesicoureteral reflux ORPHA:289365; Primary pigmented nodular adrenocortical disease ORPHA:189439; Left ventricular noncompaction ORPHA:54260; Brugada syndrome ORPHA:130; Autosomal recessive non-syndromic sensorineural deafness type DFNB ORPHA:90636; Aplasia of lacrimal and salivary glands ORPHA:86815; BNAR syndrome ORPHA:217266; Dysbetalipoproteinemia ORPHA:412; Familial dyskinesia and facial myokymia ORPHA:324588; Hyperinsulinism due to INSR deficiency ORPHA:263458; Insulin-resistance syndrome type A ORPHA:2297; Leprechaunism ORPHA:508; Lipoprotein glomerulopathy ORPHA:329481; Lissencephaly syndrome, Norman-Roberts type ORPHA:89844; Oculotrichoanal syndrome ORPHA:2717; Peripheral demyelinating neuropathy-central dysmyelinating leukodystrophy-Waardenburg syndrome-Hirschsprung disease ORPHA:163746; Rabson-Mendenhall syndrome ORPHA:769; Sea-blue histiocytosis ORPHA:158029; Transient infantile hypertriglyceridemia and hepatosteatosis ORPHA:300293; X-linked intellectual disability, Stocco Dos Santos type ORPHA:85288; Duchenne muscular dystrophy ORPHA:98896; Inherited congenital spastic tetraplegia ORPHA:210141; 12p12.1 microdeletion syndrome ORPHA:313884; Anoctamin-5-related  limb-girdle muscular dystrophy R12 ORPHA:206549; Atypical dentin dysplasia due to SMOC2 deficiency ORPHA:314721; Classical-like Ehlers-Danlos syndrome type 1 ORPHA:230839; Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency ORPHA:90791; Congenital atransferrinemia ORPHA:1195; Congenital muscular dystrophy with integrin alpha-7 deficiency ORPHA:34520; Developmental and speech delay due to SOX5 deficiency ORPHA:313892; Developmental delay due to methylmalonate semialdehyde dehydrogenase deficiency ORPHA:289307; Distal anoctaminopathy ORPHA:399096; Familial GPIHBP1 deficiency ORPHA:535458; Familial atrial tachyarrhythmia-infra-Hisian cardiac conduction disease ORPHA:436242; Familial benign flecked retina ORPHA:363989; Familial lipoprotein lipase deficiency ORPHA:309015; Familial male-limited precocious puberty ORPHA:3000; Gnathodiaphyseal dysplasia ORPHA:53697; Isolated congenital megalocornea ORPHA:91489; L-Arginine:glycine amidinotransferase deficiency ORPHA:35704; Leydig cell hypoplasia due to complete LH resistance ORPHA:96265; Leydig cell hypoplasia due to partial LH resistance ORPHA:96266; MYBPC1-related autosomal recessive non-lethal arthrogryposis multiplex congenita syndrome ORPHA:498693; Null syndrome ORPHA:280234; PLIN1-related familial partial lipodystrophy ORPHA:280356; Pelizaeus-Merzbacher disease in female carriers ORPHA:280229; Pelizaeus-Merzbacher disease, classic form ORPHA:280219; Pelizaeus-Merzbacher disease, connatal form ORPHA:280210; Pelizaeus-Merzbacher disease, transitional form ORPHA:280224; Spastic paraplegia type 2 ORPHA:99015; Spinocerebellar ataxia type 19/22 ORPHA:98772; Hypertrichotic osteochondrodysplasia, Cantu type ORPHA:1517; Preeclampsia ORPHA:275555; Waardenburg-Shah syndrome ORPHA:897; NON RARE IN EUROPE: Essential hypertension ORPHA:243761; Catecholaminergic polymorphic ventricular tachycardia ORPHA:3286; Romano-Ward syndrome ORPHA:101016; Familial atrial fibrillation ORPHA:334",0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1697334635963512; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3775879467205478; 0.4177534028018127; 0.5145066480201691; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7072638369101406; 0.7362131755977757; 0.7469385786191998,Human immunodeficiency virus 2 nef protein; Papiine alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5); Human gammaherpesvirus 4 EBNA-2 nuclear protein (gene: BYRF1); Human herpesvirus 4 type 2 EBNA-2; Human immunodeficiency virus 1 Pol (gene: gag-pol); Human alphaherpesvirus 2 envelope glycoprotein E (gene: US8); Human immunodeficiency virus nef protein (gene: nef); Cercopithecine betaherpesvirus 5 membrane glycoprotein US2 (gene: US2); Human immunodeficiency virus 1 integrase (gene: gag-pol); Monkeypox virus ankyrin-like protein; Mumps virus phoshoprotein (gene: V/P); Mumps virus genotype G phosphoprotein (gene: P),0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.7795229132668053; 0.7988086321880973; 0.7988086321880973; 0.8426793553344071; 0.9621839893030432; 0.9621839893030432,In vitro;chinese hamster ovary cell line,0.35;0.4,Homo sapiens;chemical synthesis;crigr,Homo sapiens;Mycobacterium tuberculosis (strain ATCC 35801 / TMC 107 / Erdman)
SORL1,"Colorectal Cancer; Malignant neoplasm of breast; Seizures; Diabetes; Diabetes Mellitus; Language Disorders; Acute leukemia; Multiple Sclerosis; Cognitive changes; Amyloidosis; Hallucinations; Bipolar Disorder; Plaque, Amyloid; Cerebrovascular Disorders; Diabetes Mellitus, Non-Insulin-Dependent; Schizophrenia; Hypertensive disease; Leukemia, Myelocytic, Acute; Alzheimer's Disease; Acute lymphocytic leukemia; Abnormal social behavior; Abnormal social interactions; Deposits immunoreactive to beta-amyloid protein; Epilepsy; Senile Plaques; Cholestasis; Forgetful; Neoplasm Invasiveness; Alzheimer Disease, Late Onset; Familial Alzheimer Disease (FAD); Vascular Diseases; Neurofibrillary degeneration (morphologic abnormality); Triglycerides measurement; Mild cognitive disorder; Hyperlipoproteinemia Type IIa; Cardiovascular Diseases; Huntington Disease; Social disinhibition; Agitation; Arteriosclerosis; Obesity; Memory impairment; Fasting blood glucose measurement; Atherosclerosis; Confusion; Spasmodic movement; Involuntary jerking movements; Memory Loss; Parkinsonian Disorders; Hallucinations, Sensory; Hepatitis, Toxic; Chemical and Drug Induced Liver Injury; Chemically-Induced Liver Toxicity; Drug-Induced Acute Liver Injury; Hepatitis, Drug-Induced; Myoclonus; Cerebral atrophy; Dementia; Drug-Induced Liver Disease; Alzheimer's Disease, Focal Onset; Acute Confusional Senile Dementia; Alzheimer Disease, Early Onset; Muscle Hypertonia; Impaired cognition; Presenile dementia",0.0149315928814189; 0.0191435238361999; 0.2053083986145698; 0.2277108302018961; 0.2522264785494494; 0.2747883228704706; 0.2835142372342932; 0.2835142372342932; 0.3220099003872086; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3975960596292668; 0.4100901006059349; 0.4100901006059349; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4192169590514327; 0.4506578937113162; 0.4564472886428772; 0.4675904598629673; 0.4704594475773637; 0.4753011022966241; 0.4923669467696064; 0.5019670090704682; 0.5140447474168605; 0.5188223685230745; 0.5251317541886066; 0.5393787854381349; 0.5453394612016188; 0.5514573300659174; 0.5514573300659174; 0.5568517196017908; 0.5683976277847906; 0.5916904943304121; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.6189532555846575; 0.625112405383346; 0.6294837700416086; 0.6364853529519863; 0.6910672612216457; 0.6959870102453846; 0.6959870102453846; 0.7756460653898786; 0.7780887836634591; 0.8000044931629623; 0.9212908525513646,Breast Cancer; Language Disorders; Cholestasis; Parkinson Disease; Colorectal Cancer; Semantic Dementia; Alzheimer Disease; Paroxysmal Atrial Fibrillation; Cerebral Cortical Atrophy; Dysgraphia; Cognitive Disorder; Aphasia; Atrial Fibrillation; Oculovestibuloauditory Syndrome; Oculomotor Apraxia; Mental Retardation; Impaired Cognition; Hallucinations,0.0402286636010764; 0.3094716280561038; 0.336287627428424; 0.4286813331685578; 0.4286813331685578; 0.4560460337187313; 0.4560460337187313; 0.5082542877462781; 0.5129298662020659; 0.5796489603182782; 0.6030919130927346; 0.6477775413116995; 0.6792162876553974; 0.7191962993706487; 0.7360789997461612; 0.7729545590606223; 0.781505274734613; 0.8277709367020475,Serrated polyposis syndrome ORPHA:157798; Early-onset autosomal dominant Alzheimer disease ORPHA:1020; Hypohidrosis-electrolyte imbalance-lacrimal gland dysfunction-ichthyosis-xerostomia syndrome ORPHA:528105; NON RARE IN EUROPE: Alzheimer disease ORPHA:238616; Congenital factor V deficiency ORPHA:326; East Texas bleeding disorder ORPHA:391320; X-linked Charcot-Marie-Tooth disease type 6 ORPHA:352675,0.1590470395003315; 0.1739455566145445; 0.6239678957896782; 0.6268296504510718; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,"Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85)",0.6806291584193672; 0.6806291584193672,Homo sapiens HCT116 colon carcinoma cell;Homo sapiens HEK293T embryonic kidney cell;In vitro;yeasx,0.35;0.4;0.56;0.81,Homo sapiens,Homo sapiens;chemical synthesis
SORT1,"Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Malignant neoplasm of breast; Malignant neoplasm of prostate; Malignant neoplasm of pancreas; Glioma; Prostate carcinoma; Myocardial Infarction; Diabetes; Diabetes Mellitus; Multiple Sclerosis; Cognitive changes; Thyroid Neoplasm; Creatinine measurement, serum (procedure); Amyloidosis; Diabetes Mellitus, Non-Insulin-Dependent; Schizophrenia; Alzheimer's Disease; Coronary heart disease; Adenoma; Aortic Aneurysm, Abdominal; Thyroid carcinoma; Mental Depression; Arteriosclerotic cardiovascular disease, NOS; Amyotrophic Lateral Sclerosis; Depressive disorder; Vascular Diseases; Glomerular filtration rate finding; Essential Tremor; Encephalomyelitis; Malignant neoplasm of thyroid; Neurodegenerative Disorders; Neuropathy; Dyslipidemias; Hyperlipoproteinemia Type IIa; Cardiovascular Diseases; Hypercholesterolemia; Steatohepatitis; Lipid Metabolism Disorders; Arteriosclerosis; Coronary Arteriosclerosis; Obesity; Fatty Liver; Atherosclerosis; Frontotemporal dementia; Pediatric Obesity; Low density lipoprotein cholesterol measurement; Coronary Artery Disease; Serum total cholesterol measurement; Charcot-Marie-Tooth Disease",0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0191435238361999; 0.0569142010728473; 0.0726340460169901; 0.0739788831250619; 0.0773771948186562; 0.1352936728187231; 0.2277108302018961; 0.2522264785494494; 0.2835142372342932; 0.3220099003872086; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.4126392832024548; 0.4126392832024548; 0.425419812815905; 0.4254307049060398; 0.4307603335611732; 0.4335751357405352; 0.4335751357405352; 0.4421745246585178; 0.4564472886428772; 0.4675904598629673; 0.4755217870653703; 0.4906258721078565; 0.4906258721078565; 0.5019670090704682; 0.5140447474168605; 0.5140447474168605; 0.533913711453195; 0.5393787854381349; 0.6064571148125548; 0.6496433426951205; 0.6941270729825465; 0.7240930522443176; 0.8758099322635008; 0.9662162234631484,Cholestasis; Coronary Arteriosclerosis; Cardiovascular Diseases; Coronary Artery Disease,0.336287627428424; 0.4875380732267193; 0.554079268109006; 0.7729545590606223,Familial multiple nevi flammei ORPHA:624; Sturge-Weber syndrome ORPHA:3205; Familial primary hypomagnesemia with normocalciuria and normocalcemia ORPHA:34527; Phakomatosis cesioflammea ORPHA:79483; Growth delay due to insulin-like growth factor I resistance ORPHA:73273; Primary pigmented nodular adrenocortical disease ORPHA:189439; Charcot-Marie-Tooth disease type 4H ORPHA:99954; CLCN4-related X-linked intellectual disability syndrome ORPHA:485350,0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.3762014630157917; 0.3775879467205478; 0.6239678957896782; 0.7068064785325423,,,Homo sapiens;Homo sapiens A549 lung carcinoma cell;In vitro,0.35;0.4;0.44;0.56;0.68,Homo sapiens;Human SARS coronavirus;SARS-CoV-2;ade05;chemical synthesis;ebvb9,Homo sapiens;chemical synthesis
SPAG1,"Carcinogenesis; Malignant neoplasm of pancreas; Pancreatic carcinoma; Embryonal Carcinoma; Respiratory insufficiency due to defective ciliary clearance; Nasal inflammation; Bronchiectasis; Adenocarcinoma of pancreas; Recurrent otitis media; Recurrent sinus disease; Recurrent sinusitis; Polynesian Bronchiectasis; Paranasal Sinus Diseases; Situs ambiguus; Sinusitis; Ciliary Motility Disorders; Bronchitis, Chronic; Situs Inversus; Leishmaniasis, Visceral; Rhinitis; Recurrent respiratory infections; Kartagener Syndrome; Intellectual Disability; Ciliopathies",0.0228075668512991; 0.0726340460169901; 0.0745502070959292; 0.3112516166225269; 0.3941558617476422; 0.3941558617476422; 0.4028066164685291; 0.4325044517055656; 0.4352815161963393; 0.4923669467696064; 0.4923669467696064; 0.5251317541886066; 0.5453394612016188; 0.582492855487907; 0.6150955455771212; 0.625027955184583; 0.6304655343580164; 0.6925751397474874; 0.6980473696540115; 0.738047882208201; 0.7484342194688707; 0.7651930135295156; 0.8352623613787349; 0.8849686999768298,Epilepsy; Hydrocephalus; Bronchiectasis; Lung Diseases; Nasal Polyposis; Corneal Dystrophy; Scoliosis; Asthma; Kartagener Syndrome; Sinusitis; Hearing Loss; Asthenozoospermia; Gastric Cancer; Ciliary Dyskinesia; Rhinitis; Asplenia; Situs Inversus; Otitis Media; Congenital Pectus Excavatum,0.3449614869411272; 0.3657224783929353; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4875380732267193; 0.4875380732267193; 0.504364324740411; 0.5316139823120088; 0.5576425853515448; 0.5632819212593052; 0.6420878824691651; 0.6524705037929849; 0.6564901877271138; 0.6792162876553974; 0.7049836926927165; 0.7833015488163313; 0.7979559493902503; 0.8407264689819682,Glutamate-cysteine ligase deficiency ORPHA:33574; X-linked hypophosphatemia ORPHA:89936; Primary ciliary dyskinesia ORPHA:244,0.0586579655822394; 0.1590470395003315; 0.7068064785325423,,,Homo sapiens HEK293T embryonic kidney cell,0.35,Homo sapiens,Homo sapiens
SPC25,Monocyte count procedure; Monocyte count result,0.6274540883972485; 0.6274540883972485,Liver Carcinoma; Metabolic Syndrome,0.0520696613701797; 0.4809179010794786,"Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Roberts syndrome ORPHA:3103; Denys-Drash syndrome ORPHA:220; Frasier syndrome ORPHA:347; Meacham syndrome ORPHA:3097; Male infertility with azoospermia or oligozoospermia due to single gene mutation ORPHA:399805; L-2-hydroxyglutaric aciduria ORPHA:79314; Isolated megalencephaly ORPHA:268920; Methylmalonic acidemia with homocystinuria, type cblC ORPHA:79282",0.0083045131203191; 0.0106988445340883; 0.0180064224283883; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.4548046963946745; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423,,,In vitro,0.35,chemical synthesis,Homo sapiens
STN1,"Colorectal Carcinoma; Colorectal Cancer; melanoma; Epithelial ovarian cancer; Glioma; Premature canities; Hematologic Neoplasms; Hamman-Rich syndrome; Hypertension, Portal; Hyperactive behavior; Systemic Scleroderma; Lung Neoplasms; Malignant neoplasm of lung; Idiopathic Pulmonary Fibrosis; Diabetes Mellitus, Non-Insulin-Dependent; Fetal Growth Retardation; Hereditary Nonpolyposis Colorectal Cancer; Gastroesophageal reflux disease; Generalized osteopenia; Coronary heart disease; Infant, Small for Gestational Age; Malignant Central Nervous System Neoplasm; Intrauterine retardation; Dyspnea on exertion; Bronchiectasis; Reticular pattern on pulmonary HRCT; Esophageal Varices; Ground-glass opacification on pulmonary HRCT; Honeycomb lung; Retinal telangiectasia; Rales; Pulmonary Fibrosis; Clubbed Fingers; Dystonic disease; Cardiovascular Diseases; Osteopenia; Coronary Arteriosclerosis; Cutaneous Melanoma; Cerebellar Ataxia; Acid reflux; Gastrointestinal Hemorrhage; Lung Diseases, Interstitial; Dystonia; Heartburn; Coughing; Coronary Artery Disease; Pancytopenia; Muscle Spasticity",0.0034602840073026; 0.0149315928814189; 0.0149315928814189; 0.0387439397151409; 0.0739788831250619; 0.1193558174333938; 0.1253114324938153; 0.13167400689206; 0.1328002618052838; 0.1387448809655294; 0.1900258729042946; 0.2062010908869036; 0.2714542429024338; 0.3099246715197673; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.4028066164685291; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4192169590514327; 0.4335751357405352; 0.4459714599189374; 0.4459714599189374; 0.4675904598629673; 0.4923669467696064; 0.5140447474168605; 0.5710095678317721; 0.5754799679683854; 0.5936773368594411; 0.6150955455771212; 0.6207008101484466; 0.6334536292962906; 0.641532117799187; 0.717484976234209; 0.7240930522443176; 0.7756460653898786; 0.7965501584766118,Carcinoma; Pulmonary Fibrosis; Retinal Telangiectasia; Esophageal Varix; Malignant Melanoma Of Skin; Lung Cancer; Central Nervous System Neoplasms; Lung Neoplasms; Osteopenia; Portal Hypertension; Bronchiectasis; Lung Diseases; Basal Cell Neoplasm; Honeycomb Lung; Hamman-Rich Syndrome; Hypertension; Glioma; Diffuse Interstitial Pulmonary Fibrosis; Melanoma; Dyskeratosis Congenita; Gastroesophageal Reflux Disease; Pancytopenia; Plexiform Leiomyoma; Ovarian Epithelial Carcinoma; Uterine Fibroids; Coronary Artery Disease; Chronic Obstructive Pulmonary Disease,0.0534520155998091; 0.0654534781440596; 0.336287627428424; 0.4286813331685578; 0.4286813331685578; 0.4402141802500753; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4646409362700993; 0.4646409362700993; 0.4742592264758768; 0.5234357475824973; 0.5681293104170607; 0.5875654081009305; 0.6304164862793252; 0.7729545590606223; 0.9568083835980838,Coats plus syndrome ORPHA:313838; Idiopathic pulmonary fibrosis ORPHA:2032,0.3762014630157917; 0.43936148647173,,,,,,
SULT1A1,"Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; Squamous cell carcinoma; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Urologic Neoplasms; Brain Tumor, Primary; Cancer of Urinary Tract; Malignant neoplasm of prostate; Cervical Squamous Intraepithelial Neoplasia 1; Cervical intraepithelial neoplasia grade 1; Brain Neoplasms; Neoplasm Metastasis; Malignant neoplasm of pancreas; Glioma; Endometrial Neoplasms; Glioblastoma; Pancreatic carcinoma; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Genomic Instability; Colorectal Neoplasms; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Liver carcinoma; Colon Carcinoma; Small cell carcinoma of lung; Esophageal carcinoma; Carcinoma, Transitional Cell; Carcinoma of bladder; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Colonic Neoplasms; Liver neoplasms; Cervical intraepithelial neoplasia grade 2; cervical cancer; Lung Neoplasms; Malignant tumor of colon; Prostatic Neoplasms; Diabetes; Malignant Head and Neck Neoplasm; Diabetes Mellitus; Malignant tumor of cervix; Malignant neoplasm of lung; Cervix carcinoma; Acute leukemia; Triple Negative Breast Neoplasms; Endometrial Carcinoma; Cholangiocarcinoma; Carcinoma of lung; Primary malignant neoplasm of lung; Secondary malignant neoplasm of lymph node; Chronic myeloproliferative disorder; Diabetes Mellitus, Non-Insulin-Dependent; High altitude pulmonary edema; Infant Acute Lymphoblastic Leukemia; Leukemia, Myelocytic, Acute; Cervical Squamous Cell Carcinoma In Situ; Urothelial Carcinoma; Genitourinary Cancer; Adenoma; Malignant neoplasm of male breast; Carcinoma in situ of uterine cervix; Pituitary Adenoma; Female Genital Diseases; Breast Neoplasms, Male; Carcinoma of Male Breast; Cervix Intraepithelial Neoplasia Grade 3 AJCC v7; Adenoma of large intestine; Autosome Abnormalities; Chromosome Aberrations; Nonalcoholic Steatohepatitis; Slow acetylator due to N-acetyltransferase enzyme variant; Depressive Symptoms; Myocardial Ischemia; MRSA - Methicillin resistant Staphylococcus aureus infection; Intelligence; Bile duct carcinoma; Mucocutaneous Lymph Node Syndrome; Dementia; Sudden infant death syndrome; Hyperplastic Polyp; Essential Hypertension",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0314665934969085; 0.044151975756427; 0.0492766532827251; 0.0569142010728473; 0.0593779966354549; 0.0593779966354549; 0.064548079316548; 0.0648809611869375; 0.0726340460169901; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0775520919998773; 0.0775520919998773; 0.0827744840860166; 0.084286432100041; 0.0891725280554336; 0.095319386034013; 0.1062239757831962; 0.1193558174333938; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1454373331146953; 0.1454373331146953; 0.2050045461627939; 0.2050045461627939; 0.2062010908869036; 0.223747154820789; 0.223747154820789; 0.2277108302018961; 0.2522264785494494; 0.2522264785494494; 0.2714542429024338; 0.2714542429024338; 0.2834835531038365; 0.2835142372342932; 0.2980670559114652; 0.3044782497745498; 0.340892538685018; 0.3663130598151661; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4115056600660309; 0.4126392832024548; 0.4192169590514327; 0.4192169590514327; 0.4335751357405352; 0.4335751357405352; 0.4459714599189374; 0.4506578937113162; 0.4506578937113162; 0.5683976277847906; 0.6150955455771212; 0.6294837700416086; 0.6364853529519863; 0.672336954961104; 0.7631684472516962; 0.8418436641268439,Breast Carcinoma; Urinary Tract Cancer; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Urologic Neoplasms; Myocardial Ischemia; Allergic Rhinitis; Colonic Neoplasms; Prostatic Neoplasms; Prostate Cancer,0.0075861267486594; 0.0102679590519094; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0839188440969517; 0.4560460337187313; 0.4560460337187313; 0.4809179010794786; 0.4875380732267193; 0.6104715460837368,Serrated polyposis syndrome ORPHA:157798; Acute myeloid leukemia with CEBPA somatic mutations ORPHA:319480; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency ORPHA:477857; Amelocerebrohypohidrotic syndrome ORPHA:1946,0.1590470395003315; 0.3762014630157917; 0.6239678957896782; 0.7068064785325423,,,Homo sapiens HEK293T embryonic kidney cell;yeasx,0.35;0.37,Homo sapiens,Bacillus anthracis;Homo sapiens
SUMF1,"Lysosomal Storage Diseases; Clouding of corneal stroma; Seizures; Corneal Opacity; Cataract; Multiple Sclerosis; Pfaundler-Hurler Syndrome; Hydrocephalus; Hyperplasia of forehead; Hypertrophy of forehead; Large forehead; Mucopolysacchariduria; Multiple Sulfatase Deficiency Disease; Rough hair texture; Coarse hair; Abnormality of peripheral nerve conduction; Epilepsy; Mucopolysaccharidosis, MPS-IV-A; Bulging forehead; Prominent forehead; Hypoplastic vertebral bodies; Broad hallux phalanx; Splenomegaly; Hyperammonemia; Smooth philtrum; Central nervous system lesion; Lens Opacities; Cellulitis of periorbital region; Periorbital edema; Periorbital swelling; Abnormality of the periventricular white matter; Dilated ventricles (finding); Increased CSF protein; Lower limb hyperreflexia; Supratentorial atrophy; Short stature; Mucopolysaccharidosis Type IIIA; Hepatomegaly; Peripheral demyelination; Retinal Degeneration; Degenerative brain disorder; Hydrops Fetalis; Chronic Obstructive Airway Disease; Cerebellar atrophy; Broad hallux; Dull intelligence; Low intelligence; Concave bridge of nose; Depressed nasal root/bridge; Depressed nasal bridge; Joint stiffness; Broad thumbs; Poor school performance; Central nervous system demyelination; Cerebellar Ataxia; Mental deficiency; Thickened facial skin with coarse facial features; Coarse facial features; Cerebral atrophy; Mental Retardation; Flat face; Retinal pigment epithelial abnormality; Abnormality of retinal pigmentation; Infratentorial atrophy; Thick eyebrow; Sensorineural Hearing Loss (disorder); Cerebellar degeneration; Ichthyoses; Leukodystrophy; Big calvaria; Increased size of skull; Increased head circumference; Neonatal Hypotonia; Ataxia, Spinocerebellar; Muscle Spasticity; Visual Impairment; Optic Atrophy; Hearing Loss, Partial; Low Vision; Intellectual Disability; Psychomotor regression, progressive; Loss of developmental milestones; Mental deterioration in childhood; Neurodevelopmental regression; Psychomotor regression; Psychomotor regression beginning in infancy; Psychomotor regression in infants; Developmental regression; Anteverted nostril; hearing impairment; Mental and motor retardation; Cognitive delay; Global developmental delay; Deafness; Congenital deafness",0.0798053340865682; 0.1859959283872542; 0.2053083986145698; 0.2085938372806741; 0.223747154820789; 0.2835142372342932; 0.3508665345292502; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.4103119460235835; 0.4115056600660309; 0.4126392832024548; 0.4192169590514327; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.425992946703162; 0.4335751357405352; 0.4335751357405352; 0.4381343267935581; 0.439389586518055; 0.4396723023384634; 0.4506578937113162; 0.4506578937113162; 0.4675904598629673; 0.4790179402069343; 0.4990401620718274; 0.5049674142533507; 0.5251317541886066; 0.5251317541886066; 0.5300976305939776; 0.5300976305939776; 0.5337853752290136; 0.5337853752290136; 0.533913711453195; 0.5359212109443033; 0.5393787854381349; 0.5610226870913673; 0.5655222348249326; 0.5754799679683854; 0.6035970790768342; 0.6207008101484466; 0.6222451141623291; 0.6294837700416086; 0.6319938293757544; 0.6319938293757544; 0.6545439509404224; 0.6545439509404224; 0.6545439509404224; 0.6588479076808555; 0.6891882956008074; 0.7096959691931399; 0.7129583530027284; 0.7309076068378124; 0.7484342194688707; 0.7484342194688707; 0.7511668779991656; 0.7670529315163258; 0.7756460653898786; 0.7965501584766118; 0.8098594112577364; 0.809878589520458; 0.8209296131179464; 0.8225089178916923; 0.8352623613787349; 0.839057838231319; 0.839057838231319; 0.839057838231319; 0.839057838231319; 0.839057838231319; 0.839057838231319; 0.8441962785769224; 0.8455269088566324; 0.8472019892490944; 0.8612168330350624; 0.897310588550617; 0.9238745269736108; 0.9327689937867868; 0.9559782990517682; 0.9630764048242788,Hydrocephalus; Pfaundler-Hurler Syndrome; Narcolepsy; Central Nervous System Demyelination; Hypotonia; Microcephaly; Cerebral Atrophy; Hearing Loss; Dwarfism; Cataract; Optic Atrophy; Cerebellar Atrophy; Mental Retardation; Macrocephaly; Ichthyosis; Multiple Sclerosis; Developmental Delay; Developmental Regression,0.3657224783929353; 0.3940072377207739; 0.4875380732267193; 0.4968320901822731; 0.5087473896242481; 0.5123947823327547; 0.5129298662020659; 0.5632819212593052; 0.5796489603182782; 0.6660731887258019; 0.675936313627625; 0.7112499273451761; 0.7729545590606223; 0.800821840688695; 0.850248739086744; 0.880175848034561; 0.96477535147595; 0.9772539070870868,"Sanfilippo syndrome type D ORPHA:79272; Tay-Sachs disease, B variant, adult form ORPHA:309192; Tay-Sachs disease, B variant, infantile form ORPHA:309178; Tay-Sachs disease, B variant, juvenile form ORPHA:309185; Tay-Sachs disease, B1 variant ORPHA:309239; Free sialic acid storage disease, infantile form ORPHA:309324; Intermediate severe Salla disease ORPHA:309331; Mitochondrial DNA depletion syndrome, myopathic form ORPHA:254875; Salla disease ORPHA:309334; Multiple sulfatase deficiency ORPHA:585; NON RARE IN EUROPE: Hemochromatosis type 1 ORPHA:139498; Sporadic porphyria cutanea tarda ORPHA:443057; Symptomatic form of hemochromatosis type 1 ORPHA:465508; TMEM165-CDG ORPHA:314667",0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782,,,Cercopithecus aethiops simian cells transformed with SV40;Homo sapiens QGY7703 hepatocellular carcinoma cell;yeasx,0.35;0.37;0.52,Homo sapiens;canen,Homo sapiens;Yersinia pestis
SUSD4,Breast Carcinoma; Tumor Progression; Malignant neoplasm of breast,0.0042545616049287; 0.0149315928814189; 0.0191435238361999,,,"Bilateral frontoparietal polymicrogyria ORPHA:101070; Fuhrmann syndrome ORPHA:2854; Phocomelia, Schinzel type ORPHA:2879; Ichthyosis-short stature-brachydactyly-microspherophakia syndrome ORPHA:363992",0.0586579655822394; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423,"Echovirus E21 VP1; Human enterovirus 94 VP2; Enterovirus D capsid protein 1B; Human gammaherpesvirus 8 KCP (gene: ORF4); Coxsackievirus A14 full_polyprotein 1..2192; Coxsackievirus A10 full_polyprotein 1..2193; Enterovirus A120 full_polyprotein 1..2191; Coxsackievirus A4 full_polyprotein 1..2201; Enterovirus A76 full_polyprotein 1..2198; Enterovirus A VP2 (1B); Coxsackievirus A2 full_polyprotein 1..2190; Enterovirus D protein VP0; Coxsackievirus A8 VP2 protein; Echovirus E18 full_polyprotein 1..2189; Coxsackievirus A6 VP2 protein; Echovirus E12 polyprotein; Vaccinia virus secreted complement-binding protein (gene: C3L); Vaccinia virus Ankara Complement control protein; Echovirus E24 VP3; Echovirus E7 VP3; Human enterovirus 79 1C (VP3); Echovirus E12 polyprotein region 3; Echovirus E26 VP3; Echovirus E27 VP3; Echovirus E31 VP3; Echovirus E33 VP3; Echovirus E7 VP2; Coxsackievirus B4 full_polyprotein 1..2183; Echovirus E30 full_polyprotein 1..2194; Coxsackievirus B5 VP2 capsid protein, polyprotein region 3 (gene: 1A); Echovirus 9 strain Barty VP3; Echovirus 9 strain Hill polyprotein region 3; Echovirus E11 1B(VP2); Echovirus E11 1D(VP1); Echovirus E16 VP3; Echovirus E3 VP3; Coxsackievirus B6 full_polyprotein 1..2184; Echovirus E21 VP3; Echovirus E29 VP3; Echovirus E32 VP3; Enterovirus B 1B(VP2); Enterovirus B 1C(VP3); Coxsackievirus B2 full_polyprotein 1..2187; Enterovirus B genome polyportein; Human rhinovirus B5 1B; Echovirus E11 1C(VP3); Echovirus E19 VP1; Echovirus E4 VP3; Enterovirus B111 VP3; Enterovirus B73 full_polyprotein 1..2188; Cowpox virus CPXV034 (gene: CPXV034 CDS); Monkeypox virus complement control protein; Monkeypox virus Zaire-96-I-16 D14L (gene: D14L); Echovirus E32 VP1; Enterovirus B111 VP1; Echovirus E14 VP3; Echovirus E19 VP3; Echovirus E19 VP2; Enterovirus B106 full_polyprotein 1..2192; Echovirus E15 VP2; Echovirus E5 full_polyprotein 1..2196; Echovirus E12 polyprotein region 4; Echovirus E13 VP3; Echovirus E15 VP3; Echovirus E27 VP1; Enterovirus B97 VP3; Horsepox virus HSPV028 (secreted complement-binding protein; Provisional); Echovirus E17 VP3; Echovirus E2 VP3; Echovirus E14 VP1; Echovirus E2 VP1; Echovirus E6 VP3; Enterovirus B97 VP1; Enterovirus H capsid protein VP2; Echovirus E9 full_polyprotein 1..2203; Human enterovirus 79 1B (VP2); Echovirus E15 VP1; Echovirus E17 VP2; Echovirus E17 VP1; Echovirus E29 VP2; Ectromelia virus ERPV complement binding protein; Echovirus E20 VP2; Echovirus E25 VP3; Echovirus E31 VP1; Vaccinia virus Ankara EEV type 1 membrane protein; Echovirus E16 VP2; Echovirus E26 VP2; Echovirus E3 VP1; Echovirus E33 VP2; Echovirus E4 VP2; Echovirus 9 strain Barty VP2; Echovirus E14 VP2; Echovirus E16 VP1; Echovirus E21 VP2; Echovirus E24 VP2; Echovirus E24 VP1; Echovirus E27 VP2; Echovirus E29 VP1; Echovirus E33 VP1; Echovirus E6 VP1; Enterovirus B111 VP2; Enterovirus H capsid protein VP3; Echovirus E20 VP1; Echovirus E25 VP2; Echovirus E6 VP2; Enterovirus B97 VP2; Human cosavirus B VP2; Echovirus E13 VP2; Echovirus E25 VP1; Echovirus E3 VP2; Echovirus E31 VP2; Ectromelia virus ERPV EEV complement control protein; Echovirus 9 strain Hill polyprotein region 2; Echovirus E2 VP2; Cowpox virus CPXV199 protein (gene: CPXV199 CDS); Vaccinia virus EEV membrane glycoprotein (gene: B5R); Monkeypox virus EEV type-I membrane glycoprotein; Monkeypox virus Zaire-96-I-16 EEV membrane glycoprotein (gene: B6R); Echovirus E32 VP2; Horsepox virus HSPV182 (EEV membrane glycoprotein; Provisional); Human cosavirus full_polyprotein 1..2121",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6430308263654244; 0.6621265548536891; 0.6621265548536891; 0.6621265548536891; 0.6621265548536891; 0.6682550899136019; 0.7017760963861425,,,,
SYNE3,Malignant Neoplasms; Primary malignant neoplasm; Early onset torsion dystonia,0.0991201145654548; 0.383941725017158; 0.4396723023384634,,,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome ORPHA:447997; Early-onset Lafora body disease ORPHA:324290; Generalized glucocorticoid resistance syndrome ORPHA:786; Spinocerebellar ataxia type 1 ORPHA:98755; Attenuated Chediak-Higashi syndrome ORPHA:352723; Chediak-Higashi syndrome ORPHA:167; Autosomal dominant multiple pterygium syndrome ORPHA:65743; External auditory canal aplasia/hypoplasia ORPHA:141074; Growth retardation-mild developmental delay-chronic hepatitis syndrome ORPHA:391366; Nicolaides-Baraitser syndrome ORPHA:3051; Spinocerebellar ataxia type 15/16 ORPHA:98769; Spinocerebellar ataxia type 29 ORPHA:208513; Obesity due to congenital leptin deficiency ORPHA:66628,0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423,Monkeypox virus cowpox A-type inclusion protein; Vaccinia virus cowpox A-type inclusion protein; Hendra henipavirus phosphoprotein P (gene: P/V/C),0.6362779693488597; 0.8834254233868516; 0.8919745352546131,,,,
TEKT4P2,,,,,Pyridoxal phosphate-responsive seizures ORPHA:79096,0.6239678957896782,,,,,,
TET1,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Hematopoietic Neoplasms; Epithelial ovarian cancer; Neoplasm Metastasis; Glioma; Degenerative polyarthritis; Glioblastoma; Liver carcinoma; Malignant Neoplasms; Colon Carcinoma; Hamman-Rich syndrome; Malignant neoplasm of large intestine; Colonic Neoplasms; Lung Neoplasms; Malignant tumor of colon; B-Cell Lymphomas; MIXED LINEAGE LEUKEMIA; Neoplasms; Malignant neoplasm of lung; Fibroid Tumor; Idiopathic Pulmonary Fibrosis; Leukemogenesis; Carcinoma of lung; Pheochromocytoma; Primary malignant neoplasm; Endometriosis; Uterine Fibroids; Primary malignant neoplasm of lung; Chronic myeloproliferative disorder; Schizophrenia; Leukemia, Myelocytic, Acute; Germ Cell Cancer; Alzheimer's Disease; Stomach Neoplasms; Asthma; Chronic schizophrenia; Autism Spectrum Disorders; Endometrioma; Primary cholangiocarcinoma of intrahepatic biliary tract; Intrahepatic Cholangiocarcinoma; Nephrotic Syndrome; Alzheimer Disease, Late Onset; Smooth Muscle Tumor; leukemia; Psychotic Disorders; Pain; Autoimmune Diseases; Colonic Polyps; Nonorganic psychosis; Paraganglioma; Childhood asthma",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0334891258932371; 0.0387439397151409; 0.0648809611869375; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.095319386034013; 0.0991201145654548; 0.1062239757831962; 0.13167400689206; 0.13167400689206; 0.1454373331146953; 0.2062010908869036; 0.223747154820789; 0.2522264785494494; 0.2605479444258003; 0.2714542429024338; 0.2714542429024338; 0.290158730291654; 0.3099246715197673; 0.3510063969122338; 0.3663130598151661; 0.3712878513813393; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.4028066164685291; 0.4103119460235835; 0.4115056600660309; 0.425419812815905; 0.4588513406515081; 0.4753011022966241; 0.4871698998714747; 0.5512224939896888; 0.5568517196017908; 0.578835730221474; 0.6910672612216457; 0.8000044931629623,Schizophrenia; Autism Spectrum Disorder; Psychosis; Nonorganic Psychosis,0.0531117779464085; 0.425341435586089; 0.4560460337187313; 0.6883874961919009,"Neuroblastoma ORPHA:635; Congenital communicating hydrocephalus ORPHA:269505; Hereditary retinoblastoma ORPHA:357027; Non-hereditary retinoblastoma ORPHA:357034; 46,XY partial gonadal dysgenesis ORPHA:251510; Monosomy 9q22.3 ORPHA:77301; Resistance to thyrotropin-releasing hormone syndrome ORPHA:99832; Schilbach-Rott syndrome ORPHA:2353; Short stature-optic atrophy-Pelger-Huet anomaly syndrome ORPHA:391677; Angelman syndrome due to maternal 15q11q13 deletion ORPHA:98794; Deletion 5q35 ORPHA:1627; Infantile nephronophthisis ORPHA:93591; NON RARE IN EUROPE: Primary ovarian failure ORPHA:619",0.3969770464111636; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.665250072408594; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7072638369101406; 0.7443958988603572,,,,,,
TFAP4,Colorectal Carcinoma; Colorectal Cancer; Liver carcinoma,0.0034602840073026; 0.0149315928814189; 0.095319386034013,,,COG8-CDG ORPHA:95428; Chuvash erythrocytosis ORPHA:238557; Kleefstra syndrome due to 9q34 microdeletion ORPHA:96147; Postaxial acrofacial dysostosis ORPHA:246; Von Hippel-Lindau disease ORPHA:892,0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens HCT116 colon carcinoma cell;In vitro;yeasx,0.35;0.37;0.58,Homo sapiens,Homo sapiens
TGM2,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Proliferative vitreoretinopathy; Squamous cell carcinoma; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Epithelial ovarian cancer; Brain Tumor, Primary; Malignant neoplasm of prostate; Central neuroblastoma; Primary malignant neoplasm of brain; Mammary Neoplasms, Human; Brain Neoplasms; Neoplasm Metastasis; Barrett Esophagus; Renal Cell Carcinoma; Neuroblastoma; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Glioma; Degenerative polyarthritis; Osteoporosis; Glioblastoma; Pancreatic carcinoma; Carcinoma breast stage IV; Liver Cirrhosis; Prostate carcinoma; Liver carcinoma; Malignant Neoplasms; Colon Carcinoma; Adenocarcinoma of colon; Peroxisome Biogenesis Disorder, Complementation Group C; Nephrogenic Fibrosing Dermopathy; Tumor Initiation; Carcinoma, Transitional Cell; Malignant neoplasm of large intestine; Carcinoma of bladder; Hallopeau-Siemens Disease; Hyperactive behavior; Chromophobe Renal Cell Carcinoma; Rheumatoid Arthritis; Benign neoplasm of brain, unspecified; Adrenal Gland Diseases; Recurrent Brain Neoplasm; Seizures; Desmoplastic; Cataract; Malignant tumor of colon; Diabetes; Diabetes Mellitus; Malignant neoplasm of lung; Diabetes Mellitus, Insulin-Dependent; Multiple Sclerosis; Neoplasms, Intracranial; Gastrointestinal Diseases; Conventional (Clear Cell) Renal Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Glaucoma; Carcinoma of lung; Addison's disease due to autoimmunity; Primary malignant neoplasm; Recurrent tumor; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Primary malignant neoplasm of lung; Von Hippel-Lindau Syndrome; Bipolar Disorder; Diabetes Mellitus, Non-Insulin-Dependent; Inflammation; Nuclear cataract; Sarcomatoid Renal Cell Carcinoma; Schizophrenia; Non-Small Cell Lung Carcinoma; Hypertensive disease; Secondary malignant neoplasm of liver; Collecting Duct Carcinoma of the Kidney; Alzheimer's Disease; Fibrosis, Liver; Acute Promyelocytic Leukemia; Parkinson Disease; Adenoma; Asthma; Glioblastoma Multiforme; Craniofacial dysostosis type 1; Gluten sensitivity; Carcinoma, Pancreatic Ductal; Alcoholic Steatohepatitis; Dryness of eye; Acute Erythroblastic Leukemia; Autoimmune Primary Adrenal Insufficiency; Malignant neoplasm of brain; Amyotrophic Lateral Sclerosis; Papillary Renal Cell Carcinoma; Bilateral cataracts (disorder); Meningioma, benign, no ICD-O subtype; Celiac Disease; Dry Eye Syndromes; Testicular Feminization; Cerebrovascular accident; Plasmacytosis; Acute Coronary Syndrome; Acquired Immunodeficiency Syndrome; Mental disorders; Refractory anemias; Progressive supranuclear palsy; Psoriasis; Retinoic acid syndrome; Nonalcoholic Steatohepatitis; Neurodegenerative Disorders; Neuropathy; Meningioma; Adenocarcinoma of prostate; Intestinal Diseases; Precancerous Conditions; Maturity onset diabetes mellitus in young; Dermatitis Herpetiformis; Osteoarthrosis Deformans; Cardiomyopathy, Familial Idiopathic; Huntington Disease; Myeloid Leukemia, Chronic; Impaired glucose tolerance; Steatohepatitis; Polymyositis; Graves Disease; Metastatic melanoma; Ulcerative Colitis; Enterovirus Infections; Stage IV Skin Melanoma; Lichen Planus; nervous system disorder; Muscular Dystrophy, Oculopharyngeal; Malignant neoplasm of stomach stage IV; Malabsorption Syndrome; Disseminated Malignant Neoplasm; Hepatocarcinogenesis; CATARACT, ANTERIOR POLAR; Oral Submucous Fibrosis; Autoimmune Diseases; Ataxia; Cerebellar Ataxia; Hamartoma Syndrome, Multiple; Immunoglobulin A deficiency (disorder); Atrophic; Myositis; Cystic Fibrosis; Multiple Endocrine Neoplasia Type 2a; Giant Cell Glioblastoma; Multiple malignancy; insulinoma; Hepatitis C; Dermatomyositis; Hypoglycemia; Glaucoma, Primary Open Angle; Cardiomyopathy, Dilated; Virus Diseases",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0387439397151409; 0.044151975756427; 0.0569142010728473; 0.0593779966354549; 0.064548079316548; 0.064548079316548; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0773771948186562; 0.095319386034013; 0.0991201145654548; 0.1062239757831962; 0.1112281755580192; 0.1254380558571286; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1387448809655294; 0.1461248774859792; 0.1537760235124317; 0.1602092191314262; 0.1735868515093891; 0.1770067065899052; 0.2053083986145698; 0.2085938372806741; 0.223747154820789; 0.223747154820789; 0.2277108302018961; 0.2522264785494494; 0.2714542429024338; 0.2714542429024338; 0.2835142372342932; 0.290158730291654; 0.2980670559114652; 0.2980670559114652; 0.3018974726133723; 0.3105909001629992; 0.3663130598151661; 0.3778347117514905; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4118266358241932; 0.4126392832024548; 0.4126392832024548; 0.421267417774367; 0.4213286052188015; 0.4304973629098372; 0.4304973629098372; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4396723023384634; 0.4421745246585178; 0.4459714599189374; 0.4479115285676636; 0.4506578937113162; 0.4615352570710579; 0.4675904598629673; 0.4704594475773637; 0.4704594475773637; 0.472444704048021; 0.4900770016856776; 0.4906258721078565; 0.4923669467696064; 0.4981941174985421; 0.5001612228394569; 0.5001612228394569; 0.5019670090704682; 0.5090214163899865; 0.5188223685230745; 0.5276472086074249; 0.5299466034567416; 0.5299466034567416; 0.5337853752290136; 0.533913711453195; 0.533913711453195; 0.5393787854381349; 0.5453394612016188; 0.5512224939896888; 0.5568517196017908; 0.5754799679683854; 0.589345563575654; 0.5916904943304121; 0.6002127202571572; 0.601753535647179; 0.6124306570512981; 0.625027955184583; 0.672336954961104; 0.6740259274935673; 0.6875373888914498; 0.7169459458481418; 0.7706351321777464; 0.7790800975250889; 0.8352623613787349; 0.8670707879649133; 0.9692165430561782,Breast Carcinoma; Esophagus Neoplasm; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Schizophrenia; Brain Neoplasms; Intracranial Neoplasm; Chromophobe Carcinoma; Colorectal Cancer; Papillary Renal Carcinoma; Arthritis; Renal Carcinoma; Hypertension; Giant Cell Glioblastoma; Glioblastoma; Bipolar Disorder; Osteoarthrosis Deformans; Celiac Disease; Pancreatic Neoplasm; Pancreatic Cancer,0.0075861267486594; 0.0102679590519094; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0531117779464085; 0.1534453668959814; 0.2038801271174535; 0.4286813331685578; 0.4286813331685578; 0.4286813331685578; 0.4541466895915311; 0.4541466895915311; 0.4560460337187313; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.5087473896242481; 0.6485812088066297; 0.6508151871447407; 0.802679551748655,"Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Autosomal recessive brachyolmia ORPHA:448242; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; Familial drusen ORPHA:75376; PPARG-related familial partial lipodystrophy ORPHA:79083; Primary CD59 deficiency ORPHA:169464; RIN2 syndrome ORPHA:217335; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; AGel amyloidosis ORPHA:85448; Keratolytic winter erythema ORPHA:50943; Multiple paragangliomas associated with polycythemia ORPHA:324299; Adenocarcinoma of ovary ORPHA:213504; Epithelial basement membrane dystrophy ORPHA:98956; Familial cavitary optic disc anomaly ORPHA:464760; Granular corneal dystrophy type I ORPHA:98962; Granular corneal dystrophy type II ORPHA:98963; Lattice corneal dystrophy type I ORPHA:98964; MITF-related melanoma and renal cell carcinoma predisposition syndrome ORPHA:293822; Reis-Bucklers corneal dystrophy ORPHA:98961; Thiel-Behnke corneal dystrophy ORPHA:98960; Tietz syndrome ORPHA:42665; Complement component 3 deficiency ORPHA:280133; Atypical hemolytic uremic syndrome with complement gene abnormality ORPHA:544472; De novo thrombotic microangiopathy after kidney transplantation ORPHA:244275; Immunodeficiency with factor H anomaly ORPHA:200421; Immunodeficiency with factor I anomaly ORPHA:200418; Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome ORPHA:444138; HELLP syndrome ORPHA:244242",0.00518481975049; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782,,,Homo sapiens HLMVEC lung microvascular endothelial cell;In vitro;yeasx,0.35;0.37;0.44;0.76,Homo sapiens;chemical synthesis,Homo sapiens;chemical synthesis
THBS1,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Medulloblastoma; Epithelial ovarian cancer; Skin carcinoma; Cancer of Urinary Tract; Malignant neoplasm of prostate; Central neuroblastoma; Well Differentiated Oligodendroglioma; Mammary Neoplasms, Human; Neoplasm Metastasis; Renal Cell Carcinoma; oligodendroglioma; Neuroblastoma; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Glioma; Degenerative polyarthritis; Squamous cell carcinoma of penis; Lymphoma; Glioblastoma; Pancreatic carcinoma; inflammatory joint disease; Liver Cirrhosis; Prostate carcinoma; Colorectal Neoplasms; Squamous cell carcinoma of esophagus; Liver carcinoma; Malignant Neoplasms; Osteosarcoma; Colon Carcinoma; Ganglioneuroma; Carcinoma, Transitional Cell; Malignant neoplasm of large intestine; Malignant neoplasm of endometrium; Hallopeau-Siemens Disease; Uterine Corpus Cancer; Myocardial Infarction; Solid Neoplasm; Liver neoplasms; Rheumatoid Arthritis; Sarcoma; Renal fibrosis; Marfan Syndrome; Systemic Scleroderma; cervical cancer; Lung Neoplasms; Desmoplastic; Osteosarcoma of bone; Malignant tumor of colon; Prostatic Neoplasms; Diabetes; Anoxia; Diabetes Mellitus; Arteriovenous Malformations, Cerebral; Neoplasms; Malignant tumor of cervix; Parasitic Diseases; Malignant neoplasm of lung; Clear cell sarcoma of kidney; Secondary malignant neoplasm of lung; Diabetic Retinopathy; Tumor-Associated Vasculature; Cervix carcinoma; Multiple Sclerosis; Fibroid Tumor; Cirrhosis; Conventional (Clear Cell) Renal Cell Carcinoma; Triple Negative Breast Neoplasms; Myeloid Leukemia; Pancreatic Ductal Adenocarcinoma; Endometrial Carcinoma; Hemangioma; Sjogren's Syndrome; Glaucoma; Cervical Squamous Cell Carcinoma; Penis carcinoma; Mammary Ductal Carcinoma; Carcinoma of lung; Primary malignant neoplasm; Endometriosis; Thyroid Neoplasm; Recurrent tumor; Primary malignant neoplasm of lung; ST segment elevation myocardial infarction; Secondary malignant neoplasm of lymph node; Inflammation; Pancreatitis, Chronic; Kidney Diseases; Nasopharyngeal carcinoma; Papillary thyroid carcinoma; Nephroblastoma; Schizophrenia; Malignant Glioma; Adrenocortical carcinoma; tumor vasculature; Chronic liver disease; Non-Small Cell Lung Carcinoma; Infection caused by Helicobacter pylori; Gastroesophageal reflux disease; HTLV-I Infections; Hypertensive disease; Lichen Sclerosus et Atrophicus; Skin Carcinogenesis; Bone Marrow Diseases; HIV Infections; Urothelial Carcinoma; Malformations of Cortical Development, Group II; Astrocytoma; Lymphoma, T-Cell, Cutaneous; Hemangiosarcoma; Neonatal meningitis; Thrombocythemia, Essential; Epiretinal Membrane; Primary Carcinoma; Stomach Neoplasms; Fibrosis, Liver; Acute Promyelocytic Leukemia; Parkinson Disease; Coronary heart disease; Thrombotic thrombocytopenic purpura, acquired; Direct Contact Transmission Infection; Penile Neoplasms; CARCINOMA OF VULVA; Aortic Aneurysm; Adenoma; Asthma; Focal glomerulosclerosis; Glioblastoma Multiforme; Carcinoma, Pancreatic Ductal; Diabetic Nephropathy; keratoacanthoma; Aortic Aneurysm, Abdominal; Dryness of eye; Schistosomiasis japonica; Quebec platelet disorder; Renal carcinoma; Thyroid carcinoma; Ischemia; Premature coronary artery disease; Endometrioma; Congenital Mesoblastic Nephroma; Cutaneous hypersensitivity; Fibrosis; Vulvar Lichen Sclerosus; Keratoconjunctivitis; Multiple Myeloma; Dry Eye Syndromes; Primary Myelofibrosis; Vascular occlusion; Retinoblastoma; Cerebrovascular accident; Budd-Chiari Syndrome; Congenital Thrombotic Thrombocytopenic Purpura; Hepatic Vein Thrombosis; Juvenile arthritis; Acquired Immunodeficiency Syndrome; Vascular Diseases; Congenital arteriovenous malformation; Hypertrophy of kidney; Parasitic infection; Immunologic Deficiency Syndromes; Congestive heart failure; Papilloma; Squamous cell carcinoma of skin; Heart failure; Sick Sinus Syndrome; Malignant neoplasm of thyroid; Adenocarcinoma of pancreas; Pulmonary Fibrosis; Carcinoid Tumor; Sicca Syndrome; Peripheral Vascular Diseases; Meningioma; Restenosis; Dyslipidemias; Hemorrhagic Fever with Renal Syndrome; Precancerous Conditions; Microangiopathy, Diabetic; Helminthiasis; Human T-cell lymphotrophic virus, type I [HTLV-I]; Malignant neoplasm of penis; leukemia; Chronic gastritis; Adult T Acute Lymphoblastic Leukemia; Cardiovascular Diseases; Promyelocytic leukemia; Juvenile psoriatic arthritis; Keratoconjunctivitis Sicca; Follicular thyroid carcinoma; Juvenile-Onset Still Disease; Kaposi Sarcoma; Impaired glucose tolerance; Hyperglycemia; Diarrhea; Polymyositis; Nephritis, Interstitial; Echinococcosis; Renal interstitial fibrosis; Malignant neoplasm of vulva; Metastatic melanoma; Scleroderma; Arteriosclerosis; Coronary Arteriosclerosis; Carcinoma, Lewis Lung; Obesity; Pelvic Organ Prolapse; Adenocarcinoma of lung (disorder); Reperfusion Injury; Nephritis, Tubulointerstitial; Skin lesion; Tropical Spastic Paraparesis; Synovitis; nervous system disorder; Dermatomyositis, Childhood Type; Spinal Cord Diseases; Purpura, Thrombotic Thrombocytopenic; Polycystic Ovary Syndrome; Aortic aneurysm without mention of rupture NOS; Atherosclerosis; Obesity, Visceral; Cervical Intraepithelial Neoplasia; Arthritis; Systemic candidiasis; Infiltrating Cervical Carcinoma; Arthropathy; Peripheral Arterial Diseases; Colorectal cancer metastatic; Metabolic Syndrome X; Idiopathic pulmonary arterial hypertension; Tumors of Adrenal Cortex; Ureteral obstruction; Sentinel node (disorder); Inclusion Body Myositis (disorder); Paraparesis, Spastic; Herpes Simplex Infections; Heart Diseases; Cavernous Hemangioma of Brain; Cystic Fibrosis; Tumor Angiogenesis; Inclusion Body Myopathy, Sporadic; Immune System Diseases; Dementia; Diabetic Angiopathies; Inflammatory dermatosis; Keratitis; Angiogenic Switch; Fever; Leukemia, T-Cell; polyps; Malaria, Cerebral; Malignant Childhood Neoplasm; Dermatitis; Inflammatory disorder; Meningitis; Coronary Artery Disease; Myelofibrosis; Retinitis Pigmentosa; Benign Prostatic Hyperplasia; Periodontitis; Malignant Pleural Mesothelioma; Cytomegalovirus Infections; Adult T-Cell Lymphoma/Leukemia; Metastatic Neoplasm; Hepatitis B; Presenile dementia; Overweight; Myopathy; Virus Diseases",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0354767239335874; 0.0387439397151409; 0.0482468351695405; 0.0492766532827251; 0.0569142010728473; 0.0593779966354549; 0.0617471306652618; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0745502070959292; 0.0773771948186562; 0.0773771948186562; 0.0827744840860166; 0.0919714360040484; 0.095319386034013; 0.0991201145654548; 0.1029977559100099; 0.1062239757831962; 0.1138051695421299; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1352936728187231; 0.1413782599148022; 0.1454373331146953; 0.1537760235124317; 0.1537760235124317; 0.1602092191314262; 0.1735868515093891; 0.1900258729042946; 0.2050045461627939; 0.2062010908869036; 0.2085938372806741; 0.2109483801368481; 0.223747154820789; 0.223747154820789; 0.2277108302018961; 0.2462384927636234; 0.2522264785494494; 0.2643145809900195; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2714542429024338; 0.2723545094624877; 0.2723545094624877; 0.2747883228704706; 0.2834835531038365; 0.2835142372342932; 0.290158730291654; 0.2923761731100008; 0.2980670559114652; 0.2980670559114652; 0.2980670559114652; 0.3018974726133723; 0.3044782497745498; 0.3099246715197673; 0.3099246715197673; 0.3105909001629992; 0.3199171478489988; 0.3220099003872086; 0.3638414818541592; 0.3663130598151661; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4126392832024548; 0.4126392832024548; 0.4126392832024548; 0.4186011760974318; 0.4192169590514327; 0.4192169590514327; 0.4213286052188015; 0.425419812815905; 0.425992946703162; 0.4297858918260954; 0.4304973629098372; 0.4304973629098372; 0.4307603335611732; 0.4325044517055656; 0.4335751357405352; 0.4381343267935581; 0.4396723023384634; 0.4396723023384634; 0.4396723023384634; 0.4396723023384634; 0.4421745246585178; 0.4459714599189374; 0.4479115285676636; 0.4506578937113162; 0.4506578937113162; 0.4564472886428772; 0.4564472886428772; 0.4588513406515081; 0.4615352570710579; 0.4615352570710579; 0.4675904598629673; 0.4675904598629673; 0.472444704048021; 0.4753011022966241; 0.4790179402069343; 0.4810435657134442; 0.4851378030288289; 0.4900770016856776; 0.4906258721078565; 0.4923669467696064; 0.4923669467696064; 0.4923669467696064; 0.4923669467696064; 0.4981941174985421; 0.4981941174985421; 0.5001612228394569; 0.5019670090704682; 0.5019670090704682; 0.5140447474168605; 0.5140447474168605; 0.5140447474168605; 0.5140447474168605; 0.51550637274795; 0.5188223685230745; 0.5188223685230745; 0.5251317541886066; 0.5251317541886066; 0.5252711504839724; 0.5276472086074249; 0.5299466034567416; 0.5299466034567416; 0.5299466034567416; 0.5337853752290136; 0.5359212109443033; 0.5393787854381349; 0.549941235475765; 0.5523521032803237; 0.553002957824355; 0.553002957824355; 0.553002957824355; 0.5557519470957561; 0.5557519470957561; 0.5568517196017908; 0.5568517196017908; 0.5655222348249326; 0.5710095678317721; 0.589345563575654; 0.6002127202571572; 0.6035970790768342; 0.6084642888478995; 0.610971999959321; 0.610971999959321; 0.610971999959321; 0.6124306570512981; 0.6218520979526325; 0.6222451141623291; 0.6319938293757544; 0.6364853529519863; 0.6403143122455015; 0.6447029562500783; 0.6588479076808555; 0.6627865715415371; 0.6677140893034832; 0.6691893635307453; 0.6974821940437801; 0.6980473696540115; 0.701831040553294; 0.7045203904267408; 0.7075286941606513; 0.7129583530027284; 0.7240930522443176; 0.7317475852509061; 0.7352133686428474; 0.7491018580851883; 0.7867131318906807; 0.8209296131179464; 0.8335660382047895; 0.8367216325123092; 0.8757716428200738; 0.9169959402964138; 0.9212908525513646; 0.9363897989363138; 0.9503327807211356; 0.9692165430561782,"Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Schizophrenia; Liver Cirrhosis; Arthritis; Liver Fibrosis; Juvenile Arthritis; Polyarthritis, Rheumatoid Factor Positive; Seronegative Polyarthritis; Cirrhosis; Diabetic Retinopathy; Diabetic Cardiomyopathy; Still Disease; Nephritis",0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0531117779464085; 0.4286813331685578; 0.4541466895915311; 0.4560460337187313; 0.4646409362700993; 0.4646409362700993; 0.4875380732267193; 0.4875380732267193; 0.4875380732267193; 0.4968320901822731; 0.504364324740411; 0.7662135194687344,"Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Auriculocondylar syndrome ORPHA:137888; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Chondrosarcoma ORPHA:55880; Congenital short bowel syndrome ORPHA:2301; Autosomal recessive brachyolmia ORPHA:448242; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; RIN2 syndrome ORPHA:217335; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; Familial primary localized cutaneous amyloidosis ORPHA:353220; Trichorhinophalangeal syndrome type 2 ORPHA:502; Glaucoma secondary to spherophakia/ectopia lentis and megalocornea ORPHA:238763; Adenocarcinoma of ovary ORPHA:213504; Aneurysm-osteoarthritis syndrome ORPHA:284984; Epithelial basement membrane dystrophy ORPHA:98956; Familial cavitary optic disc anomaly ORPHA:464760; Granular corneal dystrophy type I ORPHA:98962; Granular corneal dystrophy type II ORPHA:98963; Lattice corneal dystrophy type I ORPHA:98964; Reis-Bucklers corneal dystrophy ORPHA:98961; Thiel-Behnke corneal dystrophy ORPHA:98960; Alagille syndrome due to a NOTCH2 point mutation ORPHA:261629; Fibrodysplasia ossificans progressiva ORPHA:337; Hajdu-Cheney syndrome ORPHA:955; Fetal and neonatal alloimmune thrombocytopenia ORPHA:853; Autosomal dominant Emery-Dreifuss muscular dystrophy ORPHA:98853; Hemochromatosis type 5 ORPHA:447792",0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3826134188846508; 0.6268296504510718; 0.7068064785325423,Norovirus Hu/Norwalk/10074/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20047/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CBNU2/2007/KR capsid protein; Norovirus Hu/Norwalk/10247/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH13/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/Norwalk/10051/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10116/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10183/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10236/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH02/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH03/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH04/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH06/2006/TW major viral capsid protein; Norovirus Hu/GII-4/CGMH07/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH09/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH12/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH17/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/SGU-110421/KOR/2011 VP1; Norovirus Hu/GII-4/CGMH05/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH08/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/GZ2010-L26/Guangzhou/CHN/2010 major viral capsid protein (gene: VP1); Norovirus Hu/GII/Shanghai/SH2/2008/CHN VP1; Norovirus Hu/Shanghai/SH5/2009/CHN VP1; Norovirus Hu/GII-4/CGMH14/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH15/2007/TW major viral capsid protein; Norovirus Hu/Norwalk/20123/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH10/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH22/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Miranda/NSW850K/2011/AU VP1; Norovirus Hu/GII-4/CGMH18/2008/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH28/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Guangzhou/GZ2010-L88/CHN/2011 major viral capsid protein; Norovirus Hu/GII.4/Guangzhou/GZ2010-L91/CHN/2011 major viral capsid protein; Norovirus GII/Hu/JP/2010/GII.P4_GII.4/Shimada/ASC96 VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC11.3/2013/USA capsid protein VP1 (gene: VP1); Human calicivirus Hu/NLV/GII/MD145-12/1987/US capsid protein; Lordsdale virus capsid protein (gene: orf2); Norovirus Hu/GII-4/CUK-3/2008/KR capsid protein; Norovirus Hu/GII.4/CHDC3967/1988/US VP1; Norovirus Hu/GII.4/NIHIC28.4/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH11/2006/TW major viral capsid protein; Norovirus Hu/GII.4/20199/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC28.5/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20033/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH20/2009/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Berowra/NSW767L/2012/AU VP1; Norovirus Hu/GII.4/CHDC4108/1987/US VP1; Norovirus GII/Hu/TW/2012/GII.Pe_GII.4_Sydney2012/Taipei/108 VP1 (gene: VP1); Norovirus GII/Hu/TW/2012/GII.Pe_GII.4_Sydney2012/Taipei/109 VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH23/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH26/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/GZ2010-L87/Guangzhou/CHN/2011 major viral capsid protein (gene: VP1); Norovirus Hu/Norwalk/10368/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH21/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH24/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH25/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH27/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Caringbah/NSW409G/2011/AU VP1; Norovirus Hu/GII.4/HS292/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC13/2011/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC18.1/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC27.1/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/New Orleans/2010/USA VP1; Norovirus Hu/GII.4/Sydney/NSW0514/2012/AU VP1; Norovirus Hu/GII/20469/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII/BG1C0241-33/2011/BGD capsid protein VP1 (gene: VP1); Norovirus Hu/GII/Seoul1282/KOR/2010 major capsid protein; Norovirus Hu/GII/Seoul1488/KOR/2011 major capsid protein; Norovirus Hu/Norwalk/10325/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10386/2010/VNM capsid protein VP1 (gene: VP1); Norovirus GII/Hu/JP/2012/GII.Pe_GII.4_Sydney2012/Fukuyama/1 VP1 (gene: VP1); Norovirus GII/Hu/JP/2012/GII.Pe_GII.4_Sydney2012/Fukuyama/2 VP1 (gene: VP1); Norovirus GII/Hu/JP/2012/GII.Pe_GII.4_Sydney2012/Fukuyama/3 VP1 (gene: VP1); Norovirus GII/Hu/JP/2012/GII.Pe_GII.4_Sydney2012/Fukuyama/5 VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH16/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Doonside/NSW536I/2011/AU VP1; Norovirus Hu/GII.4/Hong Kong/CUHK3630/2012/CHN VP1; Norovirus Hu/GII.4/Jiangsu1/2011/CHN major capsid protein; Norovirus Hu/GII.4/NIHIC2.2/2010/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC2.3/2010/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC27.2/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10285/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10313/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10378/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/HS288/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/Hong Kong/CUHK6080/2012/CHN VP1; Norovirus Hu/GII.4/NIHIC17.1/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC17.5/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC17.6/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC17.8/2013/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC17.9/2013/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC35/2013/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/Ohio/684/USA VP1; Norovirus Hu/GII.4/Rockdale/NSW006D/2009/AU VP1,0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597,Homo sapiens HLMVEC lung microvascular endothelial cell;Homo sapiens blood plasma;In vitro;Saccharomyces cerevisiae,0.35;0.37;0.44;0.61;0.7,Homo sapiens;chemical synthesis;staa8,Homo sapiens;chemical synthesis;hcvco
TIMP2,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Colorectal Cancer; Stomach Carcinoma; Retroviridae Infections; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant mesothelioma; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Epithelial ovarian cancer; Malignant neoplasm of prostate; Central neuroblastoma; Brain Neoplasms; Neoplasm Metastasis; Renal Cell Carcinoma; Neuroblastoma; Malignant neoplasm of pancreas; Pancreatic Neoplasm; Glioma; Degenerative polyarthritis; Osteoporosis; Lymphoma; Glioblastoma; Pancreatic carcinoma; Liver Cirrhosis, Experimental; Liver Cirrhosis; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Colorectal Neoplasms; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Liver carcinoma; Osteosarcoma; Colon Carcinoma; Ameloblastoma; MYELODYSPLASTIC SYNDROME; Esophageal carcinoma; Cholestasis, Extrahepatic; Carcinoma of bladder; Malignant neoplasm of endometrium; Hallopeau-Siemens Disease; Hypertension, Portal; Uterine Corpus Cancer; Myocardial Infarction; Colonic Neoplasms; Mixed Salivary Gland Tumor; Liver neoplasms; Rheumatoid Arthritis; Invasive Carcinoma; Marfan Syndrome; Intracranial Aneurysm; stage, ovarian epithelial cancer; Systemic Scleroderma; cervical cancer; Desmoplastic; Eosinophilic esophagitis; Osteosarcoma of bone; Malignant tumor of colon; Prostatic Neoplasms; Diabetes; Hodgkin Disease; Malignant Head and Neck Neoplasm; B-Cell Lymphomas; Diabetes Mellitus; Malignant neoplasm of liver; Malignant tumor of cervix; Malignant neoplasm of lung; Secondary malignant neoplasm of lung; Cervix carcinoma; Acute leukemia; Multiple Sclerosis; Fibroid Tumor; Conventional (Clear Cell) Renal Cell Carcinoma; Endometrial Carcinoma; Hemangioma; Ehlers-Danlos Syndrome; Ischemic stroke; Carcinoma of lung; Endometriosis; Uterine Fibroids; Primary malignant neoplasm of lung; Secondary malignant neoplasm of lymph node; Gallbladder Carcinoma; Hernia, Inguinal; Diabetes Mellitus, Non-Insulin-Dependent; Laryngeal Squamous Cell Carcinoma; Interstitial lung fibrosis; Hereditary Nonpolyposis Colorectal Cancer; Malignant Glioma; tumor vasculature; Non-Small Cell Lung Carcinoma; Secondary malignant neoplasm of liver; Bronchopulmonary Dysplasia; Leukemia, Myelocytic, Acute; Hemorrhage; Valvular disease; Bulla of lung; HIV Infections; Skin Neoplasms; Astrocytoma; Osteoarthritis of the hand; Arthritis, Psoriatic; Alzheimer's Disease; Microcalcification; Lymphoma, Non-Hodgkin; Acute lymphocytic leukemia; Stomach Neoplasms; Inflammatory Bowel Diseases; Fibrosis, Liver; Parkinson Disease; Tumoral calcinosis; Cardiac fibrosis; Moyamoya disease 1; Diabetic Nephropathy; Dupuytren Contracture; Rash and Dermatitis Adverse Event Associated with Chemoradiation; Aortic Aneurysm, Abdominal; Atrial Fibrillation; Tuberculosis, Central Nervous System; Calcinosis; Moyamoya Disease; Thyroid carcinoma; Pituitary Adenoma; Amyotrophic Lateral Sclerosis; Abortion, Tubal; Dental Fluorosis, Acquired; Meningioma, benign, no ICD-O subtype; Kidney Failure, Acute; Diverticulosis; Occupational Diseases; Gastric Adenocarcinoma; Hepatosplenomegaly; Multiple Myeloma; Viral meningitis; Atherosclerotic occlusive disease; Cerebrovascular accident; Ulcer; PNEUMOTHORAX, PRIMARY SPONTANEOUS; Chronic ulcer; Acute Coronary Syndrome; Cleft palate with cleft lip; Hypertensive heart disease; Pleural Diseases; Congestive heart failure; Endocarditis; Rectal Carcinoma; Heart failure; Spontaneous abortion; Corneal pannus; Pregnancy associated hypertension; Simple renal cyst; Chronic venous insufficiency; Meningioma; Adiponectin Measurement; Aneurysm; Choriocarcinoma; leukemia; Pituitary carcinoma; Chronic kidney disease stage 5; Huntington Disease; Periodontitis, Juvenile; Myeloid Leukemia, Chronic; Tumor Expansion; Angiofibroma; Tendinopathy; Arteriovenous fistula; Dental caries; Aggressive periodontitis, generalized; M5b Acute differentiated monocytic leukemia; Chronic Obstructive Airway Disease; Carcinoma, Lewis Lung; Severe myopia; Meningitis, Bacterial; Adenocarcinoma of lung (disorder); Myopia; Kidney Failure, Chronic; Endometriosis of uterus; Malignant neoplasm of gallbladder; Arthritis; Acute periodontitis; Post MI; Caries (morphologic abnormality); Herpes Simplex Infections; Hepatitis B, Chronic; Pre-Eclampsia; Autosomal dominant retinitis pigmentosa; Diaphragmatic Hernia; Nephronophthisis; Mucocutaneous Lymph Node Syndrome; Immune System Diseases; Sepsis; Pterygium; Pleural Effusion, Malignant; Acute monocytic leukemia; Cardiomyopathies; Muscular Dystrophy, Duchenne; Myocardial Diseases, Secondary; Cardiomyopathies, Primary; Renal cyst; Left Ventricular Hypertrophy; Retinitis Pigmentosa; Neuromuscular Diseases; Pulmonary Emphysema; Diabetes Mellitus, Experimental; Streptozotocin Diabetes; Alloxan Diabetes; Periodontitis; Chronic Periodontitis; Hypertrophic Cardiomyopathy",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0387439397151409; 0.0569142010728473; 0.0593779966354549; 0.064548079316548; 0.0648809611869375; 0.0648809611869375; 0.0688152422187159; 0.0726340460169901; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0739788831250619; 0.0745502070959292; 0.0745502070959292; 0.0747863377072194; 0.0773771948186562; 0.0773771948186562; 0.0775520919998773; 0.0827744840860166; 0.084286432100041; 0.0891725280554336; 0.095319386034013; 0.1029977559100099; 0.1062239757831962; 0.1208020277850109; 0.1254380558571286; 0.1254380558571286; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.13167400689206; 0.1328002618052838; 0.1328002618052838; 0.1352936728187231; 0.1454373331146953; 0.1454373331146953; 0.1454373331146953; 0.1537760235124317; 0.1602092191314262; 0.1735868515093891; 0.1735868515093891; 0.1874735657311888; 0.1900258729042946; 0.2050045461627939; 0.2085938372806741; 0.2085938372806741; 0.2109483801368481; 0.223747154820789; 0.223747154820789; 0.2277108302018961; 0.2454476567103779; 0.2522264785494494; 0.2522264785494494; 0.2522264785494494; 0.2643145809900195; 0.2714542429024338; 0.2714542429024338; 0.2723545094624877; 0.2834835531038365; 0.2835142372342932; 0.2835142372342932; 0.290158730291654; 0.2980670559114652; 0.3044782497745498; 0.3099246715197673; 0.3283839486480793; 0.3486533561309259; 0.3663130598151661; 0.383941725017158; 0.383941725017158; 0.3902116649640871; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.3975960596292668; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4028066164685291; 0.4103119460235835; 0.4103119460235835; 0.4103119460235835; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4118266358241932; 0.4186011760974318; 0.4213286052188015; 0.4213286052188015; 0.425419812815905; 0.425419812815905; 0.429029854971378; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4335751357405352; 0.4335751357405352; 0.4396723023384634; 0.4506578937113162; 0.4561717689698902; 0.4564472886428772; 0.4588513406515081; 0.4615352570710579; 0.4704594475773637; 0.4704594475773637; 0.4714226702518064; 0.472444704048021; 0.472444704048021; 0.4753011022966241; 0.4790179402069343; 0.4790179402069343; 0.4852430673532381; 0.4852430673532381; 0.504136641473215; 0.5049674142533507; 0.5140447474168605; 0.5140447474168605; 0.5140447474168605; 0.51550637274795; 0.5239792328442205; 0.5299466034567416; 0.5453394612016188; 0.5496357724684553; 0.553002957824355; 0.553002957824355; 0.5568517196017908; 0.5956632182199403; 0.610971999959321; 0.6150955455771212; 0.6222451141623291; 0.625027955184583; 0.625027955184583; 0.625027955184583; 0.6294837700416086; 0.6319938293757544; 0.6395767498329145; 0.6496433426951205; 0.672336954961104; 0.672336954961104; 0.6989462176022242; 0.7045203904267408; 0.7068844070911514; 0.7156410971578294; 0.7240930522443176; 0.7294281406818208; 0.7352133686428474; 0.7412504828119304; 0.7674304683279349; 0.7683326132740758; 0.7683326132740758; 0.7683326132740758; 0.7867131318906807; 0.8369292123296695; 0.89450044231149,Tumoral Calcinosis; Cholestasis; Pleural Diseases; Miscarriage; Diverticular Diseases; Dupuytren Contracture; Bladder Neoplasm; Urinary Bladder Cancer; Myocardial Infarction; Eosinophilia; Respiratory Tract Diseases,0.2954316182315451; 0.336287627428424; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313; 0.4646409362700993; 0.4723647227028846; 0.4875380732267193; 0.5632819212593052; 0.7049836926927165; 0.7233086714572886,"Unverricht-Lundborg disease ORPHA:308; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Familial multiple nevi flammei ORPHA:624; Hereditary neuropathy with liability to pressure palsies ORPHA:640; RIN2 syndrome ORPHA:217335; Sturge-Weber syndrome ORPHA:3205; 19p13.3 microduplication syndrome ORPHA:447980; AGel amyloidosis ORPHA:85448; Glaucoma secondary to spherophakia/ectopia lentis and megalocornea ORPHA:238763; Keratolytic winter erythema ORPHA:50943; Malan overgrowth syndrome ORPHA:420179; Marshall-Smith syndrome ORPHA:561; Epithelial basement membrane dystrophy ORPHA:98956; Familial retinal arterial macroaneurysm ORPHA:284247; Granular corneal dystrophy type I ORPHA:98962; Granular corneal dystrophy type II ORPHA:98963; Lattice corneal dystrophy type I ORPHA:98964; Microduplication Xp11.22p11.23 syndrome ORPHA:217377; Pycnodysostosis ORPHA:763; Reis-Bucklers corneal dystrophy ORPHA:98961; Sanfilippo syndrome type D ORPHA:79272; Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome ORPHA:397933; Thiel-Behnke corneal dystrophy ORPHA:98960; Shprintzen-Goldberg syndrome ORPHA:2462; ACys amyloidosis ORPHA:100008; Action myoclonus-renal failure syndrome ORPHA:163696; Alagille syndrome due to a NOTCH2 point mutation ORPHA:261629; Fibrodysplasia ossificans progressiva ORPHA:337; Hajdu-Cheney syndrome ORPHA:955; LIMS2-related limb-girdle muscular dystrophy ORPHA:466801; Mitochondrial DNA depletion syndrome, myopathic form ORPHA:254875; Gaucher disease type 1 ORPHA:77259; Truncus arteriosus ORPHA:3384; Keratosis follicularis spinulosa decalvans ORPHA:2340; Beckwith-Wiedemann syndrome due to CDKN1C mutation ORPHA:231120; Charcot-Marie-Tooth disease type 4D ORPHA:99950; Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome ORPHA:436144; Lethal osteosclerotic bone dysplasia ORPHA:1832; Myosclerosis ORPHA:289380; Sanfilippo syndrome type C ORPHA:79271; Tangier disease ORPHA:31150; Roussy-Levy syndrome ORPHA:3115; Dejerine-Sottas syndrome ORPHA:64748; Atrophoderma vermiculata ORPHA:79100",0.0083744975290613; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.7068064785325423,,,Homo sapiens HEK293 embryonic kidney cell,0.4,Homo sapiens,Homo sapiens
TLR6,"Malignant neoplasm of prostate; Malignant neoplasm of pancreas; Pancreatic carcinoma; Prostate carcinoma; MYELODYSPLASTIC SYNDROME; Prostatic Neoplasms; Anoxia; Chondrosarcoma; Childhood Acute Lymphoblastic Leukemia; Acute pancreatitis; Tuberculosis; Tuberculosis, Pulmonary; Bipolar Disorder; Inflammation; Papillary thyroid carcinoma; Hypertensive disease; Bronchopulmonary Dysplasia; Endometritis; Proctitis; DOSAGE-SENSITIVE SEX REVERSAL; Lymphoma, Non-Hodgkin; Inflammatory Bowel Diseases; Asthma; Allergic sensitization; Aspergillosis; Necrotizing Enterocolitis; Parasitemia; Lupus Erythematosus, Systemic; Mycoses; Infant, Premature; Marginal Zone B-Cell Lymphoma; Psoriasis; Lupus Vulgaris; Syphilis; Asthma chronic; Lupus Erythematosus; Lupus Erythematosus, Discoid; Dejerine-Sottas Disease (disorder); Invasive aspergillosis; Graves Disease; Infective endocarditis; Ulcerative Colitis; Bacterial Endocarditis; Pelvic Inflammatory Disease; Pneumonia, Bacterial; Colitis; Bacterial Infections; Malaria; NONAKA MYOPATHY; Infection; Non-alcoholic Fatty Liver Disease; Dermatitis, Atopic; Allergic asthma; Mycobacterium Infections; Eczema; Hypersensitivity; Pneumonia",0.0569142010728473; 0.0726340460169901; 0.0745502070959292; 0.0773771948186562; 0.1254380558571286; 0.223747154820789; 0.2462384927636234; 0.2643145809900195; 0.3099246715197673; 0.3220099003872086; 0.3706856725676674; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.4115056600660309; 0.4118266358241932; 0.4192169590514327; 0.4213286052188015; 0.425419812815905; 0.4304973629098372; 0.4304973629098372; 0.4304973629098372; 0.4335751357405352; 0.4335751357405352; 0.4335751357405352; 0.4615352570710579; 0.4675904598629673; 0.4753011022966241; 0.4852430673532381; 0.4981941174985421; 0.4981941174985421; 0.5001612228394569; 0.5140447474168605; 0.5188223685230745; 0.5299466034567416; 0.5323590634832615; 0.5337853752290136; 0.5655222348249326; 0.5710095678317721; 0.5959654688257199; 0.625027955184583; 0.7045203904267408; 0.717484976234209; 0.7317475852509061; 0.7893058450619891; 0.8891038160665995; 0.924303335582991,Prostatic Neoplasms; Asthma; Prostate Cancer,0.4875380732267193; 0.504364324740411; 0.6104715460837368,Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome ORPHA:566175; Generalized glucocorticoid resistance syndrome ORPHA:786; Combined immunodeficiency due to Moesin deficiency ORPHA:504530; Haim-Munk syndrome ORPHA:2342; Hydranencephaly ORPHA:2177; NDE1-related microhydranencephaly ORPHA:443162; Overgrowth-macrocephaly-facial dysmorphism syndrome ORPHA:137634; Papillon-Lefevre ORPHA:678; Dehydrated hereditary stomatocytosis ORPHA:3202; Herpes simplex virus encephalitis ORPHA:1930; Autoimmune lymphoproliferative syndrome with recurrent viral infections ORPHA:275517; Cleidocranial dysplasia ORPHA:1452; Familial normophosphatemic tumoral calcinosis ORPHA:306658; Growth retardation-mild developmental delay-chronic hepatitis syndrome ORPHA:391366; MIRAGE syndrome ORPHA:494433; Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ORPHA:2504; Loeys-Dietz syndrome ORPHA:60030; Squamous cell carcinoma of salivary glands ORPHA:500481; Squamous cell carcinoma of the hypopharynx ORPHA:494547; Squamous cell carcinoma of the larynx ORPHA:494550; Squamous cell carcinoma of the lip ORPHA:502366; Squamous cell carcinoma of the nasal cavity and paranasal sinuses ORPHA:500464; Squamous cell carcinoma of the oral cavity ORPHA:502363; Squamous cell carcinoma of the oropharynx ORPHA:500478; Cryptogenic multifocal ulcerous stenosing enteritis ORPHA:468635; Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder ORPHA:477787; Aggressive systemic mastocytosis ORPHA:98850; Essential thrombocythemia ORPHA:3318,0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3826134188846508; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,In vitro;ecoli,0.58,Homo sapiens,Homo sapiens
TMSB15A,Malignant neoplasm of prostate; Central neuroblastoma; Neoplasm Metastasis; Neuroblastoma; Prostate carcinoma; Lung Neoplasms; Prostatic Neoplasms; Triple Negative Breast Neoplasms; Tuberculosis; HIV Infections,0.0569142010728473; 0.0593779966354549; 0.0648809611869375; 0.0688152422187159; 0.0773771948186562; 0.2062010908869036; 0.223747154820789; 0.2980670559114652; 0.3706856725676674; 0.3933196962529684,,,"Combined pituitary hormone deficiencies, genetic forms ORPHA:95494; Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome ORPHA:306542; Neuroblastoma ORPHA:635; Semilobar holoprosencephaly ORPHA:220386; Coralliform cataract ORPHA:98990; Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ORPHA:397623; Syndromic microphthalmia type 5 ORPHA:178364; Atrial standstill ORPHA:1344; Encephalocraniocutaneous lipomatosis ORPHA:2396; Hereditary retinoblastoma ORPHA:357027; Non-hereditary retinoblastoma ORPHA:357034; Cerulean cataract ORPHA:98989; Achondrogenesis type 2 ORPHA:93296; Autosomal dominant rhegmatogenous retinal detachment ORPHA:209867; Colobomatous optic disc-macular atrophy-chorioretinopathy syndrome ORPHA:435930; Dysspondyloenchondromatosis ORPHA:85198; Feingold syndrome type 1 ORPHA:391641; Hypochondrogenesis ORPHA:93297; Intellectual disability-developmental delay-contractures syndrome ORPHA:3454; Kniest dysplasia ORPHA:485; Legg-Calve-Perthes disease ORPHA:2380; Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis ORPHA:93279; Multiple epiphyseal dysplasia, Beighton type ORPHA:166011; Platyspondylic dysplasia, Torrance type ORPHA:85166; Spondyloepimetaphyseal dysplasia congenita, Strudwick type ORPHA:93346; Spondyloepiphyseal dysplasia congenita ORPHA:94068; Spondyloepiphyseal dysplasia with metatarsal shortening ORPHA:137678; Spondyloepiphyseal dysplasia, Stanescu type ORPHA:459051; Spondylometaphyseal dysplasia, Schmidt type ORPHA:93316; Spondyloperipheral dysplasia-short ulna syndrome ORPHA:1856; Stickler syndrome type 1 ORPHA:90653; X-linked congenital generalized hypertrichosis ORPHA:79495; X-linked intellectual disability with isolated growth hormone deficiency ORPHA:67045; Multiple benign circumferential skin creases on limbs ORPHA:2505; Isolated microphthalmia-anophthalmia-coloboma ORPHA:2542; Familial congenital mirror movements ORPHA:238722",0.0683063362547733; 0.1590470395003315; 0.3969770464111636; 0.4470672161388242; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,,,,
TNFSF9,"Colorectal Carcinoma; Ovarian Carcinoma; Colorectal Cancer; Adenocarcinoma; Malignant neoplasm of stomach; Epithelial ovarian cancer; Malignant neoplasm of prostate; Central neuroblastoma; Neuroblastoma; Lymphoma; Prostate carcinoma; Colorectal Neoplasms; Liver carcinoma; Malignant Neoplasms; Colon Carcinoma; Chronic Lymphocytic Leukemia; Rheumatoid Arthritis; cervical cancer; Malignant tumor of colon; Burkitt Lymphoma; B-Cell Lymphomas; Malignant tumor of cervix; Cervix carcinoma; Multiple Sclerosis; Primary malignant neoplasm; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Leukemia, Myelocytic, Acute; HIV Infections; Mycobacterium avium infection; Stomach Neoplasms; Lymphocytic infiltration; Mycobacterium avium-intracellulare Infection; Stromal Neoplasm; Contact hypersensitivity; Contact Dermatitis; Primary biliary cirrhosis; Crohn Disease; Arteriosclerosis; Takayasu Arteritis; Atherosclerosis; Autoimmune Diseases; Single tumor; Hereditary Diffuse Gastric Cancer; Influenza; IMMUNE SUPPRESSION; Tumor Immunity",0.0034602840073026; 0.0034602840073026; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0387439397151409; 0.0569142010728473; 0.0593779966354549; 0.0688152422187159; 0.0739788831250619; 0.0773771948186562; 0.0827744840860166; 0.095319386034013; 0.0991201145654548; 0.1062239757831962; 0.1147307578771389; 0.1537760235124317; 0.2050045461627939; 0.223747154820789; 0.2521987644415915; 0.2522264785494494; 0.2714542429024338; 0.2834835531038365; 0.2835142372342932; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3941558617476422; 0.4192169590514327; 0.4213286052188015; 0.425419812815905; 0.4615352570710579; 0.4923669467696064; 0.4981941174985421; 0.5019670090704682; 0.5188223685230745; 0.5393787854381349; 0.5512224939896888; 0.553002957824355; 0.5696906826730043; 0.7149953523738256; 0.726789939981526; 0.8148412516612868,Dermatitis; Gastric Cancer; Stomach Neoplasms,0.525214105372123; 0.6524705037929849; 0.669817442578862,Combined immunodeficiency due to CD70 deficiency ORPHA:538958; Athabaskan brainstem dysgenesis syndrome ORPHA:69739; Bosley-Salih-Alorainy syndrome ORPHA:69737; Familial atypical multiple mole melanoma syndrome ORPHA:404560; Melanoma and neural system tumor syndrome ORPHA:252206; Crisponi syndrome ORPHA:1545,0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.7068064785325423,,,Homo sapiens A549 lung carcinoma cell,0.35,Human SARS coronavirus;SARS-CoV-2,Homo sapiens
TOMM22,,,,,"Adenylosuccinate lyase deficiency ORPHA:46; Combined oxidative phosphorylation defect type 2 ORPHA:254920; Congenital generalized hypercontractile muscle stiffness syndrome ORPHA:476406; Mohr-Tranebjaerg syndrome ORPHA:52368; Multiple system atrophy, cerebellar type ORPHA:227510; Multiple system atrophy, parkinsonian type ORPHA:98933; Adult-onset autosomal recessive sideroblastic anemia ORPHA:255132; Ataxia-oculomotor apraxia type 1 ORPHA:1168; Autosomal recessive axonal neuropathy with neuromyotonia ORPHA:324442; Autosomal recessive intermediate Charcot-Marie-Tooth disease type B ORPHA:254334; Autosomal recessive optic atrophy, OPA7 type ORPHA:227976; Autosomal recessive severe congenital neutropenia due to JAGN1 deficiency ORPHA:423384; Bowen-Conradi syndrome ORPHA:1270; C11ORF73-related autosomal recessive hypomyelinating leukodystrophy ORPHA:495844; Cernunnos-XLF deficiency ORPHA:169079; Childhood-onset spasticity with hyperglycinemia ORPHA:401866; Combined oxidative phosphorylation defect type 30 ORPHA:478042; Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 ORPHA:168566; Friedreich ataxia ORPHA:95; Growth and developmental delay-hypotonia-vision impairment-lactic acidosis syndrome ORPHA:391348; Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency ORPHA:352563; Keratosis linearis-ichthyosis congenita-sclerosing keratoderma syndrome ORPHA:281201; Lenz-Majewski hyperostotic dwarfism ORPHA:2658; Mucopolysaccharidosis-like syndrome with congenital heart defects and hematopoietic disorders ORPHA:505248; Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality ORPHA:86841; Primary microcephaly-epilepsy-permanent neonatal diabetes syndrome ORPHA:306558; Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome ORPHA:488627; Syndromic sensorineural deafness due to combined oxidative phosphorylation defect ORPHA:457223; TMEM70-related mitochondrial encephalo-cardio-myopathy ORPHA:1194; Thrombocytopenia-absent radius syndrome ORPHA:3320; Leigh syndrome with nephrotic syndrome ORPHA:255249; Microphthalmia with linear skin defects syndrome ORPHA:2556; Fatal infantile cytochrome C oxidase deficiency ORPHA:1561; Trichothiodystrophy ORPHA:33364; Isolated complex III deficiency ORPHA:1460",0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7072638369101406; 0.7120423847116372,,,"Homo sapiens HEK293flp-in embryonic kidney cell;Homo sapiens HepaRG hepatoma cell;taxid:9606(""human-sk-n-be(2)"")|taxid:9606(""Homo sapiens SK-N-BE(2) neuroblastoma cell"")",0.27;0.35,Hepatitis delta virus;Homo sapiens;ZIKVK,Homo sapiens
TPM4,"Invasive Ductal Breast Carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of esophagus; Neoplasm Metastasis; Osteoporosis; Liver Cirrhosis, Experimental; Hematologic Neoplasms; Sarcoma; Post-Traumatic Osteoporosis; Osteoporosis, Senile; Inflammatory Myofibroblastic Tumor; Osteoporosis, Age-Related; Autosomal dominant macrothrombocytopenia; Weight Gain; Dengue Fever; Severe Dengue; Platelet distribution width measurement; Platelet distribution width result; Pulmonary Fibrosis - from Asbestos Exposure; Acute Coronary Syndrome; Triglycerides measurement; Precancerous Conditions; Asbestosis; Macrothrombocytopenia; Platelet mean volume determination (procedure); Condition, Preneoplastic; Platelet Count measurement",0.0149002095788623; 0.0182265588252201; 0.0191435238361999; 0.0248454592431097; 0.0648809611869375; 0.0739788831250619; 0.0747863377072194; 0.1253114324938153; 0.1537760235124317; 0.3233418869346274; 0.3544355608905275; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3975960596292668; 0.4028066164685291; 0.4028066164685291; 0.4115056600660309; 0.4115056600660309; 0.4115056600660309; 0.4118266358241932; 0.4192169590514327; 0.4479115285676636; 0.4753011022966241; 0.4753011022966241; 0.4981941174985421; 0.533913711453195; 0.7061487180640408,Esophagus Neoplasm; Breast Cancer; Platelet-type Bleeding Disorder; Inflammatory Myofibroblastic Tumor; Osteoporosis; Coronary Syndrome; Asbestosis; Macrothrombocytopenia,0.0102679590519094; 0.0402286636010764; 0.3940072377207739; 0.4286813331685578; 0.4541466895915311; 0.4560460337187313; 0.4560460337187313; 0.4560460337187313,"Congenital short bowel syndrome ORPHA:2301; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; MYH9-related disease ORPHA:182050; Quebec platelet disorder ORPHA:220436; TMEM165-CDG ORPHA:314667; Temtamy preaxial brachydactyly syndrome ORPHA:363417; Cap myopathy ORPHA:171881; Frontometaphyseal dysplasia ORPHA:1826; Skeletal Ewing sarcoma ORPHA:319; Gorlin-Chaudhry-Moss syndrome ORPHA:2095; Progeroid syndrome, Petty type ORPHA:2963; Scott syndrome ORPHA:806; Musculocontractural Ehlers-Danlos syndrome ORPHA:2953; Autosomal dominant macrothrombocytopenia ORPHA:140957; Inflammatory myofibroblastic tumor ORPHA:178342",0.0083045131203191; 0.0180064224283883; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6279395134845649; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,"Cercopithecine betaherpesvirus 5 helicase-primase helicase subunit (gene: UL105); Yaba monkey tumor virus anti-apoptotic membrane protein; Monkeypox virus Zaire-96-I-16 Hypothetical protein (gene: C7L); Vaccinia virus Ankara apoptosis inhibitor; Reston ebolavirus spike glycoprotein (gene: GP); Ebola virus - Mayinga, Zaire, 1976 virion spike glycoprotein precursor (gene: GP); Zaire ebolavirus spike glycoprotein (gene: GP); Sudan ebolavirus spike glycoprotein (gene: GP); Sudan ebolavirus - Nakisamata structural glycoprotein (gene: GP); Tai Forest ebolavirus spike glycoprotein (gene: GP); Influenza A virus (A/Hong Kong/1073/99(H9N2)) Hemagglutinin (gene: ha); Influenza A virus (A/Puerto Rico/8/1934(H1N1)) HA2 (gene: HA); Ectromelia virus ERPV hydroxysteroid dehydrogenase; Influenza A virus (A/Korea/426/1968(H2N2)) HA2 (gene: HA); Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) HA1 (gene: HA); Influenza A virus (A/California/07/2009(H1N1)) HA1 (gene: HA); Influenza A virus (A/Shanghai/02/2013(H7N9)) HA2 (gene: HA); Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) hemagglutinin (gene: HA); Monkeypox virus unknown protein; Influenza A virus (A/Puerto Rico/8/1934(H1N1)) HA1 (gene: HA); SARS coronavirus nsp8-pp1a/pp1ab (gene: orf1ab); Monkeypox virus cowpox A-type inclusion protein; Influenza A virus (A/Northern Territory/60/1968(H3N2)) HA2 (gene: HA); Influenza A virus (A/Shanghai/02/2013(H7N9)) hemagglutinin (gene: HA); Lake Victoria marburgvirus - Leiden glycoprotein (gene: GP); Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) HA2 (gene: HA); Marburg virus - Musoke, Kenya, 1980 glycoprotein (gene: GP); Influenza A virus (A/California/04/2009(H1N1)) hemagglutinin (gene: HA); Influenza A virus (A/California/07/2009(H1N1)) hemagglutinin (gene: HA); Vaccinia virus Ankara double-stranded RNA binding protein; Marburg marburgvirus glycoprotein (gene: GP); Influenza A virus (A/Korea/426/1968(H2N2)) hemagglutinin (gene: HA); Variola virus hypothetical protein (gene: A28L); Influenza A virus (A/New York/599/1996(H3N2)) hemagglutinin (gene: HA); Influenza A virus (A/New York/392/2004(H3N2)) hemagglutinin (gene: HA); Influenza A virus (A/New York/602/1996(H3N2)) hemagglutinin (gene: HA); Influenza A virus (A/New York/599/1996(H3N2)) HA2 (gene: HA); Influenza A virus (A/New York/602/1996(H3N2)) HA2 (gene: HA); Influenza A virus (A/Puerto Rico/8/1934(H1N1)) haemagglutinin (gene: HA); Influenza A virus (A/New York/392/2004(H3N2)) HA2 (gene: HA); Influenza A virus (A/Northern Territory/60/1968(H3N2)) hemagglutinin (gene: HA); Lake Victoria marburgvirus - DRC1999 glycoprotein (gene: GP); SARS coronavirus excised_polyprotein 1..4369 (gene: orf1ab); Influenza B virus (B/Memphis/12/97) HA protein; SARS coronavirus P2 full_polyprotein 1..4382; Ravn virus - Ravn, Kenya, 1987 glycoprotein (gene: GP); Cowpox virus Ati or CPXV158 protein (gene: ati); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Lake Victoria marburgvirus - Angola2005 glycoprotein (gene: GP); Human immunodeficiency virus pol protein (gene: pol); Bundibugyo ebolavirus spike glycoprotein (gene: GP); Rotavirus A NSP4; Vaccinia virus Ankara 150k A-type inclusion protein (ATI) f1; Vaccinia virus cowpox A-type inclusion protein; Hendra henipavirus phosphoprotein P (gene: P/V/C); Influenza A virus (A/California/04/2009(H1N1)) HA2 (gene: HA); Influenza A virus (A/California/07/2009(H1N1)) HA2 (gene: HA); Nipah henipavirus P phosphoprotein; Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3)",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6386053036162835; 0.6430308263654244; 0.6481498905276316; 0.6481498905276316; 0.6481498905276316; 0.664689610422691; 0.6761714078632568; 0.6761714078632568; 0.6806291584193672; 0.691145768348025; 0.6980058392556946; 0.7054555693277184; 0.7079503198328393; 0.7079503198328393; 0.7108466056279036; 0.7187273231330169; 0.7225463502962445; 0.7398997088314572; 0.7568193074461791; 0.7648879200949484; 0.7651942752688915; 0.7665923583742081; 0.776311155917498; 0.776311155917498; 0.7954342107380572; 0.8400145987535752; 0.8458935424065495; 0.8507994162096807; 0.853754994225345; 0.8834254233868516; 0.8919745352546131; 0.9285312497152513; 0.9285312497152513; 0.9511894303546532; 0.985687915361386,In vitro;yeasx,0.35;0.49,Homo sapiens;chemical synthesis,Homo sapiens;hcvjf
TRAK2,"Breast Carcinoma; Liver Cirrhosis, Experimental",0.0042545616049287; 0.0747863377072194,Breast Carcinoma,0.0075861267486594,"Recessive X-linked ichthyosis ORPHA:461; Syndromic recessive X-linked ichthyosis ORPHA:281090; Acrodysostosis ORPHA:950; Acrodysostosis with multiple hormone resistance ORPHA:280651; X-linked myotubular myopathy-abnormal genitalia syndrome ORPHA:456328; Carney complex ORPHA:1359; Familial atrial myxoma ORPHA:615; Oculocerebrofacial syndrome, Kaufman type ORPHA:2707",0.0586579655822394; 0.0586579655822394; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,yeasx,0.37,Homo sapiens,Yersinia pestis
TRIB3,"Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of prostate; Neoplasm Metastasis; Barrett Esophagus; Pancreatic Neoplasm; Degenerative polyarthritis; Liver Cirrhosis, Experimental; Prostate carcinoma; Liver carcinoma; Malignant Neoplasms; MYELODYSPLASTIC SYNDROME; Myocardial Infarction; Liver neoplasms; Systemic Scleroderma; Diabetes; Anoxia; Diabetes Mellitus; Neoplasms; Myeloid Leukemia; Marijuana Abuse; Primary malignant neoplasm; Recurrent tumor; Diabetes Mellitus, Non-Insulin-Dependent; Infection caused by Helicobacter pylori; Leukemia, Myelocytic, Acute; Acute Promyelocytic Leukemia; Coronary heart disease; Squamous cell carcinoma of tongue; Glioblastoma Multiforme; Insulin Sensitivity; Insulin Resistance; leukemia; Cardiovascular Diseases; Impaired glucose tolerance; Hyperglycemia; Arteriosclerosis; Carotid Atherosclerosis; Coronary Arteriosclerosis; Obesity; Atherosclerosis; Metabolic Syndrome X; ATRICHIA WITH PAPULAR LESIONS; Cardiovascular Abnormalities; Coronary Artery Disease; Hyperhomocysteinemia; Psoriasis vulgaris; Endothelial dysfunction",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0569142010728473; 0.0648809611869375; 0.0648809611869375; 0.0739788831250619; 0.0739788831250619; 0.0747863377072194; 0.0773771948186562; 0.095319386034013; 0.0991201145654548; 0.1254380558571286; 0.1352936728187231; 0.1454373331146953; 0.1900258729042946; 0.2277108302018961; 0.2462384927636234; 0.2522264785494494; 0.2714542429024338; 0.2980670559114652; 0.3418217363648192; 0.383941725017158; 0.383941725017158; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3975960596292668; 0.4459714599189374; 0.4588513406515081; 0.4675904598629673; 0.4900770016856776; 0.4906258721078565; 0.5019670090704682; 0.504136641473215; 0.5140447474168605; 0.5140447474168605; 0.5393787854381349; 0.5568517196017908; 0.5568517196017908; 0.5655222348249326; 0.7240930522443176; 0.7780887836634591; 0.8209296131179464; 0.82379775978369,Metabolic Syndrome; Glioblastoma; Non-Alcoholic Fatty Liver Disease,0.4809179010794786; 0.4875380732267193; 0.504364324740411,Familial atypical multiple mole melanoma syndrome ORPHA:404560; Melanoma and neural system tumor syndrome ORPHA:252206; Autosomal dominant Charcot-Marie-Tooth disease type 2D ORPHA:99938; Burkitt lymphoma ORPHA:543; Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome ORPHA:391376; Large congenital melanocytic nevus ORPHA:626; Autosomal dominant Charcot-Marie-Tooth disease type 2U ORPHA:397735; Autosomal recessive spastic paraplegia type 70 ORPHA:401835; Congenital factor XII deficiency ORPHA:330; F12-related hereditary angioedema with normal C1Inh ORPHA:100054; Isolated focal cortical dysplasia type Ia ORPHA:268973; SLC35A2-CDG ORPHA:356961; Severe early-onset pulmonary alveolar proteinosis due to MARS deficiency ORPHA:440427,0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,"Norovirus Hu/Norwalk/10074/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20047/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CBNU2/2007/KR capsid protein; Norovirus Hu/Norwalk/10247/2009/VNM capsid protein VP1 (gene: VP1); Lujo mammarenavirus multifunctional matrix-like protein; Norovirus Hu/GII-4/CGMH13/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/Norwalk/10051/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10116/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10183/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10236/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH02/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH03/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH04/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH06/2006/TW major viral capsid protein; Norovirus Hu/GII-4/CGMH07/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH09/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH12/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH17/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/SGU-110421/KOR/2011 VP1; Norovirus Hu/GII-4/CGMH05/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH08/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/GZ2010-L26/Guangzhou/CHN/2010 major viral capsid protein (gene: VP1); Norovirus Hu/GII/Shanghai/SH2/2008/CHN VP1; Human adenovirus 18 IVa2 protein (gene: IVa2); Human adenovirus 31 IVa2 protein (gene: IVa2); Norovirus Hu/Shanghai/SH5/2009/CHN VP1; Norovirus Hu/GII-4/CGMH14/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH15/2007/TW major viral capsid protein; Norovirus Hu/Norwalk/20123/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH10/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH22/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Miranda/NSW850K/2011/AU VP1; Yaba-like disease virus 140R protein (gene: 140R); Norovirus Hu/GII-4/CGMH18/2008/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH28/2010/TW major viral capsid protein (gene: VP1); Human alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5); Macacine alphaherpesvirus 1 helicase-primase helicase subunit (gene: UL5); Human adenovirus B3 protein IVa2 (gene: IVa2); Norovirus Hu/GII.4/Guangzhou/GZ2010-L88/CHN/2011 major viral capsid protein; Norovirus Hu/GII.4/Guangzhou/GZ2010-L91/CHN/2011 major viral capsid protein; Hepatovirus A 3D mature peptide; Human mastadenovirus B encapsidation protein IVa2 (gene: IVa2); Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Guanarito mammarenavirus Z protein; Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Human mastadenovirus F encapsidation protein IVa2 (gene: IVa2); Horsepox virus HSPV043 (Kelch-like protein; Provisional); Human papillomavirus type 48 regulatory protein E2 (gene: E2); Trichodysplasia spinulosa-associated polyomavirus large T antigen (gene: T); Human mastadenovirus D encapsidation protein IVa2 (gene: IVa2); Human adenovirus D10 pIVa2 (gene: pIVa2); Norovirus Hu/GII.2/HS255/2011/USA viral genome-linked protein (gene: POL); Norovirus Hu/GII.3/HK71/1978/CHN viral genome-linked protein (gene: POL); Norovirus Hu/GII.4/NIHIC17.5/2012/USA viral genome-linked protein (gene: POL); Norovirus Hu/GII.4/NIHIC17.6/2012/USA viral genome-linked protein (gene: POL); Norovirus Hu/GII.4/NIHIC17.8/2013/USA viral genome-linked protein (gene: POL); Human papillomavirus 116 E2 protein; Human enterovirus C104 3D; Human adenovirus 43 encapsidation protein IVa2 (gene: IVa2); Astrovirus MLB1 HK05 ORF1b (gene: ORF1b); Norovirus Hu/GII.4/HS292/2012/USA viral genome-linked protein (gene: POL); SARS coronavirus RNA-dependent RNA polymerase (gene: orf1ab); Echovirus E21 VP1; Human polyomavirus 10 large T Antigen; Echovirus E14 3D; Reston ebolavirus spike glycoprotein (gene: GP); Echovirus E11 3D; Cercopithecine betaherpesvirus 5 chemokine vCXCL8 (gene: UL146E); Echovirus E4 3D; WU Polyomavirus large T antigen; Coxsackievirus A22 3d; Enterovirus C109 3D; Norovirus GII/Hu/JP/2010/GII.P4_GII.4/Shimada/ASC96 VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC11.3/2013/USA capsid protein VP1 (gene: VP1); Yaba-like disease virus 14L protein (gene: 14L); Reston ebolavirus matrix protein (gene: VP40); Semliki Forest virus E2 protein; Coxsackievirus A1 3D; Enterovirus B 3D; Norovirus Hu/GII-4/CUK-3/2008/KR capsid protein; Molluscum contagiosum virus subtype 1 MC157R (gene: MC157R); Enterovirus H 3D; Norovirus Hu/GII.4/NIHIC28.4/2012/USA capsid protein VP1 (gene: VP1); Human adenovirus 46 IVa2; Norovirus GI/Hu/JP/2007/GI.P3_GI.3/Shimizu/KK2866 VP1 (gene: VP1); Monkeypox virus Zaire-96-I-16 B1R (gene: B1R); Salivirus NG-J1 3D; Echovirus 9 strain Hill polyprotein region 11; Echovirus E32 3D; Norovirus Hu/GII-4/CGMH11/2006/TW major viral capsid protein; Norovirus Hu/GII.4/NIHIC28.5/2012/USA capsid protein VP1 (gene: VP1); Alkhumra hemorrhagic fever virus non-structural protein NS1; Yaba monkey tumor virus DNA topoisomerase type I; Norovirus Hu/GI/10360/2010/VNM viral genome-linked protein (gene: POL); Human parechovirus 2A protein (gene: polyprotein); Echovirus E17 3D; Human enterovirus 94 3D; Echovirus E3 3D; Enterovirus D 3D-POL; Echovirus 9 strain Barty polymerase; Echovirus E6 3D; Human adenovirus 61 pIVa2; Norovirus Hu/GII/BG1C0405/2012/BGD viral genome-linked protein (gene: POL); Human adenovirus 16 maturation protein IVA2 (gene: IVa2); Echovirus E21 3D; Human coronavirus OC43 nucleocapsid protein; Human gammaherpesvirus 8 ORF59 (gene: ORF59); Middle East respiratory syndrome-related coronavirus nsp12 protein (gene: orf1ab); Yaba-like disease virus 77R protein (gene: 77R); Human adenovirus 52 pol (gene: pol); Human mastadenovirus A IVa2; Influenza A virus (A/Shanghai/02/2013(H7N9)) polymerase PB2 (gene: PB2); Human enteric coronavirus 4408 nucleocapsid protein (gene: N); Human respirovirus 3 C protein; Ebola virus - Mayinga, Zaire, 1976 virion spike glycoprotein precursor (gene: GP); Zaire ebolavirus spike glycoprotein (gene: GP); Titi monkey adenovirus ECC-2011 IVa2; Yaba-like disease virus 142R protein (gene: 142R); Vaccinia virus ser/thr kinase (gene: B1R); Vaccinia virus Ankara Serine/threonine-protein kinase; Ectromelia virus ERPV profilin-like protein; Human astrovirus 6 capsid protein; Influenza A virus (A/Puerto Rico/8/1934(H1N1)) polymerase PB2 (gene: PB2); Variola virus DNA topoisomerase type I (gene: I6R); Human coronavirus OC43 transmembrane domain 2 (gene: orf1ab); Human herpesvirus 3 strain Dumas nuclear matrix protein; Human papillomavirus type 68 E1 (gene: E1); Human papillomavirus type 68a E1 protein; Human papillomavirus type 68b E1 protein (gene: E1); Horsepox virus HSPV179 (Serine/Threonine protein kinase, Vaccinia Related Kinase); Human gammaherpesvirus 8 KCP (gene: ORF4); Vaccinia virus Ankara 64.7k Kelch-like protein f2; Human betacoronavirus 2c Jordan-N3/2012 N protein (gene: N); Barmah Forest virus excised_polyprotein 1..742; Human enteric coronavirus strain 4408 nucleocapsid protein; Molluscum contagiosum virus subtype 1 MC127R (gene: MC127R); Human adenovirus 1 pol; Human parainfluenza virus 1 strain Washington/1964 C protein (gene: C); Human parainfluenza virus 1 strain Washington/1964 putative Y2 protein (gene: Y2); Human parainfluenza virus 1 strain Washington/1964 Y1 protein (gene: Y1); Human respirovirus 1 Y1 protein (gene: Y1); Human respirovirus 1 C protein (gene: C); Human respirovirus 1 putative Y2 protein (gene: Y2); Human adenovirus 52 DBP (gene: DBP); Louping ill virus nonstructural protein NS3; Human polyomavirus 6 large T antigen; Human polyomavirus 9 large T antigen; Human polyomavirus IPPyV large T antigen protein (gene: large T antigen); Titi monkey adenovirus ECC-2011 pVI; Human betacoronavirus 2c EMC/2012 N protein (gene: N); Bundibugyo ebolavirus matrix protein (gene: VP40); Human betaherpesvirus 6 U37 (gene: U37); Human betaherpesvirus 6A nuclear egress lamina protein (gene: U37); Cercopithecine betaherpesvirus 5 membrane protein RL11K (gene: RL11K); Middle East respiratory syndrome-related coronavirus nucleoprotein (gene: N); Ebola virus - Mayinga, Zaire, 1976 polymerase (gene: L); Zaire ebolavirus RNA-dependent RNA polymerase (gene: L); Human mastadenovirus F DNA polymerase (gene: E2B); Norovirus GIV VPg; Human adenovirus 7 III; Rhinovirus A81 1D; Titi monkey adenovirus ECC-2011 III; Cercopithecine alphaherpesvirus 2 DNA replication origin-binding helicase (gene: UL9); Sudan ebolavirus spike glycoprotein (gene: GP); Sudan ebolavirus - Nakisamata structural glycoprotein (gene: GP); Human astrovirus 2 capsid protein precursor; Human astrovirus 4 capsid precursor protein; Human astrovirus 5 structural protein; Human bocavirus NS1 (gene: NS1); Human bocavirus 1 nonstructural protein (gene: NS1); Human bocavirus WLL-1 NS1 (gene: NS1); Human bocavirus WLL-2 NS1 (gene: NS1); Human bocavirus WLL-3 NS1 (gene: NS1); Human bocavirus isolate SH1 NS1; Human bocavirus isolate SH2 NS1; Human coronavirus HKU1 nucleocapsid phosphoprotein (gene: N); Variola virus putative metalloprotease (gene: H1L); Human enterovirus C118 VP4; Echovirus E16 VP4; Oropouche virus full_polyprotein 1..1420 (gene: M); Ross River virus C protein; Tai Forest ebolavirus matrix protein (gene: VP40); Coxsackievirus A14 full_polyprotein 1..2192; Vaccinia virus putative metalloprotease (gene: G1L); Influenza A virus (A/California/04/2009(H1N1)) polymerase PB2 (gene: PB2); Influenza A virus (A/California/07/2009(H1N1)) polymerase PB2 (gene: PB2); Vaccinia virus Ankara Metalloendopeptidase; Cowpox virus CPXV049 protein (gene: CPXV049 CDS); Mayaro virus capsid protein; Human herpesvirus 4 type 2 BLLF1; Monkeypox virus insulin metalloproteinase-like protein; Monkeypox virus Zaire-96-I-16 putative metalloprotease (gene: G1L); Ectromelia virus ERPV putative metalloprotease; Ectromelia virus ERPV dUTPase; Horsepox virus HSPV079 (Peptidase_M44); Horsepox virus HSPV042 (dUTPase; Provisional); Norwalk-like virus capsid protein; Human adenovirus 7 pIIIa; Semliki Forest virus C protein; Coxsackievirus A10 full_polyprotein 1..2193; Enterovirus A120 full_polyprotein 1..2191; Human astrovirus 5 RNA-dependent RNA polymerase; Western equine encephalitis virus C protein; Human papillomavirus 149 E2 (gene: E2); Norovirus Hu/GI.2/Jingzhou/2013401/CHN major capsid protein VP1; HBV genotype C pol (gene: P); Human adenovirus 19 DNA polymerase (gene: E2B); Rubella virus capsid protein; Human alphaherpesvirus 3 nuclear egress lamina protein (gene: ORF27); Variola virus hypothetical protein (gene: A47R); Monkeypox virus profilin-like protein; Monkeypox virus Zaire-96-I-16 A42R (gene: A42R); Horsepox virus HSPV164 (Profilin); Human betaherpesvirus 6B hypothetical protein (gene: U37); Yaba monkey tumor virus IL-18 binding protein; Molluscum contagiosum virus subtype 1 MC021L (gene: MC021L); Human mastadenovirus A pol; Monkeypox virus dUTPase; Human mastadenovirus F single-stranded DNA-binding protein (gene: E2A); Monkeypox virus Zaire-96-I-16 dUTPase (gene: C8L); Human papillomavirus 135 regulatory protein (gene: E2); HBV recombinant B/C polymerase (gene: P); Human adenovirus 14 DNA binding protein (gene: E2A); Human parechovirus RNA-dependent RNA polymerase 3D (gene: polyprotein); Vaccinia virus profilin-like protein (gene: A42R); Vaccinia virus Ankara Profilin-1-like; Cowpox virus CPXV179 protein (gene: CPXV179 CDS); Coxsackievirus A4 full_polyprotein 1..2201; Enterovirus A76 full_polyprotein 1..2198; Influenza A virus (A/Korea/426/1968(H2N2)) polymerase PB2 (gene: PB2); Human betaherpesvirus 6A protein DR1 (gene: DR1); Human betaherpesvirus 6B G-protein coupled receptor fragment (gene: U12); HBV genotype H P protein (gene: P); Human papillomavirus type 60 regulatory protein E2 (gene: E2); Human papillomavirus type 68 E6 (gene: E6); Human papillomavirus type 68b E6 protein (gene: E6); Human parainfluenza virus 4a non-structural protein V (gene: V); Human rhinovirus A30 1D; Human adenovirus 61 E2A DNA binding protein; Ross River virus excised_polyprotein 1..756; Titi monkey adenovirus ECC-2011 DBP; Influenza A virus (A/Northern Territory/60/1968(H3N2)) polymerase PB2 (gene: PB2); Macacine alphaherpesvirus 1 envelope glycoprotein G (gene: US4); Enterovirus C protein 3CD; Enterovirus C RNA-directed RNA polymerase; Human papillomavirus type 103 E2 protein; Horsepox virus HSPV074d (ribonucleoside--diphosphate reductase large subunit); Human poliovirus 1 Mahoney excised_polyprotein 1566..2209; Orf virus ORF037 putative metalloprotease; Coxsackievirus A2 full_polyprotein 1..2190; Human rhinovirus B52 3D; Human astrovirus 1 Beijing/291/2007/CHN nonstructural protein; Human betaherpesvirus 5 membrane protein UL10 (gene: UL10); Human enterovirus 94 VP1; Human papillomavirus 143 regulatory protein (gene: E2); Human T-lymphotropic virus 3 group specific antigen (gene: gag); Human parvovirus 4 VP1; Human adenovirus 3+7 DNA binding protein (gene: E2A); Human rhinovirus A23 1D (VP1); Human rhinovirus A55 1B (VP2); Human rhinovirus A74 1B (VP2); Rubella virus protease p150; Human alphaherpesvirus 2 nuclear protein UL3 (gene: UL3); Alphapapillomavirus 7 E2 protein (gene: E2); Influenza A virus (A/New York/392/2004(H3N2)) polymerase PB2 (gene: PB2); Influenza A virus (A/New York/602/1996(H3N2)) polymerase PB2 (gene: PB2); Cercopithecine betaherpesvirus 5 regulatory protein IE1 (gene: UL123); Human gammaherpesvirus 8 ORF47 (gene: ORF47); Human papillomavirus type 18 E2 protein (gene: E2); Human TMEV-like cardiovirus capsid protein VP1; Human polyomavirus 12 large T antigen; Human rhinovirus A36 1B (VP2); Human rhinovirus A49 1D; Human rhinovirus A64 1B; Human adenovirus D8 7.3kDa protein (gene: E4); Variola virus hypothetical protein (gene: B1R); Influenza A virus (A/New York/599/1996(H3N2)) polymerase PB2 (gene: PB2); Mayaro virus nonstructural protein nsP4; Human papillomavirus type 129 E2 (gene: E2); Human papillomavirus type 150 putative E2 product (gene: E2); Human parvovirus 4 G1 ORF2; Human rhinovirus A15 1D (VP1); Human rhinovirus A74 1D (VP1); Papiine alphaherpesvirus 2 envelope glycoprotein D (gene: US6); Human betacoronavirus 2c Jordan-N3/2012 S protein (gene: S); Mayaro virus excised_polyprotein 1..746; Human mastadenovirus E DNA polymerase (gene: E2B); Human papillomavirus 145 transforming protein (gene: E7); Human adenovirus 1 DBP; Human rhinovirus A1 1D; Human rhinovirus A40 1D; Papiine alphaherpesvirus 2 envelope glycoprotein G (gene: US4); Parvovirus NIH-CQV putative capsid protein (gene: cap); Human rhinovirus A66 1D; Rhinovirus B14 3D; Human rhinovirus A77 1D; SARS coronavirus nucleocapsid protein (gene: N); Human adenovirus E4 DNA polymerase; SARS coronavirus P2 nucleocapsid protein; SARS coronavirus Tor2 nucleocapsid protein; Semliki Forest virus excised_polyprotein 1..755; Human rhinovirus A96 1D; Human papillomavirus type 128 E2 (gene: E2); Cercopithecine alphaherpesvirus 2 envelope glycoprotein D (gene: US6); Aichi virus 1 VP0; Human betacoronavirus 2c EMC/2012 S protein (gene: S); Human betacoronavirus 2c England-Qatar/2012 S protein; Betacoronavirus England 1 S protein (gene: S); Chikungunya virus excised_polyprotein 1..748; Human coronavirus NL63 nucleocapsid protein; Coxsackievirus A6 3D protein; Human group 1 coronavirus associated with pneumonia nucleocapsid protein; Middle East respiratory syndrome-related coronavirus spike glycoprotein (gene: S); Eastern equine encephalitis virus NS4; Human mastadenovirus D DNA polymerase (gene: E2B); Human papillomavirus type 96 E2; Human rhinovirus A13 1D; Human rhinovirus A18 1D; Human rhinovirus A21 1D; Human rhinovirus A25 1D; Human rhinovirus A29 1D; Human adenovirus 56 DNA polymerase (gene: E2B); Human rhinovirus A45 1D; Human rhinovirus A60 1D; Human rhinovirus A89 1D; Human adenovirus 7d2 100 kDa hexon assembly-associated protein (gene: L4); Cercopithecine betaherpesvirus 5 envelope glycoprotein UL33 (gene: UL33); Human gammaherpesvirus 4 EBNA-1 protein (gene: BKRF1); Eastern equine encephalitis virus nsP4 protein; Human papillomavirus 197 E1 (gene: E1); Human papillomavirus 5 regulatory protein (gene: E2); Human papillomavirus 65 regulatory protein E2 (gene: E2); Norovirus Hu/GII.6/CHDC4073/1984/USA capsid protein VP1 (gene: VP1); Human adenovirus 19 DNA binding (gene: E2A); Human rhinovirus A15 1B (VP2); Human rhinovirus A31 1D; Human rhinovirus A32 1D; Human rhinovirus A38 1D; O'nyong-nyong virus nonstructural protein P4; Human rhinovirus A56 1D; Human rhinovirus A57 1D; Human rhinovirus A58 1D; Human rhinovirus A67 1D; Human rhinovirus A7 1B; Human rhinovirus A73 1D (VP1); Human rhinovirus A8 1D; Human betaherpesvirus 7 capsid maturation protease (gene: U53); Coxsackievirus A11 3d; Coxsackievirus A13 3d; Echovirus E7 3D; Human papillomavirus type 129 E1 (gene: E1); Human papillomavirus type 57c E2 (gene: E2); Human papillomavirus type 88 E2 protein; Human poliovirus 3 POLYM; Human rhinovirus A24 1D; Human adenovirus 64 E2A DNA binding protein; Human rhinovirus A59 1D (VP1); Human adenovirus D37 DNA-binding protein (gene: E2A); Human rhinovirus A9 1D; Human rhinovirus A90 1D; Human betaherpesvirus 5 capsid maturation protease (gene: UL80); Cercopithecine betaherpesvirus 5 membrane protein RL11G (gene: RL11G); Chikungunya virus full_polyprotein 1..1248; Human coronavirus 229E nucleocapsid protein (gene: N); Human enterovirus C102 3d; Coxsackievirus A17 3D; Coxsackievirus A18 3D protein; Human herpesvirus 3 strain Dumas membrane glycoprotein gE; Echovirus E33 3D; Human papillomavirus 152 early protein E1 (gene: E1); Human papillomavirus type 38b E2 protein (gene: E2); Human rhinovirus A33 1D; Human rhinovirus A54 1D; Human rhinovirus A55 1D (VP1); Human adenovirus 67 E2A DNA binding protein; Human rhinovirus A62 1D; Rhinovirus A98 1D; Human rhinovirus A94 1D; Human alphaherpesvirus 3 envelope glycoprotein E (gene: ORF68); Echovirus E18 full_polyprotein 1..2189; Igbo Ora virus nonstructural protein 4; Venezuelan equine encephalitis virus RNA-directed RNA polymerase nsP4 (gene: NS); Maraba virus phosphoprotein (gene: P); Western equine encephalitis virus RNA-dependent RNA polymerase catalytic subunit; Human herpesvirus 4 type 2 EBNA-1; Echovirus E24 3D; Human papillomavirus 104 E2 protein (gene: E2); Human papillomavirus 134 E2 (gene: E2); Human papillomavirus type 26 early protein (gene: E2); Norovirus Hu/GII/10002/2009/VNM capsid protein VP1 (gene: VP1); Human papillomavirus type 54 regulatory protein (gene: E2); Human TMEV-like cardiovirus protein 2B*; Human rhinovirus A19 1D; Human rhinovirus A41 1D (VP1); Human rhinovirus A44 1D (VP1); Human rhinovirus A61 1D; Human rhinovirus A76 1D; Human rhinovirus A82 1D; Human rhinovirus A88 1D (VP1); Semliki Forest virus Nonstructural protein nsP4; Cercopithecine betaherpesvirus 5 large tegument protein (gene: UL48); Cercopithecine alphaherpesvirus 2 deoxyuridine triphosphatase (gene: UL50); Middle East respiratory syndrome-related coronavirus nsp15 protein (gene: orf1ab); Echovirus E20 3D; Human papillomavirus 113 E1 protein (gene: E1); Ectromelia virus ERPV superoxide dismutase-like protein; Human papillomavirus 141 regulatory protein (gene: E2); Human papillomavirus 98 E2 protein (gene: E2); Human papillomavirus type 153 E2 protein (gene: E2); Norovirus Hu/GII.4/Randwick/NSW938K/2011/AU VP1; Human rhinovirus A10 1D; Human rhinovirus A22 1D; Saffold virus protein 2B*; Sindbis virus nsp4 nonstructural protein (putative start);; Echovirus E12 polyprotein; Monkeypox virus ser/thr protein kinase-like protein; Monkeypox virus Zaire-96-I-16 B3R (gene: B3R); Human immunodeficiency virus envelope glycoprotein (gene: env); Human betaherpesvirus 5 regulatory protein IE2 (gene: UL122); Cercopithecine betaherpesvirus 5 regulatory protein IE2 (gene: UL122); Echovirus E15 3D; Echovirus E2 3D; Human mastadenovirus D single-stranded DNA-binding protein (gene: E2A); Echovirus E26 3D; Human papillomavirus 121 regulatory protein E2 (gene: E2); Human papillomavirus 126 hypothetical protein (gene: HpV126gp2); Human papillomavirus 133 E2 (gene: E2); Human papillomavirus 148 E2 (gene: E2); Human papillomavirus 171 E2; Human papillomavirus FA75/KI88-03 E2 protein (gene: E2); Human papillomavirus type 131 E2 (gene: E2); Norovirus Hu/GII/10003/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII/10012/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10034/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10054/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10062/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10075/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10078/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10079/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10110/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10114/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10129/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10136/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10145/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10158/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10160/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10163/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10169/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10177/2009/VNM capsid protein VP1 (gene: VP1); Human adenovirus 28 single-stranded DNA binding protein (gene: E2A); Norovirus Hu/Norwalk/10179/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10182/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10194/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10203/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10204/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10222/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10238/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10255/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10296/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20010/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20014/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20019/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20067/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20069/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20092/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20093/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20118/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20122/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20128/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20135/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20139/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20140/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20142/2009/VNM capsid protein VP1 (gene: VP1); Human rhinovirus A50 1D; Human rhinovirus A85 1D; Human rhinovirus A95 1D; Ectromelia virus ERPV hemagglutinin; Papiine alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5); Banna virus strain JKT-6423 Vp7; Human betaherpesvirus 6B proteinase (gene: U53); Human enterovirus C117 3D; Echovirus E19 3D; Human papillomavirus 130 E2 (gene: E2); Human papillomavirus 178 E2 protein (gene: E2); Human papillomavirus 201 E2 (gene: E2); Human parechovirus 1 3D; Human parechovirus 8 3D; Human rhinovirus A34 1D; Human rhinovirus A63 1D; Human gammaherpesvirus 8 LANA; HBV genotype C polymerase (gene: P); Human parechovirus 4 RNA-dependent RNA Polymerase; Human rhinovirus A100 1D; Human gammaherpesvirus 4 putative BLRF2 protein (gene: BLRF2); Human gammaherpesvirus 8 ORF52 (gene: ORF52); Human herpesvirus 4 type 2 BLRF2; Norovirus GII/Hu/JP/2007/GII.P15_GII.15/Sapporo/HK299 full_polyprotein 1..1698; Norovirus Hu/GI/10360/2010/VNM protein p37 (gene: POL); Human papillomavirus type 124 regulatory protein E2 (gene: E2); Human adenovirus 19 ORF1 (gene: E4); Human papillomavirus type 92 E2; Human adenovirus 49 pIVa2; Human adenovirus 64 E4 7.4 kDa protein; Human adenovirus Chiba_E086/2012 Orf1 (gene: E4); Human adenovirus D37 14.0 kDa (gene: E4); Vaccinia virus RNA polymerase subunit (gene: E4L); Human betaherpesvirus 6 U53, protease /assembly protein (gene: U53); Human betaherpesvirus 6A capsid maturation protease (gene: U53); Cowpox virus CPXV183 protein (gene: CPXV183 CDS); Langat virus membrane-associated glycoprotein precursor; Macacine alphaherpesvirus 1 deoxyuridine triphosphatase (gene: UL50); Yaba monkey tumor virus Ser/Thr kinase; Human papillomavirus 136 regulatory protein (gene: E2); Human papillomavirus 159 E2 protein (gene: E2); Norovirus Hu/GII-4/CGMH19/2009/TW major viral capsid protein (gene: VP1); Human papillomavirus type 41 hypothetical protein (gene: ORF E7); Norovirus Hu/GII.6/GZ2010-L96/Guangzhou/CHN/2011 major viral capsid protein (gene: VP1); Human papillomavirus type 6 E2 (gene: E2); Norovirus Hu/GII/BG1C0066/2011/BGD protein p48 (gene: POL); Human adenovirus 19 pIVa2 (gene: IVa2); Orf virus ORF035 virion core protease; Coxsackievirus B4 full_polyprotein 1..2183; Human adenovirus 66 100 kDa hexon assembly-associated protein (gene: L4); Echovirus E30 full_polyprotein 1..2194; Echovirus E25 3D; Ectromelia virus ERPV virion core protease; Human papillomavirus 142 regulatory protein (gene: E2); Human papillomavirus 155 E2; Norovirus Hu/GII.3/Jingzhou/2013402/CHN nonstructural protein; Norovirus Hu/GII.4/NIHIC18.1/2012/USA protein p48 (gene: POL); Norovirus Hu/GII.4/NIHIC27.1/2012/USA protein p48 (gene: POL); Norovirus Hu/GII.4/NIHIC27.2/2012/USA protein p48 (gene: POL); Norovirus Hu/GII/BG1C0241-33/2011/BGD protein p48 (gene: POL); Human adenovirus 56 IVa2 protein (gene: IVa2); Sapovirus Hu/GI/Sapporo/MT-2010/1982 VP1; Coxsackievirus B6 full_polyprotein 1..2184; Vaccinia virus Ankara viral core cysteine proteinase; Ectromelia virus ERPV RNA polymerase 30 subunit; Human papillomavirus 127 E2; Norovirus GII/Hu/JP/2010/GII.P7_GII.7/Musashimurayama/TAKAsanKimchi full_polyprotein 1..1697; Human papillomavirus 172 E2; Human papillomavirus 197 E2 (gene: E2); Norovirus Hu/GII.3/CBNU1/2006/KOR full_polyprotein 1..1699; Norovirus Hu/GII.4/NIHIC13/2011/USA protein p48 (gene: POL); Norovirus Hu/GII/BG1C0270/2011/BGD protein p48 (gene: POL); Norovirus Hu/GII/BG1C0317/2011/BGD protein p48 (gene: POL); Tai Forest ebolavirus nucleoprotein (gene: NP); Vaccinia virus Ankara Haemagglutinin; Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) hemagglutinin (gene: HA); Coxsackievirus B2 full_polyprotein 1..2187; Monkeypox virus Zaire-96-I-16 B11R (gene: B11R); Enterovirus B genome polyportein; Human enterovirus 79 3D; Human gammaherpesvirus 4 large tegument protein (gene: BPLF1); Human herpesvirus 4 type 2 BPLF1; Echovirus E27 3D; Enterovirus B111 3D; Hepatitis C virus genotype 4 NS3 protease/helicase; Norovirus Hu/GII/Seoul1055/KOR/2010 nonstructural protein; Human parechovirus 4 3D; Human parechovirus 6 3D; Enterovirus B73 full_polyprotein 1..2188; Yaba-like disease virus 35L protein (gene: 35L); Echovirus E29 3D; Norovirus Hu/GII-4/CGMH26/2010/TW full_polyprotein 1..1699; Norovirus Hu/GII.4/Berowra/NSW767L/2012/AU full_polyprotein 1..1699; Norovirus Hu/GII.4/GZ2010-L87/Guangzhou/CHN/2011 full_polyprotein 1..1699; Norovirus Hu/GII.4/NIHIC11.3/2013/USA protein p48 (gene: POL); Human parechovirus 2 full_polyprotein 1..2179; Norovirus Hu/Norwalk/10235/2009/VNM capsid protein VP1 (gene: VP1); Echovirus E16 3D; Human papillomavirus 113 E2 protein (gene: E2); Norovirus GII.17 AKB94549.1 full_polyprotein 1..1702 (gene: ORF1); Norovirus Hu/GI.2/Leuven/2003/BEL full_polyprotein 1..1788; Norovirus Hu/GII-4/CGMH23/2010/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH25/2010/TW full_polyprotein 1..1699; Human papillomavirus type 144 regulatory protein (gene: E2); Horsepox virus HSPV002 (chemokine binding protein; Provisional); Norovirus Hu/GII/10037/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10199/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10204/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/20008/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20066/2009/VNM capsid protein VP1 (gene: VP1); Ross River virus nsP4 protein; Enterovirus B106 full_polyprotein 1..2192; Human gammaherpesvirus 4 EBNA-2 nuclear protein (gene: BYRF1); Aichi virus 1 3D; Variola virus RNA polymerase subunit (gene: E4L); Coxsackievirus B5 polyprotein region 11 (gene: 1A); Echovirus E13 3D; Monkeypox virus chemokine-binding protein; Norovirus GII/Hu/JP/2012/GII.Pe_GII.4_Sydney2012/Fukuyama/1 full_polyprotein 1..1699; Norovirus GII/Hu/TW/2012/GII.Pe_GII.4_Sydney2012/Taipei/106 full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH24/2010/TW full_polyprotein 1..1699; Norovirus Hu/GII.4/Jiangsu1/2011/CHN full_polyprotein 1..1699; Norovirus Hu/GII.4/Jiangsu2/2012/CHN full_polyprotein 1..1699; Human papillomavirus type 156 early protein E2 (gene: E2); Norovirus Hu/GII.4/gg-12-08-04/2012/KR full_polyprotein 1..1699; Norovirus Hu/GII/10002/2009/VNM protein p48 (gene: POL); Norovirus Hu/GII/10003/2009/VNM protein p48 (gene: POL); Norovirus Hu/GII/20477/2010/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10062/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10114/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10129/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10137/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10145/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10158/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10160/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10162/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10169/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10173/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10176/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10176/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10179/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10182/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10194/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10222/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10235/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10285/2010/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10325/2010/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10368/2010/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10386/2010/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/20019/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/20069/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/20092/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/20093/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/20122/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/20135/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/20139/2009/VNM protein p48 (gene: POL); Human herpesvirus 4 type 2 EBNA-2; Echovirus E5 full_polyprotein 1..2196; Chiba virus full_polyprotein 1..1785 (gene: ORF1); Variola virus hypothetical protein (gene: K7L); Yaba-like disease virus 48L protein (gene: 48L); Echovirus E12 polymerase, polyprotein region 11; Monkeypox virus viral core cysteine proteinase; Monkeypox virus Cu-Zn superoxide dismutase-like protein; Monkeypox virus Zaire-96-I-16 A46R (gene: A46R); Monkeypox virus Zaire-96-I-16 I7L (gene: I7L); Monkeypox virus Zaire-96-I-16 chemokine binding protein (gene: J1L); Human papillomavirus E2 (gene: E2); Norovirus GII/Hu/HKG/2013/GII.4/CUHK-NS-141 ORF1; Norovirus GII/Hu/JP/2012/GII.Pe_GII.4_Sydney2012/Fukuyama/2 full_polyprotein 1..1699; Norovirus GII/Hu/JP/2012/GII.Pe_GII.4_Sydney2012/Fukuyama/3 full_polyprotein 1..1699; Norovirus GII/Hu/JP/2012/GII.Pe_GII.4_Sydney2012/Fukuyama/5 full_polyprotein 1..1699; Norovirus GII/Hu/TW/2012/GII.Pe_GII.4_Sydney2012/Taipei/105 full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH06/2006/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH20/2009/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH21/2010/TW full_polyprotein 1..1699; Norovirus Hu/GII.4/Doonside/NSW536I/2011/AU full_polyprotein 1..1699; Norovirus Hu/GII.4/Hong Kong/CUHK6080/2012/CHN full_polyprotein 1..1699; Norovirus Hu/GII.4/NIHIC17.1/2012/USA protein p48 (gene: POL); Human papillomavirus type 166 E2 (gene: E2); Norovirus Hu/GII.4/NIHIC35/2013/USA protein p48 (gene: POL); Norovirus Hu/Norwalk/10116/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10148/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10163/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/20044/2009/VNM protein p48 (gene: POL); Salivirus A full_polyprotein 1..2370; Human alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Yaba monkey tumor virus 48L; Human papillomavirus 109 E2 protein (gene: E2); New Jersey polyomavirus-2013 large T antigen; Norovirus GII/Hu/JP/2007/GII.P7_GII.14/Fukuoka/KK282 full_polyprotein 1..1697; Norovirus GII/Hu/JP/2010/GII.P4_GII.4/Shimada/ASC96 full_polyprotein 1..1699; Norovirus Hu/GI.6/Kingston/ACT160D/2010/AU full_polyprotein 1..1788; Human papillomavirus 19 early protein (gene: E2); Norovirus Hu/GII.12/HS206/2010/USA full_polyprotein 1..1701; Norovirus Hu/GII.12/HS210/2010/USA full_polyprotein 1..1701; Human papillomavirus type 115 early protein E2 (gene: E2); Norovirus Hu/GII.4/Caringbah/NSW409G/2011/AU full_polyprotein 1..1699; Norovirus Hu/GII.4/Hong Kong/CUHK3630/2012/CHN full_polyprotein 1..1699; Norovirus Hu/GII.4/Jannali/NSW774M/2011/AU full_polyprotein 1..1699; Norovirus Hu/GII.4/Ohio/7I/2012/USA full_polyprotein 1..1699; Norovirus Hu/GII/BG1C0282/2011/BGD protein p48 (gene: POL); Norovirus Hu/Norwalk/10074/2009/VNM protein p48 (gene: POL); Human adenovirus 28 E3 44.5K-like protein (gene: E3); Norovirus Hu/Norwalk/10296/2010/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/20008/2009/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/20094/2009/VNM capsid protein VP1 (gene: VP1); Norovirus GII/Hu/JP/2007/GII.P21_GII.21/Kawasaki/YO284 full_polyprotein 1..1699; Norovirus GII/Hu/JP/2007/GII.P7_GII.14/Sendai/YG99 full_polyprotein 1..1697; Norovirus GII/Hu/JP/2011/GII/Yuzawa/Gira2HS full_polyprotein 1..1693; Norovirus Hu/GII-4/CGMH27/2010/TW full_polyprotein 1..1699; Norovirus Hu/GII.4/CHDC2094/1974/US full_polyprotein 1..1699; Hepatovirus A hypothetical protein; Norovirus Hu/GII.4/Randwick/NSW882J/2011/AU full_polyprotein 1..1699; Norovirus Hu/Norwalk/10137/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10223/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20044/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Shanghai/SH5/2009/CHN full_polyprotein 1..1699; Human alphaherpesvirus 1 envelope glycoprotein I (gene: US7); Echovirus E9 full_polyprotein 1..2203; Human adenovirus 7 100K; Human adenovirus 41 E3 31.6K; Human T-lymphotropic virus 3 polymerase (gene: pol); Influenza A virus (A/Korea/426/1968(H2N2)) PB1-F2 protein (gene: PB1-F2); Vaccinia virus Ankara intermediate gene transcription factor VITF-1; Influenza A virus (A/Shanghai/02/2013(H7N9)) PB1-F2 protein (gene: PB1-F2); Human calicivirus Hu/NLV/GII/MD145-12/1987/US full_polyprotein 1..1699; Norovirus GII/Hu/JP/2002/GII.P12_GII.13/Saitama/T80 full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH11/2006/TW full_polyprotein 1..1699; Norovirus Hu/GII.14/8610/Saga/2008/JPN full_polyprotein 1..1697; Norovirus Hu/GII.4/CHDC3967/1988/US full_polyprotein 1..1699; Norovirus Hu/GII.4/CHDC4871/1977/US full_polyprotein 1..1699; Human papillomavirus type 147 regulatory protein (gene: E2); Norovirus Hu/GII.4/Ohio/684/USA full_polyprotein 1..1699; Norovirus Hu/GII.4/Rockdale/NSW006D/2009/AU full_polyprotein 1..1699; Norovirus Hu/Norwalk/10313/2010/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10378/2010/VNM protein p48 (gene: POL); Snow Mountain virus full_polyprotein 1..1699 (gene: ORF1); Monkeypox virus cowpox A-type inclusion protein; Vaccinia virus viral core cysteine proteinase (gene: I7L); Human betaherpesvirus 6 U12, GCR (gene: U12); Variola virus chemokine binding protein (gene: G5R); Lordsdale virus full_polyprotein 1..1699 (gene: orf1); Human papillomavirus 123 regulatory protein E2 (gene: E2); Norovirus GII/Hu/TW/2012/GII.Pe_GII.4_Sydney2012/Taipei/108 full_polyprotein 1..1699; Norovirus GII/Hu/TW/2012/GII.Pe_GII.4_Sydney2012/Taipei/109 full_polyprotein 1..1699; Norovirus Hu/GII.4/CHDC4108/1987/US full_polyprotein 1..1699; Norovirus Hu/GII.6/GZ2010-L96/Guangzhou/CHN/2011 full_polyprotein 1..1697; Norovirus Hu/GII/10012/2009/VNM protein p48 (gene: POL); Norovirus Hu/GII/20469/2010/VNM protein p48 (gene: POL); Norovirus Hu/GII/Seoul1072/KOR/2010 nonstructural protein; Norovirus Hu/Norwalk/10162/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10173/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20016/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20035/2009/VNM capsid protein VP1 (gene: VP1); Merkel cell polyomavirus large T antigen; Human papillomavirus 107 E2 protein (gene: E2); Norovirus GII/Hu/JP/2001/GII.P22_GII.5/Saitama/T49 VP1 (gene: VP1); Norovirus GII/Hu/JP/2002/GII.P16_GII.17/Saitama/T87 full_polyprotein 1..1698; Norovirus Hu/GII-4/CBNU2/2007/KR full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH08/2006/TW full_polyprotein 1..1699; Norovirus Hu/GII.4/GZ2010-L26/Guangzhou/CHN/2010 full_polyprotein 1..1699; Norovirus Hu/GII.4/Guangzhou/GZ2010-L91/CHN/2011 full_polyprotein 1..1699; Norovirus Hu/GII.4/HS191/2004/USA full_polyprotein 1..1699; Norovirus Hu/GII.4/JB-15/KOR/2008 full_polyprotein 1..1699; Norovirus Hu/GII.4/Jingzhou/2013403/CHN nonstructural protein; Norovirus Hu/GII.4/MD-2004/2004/US full_polyprotein 1..1699; Norovirus Hu/GII.4/Miranda/NSW850K/2011/AU full_polyprotein 1..1699; Norovirus Hu/GII.4/NIHIC17.9/2013/USA protein p48 (gene: POL); Norovirus Hu/GII.4/New Orleans/2010/USA full_polyprotein 1..1699; Norovirus Hu/GII.4/Randwick/NSW938K/2011/AU full_polyprotein 1..1699; Norovirus Hu/GII.4/Sydney/NSW0514/2012/AU full_polyprotein 1..1699; Norovirus Hu/GII.g-GII.12/Wahroonga/NSW004P/2009/AU full_polyprotein 1..1701; Norovirus Hu/GII/Seoul1367/KOR/2010 nonstructural protein; Norovirus Hu/GIV.1/CCDC GR1113-59/CHN/2011 full_polyprotein 1..1687; Norovirus Hu/Norwalk/10328/2010/VNM protein p48 (gene: POL); Human adenovirus D8 pIVa2 protein (gene: pIVa2); Human adenovirus 23 CR1 b protein (gene: E3); Papiine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Yaba monkey tumor virus RNA polymerase subunit; Norovirus GII/Hu/JP/2001/GII.P22_GII.5/Saitama/T49 full_polyprotein 1..1711; Norovirus Hu/GII-4/CGMH02/2006/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH04/2006/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH07/2006/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH10/2006/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH12/2007/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH13/2007/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH14/2007/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH17/2007/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH19/2009/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CUK-3/2008/KR full_polyprotein 1..1699; Norovirus Hu/GII.12/CGMH38/2010/TW ORF1; Norovirus Hu/GII.12/CGMH40/2010/TW ORF1; Norovirus Hu/GII.12/CGMH41/2010/TW ORF1; Norovirus Hu/GII.12/CGMH42/2010/TW ORF1; Horsepox virus HSPV077 (Vaccinia virus I7 processing peptidase); Norovirus Hu/GII/Seoul1488/KOR/2011 nonstructural protein; Norovirus Hu/GII/Shanghai/SH2/2008/CHN full_polyprotein 1..1699; Norovirus Hu/GIV.1/LakeMacquarie/NSW268O/2010/AU full_polyprotein 1..1687; Human papillomavirus type 82 E2; Human immunodeficiency virus 1 Pol (gene: gag-pol); Human alphaherpesvirus 2 envelope glycoprotein E (gene: US8); Yaba monkey tumor virus DNA polymerase; Molluscum contagiosum virus subtype 1 MC039L (gene: MC039L); Human immunodeficiency virus 2 vpr protein; Echovirus E31 3D; HBV genotype H PC/C protein (gene: PC/C); Norovirus Hu/GII-4/CGMH15/2007/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH16/2007/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH18/2008/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH28/2010/TW full_polyprotein 1..1699; Norovirus Hu/GII.12/CGMH39/2010/TW ORF1; Human papillomavirus type 25 early protein (gene: E2); Norovirus Hu/GII.4/SGU-110421/KOR/2011 full_polyprotein 1..1699; Human papillomavirus type 63 hypothetical protein; Norovirus Hu/GII/Seoul1282/KOR/2010 nonstructural protein; Human parechovirus 3 full_polyprotein 1..2177; Salivirus FHB full_polyprotein 1..2365; Vaccinia virus hemagglutinin (gene: A56R); Horsepox virus HSPV189 (Serine/threonine protein kinase); Monkeypox virus DNA polymerase; Norovirus GII/Hu/JP/2001/GII.P12_GII.12/Saitama/T15 full_polyprotein 1..1699; Norovirus GII/Hu/JP/2001/GII.P12_GII.12/Saitama/T18 full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH03/2006/TW full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH05/2006/TW full_polyprotein 1..1699; Human papillomavirus 99 E2 protein (gene: E2); Human papillomavirus type 118 E2; Norovirus Hu/GII.4/NIHIC1.13/2012/USA protein p48 (gene: POL); Norovirus Hu/GII.4/NIHIC1.16/2012/USA protein p48 (gene: POL); Norovirus Hu/GII.4/Seoul/1071/2010/KOR full_polyprotein 1..1699; Human papillomavirus type 6b regulatory protein E2 (gene: E2); Human papillomavirus 105 E2 protein (gene: E2); Ectromelia virus ERPV DNA polymerase; Norovirus GII/Hu/JP/2002/GII.P5_GII.5/Saitama/T52 VP1 (gene: VP1); Norovirus GII/Hu/JP/2002/GII.P5_GII.5/Saitama/T52 full_polyprotein 1..1697; Human papillomavirus 17 early protein (gene: E2); HBV genotype B preC/C protein (gene: preC/C); HBV genotype C core protein (gene: C); Norovirus Hu/GII-4/CGMH09/2006/TW full_polyprotein 1..1699; Norovirus Hu/GII.4/Guangzhou/GZ2010-L88/CHN/2011 full_polyprotein 1..1699; Human papillomavirus type 14D early protein (gene: E2); Norovirus Hu/GII.g-GII.12/Gunnedah/NSW895P/2010/AU full_polyprotein 1..1701; Human polyomavirus 7 large T antigen; Vaccinia virus chemokine binding protein (gene: C23L); Vaccinia virus Ankara viral chemokine binding protein; Human calicivirus NLV/GII/Langen1061/2002/DE full_polyprotein 1..1699; Norovirus GI/Hu/JP/2007/GI.P8_GI.8/Nagoya/KY531 full_polyprotein 1..1799; Norovirus GII/Hu/JP/2000/GII.P12_GII.12/Saitama/KU16 full_polyprotein 1..1699; Norovirus Hu/GII-4/CGMH01/2006/TW full_polyprotein 1..1699; HBV genotype C HBeAg (gene: PreC/C); Norovirus Hu/GII-4/CGMH22/2010/TW full_polyprotein 1..1699; Human papillomavirus type 13 E2 (gene: E2); Human adenovirus 21a maturation protein IVa2 (gene: IVa2); Norovirus Hu/Shanghai/SH312/2009/CHN full_polyprotein 1..1698; Human papillomavirus type 10 envelope protein (gene: E2); Yaba-like disease virus 39L protein (gene: 39L); Human papillomavirus 167 E2 (gene: E2); HBV recombinant C/G HBeAg (gene: preC/C); Norovirus Hu/GII.4/5M/USA/2004 full_polyprotein 1..1699; Norovirus Hu/GII.4/Woonona/NSW3309/2012/AU full_polyprotein 1..1699; Human papillomavirus type 87 putative E2 protein (gene: e2); Monkeypox virus Zaire-96-I-16 DNA polymerase (gene: F8L); Human papillomavirus 111 E2 protein (gene: E2); Human papillomavirus 173 E2; Hepatitis B virus capsid protein (gene: C); Crimean-Congo hemorrhagic fever virus full_polyprotein 1..3945 (gene: RdRp); Molluscum contagiosum virus subtype 1 MC162R (gene: MC162R); Cercopithecine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); HBV recombinant B/C HBc protein (gene: C); Human papillomavirus KC5 E2 (gene: E2); Human papillomavirus type 69 E2; Human immunodeficiency virus 2 full_polyprotein 1..1550 (gene: gag-pol); Vaccinia virus DNA polymerase (gene: E9L); Human papillomavirus 110 E2 protein (gene: E2); HBV genotype C preC/C protein (gene: preC/C); Human papillomavirus type 12 early protein (gene: E2); Horsepox virus HSPV066 (DNA polymerase; Provisional); Human adenovirus 68 100 kDa hexon assembly-associated protein (gene: L4); Molluscum contagiosum virus subtype 1 MC049L (gene: MC049L); Norwalk-like virus full_polyprotein 1..1697; Alkhumra hemorrhagic fever virus non-structural protein NS3; Human papillomavirus type 49 E2 protein (gene: E2); Human betaherpesvirus 5 large tegument protein (gene: UL48); Human gammaherpesvirus 8 vIRF-4 (gene: vIRF-4); Reston ebolavirus - Reston virion spike glycoprotein precursor (gene: GP); Variola virus hypothetical protein (gene: J7R); Human enterovirus 71 HZ08/Hangzhou/2008 full_polyprotein 1..2193; Human papillomavirus 100 E2 protein (gene: E2); HBV genotype C HBc protein (gene: C); Human papillomavirus type XS2 E2 (gene: E2); Human rhinovirus A12 full_polyprotein 1..2155; Human betaherpesvirus 6 U12exon1-2, GCR (gene: U12exon1-2); Vaccinia virus Ankara DNA polymerase; Variola virus DNA polymerase (gene: E9L); Human papillomavirus 152 early protein E2 (gene: E2); Human parechovirus 5 full_polyprotein 1..2185; Cowpox virus CPXV075 protein (gene: CPXV075 CDS); Molluscum contagiosum virus subtype 1 MC161R (gene: MC161R); Human papillomavirus 4 hypothetical protein; Human T-cell leukemia virus type I Pr gag-pro (gene: gag-pro); Cercopithecine betaherpesvirus 5 membrane protein RL11M (gene: RL11M); Orf virus ORF130 putative serine/threonine protein kinase; Norovirus GI/Hu/JP/2007/GI.P3_GI.3/Shimizu/KK2866 full_polyprotein 1..1799; Cercopithecine betaherpesvirus 5 chemokine vCXCL5 (gene: UL146B); Kyasanur Forest disease virus NS3; Human papillomavirus type 45 early protein (gene: E2); Human papillomavirus type 84 putative regulatory protein E2 (gene: E2); Human rhinovirus A39 full_polyprotein 1..2157; Human herpesvirus 3 strain Dumas envelope glycoprotein gC; HBV genotype B C protein (gene: C); Human alphaherpesvirus 3 envelope glycoprotein C (gene: ORF14); Human alphaherpesvirus 1 envelope glycoprotein C (gene: UL44); Cosavirus JMY-2014 full_polyprotein 1..2119; Hepatitis C virus subtype 4a full_polyprotein 1..3008 (gene: HCV G4); Human betaherpesvirus 5 membrane glycoprotein UL18 (gene: UL18); Horsepox virus HSPV177 (Immunoglobulin like); HBV genotype C C protein (gene: C); Human rhinovirus A11 full_polyprotein 1..2153; Molluscum contagiosum virus subtype 1 MC017L (gene: MC017L); Vaccinia virus ser/thr protein kinase-like protein (gene: B12R); Human T-cell leukemia virus type I p15NC-p14PR-p95RT/IN (gene: gag-pro-pol); Human T-cell leukemia virus type I Pr gag-pro-pol (gene: gag-pro-pol); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human papillomavirus type 34 early protein (gene: E7); Rosavirus A2 full_polyprotein 1..2468; Hepatitis C virus subtype 4L full_polyprotein 1..3010; Human papillomavirus 15 early protein (gene: E2); Human papillomavirus type 78 regulatory protein E2 (gene: E2); Horsepox virus HSPV020e (ankyrin repeats); Cowpox virus CPXV206 protein (gene: CPXV206 CDS); Ectromelia virus ERPV RNA helicase; Human papillomavirus 3 envelope protein (gene: E2); Human adenovirus 64 E3 48.9 kDa protein; Human betacoronavirus 2c Jordan-N3/2012 ORF1ab protein (gene: ORF1ab); Cowpox virus CPXV194 protein (gene: CPXV194 CDS); Betacoronavirus England 1 ORF1b protein (gene: orf1ab); Human betacoronavirus 2c England-Qatar/2012 ORF1ab; Vaccinia virus Ankara serine/threonine-protein kinase-like; Hepatitis C virus subtype 1g full_polyprotein 1..3015; Human papillomavirus type 119 regulatory protein E2 (gene: E2); Coxsackievirus A5 full_polyprotein 1..2191; Human papillomavirus type 67 E2; Cercopithecine betaherpesvirus 5 membrane protein RL11Q (gene: RL11Q); Karshi virus (Royal Farm virus) full_polyprotein 1..3416; Human papillomavirus 125 putative E2 protein (gene: E2); Enterovirus C99 full_polyprotein 1..2210; Human papillomavirus type 62 putative regulatory protein E2 (gene: E2); Human papillomavirus type 86 putative regulatory protein E2 (gene: E2); Vaccinia virus Ankara soluble and cell surface interferon-alpha/beta receptor; Ectromelia virus ERPV IL-1 beta receptor; HMO Astrovirus A non-structural protein; Human adenovirus 46 423R; Human adenovirus 71 E3 CR1-beta (gene: E3); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Human papillomavirus type 112 E2 protein (gene: E2); Human enteric coronavirus strain 4408 full_polyprotein 1..4383; Human enterovirus Ningbo3-02 full_polyprotein 1..2214; Human adenovirus 43 CR1-beta protein (gene: E3); Variola virus hypothetical protein (gene: J9R); Human enterovirus Hangzhou13-02 full_polyprotein 1..2214; Human adenovirus 22 50.0 kDa protein (gene: E3); Human rhinovirus B93 full_polyprotein 1..2178; Vaccinia virus IFN-alpha/beta-receptor-like secreted glycoprotein (gene: B19R); Human papillomavirus type 34 early protein (gene: E2); Human T-lymphotropic virus 4 polymerase (gene: pol); Human adenovirus 16 100 kDa hexon assembly-associated protein (gene: L4); Variola virus hypothetical protein (gene: B20R); Horsepox virus HSPV195 (immunoglobulin like protein); Human papillomavirus type 57 E2; Horsepox virus HSPV011a; Human papillomavirus type 52 early protein (gene: E2); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Human betaherpesvirus 5 membrane glycoprotein UL11 (gene: UL11); Monkeypox virus double-stranded RNA binding protein; Monkeypox virus Zaire-96-I-16 double-strand RNA-binding protein (gene: F3L); Human alphaherpesvirus 1 large tegument protein (gene: UL36); Papiine alphaherpesvirus 2 tegument protein VP22 (gene: UL49); Human rhinovirus B17 full_polyprotein 1..2186; Human rhinovirus B37 full_polyprotein 1..2178; Human group 1 coronavirus associated with pneumonia ORF 1ab; Human foamy virus pol; Human papillomavirus type 27 early protein (gene: E2); Human papillomavirus 94 E2 protein (gene: E2); Human papillomavirus type 27b E2 protein (gene: E2); Sosuga virus phosphoprotein; Human gammaherpesvirus 4 probable membrane glycoprotein (gene: BILF2); Human herpesvirus 4 type 2 BILF2; Murray Valley encephalitis virus prodexcised_polyprotein 1..793; Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 2 large tegument protein (gene: UL36); Human immunodeficiency virus 1 integrase (gene: gag-pol); Cowpox virus CPXV212 protein (gene: CPXV212 CDS); Coxsackievirus A20 full_polyprotein 1..2208; Human papillomavirus type 106 E2 protein; Human poliovirus 3 polyprotein; West Nile virus lineage 2 excised_polyprotein 1..791 (gene: flavivirus polyprotein); Human papillomavirus type 53 early protein (gene: E2); Human poliovirus 1 enterovirus precursor polypeptide; Molluscum contagiosum virus subtype 1 MC080R (gene: MC080R); Human coronavirus 229E full_polyprotein 1..6758; Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Banna virus strain JKT-6423 vp12; Human immunodeficiency virus 2 full_polyprotein 1..521 (gene: gag-pol); Human adenovirus 54 44.5 kDa protein; Human papillomavirus type 43 E2 protein (gene: E2); Papiine alphaherpesvirus 2 large tegument protein (gene: UL36); Horsepox virus HSPV011c (ankyrin repeats); Molluscum contagiosum virus subtype 1 MC034L (gene: MC034L); Human papillomavirus type 102 E2 protein; Human papillomavirus type 30 early protein (gene: E2); Human papillomavirus type 40 early protein (gene: E2); Orf virus ORF123 ankyrin repeat protein; Human immunodeficiency virus pol protein (gene: pol); West Nile virus lineage 2 excised_polyprotein 1..2273 (gene: flavivirus polyprotein); Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Yaba monkey tumor virus 142R; Monkeypox virus ankyrin-like protein; Human papillomavirus type 7 early protein (gene: E2); Alphapapillomavirus 4 early protein E2 (gene: E2); Human papillomavirus type 2 E2 protein (gene: E2); Human adenovirus 63 CR1 beta protein (gene: E3); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Macaque simian foamy virus Pol (gene: pol); Vaccinia virus Ankara CP77 host range protein f2; Human papillomavirus type 32 early protein (gene: E2); African green monkey simian foamy virus Pol precursor (gene: pol); Ectromelia virus ERPV serine/threonine kinase; Human coronavirus NL63 full_polyprotein 1..6729; Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Simian foamy virus full_polyprotein 1..1146 (gene: pol); Vaccinia virus Ankara 54.4k ankyrin repeat protein f2; Monkeypox virus bifunctional hemagglutinin/type-I membrane glycoprotein; Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta); Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Molluscum contagiosum virus subtype 1 MC033L (gene: MC033L); Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Horsepox virus HSPV033c (ankyrin repeats); Vaccinia virus ankyrin-like protein; Vaccinia virus ankyrin-like protein (gene: C9L); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human adenovirus 58 CR1-beta (gene: E3); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Vaccinia virus Ankara CP77 host range protein f4; Human adenovirus 65 E3 CR1-b; Human adenovirus 56 CR1 beta protein (gene: E3); Human mastadenovirus D membrane glycoprotein E3 CR1-beta (gene: E3); Human adenovirus D10 CR1-beta protein (gene: E3); Ectromelia virus ERPV ankyrin; Orf virus ORF008 ankyrin repeat protein; Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D7L); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Macacine alphaherpesvirus 1 envelope glycoprotein C (gene: UL44); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human adenovirus D37 48.9 kDa (gene: E3); Human adenovirus 19 CR1-beta (gene: E3); Horsepox virus HSPV005b (ankyrin repeats); Monkeypox virus ser/thr kinase; Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human herpesvirus 3 strain Dumas ring-finger protein; Human alphaherpesvirus 3 ubiquitin E3 ligase ICP0 (gene: ORF61); Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Horsepox virus HSPV033b (Ankyrin repeats); Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Horsepox virus HSPV201a (ankyrin repeats); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Variola virus Ser/Thr kinase (gene: C14L); Vaccinia virus Ser/Thr kinase (gene: F10L); Variola virus hypothetical protein (gene: B6R); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Human gammaherpesvirus 8 ORF36 (gene: ORF36); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3)",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6386053036162835; 0.6386053036162835; 0.6386053036162835; 0.6386053036162835; 0.6386053036162835; 0.6386053036162835; 0.6386053036162835; 0.6430308263654244; 0.6430308263654244; 0.6430308263654244; 0.6430308263654244; 0.6433049303988263; 0.6462089477181691; 0.6462089477181691; 0.6462089477181691; 0.6462089477181691; 0.6462089477181691; 0.6481498905276316; 0.6481498905276316; 0.6481498905276316; 0.6481498905276316; 0.6481498905276316; 0.6481498905276316; 0.6520551900793279; 0.6532977594572624; 0.6532977594572624; 0.6594490140339321; 0.6594490140339321; 0.6621265548536891; 0.6621265548536891; 0.6621265548536891; 0.6624448726460891; 0.664689610422691; 0.664689610422691; 0.664689610422691; 0.664689610422691; 0.664689610422691; 0.6682550899136019; 0.6682550899136019; 0.6682550899136019; 0.6682550899136019; 0.6682550899136019; 0.6728266299593284; 0.6728266299593284; 0.6728266299593284; 0.6728266299593284; 0.6743504588964037; 0.6761714078632568; 0.6761714078632568; 0.6799694572854597; 0.6799694572854597; 0.6799694572854597; 0.6799694572854597; 0.6799694572854597; 0.6831027653312531; 0.6831027653312531; 0.6831027653312531; 0.6859529108680942; 0.6878183273734424; 0.6878183273734424; 0.6906952981256558; 0.691145768348025; 0.691145768348025; 0.691145768348025; 0.691145768348025; 0.6920622798772148; 0.6920622798772148; 0.6949711755793786; 0.6980058392556946; 0.6980058392556946; 0.6980058392556946; 0.7054555693277184; 0.7079503198328393; 0.7079503198328393; 0.7079503198328393; 0.7108466056279036; 0.7148278327249904; 0.7148278327249904; 0.7184028158722842; 0.7187273231330169; 0.7212352368560536; 0.7225463502962445; 0.7245718814666527; 0.7245718814666527; 0.7245718814666527; 0.7245718814666527; 0.7286961934616806; 0.7286961934616806; 0.7286961934616806; 0.7370426174990137; 0.7370426174990137; 0.7370426174990137; 0.7398997088314572; 0.7398997088314572; 0.7477109270664255; 0.7515144230790771; 0.7515144230790771; 0.7552510882381985; 0.7552510882381985; 0.7553529087917877; 0.7583344395075817; 0.7613499358173942; 0.7613499358173942; 0.7613499358173942; 0.7651942752688915; 0.7665923583742081; 0.7665923583742081; 0.7699998247318175; 0.7699998247318175; 0.7727543507468141; 0.7727543507468141; 0.7727543507468141; 0.7748546750678369; 0.7748546750678369; 0.7748546750678369; 0.776311155917498; 0.776311155917498; 0.776311155917498; 0.7819694067618216; 0.7819694067618216; 0.7819694067618216; 0.7819694067618216; 0.7879984651860477; 0.7879984651860477; 0.7879984651860477; 0.7915261921959659; 0.7944042063194328; 0.7944042063194328; 0.7954342107380572; 0.7954342107380572; 0.7954342107380572; 0.7975886343350181; 0.7975886343350181; 0.7975886343350181; 0.7975886343350181; 0.7988086321880973; 0.7988086321880973; 0.7988086321880973; 0.7988086321880973; 0.7988086321880973; 0.7988086321880973; 0.8031136315766868; 0.8031136315766868; 0.8058787113556399; 0.8071041616616108; 0.8083353323877179; 0.8090912655264054; 0.8090912655264054; 0.810147696255034; 0.8131061824896436; 0.8154217170310376; 0.8220964101663402; 0.824834816218218; 0.830387084488226; 0.8320620882218038; 0.8341674444487674; 0.8367025532839523; 0.8373747313517419; 0.8390943852085586; 0.8400145987535752; 0.8400145987535752; 0.8400145987535752; 0.8412554142619568; 0.8426793553344071; 0.8458935424065495; 0.8458935424065495; 0.8458935424065495; 0.8458935424065495; 0.8458935424065495; 0.8476709215603375; 0.8509394234802752; 0.852310831936348; 0.8537876803011069; 0.8567113603862105; 0.8572480058211756; 0.8623814598290633; 0.8656146801545769; 0.8665950357166999; 0.870986154363754; 0.875442055263636; 0.876049415394169; 0.8796869384071039; 0.8826243651582266; 0.8826243651582266; 0.8912506515619287; 0.8962695058306248; 0.9049668877841942; 0.9070151307654608; 0.9097056179628632; 0.9135411983375344; 0.9161525496917488; 0.9195586782304176; 0.9195586782304176; 0.9195586782304176; 0.9199249371723298; 0.9285312497152513; 0.9317407101292444; 0.9320456693098416; 0.93590945176733; 0.93590945176733; 0.9445347004229157; 0.9445347004229157; 0.945966103627342; 0.960637237597315; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9621839893030432; 0.9624639844306644; 0.9624639844306644; 0.9658028592930472; 0.9687365967836944; 0.970789305792858; 0.9782376397065295; 0.9782376397065295; 0.978680518510813; 0.985687915361386; 0.9867877113290736; 0.988150003801932; 0.9886132556795868; 0.9886132556795868,yeasx,0.56,Homo sapiens,Homo sapiens
TRIM6,,,Leukemia,0.7167438233451096,,,Human alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Papiine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44),0.6362779693488597; 0.6362779693488597,yeasx,0.37,Homo sapiens,coxbu
TSC22D1,"Mammary Neoplasms; Carcinogenesis; Carcinoma, Spindle-Cell; Malignant neoplasm of prostate; Carcinoma; Well Differentiated Oligodendroglioma; Carcinomatosis; Brain Neoplasms; oligodendroglioma; Lymphoma; Liver Cirrhosis, Experimental; Prostate carcinoma; Anaplastic carcinoma; Undifferentiated carcinoma; Mammary Carcinoma, Animal; Animal Mammary Neoplasms; Solid Neoplasm; cervical cancer; Malignant tumor of cervix; Cervix carcinoma; Mammary Neoplasms, Experimental; Leukemogenesis; Anaplastic astrocytoma; Diabetes Mellitus, Non-Insulin-Dependent; Leukemia, Myelocytic, Acute; Leukemia, Natural Killer Cell Large Granular Lymphocytic; Astrocytoma; Chronic Lymphoproliferative Disorder of NK-Cells; Cachexia; Glioblastoma Multiforme; Diabetic Nephropathy; Liver Neoplasms, Experimental; Experimental Hepatoma; Hepatoma, Novikoff; Hepatoma, Morris; Malignant neoplasm of salivary gland; leukemia; Breast cancer recurrent; Neoplastic Cell Transformation; Leukemia, Large Granular Lymphocytic",0.0034602840073026; 0.0228075668512991; 0.0308703957553632; 0.0569142010728473; 0.0593779966354549; 0.0617471306652618; 0.0617471306652618; 0.064548079316548; 0.0648809611869375; 0.0739788831250619; 0.0747863377072194; 0.0773771948186562; 0.084286432100041; 0.13167400689206; 0.1352936728187231; 0.1352936728187231; 0.1413782599148022; 0.2050045461627939; 0.2714542429024338; 0.2834835531038365; 0.3508665345292502; 0.3510063969122338; 0.3763374964032415; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3933196962529684; 0.3938591532700354; 0.4100742336915555; 0.4100742336915555; 0.4115056600660309; 0.4115056600660309; 0.4213286052188015; 0.4588513406515081; 0.4753011022966241; 0.5696906826730043; 0.6150955455771212,Anaplastic Carcinoma; Carcinoma,0.0402286636010764; 0.0534520155998091,Familial multiple nevi flammei ORPHA:624; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Sturge-Weber syndrome ORPHA:3205; Familial primary hypomagnesemia with normocalciuria and normocalcemia ORPHA:34527; Beckwith-Wiedemann syndrome due to CDKN1C mutation ORPHA:231120; Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome ORPHA:436144; Cystic fibrosis ORPHA:586,0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.6239678957896782; 0.6239678957896782; 0.6279395134845649,,,Homo sapiens HEK293 embryonic kidney cell;Homo sapiens HEK293flp-in T-REX embryonic kidney cell;In vitro;Saccharomyces cerevisiae;yeasx,0.4;0.46;0.55,Homo sapiens,Homo sapiens
UQCC1,"Malignant neoplasm of breast; Degenerative polyarthritis; Testicular Germ Cell Tumor; Physical Activity Measurement; Ubiquinone dehydrogenase deficiency; Hip Dislocation, Congenital; Protein C antigen measurement; Protein C measurement; Body Height",0.0191435238361999; 0.0739788831250619; 0.1735868515093891; 0.3986414839122469; 0.4028066164685291; 0.4564472886428772; 0.5916904943304121; 0.5916904943304121; 0.5936773368594411,Breast Cancer; Arthritis; Knee Osteoarthritis; Osteoarthritis Of Hip,0.0402286636010764; 0.4541466895915311; 0.5681293104170607; 0.657896505422784,,,,,Homo sapiens HEK293T embryonic kidney cell;Homo sapiens HEK293flp-in embryonic kidney cell,0.27;0.35,Human SARS coronavirus;cioin,Homo sapiens
VGLL3,Ovarian Carcinoma; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Epithelial ovarian cancer; Malignant neoplasm of prostate; Prostate carcinoma; Sarcoma; Myxoinflammatory fibroblastic sarcoma,0.0034602840073026; 0.0042545616049287; 0.0228075668512991; 0.0277695594716545; 0.0387439397151409; 0.0569142010728473; 0.0773771948186562; 0.1537760235124317; 0.3933196962529684,Breast Carcinoma,0.0075861267486594,"Congenital short bowel syndrome ORPHA:2301; Posterior urethral valve ORPHA:93110; Acromesomelic dysplasia, Hunter-Thompson type ORPHA:968; Angel-shaped phalango-epiphyseal dysplasia ORPHA:63442; Hereditary mixed polyposis syndrome ORPHA:157794; BVES-related limb-girdle muscular dystrophy ORPHA:476084; Familial isolated trichomegaly ORPHA:411788; Proximal symphalangism ORPHA:3250; ANGPT1-related hereditary angioedema with normal C1Inh ORPHA:537891; Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency ORPHA:300179; 17q23.1q23.2 microdeletion syndrome ORPHA:261279; 6q16 microdeletion syndrome ORPHA:171829; Coxopodopatellar syndrome ORPHA:1509; Familial clubfoot due to 17q23.1q23.2 microduplication ORPHA:238578; Hypomyelination-congenital cataract syndrome ORPHA:85163; Obesity due to SIM1 deficiency ORPHA:369873; SIM1-related Prader-Willi-like syndrome ORPHA:398079; Brittle cornea syndrome ORPHA:90354",0.0083045131203191; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens HEK293T embryonic kidney cell;yeasx,0.56;0.6,Homo sapiens,Homo sapiens
WNT16,Mammary Neoplasms; Colorectal Cancer; Osteoporosis; Malignant neoplasm of urinary bladder; Bladder Neoplasm; Chronic Lymphocytic Leukemia; Carcinoma of bladder; Fibroid Tumor; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemogenesis; Uterine Fibroids; Coronary heart disease; leukemia; Cardiovascular Diseases; Vitelliform Macular Dystrophy; Coffin-Siris syndrome; Becker Muscular Dystrophy; Precursor B-cell lymphoblastic leukemia; Bone Density,0.0034602840073026; 0.0149315928814189; 0.0739788831250619; 0.084286432100041; 0.0891725280554336; 0.1147307578771389; 0.13167400689206; 0.290158730291654; 0.3105909001629992; 0.3510063969122338; 0.383941725017158; 0.3933196962529684; 0.4588513406515081; 0.4675904598629673; 0.5140447474168605; 0.5188223685230745; 0.5393787854381349; 0.5451009374855866; 0.7631684472516962,Colorectal Cancer; Rheumatoid Arthritis,0.4286813331685578; 0.4560460337187313,,,,,,,,
WNT9A,Mammary Neoplasms; Lymphoid leukemia; Adenomatous Polyposis Coli,0.0034602840073026; 0.3933196962529684; 0.4749780675672355,,,SIX2-related frontonasal dysplasia ORPHA:488437; Cataract-glaucoma syndrome ORPHA:162; Idiopathic juvenile osteoporosis ORPHA:85193; 22q11.2 duplication syndrome ORPHA:1727,0.00518481975049; 0.1590470395003315; 0.1590470395003315; 0.6239678957896782,,,,,,
ZBED2,,,,,"Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944; Autosomal recessive hypohidrotic ectodermal dysplasia ORPHA:248; Fuhrmann syndrome ORPHA:2854; Phocomelia, Schinzel type ORPHA:2879",0.0180064224283883; 0.0180064224283883; 0.3775879467205478; 0.6239678957896782; 0.6239678957896782,,,,,,
ZBTB18,"Medulloblastoma; Brain Neoplasms; Glioblastoma; Seizures; Round face; Round, full face; Glioblastoma Multiforme; Epilepsy; Bulging forehead; Prominent forehead; Microcephaly; Agenesis of corpus callosum; Smooth philtrum; 3-Methylglutaconic aciduria type 2; Short stature; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Aplasia/Hypoplasia of the mandible; Micrognathism; Small head; Aplasia/Hypoplasia of the corpus callosum; Dull intelligence; Low intelligence; Concave bridge of nose; Depressed nasal root/bridge; Depressed nasal bridge; Thin upper lip vermilion; Neurodevelopmental Disorders; Low set ears; Poor school performance; Mental deficiency; Abnormality of the pinna; Simple ear; Mental Retardation; Thin lips; Generalized hypotonia; Congenital Epicanthus; Orbital separation excessive; Intellectual Disability; Childhood Glioblastoma; Adult Glioblastoma; Mental and motor retardation; Epileptic encephalopathy; Cognitive delay; Global developmental delay; Genetic Diseases, Inborn",0.0354767239335874; 0.064548079316548; 0.0745502070959292; 0.2053083986145698; 0.3706856725676674; 0.3706856725676674; 0.3933196962529684; 0.3941558617476422; 0.3941558617476422; 0.3941558617476422; 0.3975960596292668; 0.4103119460235835; 0.4126392832024548; 0.4213286052188015; 0.439389586518055; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4753011022966241; 0.4790179402069343; 0.479747709091007; 0.4906258721078565; 0.4923669467696064; 0.5300976305939776; 0.5300976305939776; 0.5337853752290136; 0.5337853752290136; 0.533913711453195; 0.5557519470957561; 0.5568517196017908; 0.5578737381206628; 0.5610226870913673; 0.6035970790768342; 0.6196470808426647; 0.6222451141623291; 0.6319938293757544; 0.6403143122455015; 0.7631684472516962; 0.8152796510476865; 0.8157137944879093; 0.8352623613787349; 0.8913309410682808; 0.8932589568643543; 0.897310588550617; 0.905697116584928; 0.9238745269736108; 0.9327689937867868; 0.9781572866315434,Microcephaly; Micrognathism; Dwarfism; Agenesis Of Corpus Callosum; Congenital Epicanthus; Mental Retardation; Multiple Congenital Anomalies; Dysmorphic Features; Movement Disorders; Developmental Delay,0.5123947823327547; 0.5234357475824973; 0.5796489603182782; 0.6252040071965056; 0.7729545590606223; 0.7729545590606223; 0.836331547891711; 0.91146174923533; 0.9334417262711258; 0.96477535147595,Early-onset Lafora body disease ORPHA:324290; Multiple endocrine neoplasia type 4 ORPHA:276152; Pseudohypoaldosteronism type 2D ORPHA:300525; Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome ORPHA:83473; Distal monosomy 1q ORPHA:36367; Hemimegalencephaly ORPHA:99802; Cardiofaciocutaneous syndrome ORPHA:1340; Uveal melanoma ORPHA:39044,0.1590470395003315; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,"Yaba-like disease virus 140R protein (gene: 140R); Yaba monkey tumor virus kelch-like protein; Vaccinia virus Ankara 64.7k Kelch-like protein f1; Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Horsepox virus HSPV008; Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Horsepox virus HSPV176 (kelch-like protein; Provisional); Yaba-like disease virus 19L protein (gene: 19L); Horsepox virus HSPV043 (Kelch-like protein; Provisional); Vaccinia virus kelch-like protein (gene: A55R); Cowpox virus CPXV215 Protein (gene: CPXV215 CDS); Cowpox virus CPXV050 (gene: CPXV050 CDS); Horsepox virus HSPV197 (Hypothetical protein); Monkeypox virus Zaire-96-I-16 B18R (gene: B18R); Vaccinia virus Ankara Kelch-like protein, modulator of inflammation; Cowpox virus CPXV013 protein (gene: CPXV013 CDS); Cowpox virus CPXV193 protein (gene: CPXV193 CDS); Monkeypox virus kelch-like protein; Horsepox virus HSPV029 (kelch-like protein; Provisional); Ectromelia virus ERPV kelch-like protein; Cowpox virus CPXV035 protein (gene: CPXV035 CDS); Vaccinia virus kelch-like protein (gene: C2L)",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597,Homo sapiens SNB-19 glioblastoma cell;Homo sapiens glioblastoma,0.35;0.4;0.53,Homo sapiens,Homo sapiens
ZBTB45,,,,,Glycogen storage disease due to muscle and heart glycogen synthase deficiency ORPHA:137625; Adrenomyeloneuropathy ORPHA:139399; Autosomal recessive ataxia due to PEX10 deficiency ORPHA:247815; B3GALT6-related spondylodysplastic Ehlers-Danlos syndrome ORPHA:536467; Basel-Vanagaite-Smirin-Yosef syndrome ORPHA:464738; X-linked cerebral adrenoleukodystrophy ORPHA:139396; Alveolar soft tissue sarcoma ORPHA:163699; ATP13A2-related juvenile neuronal ceroid lipofuscinosis ORPHA:314632; Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome ORPHA:466794; Autosomal recessive spastic paraplegia type 78 ORPHA:513436; Childhood-onset basal ganglia degeneration syndrome ORPHA:497906; Class I glucose-6-phosphate dehydrogenase deficiency ORPHA:466026; Desmoplastic/nodular medulloblastoma ORPHA:251863; Familial lambdoid synostosis ORPHA:3267; Focal dermal hypoplasia ORPHA:2092; Intellectual disability-epilepsy-extrapyramidal syndrome ORPHA:468620; Intellectual disability-strabismus syndrome ORPHA:363528; Isolated cloverleaf skull syndrome ORPHA:2343; Kufor-Rakeb syndrome ORPHA:306674; Lethal brain and heart developmental defects ORPHA:580933; Leukocyte adhesion deficiency type II ORPHA:99843; Medulloblastoma with extensive nodularity ORPHA:251858; NON RARE IN EUROPE: Glucose-6-phosphate-dehydrogenase deficiency ORPHA:362; TELO2-related intellectual disability-neurodevelopmental disorder ORPHA:488642; Cushing syndrome due to macronodular adrenal hyperplasia ORPHA:189427; Null pituitary adenoma ORPHA:314790; Pituitary gigantism ORPHA:99725; Silent pituitary adenoma ORPHA:314786; Smith-Magenis syndrome ORPHA:819,0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,"Yaba-like disease virus 140R protein (gene: 140R); Yaba monkey tumor virus kelch-like protein; Vaccinia virus Ankara 64.7k Kelch-like protein f1; Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Horsepox virus HSPV008; Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Horsepox virus HSPV176 (kelch-like protein; Provisional); Yaba-like disease virus 19L protein (gene: 19L); Horsepox virus HSPV043 (Kelch-like protein; Provisional); Vaccinia virus kelch-like protein (gene: A55R); Cowpox virus CPXV215 Protein (gene: CPXV215 CDS); Cowpox virus CPXV050 (gene: CPXV050 CDS); Horsepox virus HSPV197 (Hypothetical protein); Monkeypox virus Zaire-96-I-16 B18R (gene: B18R); Vaccinia virus Ankara Kelch-like protein, modulator of inflammation; Cowpox virus CPXV013 protein (gene: CPXV013 CDS); Cowpox virus CPXV193 protein (gene: CPXV193 CDS); Monkeypox virus kelch-like protein; Horsepox virus HSPV029 (kelch-like protein; Provisional); Ectromelia virus ERPV kelch-like protein; Cowpox virus CPXV035 protein (gene: CPXV035 CDS); Vaccinia virus kelch-like protein (gene: C2L)",0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597; 0.6362779693488597,,,,
ZCCHC12,"Papillary thyroid carcinoma; Mental Retardation, X-Linked; Intellectual Disability",0.3933196962529684; 0.7796824214131131; 0.8352623613787349,Esophagus Neoplasm,0.0102679590519094,"Autosomal spastic paraplegia type 72 ORPHA:401849; Autosomal dominant Charcot-Marie-Tooth disease type 2K ORPHA:99944; Autosomal recessive Charcot-Marie-Tooth disease with hoarseness ORPHA:101097; Autosomal recessive intermediate Charcot-Marie-Tooth disease type A ORPHA:217055; Charcot-Marie-Tooth disease type 2H ORPHA:101102; Charcot-Marie-Tooth disease type 4A ORPHA:99948; Coralliform cataract ORPHA:98990; Deafness with labyrinthine aplasia, microtia, and microdontia ORPHA:90024; Lissencephaly due to TUBA1A mutation ORPHA:171680; Oculoauricular syndrome, Schorderet type ORPHA:157962; Otodental syndrome ORPHA:2791; Primary dystonia, DYT4 type ORPHA:98805; Renal coloboma syndrome ORPHA:1475; Tubulinopathy-associated dysgyria ORPHA:467166; Hypomyelination with atrophy of basal ganglia and cerebellum ORPHA:139441; Cerulean cataract ORPHA:98989; 14q11.2 microduplication syndrome ORPHA:261229; Autosomal dominant Charcot-Marie-Tooth disease type 2 due to KIF5A mutation ORPHA:324611; Autosomal dominant Charcot-Marie-Tooth disease type 2E ORPHA:99939; Autosomal dominant keratitis ORPHA:2334; Autosomal dominant spastic paraplegia type 10 ORPHA:100991; Autosomal spastic paraplegia type 30 ORPHA:101010; Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome ORPHA:1171; Charcot-Marie-Tooth disease type 1F ORPHA:101085; Charcot-Marie-Tooth disease type 2B5 ORPHA:228374; Distal arthrogryposis type 5D ORPHA:329457; FOXG1 syndrome ORPHA:561854; FOXG1 syndrome due to 14q12 microdeletion ORPHA:261144; Foveal hypoplasia-presenile cataract syndrome ORPHA:2253; Huntington disease-like 2 ORPHA:98934; Intellectual disability, Birk-Barel type ORPHA:166108; Isolated optic nerve hypoplasia/aplasia ORPHA:137902; Isolated thyrotropin-releasing hormone deficiency ORPHA:238670; KCNQ2-related epileptic encephalopathy ORPHA:439218; Morning glory disc anomaly ORPHA:35737; Permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome ORPHA:65288; Polymicrogyria due to TUBB2B mutation ORPHA:300573; Progressive myoclonic epilepsy type 7 ORPHA:435438; Rapid-onset dystonia-parkinsonism ORPHA:71517; Spinocerebellar ataxia type 14 ORPHA:98763; Spinocerebellar ataxia type 41 ORPHA:458798; Normosmic congenital hypogonadotropic hypogonadism ORPHA:432; X-linked non-syndromic intellectual disability ORPHA:777",0.3762014630157917; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6268296504510718; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7335295427301692; 0.7730439460357812,,,,,,
ZNF703,Mammary Neoplasms; Breast Carcinoma; Malignant neoplasm of breast; Neoplasm Metastasis; Secondary malignant neoplasm of lung; Luminal B Breast Carcinoma; Metastatic Neoplasm,0.0034602840073026; 0.0042545616049287; 0.0191435238361999; 0.0648809611869375; 0.2723545094624877; 0.4459714599189374; 0.8757716428200738,,,"Craniosynostosis, Boston type ORPHA:1541; Parietal foramina with clavicular hypoplasia ORPHA:251290; 19p13.3 microduplication syndrome ORPHA:447980; Malan overgrowth syndrome ORPHA:420179; Marshall-Smith syndrome ORPHA:561; Microduplication Xp11.22p11.23 syndrome ORPHA:217377; Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome ORPHA:397933; ACys amyloidosis ORPHA:100008; Bilateral microtia-deafness-cleft palate syndrome ORPHA:140963; Microtia ORPHA:83463",0.0180064224283883; 0.0180064224283883; 0.0586579655822394; 0.0586579655822394; 0.0586579655822394; 0.1590470395003315; 0.1590470395003315; 0.3762014630157917; 0.3762014630157917; 0.3762014630157917,,,Homo sapiens HEK293T embryonic kidney cell,0.35,Homo sapiens,Homo sapiens
ZW10,Osteosarcoma,0.1029977559100099,Osteosarcoma,0.6477775413116995,Autosomal recessive Kenny-Caffey syndrome ORPHA:93324; Autosomal recessive spastic paraplegia type 62 ORPHA:401785; Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome ORPHA:436174; Combined immunodeficiency due to partial RAG1 deficiency ORPHA:231154; Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome ORPHA:496756; Fetal encasement syndrome ORPHA:465824; Hereditary coproporphyria ORPHA:79273; STT3A-CDG ORPHA:370921; Sanjad-Sakati syndrome ORPHA:2323; Dubowitz syndrome ORPHA:235; Hermansky-Pudlak syndrome without pulmonary fibrosis ORPHA:231512; Arthrogryposis-anterior horn cell disease syndrome ORPHA:53696; Combined oxidative phosphorylation defect type 39 ORPHA:565624; Endosteal sclerosis-cerebellar hypoplasia syndrome ORPHA:85186; FASTKD2-related infantile mitochondrial encephalomyopathy ORPHA:166105; Fryns syndrome ORPHA:2059; Lethal congenital contracture syndrome type 1 ORPHA:1486; Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome ORPHA:478049; Methylcobalamin deficiency type cblE ORPHA:2169; Multiple congenital anomalies-hypotonia-seizures syndrome ORPHA:280633; PLAA-associated neurodevelopmental disorder ORPHA:521426; Pyruvate dehydrogenase E2 deficiency ORPHA:79244; WARS2-related combined oxidative phosphorylation defect ORPHA:572798; X-linked sideroblastic anemia and spinocerebellar ataxia ORPHA:2802; Fever-associated acute infantile liver failure syndrome ORPHA:464724; Shwachman-Diamond syndrome ORPHA:811,0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.6239678957896782; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423; 0.7068064785325423,,,Homo sapiens;Homo sapiens HeLa epitheloid cervical carcinoma cell;Homo sapiens Huh7 hepatoma cell;In vitro,0.35;0.4,Mus musculus;chemical synthesis;ebvb9;hcvjf,Homo sapiens
